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COMPUTER APPLICATIONS IN BIOINORGANIC CHEMISTRY
By Peter M. May
Nowadays, computers play an indispensible role in the 
determination of metai-ligand formation constants and in their 
application to various situations of analytical, industrial or 
biological interest. The development of programs and simula­
tion techniques to meet some current problems in Bioinorganic 
chemistry constitutes•the broad objective of the present research
Consideration is given to the thermodynamic calculation 
of complex species concentrations in biological fluids. New 
methods of solving the mathematical relationships for metal- 
ligand solution equilibria, particularly in the simulation of 
large multicomponent systems, are investigated.
The ways in which computer simulations are involved in the 
determination of formation constants are discussed. Principles 
are developed and applied to problems concerning (i) the 
calibration of glass electrodes and (ii) the choice of complex 
species to describe metal-ligand systems under experimental 
investigation.
The function of transition elements in biological systems 
is briefly reviewed. Emphasis is given to the significance 
of low-molecular-weight complexes and h’ovi/ a knowledge of their 
in vivo behaviour can affect bioinorganic drug design. The 
relationship between copper and rheumatoid arthritis and the 
importance of equilibria in the regulation of iron metabolism 
are treated in some detail.
New simulation techniques are developed for blood plasma.
The results successfully rationalise many bioinorganic phenomena. 
In particular, the relative ability of a series of chelating 
agents to compete with proteins for metal ions in plasma is 
correlated with the urinary excretion of trace elements that 
they cause. Further simulations extend the approach to other 
biofluids and to medical solutions intended for intravenous 
infusion.
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CHAPTER ONE
INTRODUCTION
1,1 Bioinorqanic chemistry and computer applications
Bioinorganic chemistry is an interdisciplinary subject 
par excellence, Ito span is particularly broad because it 
seeks to apply the disciplines of inorganic and physical 
chemistry to the whole range of biological sciences from 
biochemistry on the one hand to physiology and medicine on 
the other. Indeed, the past decade has seen it increasingly 
concerned with the balance between human health and disease.
As in many interdisciplinary subjects, advances have often 
seemed easier to achieve because obvious directions for 
investigation have not previously been exploited. However, 
there has also been the corresponding disadvantage that a 
wide variety of material must be mastered in order to make 4 
progress. It is in this context that the computer has emerged 
as a powerful interdisciplinary tool: there are many ways 
it can bring together the theory, practices and data of 
different subject areas to help establish a new and self­
consistent science. •
Often the focus of a computer application will be a 
mathematical model. These are constructions which attempt to 
imitate reality by representing the vario-us parts of a system 
and the interrelationships which exist between them. As such, 
they are an integral part of the scientific method, being 
used to make predictions from hypotheses so that the latter 
can be confirmed or rejected by further experiment C736j. 
Models, therefore, can only portray established data in a new 
way; they do not create knowledge. Yet, they are productive
2because they uncover those unique aspects of the system 
which depend on the mutual interaction of its component 
parts.
Another less important but still valuable attribute 
of computers in interdisciplinary subject areas is their 
enormous capacity for storage and manipulation of data in 
its broadest sense. Their speed and reliability make it 
possible to accommodate systems that in the past would simply 
have been considered too complicated to analyse. Their 
robot-like character can also be exploited to provide many 
different kinds of scientific service which make the work of
a researcher less tedious and more dependable. The role of 
computers in analytical chemistry, for example, has been 
reviewed by Childs et al [114,115]. On occasion, the physical 
magnitude of some tasks is such that a whole approach may be 
infeasible without computer aid. Thus it is both in terms 
of computer simulation models and computer service programs 
that the computer applications to bioinorganic chemistry are
described in this work
31.2 Previous work
One of the main themes of this thesis concerns 
computer simulation of the low-molecular-weight complexing 
equilibria in blood plasma as applied to a variety of situa­
tions having physiological or pharmaceutical interest. The 
work is founded on a model that was originally developed by 
the author in fulfilment of the requirements for the degree 
of Master of Science at the University of Cape Town (1976). 
Accordingly, much of the research described herein is an 
extension of the earlier project and certainly could not have 
been achieved without it. This dependence makes it necessary 
at the outset to demarcate between the present and the past 
contributions. Accordingly, the previous work may be briefly
summarised as follows. . *
The initial model was designed to investigate the 
nature of the metal ion binding to ligands in normal, i.e. 
untreated, blood plasma. Perhaps the main objective was to 
accommodate the effects of metal protein binding on the 
computation of the complex species concentrations. This was 
accomplished in so far as the percentage distribution of 
transition metal ions amongst lo-w-molecular-weight ligands was 
shown to be independent of the exact extent of metal protein 
binding. This is described more fully in Chapter 4. The 
collection, assembly and processing of the necessary data for 
the model was described. A computer program, ECCLES, was 
written to cope with the very large equilibrium systems that
were simulated. Experimentally determined values for the
formation constants of the complexing reactions in the
biofluid were collected from the literature,' These were 
corrected whenever they were not applicable to physiological 
conditions of temperature and ionic strength. Where no 
experimental values were available, formation constants for 
complexes that seemed likely to be important were estimated 
from certain chemical tiends. The results of the blood plasma 
model are summarised in Chapter 4. The work has been published 
as a thesis £736] and in two research papers £1234,1250].
Two of the service computer programs dealt with in 
this thesis, namely MIX and INDEX, were also originally written 
as part of the M.Sc research. Since then these programs, as 
well as ECCLES, have been considerably developed and/or 
extended, as outlined in. Chapters 2 and 4. In the case of 
both program ECCLES and program INDEX, the FORTRAN coding 
had to be rewritten to make the programs compatible
with the St Andrews’ IBM 360/44 computer. Program MIX was 
considerably modified for the same reason.
1 • 3 Objectives and summary of the present research
The usual goal of those researching bioinorganic 
equilibria can be stated very simply: it is to measure the 
formation constants of biologically relevant metal complexes 
and to use this information to understand how the complex may 
be involved in the metabolism of the metal ion. For most 
purposes, the formation constant measurements are made using 
glass electrode potentiometry and are applied to the in vivo 
situation by some kind of simulation. This procedure 
requires a considerable amount of data processing and 
involves a variety of calculations. Certain elements of 
this work can only be performed by computer and many others 
prove very tedious to do manually. A number of computer 
programs have thus been produced by researchers in this field 
However, several areas remain in which further computer • 
applications would be very useful. .
The development of computer programs and computer 
simulation techniques to meet some of these needs constitutes 
the broad objective of the present research. The more 
specific details can be summarised as follows.
The thermodynamic application of metal-ligand 
equilibrium constants to calculate complex species concen­
trations in biological fluids is considered. Formation 
constants for a large number of therapeutic chelating agents 
are critically selected from the literature and adjusted to 
suit biological conditions of temperature and ionic strength. 
New methods of solving the mathematical equations for metal-
6ligand solution equilibria, particularly in the simulation 
of large multicomponent systems, are investigated. These 
efforts are applied to biological systems by modification 
of the ECCLES program and the extension of its database.
The ways in which computer simulations are involved 
in the determination of formation constants are outlined.
The discussion focuses on the role of simulation in the 
optimisation of titration parameter values. Principles are 
developed and applied to problems concerning (i) the cali­
bration of glass electrodes and (ii) the choice of complex ' 
species to describe metal-ligand systems under experimental 
investigation.
The function of transition metal ions in biological 
systems is briefly reviewed. Emphasis is placed on the 
biological significance of low-molecular-weight complexes 
and how a knowledge of their in vivo behaviour can affect 
bioinorganic drug design. Two areas are treated in detail. 
These are (i) the relationship between copper and rheumatoid 
arthritis and (ii) the biological transport of iron and the 
importance of equilibria in the regulation of its metabolism.
New computer simulation techniques are developed for 
blood plasma. By considering the in vivo complexing ability 
of chelating agents relative to one another, the difficulties 
associated with metal protein binding in models where exogenous 
drugs have been administered, are bypassed. The results 
successfully rationalise many bioinorganic phenomena that
hitherto have been incompletely understood. In particular 
the relative ability of a series of medical chelating 
agents to compete with proteins for metal ions in plasma 
is correlated with the urinary excretion of trace elements 
that they cause. Further simulations extend this type of 
approach to other biofluids and to solutions intended for 
intravenous infusion.
CHAPTER TWO
COMPUTER SIMULATION OF METAL ION
AND LIGAND EQUILIBRIA
02.1 The thermodynamics of metal ion and ligand interactions
Thermodynamics is a study of the effects of energy upon 
matter C639J. It is founded essentially upon three postulates, 
called the first, second and third laws, which summarise 
certain basic properties of energy that have been thoroughly 
established by cumulative scientific observation. Together 
these principles lead to a comprehensive and general descrip­
tion of how energy is liberated or consumed when chemical 
substances react. Thermodynamics can thus be used to predict 
relationships between various quantities involved in the 
reaction. Above all, it indicates whether a particular -
process is possible or not under a given set of conditions.
This is achieved by reference to an equilibrium state, i.e. 
the final position of a chemical reaction which is defined 
as being invariant with time.
It is found by experiment that when substances are 
brought together in a closed system so as to undergo chemical 
reaction, the conversion of reactants to products always remains 
incomplete no matter how long the process is allowed to continue. 
Sooner or later the decreasing concentrations of reactants and the 
increasing concentrations of products level Off and become 
constant. The state in which the concentrations no longer change 
is known as the state of chemical equilibrium.
Thermodynamics deals quantitatively with reactions at 
equilibrium. For this reason it is eminently applicable to 
one of the commonest problems in bioinorganic chemistry,
9namely, how to determine the concentrations of complex
species in biological systems. As will be discussed in 
greater detail under Section 4.1, many metal-ligand complexes 
of great physiological importance occur in amounts far below 
the present level of analytical detection. Thus, thermo­
dynamic calculations provide the only available means for 
obtaining information of this kind..
It is necessary at this stage to consider briefly 
some of the.strengths and weaknesses of a thermodynamic 
approach. As mentioned above, this is an experimentally based 
discipline. So, it does not depend on theories concerning 
the existence of atoms or molecules C639]; for example, the 
kinetic theory of matter, statistical mechanics and the Debye- 
Huckel theory lie outside its scope. As a consequence, 
thermodynamic results yield no direct information about atomic 
or molecular structure. They can likewise not be associated 
with reaction rates or mechanisms. It is in this res-triction, 
however, that thermodynamics has its greatest strength. Since 
it makes no fundamental assumptions other than those postulated 
in the three laws its 'validity does not depend on anything 
else. It is no wonder Einstein commented as follows:
“A theory is the more impressive the greater is the 
simplicity of its premises, the more different are the kinds 
of things it relates, and the more extended is its area of 
applicability. Therefore, the deep impression which classical 
thermodynamics made upon me. It is the only physical theory
10
theory of universal content concerning which I am 
convinced that, within the framework of applicability 
of its basic concepts, u/ill never be overthrown.”
Albert Einstein 
1897-1955
2.1.1 Equilibrium constants .
The thermodynamic parameter from which equilibrium 
concentrations are usually calculated is called the 
equilibrium constant. This fixed relationship between 
equilibrium concentrations was established experimentally by 
Guldberg and Waage between 1864 and 1879 as their ’’law of 
mass action” C19393. However, it was only towards the end 
of this period that Horstmann and van’t Hoff, independently, 
showed that it could be derived from the’ second law. C659J.
A theoretical basis is important because it justifies the use 
of equilibrium constants to extrapolate into regions of such 
low concentration that data cannot be checked directly against 
experiment. The equilibrium constant expression arises from 
the fact that in closed systems under given circumstances of 
temperature and pressure, the Gibbs free energy must be a 
minimum. This may be expressed alternatively as dG^ p = 0.
Equation 2.1 is obtained when this condition is applied to 
the following generalized reaction.
aA ■+• bB +...... = IL + mM •+• . .. • •
{L}1
------------------------- = K (2.1)
{A}a .
K is the equilibrium constant and the braces denote the 
thermodynamic activity of each species with respect to a 
given standard state. Although these terms are fundamental 
to the study of metal-ligand equilibria in aqueous solution, 
the literature of this field shows they are often misunder­
stood. Accordingly, certain aspects of each which are assumed 
throughout this thesis are outlined below.
The standard state for any solute species is that . 
reference solution against which changes in the Gibbs Free 
Energy and other thermodynamic quantities can be measured.
The activity of the solute species is defined in terms of
the change in chemical potential (or partial molar free energy)
p, according to equation 2.2 £6393. .
Pi = Pi + RT In a^ (2.2)
Here, a. is the activity of the solute species, Jj? itsX x
chemical potential in the standard state, R is the universal 
gas constant and T is the absolute temperature. The chemical 
potential, p, is defined in terms of the change in Gibbs Free 
Energy, G, with respect to the number of moles, n^, under 
conditions of constant temperature, T, and pressure, P, by
11
equation 2.3.
12
l,n2
M i (2.3)
The concept of activity was introduced by Lewis to 
represent the departure from ideality which is exhibited by 
real solutions 01939]'. This deviation may be quantified as 
an activity coefficient, f, which relates the activity of a 
species to its concentration, c, as shown in equation 2.4.
fi
ci
(2.4)
Conversely, the activity of an ideal solution is given 
by its concentration. In thermodynamic studies it is often 
preferable to express concentrations in terms of molality since 
this unit is independent of temperature and pressure. 
Molarities, oh the other hand, give properties which are most 
easily interpreted in terms of molecular theories and which 
permit one to ignore the solvation of solute species [1941].
So there are also good grounds for choosing molarity as the 
concentration scale and this has been adopted throughout the 
present work. .
The standard state is thus defined as that usually 
hypothetical solution at unit molar concentration whose 
properties are assumed*to be ideal 0639,1941,1942]. The 
reason for this rather abstract specification is simple: it 
makes the chemical potential such that the activity given by 
equation 2.2, becomes equal to the concentration (in the
13
appropriate units) as infinite dilution is approached. The 
nature of the standard' state has no thermodynamic significance 
so a choice can be made on the basis of convenience. The 
effect of different choices merely alters the value of the 
equilibrium constant without affecting its constancy [639].
Another way of looking at this is to consider what 
happens when the concentration of a solute species is decreased 
towards infinite dilution [1942]. Its behaviour becomes 
progressively more ideal because there is a diminishing
interaction between individual solute species. Hence the 
environment experienced by the solute becomes constant and 
the activity coefficient of the species approaches a limiting 
value which is unity if there are no components in the solution 
other than the solute and solvent in question.
It follows that the equilibrium constant shown in 
equation 2.1 can be obtained hypothetically by measuring the 
reactant and product concentrations in equilibrium as infinite 
dilution is approached. The question which must now be 
addressed is how this can be achieved in practice.
On the basis that interactions between solute species 
in solution give rise to non-ideal behaviour, it is easy to 
appreciate that electrical attractions and repulsions between 
ions must have a major effect on the properties of electrolyte 
solutions. Indeed, it was shown experimentally by Lewis and 
Randall that the activity coefficients of ions depend 
primarily on their charge and on the total concentration of 
all the charged species present in the solution. Other
• . 14 :
contributions to the ion's chemical nature have very much . 
less effect C19413 . They, therefore, introduced the concept 
of ionic strength, I, which is defined by equation 2.5. .
2c,Z? .
I = (2.5)'
2
where c^ is the concentration of the ith ion of charge Z^.
It follows that the activity coefficient of a solute species 
is approximately the same in all dilute solutions having a 
given ionic strength C1959]. •
In 1925 the Debye-HLickel limiting law was published 
C1945J. This showed how the activity coefficient of an ion 
in solution was expected to vary according to the ionic strength 
of the medium. The expression, given as 2.6, treats each ion 
as a point charge surrounded by a surplus of ions with 
opposite charge. At 25°C,
log f± = • -0.5091 (2.6)
Clearly, this simplified approach can only rationalise the 
gross effect of coulombic interactions in solution; the 
adjective "limiting" indicates that predicted and observed 
behaviour converge as the concentration of the solute is 
diminished toward infinite dilution. In practice there is 
good agreement up to ionic strengths of about 20 mmol dm 
C70j. Various extensions to the limiting law which primarily 
aim to take account of the physical size of each ion have 
subsequently been developed. These can accurately predict 
experimentally determined activity coefficient values in
• -3solutions with ionic strengths as high as 100 mmol dm C1939] . 
Attempts to apply interionic attraction theo-ries to solutions 
of mixed electrolytes, however, have met with limited success 
L713 . .
The Debye-Huckel theory substantiates the ideas of 
Lewis and Randall which led them to introduce the concept of 
ionic strength. It also provides a convenient way of extra­
polating measured activities back to infinite dilution when 
it is not feasible to do so experimentally. However, for 
many systems (especially those of biological significance) 
it is not possible to work at the exceedingly low concentrations 
that this approach properly requires [19413. As discussed 
in Section 2.1.3, moreover, the relevance of this procedure 
is open to question. An alternative is to employ a solution 
whose ionic strength is maintained constant by the addition 
of a ’’background” electrolyte. Such an approach assumes that 
the activity of a solute species under these circumstances 
will not vary as long as changes in its concentrations are very 
much smaller than those of the total electrolyte in solution.
It is thus possible to determine equilibrium constants for 
reactions taking place in the electrolyte medium. The only 
requirement .is that the actual activities of each species 
participating in the reaction can be ascertained. For 
practical purposes, however, it may be simpler to measure 
’’stoichiometric’’ constants defined in terms of concentration,
15
as shown in equation 2.7.
For the general reaction
aA + bB + ...... = IL + mM + . . . . .
K = ------------------ (2.7)
Ma.[B]b..........
•X*where K is related by expression 2.8 to the thermodynamic 
equilibrium constant K (defined in equation 2.1) as long as 
the activity coefficients, f, of each,species remain constant.
♦ •
fL,fM’
K
* (2.8)
• • •
There are now two possibilities to consider C19423. 
Firstly, if the standard state is defined in terms of pure water 
as the solvent, the activity coefficients are constant but not 
equal to unity. Their value mainly reflects the high ionic 
strength of the solution with respect to the standard state. ■ 
Note that reference is still made to infinite dilution of the 
solute species (not the background electrolyte I) but one must 
consider this infinite dilution in the ionic medium with 
respect to the same condition in pure water. Measured para­
meters must therefore be corrected using a Debye-Huckel-type 
function to obtain ’’thermodynamic values". Alternatively, one 
can define the standard state in terms of the electrolyte 
solution as the solvent. Then the activity- coefficient for 
the solute, species at infinite dilution is put at unity.
17
Initial increases in .the concentration of solute will have 
no significant effect on ionic strength because of the 
swamping excess of background electrolyte so no Debye-Hucke1
‘ J
corrections are applicable. Furthermore, as long as the
activity coefficients remain constant, "stoichiometric” quantities^
J
such as l< in equation 2.7 and 2.8 are equivalent to the 
corresponding "thermodynamic" values.
It might seem that the choice of electrolyte solution 
as the solvent in the definition of the standard state is so 
convenient that it would be adopted universally, That this 
is not the case is partly due to a lack of agreement concerning 
the salt which should be used, A large diversity of background 
concentrations have also been employed. More fundamentally, . 
one cannot justifiably assume that a change in ionic strength 
is the only reason for non-ideal behaviour E1941]. Thus, the 
activity coefficients of solute species in dilute but experi­
mentally realistic concentrations may deviate from their
values at infinite dilution but still appear constant over a
fairly wide range of concentrations. Strictly, the assumptions
should always be tested by extrapolation to infinite dilution
before results are claimed to have thermodynamic significance.
When this is not possible, it must be shown that the equilibrium
quotient remains constant over as large a variation in reactant
and product concentrations as is practicable C1941] . To
illustrate the difficulties involved, it has been suggested
that the structure of a concentrated electrolyte solution such 
■ -3as sodium perchlorate at 3 mol dm may be seriously deranged
13
at very low solute concentrations because almost all the
water present in such solutions participates in the solvation 
of the electrolyte ions; this implies a dramatic change in 
the environment of solute species at these very low concen­
trations so that their activity coefficients may rapidly or 
suddenly deviate from unity and therefore thwart attempts to 
extrapolate back to infinite dilution.
One further matter which must be dealt with in this • 
section concerns the interaction between solute species and 
the ions of an electrolyte solvent. As any such interaction 
obviously affects the environment of the solute it must - 
contribute to its activity. Much attention has been focussed 
on background salts that are as ’’inert" as possible. Potassium 
nitrate and sodium perchlorate have emerged as two of the 
most commonly used. Of course, the ’’non-coordination’’ of 
anions such as nitrate and perchlorate is a- relative phenomenon 
in which their poor ability to donate electrons to many metals 
is contrasted with respect to water molecules [392]. Thus, 
measurements in solutions of "inert’’ salts give the closest 
approximation to a solution in the pure solvent because only 
the effect of ionic strength need then be taken into account.
In practice, the nature of the electrolyte always has some 
influence [377], but the less the interaction the more applicable 
Debye-Huckel functions become. However, it is clear that this 
criterion is not relevant when the standard state is defined
in terms of• the electrolyte solution as the solvent, Linder 
these circumstances, interactions with the ions of the electrolyt 
are simply part of the interaction of the solute with the solvent
So, once again, a suitable choice of standard state and 
in particular of the background salt to maintain ionic 
strength, removes many thermodynamic difficulties. The 
only effects which need cause any concern are those leading 
to non-ideal behaviour as mentioned .in the previous paragraph.
J
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2.1.2 Competitive equilibria in aqueous solution
It is difficult to find examples set in a variety of
chemical contexts which are simple but illustrate the concept 
of equilibrium adequately. It has accordingly become popular 
in modern textbooks to treat labile metal complexing reactions 
amongst the problems and exercises dealing with the law of •
mass action. However, this presentation is prone to be over­
simplified, particularly in the neglect of the many competitive 
reactions which are usually involved. Such omission often 
leads to ill-defined or overtly incorrect results. Indeed, 
only over the last decade has the application of high speed 
computers permitted even research workers to routinely take 
into account the many possible kinds of complex species [364,1807].!
The powerful tendency of water to donate a lone pair 
of electrons to Lewis acid acceptors means that metal ions 
dissolved in water will generally exist with their coordination 
sites fully occupied by solvent molecules. Other complexing 
agents added to the solution must then compete with water in
order to bond to the metal. The extent to which their 
coordination can take place depends upon the equilibrium which 
is set up between the aquated metal ion species and the complex
3
formed by the added ligand. This is shown in the following 
example where charges have been omitted for the sake of 
simplicity and generality.
m(h2o)6 + L ml(h2o)5 + h2o
In general, successive replacement of water molecules 
can occur so that a whole series of competitive equilibria arise 
As the solvent implicitly occupies all sites which are not 
coordinated to other ligands, an abbreviated representation 
of the step-wise reactions is often used.
M + L ML
ML + L ML^ -
ML2 + L^ ML^
Each of the above reactions is characterized by an 
equilibrium constant that quantitatively represents the avidity 
with which the ligand binds to the metal compared with the 
solvent under specified conditions. Assuming that the ionic
strength of the solution is invariant, stoichiometric constants
for each reaction can be formulated as follows .
-X- CML] -X- CML2]
K1 ~ > K = - etc. (2.9)
CM] CL] z CML] CL] '
By convention these are usually expressed as "step-wise
• ML ' ....
formation constants", $ ’ , by writing each as the cumulative 
product of the individual reaction constants, K*. Thus
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ftM,L
M,L
Eml] 
CM] CL]
[ML]
CM] CL]
(2.10).2
In this way the concentration of a complex species is defined 
in terms of its formation constant and the product of its 
components’ concentrationseach raised to the power of the 
appropriate stoichiometric coefficient..
It is important to emphasise that a competitive equilibrium 
has been described, in which every species exists at the expense 
of the others. The outcome depends on a variety of factors 
but particularly oh both the absolute and relative concen­
trations of the components. Another critical element which 
should never be forgotten•(although it often is) is the solution’s 
free hydrogen ion concentration. Electron donor sites on 
ligands can bind protons as well as metal ions so there is yet _ 
another competition in solution which determines the concen­
tration of free complexing species available. This series of 
equilibrium reactions may be represented by
[HL]
L + H HL H,L3
EH] EL]
HL + H HOL H,L
EH2L] 
CH32 ElI
(2.11)
In addition to this, hydroxyl ions are much more powerful
electron donors than water molecules so alkaline conditions favour 
metal ion hydrolysis at the expense of all the other metal 
complexes present.
7.L
In general, then, a plethora of species must be 
expected whenever solutions of a metal ion an'd of a ligand 
are mixed together. The situation is even more complicated 
by the possibility of polynuclear complexes such as and
of so-called ’'mixed" species where one or more protons or 
hydroxyl ions are appended to or lost from the usual step-wise 
metal complexes. For example, these may be represented as 
MLH, MLH2, MLH j and MLOH. To accommodate all of these 
species a general formulation of the formation constants 
applicable to one metal and one ligand systems has been adopted. 
For the general reaction, . .
pL -h qM + rH L^ M^ Hp
It is pertinent to note at this stage that in all of 
the mathematical expressions dealing with equilibria in aqueous 
solution, the hydroxyl ion is equivalent to a negative hydrogen 
ion contribution. Thus, MLH , and MLOH represent the same 
complex stoichiometry. This arises out of the relationship 
between the dissociation of water and the other reactions in 
the solution by virtue of water's role in the definition of the 
standard state. Those reactions in which water is involved are 
transparent to the others. Hence, formation constants may be 
expressed in terms of hydroxyl ion concentration or instead
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may be related by the dissociation constant to the hydrogen 
ion concentration.
[01-1] = KUCH]_1 (2.13)
The basic mathematical problem to be solved in the
simulation of metal-ligand equilibria is how to calculate the 
free concentrations of each component given the total concen­
trations and all the necessary fqrmation constant values. •
Once the free concentrations are known, all the complex species 
concentrations can be readily evaluated from the formation 
constants. This matter will be dealt with in detail in Section
2.2 but certain elementary aspects are best introduced at this 
stage. For each component, a "mass balance" equation can be 
written in which the concentration of the component is summed 
over all the species.
Tl = CL3 + EHL] + EH2L3 + EML] •«- 2EML2] 4- ............
Tm = EM] + EMOH3 + EML] -i- EML2] 4- 2EM2L23 4- .....
Th = EH]- - EOH] 4- EHL] 4- 2EH9L] 4-’.............. .. .... . •
H Z (2.14)
It may be noted, incidentally, that the hydrogen ion mass 
balance constraint is often represented by the equivalent but 
unsystematic electroneutrality condition E106]. By introducing 
the equilibrium constants, these expressions resolve into a 
sum of terms containing only the free concentrations as unknowns
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tl = CL] + 6101CH][L] + B1Q2CH]2rL] + B110M[L] + ZB210OT CL]2+
tm = CM] + B01 jDOtH]'1 + CL] + ......
th = CH] - WX1 + e101mcL] +.............. .. (2.15)
It is thus possible to solve for CM], CL] and CH] simultaneously
and hence obtain the equilibrium distribution. If any of the 
free concentrations are known instead of a total value (as 
is often the case with hydrogen ions) then the number of equations 
to be solved is simply reduced. Conversely, when a free 
concentration is measured in a system where all the total 
concentrations are already known, the problem becomes over­
defined and the additional information can be used to estimate
the values of the formation constants. This is of considerable 
relevance to the discussion in Chapter 3.
2.1.3 Procuring formation constants for bioinorqanic systems 
In practice, one takes a slightly different perspective
to that presented in Section 2.1.1 when applying thermodynamic 
theory to bioinorganic formation constants. The reason is that 
biological fluids usually exist at relatively high ionic 
strengths with sodium chloride as the dominant electrolyte. 
Attempts to calculate equilibrium concentrations in such media 
are obliged to take account of this whether or not it is 
convenient or indeed even permissible from a thermodynamic 
viewpoint! Thus, there is less stress on the stringent
US’
requirements of a "thermodynamic” approach. After all,
worthwhile answers to real questions seldom lie in semantics!
The question is not so much about which standard state should 
be adopted but rather to what extent various standard states 
and other thermodynamic functions are valid in the biological 
situation. Even when it transpires that they are not strictly 
applicable, they may nevertheless be good enough to yield 
sensible results. Moreover, by comparing and contrasting 
the actual .situation with the theoretical one it is often 
possible to expose the most relevant parts and thus find the 
most vulnerable flaws in a given method.
The vast majority of formation constant measurements 
reported in the literature have assumed, for purposes of 
defining their standard state, that water is the solvent.
This reflects the thermodynamic motivation behind the research, 
especially the earlier work, which was not specifically aimed 
at determining equilibrium concentrations in applied situations. 
Unfortunately, there are few practical areas where thermodynamic 
equilibrium constants of metal-ligand reactions at infinite 
dilution in water are .relevant. So there is now a growing 
trend towards experiments designed with some ultimate objective
in mind. • ■
The most apposite temperature for formation constant 
measurements in a bioinorganic context is probably that of the 
human body, namely 37C. There is no theoretical objection with 
such a choice but a few experimental complications may be 
thereby introduced. For the most part, however, the accuracy of 
results will not be adversely affected by this because other
factors tend to be much more critical.
Zb ’
* -3The need to use sodium chloride solution at 150 mmol dm 
as the most pertinent reference for biological fluids (if not 
as the solvent in the definition of the standard state) is much 
more problematical. Ironically, experimental procedures are . 
greatly simplified because this salt can be obtained in a pure 
and dry condition, relatively easily. Thus, metal-ligand 
systems which do not interact unduly'with sodium chloride are 
best studied directly in this medium. An argument can be made 
for doing likewise with all metals and.all ligands of biological 
interest but the majority of authorities probably feel that an 
indirect approach is to be preferred [286]. When either the 
ligand binds sodium ions or the metal binds chloride to a 
significant extent,' the metal-ligand equilibria can first be 
studied in a more inert background medium. The effect of sodium 
chloride can then be quantified in the same background electrolyte 
and this information used to calculate the various interactions 
in the biological fluid. The advantage of this approach is 
that the primary metal-ligand formation constants can be readily 
compared with values in literature for .the same and other 
metal-ligand systems.
In this work the database of formation constant values 
assembled for the computer simulation of the equilibria in blood 
plasma has been substantially extended by incorporating values 
for about 30 exogenous chelating agents. Data has been critically 
selected from the literature and treated in the same way as 
previously described [736]. The account below outlines this 
procedure again but only very briefly and the reader is referred 
to the original work for more detail. Two further metal ions,
N i (11) and F e (11), have been added to the earlier list of 
Ca(II), Cu(II), Fe(XII), Pb(II), Mg(II), Mn(II) and Zn(II).
So values for Ni(II) and Fe(II) with the 40 naturally occurring 
ligands that are considered have also been provided. In 
addition, the earlier database has been rigorously updated and 
accordingly a number of extra formation constants have been 
included. The whole list of 1700 binary complex species appears 
as Appendix A2. This is to be compared with the set of under 
1000 which was prepared for the original simulations C736].
Whenever sufficient data has been available, the inte­
grated form of the van't Hoff equation has been used to correct 
formation constants to 37 C standard comparable temperature.
This is shown in equation 2.16 F6393 . •
... ......... ... ......... ...... 27
K? AH° T2 - Tj
in R < TlT2 > . (2.16)
Here, AH°, the standard change in heat content, is assumed to 
be independent of temperature, R is the gas constant and Tj, 
and 1'2 are the different temperatures in Kelvin. (^2^1^ 
the relative change in the equilibrium constant. When equation 
2.9 could not be used empirical corrections based on. various 
experimentally determined trends were employed instead [5043.
Empirical methods have also been adopted to correct for 
changes in ionic strength. With the data available, Debye-Huckel 
type corrections are almost invariably inapplicable. Fortunately, 
Gergely et al have studied the effect of both ionic strength and 
the nature of the electrolyte on the equilibrium constants of 
the complexing reactions between some amino acids and transition’
metal ions [3773 . This work has provided a valuable benchmark 
from which the direction and magnitude of adjustments can be 
judged fairly precisely.' Even more relevant in the present 
context has been the fact that the majority of medical 
chelating agents have been thoroughly investigated under a wide 
variety of experimental conditions.
Perhaps the most controversial aspect about the formation 
constant database that has been assembled is the procedure 
adopted when the literature is found to be in error, ambiguous, 
contradictory or incomplete. These circumstances often arise 
because of inherent experimental limitations which prevent the 
categorical definition of complexing species which exist in 
solution. This subject is further discussed in Section 3.3.
In selecting formation constants, an attempt has been made to 
adhere to the following policy.
(i) Averages are taken when there is little to distinguish 
between two or more values obtained by different research workers
(ii) Formation constants published by the most active, well 
established laboratories are used in preference to others. 
However, when sets of formation constants obtained in this way 
are incomplete (in the sense that they do not include all species 
which might reasonably be expected to exist in solution), then 
the set is supplemented by values from additional sources.
(iii) Educated guesses are made to obtain formation constants 
which are not otherwise available from the literature but which
seem certain to exist under some circumstances in aqueous solution.
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Such estimates are derived from various observed chemical trends, 
most notably relying on the relationship between ligand basicity 
and complex stability [364,505] and the Irving-Williams series 
for comparing the complexing ability of the first row, divalent 
transition metal ions [619].
The motive behind this approach has primarily been to ensure 
that complex species which may be important in vivo are not 
omitted because they are experimentally difficult to detect.
A degree of incompatibility between the formation constants 
used is thus introduced but the associated errors are likely 
to be small because species at or below the limit of detecta- '
bility in vitro will only seldom become significant in biological 
fluids. On the other hand, very serious errors indeed may 
occur if a complex is neglected. It should be remembered that 
to omit a complex species means that in all simulations it is 
treated as though its formation constant is zero; it is usually 
possible to estimate a better value than that.
There is one further element which combined with the above 
rules makes the procedure fail-safe. it is that the results of 
all simulations are evaluated in terms of the reliability of the 
most pertinent input data. Thus, each complex species is subjected 
to further scrutiny whenever it occurs at significant concentra­
tions in a computer model or when it may do so if its formation 
constant is reasonably increased. This highlights those values 
which are in greatest need of revision and ultimately determines 
whether they warrant experimental investigation. A good example 
of how this works is described in Section 4.2.1.
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Although the vast majority of binary formation constants 
in the database have actually been measured under one circum­
stance or another, this is not the case for the ternary 
complexes. Special methods have therefore been devised for 
including this kind of species in the computer models.
Basically, most values are calculated on the assumption that 
if parent binary complexes, MA2 and MB2, exist then the ternary 
species MAB will also occur when both ligands are mixed in 
solution with the metal ion. A statistical argument [88] predicts 
that the formation constant of such species can be estimated 
byequatiori2.17.
log
[MAB] 
[M] [A] [B]
‘ = %(log 62,A + log 32,B) + log 2 (2.17)
Clearly, this theoretical calculation of ternary formation 
constants must be subordinate to adjustments based on experi­
mental information and these, in turn, are only appropriate 
when the value in question has not been measured under biological 
conditions of temperature and ionic strength. The computer 
program MIX was written primarily with a view to assembling 
ternary formation constants in accordance with these hierachical 
requirements. However, for convenience sake, the program also 
selects those binary formation constants in the database needed 
by a model. The main alterations to the original structure of
the program have been made so as to permit the user to over­
. ! ■
ride these automatic procedures. Thus, one is now able to prevent
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constants being selected on the basis that they include one 
or more specified components. Other values can be substituted 
instead, if desired. This is particularly useful to those 
who have determined a set of constants experimentally and wish 
to establish the extent to which their new values affect previous 
models. No alterations to the database need be made. Another 
major innovation which has been made to program MIX concerns 
the elimination of some ternary complex species. Many of the 
calculated formation constants produced by the program are such 
that the complex is certain to occur at insignificant levels in 
the simulated solution. These can be identified and so omitted 
by program MIX on the basis of a preliminary calculation using 
approximate values for each free component concentration. In 
this way, about 9000 complex species are routinely considered for 
the blood plasma model described in Chapter 4 but the number is 
reduced to 5000 when the actual simulation is performed. A 
detailed description of program MIX, its input instructions 
and FORTRAN listing can be found in Appendix A3.
2•2 The simulation of multicomponent systems •
An extraordinarily large number of mathematical methods 
have been developed to calculate equilibrium concentrations* It 
is possible to reference only some of the papers which are 
relevant to one or another computer application L'8-14, 17, 84,
85, 89, 91, 92, 110-112, 119, 128, 204-206, 215, 216, 219, 245,
258, 259, 327, 510, 567, 825, 915, 1553, 1622, 1775, 1886].
Many of these approaches, however, deal with only specific equili­
brium systems and thus fail to make the most of computer facilities 
that are nowadays commonly available. The relative costs of 
human and computer time have become such that modern simulation 
programs must treat the whole gamut of systems from simple 
ligand protonation to the most complicated, polynuclear complex 
formation.
There are two well-established and commonly used computer 
programs for simulating general metal-ligand equilibria in 
solution. The first was called COMICS (for Concentrations J3f 
Metal _Ions and £omplexing Species) L1H3 and the second is 
known as HALTAFALL (from the Swedish "halta" meaning 'concentration* 
and "falla" meaning ’precipitate’) C1123• The essential differences 
between these programs can be summarised by saying that although 
HALTAFALL tends to be less efficient than COMICS for those 
systems which can be treated by them both, the former can be 
applied to a much wider range of problems. As its name implies, 
HALTAFALL can deal with systems having more than one phase,
On certain occasions this can be a very useful feature but it is 
not really relevant to the present work. Of fundamental import, 
however, is the fact that HALTAFALL can calculate free hydrogen
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.ion concentrations from a given total concentration. COMICS 
cannot. Hence, HALTAFALL must be used to simulate titrations. 
COMICS deals only with aqueous. solution and requires the free 
hydrogen ion concentration as input. When this is known, as 
in most equilibrium simulations of biofluids, the approach 
adopted by COMICS is simpler both to use and to understand so it 
is this which will be dealt with in detail.
Another program which should be mentioned at this stage 
is ECCLES (for ^valuation of Constituent Concentrations in 
JLarge lEquilibrium Systems) [736 ,12503 . Like COMICS, it is 
restricted to situations where the free hydrogen ion concentration 
of the solution is known. However, it has a variety of features 
which recommend its use even in the case oF single metal and 
single ligand simulations. It can accept the free concentration 
of any component whereas COMICS cannot. It can also scan either 
the free or the total concentration of any component. COMICS 
can only treat a series of different pH values. A full descrip­
tion of pcrogr am ECCLES, the instructions for preparing input and 
a FORTRAN listing appear in Appendix A3. The remainder of this 
Chapter is devoted to a brief outline of how ECCLES works (with 
emphasis on the improvements which have been made to the original 
version) and what advantages it offers in the simulation of
large multicomponent systems compared with COMICS.
2.2.1 Generalized simulation techniques
The nomenclature, symbols and conventions used in
Section 2.1.2 for writing the formation constant and mass balance 
expressions of binary equilibrium systems develops into a 
very cumbersome structure once four or more components are 
considered. It is therefore desirable to set out a more general 
mathematical representation by introducing a new notation and 
writing the two equations shown below: 2.19 represents the 
formation constant expression introduced as 2.12 and 2.20 is 
equivalent to the mass balance relationships depicted as 2.14.
S . = 8 . TT Xk(l?(2.19)
J J
T. = X-. + Ej Sj.k(i,j.) (2.20)
The meaning of these generalized symbols is as follows.
S = complex species concentration 
X = free component concentration •
T = total component concentration '
8 = cumulative (overall) formation constant
i = component index
j = species index
k = stoichiometric coefficient matrix
The value of k is the number of times the ith component appears 
in the jth species. Thus, the large majority of the array’s 
elements will be zero. This important point is highlighted by the 
fact that even in a system of one metal ion and two ligands, the 
binary complex species are commonly five or ten times as numerous 
as ternary ones. The discrepancy is worsened as the number of
components in the system increases.
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The chief reason for rewriting program ECCLES was to 
reduce its core storage requirement. The original version was 
itself very economic in this respect: a considerably smaller 
three dimensional array had been used instead of the two 
dimensional l< matrix. A set of number pairs was thus stored for 
every complex species to specify both the stoichiometric 
coefficients and their corresponding component indices. The 
latter information is implied by the position of an element in 
the k matrix. In the three dimensional array only 5x2 elements 
were devoted to each complex species so for every component in 
the system over ten in number, one element was saved per complex 
species. For example, in the blood plasma model having 5000 
complexes from about 50 components, this meant an economy of • 
just less than 200K computer words. This is larger than the 
total memory capacity of many computers. However, the efficiency 
did not only encompass core storage. Large scale savings of 
computer time were also made because this enormous number of 
irrelevant entries no longer had to be processed. . .
However, this approach did not go as far as it might have 
done. Up to 40 per cent of the three dimensional array still 
remained unutilized. When it became necess.ary to further reduce 
the size of the program, this wastage was an obvious target.
It.is almost entirely eliminated in the new version of ECCLES 
by employing a one dimensional array rather than the three 
dimensional one. In this, the component indices are stored alone. 
When a component appears more than once in a complex species 
this is accommodated by storing the component index an appropriate 
number of times. Thus, except for the room at the end (which 
depends solely on the total size specified), the one dimensional
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array is fully utilized. Once again, this means a saving of 
both computer time and of storage requirements. This is in 
spite of some overheads which the additional '’bookkeeping” 
introduces.
One serious disadvantage of the new method of storing the 
information about stoichiometric coefficients is that it becomes 
impossible to treat negative coefficients for the hydrogen ion 
in the conventional manner. Clearly, one could indicate the 
reciprocal of a free component concentration, for example, by 
a negative value for the component index. However, this would 
introduce an unwarranted amount of extra processing at a time- 
critical stage in the iterative calculations. It was, therefore, 
decided that, on input, ECCLES should convert all complexes with 
negative hydrogen ion subscripts into the corresponding hydroxy 
species and make a suitable adjustment to the formation constant 
(see Section ,2.1.2). This is easily done amongst the multitude 
of input checking procedures which the program implements.
A slight inconvenience to the user is that these species are not 
converted back into their original form on output, mainly 
because the program is unaware of which hydroxy species should 
be so treated. Of course, this artefact also means that
hydroxide ion must be included in the input of free concentrations
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2.2.2 Iterative procedures for large equilibrium systems
Once a set of formation constants have been specified, 
the mass balance equations for the equilibrium system become 
uniquely defined. In other words,a set of n non-linear equations 
is obtained (by substituting equation 2.19 into equation 2.20) 
where n is the number of components whose total concentration is 
known and whose free concentration is to be determined. It is . 
not generally possible to solve these equations directly because 
of their non-linear nature. The answer lies in successively 
improving some initial estimates of each free component concen­
tration. Such an iterative approach must be based on a comparison 
between the real, known total concentrations and the corresponding 
calculated values that are produced by equations 2.19 and 2.20 from 
the current, best estimates. When agreement is reached, i.e. 
the difference between the real and calculated quantities becomes 
less than a predetermined tolerance, the iteration is said to 
have converged.
The key to all numerical techniques of this kind'lies ' 
in the method by which the estimates are varied towards the final 
solution. They clearly require well devised, formulae that will 
not only avoid divergence but also utilize'a minimum of compu­
tation. This is important because hundreds of iterations may 
be' required to obtain one set of equilibrium concentrations.
A titration involves tens or hundreds of such simulations and when
it comes to the determination of formation constants described in
Chapter 3, titrations often have to be processed hundreds if 
not thousands of times. So even in these days when the cost of
computer time is falling by an order of magnitude every five 
years, inefficiency at the level of the iterative formula can 
be expensive.
On the other hand, there tends to be a balance between 
the speed of these computational algorithms and their ability 
to converge under adverse conditions, i.e. their robustness.
When an iterative procedure fails a great deal of calculation 
can be wasted. Moreover, the computer program may then simply 
be unable to cope with the problem at hand. So it is unprofitable 
to sacrifice robustness for rapid convergence.
Another aspect which must be mentioned is that many 
numerical techniques for non-linear equations have been devised 
which utilize extremely large amounts of computer memory. For 
example, by calculating and storing values for derivatives and 
second derivatives at every point in a titration it is sometimes 
possible to greatly enhance the rate of convergence. Computer 
technology has reached the stage where machines with very large 
internal core storage and/or virtual memories are becoming .
commonplace so this is an acceptable trend. However, there are 
limits even to modern facilities which prevent this kind of 
approach being used with the very large simulations of metal- 
ligand equilibria in biofluids that are described in Chapter 4.
. It should also be said that most general methods for
solving non-linear equations run into convergence difficulties as 
the number of equations increases C216]. It is thus necessary 
to look for specific mathematical methods for treating the general 
chemical problem. One that comes readily to mind is called 
successive approximation. This is a somewhat ambiguous name for
it could equally well apply to other iterative methods. In 
its simplest form it means that the equation g(x) = 0 can be 
solved for x using a formula constructed by rearranging the 
equation into a form where x = f ( x ) . Thus, one obtains 
equation 2.21.
xn = f<xn-l) (2.21)
A reasonable guess, xq, is used to obtain an improved estimate, 
x^, and this is then substituted back into 2.21 to get an even 
better value, X£ [19453.
Not all rearrangements of g(x) = 0 will produce formulae 
x = f(x) that converge. In fact, it is necessary that the 
derivative of f(x) in the interval between the initial estimate . 
and the true value is always less than unity. The smaller the 
derivative is, the more efficient the formula becomes [19453. 
Successive approximation techniques are rarely selected for their 
speed, particularly if this is to be judged by the number of 
iterations required for convergence. However, they possess three 
main advantages: ’’robust" formulae can usually be constructed, 
they usually have relatively small store core requirements 
and they involve relatively little computation. for these 
reasons, they aremost valuable for simulating very large systems.
The original version of ECCLES used three iteration 
formulae. The main one was identical to that used by program 
COMICS and is shown as equation '2.22.
(2.22)
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Here, m is a specific value of i, the component index, and 
the superscripts n, o, r and c denote the 'new', ’old', ’real’ 
and ’calculated’ quantities respectively. Thus, the square 
root of the ratio of the known total concentration to its 
calculated counterpart is used to adjust the free component
concentration.
For the initial iterations (when the estimates are 
generally very poor) a more complicated formula was derived, 
as equation 2.23.
Oy 1?. y
m ’ m
------------------------------------------- (2.23)
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This is shown
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X
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The formula requires considerably more calculation than does
2.22 but it proved worthwhile in the opening stages.
• Interestingly, certain properties of equation 2.22 become
apparent from the behaviour of equation 2.23 as it approaches 
the solution. Under these circumstances, the value oF tendsW
to unity and thus the denominator in 2.23 approaches the total 
calculated concentration. This suggests that formula 2.24 will 
become increasingly efficient as it nears the solution and it 
was accordingly introduced into program ECCLES to be used 
alternatively with 2.22 after the first 25 iterations.
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n X m (2.24)
However, it was also shown that 2.24 could normally be 
expected to ’’overshoot" the solution, i.e. to convert an estimate 
that was too large into one that was too small or vice versa. 
Iteration procedures in which equation 2.24 was introduced 
prematurely could thus oscillate back and forth with very poor 
or even no convergence capability. On the other hand, it was 
noted that by rewriting equation 2.22 as equation 2.25, the 
denominator is the geometric mean between (which would
overshoot) and rTm (which leaves unaltered).
It was thus proposed that the tendency of 2.24 to overshoot 
and to oscillate was curbed in equation 2.22. - .
The three-tier algorithm used in program ECCLES as 
described above has proved very successful in a wide variety of 
metal-ligand equilibrium simulations. Convergence was often 
found to be remarkably rapid, particularly in the case of the 
blood plasma models when, typically, the solution was reached 
after fewer than 30 iterations. However, during a project to 
determine the formation constants of the zinc-cysteinate system 
under biological conditions of temperature and ionic strength 
(see Section 4.2.1) a serious weakness was uncovered. Divergence 
was found to occur whenever polynuclear complexes of the type
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^2^3 or predominated in the solution. Neither formula
2.22 nor formula 2.24 could cope under these circumstances.
The reason for these failures emerged only after some 
investigation. Ginsburg [825] had suggested that equations like
2.22 and 2.24 could be expressed in the more general form of 
equation 2.26.
(2.26)
He argued that the optimum value of p^ .in this expression was 
related in a complicated way to the stoichiometry of all the 
complexes in the equilibrium system. That this is likely to be 
so can easily be seen from the simple case where only one species 
predominates and only one free component concentration is 
unknown. Then one can write equation 2.27.
-v-.- k(i,j)
Tm = Sj iXi (2.27)
By cancelling all the known terms, one can obtain equation 2.28.
k (m, j )
(2.28)
m
Whence, an exact solution can be obtained as equation 2.29. 
Note the relationship between pm in 2.26 and k(m,j) in 2.29
X
oy I 2^1/k(m’J) 
Xm \ cy
m-
(2.29)-
Ginsburg's mathematical analysis proved intractable and
he was unable to derive the best value to use for p [825'] .1 m
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He arbitrarily suggested that pm = 5 would be satisfactory. '
When this proposal was tested with a view to incorporating it 
into the new version of ECCLES, however, it was found to yield 
an inordinately slow rate of convergence. This is to be 
expected from discussion surrounding equation 2.24. By taking 
the fifth root of the (rTm/CTm) fraction, the factor by which 
the free concentration, °^m, is adjusted is bound to be closer 
to unity than when the square root of the ratio is used. It 
is thus apparent that the larger the value of p^, the less 
likely the iteration is to diverge or oscillate but the more 
inefficient it becomes.
Consideration of equation 2.29 and the corresponding 
relationships for more complicated situations suggests that the 
optimum value for pm is close to the maximum value of k(m,j) 
over those complex species ‘which are the major contributors to 
the total calculated concentration,CT^. On these grounds, a 
revised iteration algorithm has been implemented in the new .
version of ECCLES. In particular, a fourth iteration formula 
(2.26) is gradually introduced if there is no convergence after 
30 iterations. In this event, the values p^ are set to the 
highest value of k(i,j) found for those species which account for 
more than 1?£ of the current calculated total concentration. This 
is necessary because it was found that putting p^ = max(k(i,j)) 
over all the species led to slow convergence.
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The earlier iteration formulae are retained because of 
their proven efficiency with most systems. The only significant 
change has been to revise the calculation of Gj in equation
2.23 to take account of the more robust formula 2.26. This is 
shown as equation 2.31.
(2.31)
Evaluated in this way, equation 2.23 acts as a slight convergence 
accelerator in the later stages of the iterative procedure. 
Accordingly, it is implemented every fifty cycles to perturb 
the approach to the solution.
In a large majorityof cases, these changes have caused 
a small decrease in the rate at which program ECCLES converges. 
This is more than compensated by the additional robustness of • 
the new four-tier algorithm.
CHARTER THREE
COMPUTER SIMULATION IN THE DETERMINATION
OF FORMATION CONSTANTS
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3.1 The role of simulation in optimisation procedures
Optimisation is the process of determining those 
conditions which yield a best possible result. In the context 
of me ta-l-ligand equilibria, this means finding the values of 
one or more constant coefficients in the mathematical relation­
ships which define the system such that an optimum agreement 
between calculated quantities and their observed counterparts 
is achieved.
Those coefficients which are invariant with respect to 
a given set of data but which may alter in value from one - 
experiment or one system to another are called parameters. They 
may be either ’'local” or "global" depending on whether they apply 
to part of the data set or to the whole of it. for example, in 
potentiometric studies, formation constants are said to be global 
parameters, whereas the initial concentrations and volumes of 
each titration are local ones. Parameters are to be contrasted 
with quantities that are systematically varied through the 
titration such as a free component concentration.
To recognise an optimum agreement, one requires a precise 
criterion to distinguish between different results. Formulated 
mathematically, such a criterion is called an 'objective•function 
E207] . Depending on the circumstances, its value may have to 
be either maximised or minimised. Often, the objective function 
will be based on the difference between observed and calculated 
quantities for, clearly, the smaller this is, the better the 
agreement. Each difference is known as a residual. These need
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to be minimised over the entire range of data, By calculating 
a sum of squared residuals one obtains an overall criterion that 
neglects the sign of individual contributions. This is by far 
the most popular kind of objective function and it is embodied 
in all of the computer programs for determining formation 
constants that are discussed in this thesis. Such optimisation 
methods are collectively.known as methods of ’least squares’.
So widespread is the use of ’least squares' that every 
chemist is aware of at least one optimisation technique. This 
is associated with the statistical method called linear regres­
sion analysis by which the value of one quantity can be estimated 
from another by finding the best straight line relationship 
between them. By making certain assumptions about the quantities 
themselves and the errors -involved in their measurement it is 
possible to determine not only the best values for the slope and 
intercept parameters but also their precision and the extent to 
which confidence in a linear relationship is experimentally 
justified. The ’least squares' optimisation can be done approxi­
mately by eye (using some graphical representation of the data) 
or by calculation. In the latter case, formulae are available 
which yield values for the best slope and intercept directly 
C19483. Accordingly, very many chemical experiments have been 
designed specifically to produce data which is amenable to linear 
analysis. More complicated relationships are tackled by hand 
occasionally but unless the problem can be reduced to a linear 
form it is all too often regarded as intractable. With the advent 
of modern high speed computers, such an attitude is no longer 
justifiable.
• • ..... •.................. .. . ......... - •: ,
A host of general numerical methods for locating the 
optimum in situations where one or more parameters are unknown 
have been developed C15,16,18,65,207,209,210,227,388,397,615 ,
1006,1769,1946] . A detailed discussion of their mathematical 
foundations or of their respective merits lies outside the 
scope of the present work. Suffice it to say that many employ 
iterative procedures which may also be applied to the solution of 
non-linear equations as discussed in Section 2.2,2. This 
overlap sometimes causes confusion between the calculations for 
optimisation and those for simulation. It may help to clarify 
the position if one remembers that a non-linear equation 
g(x) = 0 can be solved by varying the value of x in such a 
way that the absolute value of the function is minimised. Or) 
the other hand, simulations are commonly employed during 
optimisation procedures, especially when a simple mathematical 
expression for the relationship between two measurable quantities 
cannot easily be found. Instead, the relationship may be 
simulated by sequential application of a series of formulae 
until the values for all the variables in the system have been 
determined. Residuals can then be obtained by comparing the 
observed data with its corresponding calculated value. Hence, 
an objective function can be evaluated.
The role of simulation in optimisation procedures is 
depicted diagrammatically in Figure 3.1. This shows how a 
measured, independent variable can be used in a simulation to 
calculate an associated value for another variable quantity that
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Figure 3*1
The role of simulation in optimisation procedures.
Measured
independent
variable
e . g.
titre vol.
Calculated 
dependent 
variable 
e . g . em f
<
Observed 
dependent 
variable 
e . g. emf
=> Residuals
Objective
function
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can also be directly observed. To do this, the whole set of 
parameters is required so if, in fact, a parameter is being 
determined a current estimate of its value must be employed.
From the behaviour of the objective function when these estimates 
are changed, the direction of the optimum is ascertained by the 
numerical optimisation technique. The estimates are then varied 
accordingly. In other words, the optimising segment follows a 
trend which, on the basis of its previous experience, seems 
likely to further decrease the objective function value. The 
new parameter estimates are used to recalculate the dependent 
variable data and so the cycle is repeated. When every small 
variation in the parameter values causes the objective function 
to increase no more.changes can be made and the optimisation is 
said to have converged on the best possible result.
In principle, the algorithm described above can determine 
the values of all the parameters in a system whenever there are 
more data points than unknowns. However, this is rarely achieved 
in practice. The main reason arises out of a phenomenon known 
as correlation. This essentially means that variations in certain 
parameters have similar effects on the objective function.
So, error in one parameter can be compensated by error in another. 
Thus, the ability of the optimisation procedure to distinguish 
between correlated parameters is degraded. With perfect data 
(i.e. no experimental error) all the parameter values could be 
determined but as experimental noise in the data increases, the 
number of such parameters decreases. Systematic errors are
£o
considerably more detrimental in this respect than random ones. 
This is because regression analysis assumes that all errors 
are normally distributed. Not all parameters are equal in this 
context: some pairs will be more highly correlated than others
The implication for experimental design is that only one 
parameter from a significantly correlated set can be determined 
by an optimisation procedure. Unfortunately, there is no sharp 
dividing line to indicate when an ill-conditioned system has
been selected. This forms the crux of the discussion in
Section 3.3.
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3.2 Optimisation procedures for glass electrode calibration
The experimental determination of free hydrogen ion activity 
or concentration is perhaps the most frequently used of all 
analytical techniques. The convenience and suitability of 
glass electrodes for this purpose has promoted their application 
in a wide variety of contexts and this has consequently been 
responsible for a great deal of research into how they function. 
Nevertheless, accurate measurements using glass electrodes 
remain more elusive than is commonly supposed. Problems con­
cerning the way in which the electrode system should be calibrated 
are probably the most worrying cause. They are crucial to the 
vast majority of potentiometric determinations of metal-ligand 
formation constants.- Accordingly, they will be considered here 
only in the context of titrations in which strong alkali is 
introduced into solutions held at constant temperature and .
ionic strength.
Consider an electromotive cell in which a test solution
surrounding a glass electrode is in electrical contact with a * 
reference electrode via a salt bridge. It could be represented
as follows:
first reference 
half-cell
(in glass electrode)
test solution
second reference 
haIf-cell
(external)
19
The boundaries, g and 1, respectively, indicate the glass 
membrane and the liquid junction at the interface between the 
salt bridge and the test solution. There are four contributions 
to the measurable potential difference between the two reference
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electrodes C3051. Two arise from the reference electrodes 
themselves, They will have opposite signs and will usually 
be of comparable magnitudes. Most importantly, their contri­
bution will be independent of the composition of the test 
solution and so may be represented as a fixed, combined ■' 
potential, E . On the other hand, the potential differences 
generated across the boundaries of g and 1 will depend heavily 
on the activities of all the chemical species on either side 
of them. Such potentials arise from the disparate rates at 
which ions are transferred across a boundary or, in the case of
the glass membrane, appear to be so transferred. Letting E 
• y
and Erepresent these boundary potentials, the measured e.m.f. 
of the cell is thus given by equation 3.1.
Ecell = Er + E1 + Eg <3-X)
In practice, it is found that the free hydrogen ion
concentration is by far the most important component determining 
the values of E and En. This is because the glass electrode . 
behaves as a selective cation exchanger for hydrogen ions C1942] 
and because the mobility of both hydrogen ions and hydroxide 
ions is so much greater than that of other species [1939]. In 
the case of the liquid junction, considerable changes in the 
composition of the test solution are required to significantly 
alter E, . So, for the time being, this will be considered as 
constant. Quite the reverse is true of the glass membrane. It 
is very sensitive to changes in hydrogen ion activity and indeed 
most glass electrodes are found experimentally to exhibit a 
Nernstian response over a wide range of concentration £19743.
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Accordingly, equation 3.1 can be re-written as equation 3.2.
^cell E + E, + E° “ In {H4} r 1 g T F • (3.2)
E° is the standard glass electrode potential at unit activity 
of hydrogen ions, R is the universal gas constant, T is the 
absolute temperature and F is the Faraday.
As long as the ionic strength of the test solution remains 
constant, the free hydrogen ion activity, {H}, can be expressed in 
terms of concentration. Hence, one obtains equation 3.3 by 
collecting together all the constants as ^cons|- and putting 
s = 2.303RT/F.
Ecell = Econst + 3 lo^H+]
The above treatment specifically avoids referring to pH. 
Nowadays this quantity is defined by IUPAC as an empirical 
function of the difference in e.m.f values of the electrode
between the test solution and one of a set of buffers prepared 
according to standard procecures CI458,1459,1479,1796,1947].
The obvious disadvantage with this approach is that it removes 
any direct relationship between pH as the experimental quantity 
and the actual free hydrogen ion concentration. By carefully 
selecting the buffer solutions which are prescribed as standards, 
significant discrepancies between pH and the activity of the 
hydrogen ion have been avoided. Nevertheless, three fundamental 
weaknesses exist.
1) In specifying the pH of a standard buffer, exact account 
must be taken of the effect of the various solute species on the
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activity of the hydrogen ion'and the degree of dissociation
of the buffering species must be precisely knou/n.
2) Even when the first point can be neglected, the pH of the
test solution does not correspond to the hydrogen ion activity 
because neither the liquid junction potential, nor the 
activity coefficients will be the same in the test solution 
as in the buffer.
5) For practical purposes, when one wishes to know the free
hydrogen ion concentration rather than its activity, an extended 
Debye-Hficke 1 type correction must still be applied to measure­
ments of pH made in the test solution. .
Quantitatively, points 2 and 5 are the most significant and
so a surfeit of methods have been developed to correct for them 
[62,291,292,324,361,450,1514,1796,1947,1974]. However, even these 
are obliged to assume that the activity of hydrogen ion in the 
buffer solution is given by 10 . With the increasing precision
of modern glass electrodes and potentiometers, this is no longer 
satisfactory [Jameson , R . F .• - personal communication].. Indeed, 
inconsistencies between different buffers would appear were they 
not defined in such a way that their pH values are adjusted to 
conform with a single, primary standard. . '
These .reservations concerning the use of buffers to calibrate 
glass electrodes are exacerbated when high concentrations of 
background electrolyte are used to maintain a constant ionic 
strength in the test solutions. Thus, researchers who employ 
potentiometric methods to measure formation constants have long
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used solutions of known hydrogen ion concentration instead [5673. 
This is often done by titrating strong acid solutions with 
strong alkali and plotting thee.m.f. at each point against
, I,
the corresponding values of log[H 3. The procedure should 
yield a straight line from which the intercept, Econsj-> in 
equation 5.5 can be obtained by extrapolation to log[H+3 - 0.
There are several reasons why an ideal response is not 
observed in practice. Chiefly, one finds that unless there 
is a sufficient excess of acid or alkali to ensure that the 
solution is concentration buffered, small errors become very 
significant. It has, for example, been shown that the presence 
of glass itself causes a large deviation [5953, a fact that can 
probably be attributed to hydrogen ion adsorption onto the glass, 
surface. Another important factor is the imperfect behaviour 
of glass electrodes in alkaline solution: many of the types 
of glass used for electrode manufacture become increasingly 
sensitive to metal ions, especially sodium ions, above 
-Iog[H+3 = 11.0 [6553. The effect of hydrogen ion concentrations 
on liquid junction potentials has already been mentioned.
Accordingly, there is a restricted range of free hydrogen 
ion concentration over which strong acid strong base
titration data is suitable for calibration purposes. The 
most linear response occurs between- ~log[Hh3 values of 2.5 and 
2.9 [5953. Data collected inside these limits with most research 
equipment can yield £const to a precision of about 0.1 mV [19743.
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This sort of precision is more than adequate for the 
determination of formation constants for biological systems.
What is less satisfactory, however, is that the critical 
measurements with most systems lie outside the calibration range. 
So hydrogen ion concentrations must be procured by extrapolation. 
Also, it is well known that the standard potential of the glass 
membrane varies from day to day (due to assymmetry effects) 
and that ^cons^ may be affected by other changes (particularly 
if the liquid junction is not perfectly reproduced). These can 
be significant even from one experiment to another C6553.
Thus, internal calibrations of the electrode, performed in the
test solution itself, are highly desirable, .
In principle, there are two main ways of achieving this 
goal. The first applies to solutions in which the introduction 
of strong acid is totally reflected as an increased free hydrogen 
ion concentration. It is then possible to calibrate by a series 
of constant additions. However, this cannot be done with weak 
acid or weak base solutions. Instead, one can calculate the 
free hydrogen ion at various points from the protonation constants 
provided these are accurately known. Very precise calibrations 
can be made in this way but they are of limited use. -Indeed, 
the object of many titrations is to measure the protonation 
constants. In these cases a number of parameters, namely,
^const aRd one or more equilibrium constants, must be determined 
simultaneously. Straightforward solutions are available only 
very rarely so general optimisation techniques must be employed.
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3.2.1 Multiple analysis of titration data ’ . .
The first extensive application of numerical methods 
to the treatment of titration data was published by Si lien 
and co-workers nearly two decades ago [15,16,18,44,45,46,47,3973. 
Since then, a large number of computer programs have been 
developed to refine formation constants. Some of these are 
discussed in Section 3.3 but here attention should be focused 
on the optimisation of other parameters, especially in the 
context of glass electrode calibration. .
Sill'en realised that the data collected during an average 
titration contained a great deal more information than was 
traditionally utilized. For example, small adjustments to the 
initial concentrations of components could significantly reduce 
the sum of squares objective function and so, conversely, this 
criterion could be used to improve the concentration values. 
Surprisingly, the idea does not seem to have been widely 
adopted, possibly because of the dangers discussed in the 
next section which are always inherent in optimisation procedures. 
Nevertheless, it seemed a potentially rewarding way to approach 
the problems of glass electrode calibration.
A computer program called MAGEC (for Multiple Analysis 
of titration data for .Glass .Electrode Calibration) was accord­
ingly developed. The overall aim was to process data from any 
titration involving acids or bases by a variety of methods so 
as to maximize the information which could be obtained from it.
Whilst the chief object was to evaluate the intercept in 
equation 3,3, it was also required that the value of any other
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parameter of the system could be examined simultaneously and 
that the effect of errors in any estimated quantity could be 
determined. The FORTRAN listing for program MAGEC is supplied 
as Appendix A4. The preparation of input data is dealt with 
in Section 3.3 and in Appendix A5. .
3.2.1.1 Analysis of strong acid versus strong base titrations. ’
MAGEC first analyses strong acid versus strong base 
titrations by the method of Gran [1613, 1614, 1770, 1771, 1780, 
1781, 1782, 1783, 17843. By transforming the potentiometric 
data into a linear form, this gives a good indication of glass 
electrode performance and also yields an endpoint that is • .
independent of the slope and intercept used in Equation 3.3. 
Furthermore, if extrapolation of the data from before the end­
point produces a value significantly lower than that obtained 
from data after the endpoint, it suggests that an alkaline titrant 
may have become contaminated with carbon dioxide from the 
atmosphere [17703. The endpoint obtained from the Gran extra­
polations provides an independent check of the MAGEC optimisa­
tion of the strong acid concentration referred to below.
Further processing of strong acid versus strong base 
titrations is divided into three stages. To begin with the input 
concentrations are used to calculate free hydrogen ion concen­
trations at each point and a linear least squares fit is performed
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on the data before and after the endpoint and over the entire 
range. This first analysis is used mainly for comparison with 
subsequent output. Due to relatively small errors in the 
concentrations of titrant and titrand, the least squares straight 
line does not normally possess a Nernstian slope. So the con­
centration of the titrand is varied slightly until the slope 
from the data before the endpoint coincides with the theoretical 
value. This optimisation yields an endpoint which has proved 
invariably to lie within the limits which can be determined 
from the Gran plot. If anything, the precision is somewhat better.
It is then possible to adjust the titrant concentration 
in a similar manner to that described above but on the basis of 
the whole range of data. Of course, to maintain the same end­
point, a corresponding change in the titrand concentration also 
needs to be made. In this way, very close agreements between the 
calculated and observed, values for the e.m.f. at each point can 
be achieved. In acid solutions, there are .often no residuals 
greater than the 0.1 mV which corresponds td the precision of 
many digital read-out research potentiometers.
The power of this analysis warrants some caution. Two 
factors critically affect the refinement of the titrant concen­
trations in the final stage. The first is the value of the 
dissociation constant of water. This parameter is very highly 
correlated with the concentration of alkali in the burette,
i.e. a small error in its value will cause a significant deviation
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in the apparent slope of the electrode response because it is 
used to convert hydroxide ion excess into .free hydrogen ion 
concentrations and so it manifests itself in the optimised alkali 
concentration. Another way of looking at this is that either 
the titrant concentration or the dissociation constant (but 
notboth) can be determined by finding the value which yields a 
most ideal least squares slope. To accommodate those situations* 
in which the dissociation constant of water is uncertain, MAGEC 
permits the user to vary the estimate systematically.
The second factor is fundamentally harder to overcome - 
than the first. It is that glass electrodes in alkaline solutions 
tend to give less than an ideal response. There is thus a limit 
to the precision with which titrant concentrations can be
determined by MAGEC; in practice, it is rather poorer than the 
accuracy with which the solutions can be prepared. This, in 
turn, suggests that it would be unwise at present to rely on a 
dissociation constant of water determined by potentiometric 
titration using glass electrodes. So the main value in analysing 
the alkaline data lies in the estimation of the errors which it 
affords and in the investigation of ways to improve the situation. 
For example, it is possible that a considerably improved optimi­
sation procedure would be possible if the effect of sodium ion 
in these alkaline solutions was taken into account.
One valuable attribute of program MAGEC that was not fully 
appreciated until after the program had been developed, concerns 
the deterioration which all glass electrodes eventually undergo.
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Lifetimes differ considerably and it is often difficult to
detect the first signs of a failing performance. The MAGEC
analysis of strong acid versus strong base titrations has proved 
very revealing in this regard: sudden and marked increases in' 
the residuals occur just prior to the electrode’s demise.
Moreover, the development of discrepancies between the endpoint 
determined by MAGEC on the basis of a Nernstian response and that 
found by the Gran plot suggests that the electrode is no longer 
functioning ideally. •
The usual procedure for analysing strong acid versus strong 
base titrations using program MAGEC is depicted in Figure 3.1.
A typical result .is shown in Example 3.1.
3.2.1.2 Analysis of titrations involving weak acids or bases.
In the case of weak liionoprotic acids and bases, MAGEC 
utilizes a number of approximation formulae' f84,213] to solve 
for the free hydrogen ion concentration at each point i’n the -
titration. Analysis of the data can then follow a similar approach 
to that described above for strong acid and strong bases.
On the whole, however, this is not very satisfactory because
it is much more difficult to know when the solution can be
considered reasonably well buffered. A very sophisticated function 
for weighting the data is required to prevent unbuffered points 
from swamping the objective function and making it insensitive to 
an improved fit between calculated and observed points in the
more important areas of the titration. •
* ~
For example, the Henderson-Hasselbalch equation:
L" s a 11 ]
- log EH+] = - log K 4- log-----------
Lacid]
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FIGURE 3,1 USE OF PROGRAM MAGEC
Flow diagram of the usual procedure with
strong acid versus strong base titrations
Symbols
APKW
ACIDV
- apparent dissociation constant of water 
titrand acid concentration (negative for alkali)
ACIDB = titrant acid concentration (negative for alkali)
EZERO = electrode intercept
SLOPE = electrode slope .
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EXAMPLE 3.1 USE OF PROGRAM MAGEC
Calibration of the glass electrode by strong acid versus
strong base titration
A solution of hydrochloric acid (10.00 cm , ca,. 50.00 mmol 
dm“3) ancj sodium chloride (20.00 cm^ , 212.0 mmol dm“^) was 
titrated with sodium hydroxide (100.0 mmol dm~3) and sodium chloride 
(100.0 mmol dm“^) solution. The sodium chloride was used to 
maintain the ionic strength (ca. 150- mmol dm~3) as constant as 
possible. The titrated solution was thermos tatted at 37.0 + 0.1°C.
A Gran plot analysis for MAGEC gave endpoints of 
4.977 + 0.002 and 4.97 + 0.03 crn^ for the acid and alkaline data 
respectively. The MAGEC optimisation analysis is summarised in 
the following table. , .
Before MAGEC 
optimisation
After optimisation 
of the acid concen­
tration
Using only the data before 
the endpoint (47 points) .
(i) electrode intercept 362.4 + 0.15 5 60.7 + 0.04
(ii) electrode slope 62.48+ 0.07 61.53+ 0.02
(iii) standard deviation 1.4 x I o-i 4.1 x 10“2
(iv) number of residuals •
greater than 0.1 mV 26 0
Using all the buffered data (63 points)
(i) electrode intercept 360.4 + 0.10 360.6 + 0. 05
(ii) electrode slope 61.53+ 0.02 61.50+ 0. 01
(iii) standard deviation 5.0 x 10 2.6 x 10 -1
(iv) number of residuals 
greater than 0.1 mV 41 15
Note: .
(i) The optimised initial acid concentration of 16.59 mmol dm"^
■ -3compares with an expected value of 16.67 mmol dm and 
yields an endpoint of 4.978 cm?
(ii) A slope of 61.50 mV corresponds to pKw = 13,310.
In practice, the calculation could be repeated using 
pK^ = 13.305 to obtain a better agreement with the 
Nernstian value (61.54). .
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Some time was spent looking for a good weighting 
procedure but this was met with no success. The motivation 
for this came from a statement by Sillen which implied that 
titre volumes should be used as the independent variable in this 
sort of optimisation procedure fl6j: free hydrogen ion concen­
trations should be calculated from titre volumes and thence
converted into values of e.m.f. In spite of this, all the opti­
misation programs in this field work the other way around, taking 
e.m.f. as the independent variable and calculating titre volumes. 
Presumably the reasons are that this is mathematically simpler 
and automatically weights the data in favour of the most buffered 
points. (In unbuffered regions, .errors in the e.m.f. values will 
have very small effects on the titre volume that is calculated.)
Accordingly, the main analysis applied by MAGEC to all 
titrations involving ligands is one of general optimisation of 
parameter values by minimising an objective function based on 
titre volumes. Any parameter can be flagged for refine-ment so 
specific procedure is left largely in the hands of the user. 
Usually, the requirement is to find the value for £cons£ in each 
of a series of titrations with the ultimate objective of deter­
mining the protonation constants of a ligand. Experience has 
shown that the best way to do this is in conjunction with another 
program that optimises protonation constants over the whole set 
of titrations (see Section 3.3). • MAGEC deals with only one 
titration at a time so no distinction is made between local and 
global parameters. Hence, it is first used to estimate E
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and the protonation constants applicable to each titration.
The constants so obtained will differ from one titration . 
to another due to experimental error so they are averaged before 
being fed (together with the various values of E nrto4.) into the 
second program for global refinement. A cycle is thus initiated 
in which improved estimates of the protonation constants are held 
invariant by MAGEC to obtain new values of E , and these are 
used in the other program to further optimise the protonation 
constants. Only one or two such iterations are usually required 
before convergence is reached. Substantially enhanced agreement 
between observed and calculated data can thus be achieved.
The above procedure is depicted diagrammatically in 
Figure 3.2. A typical result of using program MAGEC to optimise 
the electrode intercept in titrations involving ligands is shown 
in Example 3.2.
Alternatively, MAGEC may be used to check or adjust the 
concentrations of titrand or titrant.If the protonation constants' 
are known this offers a very precise analytical tool. On the •
other hand, it is sometimes possible to refine concentrations as 
well as the protonation constants and ^conoj.’ Provided the 
dangers of correlation referred to in Section 3.1 are carefully 
avoided, the program therefore offers a very effective way of 
dealing with the many ligands which have not previously been 
studied under biological conditions of temperature and ionic strength
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FIGURE 3.2 USE OF PROGRAM MAGEC
Flow diagram of the usual procedure with
Symbols
LBETA
APKW
ACIDV
ACIDB
LIG1V
EZERO
SLOPE
ligand protonation constants
apparent dissociation constant of water
titrand acid concentration (negative for alkali) 
titrant acid concentration (negative for alkali) 
ligand concentration in vessel
electrode intercept
electrode slope
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EXAMPLE 3.2 USE OF PROGRAM MAOEC
Internal calibration of the glass electrode in- titrations of .
ligand solutions
A solution of glycine (20.00 cm\ 10.12 mmol dm"^) in hydrochloric 
acid (9.936 mmol dm~^) was titrated with sodium hydroxide solution 
(100.0 mmol dm“3). A background concentration of chloride ions 
(150.0 mmol dm-^) was maintained and the solution was thermos tatted 
at 37.0 + 0.1 °C. The assumed equilibrium constants were the ionic 
product for water (pK^ = 13.310) and the acid dissociation constants 
for glycine (pKal = 2.334 and pl<a2 = 9.250). The electrode slope 
was considered to be Nernstian. The initial electrode intercept 
of 360.0 mV was refined to 363.8 mV in 7 iterations, improving the 
sum of squared residuals from 1.18 x 10-1 to 1.65 x 10-3. The random 
distribution of the final residuals in the following table is 
noteworthy. .
titre
volume (cm^)
observed 
emf (mV)
initial
residuals (cm^)
final
residuals (cm^)
0.00 220.95 -0.176 0.003
0.10 219.10 -0.173 -0.001
0.20 217.10 -0.167 -0.002
0.30 214.95 -0.159 -0.001 -
0.40 212.70 -0.150 0.001
0.50 210.30 -0.140 0.004
0.60 207.90 .. -0.135 0.002 •
0.70 205.30 -0.127 0.002
0.80 202.50 -0.118 0.003 ‘ •
0.90 199.60 -0.112 0.002
1.00 196.50 -0.106 -0.001
1.10 193.00 -0.096 0.001
1.20 189.15 -0.008 0.003
1.30 184.90 -0.075 • 0.004
1.40 180.20 -0.067 0.003
1.50 174.00 -0.046 0.013 •
1.60 168.00 -0.034 0.003
1.70 159.60 -0.022 . 0,004
1.80 148.00 -0.003 ' 0.004
1.90 129.00 -0.015 •0.002
2.00 44.00 -0.022 -0.003
2.10 -124.60 -0.028 -0.004
2.20 -145.80 -0.034 0.000
2.30 -158.50 -0.038 • 0.007
2.50 -167.95 -0.045 0.011
2.50 -175.75 -0.051 0.011- .
2.60 -182.25 -0.057 0.009
2.70 ' -188.10 -0.061 0.011
2.80 -193.70 -0.063 0.011
2.90 -198.95 -0.065 0.009
3.00 -203.95 -0.067 0.009
3.10 -208.95 -0.067 0.007
3.20 -213.90 -0.068 0.003
3.30 .-218.85 -0.068 -0.001
3.50 -229.45 -0.068 -0.006
■ 3.60 -235.00 > -0.066 • -0.008
3.70 -241.10 -0.066 -0.011
3.80 -247.50 -0.064 -0.012
3.90 -254.40 -0.064 -0.012
4.00 -261.55 -0.064 -0.012
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The numerical method used by MAGEC was first published by 
Nelder and Mead [3883 under the title ”A simplex method for 
function minimisation1'. It was chosen for tu/o main reasons 
1) The objective function is coded in FORTRAN by the user as 
an external subroutine to the optimisation program. It is, 
therefore, very easy to modify the mathematical relationships 
being investigated. 2) The optimisation routine is set up such.’ 
that the number and type of parameters being refined do not 
affect its structure in any u/ay. So these can also be changed 
very readily. These advantages as well as the apparent robustness 
of the method, heavily outweigh the fact that simplex methods 
are not amongst the most efficient algorithms available nowadays.
Whilst work on MAGEC was in progress, another program with 
similar objectives appeared in the literature [1800]. Like 
MAGEC, this permits the optimisation of any or all titration 
parameters. However, it does not offer the other facilities 
simultaneously. Thus, the two programs partially overlap and 
partially complement one another.
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3.3 Model selection
Experiment is the interpreter of nature. 
Experiments never deceive. It is our 
judgement which sometimes deceives itself 
because it expects results which experiment
refuses.
Leonardo da Vinci 
1452-1519
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In one of the earliest reviews dealing with the 
measurement of formation constants in electrolyte solu-tions,
Young and Jones commented that "we shall be fortunate if many 
more than half the values determined by methods such as these 
should eventually prove to be significant. Doubtless many 
complexes reported will be found not to exist in appreciable 
amounts and numerous others not reported will be' shown to be 
important" C19863 . It is perhaps too soon to say whether their, 
view was quantitatively pessimistic but it has proved completely 
justified in all other respects. The reason is not to be found 
in the experimental methods that have .been employed but rather 
in the way the collected data has been evaluated [3673. Before 
the advent of generalised computer programs, researchers were forced 
to make simplifying•assumptions about the equilibrium system 
that were not valid in many cases; since then, the position 
has been reversed and a multitude of spurious complex species 
have been diagnosed as a direct consequence of too much 
computational freedom.
The essential difficulty lies in model selection'.
Strictly a model is comprised of all the mathematical relation­
ships required to describe an equilibrium system, including 
the parameter values. However, as everything else is usually 
well-defined/ the term is often' used less rigorously to mean 
the set of complexes present. Thus, the problem can be restated 
as the need to select those species which exist in the
experimental solutions. Their identity is not generally known • 
in advance and neither is it easily determined from the data.
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Optimisation procedures inherently require that a 
model be specified a priori. It is used by the numerical 
technique to repeatedly simulate the experimental system .
using various sets of parameter estimates. In this u/ay, the 
best fit between calculated and observed data is obtained.
The important point is that for each model which might be chosen, 
Lhe optimisation of a parameter such .as a formation constant 
will converge on a different value. Naturally, the effect 
exerted by the parameter in question depends on its mathematical 
environment and this, in turn, is subject to the model. So 
unless the correct model is chosen, optimisation can be expected 
to yield incorrect values.
There are two complementary reasons why the correct 
model cannot automatically be selected by a numerical technique. 
Firstly, the correlation which can occur between different 
parameters (as discussed in Section 3.1) permits error in 
one parameter to compensate for error in another. Thu-s, multiple 
solutions may be found with similar values for the minimised 
objective function. Secondly, the effect of an incorrect model 
on the optimisation is ’identical to a systematic experimental 
error (vide infra) so whenever the errors in the data are not 
perfectly random and normally distributed, the uniqueness of the 
correct model is lost.
This has profound practical consequences for those who 
use computer optimisation methods for determining formation 
constants. With incorrect and sometimes even palpably unrealistic 
models one can obtain apparently satisfactory solutions. A 
common pitfall is to assume that the best model generates the
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lowest sum of squared residuals. This is fatal when the
models being compared differ in the number of parameters ■ 
being refined. (The greater the number of degrees of freedom 
enjoyed by the optimisation procedure, the better the fit 
it should find.) Conversely, good agreement can be achieved ' 
without including all the complex species in the model that 
actually exist in solution. This usually implies that inadequate 
information has been obtained experimentally. In such 
situations, apparent success-is even more readily forthcoming 
when an incorrect species with a similar effect on the objective 
function to the real one has been substituted in the model.
What can be done about these hazards? Certainly, wider 
recognition that there is no clearcut or guaranteed method for 
deciding on the most appropriate model would, in itself, reduce 
the number of erroneous formation constants appearing in the
literature. Greater frankness about those circumstances when
a scientific distinction between two or more models cannot be 
made would be encouraged. Thus, there would be fewer arbitrary - 
or prejudicial choices for the sake of simplifying results.
The words of Leonardo da Vinci cited at the beginning of this 
section might even prompt some investigators into clarifying 
the position by further experiment!
To the extent that there are no hard and fast rules 
about model selection, it may be regarded as the art of 
optimisation. This does not mean there are no guidelines or 
objective criteria, however. On the contrary, there are many.
The difficulty is to decide on their respective importance.
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Quantitatively, there are a number of statistical yard­
sticks u/hich are usually very helpful. When these are used, 
model selection becomes synonymous with statistical hypothesis 
testing. The merits of particular models are assessed by the 
overall standard deviation in titre, the standard deviations 
of the formation constants themselves and other quantities such 
as the "crystallographic R factor". These criteria could be 
relied upon exclusively, provided the differences between models 
remained statistically meaningful. Strictly, this requires that 
the experimental error is random, normally-distributed and 
wholly localised in the dependent variable. Moreover, the' 
residuals must all be weighted according to the inherent accuracy 
of the experimental measurement [16,18], Linder these conditions, 
Vacca has said "the.whole of the computer and graphical deter­
minations of stability constants should be rejected as statistical 
unsound" [1954]. The implication is that models should not be 
eliminated on statistical grounds alone unless they are very 
markedly inferior. On the other hand, the statistical criteria 
by themselves can never provide assurance that a particular model 
is the correct one. They can thus be used in a preliminary 
analysis to reject the'most unlikely possibilities but the 
final choice must almost invariably be made by other means.
In cases where there is little to choose between different 
models statistically, it becomes important to consider the 
degree to which trends in the calculated and observed data 
correspond [1652]. This is chiefly because an incorrect model
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corresponds to a systematic error so random distributions
of residuals mean an increased likelihood that a good model . 
is being used. However, there is another important factor.
The degree and nature of the correlation between parameters 
depends on the objective function used, i.e. on the way the 
calculated data is obtained and which variable is used to make 
the comparison. The different effects of choosing e.m.f. or 
titre volume as the independent variable were mentioned in 
Section 3.2.1. It is reasonable to assume that the correct 
model will duplicate observed trends most faithfully, no matter 
which way the data is processed or which objective function is 
employed. Graphical representation of the data facilitates 
this kind of evaluation and often makes it possible to distinguish 
between two or more models which are not statistically different.
There are also a variety of indicators which argue 
against models by casting doubt on a complex species they contain. 
Generally, artefacts of the optimisation procedure ,tend to be 
very sensitive to changes in the computati-onal environment.
Thus, species associated with formation constants having high 
standard deviations should always be treated with caution.
Large variations in the formation constant value obtained when 
other species are included or removed from the model are a 
similar manifestation of uncertainty and should be viewed likewise. 
In a parallel vein, it is important to check that all postulated 
species exist in significant concentration over a reasonable 
range of the data. Otherwise, the species is, at best, close 
to the limit o‘f detectability. Under these circumstances, it
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looks as though it should be included in the model only because 
it increases the number of degrees of freedom available to the 
optimisation process. It is thus wise to exclude it from the 
analysis even if it definitely does exist in solution.
It should be evident that reliable model selection requires 
a great' deal of computation. It is advisable to employ more than 
one optimisation program-and it is essential to have a variety of 
simulation procedures at one’s disposal.. Data preparation for 
many programs can, however, be very wasteful of both human time 
and computer resources. Input needs to be punched in the particular 
format for each program although their data requirements are often 
similar if not identical. Accordingly, a computer program called 
FORMAT has been written to eliminate much of this tedium. It
accepts data prepared in a standard way and writes it to an
intermediate computer file in a manner specified by the user.
The programs for which, data can be so transformed are MINIQUAD 
[3303 , MINIQUAD 76A [7763, SCOGS [1133, PSEUDOPLOT [3173 , ZPLOT, 
COMICS [111], ECCLES, and MAGEC. A major feature of the program 
is that it performs a variety of preliminary checks on the data. 
Unlike the programs for which the data is being prepared, it 
attempts to continue processing even after input errors have been 
detected. In this way, all the obvious problems are diagnosed 
in a single execution of the program. By contrast, mistakes in 
a data deck are traditionally detected one at a time because 
each error causes program termination. Therefore, there need to 
be as many computer runs as there are errors before the program 
can execute successfully. The instructions for using program 
FORMAT and the FORTRAN listing appear in Appendix A5.
CHAPTER FOUR
COMPUTER SIMULATION OF BIOINORGANIC SYSTEMS
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4 .* 1 Transition metal ions in biological systems
The transition metals normally account for less than 
10 g of a 70 kg person [294,534]. At first sight, 0.01 per cent 
may seem a paltry amount for which the term ’’trace elements” 
is indeed justified. This lack of abundance, however, belies 
their biological significance. They are amongst about 30 elements 
deprived of which, sooner or later, all mammals perish [95,1610]. 
In this respect, of the 30, none can be ranked least important!
With the exception of molybdenum, the essential transition
elements are restricted to the first of their three rows in
the periodic table. These metals have been favoured by natural 
selection because they are relatively abundant and, for the most 
part, bioavailable [2,72,301], Two special chemical features*, 
in particular, have been exploited by evolution. The first is 
their capacity to bond with a characteristic stereochemistry to 
electron donors such as oxygen, nitrogen and sulphur atoms.
The second is their facile participation in electron transfer 
reactions. These properties suit cyclic biological processes and 
have thus led to the incorporation of transition elements in 
one third of all known enzymes [73]. .
Without exaggeration, it can be said' that the crux of life 
lies in the ability of enzymes to perform and regulate the host . 
of -necessary reactions under amazingly mild conditions of
temperature and pressure. This is achieved by utilising the 
three-dimensional structure of proteins to create sites within •
. the enzyme that can become thermodynamically very reactive [73] . 
Enzymes in such a state are said to be entatic [649,913]. Metal 
ions help to invoke this condition in two main ways. By bonding
'll
to certain groups on the protein they may force it to adopt
a particular configuration. More directly, they are often
located at the active site where they become endowed with
unusual properties due to the number and heterogeneity of nearby 
donor atoms and to the changes which can be imposed on the 
hydrophilicity of their environment. These factors may jointly 
generate atypical bond lengths, distorted geometries and odd 
coordination numbers which make the intermediate activated 
complex very amenable to chemical change [545,6093.
Herein lies the reason why such small amounts of the ' 
transition metal ions in biological systems are sufficient. Their 
function is catalytic [170,563,544,574,911,1291]. The ubiquitous 
metalloproteins are involved in bioenergetics (reversibly
transporting both oxygen and electrons) and in cellular bio­
synthesis and degradation of many substances including carbohydrates 
lipids, proteins and nucleic acids. A large part of bio­
inorganic chemistry is devoted to the study of these molecules 
but so far computers have rarely, if ever,’ impinged on these 
investigations. This chapter is mainly devoted to questions 
about how transition metal ions are assimilated or eliminated by 
biological systems and how they are manipulated in vivo prior to 
metalloprotein synthesis. In this area computer models of low- 
molecular-weight complexing equilibria have made a substantial 
contribution to bioinorganic chemistry.
Investigators have gone to considerable lengths to establish 
which elements are essential [293,301,371,529,610,819,835,978, •
1650,1840]. This is usually done by rigorously excluding the 
element in question from the diet and environment of the
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experimental animal, usually a rat. Special cages must be built, 
the air cleaned and the food synthesised from the purest chemicals 
to ensure that the very lowest levels of contamination are
achieved. Sometimes it is even necessary to extend the
experiment over two generations because the requirement is so 
meagre that residual amounts in any normally born-and-bred animal 
are sufficient for good.health. Essentiality is demonstrated 
when the deteriorating condition of the subject is reversed 
solely by the addition of the element to its diet.
On the other hand, it is well known that many heavy metals 
are toxic [229,343,43 0,855,1478,153 9,1703,1755,1756,1757,1760,1818, 
1831,1881,1887,1891]. The current concern with pollution has 
focussed attention on elements such as cadmium, lead and mercury 
which can have serious and permanent ecological effects when 
they are disposed in industrial effluents. Emotions are even 
more strongly aroused by radioactive heavy metal pollutants such 
as plutonium. The poisonous nature of these metals is. to a 
large extent connected with the biological role of the essential 
transition elements. With their many and. powerful metal binding 
sites, enzymes tend to be readily inactivated by co-ordination 
to unnatural ions.[170,363,544,574,911,1291]. Moreover, the 
multitude of donor groups that are an inherent part of proteins 
provide all biological systems with an aptitude for progressive 
accumulation of heavy metals from their surroundings.
Although most first row transition metals are rigidly 
maintained in homeostatic balance, even the essential ones are 
toxic at high concentration so there is still the danger of
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excessive assimilation. There is thus a critical balance between
too much of each trace element and too little.- This fact
underlies almost all applications of bioinorganic chemistry 
to medicine. It is well illustrated in Figure 4.1 which shows 
the effect of various amounts of copper in the soil on the 
growth of oat seedlings - a marked optimum is exhibited below 
which malformation of the plants occurs because of an insufficient 
supply and above which they become increasingly poisoned.
Whilst it does not involve a transition element, another striking 
example of this phenomenon is provided by arsenic. It has been 
proved recently that this traditional remedy for aggravating 
spouses is also an essential nutrientl [1650]
Certain medical implications of the aforegoing are obvious. 
Ways must be found to eliminate specific elements in those 
suffering from trace metal overload. Conversely, effective 
(but not excessive) supplementation regimens must be made 
available to those with trace element deficiencies. The health 
of many people could thus be radically improved. It has been 
said, for example, that in terms of the number of afflicted, 
iron deficiency anaemia is second only to protein malnutrition 
C405] .
However, there are also more subtle medical effects which 
can be achieved by manipulating trace element concentrations
in vivo. Many common diseases that do not stem directly from
BO
FIGURE 4.1
Effect of copper on the height of oat-seedlings grown in nutrient 
copper-deficient medium. From left to right the quantities of copper 
present are nil, 3, 6, 10, 20, 100, 500, 2000, and 3000 pg per litre
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metal ion overload or deficiency can be alleviated because
either they, or immune responses towards them, depend on
enzymes that are activated or inactivated by transition metal
ions. Moreover, a number of transition metal ions participate 
in physiological processes such as DNA synthesis so they can 
interfere u/ith cell replication. They are thus involved at a 
fundamental level in the physiology of the disease. For 
example, cancer cells are often associated with high concentra­
tions of zinc [293] and consequently have a greater than normal 
requirement for exogenous supplies [638]. Accordingly, a great 
deal of research has gone into the relationship between metal, 
ligands and cancer [72,82,320,637] since Furst postulated a 
connection in 1963 [620] . There is even a commercially available 
anti-tumour agent called "Razoxane” that was originally synthesised 
in an attempt to produce an intracellular chelating agent 
[1808,1809,1810], More recently, there has been a rapid growth 
of interest in the role of copper in rheumatoid arthritis. This 
subject is discussed in greater detail in Section 4.2,5.- •
4.1.1 The biological significance of the Low-molecular-weight 
transition metal complexes
It is becoming established practice to classify transition 
metal species occurring in biological systems into four categories 
according to their molecular weight and the extent to which they 
are involved in the biofluid’s labile metal ion equilibria [736,1250] 
Figure 4.2 shows that there are generally three states between 
which metal ions can rapidly exchange: these are (i) certain
metal protein complexes, (ii) some low-molecular-weight complexes,
•
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FIGURE 4.2
Inert and labile metal-protein binding in vivo
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and (iii) the aquated metal ions. The fourth type of species 
occurs when the metal is irreversibly bonded by a macromolecule 
and cannot be removed without’ disrupting the protein structure. 
The aquated metal ions have to be present for thermodynamic 
reasons but they usually occur at such low concentrations that 
their participation in any biological process is virtually 
precluded. At the other-extreme, the high-molecular-weight 
species are at a kinetic disadvantage when the metal ion must 
diffuse through a biological membrane or be exchanged from one 
binding site to another. So, it is in these functions that the 
unique biological significance of the low-molecular-weight 
transition metal complexes is to be found.
In spite of their important role, the concentrations of 
the low-molecular-weight Species must be kept very low in order 
to minimise the possibility of hydrolysis, polymerisation and 
precipitation L1631]. .Moreover, the toxic effects of heavy metal 
overload are primarily manifestations of an enlargement of the 
low-molecular-weight fraction. To forestall such eventualities, 
carrier protein molecules with specific co-ordination sites 
have evolved. For the most part, the complexes they form are 
sufficiently stable and labile to ensure that all the other 
metal ion species present in the biofluid occur at very low but 
efficiently buffered levels.
There have, of course, been many attempts to assess the 
nature and magnitude of the low-molecular-weight fraction in 
biofluids such as blood plasma. Some of the first dealt with
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copper [135,280] but since then others have encompassed iron 
[131,169,200] and zinc [140]* Such experiments have done a 
great deal to establish the classification shown in Figure 4.2. 
Indeed, the results of many earlier studies can now be considered 
as invalid because the equilibrium involving low-molecular-weight 
species was ignored [369]. Yet even today identification of 
the individual complexes present in the biofluid and determina­
tion of their concentrations remains fraught with difficulty.
The concentrations are almost invariably well below the limits 
of analytical detection and techniques which alter them are 
likely to disturb the very distribution that one is attempting 
to monitor. Many common biochemical methods applied to bio­
inorganic systems suffer from this defect (e.g. dialysis or 
column chromatography). So, more than ever, it is important 
to assess the effects of the analytical technique itself on the 
system being investigated. At the current state of the art, there 
is no reliable experimental method for looking at low-molecular- 
weight transition metal ion complexes in protein-contain!ng 
biofluids. One is thus forced to rely heavily on the information 
provided by computer simulation models (Section 4.2).
A detailed.discussion of the evidence for low-molecular-
weight complexes influencing trace element metabolism is outside 
the scope of this thesis. There is such an abundance of fact 
that to deal * thoroughly with it .all would require a volume to 
itself. However, the essential features have often emerged from 
research into the physiology of iron. More work has been devoted 
to this trace element than to any other because of its essential
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part in haemoglobin. Accordingly, the reader is referred to 
Appendix A6 in which the biological significance of low- 
molecular-weight iron(III) complexes is reviewed. It is 
necessary here only to mention two of the most important 
conclusions. The first is that, in the majority of cases at 
least, transport of transition metal ions through biological 
membranes occurs by passive diffusion. This implies that the 
lipophilicity and the charge of the predominant low-molecular- 
weight complex species formed in vivo will play a dominating 
role in determining the distribution of the metal ion amongst 
different body compartments [1075,1077]. The second conclusion 
concerns the equilibrium which is set up between high- and low- 
molecular-weight complexes in biofluids. There are a growing 
number of reports in the literature to suggest that a dynamic 
"steady state" relationship is physiologically very important 
[885,946,1060,1092] . In addition to the competition between 
low-molecular-weight chelating agents and labile metal protein 
complexes this would include the cycle of inert metalloprotein . 
biosynthesis and degradation. By acting in concert,*a very 
sensitive metal ion buffering system of considerable capacity 
could be achieved. The normal incorporation of iron into ferritin 
and of copper, and zinc into metallothionein suggests that this 
is. a fundamental aspect of the homeostatic regulation of many
transition elements
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4.1.2 Bioinorganic drug design
Despite the medical rewards which adroit manipulation 
of metal ion concentrations in vivo could yield, progress in 
designing ligands for therapeutical purposes has been disappoint­
ing. In humans, even when the objective is simply to remove an 
offending metal ion or to supplement an essential one, the 
"treatments of choice" can rarely, if ever, be considered more 
than just satisfactory. There are many reasons for this. On 
the one hand, preventing excessive uptake of heavy metal ions is
one of the vital functions of the intestinal mucosa. On the
other, there are a number of inherent characteristics concerning 
the way in which chelating agents act in biological systems 
which militate against high therapeutic indices.
One aspect of the problem which is given almost universal 
cognisance concerns ligand selectivity and specificity. Clearly, 
it is desirable that the chelating agent binds the target metal 
ion strongly but leaves the multitude of other cations present 
in the body unmolested. Chemical principles for satisfying these 
criteria have long been established, One of the most obvious 
approaches to follow is Pearson's theory of Hard and Soft Acids 
and Bases (l-ISAB) r35,86,87,635,1426,19013 in which metal ions 
and ligands are classified according to their electrical
polarizability and the most powerful interaction occurs between 
species with similar characteristics. In recent years, many 
agents have been produced which are extraordinarily specific and 
selective. Indeed, the contrast between this success and the
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modest improvements achieved over the same period in chelation 
therapy itself have underlined the need to give more than the 
usual token consideration to the other factors which determine 
the overall biological response.
By far the most important aspect to which those researching 
into chelation therapy should pay greater attention concerns the 
multicompartmentai nature of physiological systems. It is 
difficult to appreciate the full implications of this for optimal 
ligand design. As mentioned in Section 4.1.1, biological transport 
in this context is by passive diffusion so an ideal agent must 
satisfy at least three requirements in order to enhance urinary 
excretion of a toxic metal £18413. It should (i) be sufficiently 
lipophilic to penetrate cell membranes in order to reach the. 
sites of heavy metal deposition, (ii) form a lipophilic metal 
complex in the body compartment where the metal has accumulated 
and (iii) change to a hydrophilic complex in plasma so that a 
concentration gradient is established and the metal can be 
eliminated via the urine and not re-distributed into other tissues. 
These are demanding conditions which cannot easily be met. They 
imply that changes in lipophilic profile must be brought about 
by varying the electrical charge on the species, something which 
can only be accomplished if pH and other compositional consider­
ations offset the increase in charge that naturally occurs with 
complex formation. Moreover, when the complex is to be excreted 
into the bile or when the drug is not administered directly 
into the bloodstream the above-mentioned requirements need to be 
modified and this means they almost invariably become more stringent
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Single ligands are thus, intrinsically, at a disadvantage. 
Many, like the polyaminocarboxylie acids, are almost entirely 
confined to extracellular space [1214,1805,18493. They are thus 
forced to rely on a supply of the toxic metal from naturally 
occurring ligands that can mediate in the metal transfer between 
body compartments. This is, of course, always a relatively 
inefficient process but.it is a particular handicap for exogenous 
ligands which have short biological half-lives in plasma. The 
disadvantage with making ligands more lipophilic is that this 
trend almost always parallels increasing toxicity [1319,1174,11751. 
Moreover, as has been noted above, there is also the risk that 
lipophilic complexes can mobilise metal deposits and transfer 
them to less propitious sites.
For these reasons, the concept of "Synergistic Chelation 
Therapy" is proposed [18411. It means the use of two drugs 
to collectively act upon the metabolism of the metal to promote 
its excretion. The simplest example occurs when one agent 
mobilises the metal in tissues while the other binds it in 
plasma for urinary excretion [16011. This may involve the intra­
cellular formation of a lipophilic complex that is dissociated 
by a more powerful hydrophilic chelator in plasma. Another 
illustration which may well prove effective in the treatment of 
siderosis would be the use of a relatively unsophisticated ligand 
to speed up the exchange of iron from transferrin to powerful 
chelating agents such as desferrioxamine [1525,17371.
Mobilisation, however, need not always depend on chelation 
per se [16021. In the case of transition metal ions with two 
oxidation states that can co-exist in vivo, redox reactions can
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rapidly release the metal co-ordinated within a protein matrix.
A change in oxidation state will usually destroy the chemical 
and stereochemical compatibility between the binding site and 
the ion. This is relevant when the protein holds the metal in 
a kinetically inert manner provided there is sufficient 
equilibrium competition to remove the metal once lability has 
been established. It should be emphasised that redoxing agents 
must act within the context of the multicomponent equilibrium 
systems that operate in biofluids so, in contrast to the 
pronounced effect which can be displayed in vitro, their impact 
on the metabolism of metal ions such as iron and copper will be 
greatly moderated by biological buffering. .
It is always tempting for those in search of better . 
chelating therapeuticals to try to exploit endogenous ligands. 
These are certainly less likely to introduce toxicological 
complications. Yet, in practice, endogenous ligands have not 
proved very successful C909]. There are a number of reasons for 
this but two are paramount: (i) in vivo concentrations_tend to
be well regulated and (ii) to have an effect, the administered 
ligand must compete with natural levels of an identical substance 
and is, relatively speaking, therefore at a disadvantage. These 
points are particularly worth noting in the context of 
Synergistic Chelation Therapy. They have pessimistic impli­
cations for chelation strategies based on ternary complex fornra- 
tion with one or more endogenous ligands, regardless of the extra 
stability often exhibited by mixed ligand complexes [see, for 
example, 1742,1841,1842 and 1956].
90
Attention has so far been focussed on chelating strategies 
aimed primarily at enhancing urinary excretion of toxic metal ions 
This is because almost all current medical chelating agents u/ork 
this \i/ay [909,816]. Elimination via the bile is another obvious 
route. The ligands are required to be sufficiently lipophilic to 
participate in the enterohepatic circulation of the bile acids and 
not be removed by renal filtration [816]. It has already been 
mentioned that the danger u/ith increasing lipophilicity is that 
the agent itself invariably tends to become more toxic. The 
dichotomy is not easily bypassed but surfactant-like molecules 
can be synthesised u/ith a range of aliphatic side-chain lengths in 
an attempt to find a happy medium. Alternatively, chelating 
agents u/ith structural features similar to those of the bile acids 
may be made so that they selectively enter the liver. The
rationale behind the development of the antitumour drug "Razoxane" 
may also be applicable: this bisdioxopiperazine, a cyclic imide 
derivative of EDTA, is sufficiently lipophilic to passively diffuse 
into cells u/here it turns into a chelating species by hydrolytic 
ring cleavage [1808,1809,1810],
The aim of this section has been to stress that the design 
of chelating therapeuticals requires more than concern u/ith good 
me ta-1-ligand specificity. Although most of the chemical
principles involved have been knou/n for a long time, it seems 
that progress in bioinorganic drug design has been slou/ because 
it is difficult to bring all the relevant factors to bear simul­
taneously. The development of sophisticated computer simulation 
models and the potential u/hich they have for improvement, encourage 
one to feel that this need not remain a drawback much longer.
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4. 2 Computer simulation of metal-ligand equilibria in biofluids
From a chemist’s viewpoint it is surprising how often 
the concept of speciation seems to have been overlooked in the 
biological sciences. No doubt the reason lies in the complexity 
of biological systems and in the very small amounts of substance 
which are often under investigation. In many circumstances it 
is difficult enough to keep track of the total concentrations,.' 
let alone worry about the stoichiometry and abundance of individual 
chemical species. However, this suggests that considerable 
advances in our knowledge of Nature can be made if and when the
identification of the actual molecules involved in biochemical 
reactions becomes possible. This is particularly true in the 
bioinorganic context where the co-ordination partners of transition 
metals are very instrumental in determining how the ion behaves 
in vivo (see, for example, Appendix A6). ■
There are a large number of biofluids where information 
about the speciation of metal complexes would be of great interest. 
Some examples are seawater, ground water, blood plasma, intestinal 
fluid, and cell cytoplasm. This has encouraged a large number 
of investigators to develop computer models for the purpose of 
calculating various equilibrium distributions. The first was a 
computer simulation of seawater by Sill6n [519,801]. This was 
met with the most remarkable success. It underlines the deep 
insight which models can provide. Sillen showed that pH buffering 
in the sea is- primarily maintained by aluminosilicate clays and 
micas. This completely overturned the assumption that carbonate
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equilibria u/ere responsible. The computer models revealed
that, contrary to wide belief, the ratio of carbonate to
bicarbonate merely reflected the prevailing pH of the solution 
and did not control it except perhaps locally [653]. Since 
then several models of other natural waters have been published 
[244,246,535].
Blood plasma has also been the subject of many computer 
simulation studies. De Haven and De Land, for instance, have 
covered many aspects of blood biochemistry in their pioneering 
development of thermodynamic models for living systems [220,281, 
378,380,381]. However, Perrin was the first to consider the 
distribution of transition elements amongst ligands in blood- 
plasma [3]. In a series of publications, the original model 
dealing with seventeen naturally-occurring amino acids interacting 
with Cu(II) and Zn(II) [158,286] has been extended to include 
Ca(II) and Mg(II) and a number of additional ligands [369,1500],
A detailed consideration of the merits of each model was included 
in this author's M.Sc thesis [736] and need not be reiterated here. 
Suffice it to say that the failure to take account of meta-l- 
protein binding in the biofluid was a major defect in the earlier 
work. In spite of attempts to improve the simulations by 
including protein species, this remains the issue most sensitive 
to criticism. The reason is that the formation constants of 
these species cannot yet be satisfactorily characterised in a 
thermodynamic sense. There are presently insurmountable 
difficulties in defining the exact stoichiometry of metal protein 
complexes, particularly with respect to the degree of protonation.
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It is possible with wel-l-behaved systems under specified
circumstances to measure "conditional constants" instead.
These partially describe the metal binding properties of the 
protein and applied with caution can provide valuable information 
about the distribution of metal ions in many biofluids. It is 
interesting to note how Perrin’s results have evolved as his 
approach towards protein binding became increasingly
sophisticated [c.f. 369 and 1500].
The computer investigations described in the remainder of
this section yield, for the most part, relative rather than 
absolute results. This is largely because of the uncertainties 
associated with metal-protein binding. Thus, computer simulation 
techniques have been developed which bypass these difficulties 
by considering the in vivo complexing ability of chelating agents 
relative to one another. Very often bioinorganic interest is 
concerned with the respective effects of a series of ligands.
In these cases, the additional confidence which can be placed 
in answers that do not depend on the exact extent of metal- . 
protein binding outweighs the disadvantages of not knowing the 
absolute concentrations which are involved.
4.2.1 Metal-ligand complex distributions in normal blood plasma
There are two important reversible metal binding proteins 
in blood plasma. These are serum albumin and transferrin. A 
great deal of work has been done to investigate their inter- 
actions both with metal ions [29,30,31,151,160,168,185,190,269,350, 
363,366,658,671,810] and low-molecular-weight anions [165,238,
247,248,290,556,1249] . Although some controversy surrounds the. 
transport of labile Zn(II) [11863, this is in the face of over­
whelming evidence that all the essential transition metal ions 
except Fe(IXI) are predominantly associated with the former _ 
protein [133,140,257,280,348,363,462,554,557,575,646,810,813,970, 
1216,12473. The same can be said of Ca(II) [1194,15273,
Mg(II) [143,1943 , Pb(H) [28,2253 and Ni(II) [910,9743 . A 
specific binding site for Cu(II) exists at the amino-terminal 
end of the serum albumin molecule [178,180,181,739,740,14683. On 
the other hand, transferrin clearly evolved to satisfy the special 
demands of iron transport in vivo [99,129,131,134,169,179,200,
353,433,483,560,589,991,992,1555,1556,17373 but it also'binds, ' 
more powerfully than serum albumin, a variety of elements such 
as cobalt, chromium and plutonium [184,190,1164,1450,1451,18263.
This knowledge of the proteins to wh'ich metal ions in 
plasma are almost exclusively attached is fundamental to the 
calculations of the complex distributions of the transition 
elements between the low-molecular-weight ligands in normal plasma. 
Except for Ca(II) and Mg(II), [136,2023, the free ion concentrations
.of the complexing metals can be anticipated to occur below the
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limits which can be detected by ion selective electrodes even 
if they were present in pure water. The multitude and diversity 
of components in plasma make the analysis orders of magnitude 
more difficult so it is extremely unlikely that direct experi­
mental determinations will become possible in the foreseeable 
future. However, the desired concentrations can be estimated 
from the "conditional" dissociation constants of the relevant 
metal protein complex by assuming that the vast proportion of 
the metal in plasma which is exchangeable is bound to the protein 
and that this quantity is negligible compared with the total 
protein concentration E736]. The best values currently available 
are shown in Table 4.1.
To compensate for the lack of analytical information * 
about the transition metal ion concentrations in plasma, there 
is a wealth of data about the levels of low-molecular-weight 
ligands. Apart from a few such as salicylate and tryptophanate 
(where association with proteins must be taken into account 
(247,556)], the ligand concentrations available for complexing 
metal ions can now be obtained routinely by column liquid 
chromatography. Representative values are listed in Table 4.2.
The concentrations appearing in Tables 4.1 and 4.2 define 
a multicomponent equilibrium mixture whose species distribution 
can. be obtained by computer simulation if all the formation 
constants for the various equilibrium reactions are known. How 
the latter values may be acquired has been described in .
Section 2.1.5. The outcome of the latest calculations for the
A4 J' *. 96
TABLE 4.1
Free concentrations of metal ions in normal
blood plasma used in the simulations ,
Metal ion
Concentration
■ ■(mol dm )
Ca2 + 1.13 X 10
Mg2+ 5.2 X io”
Zn2 + 1.0 X io”
Mn2+ 1.0 X io”
Cu2+ 1.0 X io”
Fe3 + 1.0 X 10”
Pb2+ 1.0 X io”
-3
4
9
12
18
23
14
Values baspd on those given in C7363 and [1250]
OltvOYS tX-tC-AN."* Aitc, to ev\\ © ti-tv .
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TABLE 4.2
Total ligand concentrations in human blood plasma,
fc t.^used in the computer simulations i Ue
vAAi.Lv, ftu. VAiAvVs V»u'O*.fc<rw .
mol dmr3 mol dmr3
Alanate 3.70 X ID’4 Serinate 1.22 X io-4
Aminobutyrate 2.40 X 10" 5 Threoninate 1.50 X IO"4
Arginate 9.50 X io"5 T ryptophanate 1.00 X ID-5
Asparaginate 5.50 X 10"5 T yrosinate 5.80 X io"5
Aspartate 5.00 X 10-6 Valinate 2.27 X io"4
Citrullinate 2.70 X IO"5 Histamine 3.00 X 10" 8
Cys teinate 2.30 X 10" 5 Carbonate 2.45 X io’2
Cystinate 4.00 X io-5 Phosphate 3.81 X io"4
Glutaminate 5.21 X 10"4 Silicate 1.38 X 10"4
Glutamate 4.80 X io"5 Sulphate 2.11 X io"4
Glycinate ■ 2.43 X io"4 Thiocyanate 1.40 X io"5
Histidinate 8.50 X - 510 9 Ammonia 2.40 X io"5
Hydroxyprolinate 7.00 X io"6 Citrate 1.13 X io"4
Isoleucinate 6.50 X io"5 Lactate 1.82 X io"3
Leucinate 1.24 X io"4 Malate .3.50 X io"5
Lysinate 1.78 X io"4 Oxalate 1.20 X io"5
Methionate ’ 2.90 X io"5 Pyruvate 9.50 X io"5
Ornithinate 5.80 X io"5 Salicylate 5.00 X 10~6
Phenylalanate 6.40 X io"5 Succinate 4.20 X io"5
Prolinate 2.11 X 10"4 Ascorbate 4.30 X io"5
Values based on those given in C736] and C1250]
• • 93
most predominant complexes of Ca(II), Mg(II), Cu(II), Zn(XI), 
Fe(III), Mn(II), and Pb(IX) is depicted in Table 4.3. The 
percentage distribution obtained in the original studies 
is also given for comparison.
The most striking difference which is apparent concerns 
the distribution of Zn(II). Whereas the ternary citrato- 
cys teinat'o-Zn (11) complex was originally found to account for 
over 40?o of the metal ion in the low-molecular-weight fraction, 
it is now of insignificant importance. The formation constants 
in question were redetermined by Dr.G.Berthon in St.Andrews [1632] 
in accordance with the principle laid down in Section 2.1.3 
because the literature source from which the values had been taken 
C337] was open to some question. Fears that the extraordinarily 
high value reported was merely an artefact of certain ambiguities 
in the way the citrate complexing equilibria were defined appear 
to have been justified. Substitution of the new set of formation 
constants in the model reduced the concentration of the ternary 
species by almost four orders of magnitude [1632]. - •
As a result of a number of recently published studies 
the formation constants of many other ternary complexes have also 
been updated. In this respect, Cu(II) has -received particular 
attention [15-87,1583]. However-, the effect on the computer 
simulations has been marginal. It seems that for Cu(II) and 
Zn(II), at least, the distributions shown in Table 4.3 will stand 
the test of time because the formation constants of all the .
predominant species have now been measured experimentally and 
values for many of them have been independently confirmed.
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TABLE 4.3, .
Percentage distribution of Ca(II), Cu(IX), Fe(III), Pb(II),
Mg (11) , Mn(II) and Zn(II)
ligands in human blood pla
amongst low-molecular-weight
sma as found by computer simulation
4 c-»rv>.K-*A.tv*ht,i jr*vS *» pyc-c-vi v*v>.
Percentage of the total metal
Complex species Current models Original modelE7363
CCa(COj)H]+ . 8 9
CCa(CitO)'] ~ . 4 4
CCa(P04)']- 3 3
[Ca(LactO)] + 3 3
(Ca(CO^)l . 2 2
ECu(CisO) (His0)3 ” 19 21
ECu(CisO)(HisO)HJ 15 17
CCu(HisO)2] • 11 11
[Cu(ThrO)(HisO)] 9 8
ECu(Ser0)(HisO )3 • 6 4 - .
CCu(GlyO)(HisO)] 6 3
ECu(LysO)(HisO)H]+ 5 5
CCu(ValO)(HisO)] ' 5 5
CCu (AlaO) (HisO)] 4 4
ECu(GlnO)(HisO)J 3 2
ECu(PheO)(HisO)] 2 3
[Fe(CitO)OH3 ~ 55 99
[Fe(CitO) (OH)2]’2_ 44 • - .
EFe(CitO) (SalO)]'2" • <1 <1
/con t d
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Table 4 ,3 (contd)
LPb(CysO)] 86 80
[Pb(CysO)2H]- 6 2
EPb(CisO)H] + 4 5
[Pb(CQ3)H]+ 2 2
CMg(CO3)H] + 5 . 6
CMg(CitO)']- 5 5
CMg(LactO)] + 3 2
CMg(CDj)] 2 2
rMn(C03)Hj+ . 23 24
[Mn(CitO)]- . , 10 10
EMn(CO3)] 2 2
[Zn(CysO)2]2- 36 19
[Zn(CysO) (HisO)]- . 24 12 •
[Zn(HisO)] + 4 3
CZn(CysO)2H]" 3 . 1
The ligands are represented by symbols as follows:
AlaO = alinate; CisO = cystinate; CitO = citrate;
CysO = cysteinate; GlnO = glutaminate; ClyO = glycinate;
HisO = histidinate; LactO = lactate; LysO - lysinate;’
PheO = phenylalanate; SalO = salicylate; SerO = serinate; 
ThrO = threonate; ValO = valinate.
” ' r ’"''T • .*• ’ ’’ • *....... . - - ' - > ; ■ - - ■ - • • • • ...
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Considerably more work is needed to achieve this same standard 
with the other transition elements. Fortunately, it is the 
physiology of Cu(II) and Zn(II) which provides much of the 
impetus for the computer simulation studies reported in this 
thesis. Moreover, the models serve to highlight those systems 
with the other kinds of metal ion whose solution chemistry 
should be most urgently studied.
The computed percentage distributions of the newl-y- 
included metal ions Ni(II), Fe(II) and Cu(I) in plasma are shown 
in Table 4.4. It is not possible to obtain estimates of the.free 
metal ion concentrations in the same way as for the other 
transition metal elements. There is insufficient knowledge about 
the binding of Ni(II) in blood plasma. One might expect the 
value to lie somewhere between that for Zn(XI) and that for Cu(II) 
on the basis of an intermediate binding to serum albumin. With 
iron and copper, the metal ion in the predominant meta-l-protein 
complex exists in the alternate, higher oxidation state so 
’’conditional" dissociation constants would be inapplicable. 
Instead, the levels are governed by the redox potential of plasma. 
In principle it is possible to calculate values from the Nernst 
equation using the standard redox potential of the couple between 
the metal ions in their respective oxidation states. However, 
this is subject to considerable uncertainty because plasma might 
not be at redox equilibrium. The redox potential of the biofluid 
can be gauged from the ratio of ascorbate to dehydroascorbate 
C577] but the value so obtained '(-12 mV E577]) i9 in disagreement 
with the observed distribution between cysteine and its oxidised 
counterpart cystine E666J . The matter is further confused since
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TABLE 4.4
Percentage distribution of Cu(I), Fe(II) and Ni(IJ.) amongst 
low-molecular-weight ligands in human blood plasma as found
by computer simulation
'•'/ b* it vim. tjv. eX^A.V^x.ttr«Aj» ti ■*-£
Complex Species Percentage of the total metal
[Cu(CysO)H] ' 45
CCu(CysO)'] ~ 36
L'Cu(CysO)2Hp “ 18
[Fe(C03)H] + 27
CEe(CO3)3 22
EFe(HisO)] + 11
EFe(CitO)]" 6
ENi(CysO)(HisO)j“ • 44
ENi(HisO)23 37
.9
ENi(CysO)2] . ■ 8
ENi(HisO)] + 3
The ligands are represented by the symbols defined' 
in Table 4.3. •
1U3
exact, absolute values for the standard redox potentials of 
sulphydryl compounds are not yet knou/n because such systems 
tend to poison platinum and other noble metal electrodes [1984]. 
Nevertheless, assuming that the redox potential of plasma is 
aboutzero volts, one finds the approximate concentrations for 
Fe(II) and Cu(I) corresponding to the free concentrations of 
Fe(III) and Cu(II) shou/n in Table 4.1 are 10~^ mol dm and 
lO”^ mol dm”""5 respectively.
When the free concentrations of the transition metal ions 
in the computer simulations are varied to ascertain the effects 
of possible error, a most striking fact becomes apparent. Unless 
the values are raised very considerably, the percentage distri­
butions shou/n to a precision of l?o in Tables 4.3 and 4.4 remain 
constant. In other words, the percentage of a transition metal 
in the low-molecular-weight fraction of blood plasma attached to 
specific ligands is independent of the exact free metal ion 
concentration and can thus be calculated u/ithout prior knowledge 
of the metal-protein binding constants C1234] or of the- relevant 
redox potentials. This is so because the amount of metal complex 
formed in plasma is negligible compared with the amount of 
each ligand that is present. Complex species thus have no 
significant effect on the mass balance relationships of each 
ligand and consequently, the free ligand concentrations are not 
significantly affected by the degree of complexation. Under 
these circumstances, the concentration of each complex depends 
solely on the free concentration of the metal ion. In fact, there 
is a direct proportionality between them. As this is true for
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all mononuclear species, the total concentration of each metal 
in the low-molecular-weight fraction is also directly proportional 
to the concentration of the free metal ion. Hence, the percentage 
of metal appearing in a given species is constant. Note that 
the information is relative. The absolute concentration of the 
free metal ions and of all their complex species are determined 
by the protein binding equilibria.
It should be stressed at this stage that computer simu­
lations which yield relative answers are often very easy to 
misinterpret. More than usual care must be taken to avoid ■ 
pitfalls occurring because only one part of the system is being 
modelled. This is well illustrated by the series of calculations 
reported in the earlier work [736,1250] which were made to 
determine the effect of an error in pH on the calculated percentage 
distributions. As expected, the simulations showed that the 
extent of metal compiexation tends to increase as the free hydrogen 
ion concentration is reduced. For example, the calculated total 
concentration of the copper(II) complexes rose from 6 x 10~^^ mol 
dm“3 at -log[H+] = 7.2 to 4 x 10"11 mol d'm~3 at -log[H+] = 7.6.
This does not mean, however, that the low-molecular-weight fraction 
will really be enlarged. On the contrary, as binding by proteins 
is also enhanced, the reverse is more than likely. The true 
effect of varying pH will only be seen in models which include 
formation constants for the metal-protein complexes that are 
correctly defined in terms of the free hydrogen ion concentration-.
^•2.2 The effects of exogenous chelating agents on the 
metal-ligand equilibria in blood plasma
The most serious disadvantage with simulations yielding 
relative rather than absolute answers js that useful or even 
valid comparisons between models often prove difficult to make.
This is the case when chelating agents are introduced into blood 
plasma. The obvious solution is to simulate treatment by including 
the administered drug at some realistic concentration in the 
normal model'amongst the naturall-y-occurring ligands. However, 
the results of earlier work by this author [736] and by Perrin 
[369,1500] showed that such an approach was no.t‘ ideal. The 
method makes assumptions about the way in which metal-protein 
complexes respond towards increased competition for metal ions. 
Although these were not fully considered at the time, it 
transpires that they are largely justified. Nevertheless, it is 
hard to perceive how the situation changes when the assumptions 
begin to fail. Moreover, the approach is not well suited to 
making predictions about the biological effects of a series of 
chelating agents. For example, one might like to compare the 
ability of various compounds to promote trace element excretion. 
There are two main, reasons why a straightforward approach is 
awkward. First, one must choose a particular concentration in 
plasma that is applicable to all the agents but sufficiently high 
to reveal their important characteristics. Second, many chelators, 
even at relatively low concentrations, complex almost all of the 
metal ions in the low-molecular-weight fraction. Vet it is 
evident that different agents have different bioinorganic
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properties in spite of the fact that many of them may have
captured more than 99?o of a given metal ion attached to low-' 
molecular-weight ligands. Obviously, one reason for this is 
that they are also competing for the metal ions with plasma 
proteins. Their biological effect is manifest partly because 
they enlarge the low-molecular-weight fraction.
For these reasons, an extension to the procedure adopted 
for simulating the low-molecular-weight equilibria in blood 
plasma is proposed F16O13• The relative ability of an administered 
agent to compete for metal ions in the biofluid can be obtained 
by calculating the increase in size of the metal’s low- 
molecular-weight fraction at any given ligand concentration.
This factor, defined, in equation 4.1, is called a "Plasma 
Mobilizing Index" (P.M.I.).
total concentration of all the metals’ 
low-molecular-weight complexes in the 
presence of the drug
P.M.I. = ---------- —---- - ----------- —--------------- -----—-----------— (4.1)
total concentration of all the metals’ 
low-molecular-weight complexes in 
normal plasma
Consider the effect of increasing the concentration of a 
chelating agent in blood plasma. As long as the metal complexes 
it forms remain at concentrations very much lower than the metal 
protein complexes, the latter will continue to buffer the free 
metal ion concentrations at the level normally pertaining in the 
biofluid. Thus, the distribution of the low-molecular-weight
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complexes changes because the administered chelating agent 
gains transition metal ions at the expense of the proteins and 
not the normal low-molecular-weight complexes. This situation 
changes only when the concentration of the metal-protein 
complexes begins to be significantly depleted. Whereupon the 
free metal ion concentrations will also begin to fall. Before 
this happens, however, the lo-w-molecu lar-weigh t fraction of most 
transition metal ions will have had to have been increased by 
many orders of magnitude. Many interesting physiological effects 
may be expected solely from this enlargement.
Without characterizing the metal-protein binding, it is 
not possible to calculate P.M.I. curves over the whole range of 
chelating agent concentrations in plasma. Nevertheless, it is • 
evident from equation 4.1 that the free metal ion concentration 
is a factor in every term in both the numerator and the . 
denominator of the P.M.I. quotient. As only mononuclear complexes 
are found in plasma (because of the relative abundance of ligands 
over transition metal ions), it is thus possible to cancel the 
free metal ion concentration as long as it remains buffered by 
the metal-protein complexes. Under these circumstances, P.M.I. 
values become a relative measure of the metal ion binding 
ability of different chelating agents administered into plasma. 
Curves can thus be constructed to depict how the low-molecular- 
weight fraction is enlarged as the concentration of the 
chelating agent is increased [1600,1601].
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Some examples where sufficient biological data exists 
to make for a worthwhile comparison are shown in Figure 4.3.
The P.M.I. curves are calculated for (i) ethylenediaminetetra-
. acetate (EDTA), (ii) die thylenetriaminepentaacetate (DTPA), ,
(iii) cyclohexylenedinitrilotetraacetate (CDTA), (iv) desferro- 
xamine (DFO), (v) penicillamine (Pen), (vi) 2<3-dimereapto~ 
propanol (BAL), and (vii) triethylenetetramine (Trien). Their 
order correlates strikingly well with the ab.ility of these 
agents to promote trace-metal excretion. Although direct 
comparisons between agents are not often made in the literature, 
their relative physiological efficacies appear to be as follows. 
For copper, Trien > DTPA > EDTA [944,10853; for iron, DFO >
CDTA > DTPA > EDTA > no effect [1030]; for manganese,
CDTA = DTPA > EDTA > Pen = DFO = no effect [1046,1099]; for 
lead, DTPA > EDTA > CDTA >-Pen = BAL> DFO = no effect [834, 
1047,1169,1267]; for zinc, DTPA, CDTA > EDTA > Pen > DFO = 
no effect [1096,1112,1121,1151,1343]. Chelation therapy for 
nickel has so far only been studied in terms of the ability of 
the various agents to prevent mortality, in acutely poisoned rats 
[1004,1071]. In good agreement with these observations, the 
computer simulations show that Trien and Pen are almost equally 
effective at binding exchangeable nickel ions in plasma and 
considerably better at this than the other agents investigated.
The good correlation between the calculated and observed 
data is particularly significant when one considers the major 
differences in biological response towards the chelating agents 
rather than their exact positions in the comparitive series given 
above. In this regard, the P.M.I. values, unlike the formation
iuy
FIGURE 4.3
-10 -9 -8 -7 -6
Log (total drug concentration in mol dm3)
(Shading indicates confidence placed in the respective formation 
constants)
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constants, accurately portray the physiological properties.
For example, if the excretion of lead and zinc, caused by
DTPA, EDTA and Pen is considered, both the similarity of these 
ligands in their effect on lead [834,1047,1267] and the 
systematic differences they display towards zinc [1096,1112,1121, 
1151] are reflected in Figure 4.3.
The P.M.I. curves for zinc in Figure 4.3 have been
deliberately shortened. The reason is that buffering by meta-l-
protein complexes is likely to fall off with this metal ion •
before it does so with any other. The total labile zinc con- 
r -5 • -3 ‘centration in plasma is about 10 mol dm , some two-thirds 
of the total concentration [196,345,577,606,669]. From the 
free metal ion concentration shown in Table 4.1, the total zinc 
in the low-molecular-weight fraction will account for approximately 
10 mol dm [140], Thus, the log P.M.I. values shown in 
Figure 4.3 are subject' to a limit of about 2 units. Accordingly, 
the curves must taper off sigmoidally towards higher drug con­
centrations and would do so if the meta-l-protein complex 
equilibria could be adequately represented in the simulations.
This phenomenon explains two observed characteristics of DTPA 
therapy which are otherwise difficult to comprehend [1646]. The 
P.M.I. curves suggest that at high DTPA concentrations, the 
ligand will be unable to obtain sufficient labile zinc from 
plasma proteins so there will be a significant fall in the free 
zinc ion concentration and a consequent increased binding of 
calcium ions.* This shift in the equilibrium position would 
cause a transfer of zinc from tissues into plasma but this process
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will probably be a relatively slow one. Thus, a dose of
C-a-DTPA given in five fractions produces almost twice the 
urinary excretion of zinc than does a single equimolar dose 
C1078] . Moreover, the hypothesis also accounts for the enhanced 
removal of toxic trace metals by C-a-DTPA compared with Z-n-DTPA 
C1078]i administration of the former produces a higher free 
ligand concentration because overall complexation is to some .
extent limited.
Whilst other contributions to the pharmacokinetics of the 
metal ion complexes formed in vivo can obviously be anticipated, 
the computer models show that, in most cases, the degree to 
which the agent competes for exchangeable pr otei-n-bound metal 
ions determines how effectively urinary excretion of the element 
is promoted.
Most of the agents considered in Figure 4.3 form highly 
charged complexes in blood plasma. They are thus confined to 
this body compartment until they are eliminated by the kidneys 
into the urine. Neutral complexes on the other hand may diffuse' 
through membranes (Section 4.1.1). The models are thus able to 
explain the medical observation that plumbism. is best treated 
in two stages- - initial EDTA intravenous infusions are followed 
by longer term oral therapy with Pen F11.18] . The negatively 
charged P-b-EDTA complex is strongly formed in plasma and quickly 
removed. However, lead which has dispersed into the tissues is 
inefficiently leached back into plasma by the polyaminocarboxylic 
acid. Pen forms a neutral complex which easily returns to plasma
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once a concentration gradient is established. This also
explains the experimental finding that premature treatment
with Pen can be detrimental because it actually increases lead 
deposition in essential organs C1058J . Moreover, the serious 
side-effects caused by Pen-therapy can partly be attributed to 
zinc deficiency C1048,1343j. With zinc a negatively charged 
bis-complex predominates. that is prone to urinary excretion L‘16013 .
4.2.3 Computer simulation of Total Parenteral Nutrition
Recently there has been considerable progress made in the 
treatment of gastrointestinal diseases by the introduction of 
long-term intravenous feeding regimens C1976] . The technique, 
described as Total Parenteral Nutrition (TPN), employs solutions 
with compositions that have been established as suitable for 
maintaining healthy tissue metabolism and nitrogen balance in 
patients on shorter periods of supplementation. However, the 
need to extend the duration of this kind of therapy (often to 
several months and sometimes even to years) raises serious 
questions about the levels of micronutrients which should be 
administered simultaneously. A major concern lies in the 
inadequate supply of trace metals. If these are not included 
in TPN mixtures, a variety of protein and collagen biochemical 
processes are soon impaired and this is then followed by the 
development of overt deficiency symptoms • [1873,1877,1977,1978,1979]
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Zinc is particularly important in this context because
(i) it has a major function in tissue repair [1235,1885],
(ii) its urinary excretion tends to be increased after surgery 
[1983] and (iii) urinary losses are further promoted by the TPN 
infusions themselves, more so in fact than occurs with any of 
the other transition elements {vide infra),
Some clinical attempts to supplement trace metal concen­
trations in nutritive mixtures have been made [1873,1877,1879] but 
doses appear to have been chosen somewhat randomly and very little 
correlation between administered levels, plasma concentrations 
and overall metal ion balance was observed [1879]. It has been 
suggested that supplying zinc in excess of the measurable losses 
would satisfy the body’s requirements [1981]. Such an approach 
remains empirical and difficult to generalize as this amount 
will vary from one patient to another. Furthermore, the
relationship between the nutritive requirement for a metal ion 
and its rate of excretion is obscured by the nutritive treatment 
itself, as discussed below. It was, therefore, decided-to •
investigate the effect of TPN mixtures on the metal-ligand 
equilibria in blood plasma to identify the most important 
interactions and if possible, suggest ways -of estimating the 
specific dose-s of trace elements that ought to be included in 
future TPN preparations.
It is well documented that the infusion of naturally 
occurring ligands into plasma can cause a prompt and pronounced 
increase in the urinary excretion of trace elements, especially 
zinc. For example, intravenous administration of 250 pg.hr*"^
of histidine for .three successive hours gave rise to zinc 
• -1excretion rates of 7.6, 20.2 and 16.0 pg.hr compared with 
0.4 pg.hr"'’’ beforehand [1880] . This is in ‘Line with the fact 
that oral histidine greatly increases zinc concentrations in . 
urine as has been shown u/ith rats [857] , dogs [18713 and man 
[19823 . Other natural chelating agents can produce the same 
sort of response: high.urinary zinc losses are also introduced 
by cysteine [18713 and certain sugar-amine compounds [17463 
but not by glycine [18713• ,
To identify the most predominant effects of the TPN 
infusions on the metal-ligand equilibria in blood plasma it was 
decided to imitate the infusion process by calculating the changes 
in amino acid concentrations that occur u/hen successive aliquots 
of the TPN mixture are introduced into a fixed volume of plasma. 
This static description does injustice to many aspects of the 
real system but u/ould seem to provide the most satisfactory first 
order approximation as to hou/ the ligand concentrations tend to 
be affected. There are several mitigating factors in favour of 
this approach: (i) pertinent experimental data is difficult to 
obtain, u/ould vary considerably in accordance u/ith the subject’s 
nutritional status, and could not be compared u/ith the blood plasma 
of healthy individuals, (ii) pou/erful homeostatic controls are 
imposed on plasma component concentrations, and (iii) the metal- 
ligand interactions are generally very fast, whereas the 
clinical infusion rate is relatively slow. In all the calculation 
discussed here, the nutritive mixture most commonly used in the
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TPN unit at the University Medical Centre of Poitiers has
been adopted EC.Matuchansky, personal communication]. Its 
composition is depicted in Table 4.5.
The results of the computer simulations show that the 
percentage distributions in normal plasma (Table 4.5) are largely 
unaffected by the TPN infusion. This is because the input 
ligand concentrations tend to remain in a fixed ratio to one 
another. However, there is a rapid increase in the size of the 
low-molecular-weight fraction of zinc. The appropriate P.M.I. 
curve is shown as Figure 4.4. Also included in Figure 4.4 are 
the corresponding P.M.I. curves for the infusion of the three 
amino acids, cysteine, histidine and glycine, by themselves.
It is clear that injection of the TPN fluid causes a greater 
relative mobilization of zinc from proteins than do any of the 
individual TPN components. Thus it would seem that the observed 
zinc excretion must be attributed to the additive action of 
two or more amino acids included in the fluid. Inspection of 
Figure 4.4 indicates these amino acids are probably cysteine
and histidine.
It is noteworthy that in perfect agreement with the 
animal experiments of Yunice et al. E1871] , the models predict 
cysteine will produce the greatest urinary zinc excretion, 
histidine will have a lesser effect and the influence of glycine 
will be almost negligible. The present results, however, argue 
against some interpretations made by the above-mentioned authors 
who concluded that the high excretion caused by cysteine was not 
due to an increase in filtered load. It seems highly unlikely
TABLE 4.5
Ligand composition of the nutritive mixture 
as used in the computer simulations
Ligand ■ — 3Concentration (mmol dm" ) 
s */, )
Alanate 20.66
Arginate - 27.81
Aspartate 5.824
Citrullinate 3.319
Cysteinate 1.672
Glutaminate 6.586
Glycinate 23.23
Histidinate 6.245
Isoieucinate . 7.534
Leucinate 20.53
Lysinate 18.32
Methionate 12.21
Ornithinate 3.428
Phenylalanate 14.66
Pr olinate 13.47
Serinate . . 2.397
Threonate 8.135
Tryptophanate . 2.467 '
T yrosinate 0.2674
Valinate 20.68
Phosphate 5.170 .
Sulfate 0.9690 .
Lactate 15.50
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from the results that histidine actually binds more zinc in 
plasma than cysteine and this in turn suggests that their 
in vitro techniques were hampered either by the facile aut- 
oxidaticn of thiol compounds C1985] or by a disturbance of the 
metal-ligand equilibria during their ultrafiltration procedure. 
The incrimination of cysteine as the agent primarily responsible 
for excessive zinc losses indicates that nutritionists should . 
look into the possibility of partially replacing this TPN 
component with more methionine. It has been established that 
the latter amino acid can be metabolically converted into 
cysteine Cl45,18903 so such a strategy may be able to minimise
the effect of TPN infusions on zinc balance.
Following an-idea suggested by Dr . G , Berthon, an attempt 
was made to obtain some quantitative idea as to how much of 
each trace element should routinely be added to TPN fluids. The 
object would be to replace the normal losses and compensate for 
the enhanced urinary excretion of the transition metal ions.
The proposal was to simulate the equilibria in the exogenous ‘ 
fluid using the free metal ion concentrations that pertain in 
plasma. By mixing two solutions with identical values for each 
free metal ion concentration, a redistribution of the metal ions 
amongst their- complex species would be avoided.
■ Thus, such an infusion would not disturb the normal metal 
protein binding in plasma. The increased low-molecular-weight 
complex formation would occur entirely at the expense of the 
metal ion supplement. On the other hand, if the free metal ion
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concentrations in the fluid being administered are higher or
lower than their corresponding concentrations in plasma, the
metal-protein complexes will act to buffer each free metal ion 
concentration with the consequence that the prevailing balance 
would be shifted in favour of excretion or retention of the metal.
Tables 4.6 and 4.7 show the computed percentage distribu­
tion of the predominant metal species and the total metal con­
centrations for a TPN mixture having the composition shown in 
Tables 4.1 and 4.5. By far the most important transition metal 
complexes are formed by zinc with about 90% of this metal bound 
to cysteine, histidine and glycine binary and ternary complexes. 
Within the accuracy with which the free metal ion concentrations 
are known, the predicted amounts of total metal to be included in 
the infusate are in very close agreement with the operational values 
used at present [C .Matuchansky, personal communication]. Indeed, 
they lie within the experimental limits in every case. A daily 
calculated intake of 507 mg of calcium is to be compared with 
500 mg actually administered. No doubt this eminently satisfactory 
agreement arises because the plasma free calcium ion concen­
trations are sufficiently high to have been measured directly 
by ion-sensitive electrodes [156,202]. Much greater attention 
has been paid to this alkali earth metal than to the transition . 
elements so the above result provides the strongest indication 
both of the reliability of the model and of the simulation 
technique itself. With magnesium, the predicted dose lies 
between 200 and 400 mg.day"’\ whereas the real quantity
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TABLE 4.6 ’
-• 5*
Percentage distribution of Ca(II), Mg(II), Zn(ll),
Cu(II), and Mn(II) amongst their most predominant 
complexes in the nutritive mixture at- ~logCH+3 = 7.4
y/ Mt bu. WmAaA, C-irv. b<r*.fc^vk$ tt, (.r-w
Complex species Percentage of the total metal
CCa(P04)]~ 11
[Ca(LysO)H2]3+ 1°
[Ca(lact0)] +
[Ca(ProO)HZ+]
7
5
CCa(ArgO)H]3+ 5
[Ca(GlyO)H]2+ 3
rCa(PO4)H3 2
CMg( LysO )H23 + 16
CMg (Ar gO) H] + 11
CMg(GlyO)H]2+ 5
CMg(LactO)]+ 5
CMg(ProO)H] 4 ’
CMg(P04)H3 4
CMg(LeuO)H] 3
CMg(AlaO)H]2+ 2.
fZn(HisO)(GlyO)2H] 31*
CZn(CysO)(HisO)3~ 18
CZn(HisO)2(GlyO)H] 12
/ c o n t cl
»z
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Table 4.6 (contd)
The ligands are represented by symbols as follows:
AlaO = alinate; ArgO = arginate; CisO = cystinate;
CysQ = cysteinate; GluO = glutaminate; GlyO = glycinate;
HisO = histidinate; LactO = lactate; LeuO = leucinate;
LysO = lysinate; MetO ± methionate; PheO = phenyla inate;
ProO = prolinate; ThrO = threonate; V-alO = valinate.
The calculations are based on the free metal ion concentrations 
shown in Table 4.1 and on the total ligand concentrations for 
the nutritive mixture shown in Table 4.5.
-X- ’These values are probably too high. They are calculated from 
published formation constants C158], but following the usual 
approach towards complex species which appear to be significant 
the zinc-histidinatoglycinato system is presently being 
investigated experimentally. Preliminary results suggest 
that lower formation constant values may be applicable • 
CG.Berthon, personal communication].
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TABLE 4.7
Total concentrations and predicted doses for 
Ca(II), Mg(II), Zn(II), Cu(II) and Mn(II) in 
the nutritive mixture at- ~logEH+] = 7.4
Metal Total concentration Predicted dose
(mol dm""} (mg/day)
I V. 3........iw-Lfc. V V.
Ca(II) 4.905 x io-3 ' 507
Mg(II) 4.070 x io”3 247
Zn(II) 1.914 x io”4 52
Cu(II) 7.857 x io”6 1.5
*Mn(IX) 5.557 x io-12 io-6
The calculations are based on the free metal ion 
concentrations shown in Table 4.1 and on the total 
ligand concentrations in the.nutritive mixture 
shown in Table 4.5. The predicted dose is the 
calculated amount,of each metal in 2.580 dm of 
nutritive mixture, this being the usual volume 
administered daily.
V. Va.
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administered is just outside this range at about 450 mg.day'*’^'.
This large uncertainty in the case of magnesium arises because 
neither the free ion concentration in plasma nor the relevant 
formation constants are as well known as for calcium. The 
calculated daily amount of zinc lies between 25 and 50 mg. Although 
an average oral requirement of 20 mg is not strictly comparable, 
it suggests the model’s predictions are of the correct order of 
magnitude. Furthermore, the calculated amount lies within the 
range employed by Kay and Tasman-Jones [1877]. For copper, the 
figure of 1.3 mg.day~^ is a little higher than the 250-500 pg.day”^ 
which is currently injected but is again within the limits 
suggested by Jacobson and Wester E1879J . As no signs of copper 
deficiency arise with supplementations at their present level, 
there is little incentive to recommend an increase. The very 
small predicted dose of manganese indicates that for the time 
being at least this element can be neglected.
One other application of this study which is worth 
mentioning briefly concerns the intravenous infusion of single 
component chelating agent solutions. Clinical indications for 
this kind of treatment arise when the drug cannot be given orally 
because of poor intestinal absorption L"1849j . For example, this 
method is use.d to administer EDTA. It is of considerable practical
value to redress the losses of essential transition elements
which the chelation therapy induces. To illustrate this, consid.er a 
simulation of EDTA solutions comparable to those for the TPN fluid.
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It indicates that zinc should be added to medical preparations 
2 +of calcium disodium EDTA solutions in the ratio of 1 mole Zn 
to 3 moles EDTA. This should be sufficient to prevent any 
effects arising from the zinc excretion often associated •
with this kind of therapy £883,979,1043,1048,1064,1085,1159,1160 , 
1210,1260,1522,1712]. • •
In spite of the various above-mentioned successes, a 
number of the TPN-model'o limitations must be borne in mind. 
Although the formation constants and total ligand concentrations 
are generally speaking the parameters most accurately defined, 
even these need continual reassessment and improvement. On the 
other hand, the greatest uncertainty in the model arises from an 
inadequate knowledge of the free metal ion concentrations in 
plasma. There are also difficulties associated with the redox 
equilibrium situation in biofluids. Most importantly, perhaps, 
is the assumption that perturbations of the metal-ligand equilibria 
in plasma will for the most part manifest themselves i'n a changed 
degree of metal protein binding. Of course, this will not be 
the only effect. There are also implications for the distribution 
of each metal into and out of the blood plasma compartment.
Clearly, a large increase in the low-molecular-weight complex 
concentrations will not only provoke the enhanced urinary 
excretion of the metal ion but also tend to increase the amount 
of metal being deposited in tissues. However, if one considers 
that the infusions have metal ion supplements designed to maintain 
constant the binding ability of normal plasma towards each metal 
ion, it seems reasonable to assume that the body stores of the 
metal will not be dramatically affected, .
■
1
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4.2.4 Computer simulation of other biofluids
The computer models of metal-ligand equilibria described 
so far have had one very important characteristic in common.
They all referred to solutions in which the composition of the 
low-molecular-weight fraction was fairly easily defined. The 
total ligand concentrations could be accurately determined and 
were invariant. More significantly, perhaps, the free metal 
ion concentrations tended to be well buffered. There are few 
biofluids which satisfy these criteria to the same extent as . 
blood plasma. In many other cases, far less is known about the 
identity and abundance of the low-molecular-weight ligands 
although the situation is similar to blood plasma because metal- 
protein complexes occur at relatively high concentrations. Two 
examples are cerebrospinal fluid and cell cytoplasm. These are 
not of immediate concern, however, because as soon as the necessary 
data becomes available-, very good models could be constructed 
using the simulation techniques already developed. On the 
other hand, there are some instances where it would be very 
valuable to simulate solutions even though very little can be said 
about the extent of metal ion interactions with biological binding 
sites. Intestinal fluid is a case in point. The search for 
ligands to promote the absorption of essential trace metals 
would be greatly facilitated if orally-administered solutions 
could be simulated satisfactorily.
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In the past, attempts have been made to model metal- 
liqand equilibria in stomach and intestinal juices by 
considerinq only the reactions' between the metal ion and the 
administered drug C312,316,861,1275,1603,1608j, This approximates 
best to administration on an empty stomach for it assumes that 
dietary and digestive components can be omitted since (i) the drug 
exists at relatively hiqh concentrations and (ii) gastro­
intestinal factors have a constant influence on a series of 
aqents [1608].
Unfortunately, the second point is not always valid in 
the context of metal-liqand equilibria. Firstly, complex 
formation in the biofluid depends on the degree of endogenous 
competition for the-metal ion. Secondly, the volume of liquid • 
in which the druq is taken to have dissolved can never be mere 
than arbitrary. Rememberinq that a diminished free metal ion 
concentration discriminates against polynuclear complexes and 
that dilution favours mono- over bi-s-species , it is clear that 
a unique complex distribution cannot be obtained under these 
circumstances.
One of the chief advantages with computer applications, 
however, is that it is often feasible to survey a range of 
possible solutions. Accordingly, this is proposed for those 
biofluids in which the concentrations of neither the ligands 
nor the metal ion can be easily resolved.
There are two possible alternatives which might form a 
basis for computer simulation of intestinal fluid. On the one 
hand, the interaction between the metal ion and the biological
x?
binding sites may completely remove a portion of the metal ion
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available to the druq. Conversely, the effect may be more akin 
to the bindinq by protein molecules which has previously been 
described as a means of establishing a metal ion reservoir, The 
first situation can be simulated by considering the total metal 
ion concentration, whereas, in the second case, the free metal 
ion concentration is a more appropriate parameter.
Thus, by scanning both the free and the total concentra­
tions of a metal ion in the presence of a given concentration of 
drug, the entire profile of complexes which can be formed will be 
covered. More importantly, when two drugs of the same concen­
tration are compared, these scans of metal ion concentration 
represent the two extreme possibilities which ought to be 
considered. Of course, this does not discharqe the need to 
consider the effects of each drug at different levels: the metal 
ion scans will need to be repeated at a variety ofligand concen­
trations.
In this way, two representations of the complex distribu­
tion for every system can be obtained. The amount of each complex 
which is formed is expressed as a function of the total ligand 
and either the total or the free metal ion concentration. It 
is then possible to compare agents accordinq to any well defined 
criterion. As biological interactions will be considerably 
greater for transition metal ions than for liqands, it is reasonable 
to make such comparisons on the assumption that the different agents 
exist in the biofluid at the same total concentration, but even 
this is not strictly necessary.
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To illustrate hou/ this concept may be utilized, consider 
the intestinal absorption of a metal ion and how this may be 
promoted by a series of chelating aqents. Ligands which form 
the highest concentration of neutral complexes in the intestinal 
fluid are expected to enhance passive diffusion of the metal 
ion across the epithelium most successfully. Hence, each agent 
is ranked according to this criterion using both free and total 
metal ion scans at an appropriate free hydroqen ion concentra­
tion. The order obtained from each scan will rarely conflict 
but when they do so, the effect is merely to introduce some 
ambiguity into the model’s predictions. The same can be said 
for the comparisons made at various total ligand concentrations. 
The outcome is a decisive classification of the agents into groups 
of one or more according to their predicted ability of promoting 
the absorption of the metal ion. This can be unequivocably 
checked against animal screening experiments. The procedure 
is demonstrated in Example 4.1. .
4.2.5 Computer simulation and the role of copper in rheumatoid 
arthritis . .
"It has been said that everything is known about rheumatoid
arthritis except its cause, natural history and treatment. It is
one of the perversities of the human condition that the rarer the
disease, the more clearly it seems to be understood.....”
R.C.Williams 
(Ref.1987)
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EXAMPLE 4.1 SIMULATION OF INTESTINAL FLUID
Classification of chelating agents according to
ability to promote intestinal absorption of
transition metal ions •
Kratzer and co-workers [888,1232] have studied the effect of 
various chelating agents on the absorption of zinc ions from soya 
bean protein as reflected in poultry growth rates. Their results 
for those ligands which have been included in the computer data­
base of formation constants (Appendix A2) may be summarised as 
follows;
Ligand Percentage weight gain
Hydroxyethylethylenediaminetetraacetate (HEDTA) 120 
Ethylenediaminetetraacetate (EDTA) 100 
Nitrilotriacetate (NTA) 68 
Ethylenediaminediacetate (EDDA) 64 
Diethylenetriaminepentaacetate (DTPA) 26 
Cyclohexanediaminetetraacetate (CDTA) 8 
Triethylene tetramine (TETA) 8 
Prolinate (PRO) • 8 
Glutamate (GLU) . 0
Makar and Williams [2032] have recently considered Kratzer’s 
experiments using computer simulation models and the following 
analysis can be considered as an extension of their work.
Both total and free zinc concentrations were scanned for 
each ligand as described in the text to check that the relative 
complexing ability of the chelating agents was independent of . 
the values chosen. This was found to be the case. Representative 
results using arbitrarily chosen zinc concentrations are shown in 
the following tables. Note that these represent two extreme cases: 
the first is most applicable when there is no competition from 
endogenous binding sites and the second refers to situations in 
which the free metal ion concentration is perfectly buffered by 
proteins.
TOTAL ZINC CONC. = 10~8 mol dm"3
Ligand Log of 
<-3
species concentration as a function of charge
-2 • -1 0 + 1 4-2
DTPA - 8.0 - 9.0 -11.1
EDTA -12.5 - 8.0 -11.1
HEDTA - 8.0 -12.5
NTA -9.4 — 11.6 - 8.0
CDTA - 8.0 -12.7
EDDA -15.2 -10.8 - 8.0
PRO -13.5 - 9,9 -8.8
GLU -13.1 - 9.5 - 8.3
TETA - 8,0
/ c o n t d
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FREE ZINC CONC, = IO"15 mol dm~3
Ligand Log of species concentration as -2 -1 0
! a function of charge 
+1 +2
DTPA - 4.9 - 5.9 - 8.2
EDTA - 9.2 - 4.7 - 7.9
HEDTA - 5.6 -10.1
NTA -10.9 -13.0 - 9.4
CDTA - 3.9 - 8.6-
EDDA -16.2 -11.8 - 8.9
PRO -20.0 -16.4 -15.3
GLU -16.3 -16.1
TETA -11.59
It is evident from Kratzer's results that the zinc is able 
to be transported across the epithelium as complexes which are 
not necessarily neutral. it therefore seems reasonable to assume 
that it is the concentration of species with low charge density 
(+1, 0,- -1) that will determine how much zinc is assimilated. 
Accordingly, the computer simulation results can be condensed 
as follows.
Log of the concentration of species with 
low charge density (+1, 0 ,• -1)
TZn = i0"8mol dm"3 CZn2+] = 10“15mol dm”3
DTPA -11.1 - 8.2
EDTA -11.1 - 7.9
HEDTA • - 8.0 - 5.6
NTA. - 8.0 * - 9.4
CDTA -12.7 • - 8.6
EDDA - B.O - 8.9
PRO - 8.8 -15.3
GLU - 8.3 -16.1
TETA • ~ -
The table shows that HEDTA will, under all circumstances, 
carry the metal as a complex of low charge density to a greater extent 
than any of:the other agents under consideration. In this respect, 
moreover, the ligands EDTA, DTPA and CDTA are found in the same rela­
tive order whichever model is used. Hence, it can be predicted that 
to promote zinc assimilation EDTA will be better than DTPA which in 
turn will be superior to CDTA. Finally, the models show that TETA •,
must always be amongst the agents with least effect because it is ■'
unable to form complexes with a charge less .than +2. In all these 
instances, the model's predictions are in accord with Kratzer’s 
experimental data. •
The term rheumatism is generally used to refer to 
painful disorders of the joints and muscles which cannot be 
directly related to an identifiable infection or injury. There 
is actually a wide range of connective tissue diseases which 
are rheumatoid in nature [198-7-19893 . The most common of these 
is rheumatoid arthritis. It afflicts over 5% of the population 
of the western world [19883 and is particularly prevalent amongst 
the elderly. It usually manifests itself as small nodules of 
inflamed fibrous tissues around the knuckles and wrists, 
eventually causing irreversible functional damage to the joints.
The origins of rheumatoid arthritis are unknown but many 
suggestions centre upon a breakdown of the patient’s autoimmune 
system [1987,19883.- It seems that, for one reason or another, 
an anti-inflammatory response to physical, emotional or hormonal 
stress is not properly regulated by the usual feedback mechanisms 
and the irritation thus continues to stimulate itself. It is 
clear that the disease is a complicated expression of many .
interrelated cellular and molecular processes. So, in common 
with many pathologies which stubbornly resist modern medical 
efforts, it is difficult to remedy because there is no unique 
and identifiable biochemical lesion [19873 .' However, agents 
which suppress the inflammation interrupt the self-perpetuating 
process and can thus be used to control the disease if not to cure 
it. This explains why the pain can be alleviated by a multitude 
of immunosuppressive agents as well as salicylates, certain 
acid drugs and, more recently, metals.
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4.2.5.1 Copper and inflammation
The fact that copper occurs in plant and animal tissues
was reported in 1816 [1990] but its essentiality was not established
until 1928 when copper-deficient rats were shown to develop 
anaemia [1991]. Dietary deficiencies were subsequently found in 
several larger animals [1992]. There followed a host of reports 
about disorders which arose from insufficient dietary copper, • 
ranging from bone deformation to cardiac malfunction [403,1993], 
Fortunately, the element is so widespread in nature that the daily 
intake of most mammals more than satisfies their requirements..
A general, nutritional copper deficiency in man is thqs
exceedingly rare but there is now much evidence that localised 
copper imbalance is related to rheumatoid arthritic conditions.
•I
I
■v:
For many years this evidence remained somewhat circumstantial.^
■
Elevated concentrations of total serum copper, are very charac­
teristic of the disease [470,491,494,496,1511,1970,1971,1996, 
2001,2003] but the cause of this, an increase in ceruloplasmin 
levels [491,1972,2005] is observed in many inflammatory conditions 
and may only be secondary to this kind of pathology [1969,1973, 
1995,1996,2004,2006], Likewise, many folk-lore remedies fox' 
rheumatoid arthritis (most notably copper bangles) have an obvious 
link with trace element but it is difficult to prove that they
Ia
1
■J
I
confer any real benefit. The amount of copper involved is usually
■ ■'$
very small so most assessments become dominated by psychological •a
factors. The.attitude of patients, for example, is often
substantially determined by their first experience of a treatment
.‘ti
■1
I
s
' Vi
■ -...-a
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and thus coincidental remissions, due to characteristic 4
oscillations in the severity of the disease, are prone to make 
very strong impressions. Indeed, it can be argued that any 
new approach prompted by an acute bout of suffering is more |
than likely to appear efficacious.
s
However, there is now overwhelming evidence that a direct 
connection between copper and rheumatoid arthritis exists. The «
essence of this is that (a) low-molecular-weight copper concen­
trations in plasma and synovial fluids are increased as part of 
the body's natural response to the disease and (b) when such |
increases are induced by copper administration they are observed |
' I
to have a most potent antiinflammatory effect. 7|
■' The antiinflammatory activity of a multitude of copper f
compounds has been demonstrated by several investigators using a 1
wide variety of animal screens [754,1005,1273,1603,1740,20073. 
Although there is no completely satisfactory animal model of 
rheumatoid arthritis [20083 » these results strongly suggest that 
it is in the control of inflammation that copper primarily
• J
manifests itself against the disease.
There are sharp increases in both the ceruloplasmin and 
non-ceruloplasmin concentrations in response to infections, 
irritants and inflammation [403,1996,2002,2009,20103. Lorber §
et al were the first to report statistically significant elevations M 
of total serum copper concentrations in rheumatoid arthritis [4913 .
In normal individuals ceruloplasmin accounts for most of the 
total [490,5 80,999,1466,15103 but in those suffering from ■
rheumatoid arthritis there is a large increase in the non­
ceruloplasmin fraction [4913. Certain findings that contradicted |
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the above generalisation [489] have been attributed to the 
methodologies used [490] but as Sorenson has pointed out [1740] 
they may also reflect differences in the activity of the disease 
in each of the sampled populations. It seems likely that the 
increased non-ceruloplasmin and hence increased low-molecular- 
weight copper concentrations may arise from an accelerated 
turnover of ceruloplasmin during arthritis [2005].
The first report that a low-molecular-weight copper 
complex was-effective against rheumatoid arthritis appeared 
as early as 1941 [2011]. ’ Sorenson and Hangarter have reviewed 
the treatment of some 1500 patients since then, with a variety 
of copper compounds [1611]. These preparations all bring about 
marked reductions in inflammation and Permalon particularly 
shows very few toxic reactions. Indeed, they exhibit an 
anti-ulcer activity [744,1273] which is significant because 
gastrointestinal irritation commonly necessitates treatment by 
many anti-arthritic drugs to be abandoned [1740]. This is in 
line with the role of copper in generally preventing gastro­
intestinal damage by acidic anti-inflammatory agents [1337,2012]
Sorenson has also reviewed a great deal of additional 
evidence concerning copper complexes as anti-arthritic drugs 
[1740] so only two pertinent examples that have arisen recently 
will be mentioned here. First, speculation about the thera­
peutic efficacy of copper bracelets has been placed on a more 
scientific footing: the dissolution of metallic copper in 
human sweat has been quantified [1127], its dermal penetration
studied [1470] and its positive beneficial effects against
135
rheumatoid arthritis demonstrated in a clinical trial [11273. 
Second, the need to maintain a minimum level of copper in tissues 
for the control of inflammation has been established by •
Milanino et al who showed that copper-deficient rats were 
significantly more susceptible to carrageenan-induced oedema 
than control animals [2013].
As stated previously, the mechanism by which copper acts 
as an anti-inflammatory and anti-arthritic agent is still 
unknown but.many plausible hypotheses have been put forward.
Most conventionally, the'metal may affect the balance betw.een the 
prostaglandins PGE2 and PGF^ which regulate the autoimmune response 
[779,956,20143. The anti-inflammatory activity of PGF2 is 
stimulated by the presence of Cu(II) [7793 possibly because the 
metal is required for its biosynthesis. Alternatively, Cu(II) 
may reduce the availability of glutathione, one of the PGE2 
precursors [7793 or inhibit fatty acid dioxygenase (which initiates 
the conversion of unsaturated acids to prostaglandins) ['950,10423.
Other possible roles for copper involve its metallo- 
enzymes. Lysyl oxidase, needed for collagen and elastin 
synthesis [480,785,984>12543, has attracted much attention because
W-
of the potential pathological significance of defective connective 
tissue synthesis in rheumatoid arthritis [17403. Similarly, 
diminished concentrations of the copper enzyme superoxide dismutase 
may permit increased synovial tissue irritation by hydroxyl 
and/or superoxide radicals [965,1001,1002,19583. Copper may also 
participate in the stabilization of membranes, especially the 
lysosymal membrane, by maintaining disulphide linkages in their 
oxidized form. Although it is unlikely that Cu(II) ions would
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ever be present in sufficient concentration to achieve this by 
themselves, the biological mechanism may well invoke oxidation 
by some copper-containing species.
It has been suggested that the effect of copper may be 
due to tissue irritation at the site of injection £1827,2015]. 
Indirect suppression of an experimentally induced kaolin or 
carrageenan-oedema would be expected in the face of a natural 
anti-inflammatory response. This may involve corticosteroids 
or even copper itself £1740]. However, the effect is neither 
sufficiently large nor sufficiently related to copper’s anti­
inflammatory activity to account totally for it £754,1603]. 
Nevertheless, it does raise the important point that unless 
ligands are both powerful and specific binders of the metal, in 
most biofluids dissociation of the complex is likely to occur.
In extreme circumstances, copper complexes will thus exhibit 
the well known toxic effects of copper salts, albeit to a 
lesser extent.
Too little attention has been paid in the literature to 
the labile nature of many copper complex systems in aqueous 
solution. A surprisingly large number of solids have accordingly 
been prepared (and structurally analysedl) before administration 
when a simple mixture of the ligand and copper salt would equally 
have sufficed. Conversely, experiments designed to demonstrate 
the effectiveness of pre-synthesised complexes over their 
components rarely, if ever, take sufficient account of either the 
effect of dissolution or of the species which are subsequently 
formed.
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An important example of this concerns the complexes 
of copper and salicylate. Many studies, carried out on both 
animals and humans, have concluded that a copper salicylate 
species is the active anti-rheumatoid agent [754,1049,1611,2016, 
20173. This seems unlikely in view of the general anti­
inflammatory properties of copper exhibited with a wide variety 
of ligands. It also neglects the fact, revealed by computer 
simulations of the relevant metal-ligand equilibria, that such 
complexes are thermodynamical J. y unstable in plasma. If they 
enter the biofluid as solids, the tendency will be for them to 
dissolve and, once in solution, they will rapidly dissociate.
Arena et al have thus concluded that the observed synergistic 
effects shown by copper salicylate over its components arise 
because the complex formed in intestinal fluid is neutral and 
hence facilitates the absorption of the metal ion [1607]. It is 
also conceivable that a slow dissolution of the solid might 
itself be beneficial if it served to maintain a low but constant 
concentration of the neutral species in solution.
These computer-based predictions about the fate of most 
copper complexes introduced into plasma are strongly in accord 
with the antiinflammatory screening data available for a wide 
range of copper-ligand complexes and mixtures [754,1603]. When 
the preparations are administered subcutaneously (i.e. in such 
a way that they can pass into plasma w.ithout having to traverse 
a membrane) a striking correlation emerges between the total 
amount of copper injected and the observed reduction in inflamma­
tion [1603]. This implies that the nature of the complex formed 
by the variety of ligands concerned, does not influence the result
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Rather, it is the increased availability of copper ions per se 
which affords protection against the inflammation. Whatever the 
mechanism through which copper . acts, it is able to aquire the 
metal ion from the labile equilibrium system in plasma once the 
complex has dissociated and the metal ion been distributed 
proportionally amongst serum albumin and the naturally-occurring 
low-molecular-weight ligands (see Section 4.2.1.).
In striking contrast to the results obtained when the 
copper complex solutions are administered subcutaneously, oral 
doses proved almost totally ineffective [1603]. From this it 
was concluded that the complexes in question were not sufficiently 
robust to be absorbed intact through the stomach or intestinal 
membranes. Natural homeostatic mechanisms [822,827,18393 evidently 
compete with the labile metal species to prevent excessive
assimilation of the trace element. This underlines the idea that
it is not a general copper deficiency that needs to be treated 
but rather a localised imbalance which can be corrected by an 
overall supplementation. The principles by which these homeostatic 
processes may be bypassed in order to introduce therapeutic 
amounts of copper into plasma without resorting to direct 
injection are discussed in Section 4.2.5.3.
4.2.5.2 Copper,rheumatoid arthritis and penicillamine
The simulation techniques pertinent to rheumatoid arthritis 
that were discussed in Section 4.2.4 are still too new to have 
demonstrated their full potential. However, in one major respect, 
computer models have already proved to be a valuable tool for
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unravelling the relationships between the metal ion and
ligands involved in the ’ treatment of this disease. The
instance concerns the drug penicillamine C8~mercaptovaline).
It was in the treatment of Kinnear Wilson’s disease 
that penicillamine was first clinically applied. This affliction 
arises from a defect in the mechanism through which copper is 
excreted in the bile [1013]. Untreated, it leads to an
increasing copper overload that is ultimately always fatal.
In 1954 Walshe discovered that penicillamine produces an 
extraordinary increase in urinary copper excretion and so offered 
hope to many who would otherwise have been condemned to progressive 
degeneration of the nervous system and finally to the failure of 
organs such as the liver [341,1013], A host of investigations 
concerned with the interaction between penicillamine and copper 
metabolism have followed [884,944,1021,1047,1050,1112,1119,1191, 
1285,1718,1720].
Since then, penicillamine has also been introduced for 
a wide variety of other medical purposes [492,1010,1625]. It is 
the chelating agent of choice for many heavy metal poisons 
[1012,1014,1019,1039,1048,1058,1071,1095,1096,1097,1117,1118, 
1322,1343,1721,1755,1881,1887]. Most recently, it has become 
established as one of the most effective means of combating 
rheumatoid arthritis [1105,1236,1259,1538,1576,1627] .
The mode of action of penicillamine in the treatment of 
rheumatoid arthritis is a complicated one [20.19] . The drug 
prevents connective tissue proliferation and the accummulation 
of rheumatoid components [1502,1505,1961,1962,2019] but It is
140
not known with certainty how it does so. Jaffe showed that 
there is a latent period before a course of treatment comes 
into full effect and that its influence persists long after 
discontinuation [1105,1964,1965,1966]. The pharmacokinetics 
of the compound are not responsible for this [917,1061] so that 
hypothetical mechanisms based solely on a. simple depolymerisation 
reaction [1962,1966,1967] or on the inhibition of a single 
biosynthesis [985,988,1505] are, at least, incomplete.
One aspect of the anti-rheumatoid activity of penicillamine 
may be exerted through its effect on copper metabolism. Such a 
connection was originally explored by Gerber [495,1109,1612] and 
has since gathered much support. At first sight, the excretion 
of copper caused by- the drug may appear to argue against this 
for inflammation is controlled by copper administration. However, 
the paradox disappears if ene considers penicillamine to be, 
primarily, a copper mobilizing agent. It thus results in an 
enhanced urinary excretion of the trace element but may also 
temporarily increase the concentration of copper in the tissues.
This leads to the question of how penicillamine mobilises 
copper. The compound has become something of a panacea for 
treating heavy me.tal toxicity so it is easy to conclude that 
powerful chelation lies at the heart of its effect. In other 
words, one assumes that it acts upon the labile copper equilibria 
in plasma in the same way as it.does for other transition metal 
ions like cadmium, mercury and nickel [1005,1016,1285,1718].
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The information which can be obtained from computer 
simulations of penicillamine in blood plasma suggests otherwise. 
There is a clear distinction between the interaction of this 
ligand with copper and with other metal ions. As may be seen from 
the P.M.I. curves shown in Figure 4.3 (p.109) Trien (triethylene- 
tetramine) is the most powerful of the copper binding agents 
studied. Penicillamine exhibits similarly large P.M.I. values 
at relatively low drug concentrations with zinc and lead. This 
suggests that the drugs are capable of transferring these metal 
ions from serum albumin into the low-molecular-weight fraction.
The charged, complex formed by Trien (CuL^+) is clearly amenable 
to renal excretion, as is indeed observed [9443.
The manner by which penicillamine produces its copious 
cupruresis is not so straightforward. As the vast majority of 
exchangeable copper ions in plasma are bound to serum albumin 
in their divalent state, the drug cannot interact with them without 
being oxidized [3693. On the other hand, when the oxidised form 
of the ligand is compared with Trien, it is' evident that it is . 
a relatively weak chelator of copper(II) under the conditions 
pertaining in blood plasma. This computer-based prediction 
is substantiated by the fact that penicillamine disulphide 
does not itself increase copper, excretion [13223.
The traditional biomechanism claimed to cause the copper 
excretion is that of 'reductive chelation' [7373. At best 
this is an oversimplification because a second molecule of 
reduced penicillamine would be required to bind the reduced 
copper(I) ion after it had been liberated from the protein.
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In fact, the labile nature of the equilibrium means that
special mechanisms for the metal’s release from serum albumin 
[269,737] are superfluous. Moreover, the feasibility of '
copper(I)-penicillaminate complexes existing in blood plasma 
at concentrations sufficient to give this drug its unique 
bioinorganic properties seems doubtful [1048,1112,1343]. There 
is a large surplus of ligands in plasma which prefer to bind 
copper in its higher oxidation state and furthermore, the 
penicillamine would have to compete for copper(I) ions against 
high naturally-occurring'levels of cysteine [666]. •
Such a possibility has not yet been fully assessed by
computer model calculations for it would require a complete
thermodynamic appraisal of the oxidised and reduced forms of
cysteine as well as penicillamine reacting with both oxidation
states of copper. Some of the necessary data has recently been
determined by Osterberg et al [2020] but further experimental
work and more calculations are still required. For the moment,
however, the verdict must be that the role of copper(I) complex
formation is no more than borderline: it is probably not
crucial to the mechanism by which penicillamine promotes copper
excretion. . •
Mention should be made of the red-violet, ’mixed’ copper 
•5 -complex [Cu (11) ^Cu (I) gPen^C 1] , the chemistry of which has
been widely studied under the assumption that it is biologically 
relevant. This was implied by early experiments in which this . .
polymeric species was identified in the plasma and urine of 
animals [1128]. As the experiments commenced with the administration
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of the complex, in fact they provided no evidence that it was 
formed in vivo. Computer model studies were the first to 
suggest that this could not happen in blood plasma because of 
the extremely low metal ion concentrations occurring in the 
biofluid. It was shown experimentally that the same was true 
of the .urine [14743. A comprehensive appraisal by Laurie and 
Prime [2021] has now confirmed these conclusions. Thus, if the 
complex is ever formed in vivo it must be within cells where 
the redox potential and absence of serum albumin may permit 
sufficiently high levels of eopper(I) and copper(II) ions but 
even this possibility should be regarded with considerable 
reservation. On the other hand, the slow release of both copper 
and penicillamine from this or similar complexes that will .
occur after their administration into plasma may be a means of 
producing a two-edged attack on rheumatoid arthritis.
The question thus remains: what is the modus operandi 
of penicillamine on copper metabolism and where does it act? 
Recent reports increasingly suggest that the source of the copper 
is the liver [1659,20223. As opposed to Trien which depletes 
plasma copper levels until a certain limit is reached, 
penicillamine causes an excretion of copper proportional to the 
drug’s dosage and there is a simultaneous reduction in liver 
copper concentrations [20223. These observations are consistent 
with the idea that Trien competes for the limited amount of the 
metal ion bound to serum albumin whereas penicillamine taps a 
much larger supply.
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As penicillamine and triethylenetetramine derive 
copper from different body compartments [944,1285], it seemed 
likely that simultaneous administration of the two agents 
would produce a synergistic cupruresis. This was tested in a 
recent investigation by Planas-Bohne but was not confirmed [2022]. 
It appears that there is a definite limit above which higher 
doses of either triethylenetetramine or triethylenetetramine 
and penicillamine do not cause greater copper loss. This is 
understandable if the rate of excretion is governed by the 
capacity of the labile equilibrium system in plasma. Perhaps the 
synergistic effect will be observed at drug concentrations which 
do not exceed the above-mentioned limit. If so, the required 
doses of penicillamine used to treat Wilson's disease may be 
reduced and thereby help to minimise adverse reactions to it.
Another pertinent interaction of penicillamine has just 
been established by Pi.ckup et al [2025] . They found that unlike 
patients on other anti-arthritic therapies, those taking this 
compound had significantly raised histidine concentrations in 
their blood plasma. Their observation is of particular interest 
because Gerber has demonstrated that concentrations of free 
histidine are characteristically depressed in rheumatoid arthritis 
[2025,2025] and that this permits an aggregation in synovial 
fluid of degraded gamma globulin [1109] being both inflammatory 
and antigenic [1965,2026]. The sulphydry-l-dependent denaturation 
of gamma globulin is inhibited by mixtures of cystine, histidine 
and copper(II). as well as by penicillamine disulphide and 
copper(II) [1109,1612], So it seems that complexes of the metal
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ion lie at the crux of at least two possible mechanisms by
which penicillamine may suppress the immune response. Computer 
models have played a striking role in elucidating these' 
relationships: they not only identified copper(II) cystinate
histidinate as the most appropriate ternary species for experi-
*
metal consideration, but also showed that, of all the naturally 
occurring amino acids, changes in plasma histidine concentrations 
will do the most to disturb the copper ion equilibrium with 
the tissues (see Section 4.2.1.).
The unique action of penicillamine on copper metabolism 
is likely to depend on a property that distinguishes it from 
other chelating agents particularly the very similar, naturally- 
occurring mercapto-amino acid, cysteine. There are at least” 
three possibilities to bear in mind. First, penicillamine may 
have an effect when cysteine does not because it is not 
homeostatically regulated. Second, it may disrupt copper- 
metalloprotein synthesis by being incorporated erroneously 
instead of cysteine. Third, it may specifically reduce- and 
therefore extract copper from some inert metalloprotein.
The possibility that penicillamine might be removing copper 
from plasma ceruloplasmin has been investigated C1602]. Copper 
liberated fro.m this metalloprotein could cause a very significant 
increase in the amount of the metal ion bound to serum albumin 
and to lo-w-molecular-weight ligands. Serum and ceruloplasmin 
solutions were treated with a variety of chelating agents including 
penicillamine and then separated into different fractions by 
ultrafiltration. Although the chelating agents did remove copper
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from the nietallopr otein, a comparison of their relative abilities 
to do so very strongly suggests that copper mobilization by 
penicillamine in vivo does not- occur by such a mechanism.
One potential target for penicillamine is obvious: 
metallothionein in the liver is normally rich in both zinc and 
copper .[990,1635,1636,1637,1785,1790,1791,1833] . It is tempting 
to speculate that an ability to remove transition metal ions 
from metallothionein may be partly responsible for the striking 
success of this drug in the treatment of heavy metal poisoning.
It is clear that an improved understanding of penicillamine 
biochemistry u/ould be valuable in many medical contexts. This 
section has focussed only on how the drug interacts with copper 
metabolism yet, in spite of all the research devoted to this 
question, there remains plenty of scope for further investigation.
4.2.5.3 Designing copper complexing agents for the control 
of inflammation
The ab initio design of therapeutic agents usually depends 
on a knowledge of the difference between health and disease at
a molecular level. As the causes of rheumatoid arthritis are 
not yet well understood, it may therefore seem that a complete 
cure is not likely to be soon forthcoming. However, the observed 
effect of copper on inflammation provides a basis which can be 
utilized in the meantime. Whatever the mechanisms by which the 
metal achieves its observed biological effects, the aim clearly 
should be to increase the supply of copper at the sites of injury.
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The rationale for designing rheumatoid arthritis agents 
which reduce inflammation in this way depends’ on two fundamental 
assumptions':- . .
(1) the therapeutic effect of copper administration arises from 
an increase in the total labile copper concentration in body 
compartments such as the synovial fluid, and
(2) this increase is fostered by the formation of complexes
in plasma that can diffuse into the synovial fluid, i.e. through 
the separating membrane.
From the computer simulation results summarised in Section 4.2.1 
it is evident that the supply of copper to the tissues will be 
enhanced simply by increasing the labile copper concentration 
in plasma itself. Unfortunately, the use of injections as 
the most straightforward way of accomplishing this objective is 
too hazardous to be a practicable therapeutical solution.
Humans can tolerate relatively large amounts of orall-y- 
ingested copper but very much less when the metal is intravenously 
administered. For example, copper sulphate is widely used as
an emetic in doses as high as 1 g [2027J whereas a limit for
- • _3 •
intravenous injection of less than 1 mg dm of blood plasma 
has been suggested [20283. This is because under optimum 
circumstances less than one third of dietary copper is 
assimilated [610,1466,2029,20303 and this fraction is rapidly
transported by serum albumin to the liver for ceruloplasmin 
• ’ *
synthesis. On the other hand, copper injections are likely to 
exceed the binding capacity of albumin (albeit locally) and so 
the metal ions attach themselves to non-specific protein sites. 
This leads to a much wider bodily distribution of the administered
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metal and to haemolysis of red blood corpuscles.
Although it is possible to alleviate these undesirable 
effects by giving the injections slowly or subcutaneously and 
by using chelating agents to help attain equilibrium binding, 
such a means of administering copper remains too inconvenient 
and too problematical to be widely adopted for rheumatoid 
arthritis treatment. Other ways of delivering the metal to 
inflamed tissues are therefore required. Figure4.5 shows two 
general routes by which this may be accomplished. One involves 
copper supplementation by oral or topical administration. ' The 
other is based on liberation of endogenous reserves of the metal
stored in the liver or elsewhere.
For short term therapy, aimed at correcting a localised 
copper imbalance, endogenous rather than exogenous sources seem 
to offer the simplest solution. There are three ways of achieving 
this objective:- (1) by equilibrium competition for labile 
protein bound copper, (2) by decreasing the affinity of serum 
albumin for copper by allosteric effects, and (3) by extracting 
copper from inert metalloproteins. It was suggested in
Section 4.2.5.2 that penicillamine may operate by the latter 
mechanism. Fiabane and Williams ri604j have shown that many 
ant-i-rheumatoid drugs, such as Indomethacin, Naproxen, Ketoprofen 
and . Fenoproten a3?e capable of freeing copper bound to albumin 
by distorting the protein molecule and that there are certain 
parallels between their in vitro results and the efficacy of 
these agents in animal screens. It is not yet known whether this 
is part of the drug’s action in man.
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Enlarging the lo-w-molecular-weight copper fraction in 
plasma by taking the metal from endogenous sources will cause 
a metabolic redistribution of copper at the ultimate expense 
of its storage metalloproteins. In part, this is because the 
strategy will inherently increase copper excretion, most probably 
in the faeces. Sooner or later, therefore, all such approaches 
will require copper supplementation.
The evidence reviewed in Section 4.2.5.1 shows that 
orally administered copper can be beneficial even when little 
thought has been given to how well the metal ion is absorbed. 
Applying the principles outlined in Section 4.2.4, one should 
thus be able to substantially enhance the effect of copper supple­
mentation by a careful choice of ligands to maximise the amount 
assimilated. Factors such as the lipophilicity of the ligand 
and the stability and charge of the predominant complex formed 
in intestinal fluid clearly need to be considered. With lip-o- 
philicity, a balance must be struck between the ease with which 
the species penetrate biological membranes* and their consequently 
increased toxicity. Similarly, the complex formed in intestinal 
fluid must be sufficiently robust or inert to withstand the 
competition by the metal binding species in mucosal cells 
which homeostatically regulate copper absorption but, on the other 
hand, the complex must not be so powerful that it doesn't dissociate 
after it has entered plasma.
To bypass some of these difficulties, attention has been 
drawn to the possibility of copper supplementation by dermal
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application. The effect of copper bangles arises from the
dissolution of the metal by ligands present in perspiration 
[1127,2031] but as the complexes need to penetrate the epidermis 
before they can be transported into plasma via the lymph, 
similar considerations to those discussed for intestinal absorption 
apply. .
On the other hand, dermal assimilation has the advantage 
that there is no homeostatic control mechanism to be overcome.
Thus, suitable complexes u/ill not need to be so specific for 
copper(II) or so powerful. Gastrointestinal irritation by the 
metal ion is also avoided. For these reasons, topical applica­
tions of copper complexes for the treatment of rheumatoid 
arthritis appear most promising.
Although copper complexes have been used to treat 
rheumatoid arthritis for nearly forty years, it is only recently 
that they have begun to attract widespread interest. Pharma­
ceutical preparations involving copper are now available but have 
so far not been commonly employed in rheumatoid arthritis clinics. 
This is partly because the medical profession is somewhat 
reluctant to follow a line so long advocated by folk-lore but 
also because of the difficulty in demonstrating the therapeutic 
effects of copper ions without directly injecting them in solution. 
Hopefully this will soon be resolved by the improvement of topical 
and oral agents. Such progress will only be made possible by a 
better understanding of how to manipulate the in vivo concentrations 
of transition' metal ions generally. It is in this respect that 
computer simulations will make a major contribution.
CHAPTER FIVE
CONCLUSION
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5.1 Computer applications, past, present and future
Perhaps the most striking feature of the computer 
applications described in this thesis is their wide variety. 
Programs have been developed both to assist in the determina­
tion of metal-ligand formation constants and to model a number 
of systems with .bioinorganic implications. Compared to the 
many problems which have been addressed, however, few are resol*ved. 
This is particularly true of the computer simulations because 
of the fairly broad objectives which were initially set. On 
the other hand, a start has been made which, in many respects., 
can be considered most encouraging. •
Some may feel that the non-experimental nature of the 
models means that, at best, they can only provide incidental 
detail about the behaviour of transition metal ions in vivo.
Such a view underestimates the role of models in science. Their 
purpose is to'make predictions from hypotheses. By comparing 
the results of experiments against their simulated counterparts, 
it is possible to distinguish between good and bad ideas. In 
this way, complementary hypotheses that withstand the test of 
time can ultimately be fashioned into grander theories to account 
for a variety of natural phenomena. -
Then, 'there are other, albeit less fundamental, at'tributes 
of’models that ought not be forgotten. For example, they provide 
a background against which new experiments can be devised and/or 
evaluated. Unexpected results usually arise because the theory 
is incomplete or because of an experimental artefact. In the 
first case, systematic differences between the calculated and ,
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observed quantities may suggest ways to improve the theory
and in the second case, the situation is often made clearer . 
because all the important relationships in the system already 
need to have been carefully formulated.
The emphasis which computer simulations of meta-l-ligand 
interactions in biofluids have placed on the role of equilibria 
and kinetics in the metabolism of trace elements will probably 
prove to be their greatest accomplishment. Overly fascinated .
by the spectralcharacteristics of transition metals, chemists 
have tended to forget that evolution is swayed more by their 
coordination and redoxing properties C19753 .• The models 
have provided considerable insight regarding the chemical context 
in which all bioinorganic processes must occur.
A majority of the models' most specific achievements have 
been of a negative nature. A common example concerns metal complex 
species which are postulated to exist in plasma. Provided the 
formation constants are known,the relative ability of. the
complex to exist in the biofluid at equilibrium can often be 
reliably calculated. It may then be possible to state that such 
a species cannot form spontaneously from its components under 
the particular conditions. On the other hand, it can never be 
claimed so emphatically that a particular complex does pre­
dominate or even exist for, unlike the previous conclusion which 
is relative to other species in- the solution, to be certain of 
the positive predictions requires that a.11 the important inter­
actions have been taken into account. Only when .the performance 
of the models has been substantiated over a period of many years,
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can confidence in their more positive predictions be
considered justified.
As to the future, it would seem that the present 
equilibrium simulations are only a beginning. A thorough 
understanding of normal transition metal metabolism, how it is 
modified in disease and how it may be manipulated to restore 
good health is no longer just a dream. The stage is now set. 
How soon the goal is realised depends largely on how soon 
bioinorganic scientists learn to apply current knowledge to 
medical problems at a molecular level.
One contribution to this end would be. the further 
development of models for the simulation of transition metal 
ion interactions in. biological systems. Specifically, these 
should include a better description of (i) metal binding by 
proteins, (ii) kinetic factors, (iii) multiphasic solutions 
and (iv) multicompartmental systems. Thus a truly complete 
simulation of the absorption, transport, utilization and 
excretion of the trace elements would become possible. This 
is the computer application for bioinorganic chemists in the
future.
REFERENCES
155
-X*
10
11
12
13
14 
1 5
SCHMITZ H., ‘ARZNElM-FORSCH 
WILLIAMS R.J.P., ENDEAVOUR 
PERRIN D.Da, NATURE 1965, 206, 170 
KIBBY M.R., MATURE 1969, 222, 298 
SUSO F,A. AND EDWARDS H, M., NATURE 1 972 , 236, 230 
DANES D . M . , CARTWRIGHT E . , STEVENS B . J - 
AND TOWNLEY R.R.W., SCIENCE 1973, 179, 1140 
SCHUBERT J., SCIENTIFIC.AMERICAN 1966, 214, 40 
PASSY U. AND WILDE D.J„,
SIAM J. APPLIED MATHS. 1968, 16, 363 
ZELEZNIK F.J, AND GORDON S.,
CANADIAN J, PHYS. 1966, 44, 877 
S.R., J. CHEM PHYS 
4 . CHEM PHYS
KRIEGER F.J, AND WHITE W , B . ,
J. CHEM PHYS. 1948, 16, 358 
WHITE W.B., JOHNSON S.M 
J. CHEM PHYS. 1958, 28, 751
LEVINE H.B., J. CHEM PHYS.
DYRSSEN D., INGRI N. AND SILLEN L.G.,
ACTA CHEM SCAND. 1961, 15, 694
16 SILLEN L.G., ACTA CHEM SCAND. 1962, 16, 159
17 JOHANSEN E.S., ACTA CHEM SCAND, 1967, 21, 2273
18 INGRI N. AND SILLEN I • G , ,
ACTA CHEM SCAND. 1962, 16, 173
19 BIEDERMANN G. AND CHOW J.T.,
ACTA CHEM SCAND, 1966, 20, 1376
20 LIEM D.H., ACTA CHEM SCAND. 1971, 25, 1521
21 
22 
23
1971,*21, 509 
1967, 26, 96
BRINKLEY 
BRINKLEY S.R,,
1946, 14,
1947, 15,
563
107
G * BAND DANTZIG
1962, 36, 3049
TAN FORD C., 
TANFORD C., 
GURD F.R.N.
J. AMER CHEM SOC. 
J. AMER CHEM SOC. 
AND GOODMAN D.W.S.,
1950, 72, 441 
1952, 74, 211
J , ' AMER CHEM SOC. 1952, 74, 67-0
24 KLOTZ I. M., U R 0U HART J.M. AND FIES
J. AMER CHEM SOC. 1952, 74, 5537
25 SULLIVAN J.C. AND HINDMAN J . c» ,
J. AMER CHEM SOC, 1952, 74, 6091
* 26 WARNER R .C. AND WEBER I,,
J . A M E R CHEM SOC. 1953, 75, 5086
27 WARMER R ,C. .AND WEBER I . ,
J, AMER CHEM SOC. 1953, 75, 5094
* 28 GURD F.R . N. AND MURRAY G. R, ,
J„ AMER CHEM SOC. 1954, 76, 187
* 29 KLOTZ I. M . AND MIN G W.C.L • ,
J. AMER CHFM SOC, 1954, 76, 805
* 30 KLOTZ I. M., URQUHARf J,M« , KLOTZ T
J, AMER CHEM SOC, 1955, 77 r 1919
* 31 KOLTHOFF I . M. AND WIL L E F 0 R D B . R , ,
J. AMER CHFM SOC, 1957, 79, 2656
32 RAO M.S, N. AND LAL H„,
J , -AMER CHEM SOC. 1958, 80, 3222
33 RAO M.S. N. AND LAL H „ ,
J, AMER CHEM SOC. 1958, 80, 3226
34 LAL H., J. AMER CHEM SOC - • 1959,
w f
156
x- 35 PEARSON R „ G „ , J, AMER CHEM SOC,
36 CONROW K • » JOHNSON G.D. AND BOWEN 
J, AMER CHEM SOC, 1964, 86, 1025
37 NAGANO K. AND METZLER D.E.,
J. AMER CHEM SOC. 1967, 89, 2891 
3 8 S1J S.C.K. AND SHAFER J. A.,
J. AMER CHEM SOC. 1968, 90, 3861 
39 RING K » , ANGEWANDE CHEMIE 1970,
GROSS W., ANGEWANDE CHEMIE 1971
1963, 85, 
R ■ £ . r
3533
40
9, 345 
10, 388
* 41 BIEDERMANN G . AND SILLEN L ■ 6., ARKIV KEMI 1952 , 5, 425
42 INGRI N. AND SILLEN -L.G., ARKIV KEMI 1964 , 23, 97
43 SILLEN LwG. AND WARNQVIST B ARKIV KEMI 1969, 31; 377
* 4 4 brauner P,, SILLEN L.G. AND W H I T E K E R R . ,
ARKIV KEMI 1969, 31, 365
* 45 SILLEN L.G. AND WARNQVIST B . , ARKIV KE.MI 1969, 31 , 315* 46 SILLEN L.G. AND WARNQVIST B ARKIV KEMI 1969, 31 , 341
AND WAH LB ERG 
353
*
47 ARNEK R., SILLEN L, G. 
ARKIV KEMI 1969, 31,
48PERRIN D.D,, AUST J, 
49 MACKIE J.C., AUST J. 
5 0 WILLIAMS R . J , P . ,
CHEM SOC QUARTERLY
51 PERRIN D.D., J.
52 PERRIN D.D., J„
D.D. ,
CHEM
CHEM
1 958, 
1969,
11 , 612
22, 2041
53
54
55
PERRIN
IRVING
J •
1970,
1958,
1958,
1959,
J •
24, 331 
3120 
3125 
290
CHEM SOC
REV I EWS 
CHEM SOC.
CHEM SOC.
CHEM SOC.
H.M. AND STACEY M.H 
LANSBURY R.C., PRICE V . E , AND SMEETH A.G», 
J. CHEM SOC. 1965, 1896
1961, 2019
* 56 PERRIN D.D. AND SAYCE I.G., J „ CHEM SOC. A 1 967, 82
57 PERRIN D.D. AND SHARMA V„S. , J, CHEM SOC. A 1967, 724
x- 58 PERRIN D.D. , SAYCE I.G. AND SHARMA V.S.,
J . C HE M SOC , A 1967, 1755
X- 59 PERRIN D.D. AND SAYCE I.Gt, J . CHEM SOC . A 1968, 53
x- 60 PERRIN D.D. AND SHARMA -V . S , , J. CHEM SOC. A 1968, 446
X- 61 PERRIN D.D. AND SHARMA V»S. , J. CHEM SOC. A 1969, 2060X- 62 CHILDS C.W. AND PERRIN D.D. , J. CHEM SOC. A 1969, 1039
X- 63 WILLIAMS D. R., J. CHEM SOC . A 1970, 1550
64 CUMMING G.L ROLLET J.S., ROSSOTTI F.J .C.
AND WHEWELL R.J., J. CHEM SOC,. DALTON 1972, 2652X- 65 SABATINI A. AND V A C C A A , , •
J, CHEM SOC . DALTON- 1972, 1693X- 66 WILLIAMS D. R„, J. CHEM $OC . DALTON 1972, 790X- 67 WILLIAMS D. R. AND YCO P.A.,
J. CHEM SOC . DALTON 1972, 1988X- 68 GRAHAM R.D. , WILLIAMS D.R. AND YEO P.A.,
J. CHEM SOC . PERKIN 1972, 1876X- 69 WILLIAMS D. R., J. CHEM SOC . DALTON 1973, 1064
X- 70 SCATCHARD G . , CHEM REVIEWS 1933, 13, 7
X- 71 SCATC HARD G , , CHEM REVIEWS 1936, 19, 309
X- 72 WILLIAMS D. R., CHEM REVIEWS 1972, 72, 203
X- 73 VALLEE B.L. AMD WILLIAMS R. J »P .,
43
■ W-
CHEM BRITAIN 1968, 4, 397
&
157
379
74 MARCUS Y. AND ELIEZER I.,
CO-ORDINATION CHEM REV. 1969, 4, 273
75 NANCOLLAS GUI., CO-ORDINATION CHEM REV, 1 970 , 5 ,
76 BOND A.M., CO-ORDINATION CHEM REV. 1971 ,- 6, 377
* 77 SCHWARZENBACH G., ANDEREGG G, , SCHNEIDER W.
AND SENN H., HELV CHIM ACTA 1955, 33, 1147 
78 ANDEREGG 6., HELV CHIM ACTA 1962, 45, 901
* 79 HAWKINS C.J. AND PERRIN D„D.,
INORG CHEMISTRY 1963, 2, 843 
80 TOBIAS R.S. AND YASUDA M.,
INORG CHEMISTRY 1963, 2, 1307
* 81 TING-PO I. AND NANCOLLAS G.H.,
INORG CHEMISTRY 1972, 11, 2414
* 82 WILLIAMS D.R., INORG CHIM ACTA REVIEWS 1972, 6, 
83 GERGELY A., SOVAGO I., NA6YPAL I. AND KIRALY R.,
INORG CHIM ACTA 1972, 6, 435
123
* 84 EBERHART J.G. AND SWEET T.R, »
J. CHEM education 1960, 37, 422
* 85 BARD A. J . and king M . D . ,
J . CHE M EDUCATION 1965, 42, 127
* 86 PEARSON R , G • , J » CHEM EDUCATION 1968, 45,* 87 PEARSON R • G » , J • CHEM EDUCATION 1968, 45,
* 88 SHARMA V .. S . AND SCHUBERT J . ,
J, CHEM EDUCATION 1969, 46, 506
* 89 VILLARS D • S • , - J , PHYS CHEM, 1959 , 63, 521
90 TOBIAS R ,S. AND HUGUS Z„Z„,
J. PHYS CHEM. 1961, 65, 2165
* 91 ANTHONY R.G. AND HIMMELBLAU D.M.,
J. PHYS CHEM. 1963» 67, 1080
* 92 CRUISE D.R., J. PHYS CHEM. 1964, 68, 3797
93 MARCUS Y., PURE AND APPLIED CHEM. 1969, 18, 459
94 LUCA C. AND BERT HON G.,
PURE AND APPLIED CHEM. 1972, 31, 503
* 95 WILLIAMS R.J.P., R • I . C • R E V I E W S 1963, 1, 13
96 ROPARS C. AND VIOVY R.,
BULL SOC CHIM FR. 1966, 11, 3637
97 MARTIN R-P. AND BLANC M. ,
BULL SOC CHIM FR, 1969, 6, 1866
98 BONNET M. C. ■, PARIS R.A. AND MARTIN R~P„,
BULL SOC CHIM FR, 1972, 3, 903
* 99 FEENEY R.E. AND KOMATSU ST.K.,
STRUCTURE AND BONDING 1966, 1, 149
100 WILLIAMS R.J.P. AND HALE J.D.,
STRUCTURE AND BONDING 1966, 1, 249
101 AHRLAND S., STRUCTURE AND BONDING 1968, 5r 118
102 SPIRO T.G. AND SALTMAN P.,
STRUCTURE AND BONDING 1969, 6, 116
103 NEILANDS J.B., STRUCTURE ANDBONDING 1972, 11, 145
104 BUTCHER J, AND FERNANDO Q.,
ANAL CHIM ACTA 1966, 36, 65
105 UNWIN E.A., BEIMER R.G. AND FERNANDO Q«,
ANAL CHIM ACTA 1967, 39, 95
* 106 DYRSSEN 0, AND JAGNER D.> ANAL CIIIM ACTA 1968, 42, 333 
107 ANFALT T. AND JAGNER D., ANAL CHIM ACTA 1969, 47, 57
158
* 108 LUND W., ANAL CHl M ACTA 1969, 45, 109
109 SIEFKER J.R., ANAL CHIM ACTA 1970 , 52, 545
* 110 BOS M. AND MEERSHOEK H „ Q . J . ,
ANAL CIUM ACTA 1972, 61 , 185
* 111 PERRIN 0,0. AND SAYCE I.G,, TALANTA 1967, 14, 833
* 112 1NGRI N„, KAKOLOWICZ W., SILLEN L.G. AND WARNQVIST B,»
TALANTA 1967, 14, 1261
* 113 SAYCE I.G., TALANTA 1968, 15, 1397
* 114 CHILDS C.W.r HALLMAN P.S, AND PERRIN D.D.,
TALANTA 1969, 16, 629
* 115 CHILDS C.W., HALLMAN P.S, AND PERRIN D.D.,
TALANTA 1969, 16, 1119
116 KADEN T. AND ZUBERBUHLER A., TALANTA 1971, 18, 61
117 SHARMA V,S. AND LEUSSING D.Lw, TALANTA 1971, 18, 1137
118 SAYCE I.G. AND SHARMA V.S., TALANTA 1972, 19, 831
* 119 CUMME 6,A,, TALANTA 1973 , 20, 1 009
* 120 JABALPURWALA K.E., VENKATACHALAM K.A, AND KABADI M.B,,
J. INORG NUCL CHEM, 1964, 26, 1011
* 121 JABALPURWALA K.E., V E N K A T A C H A L A M K.A. AND KABADI M.B,,
J, INORG NUCL CHEM. 1964, 26, 1027
122 THUN H», VERBEEK F. AND VAN DERLEEN W.,
J. INORG NUCL CHEM, 1967, 29, 2109
123 ROMARY J.K., DONNELLY D.L. AND ANDREWS A.C.,
J, INORG NUCL CHEM. 1967, 29, 1805
124 NAGYPAL I,, GERGELY A, AND JEKEL P,,
J, INORG NUCL CHEM. 1969, 31, 3447
125 SPESSARD J.E., J, INORG NUCL CHEM, 1970, 32, 2607
126 ROSSOTTI F.J.C., ROSSOTTI H.S, AND WHEWELL R.J.,
J, INORG NUCL CHEM, 1971, 33, 2051
127 PYTKOWICZ R.M., GEOCHEM J. 1969, 3, 181
* 128 KARPOV I.K. AND KAZMIN L.A., GEOKHIMIYA 1972, 4, 402
* 129 SCHADE A.L., OYAMA J., REINHART R.W„ AND MILLER J „ R „ ,
PROC SOC EXP BIOL MED, 1954, 87, 443
130 SUSO F.A . ANO EDWARDS H
PROC SOC FXP BIOL MED, 1971, 138, 157
131 PRASAD A ,S. AND OBERLEAS D.,
P R 0 C SOC EXP BIOL MED. 1971, 138, 932
132 FROMMER D « , CLIN SCI , 1971, 41, 485
133 GUBLER C . J . , LAKEY M. E . , CARTWRIGHT G.E.
AND W I NTROBE M it M ■, J . - CLIN INVEST, 1953
* 134 JA.NDL J.H. AND KATZ J.H.,
J. CLIN INVEST. 1963, 42, 314
* 135 NEUMANN P.Z. AND SASS-KORTSAK A,,
J. CLIN INVEST. 1967, 46, 646
136 MOORE E.W., J . CLIN INVEST - 1970, 49, 318
137 BROWN E.B. AMD ROTHER M.L.,
J. LAB CLIN M E D . 1963, 62, 357
138 CHARLEY P.J . , STITT C , , SHORE E,. AMD SALTMAN P
J. LAB CLIN MED , 1963, 61, 397
139 BROWN E.B, AND ROTHER M.L.r
J . LAB CLIN MED , 1963, 62, 804
140 PRASAD A.S. AND OBERLEAS D. r
J, LAB CLIN MED . 1970, 76, 416
.A •• < \
159
-x-
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160 
161
162
163
164
165
166
167
168
169
170
171
1972, 30, 89
1969, 22, 837
108
ANO GREENBERG D.M.,
ANAL BIOCHEM, 
HIRSII-K0L3 H,, 
ANAL BIOCHEM,
*
COOK J,, j. LAB CLIN MED. 1970, 76, 497 
PEDERSEN K.O., SCANO J, CLIN LAB INVEST.
PORS NIELSEN S,,
SCAND J„ CLIN LAB INVEST. 1969, 23, 219 
CARTWRIGHT G . E , ANO WINTROBE M „ M . ,
AMER J, CLINICAL NUTRITION 1964, 14, 224 
BLOCK W.D., MARKOVS M.E. ANO STEELE B.F.,
AMER J, CLINICAL NUTRITION 1969, 22, 33 
DOWDY R.P., AMER J. CLINICAL NUTRITION 
MALMSTROM B,G, ANO NEI LANDS J.B,,
ANN REV BIOCHEM. 1964, 33, 331 
CUMMINGS N.A., KUFF E.L, AND SOBER H , A „ ,
1968, 22,
KOLB H.J,
1970, 34, 517 
H A Y A S H I T.T. AND G I L LIN G 8„,
ANAL BIOCHEM, 1970, 36, 343 
SUDMEIER J.L, AND PESEK J,J,,
ANAL BIOCHEM. 1971, 41, 39
SIGEL H., GRIESSER R., PR1JS B., MCCORMICK D.B,
ANO JOINER M.G„, ARCH BIOCHEM BIOPHYS, 1969, 130, 
GRIESSER R . , MCCORMICK 0 . B . , P R I J S 0 , ANO SIGEL H,, 
ARCH BIOCHEM BIOPHYS, 1971, 144, 628
PLOCKE D.J. ANO VALLEE B.L.,
BIOCHEMISTRY 1962, 1, 1039
MILDVAN A.S, AND COHN M., BIOCHEMISTRY 1963, 2, 91 
BOTTS J., CHASIUN A, AND SCHMIDT L, ,
BIOCHEMISTRY 1966, 5, 1360
REYNOLDS F.H., BURKHARD R.K. AND MUELLER D.D.,
BIOCHEMISTRY 1973, 12, 359
HALLMAN P „ S . , PERRIN D „ D • AND WATT A , E , ,
BIOCHEM .J , 1 971 , 1 21 , 549
GROEN J,, BIOCHIM BIOPHYS ACTA 1947, 1, 315 
PETERS T., BIOCHIM BIOPHYS ACTA I960, 39, 546 
CHARLEY P,J„, SARKAR B,, STITT C. AND SALTMAN p , , 
BIOCHIM BIOPHYS ACTA 1963, 69, 313
AASA R „ , MALMSTROM B.G,, SALTMAN P, ANO VANNGARD T., 
BIOCHIM BIOPHYS ACTA 1963, 75, 203 
HELBOCK H.J. AND SALTMAN P„, •
BIOCHIM BIOPHYS ACTA 1967, 135, 979 
GIROUX E.L. AND HENKIN R.I.,
BIOCHIM BIOPHYS ACTA 1972, 273, 64 
LIEM H.H. AND MULLER«EBERHARD U,,
BIOCHEM BIOPHYS RES COMMON 1971, 42, 634 
SARKAR B. AND KRUCK T.P.A.,
CANADIAN J, BIOCHEM. 1967, 45, 2046
SARKAR B., BERSOHN M„, WIGFIELD Y. AND CHIANG T«C„,
CANADIAN J. BIOCHEM. 1968, 46, 595,.
SARKAR B. ANO WIGFIELD Y . ,
CANADIAN J« BIOCHEM. 1968, 46, 601
SARKAR B., CANADIAN J. BIOCHEM, 1970, 48, 1339 
BLAIR J.MCD,, EUROPEAN J, BIOCHEM, 1970, 13, 384 
GUPTA G.S., IND J. BIOCHEM, 1969, 6, 94
514
160
17?
173
174
175
176
177
* 178
* 179
* 180
* 181
182
* 183
* 184
* 135 
186
* 187 
188 
1 39
* 190 
191
* 192 
193
* 194 
195
* 196
* 197
198
199
* 200
201
* 202 
203
MAZUR Am GREEN $„ ANO CARLETON A,t
J, BIOL CHEM, 1 960, 235 , 595
BRESLOW E., J. BIOL CHEM. 1 964 , 239, 3252
BATES G.W., BILLUPS C. AND SALTMAN P,,
J. BIOL CHEM, 1967, 242, 2810
BATES G«W., BILLUPS C . AND SALTMAN P.,
J. BIOL CHEM. 1967, 242, 2816 
SARKAR B. AND WIGFIELD Y»,
J, BIOL CHEM, 1967, 242, 5572 
PETERS T, AND HAWN C., J. BIOL CHEM 
PETERS T. AND BLUMENSTOCK F.A.,
J, BIOL CHEM. 1967, 242, 1574 
AISEN P„, AASA R,, MALMSTROM B.G 
J. BIOL CHEM. 1967, 242, 2484
SHEARER W.T., BRADSHAW ROA. AND GURD
1967, 242, 5451 
SHEARER W.T, AND GURD
1968, 243, 3817
J. BIOL CHEM. 1969, 244, 3613
1967, 242, 1566
and vanngard T
F . R . N » I
F . R . N
J. BIOL CHEM. 
BRADSHAW R.A., 
J. BIOL CHEM. 
LEHRER S.S,. ,
FREEMAN II. C . AND MARTIN R~P„,
J, BIOL CHEM. 1969, 244, 4823
AISEN P„, AASA R, AND REDFIELD A.G..
J. BIOL CHEM. 1969, 244, 4628
LAU S~J, AND SARKAR B», J. BIOL CHEM. 1971, 246, 5938 
MARTIN R-P.r MOSOMI L. AND SARKAR B.,
J. BIOL CHEM. 1971, 246, 5944 
VAN CAMPEM D.» J. NUTRITION 1973, 103, 139 
CHENOWETH M.B., CLIN PHARMACOL T'HERAP, 1968, 9, 365 
SINN I AH R. AND NEILL D.W.,
J. CLIN PATHOL, 1968, 21, 603
PETERS T,» ADV CLIN CHEM. 1970, 13, 3?
SASS-KORTSAK A., ADV CLIN CHEM. 1965, 8, 1 
RISPENS P. AND ET. AL., CLIN CHIM ACTA 1968, 22, 627 
SINCLAIR M.J., HART R.A., POPE H.M. AND CAMPBELL E.J., 
CLIN CHIM ACTA 1968, 19, 63
USHER D,J. AND DEE GAN T,, CLIN CHIM ACTA 
LEONARD P.J., PERSAUD J. AND MOTWANI R.,
CLIN CHIM ACTA 1971, 35, 409
SCHROEDER H.A. AND NASON A.P., ‘
CLIN CHEM. 1971, 17, 461
MAAS VAN HElJST A.N.P, AND VISSER 3 . F „ ,
CLIN CHIM ACTA 1971, 33, 325
JACOBS J.S., HATTNER R.S. AND BERNSTEIN D.S.,
CLIN CHIM ACTA 1971, 31, 467
POSTMES TH.J. AND COENEGRACHT J.M.,
CLIN CHIM ACTA 1972, 38, 313
VAN DER HEUL C., VAN EIJK H.G., WILTINK W „ F .
AND LEIJNSE B,, CLIN CHIM ACTA 1972, 38, 347
PICCARDI G . , NYSSEN M. AND DOR CHE J.,
CLIN CHIM ACTA 1972, 40, 219
LINDGARDE F., CLIN CHIM ACTA 1972, 40, 477
HALLIDAY J.W. AND POWELL L.W.,
CLIN CHIM ACTA 1973, 43, 267
1970, 29, 361
161
■X- 204 STOREY S.H. AND VAN ZEGGEREN F,,
CANADIAN J , CHEM ENG. 1964,. 42, 54
* 205 STOREY S.H, AND VAN ZEGGEREN F.,
CANADIAN J . CHEM ENG, 1967, 45, 3 23
* 206 STOREY S.H, AND VAN ZEGGEREN F.,
CANADIAN J. CHEM ENG. 1970, 48, 591
* 207 BOAS A.H., CHEM ENG. 1962, 69, De.c 10, 147
208 ANDERSEN L. B . , CHEM ENG, 1962, 69, 'Nov 26, 125
* 209 BOAS A. II., CHEM ENG. 1963, 70, 1Har 4, 97
•X- 210 BOAS A, II., CHEM ENG. 1963, 70, Jan 7, 95
211 silberberg m,y„, CHEM ENG. 1966 , 73, ’ Apr 8 , 132
212 VARGA L.P., ANAL CHEM, 1969 , 41 , 323
213 KANKARE J.J,, ANAL CHEM. 1970, 42, 1322
* 214 TING-PO I. AND NANCOLLAS G . H » ,
ANAL CHEM. 1972, 44, 1940
* 215 KAN DINER H . J , AND BRINKLEY S - R . ,
IND ENG CHEM, 1950, 42, 850
* 216 ZELEZNIK F.J. AND GORDON -
. IND ENG CHEM. 1968, 60, 27 
217 SA’NDERSON R.V. AND CHIEN H. H. Y . , ,• ’
IND ENG CHEM. 1973, 12, 81 -
21S GROVES P.D., BUCK P.J. AND HOMER J»,
CHEM AND IND, 1967, 32, 915 •
* 219 NEEDES C.R.S., NAT.INST METALLURGY 1 970, 1 093 , 1
* 220 DE LAND E.C, AND BRADHAM G,B. ,
ANN N.Y. ACAD SCI. 1966, 128, 795
221 MARTIN R-P, AND PARIS R.A.,
COMP RENO ACAD SCI, 1963, 257, 3932
222 BRUN B„, KARMENKA N. AND SALVINIEN J,,
COMP REND ACAD SCI <SER C) 1969, 269, 65 •
223 CROMER-MORIN M., MARTIN R-P, AND SCHARFF J~P„,
COMP REND ACAD SCI (S£R C) 1973-, 277, 1339
224 SIGEL H. AND MCCORMICK D.I3,, ' . .
ACCOUNTS OF CHEM RES, 1970, 3, 201
* 225 PFORDTE K., ACTA BIOL MED GERM, 1971, 27, 527 
226 ENDRENYI L, AND KWONG F.H.F.,
ACTA BIOL MED GERM, 1973, 31, 495
* 227 ADAM p,, ACTA TECH BELG. 1970,’6, 13
228 SHARMA V.S., . '
AMER CHEM SOC DIV AIR WATER WASTE CHEM. 1969, 9, 118
* 229 GRIFFIN R.M. AND MA.TSON W.R.,
AMER IND HYG ASS J. 1972, 33, 373
230 CHALLEN R.G., AUST J HOSP PHARM. 1973, 3, 71
231 ZIMMER C.H., LUCK C,. , FRITZSCHE H, ANO TRIEBEL H.,
BIOPOLYMERS 1971 10, 441
232 VAN POUCKE L.C., THIERS 6.F, AND EECKHAUT 2.,
BULL SOC CHIM BELG. 1972, 81, 357
233 IJ-LMGREN P. AND WAHLBERG 0., CHEM SCRIPTA 1973 , 3, 1 59
234 FOSBERG 0,, JOHANSSON K«, ULMGREN P. AND WAHLBERG 08 , 
CHEM SCRIPTA 1973, 3, 153
* 235 ULMGREN p. AND WAHLBERG 0,, CHEM SCRIPTA 1973, 3, 193
236 MAGLIULO A,. CHEMISTRY 1974, 47, 25 •
237 HAVELKOVA L. AND BARTUSEK M „ ,
COLLECT CZECH.CHEM COMMUN. 1969, 34, 3722
162
* 238 KARPENKO V, AND KALOUS V,,
COLLECT CZECH CHEM COMMON, 1973, 38, 2684
239 FULLER R.W. ANO RO.USH B.W.,
COMP BIOCHEM PHYSIOL, 1973, 46, 273
240 CIAVATTA L, , CORSI SEVIEN CHIM, 1968, 8, 73
241 PFEILSTICKER K,,
DEUTSCHE LIBENSM-RUNDSCHAU 1969, 65, 348
242 BRONNER F., ENG PRINCIPLES PHYSIOL, 1973, 6, 227
* 243 baranowska-zralko M. AND BIERNAT J.,
ELECTROCHIMICA ACTA 1972, 17, 1877
* 244 CILLEY W.A. AND NICHOLSON D.A.,
ENVIRON LETTERS 1971, 2, 121
* 245 MOREL F. AND MORGAN J.,
ENVIRON SCI TECHNOL. 1972, 6, 58
* 246 FALLS C.P. AND VARGA L.P,,
ENVIRON SCI TECHNOL. 1973, 7, 319
* 247 MCARTHUR J.N. AND SMITH M.J.H.,
F.E.B.S LETTERS 1968, 1, 332
* 248 JACOBSEN J,, F.E.B.S LETTERS 1969, 5, 112
* 249 TRIKHA K.C., NAIR B.C. AND SINGH R „ P , ,
INDIAN J, CHEM, 1968, 6, 532 
250 PALRECHA M,M. AND GAIJR J.N.,
INDIAN J. CHEM. 1969, 7, 1035
* 251 CHIDAMBARAM M.V. AND BHATTACHARYA P.K, ,
INDIAN J. CHEM. 1970, 8, 941
* 252 RAMAMOORTHY S. AND SANTAPPA M.,
INDIAN J , CHEM. 1971, 9, 381
* 253 SEKHON B.S., SINGH P.P. AND CHOPRA S.U,
INDIAN J . CHEM, 1971, 9, 485
* 254 80SCH-REIG- F, AND BURRIEL F.,
INFORM QUIM ANAL. 1968, 22, 207
* 255 BOSCH-REIG F. AND BURRIEL F.,.
INFORM QUIM ANAL. 1968, 22, 193
* 256 BOSCH-REIG F. AND BURRIEL F,,
INFORM QUIM ANAL- 1969, 23, 5
* 257 NANDEDKAR A.K.N.r NURSE C.E. AMD FRIEDBERG F.,
INT J, PEPTIDE AND PROTEIN RESEARCH 1973, 5, 279
* 258 BUGAEVSKII A,A., RUDNAYA L.E. AND MUKHINA T.P..
J. ANAL CHEM U.S.S.R. 1972, 27, 1522
* 259 MUKHINA T.P., BUGAEVSKII A.A. AND RUDNAYA L.E,,
J. ANAL CHEM U.S.S.R, 1972, 27, 1527
260 GEDANSKY L.M., UOOLLEY E.M. AND HEPLER L.G.,
J. CHCM THERMODYNAMICS 1970, 2, 561
261 PELLETIER 5., J, CHIM PHYS PHYSIOCHlM. 1972, 69, 751
262 HABASHY G.M.,
J, ELECTROANAL CHEM INTERFAC ELECTROCHEM 1969, 21, 357
263 FRITZE K. AND ROBERTSON R,,
J. RADIOANAL CHEM. 1968, 1, 463
264 BRUNETTI A.P., BURKE E.J., LIM M.C,
AN‘D NANCOLLAS G.H., J. SOLN CHEM, 1972, 1, 153
265 MAGAR M.E., STEINER R.F, AND FLETCHER J.,
J. THEOR BIOL, 1971, 32, 59
266 HULME E.C., J. THEOR BIOL. 1971, 31, 131
267 NAGYPAL GERGELY A, AND FARKAS E.,
MAGYAR KE'IIAJ FOLYOIRAT 1973, 79, 303
268 KAPOOR R.C. AND J A ILWAL J,K,,
MICROCHEM J. 1971, 16, 501
* 269 SUGIURA Y. AMD TANAKA H » ,
MOLECULAR PHARMACOL* 1972, 8, 249
* 270 EDSALL J,T., N . A „ $ . A . SPEC PUBL. 1968, 188, 1 5
* 271 Loom S.A.K. AMD KHAN A.R.,
PAK J. SCI IND RESEARCH 1970, 13, 202 
272 VOSK.IAN H,, ROUSSELET F. AND GIRARD M.L.,
PATHOL BIOL. 1973, 21, 33
* 273 DOORNBOS D.A., PHARM WEEKBLAD 1968, 103, 1213
274 ALBERT E., PHARMA KOPSYCHIAT 1973, 6, 229
275 STUMM W. , PRINC' APPLIED WATER C'HEM, 1965 , 520
* 276'SUNDARESAN R. AND SUNDARAM A.K.,
PROC INDIAN ACAD SCIENCE T973, 73, 218
* 277 OSTERBERG R.,
PROC INT CONF CO-ORD CHEM (PROC SYMP), 1970, 1 , 221
ROSSOTTI F.J .C . AND WHEWELL R.J.
PROC INT CONF CO-ORD CHEM (PROC SYMP), 1970, 1 , 233
MARTIN R- P.,
PROC INT CONF CO-ORD CHEM (PROC SYMP). 1970, 1 , 181
* 280 SASS-KORTSAK A. AND ET. AL.,
'PROGRESS IN NEUROGENETICS’* VOL I PROC,
2ND INT CONG NEUROGENETICS, 1967, 625
* 281 DE HAVEN J.C., RAND CORP MEM, 1968, 5691
* 2S2 SYCHEV A.YA, AND MITSUL N.S.,
RUSS J, INORG CHEM. 1967, 12, 1120
283 KRISS E„E. AND YATSIMIRSKII K.B.,
RUSS J. INORG CHEM, 1968, 13, 1223
284 MIRONOV V.E., MAKASHEV Y.A., MAURINA I. AN.D
K R YZ II ANO VS K I I M.M., RUSS J. INORG CHEM, 1970, 1 5, 668
285 BE LEVANTS I; V V.I. AND PESHCHEVITSKII B,I.,
RUSS J, INORG CHEM, 1972, 17, 1082
* 286 PERRIN D.D., SUOMEN KEMISTILEHTI 1969, 42, 205
* 287 DAS R.C., DASH A.C., SATYANARAYAN D. AND DASH U.N.,
THERMOCHIMrCA ACTA 1971, 2, 435
* 238 TING-PO I., BURKE E.J., MEYER J.L. AND NANCOLLAS G.H.,
THERMOCIJIMICA ACTA 1 973 , 5, 463 
289 FELL G.S., CANNING E., HUSAIN S.L* AND SCOTT R»,
TRACE SUBST ENVIRON HEALTH 1971, 293
-X- 290 KALISKER A, AND DIXON R.L.,
J . WEST PHARMACOL SOCIETY 1969, 12, 65
* 291 M C B R Y D E W.A.E . , ANALYST 1969, 94, 337.
* 292 M C B R Y D E W-A.E-, ANALYST 1971, 96, 739
•X- 293 VALLEE B „L», PHYSIOL REVIEWS 1959 , 39, 443
* 294 W ILHAMS D.R,, EDUCATION IN CHEM, 1973, 10, 56
295 JACOBS A ., SYMP ADVANCED MEDICINE 197T, 7, 191
296 DAVISON C. AND SMITH P,K.
J, PHARM EXP THER. 1961 , 133, 161
297 TERATO K . , F.UJITA T. AND YOSHINO Y.
DIGESTIVE DISEASES 1973, 18, 121 
298 TERATO K,,' HIRAMATSU Y. AND YOSHINO Y, ,
DIGESTIVE DISEASES 1973, 18, 129
164
299 ZELEZNIK F.J., ASSOC COMP MACH J. 1968, 15, 265
300 STUCKI J,W„,. EXPERIENTIA 1974, 30, 168
* 301 FRIEDEN E«, SC IENTlFIC AMERICAN 1972, 227, 52 
3 02 SULLIVAN J . C . , RYDBERG J . AND MILLER W , F « ,
ACTA CHEM SCAND. 1959, 13, 2023
303 SCHRODER K . H., ACTA CHEM SCAND, 1966, 20, 1401
304 KWIK W,L,, PURDY E, AND STIEFEL E.I.,
J, AMER CHEM SOC. 1974, 96, 1638
* 305 SCHWABE K, AND SUSCHKE H.D.,
AN6E.WANDE CHEMIE 1964, 3, 36
* 306 KRUCK T.P.A. AND SARKAR B.,
CANADIAN J. CHEM, 1973, 51, 3549 
307 SARKAR B. AND KRUCK T.P.A.,
CANADIAN J. CHEM. 1973, 51, 3541 
308' KRUCK T.P.A. AND SARKAR B.,
3572
CANADIAN J, CHEM. 1973, 51, 3555
309 KRUCK T.P.A. AND SARKAR B,,
CANADIAN J. CHEM. 1973, 51, 3563
310 MCBRYDE W.A.E., CANADIAN J, CHEM.. 1973, 51 ,
* 311 CORRIE ‘ 
J, CHEM
A.M., TOUCHE M.L.D, AND WILLIAMS D.R.,
SOC. DALTON 1973, 2561
* 312 BAXTER A.C. AND WILLIAMS D.R.,
J , CHEM SOC, DALTON 1974, 1117
* 313 MAKAR G .K.R. AND WILLIAMS D.R.,
J. CHEM SOC. DALTON 1974, 1121
* 314 GRAHAM R.D. AND WILLIAMS D.R.,
J. CHEM SOC. DALTON 1974, 1123
* 315 WALKER M.D. AND WILLIAMS D.R.,
J . CHEM SOC, DALTON 1974, 1186
* 316 CAPE J. N., COOK D.H. AND WILLIAMS D.R.,
J, CHEM SOC. DALTON 1974, 1849
* 317 CORRIE A.M., TOUCHE M.L.D. AND WILLIAMS D.R.,
J. CHEM SOC, DALTON 1975, 105
318 COOKSON R.F,, CHEM REVIEWS 1974, 74, 5
319 OS.TERB.ERG R», CO-ORDINATION CHEM REV, 1974,* 320 CLEARE M.J., CO-ORDINATION CHEM REV- 1974,* 321 CHILDS C . W . , I N 0 R G CHEMISTRY 1970, 9, 2465
322 DURST R .A., J . CHEM EDUCATION 1967, 44, 175
323 CRICHTON R.R., STRUCTURE AND BONDING 1973, 
* 324 IRVING II.M., MILES M,G. AND PETTIT L.D.,
12, 309 
12, 349
17, 67
ANAL CHIM ACTA 1967, 38, 475 
325 DUNSMORE H.S. AND MIDGLEY D.,
A N A L C H I M ACTA 1972, 61, 115
326 ZUR N E D D E N P. , MERCINY E. AND DUYCKAERTS G
ANAL CHIM acta 1973, 64, 197
327 DUNSMORE H ,s. AND MIDGLEY D.,
ANAL C II I M acta 1974, 72, 121
* 328 HANSEN E.H. AND RUZlCKA J., TALANTA 1973, 20, 1105 
329 GANS P. AND VACCA A., TALANTA 1974, 21, 45
* 330 SABATINI A., VACCA A. AND GANS P.,
TALANTA 1974, 21, 53
* 331 VELINOV G., ZIKOLOV P,, TCHAKAROVA P„ AND BUDEVSKY 0,,
TALANTA 1974, 21, 163
1165
332
-x- 333
334
* 335
* ‘ 336
* 337
333
339
340
* 341
342
* 3 43
344
* 345
346
347
* 348 
349
* 3 50
351
355
356
357
358
359
360 
* 361
362
CHAPMAN B.E., MACDERMOTT T.E» AND O’SULLIVAN W.J
BIOINORG CHEM. 1.973, 3, 27
CLARKE E.R. AND MARTELL A.E., .
J. INORG NUCL CHEM. 1970, 32, 91 1 
GERGELY A. AND SOVAGQ I.,
J. INORG NUCL CHEM, 1973, 35, 4355 
NAGYPAL I , , GERGELY A. AND FARKAS E,,
J. INORG NUCL CliEM. 1974, 36, 699 
MARTIN R.B. AND PRADOS R.,
J. INORG NUCL CHEM. 1974, 36, 1665 
RAMAMOORTHY S. AND MANNING P.6, ,
J. INORG NUCL CHEM. 1974, 36, 1671 
PASINI A. AND CASELLA I.., •
J. INORG NUCL CHEM. 1974, 36, 2133 
BENNETT L-E., PROGRESS IN INORGANIC CHEM 
SARKAR B. AND KRUCK T.P.A.,
BIOCHEMISTRY OF COPPER’
WALSHE J.M., PROC.SYMP
1973,. 18, 1
PROC.SYMP. ’THE 
ED PEISACH J. ET AL- 1965, 183 
’THE BIOCHEMISTRY OF COPPER’
ED PEISACH J, ET AL« 1965, 475 ‘
WALSHE J.M., AMER J. MEDICINE 1956, 21, 487
VALLEE B.L. AND ULMER D.D.,
ANN REV BIOCHEM, 1972, 41, 91 .
CHARLEY P.J,, ROSENSTEIN M,r SHORE E» AND SALTMAN P., 
ARCH BIOCHEM OIOPHYS. 1960, 88, 222
PARISI A.F, AND VALLEE B.L.,
BIOCHEMISTRY 1970, 9, 2421
BARDSLEY W.G. AND CHILDS R.E.,
BIOCHEM J. 1974, 137, 55
BARDSLEY W.G,, CHILDS R.E. AND CRAB BE M.J.C.t
BIOCHEM J. 1974, 137, 61
SCHADE A.L., NUTR REVIEWS 19.55 , 13 , 225
VALLEE B.L'., ADV PROTEIN CHEM. 1955, 1 0, 31 ?
GURD F.R.N, AND WILCOX P.E.,
ADV PROTEIN CHEM. 1956, 11, 311
SHARPLESS N.S., MUF.NTER M.D., TYCE G. M, AND OWEN C.A.,
CLIN CHIM ACTA 1 972, 37, 359
352 BIESOLD D, AND GUNTHER K.,
CLIN CHIM ACTA 1972, 42, 353
353 LAURELL C. B. , BLOOD 1951 , 6, 183
354 CROSBY W.H • f BLOOD 1963, 22, 441
HENKIN R , I „ , SCHULMAN J.D., SCHULMAN C.B,
AND BRONZERT D.A., J, PEDIATRICS 1973, 82, 831 
SASS-KORTSAK A, AND SARKAR B . ,
J, PEDIATRICS 1973, 82, 905 
DANKS D.Mw, CAMPBELL P.E., STEVENS B.J.,
AND CARTWRIGHT E. , PEDIATRICS 1972 , 50,
MAYNE V. 
188
GILL W , N . , 
GILL W.N., 
GILL W , N , , 
IIEDWIG G.R 
ANAL CHEM.
CHEM ENG, 1962, Oct. 1, 97
CHEM ENG, 1962, Apr 30, 109
CHEM ENG, 1962, May 28, 121
AND POWELL H.K.J.,
1971, 43, 1206
WILLIAMS D.R., ’THE CHEMISTRY OF TRACE METALS IN VIVO 
AND THE BIOLOGY OF ZINC. ’
166
* 3 63
* 3 64 
365
* 3 66
* 36?
368
* 369
370
* 371
372 
3 73
374
375
376
* 377
* 378
379
* 380
* 381
382
383
* 334
385
386
* 387
* 383
389
390
391
* 392 
393
* 394
* 395
396
KENCH J.E.,
THE DANIEL HAHN MEMORIAL LECTURE, U.C.T. 1969, 1 B
BECK M.T., ’THE CHEMISTRY OF COMPLEX EQUILIBRIA’, 1970 < 
ANGELIC! R.J., 'INORGANIC BIOCHEMISTRY’ VOL I I
ED, EICHHORN G.L. 1973, 63 |
BRESLOW E., ’INORGANIC BIOCHEMISTRY' VOL I J
ED, EICHHORN G.L. 1 973 , 227 , -I
ROSSOTTI F.J.C, AND ROSSOTTI II. S.,
'THE DETERMINATION OF STABILITY CONSTANTS’. 1961, 321 
JAMESON R.F., M.T.P. INTERNAT REVIEW OF SCIENCE, %
SERIES I VOL .10 ED, SKINNER H.A. 19?3 i
PERRIN D.D, AND AGARWAL R.P., 'METAL IONS IN j
BIOLOGICAL SYSTEMS.' VOL II. ED. SIGEL H, 1973, 167 
GOLDSTEIN A., ARONOW L. AND KALMAN S.M., |
’THE PRINCIPLES OF DRUG ACTION’, 4
WEST E.S., TODD W.R., MASON W.R, AND VAN BRUGGEN ' J . T , , -A
’THE TEXT BOOK OF BIOCHEMISTRY’, 1966, 1376 |
BRESLOW R., CHEM SOCIETY REVIEWS 1972, 1, 553
OHTAKI H, AND BIEDERMANN G,, ' 4
BULL SOC CHEM JAPAN 1971 , 44, 1 51 5
SAHU C.R, AND MITRA A.K., 'I
J. INDIAN CHEM SOCIETY 1971, 48, 795 1
LOMAX G.D., J, MED LAB TECH, 1970, 27, 61 ‘ 5
FOYE W.O., BAUM M.d. AND WILLIAMS D.A.,
J. PHARM SCI . ' 1967, 56, 332- |
GERGELY A,, NAGYPAL I, AND FARKAS E., 5
MAGYAR KEMIAI FOLYOIRAT 1974, 80, 25 • S
DANTZIG G.B. AND ET. AL,, • 4
PERSPECTIVES IN BIOL AND MED. 1961,. 4, 324
SARKAR B. AND KRUCK T.P.A., 4
PROC INT CONF CO-ORD CHEM (PROC SYMP). 1972, 395 ;
DE LAND E.C,, RAND CORP MEM, ’1966, 4962
DE LAND E.C, AND HEIRSCHFELDT R„ ,
RAND CORP MEM. 1967, 5254
CAPALNA S., REV ROUM PHYSIOL. 1972, 9, 273
BARLIN G.B. AND PERRIN D.D,, 4
TECHNIQUES OF CHEMISTRY 1972, 4, 611
ALBERT A., BIOCHEM J. 1950, 47, 531 %
TAN FORD C . , SWANSON 5 , A , AND SHORE W . S , , 4
J, AMER CHEM SOC, 1955, 77, 6414
MARTINEZ-TORRES C, AND LAYRISSE M.,
WORLD REVIEW NUTR DIETETICS 1974, 19, 51 |
STANCHEVA P., NAUCH TR, VISSH PEDAGOG 1970, 8, 103 
NELDER J,A. AND MEAD R., COMPUT J, 1 965 , 7, 308 
TEWARI K.C., LEE J. AND LI N.C.,
TRANS FAR SOC, 1970, 66, 2069 4
ANON,, J. CHEM SOC. B . '
ANON,, J. CHEM SOC, FARADAY ' — •
ROSENTHAL M.R., J. CHEM EDUCATION 1973, 50, 331 .J
O'DELL B.L., AMER J. CLINICAL NUTRITION 1969, 22, 1315% 
CHILDS C.W., J. PHYS CHEM. 1969, 73, 2956 '
WILLIAMS D.R., PROC SUMMER SCHOOL 'STABILITY 
CONSTANTS'. B I VI G LI ANO , I T A I.Y 1974, 1 25 J
GUBLER C.J., SCIENCE 1956, 123, 87 . 1
167
* 397 SILLEN l.G„, ACTA CHEM S C A N I) „ 1964, 18, 1085
398 CHRISTENSEN J.J., HILL J.O. AND IZATT R.M.,
SCIENCE 1971, 174, 459
399 SUMMONS R.E. AND ET, AL-, ANAL CHEM. 1974, 46, 582
400 FORTH W. AND RUMMEL W., PHYSIOL REVIEWS 1973, 53, 724
401 ADAMSON J.W, AND FINCH C.A.,
ANN REV PHYSIOLOGY 1975, 37, 351
402 PULLMAN T.N,, LAVENDER A.R, AND FORLAND M„,
ANN REV MEDICINE 1963, 14, 175
* 403 EVANS G,W., PHYSIOL REVIEWS 1973, 53, 535 
404 GANZONI A.M., BAVIERA 8, AND HAHN D,,
. EXPERIENTIA 1974, 30, 32
* 405 COONS C.M., ANN REV BIOCHEM. 1964, 33, 459
406 RATLEDGE C . AND MARSHALL B.J.,
BIOCHIM BIOPHYS ACTA 1972, 279, 58
407 KORNFELD S„, BIOCHIM BIOPHYS ACTA 1969, 194, 25
408 HOKIN L.E. AND HOKIN M.R., SCIENTIFIC AMERICAN
409 PRICE E.M. AND GIBSON J.F., -
BIOCHEM BIOPHYS RES COMMUN 1972, 46, 646
410 VAN SNICK J.L., MASSON P.L. AND HEREMANS J * F , , '
BIOCHIM BIOPHYS ACTA 1973, 322, 231
411 ULMER D.D., BIOCHIM BIOPHYS ACTA 1969, 181, 305
412 MARCEAU N, AND ASPIN N., ••
BIOCHIM BIOPHYS ACTA 1973, 293, 338
413 BJNFORD J„S. AND FOSTER J.C.,
Jr BIOL CHEM. 1974, 249, 407
414 RATLEDGE C , , MARSHALL B.J., MACHAM L,P.
AND BROWN K„A *, BIOCHIM BIOPHYS ACTA 1 974, 372, 39
415 FROST G.E, AND ROSENBERG H , ,
BIOCHIM BIOPHYS ACTA 1973, 330, 90
416 OSHIMA R.G., WILLIS R.C., FURLONG C.E.
AND SCHNEIDER J,A., J, BIOL CHEM. 1974 , 249, 6033
417 HAHN P.F., BALE W.F., ROSS J., BALFOUR W.M. AND WHIPPLE 
6.H., J„ EXPERIMENTAL MEDICINE 1943, 78, 169
418 TIMBERLAKE C.F., J, CHEM SOC. 1964, 5078
419 CANHAM G.W.R, AND LEVER A.P.B.,
J, CHEM EDUCATION 1972, 49, 656
420 SMITH P.M., STUDLEY F. AND WILLIAMS R«,
BRIT J, HAEMATOLOGY 1969, 16, 443
421 CUMMING R.L.C., SMITH J.A., MILLAR J.A. ‘
AND GOLDBERG A., BRIT J. HAEMATOLOGY 1970, 18, 653
422 JIRKA Mr, BLANICKY P. AND CERNA M.,
CLIN CIIIM ACTA 1974 , 56, 31
423 KRAUSE R,D, AND LOTT J.A., CLIN CHEM, 1974 , 20, 775
424 CALLENDER S,T.,
'BIOMEMBRANES’. VOL.4B. ED, SMYTH D.H. 1974, 761 
*425 RAMAMOORTHY Sr AND MANNING P.G., .
J.-INORG NUCL CHEM. 1975, 37, 363 
*426 LENZ G.R. AND MARTELL A.E., BIOCHEMISTRY 1964, 3, 745
427 KLEIN B., CLIN TOXICOLOGY. 1971, 4, 631
* 428 WEBER O.A. AND SIMEON V „L.,
BIOCHIM BIOPHYS ACTA 1971, 244, 94 •
168
429 OSTERBERG R. AND SJOBERG
J, INORG NUCL CHEM. 1975, 37, 815
* 430 BRYCE-SMITH D., CHEM BRITAIN 1972, 8, 240
431 BRYCE-SMITH D, AND WALDRON H.A,r 
CHEM BRITAIN 1974, 10, 202
432 BRYCE-SMITH D. AND WALDRON H „ A , ,
CHEM BRITAIN 1974, 10, 205
* 433 AISEN P,, LEIBMAN A, AND REICH H , A „ ,
J, BIOL CHEM, 1966, 241, 1666 
434 GARRELS R.M. AND CHRIST C.L.,
'SOLUTIONS, MINERALS AND. EQUILIBRIA',
* 435 AGARWAL R.'P. AND PERRIN D.O.,
J, CHEM SOC. DALTON 1975, 268
436 HOEKSTRA W.6., ’
• AMER J, CLINICAL NUTRITION 1969, 22, 1268
437 BECK M-T. AND ORSZAGH I, , ’
J, INORG NUCL CHEM, 1975, 37, 328
438 NAGYPAL I,, MAGYAR KEMIAI FOLYOIRAT 1974, 80, 49
439 LLAURADO J.G., ENG PRINCIPLES PHYSIOL, 1973, 2, 347
* 440 FIELD T.8,, MCCOURT J.L. AND MCBRYDE W.A.E.r
CANADIAN J. CHEM, 1974, 52, 3119
441 KROE D.J., KAUFMAN N,, KLAVINS J.V. AND KINNEY T.D,, 
AMER J, PHYSIOLOGY 1966, 211, 414
442 PAPE L., MULTANI J.S., STITT C. AND SALTMAN P„, 
BIOCHEMISTRY 1968, 7, 606
443 PAPE L., MULTANI J.S., STITT Co AND SALTMAN P, , 
BIOCHEMISTRY .1968, 7, 613
444 FISCHER D.S. AND PRICE D.C.,
PROC SOC EXP BIOL MED, i963, 112, 228
445 CARR C.W., ARCH BIOCHEM BIOPHYS, 1953, 43r 147
446 CARR C,W. AND WOODS K»R.,
ARCH BIOCHEM BIOPHYS, 1955, 55, 1
447 DOWDLE E.B., SCHACHTER D, AND SCHENKER H»,
AMER J, PHYSIOLOGY 1960, 198, 609
* 448 ULMGREN P, AND WAHLBERG 0,,
ACTA CHEM SCAND, 1974, 28, 631 
449 CIAVATTA L. AND GRIMALDI M,,
J, INORG NUCL CHEM. 1975, 37, 163
* 450 BAUMANN E.W., ANAL CHIM ACTA 1973, 64, 284
451 MORGAN E.H., HUEHNS E.R. AND FINCH C.A»,
AMER J, PHYSIOLOGY 1966, 210, 579
452 ROSSOTTI H.S., TALANTA 1974, 21, 809.
453 MARTIN R-P., PETIT-RAMEL M.M, AND SCHARFF ,1-P., 'METAL 
IONS IN BIOLOGICAL SYSTEMS.' ED, SIGEL H. 1973, 1
454 OOSTERHUIS W.T., STRUCTURE AND BONDING 1974, 20, 59
455 BARKER P., CHEM BRITAIN 1975, 11, 13
456 MILDVAN A.S, AND GRISHAM C.M.,
STRUCTURE AND BONDING 1974, 20, 1 -
* 457 FIELD T.B-, COBURN J., MCCOURT J.L. .
• AND MCBRYDE W.A.E., ANAL CHIM ACTA 1975, 74, 101
458 FLETCHER J.- AND HUEHNS E.R., NATURE 1967, 21 5 , 584
459 FLETCHER J. AND HUEHNS E.R., NATURE 1968, 218, 1211
* 460 MEYER J.L., ANAL BIOCHEM, 1974, 62. 295
169
461 HELBOCK H . J „ , FORTE J , G» ANO SALTMAN P.,
BIOCHIM BIOPHYS ACTA 1966, 126. 81
* 462 HANCOCK R.G.V., EVANS D,J,R, AND FRITZE K„, '
BIOCHIM BIOPHYS ACTA 1973, 320, 486
463 6ABER B „ P, AND AISEN P, ,
BIOCHIM BIOPHYS ACTA 1970, 221, 228
464 HOPPING J,M, AND RULIFFSON W.S.,
AMER J, PHYSIOLOGY 1966, 210, 1316
465 VAN DER LINDEN W.E, AND BEERS C , ,
ANAL CHIM ACTA 1 973, 68, 143
* 466 MCAULIFFE C.A. AND MURRAY S.G.,
INORG CHIM ACTA REVIEWS 1972, 103
467 CHASTON J, CHEM EDUCATION 1975, 52, 209
468 BOTHWELL T.H, AND CHARLTON R.W.i 
• ANN REV MEDICINE 1970, 21, 145
469 MCARTHUR J.N,, DAWKINS P , D t,, SMITH M.J.H.
AND HAMILTON' E.B.D,, BRIT MEDICAL J, 1971, 2, 677
* 470 NIEDERMEIER W- AND GRIGGS J , H, ,
J. CHRONIC DISEASES 1971, 23, 527 
471 TURNBULL A., '
RHEUMATOLOGY AND PHYSICAL MEDICINE 1971, 11, 53 
47? FAIRBANKS V„F,, ANN INTERNAL MEDICINE 1971, 74, 292
473 KUGELMASS I.N., •
’BIOCHEMICAL DISEASES (CHEMICAL PEDIATRICS)’,. 1964, 62
474 KUGELMASS UN.,
'BIOCHEMICAL DISEASES (CHEMICAL PEDIATRICS)', 1964, 466
475 GARFINKEL D-, ACHS M „ J , AND DZUBOW L», '
FED PROC, 1974, 33, 175
476 GARFINKEL D,f ACHS M . J . AND DZUBOW L.,
FED PROC, 1974, 33, 176
477 HOEKSTRA W.G., FED PROC, 1971, 30, 983
478 GOLDSTEIN N,P„, SMITH L,H, AND MCCALL U U ,
FED PROC. 1971, 30, 1011
. 479 WESTMORELAND N,, FED PROC. 1971, 30, 1001
* 480 CARNES W.H., FED PROC. 1971, 30, 995 •
481 LEACH R.M., FED PROC, 1971, 30, 991
482 PROCKOP D.J., FED PROC, 1971, 30, 984
* 483 JANDL J.H-, INMAN J.K,, SIMMONS R.L. AND ALLEN D,W„,
J . CLIN INVEST, 1959, 38, 161
484 JACOBS P„, BOTHWELL T.H. AND CHARLTON R,W,,
AMER J, PHYSIOLOGY 1966, 210, 694
485 AI SEN P., 'INORGANIC BIOCHEMISTRY' VOL J
ED. EICHHORN G.L. 1973, 280 ’
* 486 PETIT-RAMEL M.M. AND KHALIL I,,
BULL SOC CHIM FR. 1974, 1259
487 MILDVAN A.S., ANN REV BIOCHEM, 1 974 , 43, 357
488 MILLER W.J., AMER J, CLINICAL NUTRITION 1969, 22, 1323
* 489 STERNLIEB I., SANDSON J,I., MORELL A.G., KOROTKIN E ,
AND SC HEIN BERG UH,,
ARTHRITIS AND RHEUMATISM 1969, 12, 458
* 490 LORBER A., ARTHRITIS AND RHEUMATISM 1969, 12, 459
* 491 LORBER A,, CUTLER L-S. AND CHANG C.C-,
ARTHRITIS'AND RHEUMATISM 1968, 1 1, 65
* 492 LORBER A., NATURE 1966, 210, 1235
170
* 493
* 494 
495
* 496
497
49S
* ' 499
* 500
501
502
503
* 504
* 505
506
507
508
509
* 510 
511
* 512
513
* 514
* 515
* 516
517
* 518
* 519
520
521
522
523
* 5 24
GERBER D.A., ARTHRITIS AND RHEUMATISM 1974, 17, 85 
NIEDERMEIER W,, ANN RHEUMATIC DISEASES 1965, 24, 544 
NIEDERMEIER W., .ANN RHEUMATIC DISEASES 1968, 27, 71 
NIEDERMEIER W., PRILLAMAN W.W. AND GRIGGS J, H.r 
ARTHRITIS AMD RHEUMATISM 1971, 14, 533
GARDNER D.I.,
'THE PATHOLOGY OF RHEUMATOID ARTHRITIS',, 1972, 156 
5UNDBERG R.J. AND MARTIN R.B., •
CHEM REVIEWS 1974, 74, 471
AGARWAL R,P„ AND PERRIN D,0,,
J, CHEM SOC. DALTON 1975, 1045
GERGELY A. A’ND KISS T.,
MAGYAR KEMIAI FOLYOIRAT 1975, 81, 15
HERMAN H.B. AND RECHNITZ G.A,,
ANAL LETTERS 1975, 8, 147
SIGEL H,, ANGEWANDE CHEMIE 1975, 14, 391 .
WALKER M.D, AND WILLIAMS D.R.,
BIOINORG CHEM, 1975, 4, 117 
GERGELY A., NAGYPAL I- AND FARKAS E ,
J, INORG NUCL CHEM, 1975, 37, 551 
SIGEL H., J. INORG NUCL CHEM. 1975# 37, 507 
NEILANDS J,8., BACTERIOLOGICAL REVIEWS 1957, 21, 101 
SALTMAN P., J. CHEM EDUCATION 1965, 42, 682 .
SPIRO T.G,, PAPE L, AND SALTMAN P„,
J, AMER CHEM SOC, 1967, 89, 5555 
SPIRO T.G-, BATES G.W. AND SALTMAN P.,
J. AMER CHEM SOC, 1967, 89, 5559
KARLSSON F, AND VESTIN R., CHEM SCRlPTA 1972,' 2, 207 
BURTON A.C., ANN REV PHYSIOLOGY 1975, 37, 1 
RAMAMOORTHY S, AND MANNING P.G., ’
J, INORG NUCL CHEM. 1973, 35, 1571
LOKK.EN P.M., HALAS E.S. AND 5ANDSTEAD H.H.,
PROC SOC EXP BIOL MED, 1973, 144, 680
SINGH M.K. AMD SRIVASTAVA M.N.,
J, INORG NUCL CHEM, 1973, 35, 2433
TEWARI K.C. AND SRIVASTAVA M.N., .
J, INORG NUCL CHEM, 1973, 35, 2441
BOTTARI E. AND VICEDOMINI M,,
J. INORG NUCL CHEM. 1973, 35, 2447
VACCA A,, S A B A T I N I A, AND G RIS TIN A M . A . ,
CO-ORDINATION CHEM REV. 1972, 8, 44
GERGELY A., MOJZES J, AND KASSAI-BAZSA Z,,
J, INORG NUCL CHEM. 1972, 34, 1277
SILLEN L.G., CHEM BRITAIN 1967, 3, 291
LEVINE P.H., LEVINE A,J. AND WEINTRAUB L-R.»
J, LAB CLIN MED. 1972, 80, 333
POLLACK S., CAMPANA T. AND ARCARIO A.,
J, LAB CLIN MED, 1972, 80, 322
SHEEHAN R.G. AND FRENKEL E.P., ’
J< CLIN INVEST. 1972, 51, 224
SHEEHAN R.G., PROC SOC EXP BIOL MED, 1974, 146, 993 
RAMAMOORTHY S, AND MANNING P.6.,
J, INORG NUCL CHEM, 1973, 35, 1279
171
525
526
527
528
* 529
530
531
532
533
* 534
* 535
536
537
538
539
540
541
542
543
* 544
* 545
546
547
548
549
550
551
552
BRANEGARD B, AND OSTERBERG R.,
CLIN CHIM ACTA 1974, 54, 55
EASTMAN J.W., REHFELD S„J, ANO LOKEN H„,
CLIN CHIM ACTA 1975, 58, 233
SZELENYI I., WORLD REVIEW NUTR DIETETICS 1973, 17, 189 
KENNY A . D . AND D A C K E C , G . ,
1975, 20, 231 
1970, 12, 208
15, 139
WORLD REVIEW NUTR DIETETICS 
SPIVEY FOX M.R.,
WORLD REVIEW NUTR DIETETICS 
GOLDSTEIN N.P. AND OWEN C.A.,
MAYO CLIN PROC. 1974, 49, 363 
PRUDEN E.L. AND CREASON P.L,,
CLIN CHIM ACTA 1970, 27, 19 
HEATON F.W., CLIN CHIM ACTA 1967
BASELT R.C., WRIGHT J.A. AND CRAVEY R.H.,
CLIN CHEM, T975, 21, 44 
WILLIAMS D . R . ,
'THE METALS OF LIFE', VAN NOSTRAND RE INHOLD CO. 1971,8 
RAMAMOO.RTHY S. AND KUSHNER D. J , , 'NATURE 1 975 , 256, 399 
EDUCATION IN CHEM, 1974, 11, 124 
EDUCATION IN CHEM. 1974, 11, 166 
'ADVANCES IN CHEMISTRY SERIES’
WILLIAMS D.R,, 
WILLIAMS D.R., 
SCHRAUZER G.N., 100
BIOINORGANIC CHEM ED. GOULD R.F. 1971, 1
BRESLOW R ’ADVANCES IN CHEMISTRY SERIES'. 100
BIOINORGANIC CHEM. ED. GOULD R.F. 1971, 21
ALLEN A.D., 'ADVANCES IN CHEMISTRY SERIES'. 100.
1971, 79BIOINORGANIC CHEM. ED. GOULD R.F.
VAN TAMELEN E . E » , 'ADVANCES IN CHEMISTRY SERIES',
100. BIOINORGANIC CHEM. ED. GOULD R.F. 1971, 95 
EICHHORN G.L. ET.AL., 'ADVANCES IN CHEMISTRY SERIES'. 
100, BIOINORGANIC CHEM. ED. GOULD R.F, 1971, 135 .
WILLIAMS R.J.P., 'ADVANCES IN CHEMISTRY SERIES'. 100. 
BIOINORGANIC CHEM, ED, GOULD R.F. 1971, 155 
EATON D.R,, 'ADVANCES IN CHEMISTRY SERIES’. 100. 
BIOINORGANIC CHEM. ED. GOULD R,F. 1971, 174 
ULMER D.D. .AND VALLEE B.L.»
'ADVANCES IN CHEMISTRY SERIES'. 100.
BIOINORGANIC CHEM. ED, GOULD R.F, 1971, 187 
HARDY R.W.F., BURNS R.C. AND PARSHALL G,W,,
'ADVANCES IN CHEMISTRY SERIES'. 100,
BIOINORGANIC CHEM, ED. GOULD R.F. 1971, 219 
FRIEDEN E„, 'ADVANCES IN CHEMISTRY SERIES’, 100, 
BIOINORGANIC CHEM. ED. GOULD R.F. 1971, 292 
WILLIAMS R.J.P., NATURE 1959, 184, 44
LOURIA D.B., JOSELOW' M.M. AND BROWDER A.A,,
ANN INTERNAL MEDICINE 1972, 76, 307 
HARDY R.W.F. AND BURNS R.C.,
ANN REV BIOCHEM. 1968, 37, 331
WEBB E.C., 'COMPREHENSIVE BIOCHEMISTRY', VOL 12,
ED. FLORKIN M, & STOTZ E.H. 1964, 1 
VALLEE B.L. AND COLEMAN J,E„,
'COMPREHENSIVE BIOCHEMISTRY’, VOL 12.
ED. FLORKIN M. & STOTZ E.H. 1964, 165-
: s5
172
553
* 554
555
* 556
* • 557
558
559
* 560
561
562
563
564
565
566
* 567
568
569
570
571
572
573
* 574
* 575 
576
* 577
578
579
FORADORI A . C . , 
COTZIAS G.C.,
1966, 5, 2523
O'DELL B.L, 'AND CAMPBELL 8.J.,
’COMPREHENSIVE BIOCHEMISTRY'. VOL 21.
ED. FLORKIN M. & STOTZ E. II. 1971, 179
BERTINCHAMPS A., 6ULIB0N J,M. AND 
J. GENERAL PHYSIOLOGY 1967, 50, 2255
KOWARSKI $., BLAIR-STANEK C,S. AND SCHACHrER D.,
AMER J. PHYSIOLOGY 1974, 226, 401 
MCMENAMY R.H. AND ONCLEY J.L.,
J. BIOL CHEM. 1958, 233, 1436 
BOYETT J.D, AND SULLIVAN J.F.,
METABOLISM 1970, 19, 148
MCMENAMY R,H>, LUND C.C, AND ONCLEY J.L.,
J. CLIN INVEST. 1957, 36, 1672 
HIMMELHOCH S.R., SOBER H.A., VALLEE B.L,,
PETERSEN E.A. AND FUWA K,, BIOCHEMISTRY
AISEN P., BRIT J. HAEMATOLOGY 1974, 26, 159 
MILDVAN A.S. AND COHN M » , ADV ENZYMOLOGY 1970, 33, 1 
BLACK S., ADV ENZYMOLOGY 1973, 38, 193 
MCLEAN F.C., 'MINERAL METABOLISM'. VOL IA 
ED. COMAR C.L. & BRONNER F, 1960, 1 
KOEFOED-JOHNSON V. AND USSING H.H.,
'MINERAL METABOLISM’. VOL IA
ED. COMAR C.L- & BRONNER F, 1960, 169
BERGER E.Y., ’MINERAL METABOLISM’. VOL IA
ED. COMAR C.L. & BRONNER F. 1960, 249
MOORE C.V, AND DUBACH R., ’MINERAL METABOLISM’.
VOL I IB ED. COMAR C.L. & BRONNER F. 1962, 287 
ADELSTEIN S.J. AND VALLEE B.L,, ’MINERAL METABOLISM’. 
COMAR C.L. & BRONNER F. 1962, 371 
•MINERAL METABOLISM'. VOL IIB 
8 BRONNER F. 1962, 403 
'MINERAL MET ABO L.I SM ’ . VOL I IB 
X BRONNER F. 1962, 443 
AND DICKERSON J . W . T . ,
VOL IIB ED 
COTZIAS G.C., 
ED. COMAR C.L 
VALLEE B.L., 
ED. COMAR C.L 
WIDDOWSON E.M
'MINERAL METABOLISM'. VOL IIA 
ED. COMAR C.L. & BRONNER F. 1964,
’MINERAL METABOLISM', VOL IIA 
L. 8 BRONNER F. 1964, 34 2.
1970, 445 
VOL I
VOL II
BRONNER F.,
ED, COMAR C
THOMAS W.C. AND HOWARD J.E., 'MINERAL METABOLISM*. 
VOL IIA ED. COMAR C.L. & BRONNER F, 1964, 446 
WACKER W.E.C. AND VALLEE B.L., 'MINERAL METABOLISM’ 
VOL IIA ED. COMAR C.L. & BRONNER F. 1964, 483 
MILDVAN A.S,,
. VOL II ED, BOYER P.D 
’THE PLASMA PROTEINS'.
1960, 349
'THE PLASMA PROTEINS’,
1960, 59
DOCUMENTA GEIGY,
DIEM K. & LENTNER
’THE ENZYMES’ ,
LAURELL C.B.,
ED. PUTNAM F.W 
FISHMAN W.H.,
ED. PUTNAM F.W 
GEIGY PHARMACEUTICAL, 
SCIENTIFIC TABLES ED 
FREEMAN H.C.,
C, 1970 
VOL I’INORGANIC BIOCHEMISTRY' 
L. 1973, 121ED, EICHHORN G 
HARRISON P.M. AND HOY T.G., 'INORGANIC BIOCHEMISTRY’ 
VOL I ED. EICHHORN G.L. 1973, 253
173
580
531
532
583
584
585
586
587
538
589.
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
'INORGANIC
1973, 306 
VOL I
W,, 'INORGANIC 
1973, 745 
VOL II
VOL I I
VOL II
R I F K I N D J . M , , 
ED. EICHHORN G 
EICHHORN G.L., 
ED. EICHHORN G 
EICHHORN G„L«, 
ED. EICHHORN G
SCHEINBERGI.H, AND M 0 R E L L A, G 
BIOCHEMISTRY' VOL I ED. EICHHORN G.L. 
SCRUTTQN M „ C „ , 'INORGANIC BIOCHEMISTRY' 
ED. EICHHORN G.L. 1973, 381
HARDY R.W.F., BURNS R.C. AND PARSHALL G, 
BIOCHEMISTRY' VOL II ED. EICHHORN G.L.
'INORGANIC BIOCHEMISTRY’ 
L. 1973, 832
'INORGANIC BIOCHEMISTRY* 
L. 1973, 1191
'INORGANIC BIOCHEMISTRY' 
I. 1973, 1210
HARRIS D.I.M. AND SASS-KORTSAK A.,
4, CLIN INVEST. 1967, 46, 659 
HILL C.H., STARCHER B, AND KIM C,,
1 967, 26, 129
P. ,
FED PROC
SPIRO T.G. AND SALTMAN 
MEDICINE' .
MORGAN E.H
'IRON IN BIOCHEMISTRY AND 
ED. JACOBS A. AND NORWOOD M. 1974, 1- 
'IRON IN BIOCHEMISTRY AND MEDICINE',
ED. JACOBS A. AND NORWOOD M. 1974, 29 -
HARRISON P.M., HOARE R.J., IIOY T.G, AND MACARA I , G. > 
'IRON IN BIOCHEMISTRY AND MEDICINE'.
ED. JACOBS A. AND WORWOOD M, 1974, 73 •
MOORE M,R. AND GOLDBERG A., 'IRON IN BIOCHEMISTRY AND 
MEDICINE’. ED, JACOBS A, AND NORWOOD M, 1974, 115 
JACKSON A.H., 'IRON IN BIOCHEMISTRY AND MEDICINE’.
ED. JACOBS A, AND WORWOOD M, 1974, 145
WILLIAMS R.J.P., 'IRON IN BIOCHEMISTRY AND MEDICINE'. 
ED. JACOBS A, AND WORWOOD M. 1974, 183 .
NICHOLLS P. AND ELLIOT W.B., 'IRON IN BIOCHEMISTRY AND 
MEDICINE’, ED. JACOBS A. AND NORWOOD M. 1974, 221 
HALL D.O., CAMMACK R. AND RAO K.K.,
’IRON IN BIOCHEMISTRY AND MEDICINE’, . .
ED, JACOBS A. AND WORWOOD M. 1974, 279
'IRON IN BIOCHEMISTRY AND MEDICINE',
AND WORWOOD M, 1974, 336 
•IRON IN BIOCHEMISTRY AND MEDICINE’.
WORWOOD M., 
ED. JACOBS A 
TURNBULL A., 
ED, JACOBS A 
JACOBS A.,
AND WORWOOD M. 1974, 369
'IRON IN BIOCHEMISTRY AND MEDICINE'.
ED. JACOBS A, AND WORWOOD M, 1974, 405 •
DALLMAN P,, 'IRON IN BIOCHEMISTRY AND MEDICINE',
ED. JACOBS A. AND WORWOOD M, 1974, 437 
CALLENDER S.T., 'IRON IN BIOCHEMISTRY AND MEDICINE’, 
ED. JACOBS A, AND WORWOOD M, 1974, 529 •
SCHUTTE K.H.,
'THE BIOLOGY OF THE TRACE ELEMENTS', 1964
LANGLEY L.L., 'HOMEOSTASIS', 1965
IVERSEN O.H., 'HOMEOSTATIC REGULATORS',
ED, WOLSTENHOLME G.E.W. AND KNIGHT J. 1969, 15 
SHANNON L.V., PH.D, THESIS, UNIVERSITY OF CAPE TOWN. 
ATOMIC ENERGY BOARD,, SOUTH AFRICAN GOVERNMENT GAZETTE 
NO 2134 4TH OCTOBER 1968. •
HARPER H.A., ’REVIEW OF PHYSIOLOGICAL CHEMISTRY’,
LANGE MEDICAL.PUBLICATIONS, 1971, 392
174
7
1965, 23, 38607
608
* 609
* 610
611
612
613
614
* 615
616
617
618
* 619
* 620
621
622
623
624
625
626
627
628
629
* 630
631
632
633
634
* 63 5
1966, 19, 1007
274
GOODWIN D.A. 
1974, 250, 587
MILLS C.F., PROC NUTRITION SOC 
MALKIN R. AND MALMSTROM B.G.,
ADV ENZYMOL0GY 1970, 33, 177 
VALLEE B.L. AND RIORDAN J.,
ANN REV BIOCHEM. 1969, 38, 733 
SCHROEDER H.A., NASON A.P., TIPTON I-H 
AND BALASSA J.J., J. CHRONIC DISEASES 
AISEN P. AND LEIBMAN A.,
BIOCHEM BIOPHYS RES COMMON 1968, 32, 220 
COTZIAS G.C., MILLER S.T. AND EDWARDS J.,
J. LAB CLIN MED. 1966, 67, 836
BEUTLER E. AND BUTTENWIESER E „ ,
J. LAB CLIN MED. i960, 55,
SUNDBERG M.W,, M E A R E S C . F . ,
AND DI AMANT I C . I . , NATURE 
DIXON L.C.W.,
‘NONLINEAR OPTIMISATION’. ENG. UNIV. PRESS. 1972, 8
CLIFTON G.MMILLER W.J., MORTON J.D., PITTS W.J, AND 
PROC SOC EXP BIOL MED. 1965, 118, 427 
SANDSTEAD H.H. AND SHEPARD G . H . ,
PROC SOC EXP BIOL MED. 1968, 128, 687 
BELL G.H., DAVIDSON J.N. AND SCARBOROUGH B.,
‘TEXTBOOK OF PHYSIOLOGY AND BIOCHEMISTRY’. E.S.S. 
LIVINGSTONE LTD. 1968
COTTON F.A. AND WILKINSON G,., ’ADVANCED INORGANIC 
CHEMISTRY’. 3RD ED. INTERSCIENCE. 1972, 690 
FURST A., ‘THE CHEMISTRY OF CHELATION IN CANCER’.
C.C.THOMAS, 1963, 1
FREUDENSTEIN F. AND ROTH 8,,
ASSOC COMP' MACH J. 1963 , 1 0, 550 
MENKES J.H., ALTER M., STEIGLEDER 
AND SUNG J.H., PEDIATRICS 1962,
VERITY M.A. AND GAMBELL J.K., •
BIOCHEM J. 1968, 108, 239 
SCHRAUZER G.N., ANGEWANDE CHEMIE 
MILLER J.P.G. AND PERKINS D.J.,
EUROPEAN J, BIOCHEM. 1969, 10, 146 
SEELIG M.S., AMER J. CLINICAL NUTRITION 
SCHADE S.G., FELSHER B.F., BERNIER G.M.
AND CONRAD M.E., J. LAB CLIN MED. 1970,
DANKS D.M. AND ET. AL., LANCET 1972, 1,
DYRSSEN D. , JAGNER D. AND WENGEL IN F.,
'COMPUTER CALCULATION OF IONIC EQUILIBRIA AND TITRATION 
PROCEDURES'. 1968
KHURANA S.C., NIGAM I.J., SAXENA S.P. AND 
AUST J. CHEM. 1975, 28, 1617 
SINK A S.N. AND GABRIELI E . R .
AMER J. CLINICAL PATHOLOGY 1970, 54, 570 
NORWOOD M. AND JACOBS A.,
BRIT J. HAEMATOLOGY 1972, 22, 265 
MILLS C,F., BIOCHEM J. 1956, 63, 190 
WALDRON H.A., NATURE 1975, 253, 345 
PEARSON R.G., CHEM BRITAIN 1967, 3, 103
 Pi . ,
G.K., WEAKLEY D.R 
29, 764
1975, 14, 514
75, 435 
1100
1972, 25, 1022
•X
GUPTA C.M
3$
175
*
*
*
DRAGO R.S., ' CHEM BRITAIN 1967, 3, 516
FURST A,, GEOLOGY SQC AMER MEM, 1971, 123, 109 
FERGUSON L.N,, CHEM SOCIETY REVIEWS 1975, 4, 239 
GLASSTONE S., ’THERMODYNAMICS FOR CHEMISTS’*
VAN NOSTRAND CO„, PRINCETON, NEW JERSEY 1947, 273 
THOMAS F.B., PK.D. THESIS, UNIVERSITY OF. TEXAS. 1974 
SARKAR B„, KRUCK T.P.A. AND APPLETON D»,
CHEM CANADA 1972, 10, 25
DAVYDOVA S.L. AND PLATE N,A„,
636
637
638
639
640
641
64 2
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
*
* 1971, 5, 137
1966, 661
*
*
*
CO-ORDINATION CHEM REV. 1975, 16, 195
MCAULIFFE C . A . AND CHOW $„T„,
PROGRESS IN INORGANIC CHEM, 1975, 19, 51
TURNER M.W. AND HULME B,, ’THE PLASMA PROTEINS’, 
PITMAN MEDICAL AND SCIENTIFIC PUB, 1971 
TOPHAM R.W. AND FRIEDEN E. ,
J. BIOL CHEM, 1970, 245, 6698 ’
VIKBLADIi I,, SCAND J. CLIN LAB INVEST, 1950, 2, 1 43 
SPECTOR Ww(EDlTOR), ’HANDBOOK OF BIOLOGICAL DATA’, 
U.S. AIRFORCE PUBLICATION, 1956
DITTMER D.(EDITOR), ’BLOOD AND OTHER BODY FLUIDS'. 
FED,AM,SOC,EXP.BIOL. 1961
WILLIAMS R.J.P., INORG CHIM ACTA REVIEWS 
WERNER A,, CHYMIA 1967, 12, 189
GREEN R, ET.AL., AMER J, MEDICINE 1968, 45, 336 
PERRIN D.D. AND SAYCE 1,6,,. CHEM AND IN D 
RILEY J,p. AND CHESTER R,, ’INTRODUCTION TO MARINE 
CHEMISTRY’. ACADEMIC PRESS, 1971, 123 .
NANCOLLAS G.H., ’INTERACTIONS IN ELECTROLYTE 
SOLUTIONS'. ELSEVIER PUB. CO, 1966 
ALBERT A. AND SERJEANT E,P„, 'THE DETERMI NATION ’OF 
IONIZATION CONSTANTS' CHAPMAN HALL, LONDON 1971, 334 
LEWIS J, AND WILKINS R.G., '
'MODERN COORDINATION CHEMISTRY’, INTERSC I ENCE . 1960
STEINHARDT J, AMD REYNOLDS J.A., ’MULTIPLE EQUILIBRIA 
IN PROTEINS'. ACADEMIC PRESS, 1969
HAUROWITZ F., 'THE CHEMISTRY AND FUNCTIONS OF 
PROTEINS’, ACADEMIC PRESS, 1963 
VAN HOLDE K , E , ,
'PHYSICAL BIOCHEMISTRY.’, PRENTICE-HALL INC. 1971 
HUGHES M.N., 'INORGANIC CHEMISTRY OF BIOLOGICAL 
PROCESSES'. WILEY 8 SONS. 1975
OCHIAI E.I.,
*
’BIOINORGANIC CHEMISTRY’, 
EDSALL J.T. AND WYMAN J,, 
'BIOPHYSICAL CHEMISTRY'. 
DEBEYE p. AND HUCKEL E., 
DEBEYE P, AND HUCKEL E., 
THOMSON A. J.,
BRIGHAM M,P.,
‘ CLIN INVEST
ALLYN S BACON, INC, 1977
ACADEMIC PRESS 1953
1923, 24, 185PHYSIK Z,
PHYSIK Z. 1923, 24, 305 
NATURE 1975, 257, 536 
STEIN W.H. AND MOORE $s,
. 1960, 39, 1633J
BLAEDEL W.J. AND DINWIDDIE D.E,, 
ANAL CHEM, 1974, 46, 873
176
* 668 HARD EL M,, *
HOPPE SEYLER Z. PHYSIOL CHEM. 1966, 346# 224
* 669 VALLEE 3.L., WACKER W.E.C., BARTHOLOMAY A„F*
AND HOCH F.L., ANN INTERNAL MEDICINE 1959, 50, 1077 
670 VALLEE B.L. AND GIBSON J.F.,
J, BIOL CBFM. 1948, 176, 445
* 671 ALLISON A,(EDITOR), 'STRUCTURE AND FUNCTION OF PLASMA
PROTEINS’, VOL I- PLENUM PRESS, 1974 •
672 VALLEE B.L. AND WACKER W.E.C,, ’THE PROTEINS’. 2ND ED
ED. NEURATH H. VOL V, METALLOPROTEI NS. 1970
673 LEHN J.M., STRUCTURE AND BONDING 1973, 16, 1
674 TRUTER M.R.i STRUCTURE AND BONDING 1973, 16, 71
675 MEIER P.CH. AND NORF W.E.,
STRUCTURE AND BONDING 1973, 16, 113
676 HLADKY S.B., GORDON L.G.M. AND HAYDON D.A,,
ANN REV PHYSICAL CHEM. 1974, 25, 11 •
677 DAVSON H.,
‘A TEXTBOOK OF GENERAL PHYSIOLOGY’, 4TH EDITION.
678 RITSMA J.H. AND JELLINEK F„, . •
REC TRAV CHIM PAYS-3AS, 1972, 91, 923
679 MEYER J,L, AND BAUMAN J,E„,
J. AMER CHEM SOC. 1970, 92, 4210
680 KARCZYNSKI F., ROCZ CHEM 1970, 44, 967 ‘ .
681 HAY R.W. AMD MORRIS P.J.,
J. CHEM SOC, -PERKIN 1972, 1022
682 KACZMAREK N., KARCZYNSKI F. AND KUPRYSZEWSKI G,,
ROCZ CHEM 1972, 46, 771
683 LETTER J.E. AND BAUMAN J.E.,
J. AMER CHEM SOC, 1970, 92, 443
684 NAKAYAMA F. S., J. PHYS CHEM, 1970, 74, 2726
685 SANTSCHI P.H. AND SCHINDLER P.W,,
J. CHEM SOC, DALTON 1974, 181
686 WEBER W.J, AND STUMM W., .
J. INORG NUCL CHEM. 1965, 27, 237
687 POLASEK M, AND SARTUSEK M»,
SCR FAC SCI NATURE UNIV PURKYRNI ANAE 1971, 9, 109
688 LODZINSKA A., ROCZ CHEM 1967, 41, 1007
689 KRAVTSOV V.I. AND CHAMAEV V.N.,
VESTN LENINGRAD UNIV FIZ KBIM 1971, 3, 92
690 BESSE G., CHABARD J.L., VOISSIERE G,» PETIT J,
AND BERGER J . A. , BULL SOC CHIM FR„ 1970, 1 1 , 4166
691 KHALIL I, AND PETIT-RAMEL M,M«,
BULL SOC CHIM FR. 1973, 6, 1908
692 RUMBAUT N.A., BULL SOC CHIM BELG, 1971, 80, 63
693 PYATNITSKH I.V, AND KOLOMIETS L.L.,
UKR KHIM Z. 1969, 35, 1019
694 ASAWA H.G. AND DHOOT L.N.,
Z, PHYS CHEM (LEIPZIG) 1972, 250, 180
695 GHOSH R. AND NAIR V.,
J, INORG NUCL CHEM. 1970, 32, 3025
696 RAMAMOORTHY S. AND SANTAPPA M.,
J, INORG NUCL CHEM. 1968, 30, 2393
697 WARNKE Z. AND KWIATKOWSKI E», ROCZ CHEM 1973, 47, 467
177
698
699
700
701
702
703
704
705
706
707
708
709
MCAULEY A 
TRANS FAR SOC. 
GOROIENKO V.I. 
Z. OBSHCH KHIM 
SMYSHLYAEV S.I
710
711
712
713
714
715
DAS A.R. AND NAIR V.,
J. INORG NUCL CHEM. 1975, 37, 2121 
MCAULEY A. AND NANCOLLAS G.H.,
AND NANCOLLAS G.H.,
1960, 56, 1165 
AND MIKHARLYUK YU,I„,
1971, 41, 507
, VOITKO L.M, AND VOSCHENKO L.A.,
TR KRASNODAR POLITEKH INST 1970, 29, 34 
STEPANOV A.V. AND PAZUKHIN E.M.,
Z. NEORG KHIM 1970, 15, 1483
KRAVTSOV V.I. AND CHAMAEV V.N.,
VESTN LENINGRAD UNIV FIZ KHIM 1967, 22, 94 
KANEMURA Y. AND WATTERS J.I.,
4. INORG NUCL CHEM. 1967, 29, 1701 
ZOLOTUKHIN V.K., Z, NEORG KHIM 1963, 13, 702 
STARY 4. AMD LILJENZIN J.O.,
RADIOCHEM RADIOANAL LETT. 1969, 1, 273 
KLATT L.N., ANAL CHEM. 1970, 42, 1837 
BENNES R„,
4. ELECTROANAL CHEM INTERFAC ELECTROCHEM 1972, 36, 
TALLMAN D.E. AND LEIJSSING D.L.,
4, CHEM SOC# 1961, 2215|
%
11
J. AMER CHEM SOC. 1969, 91, 6253
RAMAMOORTHY S., RAGHAVAN A., V I J AYARAGHAVAN B.R.
AND SANTAPPA M., 4- INORG- NUCL CHEM. 1969, 31, 1851
DRAGAN S.V. AND MILENKOV V,,
GLAS HEM DRUS BEOGRAD 31 ,. 129
30, 79
30, 63
718
719
DRAGAN S.V. AND MILENKOV V,,
GLAS HEM DRUS BEOGRAD 1965,
DRAGAN S.V. AND MILENKOV V.,
GLAS HEM DRUS BEOGRAD 1965,
MUSIL 4., DOLEZAL 4. AND VORLICEK 4.,
4. ELECTROANAL
716 KNOWLES C.F. AND HODGKINSON A,,
717 SAMSONOVA N.P., FEDEROV V.A 
Z, FIZ KHIM 1972, 46, 2153 
FEDEROV V.A., SAMSONOVA N.P 
RUSS 4. INORG CHEM. 1970, 15, 2562
ZUBLANOVSKII V.S., BELINSKII V.N, AND ZOSIMOVICH D.P., 
Z. NEORG KHIM 1971, 16, 3009
720 KALINICHENKO I.E., UKR KHIM Z. 1970, 36, 92
721
722
ELECTROCHEM 1970, 2 4, 447
 ANALYST 1972, 97, 474
AND MIRONOV V o E * ,
AND MIRONOV V.E.,
#3
HURNIK B., ROCZ CHEM 1971, 45, 147 
HEGEDUS-WEIN I., SZABO E. AND SZAM I.,
KISERL ORVOSTUD 
DA FONSECA-WOtLHEIM, 
Z. KLIN CHEM BIOC HEM.
1973, 25, 217
723
724
725
726
727
1973, 11, 426 
SCHNEIDER 4.A., BRADLEY K.H. AND SEEGMILLER 4.E., 
ANAL BIOCHEM. 1968, 23, 129
SANDERS G.T.B. AND THORNTON W„,
CLIN CHIM ACTA 1973, 46, 465 
SCHUBERT J., ’IRON METABOLISM’.
ED, GROSS F. SPRINGER-VERLAG, BERLIN 1964, 466 
BOTTARI E- AND VICEDOMINI M.,
GAZZ CHIM ITAL. 1971, 101, 860
178
728
729
730
731
732
733
734
735
* 736'
* 737
738
* 739
* 740
741
742
743
* 744
745
74 6 
74 7
748
749
750
751
752
753
* 754
755
756
757
758
759
760
TOPUZOVSKI 8,,
GOD SB, PRIR-MAT FAK UNIV SKOPJE 1972, 22, 185 
BQTTARI E, AND VKEDOMINI M,,
J, INORG NIJCL CHEM, 1 973 , 35, 1 269
VELAPOLDI R.A. AND MEN,IS 0,, CLIN CHEM. 1971, 17
FORNARI Gw, MARCHESI N, AND SORBINI C.A.,
RASS FISIOPATOL CLIN TER. 1967, 39, 423 
ZENDER R., DE TORRENTE C- AND SCHNEIDER U,,
CLIN CHIM ACTA 1969, 24, 335 
PRYCE J.D., ANALYST 1969, 94, 1151 
ABDULLAEVA D,A.,
MATER RESPU3 NAUCH-TECH KONF MOIODYKH 1967, 79 
SZABO E«, HEGEDUS-WEIN I. AND SZAM I.,
Z, GESANTE INN MED IHRE GRENZGEB 1970, 25, 27 
MAY P.M,, ,M.5C. THESIS. UNIVERSITY OF CAPE TOWN.
PEISACH J. ANO BLUMBERG W.E.,
MOLECULAR PHARMACOL- 1969, 5, 200
NEILD G „ H • , GARTNER H.-V. ANO BOHLE A.,
LANCET 1975, 1201
DIXON j.W. ANO SARKAR B,,
J. BIOL CHEM. 1974, 249, 5872
LAU S-J,, KRUCK T.P-A, AND SARKAR B.,
J. BIOL CHEM, 1974, 249, 5878
CARTER S.K. AND SLAVIK M.,
11651
1
19761
ANN REV PHARMACOLOGY 1974, 14, 157
CHASSEAUD L-F. AND TAYLOR T „ ,
ANN REV PHARMACOLOGY 1974, 14, 35
FASSETT D.W., ANN REV PHARMACOLOGY 1975, 15, 425 
GUBLER C.J., CARTWRIGHT G.E. AND WINTR03E M.M„,
J. BIOL CHEM, 1957, 224, 533
MELGAR E. ANO GOLDTHWAIT D.A.,
J, BIOL CHEM, 1968, 243, 4409
ALGER T.D., BIOCHEMISTRY 1970, 9, 3248
CHESTERS J.K., BIOCHEM J. 1972, 130, 133
DAVIS P.S., MULTANI J.S., CEPURNEF.K C,P. ANO SALTMAN P,, 
BIOCHEM BIOPHYS RES COMMON 1969, 37, 532 
WILLIAMS R.'j.P.,
RECENT RESULTS CANCER RES. 1974, 48, 1
THOMSON A.J., RECENT RESULTS CANCER RES. 1974, 48, 33 
AULO D.5., KAWAGUCHI H., LIVINGSTONE D.M. AND VALLEE 
B.L., BIOCHEM BIOPHYS RES COMMUN 1975, 62, 296 
CHARLSON A.J., TRAINOR K.E. AND WATTON E.C.,
J. PROC R. SOC N.S.W. 1975, 108, 6
TERHUNE M.W. AND SANDSTEAD H,H„, SCIENCE 1972, 177, 68 
SORENSON J.R.J., J.-MED CHEM, 1976, 19, 135 
RUBIN H„, PROC NAT ACAD SCI U.S.A. 1972, 69, 712 
HAHN D. AND GANZON! A.M., ACTA HAEMATOL. 19/5, 53, 321 
CLEARE M.J. AND HOESCHELE J.D.,
BIOINORG CHEM. 1973, 2, 187
ONKELINX C., BECKER J. AND SUNDERMAN F.W.,
RES COMM CHEM PATH PHARMACOL. 1973, 6, 663 
WHITEHOUSE .M.W, , AGENTS AND ACTIONS 1975 , 5 , 508 
SLATER J.P., MILDVAN A.S. AND LOEB L.A-,
BIOCHEM BIOPHYS RES COMMUN 1971, 44, 37
••/'Sr
179
761 WESER U,, SEEBER S . ANO WARNECKE P,,
BIOCHIM BIOPHYS ACTA 1969, 1-79, 422
762 ZIMMER C.H., LUCK G. ANO TRIEBEL H,,
BIOPOLYMERS 1974, 13, 425
763 RICHARD H», SCHREIBER J.P. AND DAUNE M„,
BIOPOLYMERS 1973, 12, 1
764 HOLMAN L,R. AND JORDAN D.O,, •
BIOPOLYMERS 1972, 12, 1661
765 BROWN N.C-, ELIASSON R., REICHARD P. AND THELANDER L», 
EUROPEAN J, BIOCHEM. 1969, 9, 512
766 FROMMER D,, GUT 1974, 15, 125
767 WACKER W.E.C. AND VALLEE B.L., ■’
J. BIOL CHEM. 1959, 234, 3257
768 FERNANDEZ-MADRID F., PRASAD A.S, AND OBERLEAS D.,
J, LAB CLIN MED, 1973, 82, 951
769 PRASAD A.S. AND OBERLEAS D.,
J. LAB CLIN MED. 1974, 83, 634
770 R0SEN3ERG B., VAN CAMP L. AND KRIGAS T,, '
NATURE 1965, 205, 698
771 KORANT B.D., KAtJER J.C, AND BUTTERWORTH B ,'E.»
NATURE 1974, 243, 588
772 SCRUTTON M.C., WU C.H. AND GOLDTHWAIT D.A., . ■
PROC NAT ACAD SCI U.S.A. 1971, 68, 2497 *'
773 GUNN S.A., GOULD T.C. AND ANDERSON W.A.D.,
PROC SOC EXP BIOL MED. 1964, 115, 653
774 TISMAN G., HERBERT V., GO LE T. AND BRENNER L , ,
PROC SOC EXP 9I0L MED, 1972, 139, 355
775 OBERLEAS D. AND PRASAD A.S,, PROC.SYMP, ’TRACE ELEMENT 
METABOLISM IN MAN AND ANIMALS’, 2ND. 1973, 730
* 776 GANS P., SABATINI A. AND VACCA A., ’
INORG CHIM ACTA 1976, 18, 237
777 STITT C., CHARLEY P.J., BUTT E.M. AND SALTMAN P.,
PROC SOC EXP BIOL MED, 1962, 110, 70 • •
778 WRANGLEN G„, j. ELECTROCHEM SOC, 1976, 123, 36
* 779 MADDOX I.S., BIOCHIM BIOPHYS ACTA 1973, 306, 74
780 BAGLEY D.H., ZAPOLSKI E.J., RUBIN M.
AND PRINCIOTTO J.V., CLIN CHIM ACTA -1971, 35, 311
781 BAGLEY D.H., ZAPOLSKI E.J., RUBIN M. ANO PRINCIOTTO 
J.V., AMER J, OBSTET GYNECOL. -1968, 102, 291
782 ACHESON L.S, AND SCHULTZ S.G., ‘ ’
BIOCHIM BIOPHYS ACTA 1972, 255, 479
783 FOULKES E.C, AND GIESKE T.,
BIOCHIM BIOPHYS ACTA 1973, 318, 439
784 MORGAN E.H., BIOCHIM BIOPHYS ACTA 1971, 244, 103
* 785 CHVAPIL M., HURYCH J., EHRLICHOVA E. AND CMUCHALOVA B,,
BIOCHIM BIOPHYS ACTA 1967, 140, 339 
736 STEVEN F.S., BIOCHIM BIOPHYS ACTA 1967, 140, 522
787 GOLLAN J.L., CLIN SCI. MOLEC MED. 1975, 49, 237
788 DYRSSEN D, AND WEDBORG M,, SEA 1974, 5, 181
789 HOFMANN IJ . AND SEGEWITZ G,,
ARCH TOXICOL, 1975, 34, 213
790 CHERVU L.R. AND STERNLIEB I,, ’
J. NUCLEAR MEDICINE 1974, 15, 1011
791 6RUDEN N., TO-XICOLOGY 1975 , 5 , 1 63
.180
792 KARTELL A.E,, PURE AND APPLIED CHEM. 1975, 44, 81
79.3 SOBOTKA T-J,,. BRODIE R.E. AND COOK M.P,, .
TOXICOLOGY 1975, 5, 175
794 WILLIAMS D.A., WALZ D.T. AND FOYE W.Q.,
J. PHARM SCI, 1976, 65, 127
795 TANDON S,K. AND SINGH J., TOXICOLOGY 1975, 5, 237
796 STERNLIEB I. ET.AL., GASTROENTEROLOGY 1973, 64, 99
797 FUCHS C., DORN D-, MCINTOSH C, AND SCHEIER F»,
CLIN CHIM ACTA 1976, 67, 99
798 LEWIS K.O.. GUT 1973, 14, 221
* 799 PERSSON H,, ACTA CHEM SCAND, 1971, 25, 1775
* 800 GOULD R.O, AND RANKIN A.F„, .
CHEM COMMUNICATIONS 1970, 489
* 801 SI LIEN L.G„, SVENSK KEMISK TIDSKRIFT 1963 , 75, 1 61
802 PERDUE E.M., BECK K.C, AND REUTER J.H.,
NATURE 1976,- 260, 418
803 RAINSFORO K.D., AGENTS AND ACTIONS 1975, 5, 326
* 304 SIMEONOV/A T, AND STANCHEVA P.,
NRPB TECHNICAL REPORTS 1974, 12,135
80 5 SENS I P , AND TERENSI E. ,
ISRAEL J, CHEMISTRY 1975, 14, 177
806 FIELD L. ET.AL., .J. MED CHEM, 1973, 16, 1152
807 OWEN C.A. AND HAZELRIG J.B., ’BIRTH DEFECTS ORIGINAL 
ARTICLE SER’, VOL IV, WILSONS DISEASE. 1968, 1
808 SILVERBERG M,, NEUMANN P„ Z „ AND ROTENBERG A.0„,
’BIRTH OEFECTS ORIGINAL ARTICLE SER’, VOL IV. .
WILSONS DISEASE, 1968, 8
809 FARRER P.A. AND MISTILIS S.P., ’BIRTH DEFECTS ORIGINAL 
ARTICLE SER’. VOL IV. WILSONS DISEASE, 1968, 14
* 810 GIROUX E.l. AND HENKIN R. I.,
BIOINORG CHEM, 1972, 2, 125 -
311 KOJIMA S., KIYOZUMI M» AND SAITO K.,
CHEM PHARM BULL, 1976, 24, 16
* 812 OLIN A, AND SVANSTROM P.,
ACTA CHEM SCAND, 1975, 29, .849
* 813 GIROUX E.L., BIOCHEM MEDICINE 1975, 12, 258
814 HEMMAPLARDH D. AND MORGAN E,H»,
BIOCHIM BIOPHYS ACTA 1.974, 373, 84 •
815 STERNLIEB I,, GASTROENTEROLOGY 1967, 52, 1038
* 816 JONES M.M. AND ET. AL,,
J, INORG NUCL CHEM. 1976, 33, 613
* 817 BRUN P.F. AND SCHRODER K.H.,
J„ ELECTROANAL CHEM INTERFAC ELECTROCHEM . 1975, 66, 9
818 AINSCOUGH E,W, AND BRODIE A „ M, ,
J, CHEM EDUCATION 1976, 53, 156
* 819 SANDSTEAD H.H.,
AMER J. CLINICAL NUTRITION 1973, 26, 1851
820 PRINCIOTTO J.V. AND ET. AL., ,
BIOCHEM MEDICINE 1970, 3, 289 .
821 MANIS J.G, AND SCHACHTER D.,
AMER J, PHYSIOLOGY 1962, 203, 73
* 822 OWEN C,A-,. AMER J. PHYSIOLOGY 1964, 207, 1203
181
-x-
823
824
825 
S26
827
823
829
830
831
832
833
83 4
835
836
837
838
839
840
841
842
843
844
845
846
847
843
*
*
BF.RTINCH AMPS A., MILLER S.T. AND COTZIAS G, C. ,
AMER J. PHYSIOLOGY 1966, 211, 217
RUBIN M. AND ET„ A‘L., BIOCHEM MEDICINE 1970, 3, 271 
GINZBURG G„, TALANTA 1976, 23, 149 ‘
OKUNEWICK J.P., POND B. AND HENNESSY T.G.,
AMER PHYSIOLOGY 1962, 202, 926 .
OWEN C.A., AMER J. PHYSIOLOGY 1965, 209, 900 
WALDMANN-MEYER H., J. BIOL CHEM, i960, 235, 3337 
MARTELL A.E., ANN N.Y. ACAD SCI. i960, 88, 284 
KROLL H. AND GORDON M„,
ANN N.Y. ACA.D SCI, 1960, 88, 341
WEINER M., ANN N.Y. ACAD SCI, 1960, 88, 426 
SPENCER H., ANN N.Y, ACAD SCI. I960, 38, 435 
RUBIN M, AND PRINCIOTTO J.V.,
ANN N.Y. ACAD SCI. 1960, 88, 450
HAMMOND P.B. AND ARONSON A.L., ’
ANN N.Y. ACAD SCI. 1960, 88, 498
LEACH R.M., PROC.SYMP. ’TRACE ELEMENT METABOLISM IN 
MAN AND ANIMALS’, 2ND. 1973, 51
CHRISTOPHER J.P., HEGENAUER J.C. AND SAlTMAN P», 
PROC.SYMP. ’TRACE ELEMENT METABOLISM IN MAN AND
ANIMALS', 2ND. 1973, 133
FORTH W,, PROC.SYMP. 'TRACE ELEMENT METABOLISM IN MAN 
AND ANIMALS’, 2ND. 1973, 199
BEISEL W.R., PEKAREK R.S. AND WANNEMACHER R.W., 
PROC.SYMP. ’TRACE ELEMENT METABOLISM IN MAN AND 
ANIMALS’, 2ND. 1973, 217 •
WEINBERG E.D., PROC.SYMP. ’TRACE ELEMENT METABOLISM IN 
MAN AND ANIMALS’, 2ND. 1973, 241
EVANS G.W.' AND HAHN C.J., PROC.SYMP. ’TRACE ELEMENT 
METABOLISM IN MAN AND ANIMALS’, 2ND. 1973, 497 
SCHWARZ F.J. AND K1RCHGESSNER 'M., PROC.SYMP? ’TRACE 
ELEMENT METABOLISM IN MAN AND ANIMALS’, 2ND. 1973, 519 
GRASSMANN E. AND KIRCHGESSNER M„, PROC.SYMP. 'TRACE 
ELEMENT METABOLISM IN MAN' AND ANIMALS’, 2ND. 1973, 523 
KRATZER F.H., PROC.SYMP. ’TRACE ELEMENT METABOLISM IN 
MAN AND ANIMALS’, 2ND, 1973, 527
LANTZSCH H.-J, AND MF.NKE K.H., PROC.SYMP. 'TRACE 
ELEMENT METABOLISM IN MAN AND ANIMALS', 2ND. 1973, 531 
PALLAUF J, AND KIRCHGESSNER M., PROC.SYMP. 'TRACE 
ELEMENT METABOLISM IN MAN AND ANIMALS’, 2ND. 1973, 534 
LASSITER J.W. ET.AL,, PROC.SYMP. ’TRACE ELEMENT 
METABOLISM IN MAN AND ANIMALS’, 2ND, 1973, 557 
ONKELINX C., BECKER J, AND SUNDERMAN F.W.,
PROC.SYMP. 'TRACE ELEMENT METABOLISM IN MAN AND
ANIMALS', 2ND. 1973, 560
HITCHCOCK J.P., KU P.K. AND MILLER E.R.,
PROC.SYMP, 'TRACE’ ELEMENT METABOLISM IN MAN AND 
ANIMALS', 2ND. 1973, 598 ‘ •
STRAIN W.H. ET.AL,, PROC.SYMP, ’TRACE ELEMENT 
METABOLISM IN MAN AND ANIMALS', 2ND, 1973, 644 
EATOUGH O.J. ET.AL,, PROC.SYMP. ’TRACE ELEMENT 
METABOLISM IN MAN AND ANIMALS', 2ND. 1973, 659
849
850
182
851 HI’NKIN R.I,, PROC.SYMP. ’TRACE ELEMENT METABOLISM IN 
MAN ANO ANIMALS’, 2ND, 1973 , 647
852 GROPPEL B. ET.AL., PROC.SYMP, ’TRACE ELEMENT 
METABOLISM IN MAN ANO ANIMALS', 2ND, 1973, 665
853 NEILANOS J.8,, AOV EXP NEO BIOL, 1 973 , 40 , 13
854 LINDENBAUM A., AOV EXP MEO BIOL, 1973, 40, 67
* 855 SCHUBERT J., AOV EXP MEO BIOL, 1973, 40, 239
856 EVANS G.W. ANO HAHN C,J„,
AOV EXP MED BIOL, 1974, 48, 285
857 HENKIN R.I., AOV EXP MEO BIOL. 1974, 48, 299
* 858 KRUCK T.P.A,, LAU S~J „ ANO SARKAR B„,
. . CANADIAN J. CHEM, 1976, ’54, 1300
859 CHESTERS J.K., PROC.SYMP, 'TRACE ELEMENT METABOLISM IN 
MAN ANO ANIMALS’., 2ND. 1973, 39
* 860- CORRIB A.M„, WALKER M.D. ANO WILLIAMS 0 „ R, ,
J, CHEM SOC, DALTON 1976, -101 2
* 861 MAKAR G.K.R., TOUCHE M.L.D. AND WILLIAMS O.R.,
J. CHEM SOC. DALTON 1976, 1016
862 HETH D.A. ANO HOEKSTRA W.G.,
J, NUTRITION 1965, 85, 367
863 PEARSON W.N, ANO REICH M,, J, NUTRITION 1965, 87, 117
864 HETH D.A., BECKER W.M. AND HOEKSTRA W.G.,
J. NUTRITION 1966, 88, 331
865 NIELSEN F.H., SUNDE M.L. ANO HOEKSTRA W.G.,
J. NUTRITION 1966, 89, 24
866 NIELSEN F.H., SUNDE M.L. ANO HOEKSTRA W.G.,
J, NUTRITION 1966, 89, 35
867 NEILL O.W., MUHRER M.E. ANO O’DELL 8. L ■,
J. NUTRITION 1966, 90, 56
868 STARCHER B., J. NUTRITION 1969, 97, 321
869 VAN CAMPEN 0., J. NUTRITION 1972, 102, 165
870 VAN CAMPEN 0. ANO HOUSE W,A„,
J. NUTRITION 1974, 104, 84
871 MURTHY L., KLEVAY L-M. AND PETERING H.G.,
J. NUTRITION 1974, 104, 1453
872 BROWN E . B. ANO JUSTUS B.W.r
AMER J. PHYSIOLOGY 1958, 194, 319
873 COTZIAS G.C., BORG O.C. ANO SELLECK B, ,
AMER J. physiology 1962, 202, 359
874 RULIFFSON W.S. AND HOPPING J . M * ,
AMER J. PHYSIOLOGY 1963 , 204, 171
875 COTZIAS G.C. AND PAPAVASILIOU P.S, ,
AMER J. PHYSIOLOGY 1964, 206, 787
876 MANIS J . G. AND SCHACHTER 0 •,
AMER J, PHYSIOLOGY 1964 , 207, 893
877 BRITTON A.A, ANO COTZIAS G , C»,
AMER J. PHYSIOLOGY 1966, 211 , 203
878 PAPAVASILIOU P.S., MILLER S.T. AND COTZIAS
AMER J, PHYSIOLOGY 1966, 211 , 211
879 PERRY H.M, ANO ERLANGER M.,
AMER J, PHYSIOLOGY 1971, 220, 808
880 OWEN C.A., AMER J, PHYSIOLOGY 1971, 221, 1722
881 THOMSON A.’B.R. AND VALBERG L.S.,
AMER J, PHYSIOLOGY 1972, 223, 1327
183
*
*
*
882 HAMILTON D.L, AND VALBERG L . S „ ,
AMER J, PHYSIOLOGY 1 974 , 227, 1033
883 FOULKES E.C., AMER J. PHYSIOLOGY 1 974, 227, 1356
884 OWEN C.A., RANDALL R.V. AND GOLDSTEIN N»P, ,
AMER J. PHYSIOLOGY 1975, 228, 88
885 LINDER M , C „ , DUNN V . , ISAACS E., JONES D., LIM S.
AND MUNRO H.N., AMER J. PHYSIOLOGY 1975, 228, 196
886 EVANS G.W., GRACE C.l. AND VOTAVA H.J.,
AMER J, PHYSIOLOGY 1975, 228, 501
887 HAHN C.J. AND EVANS G.W.,
AMER J. PIIYS.IOLOGY 1975 , 228, 1 020
888 KOIKE T.I., KRATZER F.H. AND VOHRA P,,
PROC SOC EXP BIOL MED. 1964, 117, 483
889 HADDOCK E.P., ZAPOLSKI E.J., RUBIN M. AND PRlNCIOTTO 
J.V., PROC SOC EXP BIOL MED. 1965, 120, 663
390 EVANS G.W. AND CORNATZER W.E., ’
*
PROC SOC EXP BIOL MED. 1971, 136, 719
891 EVANS G.W., GRACE C.l, AND HAHN C.J.,
PROC SOC EXP BIOL MED, 1973, 143, 723
892 HAHN C.J. AND EVANS G.W.,
PROC SOC EXP BIOL MED, 1973, 144, 793
893 DAVIDSON I.W.F., BURT R.L. AND PARKER J.C.,
PROC SOC EXP BIOL MED, 1974, 147, 720
894 EMES J.H, AND ARTHUR D,,
PROC SOC EXP BIOL MED. 1975, 148, 86
895 SCHWARZ F.J. AND MATRONE G.,
PROC SOC EXP BIOL MED, 1975, 149, 888 .
896 KIRCHGESSNER M»,
MITT. GEB, LEBENSMITTELUNTERS. HYG. 1972, 63, 163
897 LANTZSCH H.-J. AND MENKE K. II, ,
*
Z. TIERPHYSIOL TIERERNAHRG. FUTTERMITT. 1973, 32,
898 KIRCHGESSNFR M., WESER U. AND’MULLER II, L»,
Z. TIERPHYSIOL TIERERNAHRG, FUTTERMITT, 1967, 22,
899 KIRCHGESSNER M., WESER U. AND MULLER H.L.,
Z, TIERPHYSIOL TIERERNAHRG. FUTTERMITT, 1967, 23,
900 GRASSMANN E. AND KIRCHGESSNER M.,
Z, TIERPHYSIOL TIERERNAHRG. FUTTERMITT, 1969, 25,
901 KIRCHGESSNER M, AND GRASSMANN E„,
Z. TIERPHYSIOL TIERERNAHRG. FUTTERMITT, 1970, 26,
902 GRASSMANN E., WETZSTEIN A, AND KIRCHGESSNER M „ ,
Z. TIERPHYSIOL TIERERNAHRG, FUTTERMITT, 1971, 28,
903 SCHWARZ F.J., GRASSMANN E. AND KIRCHGESSNER M„,
Z, TIERPHYSIOL TIERERNAHRG, FUTTERMITT, 1973, 31,
904 LANTZSCH H.-J. AND MENKE K.H.,
Z. TIERPHYSIOL TIERERNAHRG. FUTTERMITT. 1974, 34, 
90 5 S C HN E GG A. AND KIRCHGESSNER M , ,
Z. TIERPHYSIOL TIERERNAHRG, FUTTERMITT. 1975 , 36,
906 SCHNEGG A. AND KIRCHGESSNER M,,'
INT J. VITAMIN AND NUTR. RES, 1976, 46, 96
907 RUIZ-TORRES A., ARZNEIM’FORSCH 1974, 24, 914
908 LOMBARDINO J.G., OTTERNESS I.G, AND WISEMAN E.H,, 
ARZNEIM-FORSCH 1975, 25, 1629
909 JONES M,M. AND PRATT T.H.,
J. CHEM EDUCATION 1976, 53, 342 .
129
76
28
125
340
28
98
43
63
184
* 910
* 911
912
* 913
914
* 915
916
* 917
918
* 919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
* 944
ASATO N,, VAN SOESTBERGEN M, AND SUNDERMAN F.W,,
CLIN CHEM. 1975, 21, 521 
MEERS J.Lw, CHEM BRITAIN 1976, 12, 115 
KILL H.A.O., CHEM BRITAIN 1976, 12, 119 
RADDA G.K. AND WILLIAMS R.J.P.,
CHEM BRITAIN 1976, 12, 124 
RICHMOND V.S., WORWOOD M. AND JAC03S A.,
BRIT J, HAEMATOLOGY 1972, 23, 605 
MAGGIORE R., MUSUMECI S. AND SAMMARTANO S,,
TALAMTA 1976, 23, 43 
THERON J.J..AND MEKEL R.O.P.M,,
BRIT J. HAEMATOLOGY 1971, 21, 165 
EMERY T,, BIOCHIM BIOPHYS ACTA . 1974, 363, 219 
TANDON S„K. AND MATHUR A,K»,
ACTA PHARMACOL TOXICOL. 19.76, 38, 401 
BILINSKI H„, • ARCH HIGIJENU RADA TOK.
BEAMISH M.R. ET.AL., BRIT J. HAEMATOLOGY 1974, 27, 219 
GRAZIANO J.H., GRADY R.W, AND GERAMI A., .
J, PHAR.M EXP THER, 1 974 , 190, 570 
ROMSLO I. AND FLATMARK T,,
BIOCHIM BIOPHYS ACTA 1973, 305, 29 .
VALBERG L.S, AND SINCLAIR D.G., .
1971, 50, 2384
NATURE 1967, 213, 291
1975, 26, 119
THOMSON A.B.R., 
J. CLIN INVEST.
51, 790
1974, 60, 641
125
GUT
109
259
FARRER P.A, AND MISTILIS S,P,,
WHITE J.M-, NATURE 1967, 667 
GOLDBERG A., POSTGRAD MED J, 1975, 51, 747 
WHITE J.M., POSTGRAD MED J. 1975, 51, 755 
CHAMBERLAIN A. ET.AL, POSTGRAD MED J, 1975,
WASE A.W., GOSS D.M. AND BOYD M, ,J , ,
ARCH BIOCHEM BIOPHYS. 1954, 51, 1 
VAN CAMPEN D„, FED PROC, 1974, 33, 100 ’
COLEMAN J.E,, BIOCHEM BIOPHYS RES COMMON 
RICHARDS M.P. AND COUSINS R , J . ,
BIOCHEM BIOPHYS RES COM.MUN 1 975 , 64 r 1215 
CRICHTON R.R., F.E.B.S LETTERS 1973, 34,
PAVLETICH K,» KUO S.-C. AND LAMPEN J.O., -
BIOCHEM BIOPHYS RES COMMUN 1974, 60, 942 
BAGLEY D.H., ZAPOLSKI E.J., RUBIN M, AND PRlNCIOTTO 
J.V.,* PROC SOC EXP BIOL MED, 1968, 127, 798 
PRlNCIOTTO J.V., RUBIN M., SHASHATY G . C „
AND ZAPOLSKI E.J., J. CLIN INVEST, 1964, 43, 825 
HERSHKO C,, J, LAB CLIN MED, 1975, 85, 913 
LOEHRY C.A., PARISH D, AND BAKER J,,
DISLER P.B. AND ET, AL.,
SOUTH AFRICAN J, MED’ SCI, 1 975, 40,
JUGO MALJKOVIC T. AND KOSTIAL K,,
TOXICOLOGY APPL PHARMACOL, 1975, 34#
JUGO S., MALJKOVIC T, AND KOSTIAL K , ,
ENVIRON RESEARCH 1975, 10, 271 •
SCHWARZ F,J. AND KIRCHGESSNER M.,
Z. TIERPHYSI'OL TIERERNAHRG, FUTTERMITT 
FLATMARK T-, AND ROMSLO I,,
J, BIOL CHEM. 1975, 250, 6433 
WALSHE J.M,, QUART J. MEDICINE 1973, 42, 441
1973, 14, 773
1975, 35, 257 J
J- ’ *• ’5 M b .
J
185
*
•X*
I
4
COHEN N „ AND GUILMETTE R,, BIOINORG CHEM 
CAVILL I., WORWOQD M, AND JACOBS A * ,
NATURE 1975, 256, 328
BORGGAARD 0 , K • , ACTA CHEM SCAND.
MADSEN H.E.L., ACTA CHEM SCAND,
MADSEN H-E-L-, ACTA CHEM SCAND,
LANDS W.F-M. AND LE TELLIER P.R„,
ADV BIOSCI. 1972, 9, 15
AISEN P,, LEIBMAN A, AND PINKOWITZ R.A.,
ADV.EXP MED BIOL- 1974, 48, '125 
CHARLTON R,W. AND ET. AL-,
SOUTH AFRICAN MEDICAL J.
EICHHORN G,L. ET-AL-, A 
COTZIAS G-C-, BORG D.C.
AMER J, PHYSIOLOGY 1961 
OWEN C-A. AN.D HAZELRIG J.8’.,
AMER J. PHYSIOLOGY 1<
LANDS W.E.M., LEE R. I 
ANN N„Y. ACAD SCI, 1<
BERMAN' M,8, AND MARIABE R.
ANN OPTHALMOL- 1973, 5 
CASH W-D. ET-AL-, ARCH 
FORTH W,, RUMMEL W. AND 
ARCH EXPTL PATHOL PHARM
960 FORTH W. ET-AL.,
ARCH EXPTL PATHOL PHARM, 1965, 252, 242
961 MILLER W-J- ET-AL,, J. NUTRITION 1966, 90, 335
962 SIEGEL R,C,, PINNELL S.R, AND MARTIN 
BIOCHEMISTRY 1970, 9, 4',S6
EVANS G.W., MAJORS P.F. AND CORNATZER W„E„, 
BIOCHEM BIOPHYS RES COMMON 
HSIEH H.S- AND FRIEDEN E-,
BIOCHEM BIOPHYS RES COMMUM 
GODA k
945
946
947
948
949
950
951
95?
953
954
955
956
957
958
959
963
964
965
966
1976, 5, 2 03 g
1972, 26, 393
1975, 29, 745
1976, 30, 306
» ,
1971 , 178
DV EXP MED BIOL-
AND SELLECK B-,
, 201, 63
 ,
, 215, 334
SMITH W - L ,,
, 180, 107
 •,
1193
BIOCHEM BIOPHYS,
S E I F E N E « ,
1965, 252, 224
1973, 40, 43
1968, 128, 456|
G - R - ,
 . E „ 
1970, 40, 1142
13261975, 67,
AND KIMURA T-,
1976, 69, 687
DE ALVARE L-R-,
BIOCHEM BIOPHYS RES COMMUN 
FIELDING J. AND SPEYER B,E,,
BIOCHIM BIOPHYS ACTA 1974, 363, 387
967 ROMSLO I., BIOCHIM BIOPHYS ACTA 1975, 387, 69
968 KIRCHGESSNER M, , SCHWARZ F-J- AND GRASSMANN E „, 
BIOINORG CHEM. 1973, 2, 255
969 EVANS G.W., GRACE C-I. AND HAHN C,J,,
BIOINORG CHEM. 1974, 3, 115
970 GIROUX E-L-, OURIEUX M, AND SCHECHTER P-J,,
BIOINORG CHEM, 1976, 5, 211
971 BEDARD Y.C., PINKERTON P-H, AND SIMON G,T,,
BLOOD 1973, 42, 131
97? PINKERTON P-H- AND ET- AL-,
BRIT J- HAEMATOLOGY 1970, 18, 211
973 LANE R.S., BRIT J. HAEMATOLOGY 1975, 29, 511
974 VAN S0ESTBER6EN M. AND SUNDERMAN F.W.,
CLIN CHEM, .1972, 18, 1478
975 HORAK E, AMD SUNDERMAN F.W., CLIN CHEM- 1973, 19,
976 WALDRON H-A-, ENVIRON HEALTH 1974, 29, 271
429
186
977
* 978
* 979
98 0
981
982
983
* 984
* 98 5
986
987
* 988
989
* 990
* 991
* 992
993
99 4
995
996
997
998
* 999
1 000
* 1001 
* 1002
* 1 003
* 1004
* 1005
* 1006 
* 1007
*1008
hahn c,j,f Grace c.i. and evans g\w„,
FED PROC, 1 973 , 32 , No.3804, 895 
H, AMD O.LLERJCH D.A.,
1974, 33, 1767
AND ROSOFF B., HEALTH PHYS, 1966, 12, 475 
ET.At0, J. ANIM SCI. 1976, 42, 630
NIELSEN F 
FED PROC. 
SPENCER H 
ABRAMS E,
SALTMAN P,, FISKIN R.D, AND BELLINGER S.B.,
J. BIOL CHEM. 1 956, 22-0 , 741
SALTMAN P., FISKIN R.D., BELLINGER S.B, AND ALEX T,, 
J, BIOL CHEM. 1956, 220, 751
SALTMAN P., FRISCH H.L., FISKIN R.D. AND ALEX T,,
J. BIOL CHEM’. 1 956, 221 , 777
MILLER E.J., MARTIN G.R., MECCA C . E „ AND PIEZ K , A „ ,
J, BIOL CHEM. 1965, 240, 3623
NIMNI M.E., J. BIOL CHEM. 1968, 243, 1457
DAVISON A.J-, J. BIOL CHEM. 1968, 243, 6064
EICHHORN G.L., CLARK P. AND TARIEN E.,
J. BIOL CHEM. 1969, 244, 937
DESHMUKH K. AND NIMNI M.E.,
J. BIOL CHEM, 1969, 244, 1787
WANG C.C. AND NEWTON A,, J. BIOL CHEM. 1971, 246, 2147
4
KAGI J.H.R., LOURIA D.B., WHANGER P.D., BETHUNE J.L.
1974, 249, 3537AND VALLEE B.L., J- BIOL CHEM 
BATES G.W. AND SCHLABACH M.R.,
J. BIOL CHEM. 1975, 250, 2177 
SCHLABACH M.R. AND BATES G.W.,
J, BIOL CHEM. 1975, 250, 2182 
PRASAD A . 5., OBERLEAS D., WOLF 
J, CLIN INVEST. 1967, 46, 549 
BRITT IN G.-M. AND RAVAL I),,
J, LAB CLIN MED. 1970, 75, 811 
BECKER W.M. AND HOEKSTRA W.G.,
J. NUTRITION 1968, 94, 455
SMITH C.J, AND HACKLEY B., J.NUTRITION 1968, 95, 541 
STAKE P.E3 AND ET, AL., J. NUTRITION 1974, 104, 1279 
BEDARD Y.C., RUBIN H., PINKERTON P.H, AND SIMON G.T., 
1974, 30, 155
ALPERT $„ AND STERNLIEB U,
P . AND H 0 R WIT Z J , P , ,
LAB INVEST
AISEN P,, MORELL A„G„,
NATURE 1964, 203, 873
SALTMAN P„, HEGEMAUER J.C. AND CHRISTOPHER J.P.,
ANN CLIN LAB SCI. 1976, 6, 167
RICHARDSON T., J. PHARM PHARMACOL. 1976, 28, 666 
OYANAGUI Y., BIOCHEM PHARMACOL. 1976, 25, 1465 
WALSHE J.M., CLIN SCI. 1963, 25, 405
SUNDERMAN F.W., KASPRZAK K., HORAK E», GlTLlTZ P „ AND 
ONKELINX C., TOXICOLOGY APPL PHARMACOL. 1976, 38, 177 
RAINSFORD K.D. AND WHITEHOUSE M.W„,
J. PHARM PHARMACOL. 1976, 28, 83 
GANS P., CO-ORDINATION CHEM REV, 1976, 19,
C 0 R R I E A.M. AND WILLIAMS D . R . ,
J. CHEM SOC, DALTON 1976, 1068 
FAZAKERLEY G.V., JACKSON G.E. AND LINDER P.W.,
J. INORG NUCL CHEM. 1976, 33, 1397
99
187
1 009
1010
1011 
* 1012
* 1013
* 1014 
1015
* 1016
1017
1018
* 1019 
1 020.
* 1021 
1022
1023
1024
1974, 23, 901 
1962, 1, 1454
1025
1026 
1027
KRUCK T.P.A. AND SARKAR B.,
INORG CHEMISTRY 1975, 14, 2383 
BOSTROM H, AND WESTER P.0,,
ACTA MED SCAND, 1967, 181, 475 
GABARD B., BIOCHEM PHARMACOL.
OHLSSON W.T.L., BRIT MEDICAL J
CARTWRIGHT G.E. ET.A, J. CLIN INVEST, 1954, 33, 1487 
BOULDING JJ. AND BAKER R.A., LANCET 1 957, 2 , 985 
OSBORN S.8. AND WALSHE J.M., LANCET 1958, 1 , 70 
HILL L. AND WALSHE J.M., LANCET 1959, 2, 444 
WENDEl O.W., LANCET 1961, 1, 1292 
BEYER M.G., K I R C H GESSN ER' M . AND STEINHART Ho 
LANDWIRTSCH PORSCH, 1976, 29, 53 
LEHNERT G. ET.AL., MED WELT, 1970, 9, 346 
ROSOFF B. AND SPENCER H,, NATURE 1965, 207, 652 
O'REILLY S. AND BANK W,, NATURE 1966, 212, 1597 
PINKERTON P.H. AND BANNERMAN R.M.,
NATURE 1967, 216, 482
STERNLIEB I., VAN DEN HAMER C.J,A. AND ALPERT S., 
NATURE. -1967, 216, 824 ’
B A L C E R Z A K S-P . AND G RE E N B ER 6 E R N . J . ,
NATURE 1968, 220, 270 .
MANIS J.Gw, NATURE 1970, 227, 385
AND AISEN P., NATURE 1975, 257, 821 
EDWARDS A, AND JACOBS A.,
HARRIS D.C,
WORWOOD M.,
NATURE 1971, 229, 409
1028 VANE J.R., NATURE 1971, 231, 232
1029 PLANAS-BOHNE F., HARMUTH-HQENE 
NAUNYN-SCH ARCH PHARM EXP PATH 
GUNTHER R,,
NAUNYN-SCH ARCH PHARM EXP PATH
RUMMEL Ww, FORTH W. AND PPLEGER K«, *
NUCL MED SUPPL, 1967, 5, 129
1032 MOORE M.R,, POSTGRAD MED J« 1975, 51, 760
1033
A.E. AND WEBER K.M., 
1967, 257, 409
* 103 0
1031
1969, 262, 405
S E L H I H . S . AND WHITE .J . M . ,
POSTGRAD med J . 1975 , 51, 765
103 4 BARLTROP D„ AND SMITH A.M„
POSTGRAD med J . 1975, 51 , 770
1035 BARLTROP D, AND KHOO H ,E, ,
POSTGRAD med J . 1975, 51, 795
1036 WETHERILL G. W » , RABINOWITZ M.B
PROC, ANN N. S.F . TRACE CONTAM
AND KOPPLE J 
'NF. I.
D.
1973, 510
1974, 16, 52
1037 SARKAR Bo,
PROC INT CONF CO-ORD CHEM (PROC SYMp).
1033 MANIS J.G. AND SCHACHTER D,»
PROC SOC EXP BIOL MED. 1965, 119, 1185 
* 1039 RUBIN M. ET.AL., PROC SOC EXP BIOL MED, 1967, 124, 
1040
29
1041
* 1042
* 1043
E , AND WIN T R 0 B E M » M , » 
1968, 127, 977
LEE G.R., CARTWRIGHT G 
PROC SOC EXP BIOL MED.
SUSO F.A. AND EDWARDS H.M., •
PROC SOC EXP BIOL MED. 1971, 137, 306 
LE TELLIER P.R., SMITH W.L. AND LANDS W.E.M., 
PROSTAGLANDINS 1973, 4, 837
IL’IN L.A. ET.AL., RAD I OB I 0 LOG IYA 1964, 4, 926
, -..Kt-
.108
104 A
1045
* 1046
* 1047
* 1048
* 1049
* 1050
1051
1052
1053
1054
1055
1056
1057
* 1058
* 1059
* 1060
* 1061 
1062
1063
* 1064
1065
1066
1067
1068
1069
1070
* 1071
* 10,72
1073
1074
* 1075
HALLBER6 L„, • 3
RADIOISOTOPE HAEMATOL., INT SYMP. 1962, 1, 47 
JAFFE I.A., MERRIMAN p. AND JACOBUS D»,
SCIENCE 1968, 161 , 1016 J
NADOLNY WP, STRAHLEMTHERAPIE 1971 , 1 41 , 1 00 
HAMMOND P.B., TOXICOLOGY APPL PHARMACOL. 1973, 26, 24ll 
MCCALL J.T., MCLENNAN K. G. , GOLDSTEIN N.P, AND RANDALL 
R.V., TRACE SUBST ENVIRON HEALTH 1968, 2, 127 3
SORENSON J.R.J.,
TRACE SUBST ENVIRON HEALTH 
KATSUK1 S, AND OKUMURA M.,
ARTICLE SER’. VOL IV. WILSONS DISEASE.
KIRCHGESSNER M. AND GRASSMANN E.,
Z. TIERPHYSIOL TIERERNAHRG , FUTTERMITT,
1974, 8, 305
’BIRTH DEFECTS ORIGINAL
FUTTERMITT.
1968, 136
1970, 26, 3
E. ,
1973, 31 , 103Z. TIERPHYSIOL TIERERNAHRG 
GRUDEN N. AND STANTlC M,,- 
SCI TOTAL ENVIRON. 1975, 3, 288 
SWENERTQN H. AND HURLEY L.S., SCIENCE 
WEINBERG E.D., .
PERSPECTIVES IN BIOL AND MED, 1962, 5, 432 
AND WEI E.,
1,971 , 173, 62
GARBER B.T
TOXICOLOGY APPL PHARMACOL. 1974, 27, 685
SUNDERMAN F.W., ANN CLIN LAB SCI, 1975, 5, 132 
MCCLAIN R.M. AND SIEKIERKA J.J.,
TOXICOLOGY APPL PHARMACOL, 1975, 31, 443 
JOSHI J.I). AND BHATTACHARYA P.Kw,
INDIAN J, CHEM. 1975, 13, 88
WHITE G.P., BAILEY-WOOD R. AND JACOBS A., •
CLIN SCI. MOLEC MED, 1976, 50, 145
POLIG E. AND PLANAS-BOHNE F., BIOPHYSIK 1973, 10, 321 
STAND F, ROSOFF B., WILLIAMS G,L. AND SPENCER H,, .
J, PHARM EXP THER. 1962, 138, 399
MILLER J.J., J. APPLIED NUTRITION 1 972 , 24 , 40 
SPENCER H, AND ROSOFF B , , HEALTH PHYS, 1966, 12, 475 
SLOBODIEN M.J., BRODSKY A,, KF. C.H. AND HORM I,,
HEALTH PHYS. 1973, 24, 327 •
DUNCAN J„R„ AND DREOSI I , E „ , . '
SOUTH AFRICAN MEDICAL J. 1976, 50, 711 • • ■
FOUAD M.T., J, APPLIED NUTRITION 1976, 28, 6 
S U S 0 F , A • A N D E 0 W A R 0 S H . M , ,
POULTRY SCIENCE 1968, 47, 1417
BRUGSCH H.G,, J, OCCUPATIONAL MED. 1965, 7, 394 
AS TIME AD H., ASIIMEAD D. AND JENSEN N„,
J, APPLIED NUTRITION 1974, 26, 5
HORAK E., SUNDERMAN F.W. AND SARKAR B., 
R-ES COMM CHEM PATH PHARMACOL. 1976, 14 
KUMARI V., SHARMA R.C. AND CHATURVEDI G 
BULL ACAD POL SCI, 1975, 23, 295 
PETERS T., DEGENS E.T. AND ROSS J., 
GASTROENTEROLOGY 1971, 61, 315 1
CONRAD M.E., GASTROENTEROLOGY 1969, 
PERRIN D,D», .TOPICS IN CURRENT CHEM.
153
K.,
57, 225 
1976, 64, 183
•*;
1
189
1076 DEGENS E.T.,
PROC.INT,CONGRESS CHEMOTHERAPY, 9TH. LONDON 1976, 3
* 1077 PERRIN P.D., 'CHEMICAL ANALYSIS MONOGRAPHS’. VOL 33.
ED. LIVING P.J. & KOLTHOFF I.M. 1970, 183
* 1078 CATSCH A. AND HARMUTH-HOENE A.E.,
8IOCHEM PHARMACOL. 1975, 24, 1557 
1079 CATSCH A., 'FUNDAMENTALS OF BIOCHEMICAL PHARMACOLOGY'
ED, BACQ Z . M . ET.AL. 1971, 411
1080 EICHHORN G.L. , ' IRON METABOLISM',
ED, GROSS F, SPRINGER-VERLAG, BERLIN 1964, 9
1081 POLYCOVE M., ' IRON METABOLISM',
ED, GROSS F. SPRINGER-VERLAG, BERLIN 1964, 148
1082 BOTHWELL T.H. , 'IRON METABOLISM',
ED„ GROSS F. SPRINGER-VERLAG, BERLIN 1964 , 362
1 083' FINCH C.A • , 'IRON METABOLISM’.
ED, GROSS F, . SPRINGER-VERLAG, BERLIN 1964, 452
1084 CHENOWETH M.B ., PHARM REVIEWS 1956, 8, 57
* 1085 TRIPOD J, , ' IRON METABOLISM'.
ED. GROSS F, SPRINGER-VERLAG, BERLIN 1964, 503
1086 MOESCHLIN S, AND SCHNIDER U., 'IRON METABOLISM',
ED. GROSS F. SPRINGER-VERLAG, BERLIN 1964 , 525
1087 WOHLER F, , ' IRON METABOLISM'.
ED, GROSS F. SPRINGER-VERLAG, BERLIN 1964 , 551 '
1088 BRICK l.B , AND RATH C.E., 'IRON METABOLISM’
ED, GROSS F, SPRINGER-VERLAG, BERLIN 1964, 568
1089 ANON,, ' IRON METABOLISM’ .
ED. GROSS F. SPRINGER-VERLAG, BERLIN 1964, 580
1090 HUEBERS H . AND HUEBERS E., 'IRON METABOLISM AND ITS
DISORDERS » ED, KIEF H. 1975, 13
1091 BROWN E,B • , ’IRON METABOLISM AND ITS DISORDERS' ,
ED, KIEF H. 1975, 71
*1092 BOM FORD A . ET .AL,, 'IRON METABOLISM AND ITS DISORDERS
ED, KIEF H, 1975, 211
1093 BOTHWELL T.H, AND CHARLTON R.W., 'IRON METABOLISM AND
ITS DISORDERS'. ED, KIEF H, 1973, 221 
1094 MODELL C.B., 'IRON METABOLISM AMD ITS DISORDERS’,
ED, KIEF H; 1975, 230
*1 095 CASTELLIMO N , , FOLIA MEDICA 1971 , 54, 1
*1096 MACFARLANE M.D., LANCET 1974, 2, 962
*1097 LYLE W.H.r LANCET 1974, 2, 1140 
1098 CATSCH A., ARZNEIM-FORSCH 1962, 12, 924
*1099 KUHN A,, STRAHLENTHERAP IE 1969, 137, 101 
110 0 P R 0 P P E R R , D . , SHURIN S . B . AND NATHAN D , G » »
NEW ENGLAND J. MEDICINE 1976, 294, 1421 
1101 SPENCER H. ET.AL., RADIATION RESEARCH 1965, 24, 432 
110 2 MICHAEL W.R, AND W A KIM J,M . ,
TOXICOLOGY APPL PHARMACOL, 1973, 24, 519
1103 WINEK C.L., CLIN CHEM, 1976, 22, 832
1104 TANDON S.K. ET.AL., ENVIRON RESEARCH 1975, 9, 18 
*1105 JAFFE I.A., ARTHRITIS AND RHEUMATISM ' 1970, 1 3 , 436
1106 SCUDDER P., -STOCKS J. AND PORMANDY M,,
CLIN CHIM ACTA 1976, 69, 397
1107 HEINRICH II.C., BARTELS H., GABBE E. E „ . KUGLER G „
AND OPPITZ K.H., ARZNE I M-FORSCH .1972, 22, 1091
190
1108 ZYL1CZ ET.AL., INT J« RADIAT BIOL. 1975, 28, 125
* 1109 GERBER D.A., ARTHRITIS AND RHEUMATISM 1976, 19, 593
1110 MARRIOTT J. 'AND PERKINS DU., '
BIOCHIM BIOPHYS ACTA 1966, 117, 387
1111 MARRIOTT J, AND PERKINS DJ,,
BIOCHIM BIOPHYS ACTA 1966, 117, 395
111? MCCALL JoT., GOLDSTEIN N.P. AND RANDALL R.V.,
AMER J. MED SCI. 1967, 254, 35
1113 DU KHUONG L., ARZNEIM»FORSCH 1965 , 1 5, 387
1114 CATSCH A., ARZNEIM-FORSCH 1967, 17, 493
1115 PLA'NAS-BOHNE F. AND LESSMAN J.,
ARZNEIM-FORSCH 1969, 19, 944
1116 SEMENOV DU. AND TR EGUB ENKO I , P, , '
BIOKHIMIYA 196.2 , 27, 31 7 •
* 1117 STOVER B.J., RUHMANN A.G. AND ATHERTON D.R.,
INT 1. RADIAT BIOL. 1966,. 11 , 27
* 1118 CHISOLM J,J,, J, PEDIATRICS 1968, 73, 1
* 1119 VITALE L.F. ET.AL., J. PEDIATRICS 1973, 83, 1041
1120 ARONSON A.L. AND HAMMOND P.B., .
,J. PHARM EXP THER. 1 964, 146, 241
* 1121 EYBL U. ET.AL», Z. GESAMTE EXP MED. 1970, 152, 274
1122 WHITEHOUSE M.W., AGENTS AND ACTIONS 1976, 6, 201
1123 PLANAS-BQHNF. F. AND OLINGER H», ■
HEALTH PHYS. 1976, 31, 165
1124 FRIED J.F., LINDENBAUM A. AND SCHUBERT J.,
PROC SOC EXP BIOL MED. 1959, 100, 570
1125 SCHUBERT J., ANN REV NUCLEAR SCIENCE 1955, 5, 369
1126 RUBIN M., HOULIHAN J. AND PRINCIOTTO J.V.,
PROC SOC EXP BIOL MED. 1960, 103, 663
* 1127 WALKER W.R. AND KEATS D.M.,
AGENTS AND ACTIONS 1976, 6, 454
* 1128 WRIGHT J.R. AND FRIEOEN £., ‘
BIOINORG CHEM. 1975, 4, 163
* 1129 LINDER P.W., WILLIAMS D.R. AND STANFORD M ,, J . ,
J. INORG NUCL CHEM. 1976, 38, 1847
* 1130 TOUCHE M.L.D. AND WILLI AMS D,R.,
J. CHEM SOC. DALTON 1976, 1355
1131 SEIDEL A., RADIATION RESEARCH 1973, 54, 304
1132 CHABEREK S. AND MARTELL A.E., '
’ORGANIC SEQUESTERING AGENTS’. WILEY, NEW YORK. 1959
1133 HOLTZMAN N.A,, FED PROC. 1976, 35, 2276
1134 BANNERMAN R.M., FED PROC. 1976, 35, 2281
1135 GILES H«, MOORE C,J. AND STILL B.M.,
LANCET 1955, 1, 183
1136 CHARLTON R.W., JACOBS P„, TORRANCE J.D.
AND BOTHWELL T.H., ' J, CLIN INVEST. 1965, 44, 543
1137 BATES G.W. AND SCHLABACH M.R.,
J, BIOL CHEM. 1973, 248, 3228
1138 HAHN D», EUROPEAN J, BIOCHEM, 1973, 34, 311
1139 RABINOWITZ M.B., WETHERILL G.W. AND K'OPPLE J.D,,
J. CLIN INVEST. 1976, 58, 260
1140 PETERS G.r KEBERLE H „ , SCHMID K, AND BRUNNER H.r 
BIOCHEM PHARMACOL. 1966, 15, 93
191
1141 ANGHILERI LiJ,, BIOCHEM PHARMACOL, 1967, 16, 2033
1142 UPSCHITZ D.A. ANO ET„ AL.,
BRIT J9 HAEMATOLOGY 1971, 20, 395
1143 WHITE G.P., JACOBS' A,, GRADY R.W, AND CERAMI A,,
BRIT J, HAEMATOLOGY 1976, 33, 487
1144 FIGUEROA W.G, AND THOMPSON J,H,,
AMER J, PHYSIOLOGY 1968, 215, 807
1145 BROWN E.B., HWANG Y, AND ALLGOOD J.W., ,
J„ LAB CLIN MED. 1967, 69, 382
■1146 FAHEY J.L., RATH C „ E , , PRINCIOTTO J.V., BRICK I.8.
AND RUBIN M», J, LAB CLIN MED. 1961, 57, 436
1147 JACOBS A., KAYE M.D. AND TREVETT D,,
J. LAB CLIN MED, 1969, 74, 212
1148 KARABUS C.D, AND FIELDING J,.,
BRIT J. HAEMATOLOGY 1967, 13, 924
1149 HALLBERG L. AND HEDENBERG L.,
SCAND J, HAEMATOLOGY 1965, 2, 67
1150 JACOBS A., CLIN HAEMATOLOGY 1973, 2, 323 
* 1151 SILVA A,J,, FLESHMAN D.G. AND SHORE B « ,
HEALTH PHYS. 1973, 24, 535
1152 NAGARAJAN B., SI VARAMAKRISHNAN V. AND BrAHMANANDAM 5», 
BIOCHEM J, 1964, 92, 531
1153 BANNERMAN R.M., CALLENDER S,T. AND WILLIAMS D.L.,
BRIT MEDICAL J. 1962, 2, 1573
1154 SMITH S.R., BRIT MEDICAL J, 1962, 2, 1577
1155 BARR D.G.D. AND FRASER D.K.Bo,
BRIT MEDICAL J . 1968, 1 , 737
1156 FINCH C.A, ET.AL., MEDICINE 1970, 49, 17
1157 BOS M. AMD LENGTON W., ANAL CHIM ACTA 1975, 76, 149
1158 SAHAGIAN HARDING-BARLOW I w AND PERRY H.M.,
J, NUTRITION 1967, 93, 291
* 1159 MILLAR M.J., FISCHER M.I., MAWSON C„A „
AND ELCOATE P.V., NATURE 1954, 174, 881
* 1160 ROSOFF B», HART H., METHFESSEL AeH . AND SPENCfjR H.,
J. APPLIED PHYSIOLOGY 1971, 30, 12
* 1161 GERGELY A. AND FARKAS E.,
MAGYAR KEMIAI FOLYOIRAT 1975, 81, 471
1162 CHAUSMER A . 8 . ,
NUTR REPORTS INTERNATIONAL 1976, 14, 323
1163 SCHROEDER H.A., NASOW A.P. AND TIPTON I.H.,
J. CHRONIC DISEASES 1967, 20, 869
* 1164 NANDEDKAR A.K.N., BASU P.K. AND FRIEDBERG F.r
BIOINORG CHEM. 1972, 2, 149
1165 HAMBIDGE Ka, AMER J. CLINICAL NUTRITION 1974, 27, 5C
1166 SCHROEDER H.A., •
AMER J. CLINICAL NUTRITION 1968, 21, 230
1167 MERTZ W„, TOEPFER F.W., ROGINSKI E.E.
AND POLANSKY M.M., FED PROC,. 1974, 33, 2275
1168 HUEBERS H., HUEBERS E., FORTH W. AND RUMMEL W.,
LIFE SCIENCES 1971, 10, 1141
* 1169 HAMMOND P.B,, TOXICOLOGY APPL PHARMACOL, 1971, 18, 2 
1170 STILLWELL W. AND WINTER H.C.,
BIOCHEM BIOPHYS RES COMMON 1974, 56, 6l7
192
*
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180 
1181­
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201 
1 202.
1203
MARSH L, ANO FRASER F.C LANCET 1973, 2, 846
1972, 175, 72 
391 ’
SINGER S,J, ANO NICOLSON G.L., SCIENCE 
SOLVELL I.,, J, CHEM EDUCATION 1971, 48 
ALBERT A., 'SELECTIVE TOXICITY’. 5TH '
ED. CHAPMAN & HALL, LONDON. 1973, 17 
ALBERT A., 'SELECTIVE TOXICITY’. 5TH 
ED. CHAPMAN g HALL, LONDON. 1973, 334 
HALLBERG L. AND SOLVELL L.,
ACTA MED SCAND. 1966, 459, 23
HALLBERG L., NORRBY A. AND SOLVELL L., .
SCAND J. HAEMATOLOGY 1971, 8, 104
CONRAD M.E. AND CROSBY W.H., BLOOD 1963, 22, 406
JACOBS A. AND MILES P.M., GUT 1970, 11, 732
JACOBS A., J, CLIN PATHOL. 1971, 24, 55
JACOBS A. AND MILES P.M., BRIT MEDICAL J, 1969, 4, 773
WOHLER F., ’IRON DEFICIENCY’.
ED. HALLBERG' L. ET.AL. ACADEMIC PRESS. 1970, 551 
'IRON DEFICIENCY'. .
L. ET.AL. ACADEMIC PRESS. 1970, 573
BUSE G>, AN6EWANDE CHEMIE 1971,' 10, 663 
HERSHKO C., COOK J. AND FINCH C.A.,
J. LAB CLIN MED, 1973, 81, 876
EVANS G.W., PROC SOC EXP BIOL MED, 1976, 151, 775 
MCCANCE R.A. AND WIDDOWSON E.M.,
BIOCHEM J, 1942, 36, 692
HARDY H.L., ELKINS H.B., RUOTOLO B.P.W., QUINBY J,
AND BAKER W.H., J. AMER MED ASSOC, 1954, 154, 1171 
ROONEY P.J., LEE P.r BROOKES Po AND CARSON DICK W,, 
CURRENT MED RES OPINION 1973, 1, 501
GOLDBERG A,, SMITH J.Aq AND LOCHHEAD A.C.,
BRIT MEDICAL J . 1963, 1, 1 270
STRICKLAND G.T., BLACKWELL R.Q 
1971, 51, 31
*
*
SOLVELL L., 
ED. HALLBERG
AND WATTEN R.H.,
1971, 220, 135
AMER J, MEDICINE 
IRVING H.M. AND ROSSOTTI H.S.,
ACTA CHEM SCAND, 1956, 10, 72 
FRIEDEN E. AND -HSIEH H.S., '
ADV EN2YMOLOGY 1976, 44, 187 
MANIS J.G., AMER J, PHYSIOLOGY 
GIJY M.J, AND SCHACHTER 0.,
AMER J. PHYSIOLOGY 1975, 229, 790
SMITH R.S., ANN N.Y. ACAD SCI, 1964, 119, 776
BRUNSTROM G.M., KARABUS C. AND FIELDING J.,
BRIT J, HAEMATOLOGY 1968, 14, 525 '
COTZIAS G.C., PAPAVASILIOU P.S., GINOS J., STECK A. 
AND DUBY ANN REV MEDICINE 1971, 22, 305
PLANAS-BOiiNE F., ARZNEIM-FORSCH 1 972, 22, 1426 
HARRIS D . C , AND A I S E N P . ,
BIOCHIM BIOPHYS ACTA 1973, 329, 156 
DAVIS P.S. AND DEI.LER D.J., AUST ANN MED 
POIEZ B„JO, BATTULA N. AND LOEB L.A.,‘
BIOCHEM BIOPHYS RES- COMMUN 1974, 56, 959 
SIROVER M.A. AND LOEB L.A.,
BIOCHEM BIOPHYS RES COMMUN 1976, 70, 812
1967, 16, 70
193 ; $
S-..4'
1204 beutler E., BLOOD 1960, 15, 288
1205 MULLER- EBERHARD U , , FRLANSON M «E., GINN H . E ,
AND SMITH C.H., BLOOD 1963, 22, 209
1206 S C H A D E S.G., BERNIER G.M. AND CONRAD M.E.,
BRIT J . haematology 1969, 17, 187
1207 WAPNICK A.A, AND ET. A L. ,
BRIT J. HAEMATOLOGY 1969, 17, 563
1208 EDWARDS $»A. AND FIELDING J.,
BRIT J . HAEMATOLOGY 1971, 20, 405
1209 BARRY M ., FLYNN D.M. , LETSKY E ,A. AND R I SOON R.A
BRIT MEDICAL J . 1974, 2, 16
* 1210 RIEDERS F.< FED PROC. 1955, 14, 332
1211 EDWARDS J. AND HOKE J.E., CLIN RESEARCH 1975, 23, 262
1212 HARMUTH»HOENE A.E,, VLAOAR M. AND OHRTMANN R.,
.CHEM. BIOL INTERACTIONS 1970, 1 , 271
1213 BLONDEAU J-P AND RQBEL P.,<
EUROPEAN J. BIOCHEM, 1975, 55, 375
1214 CATSCH A. AND LE D.KH., EXPERIENTIA 1965, 21, 724
1215 HANLON D.P. AND SHUMAN S„, EXPERIENTIA 1975 , .31 , 1 005
* 1216 FRIEDBERG F., F.E.B.S LETTERS 1975, 59, 140
1217 GRYDER J.W., FED PROC. SUPPLEMENT 10. 1961, 20, 19
1213 REUBER M.D. AND BRADLEY J . E . ,
J. AMER MED ASSOC. 1960, 174, 263
1219 BARRIE H. AND WILSON B . D . R , ,
J. AMER MED ASSOC, 1962, 180, 244
1220 YOSHINO Y. AND HIRAMATSU Y., J. BIOCHEM. 1974, 75, 221
1221 FOREMAN H., VIER M, AND MAGEE M„,
J. BIOL CHEM, ‘1953, 203, 1045
1222 RUBIN H„, J. CELL PHYSIOL. 1973, 82, 231
1223 CLETON F . , TURNBULL A, AND FINCH C*A.»
J, CLIN INVEST. 1963, 42, 327
1224 SCHROEDER R.A. AND PERRY H.M.,
J, LAB CLIN MED. 1955, 46, 416
1225 MORGAN E.H., MARSAGLIA G., GIBLETT E»R.
AND FINCH C.A., J, LAB CLIN MED, 1967, 69, 370
1226 STEELE T.H., J. LAB CLIN MED, 1973, 81, 205
1227 JENSEN W.N. AND KAMIN H,,
J, LAB CUN MED. 1957, 49, 200
1228 BROWN E.B., OKADA S., AWAI M. AND CHIPMAN B.»
J, LAB CLIN MED. 1975, 86, 576
1229 VOHRA P. AND KRATZER F.H., J. NUTRITION 1966, 89, 106
1230 HARMUTH-HOENE A.E., STRAHLENTHERAP IE 1967» 134, 110
1231 SUNDERMAN F.W., J, NEW DRUGS 1964, 4, 154
* 1232 VOHRA P. AND KRATZER F.H., J. NUTRITION 1964, 82, 249 
1233 FREISER H., FERNANDO Q. AND CHENEY G » E , ,
J, PHYS CHEM, 1959,' 63 , 250
* 1234 MAY P.M., LINDER P.W. AND WILLIAMS D.R.,
EXPERIENTIA 1976, 32, 1492
* 1235 PORJES W.J., HENZEL J.H., ROB C.G. AND STRAIN W.H.,
LANCET 1967, 1, 121
* 1236 MULTICENTRE TRIAL, LANCET 1973, 1, 275 
1237 MOYNAHAN E,J.f LANCET 1974, 2, 399 
1233 SIMKIN P.A., LANCET 1976, 2, 539
194
*
-x-
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259 
1 260 
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
*
MCALLISTER W.A.C, AND VALE LANCET 1976, 2, 631
SHEEHAN R.G., AMER J, PHYSIOLOGY 1 976, 231 , 1 438 
SCHUBERT J- AND LINDENBAUM A,,
’METAL BINDING IN MEDICINE’, •
ED.SEVEN M. & JOHNSON L. J. B-LIPPINCOTT CO, I 960, 68
FOREMAN H-, ’METAL BINDING IN MEDICINE’ *
ED, SEVEN M. & JOHNSON L. J. B.LIPPINCOTT co, I960, 82
SPENCER H., ’METAL BINDING IN MEDICINE’
ED, SEVEN M. 8 JOHNSON L- J, B.LIPPINCOTT co. 1960, 104
*
*
*
*
*
PETERS R.A„r STOCKEN I.A. AND THOMPSON R.H.S,,
NATURE 1945, 156, 616
SCHUBERT J, AND PRIED J.F., NATURE I960, 185, 551
LINDENBAUM A,, NATURE I960, 187, 575
OKUNEWICK J.P., SCHJEIDE 0 . A , , CARLSEN E-N-
AND HENNESSY T.G., NATURE 1963, 198, 966
BUTZOW J.J. AND EICHHORN G.L., NATURE 1 975 , 254, 358
ANGHILERI L . J , , NATURWISSENCHAFTEN 1968, 55, 1 82
MAY P.M., LINDER P. W w AND WILLIAMS D.R.,
J, CHEM SOC, DALTON .1977, 588 
SCHNEGG A. AND KIRCHGESSNER M,,
NUTR METAB, 1975, 19, 268
CATSCH A., NATURWISSENCHAFTEN 1968, 55, 473
EVANS G,W. AND LE BLANC F.N., ' •
NUTR REPORTS INTERNATIONAL 1976, 14» 281 
HARRIS E.D., • PROC NAT ACAD SCI UwS.A, 1976, 73, 371 
STEVENS E-, ROSOFF 9,, WEINER M, AND SPENCER H,,
PROC 3OC EXP BIOL MED, 1962, 111, 235 .
LANDES D.R., PROC SOC EXP BIOL MED, 1975, 150, 686 
COOK J,, HOFFMAN F..Q, AND DI LUZIO N-R.,
PROC SOC EXP BIOL MED, 1975, 150, 741
SALTMAN P. AND HELBOCK H. J , , ROC.SYMP. ’RADIOISOTOPES 
ANIMAL NUTR, PHYSIOL,’, PRAGUE, 1964, 301 
CROUZET J. ET.AL., REV RHEUM.• 1 973 , 40 , 485
HAVLICEK F,» STRAHLENTHERAPIE 1967, 134, 296 
PLANAS-BOHNE F., HARMUTHHIOENE A „ E , , KUERZINGER K.
AND HAVLICEK F», STRAHLENTHERAPIE 1968, 136, 609 
WYNN J.E., VAN’T RIET B. AND BORZELLECA J.F.r 
TOXICOLOGY APPL PHARMACOL, 1970, 16, 807 
SCHWARZ F,J. AND KIRCHGESSNER M,r
Z. TIERPHYSIOL TIERERNAHRG. FUTTERMITT. 1976, 37, 31 
WEINTRAUB L.R., CONRAD M,E. AND CROSBY W.H.,
BLOOD 1964, 24, 19
RUBIN M. ET.AL., SCIENCE 1953, 117, 659
HYDE A.S., AMER J, PHYSIOLOGY 1957, 191, 265 
HAMMOND P.B., ARONSON A . L • AND OLSON W.C.,
J, PHARM EXP THER. 1967, 157, 196 
OATES G.W., WORKMAN E.F. AND SCHLABACH M.R.r 
BIOCHEM BIOPHYS RES COMMUN 1973, 50, 84 
ZAPOLSKl E.J., GANZ R. AND PRINCIOTTO J.V.,
AMER J, PHYSIOLOGY 1974, 226, 334
HARRIS D.C. AND AISEN P., BIOCHEMISTRY 1975, 14, 262 
GRADY R.W., GRAZIANO J.H,, AKERS H.A. AND CERAMI A,,
J, PHARM EXP THER, 1976, 196, 478
195
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
, 317 
SALTMAN p 
21 311
AGARWAL R,P. AND PERRIN D«D-,
J. CHEM SOC. DALTON 1977, 53 
SORENSON J.RJ,, INFLAMMATION 1976»
BATES G.W., HE GENAUER J.C., RENNER J.,
AND SPIRO T.6., BIOINORG CHEM, 1973,
ROOS J.T.H. AND WILLIAMS D.R,,
J. INORG NUCL CHEM, 1977, 39, 367 
BUCKINGHAM D.A. AND SARGESON A.M.,
’CHELATING AGENTS AND METAL CHELATES’
ED,DWYER F.& MELLOR D. ACADEMIC 1964, 237 $
SHULMAN A, AND DWYER F. P, , ’CHELATING AGENTS AMD METAlf 
CHELATES’ ED.DWYER F,& MELLOR D, ACADEMIC 1964, 383 
BRISE II, AND HALLBERG L„, •-?
ACTA MED SCAND, SUPP. 1962, 376, 7 J
WEINZIERL S.M. AND WEBB M „ ,
BRIT J. CANCER 1972, 26, 279 3
HARKER L.A., FUNK D.D. AND FINCH C, A • , 1
AMER J, MEDICINE 1968, 45, 105 1
KEBERLE H., ANN N.Y. ACAD SCI. 1964, 119, 758
MARTINEZ-TORRES C. AND LAYRISSE M.,
BLOOD 1970, 35, 669 ??
KROE D.J., KINNEY T.D., KAUFMAN N. AND KLAVINS J.V., (
BLOOD 1963, 21, 546
JACOBS A, AND MILES P.M., GUT 1969» 10, 226
WALSHE J.M., CLIN SCI. 1964, 26, 461 'i
JACOBS A. AND MILES P.M., CLIN CHIM ACTA 1969, 24, 87^ 
FILATOVA L.N., RUSS J, INORG CHEM. 1974, 19, 3335 
WILLIAMS D.R., ’AN INTRODUCTION TO BI 0 INQRGAN IC 
CHEMISTRY’ El).WILLIAMS D.R. C.C.THOMAS 1976, 5 
OSTEROERG R., ’AN INTRODUCTION TO B I 0 I MORGAN JC
CHEMISTRY’ ED.WILLIAMS D.R, C.C.THOMAS 1976, 13. 
JAMESON R.F., ’AN INTRODUCTION TO BlOINORGANlC 
CHEMISTRY’ ED,WILLIAMS D.R. C.C.THOMAS 1976, 29 
HAY R.W., ’AN INTRODUCTION TO BlOINORGANlC CHEMISTRY’ > 
ED,WILLIAMS D.R. C.C,THOMAS 1976, 51
JAMESON R.F, AND BLACKBURN N.J.,
’AN INTRODUCTION TO BIOINORGANIC CHEMISTRY’
ED.WILLIAMS D.R. C.C.THOMAS 1976, 90
MARTIN R-P. AND SCHARFF J-P,,
’AN INTRODUCTION TO BIOINORGANIC CHEMISTRY*
ED.WILLIAMS D.R. C.C.THOMAS 1976, 120
BATES G.W. AND SALTMAN P„,
’AN INTRODUCTION TO BIOINORGANIC CHEMISTRY’
ED,WILLIAMS D.R. C.C,THOMAS 1976, 145
BYGRAVE F.L., ’AN INTRODUCTION TO BlOINORGANlC
CHEMISTRY* ED,WILLIAMS D.R. C.C,THOMAS 1976, 171 
WILLIAMS D.R., ’AN INTRODUCTION TO BIOINORGANIC 
CHEMISTRY’ ED,WILLIAMS D.R, - C.C.THOMAS 1976, 190
MALCOLM A.D.B AN INTRODUCTION JO BlOINORGANlC
CHEMISTRY’ ED,WILLIAMS D.R. C.C,THOMAS 1976, 209 
MOODY G.J, AND THOMAS J „ D , R . ,
’AN INTRODUCTION TO BIOINORGANIC CHEMISTRY’
ED.WILLIAMS D.R, C.C,THOMAS 1976, 220
196
1299
1300
1301
1302
1303
1304
1305
1306
1307 
1 3 08
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
GLIDEwELL C., ’AN INTRODUCTION TO BIOINORGANIC 
CHEMISTRY’ ED.WILLIAMS D.R. C.C.THOMAS 1976, 236 
FELL G.S. AND SMITH H»,
'AN INTRODUCTION TO BIOINORGANIC CHEMISTRY’
ED.WILLIAMS D.R. C.C,THOMAS 1976, 254
FENTON D.E., ’AN INTRODUCTION TO B101 MORGAN I C '
CHEMISTRY* ED.WILLIAMS D.R. C.C,THOMAS 1976, 281 
KOROS E., ’AN INTRODUCTION TO BIOINORGANIC CHEMISTRY' 
ED.WILLIAMS D.R. C-C.THOMAS 1976, 303
SARKAR B., 'AN INTRODUCTION TO BIOINORGANIC CHEMISTRY’ 
ED.WILLIAMS D.R. C.C.THOMAS 1976, 313 
WILLIAMS D.R,, ’AN INTRODUCTION TO BIOINORGANIC 
CHEMISTRY’ ED.WILLIAMS D.R. C.C.THOMAS 1976, 334 
PERRIN D.D. AND AGARWAL R.P.,
'AN INTRODUCTION TO BIOINORGANIC CHEMISTRY'
ED.WILLIAMS D.R, C.C.THOMAS 1976, 361 •
WILLIAMS R.J.P., FED PROC. SUPPLEMENT 10. 1960, 19, 5
PEARSON R.G., FED PROC. SUPPLEMENT 10. I960, 19, 14
M C C A N C E R . A . AND WID D 0 W S 0 N E . M . , LANCET 
RE IL LEY C.N., FED PROC. SUPPLEMENT 10.
GUSTAFSON R.L., FED PROC. SUPPLEMENT 10.
MARTELL A.E., FED PROC- SUPPLEMENT 10.
EICHHORN G.L. , FED PROC. SUPPLEMENT 10 
MARTIN R.B., FED PROC. SUPPLEMENT 10.
*
*
1937, 1, 680 
1960, 19, 22 
1 960, .19, 32 
1960, 19, 35
I960, 19, 40
I960, 19, 54
1960, 19, 60 
1960, 19, 93
1960, 19, 125 
1960, 19,129
I960, 19, 132
KEHOE R.E., 
HARDY H.L., 
CATSCH A., 
SCHUBERT J., 
G R A N I C K $ . , 
GRANICK S,,
1 960, 
1 960,
MALMSTROM B . G.» , FED PROC, SUPPLEMENT 10 
C0T2IAS G.C., FED PROC. SUPPLEMENT 10,
CHENOWETH M.B., FED PROC. SUPPLEMENT 10 
PHILIPS F.S., FED PROC. SUPPLEMENT 10.
WEINBERG E.D., FED PROC. SUPPLEMENT 10.
ALBERT FED PROC. SUPPLEMENT 10, 1960, 19, 137
RUBIN M., FED PROC. SUPPLEMENT 10. i960, 19, 149
WESTERFELD W.W., •
FED PROC. SUPPLEMENT 10. 1960, 19, 153
APOSHIAN H.V., FED PROC. SUPPLEMENT 10B 1960,19,
FOREMAN H., FED PROC. SUPPLEMENT 10. 1960, 19, 191
FED PROC, SUPPLEMENT 10.
FED PROC. SUPPLEMENT 10.
FED PROC. SUPPLEMENT 10.
FED PROC. SUPPLEMENT 10
BULL N.Y, ACAD MED, 1954, 30, 31
J, BIOL CHEM, 1946, 164, 73/
CONRAD M.E., WEINTRAUB L. R. AND CROSBY W.H.,
J. CLIN INVEST. 1964, 43, 963
MOORE C.V., HARVEY LECTURES 1961, 55, 67 
SOLVELL L., ACTA MED SCAND. SUPP. i960, 358, 71 
GREENBERG G . R • AND W I N T R 0 B E M.M,,
J. BIOL CHEM. 1946, 165, 397 
HALLBERG L. AND SOLVELL L,, ' ■
ACTA MED SCAND. SUPP, I960, 358, 19"
WHEBY M.S. AND CROSBY W, H . ,
135
19, 196 
19, 199 
1960, 19, 206 
1960, 19, 219
BLOOD 1963, 22, 416
CONRAD M.E WEINTRAUB L.R., SEARS D.A
AND CROSBY W.H., AMER J, PHYSIOLOGY 
BOYLE E,, FREEMAN P.C., GOUDIE A. C, , 
AND THOMSON M , , J. PHARM PHARMACOL.
1966, 211, 1125 
MANDAN F.R,
1976, 28, 865
197
1358 WEINTRAUB UR., WEINSTEIN M.B., HUSER H.J,
AND RAFAL S „ , J. CLIN INVEST. 1968, 47, 531
1339 KUHN I.N., MONSEN E.R., COOK J, ANO FINCH C.A.,
J. LAB CLIN MED. 1968, 71, 715 .
1340 CONRAD M.E. AND CROSBY W.H., BLOOD 1963, 22, 406
1341 POLLACK S,, KAUFMAN R.M, AND CROSBY W.H.,
BLOOD 1964, 24, 577 .
1342 WKE3Y M.S. AND JONES L.G., .
J, CLIN INVEST. 1963, 42, 1007
* ’1343 MCCALL J.T., GOLDSTEIN N.P, AND RANDALL R.V.r
TRACE SUBST ENVIRON HEALTH 1969, 3, 91
1344 AISEN P. ET.AL., NATURE 1970. 226, 859
1345 BARRY M., CARTEI G, AND SHERLOCK GUT 1970, 11, 891
1346 FORTH W., NELL G. AND RUMMEL W,,
TRACE SUBST ENVIRON HEALTH 1973, 7, 339
1347 BROWN E.B., DUBACH R. AND MOORE C.V., .
J. LAB CLIN MED. 1958, 52, 335
13 48 LINKENHEIMER W.H, ,
TOXICOLOGY APPL PHARMACOL. 1964, 6, 669
1 349 EDWARDS J,, URSILLO R.C. AND HOKE J . E, , .
BRIT J. HAEMATOLOGY 1974, 28, 445
1350 IIUEBERS H., IIUEBERS E., FORTH W. AND RUMMEL W „ ,
HOPPE SEYLER Z. PHYSIOL CHEM. 1973, 354, 1156 •
1351 BOTHWELL T.H., pIRZIO-B I ROLI G , AND FINCH C . A „ ,
J. LAB CUN MED, 1958, 51 , 24
1352 HERNDON J.F. AND ET. AL„, J. NUTRITION 1958, 64, 615
1353 KROE D.J., KINNEY T.D., KAUFMAN N, AND KLAVINS J.V., 
BLOOD 1963, 21, 546
1354 SMITH M.D. AND PANNACCIULLI I.M,,
BRIT J, HAEMATOLOGY 1-958, 4, 428.
1355 JACOBS A., CIBA FOUND. SYMP IRON METABOLISM, NO. 51.
ELSEVIER,AMSTERDAM 1977, 91 .
1356 JACOBS A. AND WORWOOD M.,
PROGRESS IN HAEMATOL, 1975, 9, 1
1357 WORWOOD M,, SEMINARS IN HAEMATOL, 1977, 14, 3
1358 JACOBS Aw, SEMINARS IN HAEMATOL. 1977, 14, 89
1359 CRICHTON R.R., ANGEWANDE CHEMIE 1973, 12, 57
1360 JONES M.M, AND JOHNSTON D.O., NATURE 1967, 216, 509
1361 BOROVA J,, PONKA P. AND NEUWIRT J,,.
BIOCHIM BIOPHYS ACTA 1973, 320, 143
1362 LYNCH S.R., UPSCHITZ D.A., BOTHWELL T.H,
AND CHARLTON R.W., ’IRON IN BIOCHEMISTRY AND 
MEDICINE'. ED. JACOBS A, AND WORWOOD M. 1974, 564
1363 FALBE-HANSEN I, AND LOTHE K.,
ACTA PHYSIOL SCAND. 1962, 54, 97
1364 ZAIL S.S., CHARLTON R.W., TORRANCE J,D,
AND BOTHWELL T.H., J. CLIN INVEST, 1964, 43, 670
1365 PRIMOSIGH J.V, AND THOMAS EJ>,,.
J. CLIN INVEST, 1968, 47, 1473 ! •
1366 ST-ORRING P.U AND FATIH S „ ,
BIOCHIM BIOPHYS ACTA 1975, 392, 26
1367 ROSS J,, J, CLIN INVEST. 1946, 25, 933
1368 UPSCHITZ D,A» AND ET. AL„,
BRIT J, HAEMATOLOGY 1971, 21, 289
198
1369 CUMMING RnL'.C., GOLDBERG A., MORROW J. AND SMITH J,A,, 
LANCET 1967, 1, 71
1370 RICKETTS C„, JACOBS A, AND CAVILL !»,
BRIT J. HAEMATOLOGY 1975, 31, 65
1371 SUMMERS M.R. AND JACOBS A.,
BRIT J. HAEMATOLOGY 1976, 34, 221
1372 HALLIDAY J.W., POWELL L.W. AND MACK V.,
BRIT J HAEMATOLOGY 1976, 34, 237 .
1373 NORWOOD M. AND JACOBS A., LIFE SCIENCES 1971, 10, 1363 
’1374 GOLBERG L. AND MARTIN L - E .,
LIFE SCIENCES 1964, 3, 1465
1375 BATES G.W., BOYER J,, HEGENAUER J.C„ AND SALTMAN P,,
AMER J. CLINICAL NUTRITION 1972, 25, 983
1376 CARMICHAEL D„, CHRISTOPHER J.P., HEGENAUER J.C. AND 
SALTMAN P,, AMER J. CLINICAL NUTRITION 1975, 28, 487
1377 MULTANI J.S., CEPURNEEK C.P., DAVIS P.S. .
AND SALTMAN P,, BIOCHEMISTRY 1970, 9, 3970
1378 AASA R„, MALMSTROM B.G., SALTMAN P, AND VANNGARD T.r 
BIOCHIM BIOPHYS ACTA 1964, 88, 430
1379 TERATO K., FUJITA T. AND YOSHINO Y.,
J, PHARM SOC JAP, 1972, 92, 1247
1380 BANNERMAN R.M., O'BRIEN J.R.P. AND WITTS L.J.,
BLOOD 1962, 20, 532 • ’
1381 AASA R., BIOCHEM BIOPHYS RES COMMUN 1972, 49, 806
1382 CHERNELCH M. AND BROWN E»B.., NATURE 1970, 226, 356
1383 GUSTAFSON R„L- AND MARTELL A.E.,
J. PHYS CHEM, 1963, 67, 576
1384 DAVIS P.S., LUKE C.G, AMD DELLER D.J,, ‘
LANCET 1966, 2, 1431
1385 DAVIS P.s. AND DELLER D.J,, NATURE 1966, 212, 404
1386 DAVIS P.S., LUKE C.G. AND DELLER D.J.,
NATURE 1967, 214, 1126 .
1387 FINCH C.A« AND HOSAIN F»,
J. LAB CLIN MED, 1964, 64, 905
1388 FORTH W. AND SEIFEN E,,
ARCH EXPTL PATHOL PHARM. 1961, 241, 566
1389 KRAUSE U. AND JENNER H.,
ACTA SOC MEDICORUM 1970, 75, 266 
1 390 MENDEL G.A., BLOOD 1961 , 18, 727 .
1391 MANIS J,6. AND SCHACHTER D.,
AMER J, PHYSIOLOGY 1962, 203, 81
1392 BEUTLER E-, KELLY B.M. AND BEUTLER F,,
AMER J. CLINICAL NUTRITION 1962, 11, 559
1393 POLLACK S., BALCERZAK S,P. AND CROSBY W, H.,
BLOOD 1963, 21, 33
1394 WHEBY M.S. AND UMPIERRE G»,
NEW ENGLAND J, MEDICINE 1964, 271, 1391
1395 HAHN P.F., BALE W.F,, LAWRENCE .E.0. AND WHIPPLE G.H.,
J. EXPERIMENTAL MEDICINE 1939, 69,"739
1396 BROWN J.C. AND TIFFIN L.O., '
PLANT PHYSIOL- 1965, 40, 395
1397 TIFFIN L.O., PLANT PHYSIOL, 1966, 41, 510
1398 TIFFIN L.O., PLANT PHYSIOL. 1966, 41, 515
199
1399
1400
1401
1402
* 1403
* 14 0 4
1405
1406
1407 
14 08
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
* 1426
1427
1428
WHEBY M » 8 • , JONES L.G. ANO CROSBY
J. CLIN INVEST. 1964, 43, 1433
MAY P.M., J, ANATOMY 1977, 123, 263
OKADA $., CHIPMAN B. ANO DROWN E.B., .
J. LAB CLIN MED. 1977, 89, 51
POLYCOVE M., SALTMAN P„, FISH M„, NEWMAN R.
AND TONO M., CLIN RESEARCH 1972, 2?, 183
HAMM R.E., SCHULL C-M. AND GRANT D.M,,
J. AMER CHEM SOC. 1954, 76, 2111
PECSOK R.L. AND SANDERA J., -
J. AMER CHEM SOC. 1955, 77, 1489
SALTMAN P,, CHARLEY P.J. AND SARKAR B.,
FED PROC. 1962, 21, 307
KROE D.J., KAUFMAN N., KINNEY T.D. AND KLAVINS J.V.,
FED PROC. 1964, 23, 511
VAN CAMPEN D. AND GROSS E., J, NUTRITION 1969, -99, 68 
CONRAD M.E. AND SCHADE S.G., •
GASTROENTEROLOGY 1968, 55, 35
FORTH W., LICHTENBERG H, AND RUMMEL W.,
ARCH EXPTL PATHOL PHARM. 1965, 250, 234
RUMMEL W., ARCH EXPTL PATHOL PHARM, 1965, 250, 189 
PEARSON W.N, AND REICH M . , J. NUTRITION 1969, 99, 137 
WORWOOD M. AND JACOBS A., .
BRIT J, HAEMATOLOGY 1971, 20, 537
LARSEN B.A., B.IDWELL R.G-S, AND HAWKINS W.W.r
CANADIAN J. BIOCHEM. 1960, 38, 51
HAWKINS W.W. AND FINCH C.A.,
J. LAB CUN MED. 1960, 55, 21 6
GREEN S. AND MAZUR A., J. BIOL CHEM, 1957, 227, 653 
COHN M, AND TOWNSEND J., NATURE 1954, 173, 1090 
BOULARD M,, DELIN M. AND NAJEAN Y „ C „ ,
PROC .SOC EXP BIOL MED. 1972, 439, 1379
YOSHINO Y, AND MANIS J.G,,
AMER J, PHYSIOLOGY 1973, 225 , 1276
POLYCOVE M. AND MORTIMER R»,
J. CLIN INVEST. 1961, 40, 753
BAILEY-WOOD R., WHITE G.P, AND JACOBS A.,
BRIT J. EXP PATH, 1975, 56, 358
BLUMBERG W.E., EISlNGER J,, AI3EN P„, MORELL A.G.
AND SCHEINBERG I.H., J. BIOL CHEM. 1963, 238, 1675 
MALMSTROM B.G- AND VANNGARD T,,
J. MOLECULAR BIOL, 1960, 2, 118
HALLBERG L. AND HEDENBERG L, ,
SCAND J. HAEMATOLOGY 1965, 2, 277
HALLBERG L . , HEDENBERG L , AND WEIN FE LD A , ,
SCAND J, HAEMATOLOGY 1966, 3, 85
BROMAN L.» MALMSTROM B.G,, AASA R. AND VANNGARD T.,
J, MOLECULAR BIOL, 1962, 5 
BASOLO F. AND PEARSON R.G.r 
REACTIONS.’ 2ND ED. WILEY 
WORKMAN E-F. AND BATES G.W. 
BIOCHEM BIOPHYS RES COMMON 
NIEDERER W., EXPERlENTIA
, 301­
’ ME CHAN ISMS OF 
1967, 114
*1974, 58r 787 
1970, 26, 213
INORGANIC'
200
1429
1430
1431
1432
1433 
143 4 
143 5
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449 
* 14 5 0
* 1451
1452
1453 
14 5 4
1455
1456
1457
* 14 5 8
* 14 59
1460
1461
1462
UPSCHITZ 0-A. AND ET. AL.» '
BRIT J, HAEMATOLOGY 1971, 20, 155
ROSS J,, KOCHWA S, AND WASSERMAN L.R.,
BIOCHIM BIOPHYS ACTA 1968, 154, 70 .
CAVILL I., J, CLIN PATHOL? 1971, 24, 472
BULMAN R.A., NRPB TECHNICAL REPORTS 1976, 0
BULMAN R . A „ , STRUCTURE AND BONDING 1978, 34, 39 
FRANCIS C.W., USAEC TECHNICAL REPORTS 1973,-2, 67 
BULMAN R.A,, GRIFFIN R.J, AND RUSSELL A „ To,
TOXICOLOGY APPL PHARMACOL, 1978, 0
PAINE D„, JOHNSON J.E. AND WATTERS R-l.,
PROC-SYMP. '-SAFETY IN PLUTONIUM HANDLING FACILITIES’ 
USAEC CONF-710401 1971, 407
POLZER W.L., PROC.SYMP. ^SAFETY IN PLUTONIUM HANDLING
FACILITIES’ USAEC CONF-710401 1971, 411
SILVER G.L., USAEC TECHNICAL REPORTS 1971, 0 .
BULMAN R . A „ , GRIFFIN R.J. AND RUSSELL A.T„,
TOXICOLOGY APPL PHARMACOL, 1977, 41, 123 
SCHELL W.R, AND WATTERS R.L.,
HEALTH PHYS, 1975, 29, 589
ANDELMAN J.B AND ROZZELL T.C., 
SERIES’, 93, ED. FREILING S.C 
ROZZELL T.C. AND ANDELMAN J.B, 
SERIES’. 93. ED. FREILING S.C 
CLEVELAND J.M.,
WILLIAMS D.R.,
’ADVANCES IN CHEMISTRY 
1970, 118
’ADVANCES IN CHEMISTRY 
1970, 280
CO-ORDINATION CHEM REV, 1970, 5, 101 
CHEM BRITAIN 1978, 14, 282
TAYLOR D.M, 
ELEMENTS’ . 
TAYLOR D.M, 
ELEMENTS’ .• 
MOELLER T,, J 
K A R R A K E R D . G , , 
JOHNSON 0., J 
POPPLEWELL D.S
1973, 2, 62
’URANIUM, PLUTONIUM AND TRANSPLUTON IC 
ED, HODGE H.C. ET.AL. 1973, 323
’URANIUM, PLUTONIUM AND TRANSPLUTONIC 
ED. HODGE H.C- ET.AL. 1973, 719
. CHEM EDUCATION 1970, 47, 417 
J. CHEM EDUCATION 1970, 47, 424 
CHEM EDUCATION 1970, 47, 431 
STRADLING G.N. AND HAM 6,J., 
RADIATION RESEARCH 1975, 62, 513
POPPLEWELL D.S,, DIAGNOSIS AND TREATMENT OF 
INCORPORATED RADIONUCLIDES’. IAEA 1976, 25 
GRIMES J.H, DIAGNOSIS AND TREATMENT OF INCORPORATED 
RADIONUCLIDES’, IAEA 1976, 419
PRICE K.R., USAEC TECHNICAL REPORTS 
POPPLEWELL D.S., HEALTH PHYS, 1973, 25, 413 
SMITH H,, STRADLING G.N., BULMAN R.A. AND HAM G.J., 
HEALTH PHYS. 1976, 30, 318
DAVIES I.R., SERJEANT E.P. AND WARNER A.G.,
J, CHEM EDUCATION 1977, 5^, 649
COVINGTON A.K., LAB PRACTICE 1977, 26, 46? 
COVINGTON A.K. AND FERRA M.I.A.,
ANAL CHEM. 1977, 49, 1363 • •
SCHWABE K., ’ADVANCES IN ANALYTICAI CHEM ISTRY & 
INSTRUMENTATION’ 10. ED.NURNBERG H 1974, 495 
FRICKE G.H. AND KUNIZ M.J.,
J. CHEM EDUCATION 1977, 54, 517
STEELINK C., J, CHEM EDUCATION 1977, 54, 599 
THAYER J.S., J, CHEM EDUCATION 1977, 54, 604
201
*
*
*
*
*
*
*
1663 THAYER J.S., J. CHEM EDUCATION 197?, 54, 662
1464 RAMSAY C.G„, J, CHEM EDUCATION 197?, 54, 714
1465 GIROUX E.L. AND PRAKASH N.J.,
J, PHARM SCI, 1977, 66, 391
1466 BEARN A.G. AND KUNKEL II.6.,
PROC SOC EXP BIOL MED, 1954, 85, 44
1467 LAURIE S.H. AND SARKAR B.,
J. CHEM SOC, DALTON 1977, 1822
1468 IYER K.S., LAU S-J . , LAURIE S.H, AND SARKAR B„,
BIOCHEM J, 1978, 169, 61
1469 WALKER W.R., CHEM AUSTRALIA 1977, 44, 247
1470 WALKER W.R., REEVES R.R., BROSNAN M. AND COLEMAN G D . , 
BIOINORG CHEM. 1977, 7, 271
1471 DECSY M.I. AND SUNDERMAN F.W.,
BIOINORG CHEM. 1974, 3, 95
1472 KASPER C.B., DEUTSCH H.F. AND BEINERT H.,
J. BIOL CHEM, 1963, 238, 2338
1 473 PIPPARD M.J., CALLENDER S.T. AND WEATHERALL D.J.,' 
LANCET 1977, 1101
1 474 SHALOUHI T„, EVANS P,T. AND WRIGHT J . R,, ''
PHYSIOL CHEM PHYSICS 1976, 8, 337
1475 SPOOR N.L., NRPB TECHNICAL REPORTS 1977, 0 .
1476 SANDERSON M.D. AND. WILLIAMS D.R., *'
J. INORG NIJCL CHEM, 1977, 39, 641
1 477 MATHESON I.A, AND WILLIAMS D.R.,
J, CHEM EDUCATION 1973, 50, 345
1 478 SEVEN M„J., GOTTLIEB H „ , ISRAEL H, L. » REINIIOLD J.G.
AND RUBIN M., AMER J. MED SCI, 1954, 228, 646
1479 BATES R.G., ’ANALYTICAL CHEMISTRY’ RINGBQM ISSUE, 
ED.WANNINEN E. PERGAMON,OX FORD 1977, 23
1480 SARNESKI J . E , AND REILLEY G • N » ,
'ANALYTICAL CHEMISTRY’ R I NGBOM . ISSUE•
ED.WANNINEN E. PERGAMON,OXFORD 1977, 35 - •
1481 ANDEREGG G., 'ANALYTICAL CHEMISTRY' RINGBOM ISSUE, 
ED.WANNINEN E, PERGAMON,OXFORD 1977, 51
1482 BECK M.T.i ’ANALYTICAL CHEMISTRY’ RINGBOM ISSUE, 
ED.WANNINEN E. PERGAMON,OX FORD 1977, 59
1483 BURGER K.r 'ANALYTICAL CHEMISTRY’ RINGBOM ISSUE, 
ED.WANNINEN E. PERGAMON,OX FORD 1977, 81
1484 NASANEN R«, LINDELL E. AND TILUS P.,
'.ANALYTICAL CHEMISTRY' RINGBOM ISSUF.1 
ED.WANNINEN E. PERGAMON,OXFORD 1977, 95
1485 OSTERBERG R., 'ANALYTICAL CHEMISTRY' RINGBOM ISSUE, 
ED.WANNINEN E, PERGAMON , OX FORD 1977, 1 03
1486 PERRIN D.D., 'ANALYTICAL CHEMISTRY' RI NGBOM ISSUE, 
ED.WANNINEN E, PERGAMON,OX FORD 1977, 1 13
1487 PETIT-RAMEL M.M, AMD PARIS M.R., .•
''ANALYTICAL CHEMISTRY' RINGBOM ISSUE,
ED.WANNINEN E, PERGAMON,OX FORD 1977, 1 23 .
1488 BJERRUM J., 'ANALYTICAL CHEMISTRY' RINGBQM ISSUE, 
ED.WANNINEN E, PERGAMON,OX FORD 1977, 143
1 489 BUDEVSKY 0., 'ANALYTICAL CHEMISTRY •' RINGBOM ISSUE, ‘
• ED.WANNINEN E. PERGAMON,OX FORD 1977, 169
202
1490
1491
1492
1493
14 94
1495
1496
1497
1493
1499
* 1500
1501
1502
1503
15 04
1505
1506
.1507
1503
1 509
1510
1511
1512
1513
1514
1515
1516
PRIBIL R., 
EO.WANNINEN E. 
LAITINEN H.A., 
EO.WANNINEN E.
harju l. and skrifvars b.,
’ANALYTICAL CHEMISTRY’ RlNGBOM ISSUE,
EO.WANNINEN E. PERGAMON,OX FORD 1977, 175 •
ANALYTICAL CHEMISTRY' RlNGBOM ISSUE, 
PERGAMON,OXFORD 1977, 219 
'ANALYTICAL CHEMISTRY' RlNGBOM ISSUE, 
PERGAMON,OXFORD 1977, 305
PRETSCH t,, BUCHJ R,, AMMANN D. AND SIMON W.» 
•ANALYTICAL CHEMISTRY' RlNGBOM ISSUE,
EO.WANNINEN E. PERGAMON,OX FORD 1977, 321 
PUNG.OR E., TOTH K, AND NAGY G.,
'ANALYTICAL CHEMISTRY' RlNGBOM ISSUE,
EO.WANNINEN E. PERGAMON , OX FORD 1977, 331 
BERMEJO-MARTINEZ F. AND RODRIGUEZ-VAZQUEZ J., 
'ANALYTICAL CHEMISTRY' RlNGBOM ISSUE,
ED.W.ANNINEN E. PERGAMON , OX FORD 1977, 537 
HIRSCH R.F.,- 'ANALYTICAL CHEMISTRY’ RlNGBOM ISSUE, 
EO.WANNINEN E. PERGAMON,OX FORD 1977, 577 '
LAURIE S.H. AND GARDENER C , S .,
EDUCATION IN CHEM. 1977, 13, 71 •'
NEUMANN P.Z, AND SILVERBERG M., NATURE 1966, 210, 414 
scheinberg i.h. AND STERNLIEB I,, .
PHARM REVIEWS 1960, 12, 355 .
AGARWAL R.P. AND PERRIN D.D.,
AGENTS AND ACTIONS 1976, 6, 667
FITCH F.W. AND MCKEARN T . J » , PROC , I NT , SYMP.
'INFLAMMATION AND ANTIINFLAMMATORY DRUGS' 1975-, 71 
UITTO J.J, AND- PROCKOP D.J., PROC.I NT.SYMP. 
'INFLAMMATION AND ANTIINFLAMMATORY DRUGS’ 19?5, 129 
FERRIERA S.H., FLOWER R., MONCADA S. AND VANE J , R. , 
PROC.INT.SYMP.
'INFLAMMATION AND ANTIINFLAMMATORY DRUGS'- 1975, 133 
ALARCON-SEGOVIA D,, PROC.I NT.SYMP.
'INFLAMMATION AND ANTIINFLAMMATORY DRUGS' 1975, 183 
LINDNER J, AND GRASEDYCK K»» PROC,I NT - SYMP. 
'INFLAMMATION AND ANTIINFLAMMATORY DRUGS' 19?5, 255 
ALBERT A,,.RUB3G S.D., GOLDACRE R.J. AND BALFOUR B.G., 
BRIT J, EXP PATH. 1947, 28, 69
LYLE W.H., POSTGRAD MED J. 1974, 50, 107 
WILSON E.W. AND MARTIN R.B.,
ARCH BIOCHEM BIOPHYS, 1971, 142, 445 
AISEN P. AND MORELL A.G.,
J. BIOL CHEM. 1965, 240, 1974 
SCHEINBERG I.H. AND MORELL A.G., ’
J. CLIN INVEST. 1957, 36, 1193 
SORENSON J.R.J. AND ’DI TOMMASO D»,
ANN RHEUMATIC DISEASES 1976, 35, 186 
BARNEKOW A. AND WINKELMANN G., EXP HEMAT 
FRIEDHEIM E.f CQRVI C. AND WAKKER C „ H.»
J. PHARM PHARMACOL. 1976, 28, 711 •
MIDGLEY D., ANAL CHEM. 1977, 49, 1211 
NAJARIAN R.C., HARRIS D.C. AND AISEN P.,
J. BIOL CHEM. 1978, 253, 38 
WILLIAMS D.R., J. INORG NUCL CHEM.
1976, 4, 70
1977, 39, 711
203
1517 BATES G . W. AND WERNICKE J.,
J. BIOL CHEM, 1971, 246, 3679
1518 GABARD B., ACTA PHARMACOL TOXICOL. 1976, 39, 250
1519 PLANAS-BOHNE F„, ARCH TOXICOL. 1977, 37, 219 
1 520 CASSATT J.C., J. BIOL CHEM. 1973, 248, 6129 
1521 GABARD B., ARCH TOXICOL. 1976, 35, 15
* 1522 CATSCH A,, HARMUTH-MOENE A.E., HAVLICEK F,
AND CARPY S., PROC.SYMP, 'DIAGNOSIS AND TREATMENT OF 
DEPOSITED RADIONUCLIDES'. 1967, 413
1 523 CRAMPTON R.F., MATTHEWS D.M. AND POISNER R. ,
J. PHYSIOLOGY 1965, 178, 111
1 524 LAL H„ AND RAO M.S.N.,
J, AMER CHEM SOC. 1957, 79, 3050
* 1525 POLLACK AISEM P., LASKY F.D. AND VANDERHOFF G«,
BRIT J, HAEMATOLOGY 1976, 34, 231 
1 526 NOMOTO S. AND SUNDERMAN F.W., CLIN CHEM. 1970, 16, 47
* 1527 TOFFALETTI J., GITELMAN H.J. AND SAVORY J.,
CLIN CHEM. 1976, 22, 1968 •
1528 MCNEELY M.D., NECHAY M.W. AND SUNDERMAN F,W.»
CLIN CHEM. 1972, 18, 992 -
* 1529 HEDSTROM H, OLIN A,, SVANSTROM P. AND ASLIN E , ,
J. INORG N1.JCL CHEM. 1977, 39, 1191
1530 ANON., BRIT MEDICAL J. 1978, 599 •*
1531 BROWN D,H.» MCKINLEY 6.C. AND SMITH W,E,,
J. CHEM SOC. DALTON 1978, 199
1532 KEIL L«, MOODY G.J. AND THOMAS J.D.R,,
ANALYST 1977, 102, 274
1533 KONTOYANNAKOS J., MOODY G.J. AND THOMAS J.D.R.,
ANAL CHIM ACTA 1976, 85, 47
1534 CRAGGS A., MOODY G.J., THOMAS J.D.R. AND WILLCOX A., 
TALANTA 1976, 23, 799
1 535 ABBARAH T • R * , FREDELL J.E. AND. ELLENZ G.B.,
J. AMER MED ASSOC. 1976, 236, 2320 • •
1536 VERSIECK J, AND ET. AL., CLIN CHEM. 1978, ?4, 303
1537 CROMBIE D.J., MOODY G.J, AND THOMAS J.D.R.,
ANAL CHIM ACTA 1975, 80, 1
* 1538 SHIOKAWA Y. ET.AL,
ARTHRITIS AND RHEUMATISM 1977,‘20, 1464
* 1539 HAMMOND P.B., ANN REV PHARMACOLOGY 197?, 17, 197
1540 BIGGINS P.D.E AND HARRISON R.M., NATURE 1978, 272, 52
1541 ANON., CHEM AND ENG. NEWS 1977, 24
1542 FENTON D.E., CHEM REVIEWS 1977, 6, 325
1543 LLOYD R.D. AND ET, AL., HEALTH PHYS, 1976, 31, 281
1544 VOLF V,, HEALTH PHYS. 1976, 31, 290
1545 PIOTROWSKI J.K. AND SZYMANSKA J.A,,
J. TOXICOL ENVIRON HEALTH 1976, 1, 991
1546 NAYAN R, AND DEY A.K., .
J, INORG NUCL CHEM, 1978, 40, 289
1547 HOJO Y., SUGIURA Y. AND TANAKA H.,
J, INORG NUCL CHEM. 1977, 39, 715
1548 DU PREEZ J.G.H., GELLATLY P.L. AND ROHWER H.E.,
J. INORG NUCL CHEM. 1977, 39, 1173 •
1549 SABBIONI E. AND MARAFANTE E., "
CHEM BIOL INTERACTIONS 1976, 15, 1
204
COATES R.L.'AND JONES M.M.,
J. INORG MUCL CHEM. 1977, 39, 677 
KOSTIN K. ANO MCLEAOO G.C.,
TOPICS IN CURRENT CHEM, 1977, 69, 1 
PERRIN 0,0.,
1550
1551
1552
1553
1554
* 1555
* 1556
1557
1558
1559
1560
1561
1562
1563 
1 564
1565
1566
1567
1568
1569
1570
1571
* 1572
1573
1574
1575
* 1576
1577
1578
* 1579
PROCUNT.CONGRESS CHEMOTHERAPY, 9TH. LONDON 1975 , 209 
LEGGETT 0 . J . , TALANTA 1977, 24, 535 
YOUNG S., BAKER E., GOMPERTS B.D. AND HUEHNS E.R., 
’PROTEINS OF IRON.STORAGE AND TRANSPORT IN BIOCHEM 8 
MED’, ED.CRIGHTON R 1975, 417
CHASTEEN N.D., CO-ORDINATION CHEM REV. 1977, 22, 1 
ZAPOLSKI E.J. AND PRINCIOTTO J.V.,
•PROTEINS OF IRON METABOLISM’,
ED, BROWN E.B. GRIJNE & STRATTON INC, 1 977, 205 
BAKER E„, VICARY F.R, AND HUEHNS E.R.,
’PROTEINS OF IRON METABOLISM’.
ED, BROWN E.B. GRUNE S STRATTON INC, 1977, 327 
BAKER E,, MORTON A.G, AND TAVILL A.S.,
’PROTEINS OF IRON STORAGE AND TRANSPORT IN BIOCHEM 8 
MED’. ED.CRIGHTON R 1975, 173
OLIN A, AND WALLEN B., TALANTA 1977, 24, 303
SEGEWITZ G., Z. NATUR FORSC HUNG 1*972, 27, 1370 
NEUMANN P.Z. AND SILVERBERG M„, NATURE 1967, 775 
TANDON S.K. AND MATHUR A.K., CHEMOSPNERE 1976, 5, 319 
FARRELL J.J,, J, CHEM EDUCATION 1977, 54, 445 
PLANAS-BOHNE F. AND LOHBREIER J,,
DIAGNOSIS AND TREATMENT OF INCORPORATED RADIONUCLIDES’. 
IAEA 1976, 505
SALTMAN P. AND HEGENAUER J.C.,
AMER J, CLINICAL NUTRITION 1976, 29, 936
EVANS G.W., PEKAREK R.S., ALLEN K.G.D. AND JOHNSON P.E,
AMER J. CLINICAL NUTRITION 1.977, 30, 654
HEGENAUER J.C., SALTMAN P. AND VANDERLIP J,r
AMER J, CLINICAL NUTRITION 1977, 30, 655
MULLER W.H. AND MULLER W.A., f
1974, 61, 455 
MULLER W.A. AND LINZNER U,,
1977, 64, 96
1977, 153, 570
NATURWISSENCHAFTEN 
MULLER W.H.,
NATURWISSENCHAFTEN 
MULLER W.H., , S T R A H L E NTH E R A P I E 
MULLER W.H. AND BEAUMARTIN J,,
ANAL CHEM. 1974, 46, 2218 
HAY R.W,, MORRIS P.J. AND PERRIN 0,0.,
AUST J , CHEM. 1968, 21 , 1 073 
MULLER W.H. AND BEAUMARTIN J.,
LIFE SCIENCES 1976, 17, 1815 
PLANAS-BOHNE F., HEALTH PHYS,
WARD C. ET.AL.,
AMER J. CLINICAL NUTRITION 1977, 30, 1054
KALLIOMAKI J.L., CURRENT THER RESEARCH 1977, 21, 815 
PLANT IN 1,0. AND STRAND BERG P.O.,
ACTA RHEUM SCAND, 1965, 11, 30
OLIN A. AND SVANSTROM P,, ACTA CHEM SCAND, 1978, 0 
MALIK G.S., SINGH S-P, AND TANDON J.P.,
J, INORG NUCL CHEM, 1977, 39, 1279
1976, 31, 165
205
X 1580 DANIELE p,G« AND OSTACOLI G.,
ANN CHIMICA 1976, 66, 387
1581 MIGAL P.K AND GERBELEU A.P.,
RUSS .J. INORG CHEM. 1971, 16, 295
1 582 KARUCEK R., COLLECT CZECH CHEM COMMON, 1975 , 40 , 3825< 
1 583 SHARMA G. AND TANDQN J . P. , TALANTA 1971, 18, 1163
1584 JOSHI J.D. AND BHATTACHARYA P.K.,
J, INDIAN CHEM SOCIETY 1973, 50, 344
1585 JACOBS A., BLOOD 1977, 0
1 586 WILLIAMS R.J.P., PROC ROY IN-ST GT BRIT. 1976, 49, 93
1587 PETTIT L.D. AND SWASH J.L.M.,
J, CHEM SOC. DALTON 1976, 588
1588 BROOKES G. AND PETTIT L.D., •
J. CHEM SOC. DALTON 1977, 1918-
* 1589. ISRAELI J. AND CECCHETTI M., TALANTA 1968, 15, 1031
’ 1590 DE BRABANDER H.F,, CREYF H.S., GOEMlNNE A.M.
AND VAN POUC'KE L.C., TALANTA 1 976, 23, 405
* 1591 BILINSKI H., HlJSTON R. AND STUMM W,,
ANAL CHIM ACTA 1976, 84, 157 .
159? STOTTER D.A., J. INORG NUCL CHEM. 1977, 39, 721
’ 1593 AGUILAR M., ALEGRET S. AND CASASSAS E.,
J..INORG NUCL CHEM. 1977, 39, 733
■ 1594 KAPOOR R.C., JAILWAL J.K. AND KISHAN J., •
J. INORG NUCL CHEM. 1978, 40, 155 
1 595 KHURANA S.C. AND NIGAM I.J.,
J. INORG NUCL CHEM. 1978, 40, 159
■ 1596 PARIKH P.C. AND BHATTACHARYA P.K., '
J.. INDIAN CHEM’ SOCIETY 1973 , 50, 804 
1 597 DAVID P.G. AND DAVID F, , J. COORD CHEM. 1977, 6, 211
1598 BLAIS M-J. AND BERTHON G.,
CANADIAN J. CHEM. 1977, 55, 199
1599 SARKAR B., SAS5-KORTSAK A., CLARKE R., LAURIE S.H,
AND WEI P., PROC ROY SOC MED. SUPP 3. 1977, 70, 13
1600 MAY P.M. AND WILLIAMS D.R.,
PROC ROY SOC MED. SUPP 3. 1977, 70, 19
* 1601 MAY P.M, AND WILLIAMS D.R.,
F.E.B.S LETTERS 1977, 78, 134 
<• 1 602 JACKSON G.E., MAY P.M, AND WILLIAMS D.R.,
F.E.B.S LETTERS 1978, 90, 173 
<• 1603 JACKSON G.E., MAY P.M. AND WILLIAMS D.R.,
J. INORG NUCL CHEM. 1978, 40, 1189
* 1604 FIABANE A.M. AND WILLIAMS D.R.,
J. INORG NUCL CHEM. 1978, 40, 1195 '
1605 FIABANE A.M,, TOUCHE M.L.D. AND WILLIAMS D.R.,
J. INORG NUCL CHEM. 1978, 40, 1201
* 1606 MICHELONI M., MAY P.M. AND WILLIAMS D.R.,
J. INORG NUCL CHEM. 1973, 40, 1209
* 1607 ARENA G., KAVU G. AND WILLIAMS D,R.,
J. INORG NUCL CHEM, 1978, 40, 1221
* 1608 JACKSON G.E., MAY P.M. AND WILLIAMS D;R.,
J. INORG NUCL CHEM. 1978, 40, 1227
* 1609 JACKSON G.E., MAY P.M. AND WILLIAMS D.R.,
J, INORG NUCL CHEM. 1973, 40, 9999
- -
206
* 1610
* 1611
* 1 61 2
* 1613
* 1614
1615
1616
1617
1618
1619
1620
1621
* 1622
1623
1624
* 1625
1626
* 1627 
1628
1629
1630
* 1631
* 1632
1633
1634
* 1635
* 163 6
* 1637
FIABANE A.M. 'AND WILLIAMS D.R., ’THE PRINCIPLES OF 
BIO-INORGANIC CHEMISTRY’ CHEM SOC MONOGRAPH 31 1977, 7
SORENSON J . R . J . AND HANGARTER W,,
INFLAMMATION 1977, 2, 217 .
GERBER D.A., BIOCHEM PHARMACOL. 1978, 27, 469
GRAN G., ANALYST 1952, 77, 661
INGMAN F. AND STILL E», ’ANALYTICAL CHEMISTRY* RINGBOM 
ISSUE, ED.WANNINEN E. PERGAMON,OXFORD 1977, 183 
FRAZER J.W, SELIG W. AND RIGDON L.P.,
ANAL CHEM. 1977, 49, 1250
KELSON J.R. AND SHAMBERFER R.J.,
CLIN CHEM. 1978, 24, 240
COTTON S.A,, EDUCATION IN CHEM. 1977, 13, 180
CLEVELAND J.M., ‘THE CHEMISTRY OF PLUTONIUM’ GORDON & 
BREACH N.Y. 1970
WHITEHOUSE M.W., HANLEY W.S. AND FIELD L., .
ARTHRITIS AND RHEUMATISM 1977, 20, 1035 
JACOBS A., WHITE G.P, AND TAIT G.P.,
BIOCHEM BIOPHYS RES COMMON 1977, 74, 1626 
GIROUX E.L., PRAKASH N.J. AND SCHECHTER P.J.,
CLIN EXP PHARM PHYSIOL. 1977, 4, 27 
KAHN H.L. AND CUMME G.A,,
ACTA BIOL MED GERM. 1976, 35, 1571 .
KAHN H.L.,
'ADVANCES IN CHEMISTRY SERIES', 73. ACS. 1968, 183 
PREECE A.W., LIGHT P.A., EVANS P.A, AND NUNN A.D.,
LANCET 1977, 1, 953
JAIN S., SCHEUER P.J., SAMOURIAN S„, MCGEE J.O’D.
AND SHERLOCK 5„, LANCET 1977, 1, 831 
ARONOW R.,BREGE B., CHEN H.Y. AND SMITH R.G.,
CLIN TOXICOLOGY. 1977, 11, 221
DIPPY J.E., BRIT J. CLIN PRACTICE 1977, 31, 5
RUPP H. AND WESER U.,
BIOCHEM BIOPHYS RES COMMUN 1976, 72, 223
JELLUM E., AASETH J. AND MUNTHE E.,
PROC ROY SOC MED. SUPP 3. 1977, 70, 136
SIMKIN P.A., PROGRESS CLIN BIOL RES. 1977, 14, 343 
MAY P.M., WILLIAMS D.R, AND LINDER P.W., ’METAL IONS 
IN BIOLOGICAL SYSTEMS.’ VOL VII ED- SIGEL H, 1978, 29 
BERTHON G., MAY P.M. AND WILLIAMS D.R.,
J. CHEM SOC. DALTON 1978, 1433
FRIEDEN E», PROC.SYMP, ’TRACE ELEMENT METABOLISM IN
MAN AND ANIMALS’, 3RD, FREISING 1973, 8
FRIEDEN E., PROC.SYMP, 'TRACE ELEMENT METABOLISM IN
MAN AND ANIMALS’, 3RD, FREISING 1978, 36
BREMNER I., HOEKSTRA W.G., DAVIES N.J.
AND WILLIAMS R., PROC.SYMP, ’TRACE ELEMENT METABOLISM 
IN MAN AND ANIMALS’, 3RD, FREISING 1978, 44 
HOEKSTRA W.G., BRFMNER I, AND DAVIES N.J.,
PR-QC.SYMP. 'TRACE ELEMENT METABOLISM IN MAN AND 
ANIMALS’, 3RD, FREISING 1978, 52
COUSINS R.J., PROC.SYMP. 'TRACE ELEMENT METABOLISM IN 
MAN AND ANIMALS’, 3RD, FREISING 1973, 57
207
EVANS G.U. 
METABOLISM 
WEIGAND E, 
PROC.SYMP. 
ANIMALS',
SCHWARZ F,
P R 0 C , S Y M P . 
ANIMALS’, 
elmes m,e,
MAN ANO ANIMALS’ 
HATHCOCK J . AND
1638
1639
1640
1641
1642
1643
1644
1645
* 1646
1647
1648
1649
* 1650
1651
1652
1653
1654
1655
1656
1657
1658
AND JOHNSON P , E . ,
IN MAN AND ANIMALS'
AND KIRCHGESSNER M,,
•TRACE ELEMENT METABOLISM 
3RD, FREISING 1978, 106 
J, AND KIRCHGESSNER M.,
•TRACE ELEMENT METABOLISM 
3RD, FREISING 1978, 110
, PROC.SYMP, 'TRACE ELEMENT 
, 3RD, FREISING 1978, 
ABRAHAM C., PROC.SYMP.
PROC.SYMP. 'TRACE ELEMENT 
, 3RD, FREISING 1978, 98
IN MAN AND
IN MAN AND
METABOLISM IN 
122
’TRACE ELEMENT
METABOLISM 
SALTMAN P, 
PROC.SYMP.
126*IN MAN AND ANIMALS', 3RD, FREISING 1978, 
HEGENAIJER J.C., RIPLEY L- AND MORRISON J.,
'TRACE ELEMENT METABOLISM IN MAN AND 
ANIMALS', 3RD, FREISING 1978, 145
POPOV B.V. AND BESEL V.S., PROC.SYMP. 'TRACE ELEMENT 
METABOLISM IN MAN AND ANIMALS', 3RD, FREISING 1978, 168 
HOUSE W.A., WELSH R.M. AND VAN CAMPEN D „ ,
PROC.SYMP. 'TRACE ELEMENT METABOLISM IN MAN AND
ANIMALS', 3RD, FREISING 1978, 171
MAY P.M. AND WILLIAMS D.R., PROC.SYMP. 'TRACE ELEMENT 
METABOLISM IN MAN AND ANIMALS', 3RD, FREISING 1978, 179 
IIENKIN R , I » , PROC.SYMP, 'TRACE ELEMENT METABOLISM IN 
MAN AND ANIMALS’, 3RD, FREISING 1978, 190
SANDSTEAD H, H. , FOSMIRE G., IIALAS E.S., STROBEL D,
AND DUERRE J., PROC.SYMP. 'TRACE ELEMENT METABOLISM 
ANIMALS’, 3RD. FREISING 1978, 203 
AND KIRCHGESSNER M.,
'TRACE ELEMENT METABOLISM IN MAN AND 
3RD, FREISING 1978, 236
H., MYRON D.R, AND UTHUS E.O.,
'TRACE ELEMENT METABOLISM IN MAN AND 
3RD, FREISING 1978, 244
RABBANI P., ABBASI A,, BOWERSOX E.
IN MAN AND 
S.CHNEGG A. 
PROC.SYMP. 
ANIMALS' , 
NIELSEN F 
PROC.SYMP 
ANIMALS’ , 
PRASAD A. S
AND
AND FOX M.R.S., PROC.SYMP. 'TRACE ELEMENT METABOLISM 
IN MAN AND ANIMALS', 3RD, FREISING 1978, 280 
HEN-KIN R.I., PROC.SYMP. 'TRACE ELEMENT METABOLISM IN 
MAN AND ANIMALS', 3RD, FREISING 1978, 286 
BARLTROP D. AND STREHLOW C.D., ' .
PROC.SYMP, 'TRACE ELEMENT METABOLISM IN MAN 
A-NIMALS', 3RD, FREISING 1978, 332
PORIES W.J., OE WYS W,, FLYNN D.M.,
AND STRAIN W.H., PROC.SYMP. 'TRACE
IN MAN AND ANIMALS', 3RD, FREISING 
MATHIJR A. ET AL, PROC.SYMP, 'TRACE
IN MAN AND ANIMALS’, 3RD, FREISING
TOWNSEND S.F, AND SORENSON J.R.J., .
PROC.SYMP, 'TRACE ELEMENT METABOLISM IN
ANIMALS', 3RD, FREISING 1978, 370
DANKS D.M. AND SMITH A.L., PROC.SYMP, 'TRACE ELEMENT 
METABOLISM IN MAN AND ANIMALS', 3RD, FREISING 1978, 373 
DANKS D.M., CAMAKARISJ. AND STEVENS B.J., ’
PROC.SYMP. 'TRACE ELEMENT METABOLISM
E.G.
METABOLISM 
1978, 354
ELEMENT METABOLISM 
1978, 359
MANSOUR
element
MAN AND
IN MAN AND
ANIMALS', 3RD,' FREISING 1978, 401
208
x- 1659 MENKE K.H., LANTZSCH H.~J. AND SHENKEL H,f
PROC.SYMP, 'TRACE ELEMENT METABOLISM IN MAN AND
• ANIMALS’, 3RD, FREISING 1978, 456 *
1660 GRAZIANO J.H., PROC.SYMP. 'TRACE ELEMENT METABOLISM IN 
MAN AND ANIMALS', 3RD, FREISING 19?3, 60S
1661 FORTH W., PROC.SYMP. 'TRACE ELEMENT METABOLISM IN MAN 
AND ANIMALS', 3RD, FREISING 1978, 638
1662 KENKIN R.I., PROC.SYMP. 'TRACE ELEMENT METABOLISM IN 
MAN AND ANIMALS', 3RD, FREISING 1978, 650
1663 JENNE E.A, AMD LUOMA S.N.,
PROC.SYMP, 'BIOLOGICAL IMPLICATIONS OF METALS IN THE 
ENVIRONMENT' ERDA 4 1977, 110
1664 KLEINMAN M.T., KNEIP T.J., BERNSTEIN D.M.
AND EISENBUD M., PROC.SYMP. 'BIOLOGICAL IMPLICATIONS 
OF METALS IN THE ENVIRONMENT' ERDA 4 1977, 144
1665 WILLIAMS S.L., AULENBACH D.B. AND CLESCCRI N.L., 
PROC.SYMP. 'BIOLOGICAL IMPLICATIONS OF METALS IN-THE
. ENVIRONMENT' ERDA 4 1977, 153
1666 MCNURNEY J.M., LARIMORE R.W. AND WETZEL M-„ J . ,
PROC.SYMP. 'BIOLOGICAL IMPLICATIONS OF METALS IN THE 
ENVIRONMENT' ERDA 4 1977, 167
1667 HOLDREN G.R. AND BRICKER O.P., ' ••
PROC.SYMP, 'BIOLOGICAL IMPLICATIONS OF METALS IN THE 
ENVIRONMENT' ERDA 4 1977, 178
1668 MACCARTHY P. AND MARK H.B.,
PROC.SYMP. 'BIOLOGICAL IMPLICATIONS OF METALS IN THE 
ENVIRONMENT' ERDA 4 1977, 197 •
1669 JENNE E.A. AND LUOMA S.M.,
PROC.SYMP. 'BIOLOGICAL IMPLICATIONS OF METALS IN THE 
ENVIRONMENT' ERDA 4 1977, 213
1670 GARLAND T.R. AND WILDUNG R.E., -
PROC.SYMP. 'BIOLOGICAL IMPLICATIONS OF METALS IN THE 
ENVIRONMENT' ERDA 4 1977, 254
1671 TIFFIN L.O., PROC.SYMP. 'BIOLOGICAL IMPLICATIONS OF
METALS IN THE ENVIRONMENT' ERDA 4 1977, 315
1672 SARSFIELD L.J, AND MANCY K.H., .
PROC.SYMP, 'BIOLOGICAL IMPLICATIONS OF METALS IN THE 
ENVIRONMENT' ERDA 4 1977, 335.
1673 BARBER 5.A. AND CLAASSEN N., •
PROC.SYMP. 'BIOLOGICAL IMPLICATIONS OF METALS IN THE 
ENVIRONMENT’ ERDA 4 1977, 358
1674 WALLACE A. AND ROMNEY E.M.,
PROC.SYMP. 'BIOLOGICAL IMPLICATIONS OF METALS IN THE 
ENVIRONMENT' ERDA 4 1977, 370
1675 FURST A., PROC.SYMP, 'BIOLOGICAL IMPLICATIONS OF
METALS IN THE ENVIRONMENT' ERDA 4 1977, 426 .
1676 RAGAN H.A., PROC.SYMP. 'BIOLOGICAL IMPLICATIONS OF
METALS IN THE ENVIRONMENT’ ERDA 4 1977, 570
1677 VAUGHAN B.E., PROC.SYMP. 'BIOLOGICAL IMPLICATIONS OF
METALS IN THE ENVIRONMENT’ ERDA 4 1977, 648
1678 LETSKY E . A . , ’BIRTH DEFECTS; ORIGINAL ARTICLE SER'. • 
VOL XII IRON MET, S THALASSEMIA, 1976, 31
1679 PETERSON C.M..AND JONES R.L.,
'BIRTH DEFECTS; ORIGINAL ARTICLE SER*.
VOL XII IRON MET. & THALASSEMIA, 1976, 187
•_i?\ A' J. -A?"- AfcriCf
209
1630
1631
1682
1683
1634
1685
1686 
1687 
1683 
1639 
1 690
1691
1692
1693
1694
1695
1696 
* 1697
1693
1699
1700
1701
1702 
* 1703
1704
1705
1706
1707
1708
1709
1710
NIENHUIS A.W. ET A L. , 'BIRTH DEFECTS; ORIGINAL ARTICLE 
SLR’, VOL XII IRON MET, & THALASSEMIA, 1976, 177 
MODELL B. AMD MATHEWS R„,
'BIRTH DEFECTS: ORIGINAL ARTICLE SER». •
VQL XII IRON MET, & THALASSEMIA, 1976, 13
HENTZ F.C. AND LONG G.G.,
J, CULM EDUCATION 1978, 55, 55
DUURSMA E,K, AND SEVENHUYSEN W,, ' .
NETHERLANDS J, OF SEA RESEARCH 1966, 3, 95 
DAVEY E.W., MORGAN M.J. AND ERICKSON S.J.,
LIMNOL OCEANOGR, 1973, 18, 993
CHAU Y,K. ET AL.» J. CHROMAT SCI, 1973, 2, 579 
SCHWARTZ M.K., CANCER RESEARCH 1975, 35, 3481 
RA3ENSTEIN D.L., J, CHEM EDUCATION 1978, 55, 292 
HARRISON F.L., NUCLEAR TECHNOLOGY 1971, 2, 444 
WILSON R.C.H., J, FISH RES BOARD CANADA 1972, 29, 1500 
MUNRO H.N. AND LINDER M,C,,
PHYSIOL REVIEWS 1978, 58, 317
FOSMIRE G,, J, CHEM EDUCATION 1 972 , 49, 204
BI ESINGER K.E. AND CHRISTENSEN G.M„,
J, FISH RES BOARD CANADA 1972, 29, 1691
BIRKER P.J.M., FREEMAN II. C, AND PAMSHAW J.A.M.,
PROC.SYMP, 'TRACE ELEMENT METABOLISM IN MAN AND ' •
ANIMALS’, 3RD, FREISING 1978, 409 
RAMAMOORTHY $, AND KUSHNER D.J.,
J, FISH RES BOARD CANADA 1975, 32, 1755
CHAU Y.K. ET Al„, .
J. FISH RES BOARD CANADA 1974, 31, 1515 
SMITH D.D., J, CHEM EDUCATION 1978, 55, 334 
OHTAKI II,,' OYAMA N.» SHIRATO T, AND MATSUDA H , ,
BULL SOC CHEM JAPAN 1976, 49, 3047 
CZECH M.P, AND FAIN J.N., ’
J, BIOL CHEM, 1972, 247, 6218.
LEBER A.P, AND MIYA T.S,, 
TOXICOLOGY APPL PHARMACOL,
LEEPER 
ANON , ,
1 957,
R , L , , 
1947,
1976, 37# 403
83, 123
SOIL SCI, 1957, 84, 55 
63, 79
PLUTONIUM' MEDICAL RESEARCH
AND STALKER D.M,,
1978, 9, 47
SEVEN M.J. 
ED.SEVEN M 
FIGUEROA W 
ED.SEVEN M 
FOREMAN U. 
ED,SEVEN M
MASSEY H.F., SOIL SCI,
DEKOCK P,C. AND MITCHELL 
G.W., SOIL SCI.
'THE TOXICITY OF
COUNCIL, 1975, 1 
MCCONNELL A.A., NUTTALL R.H 
TALANTA 1978, 25, 425
G E R G E L Y A. AND S 0 V A G 0 I . , B I 0 IN 0 R G CHEM
KARTELL A.E., 'METAL BINDING IN MEDICINE’. 
ED.SEVEN M. 8 JOHNSON L. J . B . LIPPINCOTT CO, 
SCHROEDER H.A., 'METAL BINDING IN MEDICINE' 
ED,SEVEN M. 8 JOHNSON L, J . B . LIPPINCOTT CO, 
'METAL BINDING IN MEDICINE'.
& JOHNSON Lr J.B.LIPPIN COTT CO. 
G,, 'METAL BINDING IN MEDICINE', 
& JOHNSON L. J • B , LIPPINCOTT CO.
'METAL BINDING IN MEDICINE',
& JOHNSON L, J .B.LIPPINCOTT CO.
1960, 1
1960, 59
1960, 95
1960, 146
1960, 160
210
1711
* 1712
1713
1714
171 5
1716
1717
* 1718
1719
* 1720
* 1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
I960, 225
I960, 230
1960, 241
1960, 245
SPENCER H« AND LAZLO I)., ’METAL BINDING IN MEDICINE', 
ED,SEVEN M„ S JOHNSON L. J . B . LIPPINCOTT CO. 1960, 169 
PERRY H.M, AND CAMEL G . H . » ‘METAL BINDING IN MEDICINE’ 
ED.SEVEN M. & JOHNSON I. J.B,LIPPINCOTT CO, I960 . 209 
JOHNSON L,A. AND SEVEN M.J.,
•METAL BINDING IN MEDICINE’,
ED,SEVEN M. & JOHNSON L. J . B . LIPPINCOTT CO 
KORMAN S., ’METAL BINDING IN MEDICINE',
ED,SEVEN M. X JOHNSON L, J , B . L I PPINCOTT CO 
SALTMAN P, AND CHARLEY P.J.,
'METAL BINDING IN MEDICINE',
ED.SEVEN M. & JOHNSON L. J , B . L I PPINCOTT CO 
GREENBERG J, AND DUDLEY H.C.,
'METAL BINDING IN MEDICINE’,
ED,SEVEN M. & JOHNSON L. J»B«L I PPINCOTT CO 
SHIELDS G.S., MARKOWITZ H,, CARTWRIGHT G.E,
AND WINTROBE M.M., 'METAL BINDING IN MEDICINE',
ED,SEVEN M. X JOHNSON L. J . B . LIPPINCOTT CO. I960, 259 
-WALSHE J.M., 'METAL BINDING IN MEDICINE'.
ED,SEVEN M, & JOHNSON L. J . B , L I PPINCOTT CO,
UZMAN L.L,, 'METAL BINDING IN MEDICINE',
ED,SEVEN M. & JOHNSON L. J , B . L I PPINCOTT CO.
5CHEINBERG I.H, AND STERNLIEB I,,
'METAL BINDING IN MEDICINE*.
ED.SEVEN M, & JOHNSON L. J . B . L I PPINCOTT CO =
APOSHIAN H.V., 'METAL BINDING IN MEDICINE'
ED.SEVEN M, S JOHNSON L. J . B . L I PPINCOTT CO,
GEMMILL C.L., 'METAL BINDING IN MEDICINE’,
ED,SEVEN M, & JOHNSON L. J , B , LIPPINCOTT CO.
SCHUBERT J.r 'METAL BINDING IN MEDICINE'.
ED.SEVEN M. & JOHNSON L, 4 • B . L I PP I N.C OTT CO.
D,, 'METAL BINDING-IN MEDICINE’
& JOHNSON L, 4 .3. LIPPINCOTT CO.
'METAL BINDING IN MEDICINE',
& JOHNSON L. J.B. LIPPINCOTT CO.
F., PROC.SYMP, 'DEVELOPMENT OF IRON 
CHELATORS FOR CLINICAL USE' DHEW 76-994 1975, 1
NEILANDS J.B., PROC.SYMP, 'DEVELOPMENT OF IRON
WEINBERG E 
ED,SEVEN M 
FIJRST A,, 
ED,'SEVEN M 
ANDERSON W
1960, 265
1960, 269
1960, 275
1960. 290
1960, 321 
1960, 325 
1960, 329
1960, 336
CHELATORS FOR CLINICAL USE' DH’EW 76-994 1975 , 5
KE LLER-SCH I F.RLE J N » PROC.SYMP, 'DEVELOPMENT OF IRON 
CHELATORS FOR CLINICAL USE' DHEW 76-994 1975, 53
PROPPER R.D., SHURIN S.B. AND NATHAN D.G», ■
PROC.SYMP. 'DEVELOPMENT OF IRON CHELATORS FOR CLINICAL 
USE' DHEW 76-994 1975, 83
NIENHUI3 A.W, AND ANDERSON W.F.,
PROC.SYMP. 'DEVELOPMENT OF IRON CHELATORS FOR CLINICAL 
USE' DHEW 76-994 1975, 115 . ’
PITT C.G, AND GUPTA G,, PROC.SYMP. 'DEVELOPMENT OF 
IRON CHELATORS FOR CLINICAL USE' DHEW 76-994 1975, 137
CRUMBLISS A.L., PALMER R.A., SPRINKLE K.A,
AND WHITCOMB D.R., PROC.SYMP, 'DEVELOPMENT OF IRON 
CHELATORS FOR CLINICAL USE' DHEW 76-994 1975 , 175
211
1733 BYERS B.R., GAINES C.G. ANO SClORTINO C.V.,
PROC.SYMP. 'DEVELOPMENT OF.IRON CHELATORS FOR CLINICAL 
USE’ DHEW 76-994 1 975, 213 '
1734 GRALLA E.J., PROC.SYMP. 'DEVELOPMENT OF IRON CHELATORS
FOR CLINICAL USE' DREW 76-994 1975, 229
1735 CERAMI A., GRAZIANO J.H., GRADY R.W.
AND PETERSON C.M,, PROC.SYMP. 'DEVELOPMENT OF IRON 
CHELATORS FOR CLINICAL USE' DHEW 76-994 1975, 261
1736 CHARLTON R.W. AND BOTHWELL T.H.,
'BIRTH DEFECTS; ORIGINAL ARTICLE SER',
VOL XII IRON MET, & THALASSEMIA, 1976, 63
* 1737 AISEN P., 'BIRTH DEFECTS; ORIGINAL ARTICLE SER'» •
VOL XII IRON MET, & THALASSEMIA, 1976, 81
1738 GRAZIANO JaH., 'BIRTH DEFECTS; ORIGINAL ARTICLE SER', 
VOL XII- IRON MET, & THALASSEMIA, 1976, 135
1739 GRADY R.W,, 'BIRTH DEFECTS; ORIGINAL ARTICLE SER',
VOL XII IRON MET, & THALASSEMIA, 1976, 161
* 1740 SORENSON J.R.J*, -
. PROGRESS IN MEDICINAL CHEM. 1978, 15, 211
1741 PAULING I,, PROC NAT ACAD SCI U.S.A- 19.76, 73, 4290
* 1742 SCHUBERT J, AND DERR S.K., NATURE 1978, 275, 311
1743 PRQPPER R.D. AND ET, AL.,
NEW ENGLAND J. MEDICINE 1977, 297, 418 '
1744 WHITE G.P., JACOBS A., GRADY R.W, ANO CERAMI A,,
BLOOD 1976, 48, 923
* 1745 SOVAGQ I,, KISS T, AND GERGELY A., -
J. CHEM SOC, DALTON 1978, 964
* 1746 FREEMAN J.B., STEGINK L.D., MEYER P. D. , FRY L.K.
AND DENBESTEN I., J. SURGICAL RES, 1975, 18, 463
1747 WHITE G.P,- AND JACOBS A,, • .
BIOCHIM BIOPHYS ACTA 1978, 543, 217
1 748 BAES C.F, AND MESMER R.E., 'THE. HYDROLYSIS OF CATIONS' 
JOHN WILEY 8 SONS NJ, 1976, ‘9 . .
1749 BAES C,F. AND MESMER R. E,, 'THE HYDROLYSIS OF CATIONS’ 
JOHN WILEY & SONS N.Y, 1976, 49
1750 NELSON H.C. AND WATT G.W.,
J, INORG NUCL CHEM, 1979, 41, 99
1751 MITCHELL W.G. AND JONES M,M„, •
J, INORG NUCL CHEM, 1978, 40, 1957 ‘
1752 GOSALVEZ M,, BLANCO M.F., VIVERO C, AND VALLES F,,
EUROPEAN J. CANCER . 1978, 14, 1185 ■
* 1 753 ORAMA M., AHTOIA R, AND. KUUKKA P,,
FINN CHEM LETTERS 1976, 161
* 1754 JANJIC T.J., PFENDT L.B. AND POPOV V., .
J, INORG NUCL CHEM. 1979, 41, 63
* 1755 DREISBACH R.H., 'HANDBOOK OF POISONING' 7TH
ED, LANGE MEDICAL PUBLICATIONS 1971, 192
* 1756 CLARKSON T.W. AND DI STEFANO V., .
'DRILLS PHARMACOLOGY IN MEDICINE’ 4T^ ED.
ED. DIPALMA J.R, MCGRAW-HILL 1971, 1101
* 1757 HODGE H.C,, LEACH L.J., SMITH F,A», STRAIN W.H,
AND TAVES D, R. , 'DRILLS PHARMACOLOGY IN MEDICINE’ 4TH 
. ED. ED, DIPALMA J , R . MC GR AW-III L L 1971, 1120
.212
1758
1759
* 1760
1761
1762
* 1763
1764
1765
1766
1767
1768
* 1769
* 1770
* 1771
1772
1773
1774
* 1775
1776
1777
1778
* 1779
* 1780
* 1781
* 1782
* 1783
* 1784
* 1785
1786
1787
1788
1789
* 1790
* 1791
ALCOCK R.M., HARTLEY 
J, CHEM SOC. DALTON 
ROSSOTTI F„J
1972, 49, 313 
1974, 51, 812 
1976, 53, 771 
1978, 55, 99
1978, 55, 631 
1978, 55, 635
CAMMARATA A. AND MARTIN A.N.,
’MEDICINAL CHEMISTRY' 3RD ED,
ED. BURGER A. PART I W I LEY~INTERSCIENCE 1970, 118 
COYNE W.E., ’MEDICINAL CHEMISTRY' 3RD ED.,
ED. BURGER A, PART II W I L C Y - I N T E R S C I E N C E 1970, 953 
DEICHMANN W.B. AND GERARDE H.W., 'TOXICOLOGY OF DRUGS 
AND CHEMICALS' ACADEMIC PRESS N.Y- & LONDON 1972 
HUNT G.R.A., TIPPING L.R.H. AND BELMONT M, R„ ,
BIOPHYS CHCM, 1978, 8, 341
AHRLAND S., ACTA CHEM SCAND. 1951, 5, 199
POULSEN I. AND BJERRLJM J.,
ACTA CHEM SCAND. 1955, 9, 1407
BIEDERMANN G., ACTA CHEM SCAND. 1956, 10, 1340 
G R E N T H E I. AND N 0 R E N B . ,
ACTA CHEM SCAND. i960, 14, 2216 
INGRI N., ACTA CHEM SCAND. 1962, 16, 439 
JOHANSSON l„, ACTA CHEM SCAND, 1970, 24, 1572 
LAURIE S.H., LUND T. AND RAYNOR J.B.,
J. CHEM SOC. DALTON 1975, 1389
F . R . AND ROGERS D.E.,
1978, 115
C. AND ROSSOTTI H.S.,
J. CHEM EDUCATION 1965, 42, 375 
KOZAREK W.J. AND FERNANDO Q.,
J. CHEM EDUCATION 1972, 49, 202 
LEFELHOCZ J.F., J. CHEM EDUCATION 
URENEMAN G.L., J, CHEM EDUCATION 
BRAND M.J.D., J, CHEM EDUCATION 
STAIRS R.A., J. CHEM EDUCATION 
ALEXANDER J.J. AND DORSEY J . G.,
J, CHEM EDUCATION 1978, 55, 207 
OCHIAI E.I., J. CHEM EDUCATION 
ADAMSON A.W., J. CHEM EDUCATION 
DANIELE P.G, AND OSTACOLI G,,
J, INORG NUCL CHEM. 1978, 40, 1273 '
BUFFLE J., PARTHASARATHY N, AND MONNIER D.,
ANAL CHIM ACTA 1972, 59, 427
BUFFLE J., ANAL CHIM ACTA 1972, 59, 439
PARTHASARATHY N., BUFFLE J. AND MONNIER D,,
ANAL CHIM ACTA 1972, 59, 447 
MCCALLUM C, AND MIDGLEY D.,
ANAL CHIM ACTA 1973, 65, 155
IIANSSON I. AND JAGNER D., ANAL CHIM ACTA 1973, 65, 363 
RIORDAN J. AND GOWER I.,
BIOCHIM BIOPHYS ACTA 1975, 411, 393 
KOLLER M.E., ROMSLO I. AND FLATMARK T.,
BIOCHIM BIOPHYS ACTA 1976, 449, 480
FARE G AND HOWELL J. S „ , CANCER. RESEARCH 1964, 24, 1280 
CAPPUCCINO J.C., BANKS S., BROWN G., GEORGE M.
AND TARNOWSKI G.S., CANCER RESEARCH 1967, 27, 968 
KAMAMOTO Y „ » MAKIURA S.f SUGIHARA S., HIASA Y„,
ARAI M„ ANO ITO N., CANCER RESEARCH
BUHLER R.H . 0 . AND K A G I J . H , R . ,
F.E.B.S LETTERS 1974, 39, 229 
RUPP H, AND WESER U«, F.E.B.S LETTERS
1973, 33, 1129
1974, 44, 293
... j* J. 4 ■■■ i-•
213
179? MCKEE D,J. AND FRIEDEN E , ♦ BIOCHEMISTRY 1971, 10, 388
179.3 LYK2NS UF.r.AKEY C.W., CHRISTIAN E „ G „ , DUVAL G.E, .
AND TOPHAM R , W „ , BIOCHEMISTRY 1977, 16, 693
1794 ATKINS G . L , , * MULT I COMPARTMENT MODELS IN BIOLOGICAL
SYSTEMS' METHUEN, LONDON 1969
1795 SUNDERMAN F.W., ANN CLIN LAB SCI. 1973, 3, 156
* 1796 LUBRAN MJ4., ANN CLIN 1. A B SCI . 1973, 3, 181
1797 COHN J.R. AND EMMETT E.A,,
ANN CLIN LAB SCI. 1978, 8, 2.70
* 1798 DANIELE P.G,, OSTACOLI G. AND AMICO P.,
TALANTA 1978, 25, 177 .
1799 HARRIS W.E., TALANTA 1978, 25, 325
* 1 800 ARENA G, , RIZZARELLI E. , SAMMARTANO S. AND RIGANO C., ■
TALANTA 1979, 26, 1 
1801* NAGYPAL I., PAKA I AND ZEKANY L.,
TALANTA 1978, 25, 549
1802 OLIN A. AND WALLEN B.f
STRUCTURE AND BONDING 1978, 25, 720
1803 SCHANKER L.S., TOCCO D.J., BRODIE B.B,
AND HOGBEN C.A.M., J. PHARM EXP THER. 1958, 123, 81
1804 IANNACCONE A., BOSCOLO P, AND BOMBARDIERI G-»
LIFE SCIENCES 1976, 19, 427
* 1805 WAXMAN H.S. AND BROWN E,B«,
PROGRESS IN HAEMATOL. 1969, 6, 338
1806 STEFANINI S., CHIANCONE E,, VECCHINI P, Ard ANTONINI E, 
MOLECULAR CELLULAR BJOCHEM. 1976, 13, 55
1807 BECK M.T., PU.RE AND APPLIED CHEM, 1977, 49, 129
* 1803 CREIGHTON A.M., HELLMANN K, AND WHITECROSS S.,
NATURE 1969, 222, 384
* 1809 CREIGHTON A.M., JEFFERY W.A. AND LONG J.,
PROC,INT.SYMP. MED CHEM VI , SUSSEX UNIVERSITY 1978
* 1810 CREIGHTON A.M., PROC • I NT . SYMP. MED CHEM VII 1978
1811 GERMAN D.P. AND ET, AL.,
BRIT J. NUTRITION 1978, 39, 383
1812 SHOKEIR M.H.K., CLIN BIOCHEM. 1972i 5, 115
1813 WEBER P „ M • , O’REILLY S„, POLYCOVE M. AND SHIPLEY [,,,
J, NUCLEAR*MEDICINE 1969, 10, 591
1814 CHARLSON A.J. AND ET. AL.,
J, CLIN HEMATOL ONCOL. 1977, 7, 293
* 1815 DANIELE P.G. AND OSTACOLI G,»
ANN CHIMICA 1976, 66, 537
1816 HENDEL R,C. AND SUNDERMAN F.W.,
RES COMM CHEM PATH PHARMACOL. 1972, 4, 141
1817 NOMOTO S,f DECSY M.I., MURPHY J.R, AND SUNDERMAN F.W., 
BIOCHEM MEDICINE 1973, 8, 171
* 1818 BARBOUR 3.H., BISCHEL M. AND ABRAMS D.E.,
NEPHRON 1971, 8, 455
1819 ROESER H.P., LEE G, R. , NACHT S. AND CARTWRIGHT G.E,,
J, CLIN INVEST. 1970, 49, 2408
* 1820-MICHELONI M,, SABATINI A. AND VACCA A,,
INORG CHIM ACTA 1977, 25, 41 
1821 BROWN D.A., CHIDAMBARAM M,V., CLARKE J.J.
AND MCALEESE D.M., BIOINORG CHEM, 1978, 9, 255
1822 MIKELENS P.'AND LEVINSON W,,
BIOINORG CHEM. 1978, 9, 421
1823 ALBERGONI V., FAVE.RO N, AND ROCCO 6.P.,
BIOINORG CHEM, 1978, 9, 431
1824 ADAMS W.S., LESLIE A. AND LEVIN M.H.,
PROC SOC EXP BIOL MED. 1950, 74, 46
1 825 ANGHILERI L.J., ARZNEIM-FORSCH 1977, 27, 1 177 
1826 NANDEDKAR A.K.N., HONG M.S. AND FRIEDBERG F»,
BIOCHEM MEDICINE 1974, 9, 177 
1 827 LEWIS A,J., AGENTS AND ACTIONS 1978, 8, 244
1828 URRY D.W.r ANN N.Y. ACAD SCI. 1978, 307, 3
1829 WESER U„, RIGHTER C., WENDEL A, AND YOUNES M,, 
BIOINORG CBEM. 1978, 8, 201
1830 WALSHE J.M., LANCET 1956, 1, 25
1831 KLEIN W.J., METZ E.N. AND PRICE A.R.,
ARCH INTERN MED. 1972, 129, 578
1832 SUGIURA Y. AND TANAKA H.,
CHEM PHARM BULL. 1970, 18, 363
1833 EVANS G.W., NUTR REVIEWS 1971, 29, 195
1834 CHANG C.C. AND TATUM M.J,, CONTRACEPTION 1970, 1,
1835 BESWICK P.H. AND ET, AL,,
CHEM BIOL INTERACTIONS 1976, 14, 347
1836 CARTWRIGHT G.E. AND WINTROBE M.M.,
AMER J, CLINICAL NUTRITION 1964, 15, 94
1837 TIPTON I.H., STEWART P.L, AND DICKSON J,,
HEALTH PHYS. 1969, 16, 455
1838 VAN CAMPEN D, AND MITCHELL E.A.,
J. NUTRITION 1965, 86, 120
1839 MARCEAU N., ASPIN M. AND SASS-KQRTSAK A.,
AMER J. PHYSIOLOGY 1970, 218, 377 ’
1840 BURCH R.E., HAHN H.J.K. AND SULLIVAN J.F.,
CLIN. CHEM. 1975 , 21 , 501
1841 MAY P.M. AND WILLIAMS D.R., NATURE 1979, 278, 581
1842 SCHUBERT J. AND DERR S.K., NATURE 1979, 278, 581
1843 AJSEN P„, LEIBMAN A. AND ZWEIER J,,
J. BIOL CHEM. 1978, 253, 1930
1844 MACARA I.G., HOY T.G. AND HARRISON P.M,,
BIOCHEM J. 1972, 126, 151
1845 MACARA I.G., HOY T.G. AND HARRISON P.M.,
BIOCHEM J , 1973, 135,' 785
1846 BALCERZAK S.P., JENSEN W.N. AND POLLACK S, ,
SCAND J, HAEMATOLOGY 1966, 3, 205
1847 HALLBERG L. AND HEDENBERG L.,
SCAND J. HAEMATOLOGY 1967, 4, 11
1848 NIELSEN F.H., ACTA MED SCAND. 1963, 173, 499
1849 FOREMAN 
J. LAB
H. AND TRUJILLO T.T.,
CLIN MED . 1954, 43, 566
1850 MCMAHON F.G . , J . LAB CLIN MED.. 195-6 , 48, 589
1851 AWA I M. AND BROWN E . B., J , LAB CLIN MED. 1969, 73
1852 GREEN BERGER N , J . , BALCERZAK S.P. AND ACKERMAN G.A.,
J. LAB CLIN MED. 1969, 73, 711
1853 BRITTIN G.M . AND CNEE Q.T.,
J . LAB CLIN MED, 1969, -74, 53
215
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
*
*
HERSHKO C., COOK J. AND FINCH C.A.,
J, LA8 CUN MED, 1972, 80, 624
GITLIN D. AND CRUCHAUD A,,
J. CLIN INVEST. 1962, 41, 344
THIRAYOTHIN P. AND CROSBY W.H.,
J, CLIN INVEST. 1962, 41, 1206
MOORE E.W., LINSCHEER W.G. AND KEENE W.R.,
J, CLIN INVEST. 1964, 43, 1282
LEE G.R., MACHT S., LUKENS J.N, AND CARTWRIGHT G.E.,
J. CLIN INVEST. 1968, 47, 2058
COOK J., MARSAGLIA G., ESCHBACH J.W., FUNK D.D,
AND FINCH C.A., J. CLIN INVEST. 1970, 49, 197 
FILLET G.» COOK J. AND FINCH C.A.,
J, CLIN INVEST. 1974, 53, 1527
MUNRO H.N., FED PROC, 1977, 36, 2015
LINDER M.C. AND MUNRO H.N., FED PROC. 1977, 36, 2017
JACOBS A., FED PROC. 1977, 36, 2024
COOK J,, FED PROC. 1977, 36, 2028
KRANTZ S., GOLDWASSER E. AND JACOBSON L.O.,
BLOOD 1959, 14, 654
ASTALDI G., MEARDI G, AND LISINO T.,
BLOOD 1966, 28, 70
PLOEM J.E., DE WAEL J., VERLOOP M.C. AND PUNT K.
BRIT J. HAEMATOLOGY 1966, 12, 396
SMITH J.A., DRYSDALE J.W., GOLDBERG A. AND MUNRO H.N., 
BRIT J. HAEMATOLOGY 1963, 14, 79 
MEYER-BRUMOT H. AND KEBERLE H,,
AMER J. PHYSIOLOGY 1968, 214, 1193
MANSOUR M.M., SCHULERT A.R. AND GLASSER S.R.,
AMER J. PHYSIOLOGY 1972, 222, 1628 
YUNICE A.A. AND ET. AL.,
AMER J. PHYSIOLOGY 1973, 235, -40
MACDERMOTT R.P. AND GREENBERGER N.J.,'
GASTROENTEROLOGY 1969, 57, 117
SOLOMONS N.W. AND ET. AL.,
GASTROENTEROLOGY 1976, 70, 1022
*
*
*
*
*
BRITTIN G.M., HALEY J. AND BRECHER G.,
PROC SOC EXP BIOL MED. 1968, 128, 178
GREENMAN J AND JACOBS A., GUT’ 1975, 16, 613
HALLBOOK T. AND LANNER E., LANCET 1972, 2, 780 
KAY R.G. AND TASMAN-JONES C., LANCET 1975, 2, 605 
ZAHRINGER J., KONIJN A.M., BALIGA B.S. AND MUNRO H.N., 
BIOCHEM BIOPHYS RES COMMON 1975, 65, 583
JACOBSON S. AND WESTER P.O.,
BRIT J. NUTRITION 1977, 37, 107
FREEMAN R.M. AND TAYLOR P.R.,
AMER J. CLINICAL NUTRITION 1977, 30, 523
HOLTZMAN N.A., ELLIOT D.A. AND HELLER R.H.,
NFW ENGLAND J. MEDICINE 1966, 275, 347
FIELDING J., J. CLIN PATHOL. 1965, 18, 88
FALCHUK K.H, AND KRISHAN A.,
CANCER RESEARCH 1977, 37, 2050
HELLMANN K. AND FIELD E.O,
J. NAT CANCER'INST. 1970, 44, 539
216
* 1385 HALSTED J.A., SMITH J.C. AND IRWIN M.I.,
J. NUTRITION 1974, 104, 345
* 1886 FEENSTRA T.P, , J, CHEM EDUCATION 1979, 56, 105
* 1887 SELANDER S , , BRIT J, IND MED, 1967, 24, 272
1888 SWINBURNE K., LOSOWSKY M.S. AND HALL D.A.,
PROC ROY SOC MED. 1963, 818 '
1889 KIMBER C.L., MUKHERJEE T, AND DELLER D.J.,
DIGESTIVE DISEASES 1973, 18, 781
* 1890 ROSE W.C., NUTR ABSTR REVIEWS 1957, 27, 631
* 1891 CHUTTANI H.K., GUPTA P.S., GULATI S. AND GUPTA D.N.,
AMER J. MEDICINE 1965, 39, 849
1892 SHAH K.D. AND WRIGHT U.,‘
ANN RHEUMATIC DISEASES 1968, 27, 151
1 893 SANDSTEAD H,H.,'BURK R.F., BOOTH G.N. AND DARBY W.J„,
• MED CLIN NORTH AMER. 1970, 54, 1509
1394 CAVILL I. AND RICKETTS C.,‘ 'IRON IN BIOCHEMISTRY AND 
MEDICINE’, ED. JACOBS A, AND WORWOQD M. 1974, 613
1895 BERZUINI C., COLLI FRANZONE P., STEFANELLI M.
AND VIGANOTTI C., COMPUT BIOMED.RES. 1 978, 1 1 , 209
1896 VUILIE•J.~C, , ACTA PHYSIOL SCAND SUPP. 1 965 , 253 , 1
1897 VUILLE J.~C., ACTA PHYSIOL SCAND SUPP, 1965, 253, 63
1898 WORKMAN E.F. AND BATES G.W., '
J, TNOR.G B IOC HEM. 1979, 1 0, 41
1399 TAYLOR M.R.H, AND GATENBY P.B.B.,
BRIT J. HAEMATOLOGY 1966, 12, 747
1900 PERRIN D.D.,
’ORGANIC COMPLEXING AGENTS’ I NTERSC I ENCE, N.Y. 1964
* 1901 PEARSON R.G., ’HARD AND SOFT ACIDS AND BASES’ DOWDEN
HUTCHINSON 8 ROSS, PENN, 1972 , 1
190? SCHWARZENBACH G „ , ’COMPLEXOMETRIC TITRATIONS’ WILEY 
INTERSCIENCE, N.Y. 1957 .
1903 ORGEL L.E., •
'THE ORIGINS OF LIFE’ CHAPMAN HALL, LONDON 1973
1904 WILLIAMS J, AND EVANS R.W.,
•PROTEINS OF IRON METABOLISM’,
ED. BROWN E.B. ET.AL GRUNE & STRATTON 1977, 169
1905 GRAHAM G.A. AND BATES G.W.,
'PROTEINS OF IRON METABOLISM’, .
ED, BROWN E.B. ET.AL GRUNE & STRATTON 1977, 273
1906 AISEN P,, LEIBMAN A,, YANG HU H-Y. AND SKOULTCHI A,I., 
’ P R 0 T E I N S 0 F I R 0 N M E T A B Q L I S M ’ ,
ED. BROWN E.B. ET.AL GRUNE % STRATTON 1977, 281
1907 MARTINEZ-MEDELLIN J,, SCHULMAN H.M., DE MIGUEL E,
AND BENAVIDES L., ’PROTEINS OF IRON METABOLISM’,
ED. BROWN E.B, ET.AL GRUNE & STRATTON 1977, 305
1908 FIELDING J. AND SPEYER B.E., •
•PROTEINS OF IRON METABOLISM’,
ED, BROWN E.B. ET.AL GRUNE 8 STRATTON 1977, 311
1909 P0NKA P„, NEUWIRT J,, BOROVA J. AND FUCHS 0., 
•'PROTEINS OF IRON METABOLISM',
ED. BROWN E.B. ET.AL GRUNE 8 STRATTON 1977, 319
1910 BAKER E . , VI CARY F.R. AND HUEHNS E.R.,
'PROTEINS ‘OF IRON METABOLISM',
ED. BROWN E.B. ET.AL GRUNE & STRATTON 1977, 327
217
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
TRUMP B.F. ANO BEREZESKY I,KM
•PROTEINS OF IRON METABOLISM’,
ED. BROWN E.B. ET.AL GRUNE & STRATTON 1977, 359 
CHARLTON R.W, AND ET, At,.,
•PROTEINS OF IRON METABOLISM’,
ED. BROWN E.B. ET.AL GRUNE & STRATTON 1977, 387 
POLLACK S. AND LASKY F.D.,
•PROTEINS OF IRON METABOLISM’,
ED. BROWN E.B. ET.AL GRUNE & STRATTON 1977, 393 
YOSHINO Y., HIRAI Y. AND YORDANOVA E - ,
•PROTEINS OF IRON METABOLISM',
ED. BROWN E.'B. ET.AL GRUNE 8 STRATTON 1977, 397 
HEGENAUER J.C., RIPLEY L. AND SALTMAN P.,
•PROTEINS OF IRON METABOLISM',
ED. BROWN E.B. ET.AL GRUNE & STRATTON 19/7, 403 
HERSHKO C. AND KONIJN A.M.,
•PROTEINS OF IRON METABOLISM’,
ED. BROWN E.B. ET.AL GRUNE & STRATTON 1977, 417 
ZAHRINGER J., BALIGA B.S. AND MUNRO H.N.,
PROC NAT ACAD SCI U.S.A. 1976, 73, 857
HOY T.G., HARRISON P.M., SABIR M, AND MACARA I.G.,
BJOCHEM J. 1974, 137, 67
BECK M.T., 'METAL IONS IN BIOLOGICAL SYSTEMS.' VOL 
VII ED. SIGEL H. 1978, 1
PINKERTON P.H., ANN INTERNAL MEDICINE 1969, 70, 401 
YORDANOVA E«, PERFANOV K. AND SLIVKOVA L*,
FOLIA HAEMATOLIGIA 1970, 94, 350
HUGHES E.R., 'METAL IONS IN BIOLOGICAL SYSTEMS,’ VOL 
VII ED. SIGEL H. 1978, 351
HARRISON P.M., SEMINARS IN HAEMATOL* 1977, 14, 55 
EMERY T., 'METAL IONS IN BIOLOGICAL SYSTEMS.' VOL VII 
ED. SIGEL H. '1978, 77
JOHNSON L.E., MANNING R.P., MCKEE L.C,
AND CHESHIRE J.R., SIMULATION 1973, 20, 91
SHARNEY L., TENDLER D., STEVENSON J.C.
AND WASSERMAN L.R., MED RES ENG. 1971, 10, 4 
BRODANOVA M., BRODAN V., HAJEK M., KUHN E.
AND VALEK I., ACTA UNIV CAROLINAE MED. 1970, 16, 13 
POLYCOVE M-. AND MORTIMER R.,
J, CLIN INVEST. 1961, 40, 753
GROTH T,, SCHNEIDER W,, SANDEWALL E. AND VUllLE J.-C., 
COMPUT PROG BIOMED. 1970, 1, 90 
NOONEY G.C., BIOPHYS J. 1965, 5, 755 
SHARNEY L., WASSERMAN L.R., SCHWARTZ L.
AND TENDLER 0., ANN N,Y» ACAD SCI. 1963, 108, 230 
MONOT C., NAJEAN Y.C., DRESCH C. AND MARTIN J.,
MATH BIOSCI . 1975, 27, 145
GARBY L,, SCHNEIDER W, , SUNOGUIST 0. AND VUllLE J.~C., 
ACTA PHYSIOL SCAND SUPP. 1963, 216, 1 
ELMLINGER P.J., HUFF R.L., TOBIAS C.A.
AND LAWRENCE J.H., ACTA HAEMATOL. 1953, 9, 73 
NAJEAN Y.C., DRESCH C., ARDAILLOU N. AND BERNARD J,, 
AMER J, PHYSIOLOGY 1967, 213, 533 
SHARNEY L., SCHWARTZ I., WASSERMAN L-R., PORT S.
AND LEAVITT 0,, PROC SOC EXP BIOL MED, 1954, 87, 489
218
1937
1938
* 1939
1940
* 1941
* 1942
* 1943
1944
* 194 5
* 1946
* 1947
* 1948
1949
1950
1951
1952
1953
* 1954
1955
* 1956 
1957
* 1958
1959
1960
* 1961
* 1962
* 1963
* 1966
* 1965
* 1966
* 1967 
1968
HUFF R.L. ANO ET. AU, J. CUN INVEST- 1950, 29, 1 041 
HUFF R.L. ANO ET. AU, J, CLIN INVEST, 1 951 , 30, 1 51 2 
GlASSTONE S., ’ELEMENTS OF PHYSICAL CHEMISTRY’ 2ND ED, 
MACMILLAN ANO CO, LONDON I960, 258
JAMESON R,F„, PROC, SUMMER SCHOOL ’BIOENERGETICS ANO 
THERMODYNAMICS’, TABIANO, ITALY 1979
JAMESON R.F., PROC, SUMMER SCHOOL ’BIOENERGETICS AND 
THERMODYNAMICS’, TABIANO, ITALY 1979, 9999 
ROSSOTTI H.S.,
’THE STUDY OF IONIC EQUILIBRIA’ LONGMAN, LONDON 1978, 
BARROW G.M.,
•PHYSICAL CHEMISTRY’ 2ND ED. MCGRAW~HILL, TOKYO 1966 
AMICO P. AND ET, AL., INORG CHIM ACTA 1979, 35, 383 
NASSIFF P.J. AND BOYKO E.R.,
J, CHEM EDUCATION 1978, 55, 377
BOAS A.H., CHEM ENG. 1963, 70, Feb 4, 105
BATES R.G,, ’DETERMINATION OF PH’ 2ND ED,
JOHN WILEY & SONS, NEW YORK 1973
MACKIE.R.M,, SHEPARD T.M.', AND .VINCENT C.A.
’MATHEMATICAL METHODS FOR CHEMISTS’ ENGLISH
PRESS, LONDON 1972, 102 
PROC SUMMER SCHOOL 'STABILITY 
ITALY 1974, 11 *
,, PROC SUMMER SCHOOL ’STABILITY
BIVIGLIANO, ITALY 1974, 31 
PROC SUMMER SCHOOL 'STABILITY CONSTANTS’ 
ITALY 1974, 39
V,, PROC SUMMER SCHOOL ’STABILITY
BIVIGLIANO, ITALY 1974, 53 
-, PROC SUMMER SCHOOL ’STABILITY
BIVIGLIANO, ITALY 1974, 97
STABILITY CONSTANTS',
UNIVERSITIES 
ANDEREGG G„, 
BIVIGLIANO, 
BIEDERMANN G 
CONSTANTS’. 
AllRLAND 5., 
BIVIGLIANO, 
TYRRELL H.J. 
CONSTANTS’. 
BIEDERMANN G 
CONSTANTS’. 
VACCA A,, 
BIVIGLIANO
CONSTANTS
’STABILITY
151
D.A. .BULMAN R.A., 
NATURE 1979, 
MCCORD J.M., 
ELMES M.E., 
WALKER J.R., W
PROC SUMMER SCHOOL 
ITALY 1974, 105
SCHWARZENBACH G., PROC SUMMER SCHOOL 
CONSTANTS’. BIVIGLIANO, ITALY 1974,
SCHUBERT J., NATURE 1979, 281, 406 
CRAWLEY F.E.H. AND GEDEN
281, 406 ' .
SCIENCE 1974, 185, 529 
LANCET 1974, 1329 
SMITH M.J.II., ford-hutchinson A-
AND BILLIMORIA F.J., NATURE 1974, 254, 444 
LYLE W.H., 'DISTAM1NE, D-PENICILLAMlNE,
A REVIEW’ DISTA PRODUCTS, LIVERPOOL 1973 
DEUTSCH H.F. AND MORTON J.I., SCIENCE 1957, 
SCHMIDT F.R. AND TESAR J.T.,
J, CHRONIC DISEASES 1972, 25, 433 
JAFFE I,A., J, LAB CLIN MED. 1962, 60, 409 
JAFFE I,A., ANN RHEUMATIC DISEASES 1963, 22 
JAFFE I.A., ARTHRITIS AND RHEUMATISM 1 962 , 
JAFFE I,A., ANN INTERNAL MEDICINE 1964, 61 , 
PROHASKA E-, SCHWAGERL W. AND JESSERER II., 
KLIN WOCHENSCHRIFT 1965, 43, 141
125, 600
71
, 122 
556
1
219
* 1969 LEWIS R„A. ET Ab, J. LAB CLIN MID. 1976, 83, 375 ’
* 1970 GONCHARIK I.I. AND GONCHARIK I.. A, ,
BIOKHIMIYA 1973, .1 , 1 16
* 1971 BAJPAYEE D.P., ANN RHEUMATIC DISEASES 1975, 34, 162 
1972 SCUDDER P. AND ET, AL.,
ANN RHEUMATIC DISEASES 1978, 37, 67
* 1973 JAYSON M.I.V., DAVIS P., WHICKER J.T. AND WALTERS G,,
ANN RHEUMATIC DISEASES 1976, 35, 443
* 1974 JAMESON R.F. AND WILSON M.F.,
J, CHEM SOC, DALTON 1972, 2607
* 1975 WILLIAMS R.J.P,, CHEM BRITAIN 1979, 0
* 1976 JEEJEEBHOY K'.N., GASTROENTEROLOGY 1973 , 65 , 81 1
* 1977 ULMER D.D., NEW ENGLAND J. MEDICINE 1977, 297, 318
* 1978 TUCKER S.B., SCHROETER A.L.’ANO BROWN P.W.,
J, AMER MED ASSOC, 1976, 235, 2399
* 1979 VILTER R.W., BROZIAN R.C. AND HESS E.V., •
NEW ENGLAND J, MEDICINE 1975, 291, 188 
1980 LONNERDAL B,, STANISLOWSKJ A.G. AND HURLEY L.S.,
J. INORG BIOCHEM. 1980, 12, 71
* 1931 WOLMAN S.L., ANDERSON G.H., MARLISS E„B.
AND JEEJEEBHOY K.N,, GASTROENTEROLOGY 1979, 76, 458
* 1982 HENKIN R.I., KEISER H.R. AND BRONZERT D.A.,
J. CLIN INVEST, 1972, 51, 44 • .
* 1983 FELL G.S. ET AL,, LANCET 1973, 11, 280
* 1934 JOCELYN P.C.,. ’THE BIOCHEMISTRY OF THE $H GROUP’,
ACADEMIC PRESS, LONDON 1972
* 1985 JOCELYN P.C., EUROPEAN J. BIOCHEM, 1967, 2, 327 
1936 YOUNG T,F» AND JONES A.C,,
ANN REV PHYSICAL CHEM, 1952, 3, 275
* 1987 WILLIAMS R., ’RHEUMATOID ARTHRITIS AS A SYSTEMIC
DISEASE' ED, SMITH L.H. W , B.SAUNDER 1974
* 1988 HOLLANDER J.L., ’ARTHRITIS AND ALLIED CONDITIONS’, 8TH
ED., ED, HOLLANDER J.L. LEA&FEBI 1972, 3
* 1989 WOOD P.H.N., ’COPEMANS TEXTBOOK OF THE RHEUMATOID
DISEASES’, 5TH ED., ED. SCOTT J,T, 1978, 14
* 1990 BUCHOLZ C.F., REP PHARM. 1816, 2, 253
* 1991 HART E.B., STEENBOCK H., WADDELL J, AND ELVEHJEM C.A.,
J. BIOL CHEM, 1928, 77, 797
* 1992 DAVIES I.J.T., 'THE CLINICAL SIGNIFICANCE OF THE
ESSENTIAL BIOLOGICAL METALS' HEINEMANN 1972
* 1993 UNDERWOOD E.J., ’TRACE ELEMENTS IN HUMAN AND ANIMAL
NUTRITION', 3RD ED., ACADEMIC, N.Y. 1971 
1994 OSTERBERG R., BRANEGARD B. AND LIGAARDEN P,,
BIOINORG CHEM. 1975, 5, 149
* 1995 GUBLER C.J., LAHEY M.E,, CARTWRIGHT G.E,
AND WINTROBE M.M., AMER J. PHYSIOLOGY 1952, 171, 652
* 1996 HEILMEYER L. AND STUWE G.,
• KLIN WOCHENSCHRIFT 1938, 17, 925
1997 METZLER D.E,, 'BIOCHEMISTRY, THE CHEMICAL REACTIONS OF
LIVING CELLS’, ACADEMIC PRESS, 1977 •
1998 JACOBS A. AND NORWOOD M», 'METALS AND THE LIVER’,
ED, POWELL L.W. MARCEL DEKKER, N.Y. 1973, 3
220
1999 HALLIDAY J.W. AND POWELL L.W., 'METALS AND THE LIVER’ 
ED, POWELL L.W. MARCEL DEKKER, N.Y. 1978, 53
2000 MAY P.M. ANO WILLIAMS D.R., ’IRON IN BIOCHEMISTRY AND 
MEDICINE’ VOL II ED. JACOBS A. & WORWOQD M. 1980
* 2001 BRENDSTRUP P., ACTA MED SCAND, 1953, 146, 384 .
* 2002 CARTWRIGHT G.E, AND WINTROBE M.M.,
J. CLIN INVEST, 1949, 28, 86 .
* 2003 SORENSON J.R.J., INORG PERSPEC BIOL MED, 1978, 2, 1
* .2004 SORENSON J.R.J., 'ASPIRIN AND RELATED DRUGS’
ED. BRUNE K- & WHITEHOUSE M. BIRKHAUSER VER 1980, 83
* 2005 KOSKELO P. , KEKK1 M., VIRKKUNEN M., LASSUS A.
AND SOMER R. , ACTA RHEUM SCAND . 1966, 12 , 261
* 2006 BRENDSTRUP P.r ACTA MED SCAND. 1953, 145 , 315
•ft 2007 DEN KO C,W. AND WHITEHOUSE M.W.,
J. RHEUMATOL, 1976, 3, 54
* 2008 LOEWI G„, PROGRESS IN IMMUNOL. 1974, 5, 293
* 2009 WINTROBE M M• 1 ’ W 9 CARTWRIGHT G.E. AND GUBLER C » J » ,
J. NUTRITION 1953, 50, 395
* 2010 MARKOWITZ H», GUBLER C.J. AND MAHONEY J.P,,
J. CLIN INVEST. 1955, 34, 1498
* 2011 FENZ E., MUNCH MED WOCHENSCHR. 1941 , 18, 398
* 2012 RAINSFORD K.D, AND WHITEHOUSE M.W.,
EXPERIENTIA 1976, 32, 1172 ' •
* 2013 MILANINO R., MAZZOLI S., PASSARELLA E., TARTER G.
AND VELO G.P.-, AGENTS AND ACTIONS 1978, 8, 618
* 2014 LEE R. AND LANDS W.E.M.,
BIOCHIM BIOPHYS ACTA 1972, 260, 203 •
* 2015 BONTA I.L.,
ACTA PHYSIOL PHARMACOL NEDERLAND 1969, 15, 138
* 2016 HANGARTER W. AND LUBKE A,,
DEUTSCH MED WOCHENSCHR. 1952, 77, 870- .
* 2017 WALKER W.R. AND REEVES R.R., ’
'ASPIRIN AND RELATED DRUGS’ •
ED. BRUNE K. & WHITEHOUSE M, BIRKHAUSER VER 1977, 109 
2018 TAVILL A.S, AND MORTON A.G,, 'METALS AND THE LIVER’,
ED. POWELL L.W, MARCEL DEKKER, N.Y, 1978, 93
* 2019 MUNTHE E., JELLUM E. AND AASETH J.,
PROC CONF. ’FUNDAMENTAL STUDIES ON PENICILLAMINE FOR 
RHEUMATOID- DISEASES 1.979, 6
* 2020 OSTERBERG R,, LIGAARDEN P, AND PERSSON 0.,
J. INORG BIOCHEM. 1979, 10, 341
* 2021 LAURIE S.H. AND PRIME D.M.,
J. INORG BIOCHEM. 1979, 11, 229
* 2022 PLANAS-BOHNE F.,
TOXICOLOGY APPL PHARMACOL. 1979, 50, 337
* 2023 GERBER D.A. AND GERBER M.G.,
J. CHRONIC DISEASES 1977, 30, 115 
2024 GERBER D.A., J. CLIN INVEST. 1975, 55, 1164
* 2025 PICKUP M.E., DIXON J.S., LOWE J.R, AND WRIGIIT V.,
CANADIAN J, RHEUMATOL. 1980, 0
* 2026 MCCLUSKEY R.T., MILLER F. AND BENACF.RRAF B.,
J, EXPERIMENTAL MEDICINE 1962, 115, 253
* 2027 KARLSON B. AND NOREN L,,
ACTA PAEDIAT SCAND. 1965, 54, 331
221
* 2028
* 2029
* 2030
* 2031
* 2032
OSTERBERG R,, SJOBERG B. AND BRANEGARD Be,
•A CRITICAL REVIEW OF COPPER IN MEDICINE*, INCRA234,
I NT.COPPER RES ASSO 197 5
BUSH J,A. AND ET. AL., 4. CLIN INVEST. 1955, 34, 1766 
TIPTON I.H., STEWART P.L. AND MARTIN P.G.,
HEALTH PHYS. 1966, 12, 1683
WALKER W.R. AND GRIFFIN B.J., SEARCH 1976# 7, 100 
MAKAR G.K.R. AND WILLIAMS D,R.,
J. INORG NUCL CHEM, 1977, 39, 201
APPENDIX A1
Instructions and FORTRAN listing of 
the computer program INDEX
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i,,
• v .<
• 7
DATA PREPARATION FOR PROCESSING LITERATURE REFERENCES 
BY COMPUTER USING PROGRAM INDEX ., ,
This document describes how the input data for program ;
INDEX in the Bio-inorganic Chemistry computer library 
held by the South West Universities Computer Network should 
be punched onto data cards. It refers only to the way in 
which the data should be coded. A separate document entitled 
"The LITREF Macro" gives details of the Job Control commands 
required to call and execute the programs.
*.>***» . ' »*- .
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Int roduct ion
Program INDEX is used to produce lists of literature
references sorted according to one of the following:
(i) the order in which they were entered, (ii) journal 
name, (iii) author name, (iv) keyword, (v) date,
(vi) Chemical Abstract number, and (vii) a list of reference 
numbers provided by the user. . .
The input consists of alphanumeric strings which specify 
each author, journal, book and keyword in coded form. The 
year, journal volume and initial page number of each reference 
are also entered. In addition, there is the option to include 
the Chemical Abstract number of the reference and a user- 
designated alphanumeric string which can be used to indicate 
whether a photocopy has been procured and if so where it is 
filed. ’
Each author, journal, book title and keyword is assigned 
a sequence number. Except for the list of authors, these 
are common to all users and must be taken from current lists 
available from P.M.M. If a reference is not covered in this 
respect by the existing journal, book or keyword lists, these 
can be updated to include new entries by P.M.M. upon request.
The data for the LITREF Macro is divided into two sections.' 
Details of each are provided below. They are separated in 
the input data file by one blank card. Both the author and 
the reference entries may be made in any order so that a 
literature database may be built up sequentially. However,' 
the sequence numbers given by the user to both the authors and 
the references must be complete and in order.
Stage 1: The list of authors • • ' •
This stage of the input data begins with a card reading 
'AUTHOR LIST', beginning in column 1. This is immediately 
followed by a set of cards containing the sequence number ■ 
and name of each author. .
The first four columns on each card hold ‘the sequence number 
as a left-justified integer. The next column is left blank. . 
Columns 6-26 hold the author name as a right-justified 
alphanumeric string in which the surname appears first and the 
initials follow after a single space. Initials should each be 
separated by a full stop without the spacing. .
For example: ; .
AUTHOR LIST -
0001 DICKENS C.
0002 DARWIN C. ' 
0003 SHAKESPEARE W. 
0004 POE E.A.
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Stage 2: The list of references
This stage of the input data begins with a card reading 
'REFERENCES', beginning in column 1. This is immediately 
followed by the list of references. Each comprises at 
least four cards.
1. The first card contains the following information:
(a) The sequence number of the reference
(b) The Chemical Abstract number (optional)- - .
(c) The journal number . ..
(d) The year ' ' “ .
(e) The volume number of .the journal .
(f) The page number of the reference ■’
(g) The users identifying initials and a two-lettered 
filing code (the latter is optional)
(h) The sequence numbers for up to 7 authors
(i) An alphanumeric string that is to appear next to the 
page number (optional)
FORMAT (14, 19, 415, IX, A4, 715, 3X, A4) ’
Note that except for the Chemical Abstract number each item . 
consists of 4 digits or characters. Thus the above format 
is such that all except the last are separated from one . 
another by a blank space. •
2. The second card contains a string of up to 20 keyword 
numbers. There must be at least one per reference. As 
these are of three digits each, the format is such that again 
each is separated from the previous one by a blank space. 
However, the first column must be left blank.
FORMAT (2014) •' ■' :n .•’> : .
3. The third and subsequent cards carry the title of the 
article. Up to six lines are permitted. All must be
left-justified. , , '
FORMAT (20A4) “ ’ ' ‘ ' • ' . " '' '
One blank card to delimit the reference from the next one. 
For example, the reference data could begin as follows.
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REFERENCES . • . .
0001 72345670 0078 1975 0001 1234 PMXX 0001 . . •
023 009 114 099 • . • .
THE MISERLY SIDE OF MR.MlCAWBER
0002 0001 1956 0101 0001 PMZZ 0003 0004
105
AN INTERESTING STUDY BY TWO AUTHORS WHO WERE NOT EVEN 
CONTEMPORARIES . ..... .
0003 890000123 0111 1922 0122 0066 PMYY 0004 0002 
• 002 .
THE ORIGIN OF THE CROW SPECIES . •
The following idiosyncrasies may be useful to the advanced user.
1. Books are referenced by indicating a journal number of 0001. 
On such occasions the sequence number of the book is entered
in place of the journal’s volume number. For example,
reference 0002 above refers to a book u/hose title has the 
sequence number 0101. . •
2. If the year is coded as 9999 then-this figure is omitted 
whenever the reference is printed out.
3. If the page number of a book is coded as 0000, the title
card of the reference is not printed. Nevertheless, a dummy 
title must be supplied on input. By convention this is the 
single word ’BOOK*. ■ • .
4. The final four character alphanumeric string on the first
card of each reference is conventionally reserved for those 
journals which designate pages by a combination of letters and 
digits. The former can be appended to the page number by 
entering the appropriate letters in columns 77-80. ,
5. The two elements of a Chemical Abstract number should be
separated by as many zeros as are required to fill the.entire 
field of nine columns. Hence, 89:123 becomes 890000123 and 
72:345678 becomes 72345678. The parity letter used by :
Chemical Abstracts is omitted. '
6. Several options are available when the user specifies a 
list of numbers for those references that are required to be 
printed. Ordinarily, a list is produced in the order given 
but numbered sequentially from one onwards. A negative number 
entered as a dummy for the first reference will cause the 
list to be printed with the user’s reference number and filing 
code rather than the sequential numbers -described above. By . 
specifying -999 as the dummy first reference, the list of 
numbers is treated as though it had been sorted .according to 
the first named author of each reference. These facilities . 
are useful when preparing publications for journals with 
different requirements concerning the format of references.
FLOW DIAGRAM FOR PROGRAM INDEX
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Stop
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C PROGRAM INDEX.
r* nw «.<• »»* mm mn *•* n. »* »** ***• w* “W
o 
o 
<-
» <
-j 
. 
on
 
<-
>o
THIS PROGRAM SETS UP AND OPERATES A LITERATURE 
. INDEX AND CATALOGUE
IT WAS DEVELOPED AT THE UNIVERSITY OF CAPE TOWN 
DURING 1975
AND REWRITTEN AT THE UNIVERSITY OF ST. ANDREWS IN 
1976,
IT WAS MODIFIED AT UWIST BETWEEN 1978 AND 1980,
LAST ALTERED ON 8/2/1980,
THE PROGRAM IS WRITTEN IN FORTRAN IV
IMPLICIT INTEGER(A-Z) *
DIMENSION REF (12,2000) , REFA(2,5000), REFK(2,7000> 
DIMENSION KEY(12,350), J URNAL(1 2,400),
BOOK(20,150), CM(2000>, . •
1 FCC2000), AUTHOR(7,2500), RC2500), S(2500),
T(2500) ’
DIMENSION MUMBERC20), LITC11), LINE18C18),
. LISTIT(SOO)
DIMENSION TIE1C2), TIE2(2), REFSRT(2000)
LOGICAL LABS, LKEY, NEW
COMMON /ONE/ NUNES, MLINES, LABS, LKEY 
COMMON /TWO/ IN, OUT, FSEQ, FDEF
COMMON /THREE/ LINE20(20), NUHBER(20>, PAGEOO), 
NEW
EQUIVALENCE
EQUIVALENCE
EQUIVALENCE
EQUIVALENCE
(REF(1,1), AUTHOR(1,1)), (REFK(1,1), 
R(1)>
(R(2500), TIE1(D), (S(2500), TIE2(1>) 
(S(1 ) , TIE1(2)), (T(1), TIE2(2))
(REF(1 ,MR + 1 ) , FC(D), (FC(MR + 1), CM(1>)
DATA NUMBER/’1 23456789
10 11 12 13-1
14 1 5 16 17 18 19 20'/
DATA LIT/' JOURBOOKKEYWAUTHET. AL,
CREACHROSELEREFE’/
1 000 FORMAT(11,2X,A4»7X<A4)
1001 FORNAT(20A4)
1101 FORMAT (14 , I 9,4 I 5,1 715,3 11 ,A4)
1121 FORMAT(2014)
3121 FORM AT ( / / / ' 0 ' ,ON L Y SIX TITLE LINES ARE 
PERMITTED.’,/'O',
1 ’ERROR ON CARD NUMBER ' , I 5, / / / / )
2211 FORMAT(214,10A4) -
2401 FURMATO1I4,2A4,18)
228
3140 FORMAT(//’0 *,*MIS$I NG REFERENCE NUMBER',16,//)
3275 FORMAT(’0’,10X,A4,5X,20l5) .
3285 FORMATC ’,1OX,4(I8,' » ' , I 4,1 0 X) )
3649 FORMATCO',T30,20 (111*) CSX, » INCORRECT KEYWORD NO. IN
REF’ ,15f/)
3650 FORMATC 1 ’ C INDEX SYSTEM CREATED.’,/’
’,20C1H*),///’O’,T2 5, ’NUMBER .
1 OF DATA CARDS =',15,/’ T25NUMBER OF REFERENCES
, I 5 </’ ’, ■
2 T25,'NUMBER OF AUTHORS =',I5,/’ T25,’NUMBER OF
KEYWORDS = ’,
3 I 5 , / ’ ',T25, ’NUMBER OF JOURNALS ~,I 4,/’
' ,T25, 'NUMBER OT BOOKS ~
4’,14,/’ T25,’NUMBER OF AUTHOR ENTRIES ~ , I 5,/'
*,T25, .
5'NUMOER OF KEYWORD ENTRIES ~’,I5,/’ ’,T25,
6’NUMBER OF TITLE LINES =’,15,/' ',T25,
7'SELECTOR CODE = ’ ,I 5,//////) '
3810 FORMATC'O’, ’ERROR TERMINATION',/' ',’CODE ' ,I 6,/'
','CARD’,16) . . •
3811 FORMATC'O','NJ =',I5,3X,’NB = ',15,3X,’NK
= ’, I5,3X, 'NR =',16,////)
3961 FORMATC‘1’,///'05X,’KEY TO THE REFERENCE
• NUMBERS',///'O',5X,
1 2( 'REFERENCE' ,4X, 'CATALOGUE',15X),/////)
3965 FORMATC ' , 5X , 2 (16,7X , I 6,1 SX ) )
3966 FORMATC//'0','ERRGR(S) IN REFERENCE LIST’,/)
3999 FORMATC* SUCCESSFUL TERMINATION.’,///)
9999 FORMATC’1’) '
n 
n 
nr
, n
INITIALISATION,
MR = 2000 
MA a 2500 
MJ = 400 
MK = 350 
-MB a 150 
MRA = 5000 
MRK a 7000
OUT = 6
FSEQ a 2
FTEMP a 3
FDEF « 4
NCARD a 5
IN = .NCARD
MLINES a 1000000
NJ a 0
NB = 0
NK « 0
NR ~ 0
NERR a 0
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C
c
DO 50 1=1,20
50 NUMBER (I) = MUMSER(I) 
M « L X T < 1 ?
DO 51 J=1,MK 
DO 51 1=1,12
51 KEY(I,J) « M 
DO 52 J=1,MJ 
DO 52 1=1,12
52 JURNAl(I,J) = M 
DO 53 J=1,M8
DO 53 1=1,20
53 BOOK(I,J? = 1-1 .
DO 54 J=1, MA
DO 54 1”1,F
54 AUTHOR(1,0) = M
o 
o 
o r> 
—
i 
<n
 (~
i
REAIXNCARD, 1000) J, I, K 
WRITE(OUT,10073) J , I , K ‘
8 FORMAT ( *0’ , I 5,5X,A4,5X,A4)
NN = 1
IF(J.NE.O) IN « J
INFO - NCAT=6;CREATE ONLY? NCAT=7;CREATE & LIST 
NCAT .= 0 •
IF(I.EQ.LIT(8)) NCAT = 7
1 F(I • EU„LIT(8)) I = K
I F ( I „EQ„LIT<9 ) ) NCAT = NCAT + 1
1F(I,EQ.LIT(2)) NCAT = NCAT + 2
I F(I«EQ,LIT(5 ) ) NCAT = NCAT + 3
IF(I,EQ«LIT(4)) NCAT ~ NCAT + 4
IFU.EQ.LITdO)) NCAT = NCAT + 5
I F (I . EQ. LIT (1 ) . AND. K. EQ. LITC1 ) ) NCAT = 6 
I F(NCAT.EQwO) STOP 1000 
I F ( hl C AT • LT « 6) GO TO 600 •
CREATE THE INDEX
CODE 1
WRITE(OUT,9999)
IR = 6
NN = 2 ; '
READ(I N,1001) IXA
1F(IXA.NE,LIT(2)) GO TO 801
CAUL NULISTCJ URNAL,MJ,12,NJ,NN,IN,OUT,L I N E 2 0 , R , S , T) 
I F<NJ .LE„O> GO TO 801
CALL LI ST(J URNAL,12,NJ,OUT) • •
WRITE(OUT,9999) ’
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CODE 2
C
READ <IN,1001) IXA 
NN " NN + 1
IF(IXA•NE.LIT(3 ) ) GO TO 802
CALL HU LI ST(BOOK,MB,20,NB,NN,IN,OUT,L I N E 2 0 , R , S , T ) 
IF(NB.LE.O) GO TO 802 
CALL LI$T(BOOK,20,NB,OUT)
WRITE(OUT,9999)
C
c
CODE 3
C • * ’
READ(IN,1001) IXA 
NN ~ NN + 1
I F( IXA.NE.LIT(4)) GO TO 803
CALL N U LIS T(K E Y,M K,12,N K,N N, I N , 0 U T,LIN E 2 0,R,S,T) 
IF(NK.LE.O) GO TO 803 
CALL LI ST(KEY,12,NK,OUT)
WRITE(OUT,9999)
C
C . .
CODE 4
C
READ(IN,1001) IXA 
NN = NN + 1
I F (I X A • N E « L I T ( 5 ) ) GO TO 804
CALL NULIST(AUTHOR,MA,7,NA,NN, I N , OUT,LI ME20,R,S,T) 
IF(NA.LE.O) GQ TO 804 
CALL LI ST(AUTHOR,7,NA,OUT)
WR I Tfc(OUT,9999)
C
C
CODE 5
C
READ(IN,1OO1) ‘ IXA 
NN = NN + 1
IF(IXA,NE,LIT(11)) GO TO 805 
NET » 1
DO 126 NR=1,MR
READ (IN, 11 01 ,ERR=805,END-130) LINE18 
NN = NN + 1
I E(LINE18(1).EQ,0) GO TO 130 
I F(LIN£18(1)„NE„NR) GO.TO 140 
WRITE(FTEMP,11O1 ) HNE18 
J = LINE18(3)
I F( J .GT.NJ-OR. J . LE„O). GO TO 805
R(NR) « (LINL18(4) * 10000) + JURNAL(1,J)
S(NR) = (LINE18C5) * 10000) + LINE18(6)
T(NR) - NR
L = 1
IA « LINE18(8)
I F(I A • GT„NA.OR„IA.LE„0) GO TO 805 •
1 ~ AUTHOR(2,I A) + 2
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D0 1 01 M = 3 t I
L I NE20 < L) - AUTHORCM,IA)
101 U « L + 1 . .
LINE20CL) ~ LITC1)
I. L + 1
I F ( LI N E1 S (1 6) -NE»0»OR•UNE13(17) .NE.O) GO TO 110 
N = L
DO 103 J=9,14 
IA = UNE18U)
IF(IA.EO.O) GO TO 115
1 F (IA■GT.NA.OR•IA•LE.0) GO TO 805
I = AUTHOR(2,I A) * 2
DO 102 M=3,I
IF(N.GT.2O) GO TO 110
LINE20CN) =? AUTHORCM,IA)
102 N = N + 1 
IFCN.GT.20) GO TO 103 
LINE20CN) = LITC1)
N = N + 1 ■
103 CONTINUE 
GO TO 115
110 LINE20CL) » LITC6)
L = 0 + 1
LINE20CL) ~ LIT(7)
N = L + 1
115 IFCN.GT.20) GO TO 120 
DO 116 M=N,20
116 UNE20CM) ~ LIT(1)
r>
 <-
) <~
>
120 I - NRT.
WRITE(FDEF,REC=NRT) UNE20 
NRT « NRT * 1 
NN = NN + 1
READ(IN,1121,ERR-805) LINE20 
WR I TE(FTEMP,1121) LINE20 
DO 121 1=1,6
NN = NN + I
READ(IN,1001,END=125) LINE20 
IF(LINE20(1).EQ.LIT(1)> GO TO 125 
WRITE(FDEF,REC=NRT) LINE20
121 NRT = NRT + 1 
WRITE(OUT,3121) NN 
GO TO 815
125 WRITE(FTEMP,1121) I, I,
CM(NR) = LINE18C2)
126 FC(NR) = LINE1S(7)
STOP 1126
130 NR = NR - 1 
NRT = NRT + 1 
ENDFILE FTEMP 
GO TO 200
C
C
232
c
140 WRITE(OUT,3140) NR 
WRITE(OUT,3810)
STOP 1140
oo
o 
oo
oo
o 
o 
o 
<-
> 
oo
no
oo
URGIN' THE PERMANENT SEQUENTIAL FILE.
STORE AUTHOR, JOURNAL, BOOK AND KEYWORD LISTS,
200 WR1TE(FSEO,1121) NA, NJ, NB, NK
DO 202 PQS-1,NA .
DO 201 J=1,NA
I F(AUTHOR(1,J).EQ,P9S) GO TO 202
201 CONTINUE 
STOP 1201
202 WRITECFSEQ,2211) J, (AUTHOR (I,J), 1=2,7)
I F(NCAT.GT„7) GO 
DO 211 J = 1 , N J
211 WRITE(FSEQ,2211 ) 
DO 213 J=1,NB 
WRITE(FSEQ,1121)
213 WRITE(FSEQ,1001 ) 
DO 216 J“1,N K
216 WRITE(FSEQ,2211 )
TO 250
(J URNAL(I,J), 1=1,12)
BOOK(1,J), B00K(2,J) 
(BOQK(I,J), 1=3,20)
(KEY(I,J>, 1=1,12)
SORT THE REFERENCES AND STORE THE RESULT IN REFSRT.
250 CALL ORDER(R,S,T,NR) 
DO 251 J=1,NR
251 REFSRT(J) = T(J)
OUTPUT FILING CODE AND CHEMICAL ABSTRACT NUMBER 
LISTS,
C . •
C 1 ’ .
DO 271 IR = 1,NR 
R(IR) = FC(IR)
271 S(IR) * IR
CALL 0 R D E R ( R , S , T, N R )
M = 1 ■
J « ‘0 '
DO 275 IR = 1,NR
IF(R(IR),EQ,R<M),AND.J,LT • 20) GO TO 274 
WRITE(OUT,3275) R(M), (LINE20G), 1=1,J)
J = 0 .
R! « JR • '
274 J = J + 1 .
275 LINE2O(J) = S(JR)
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WIUTE(OUT,3275> R(M), <LINE20(I),
WRITE(OUT <9999? ■
C
c
c
J = 0 ‘ '
00 281 IR = 1,NR
IFCCUCIR? .IT.25000000) GO TO 281 
4 = 4 + 1
R(J) = CM(IR? • '
S(4? = IR . .
281 CONTINUE • ’
IF(4.IT,10? GO TO 300 .
CALL 0RDER(R,S,T,4? • •
L =• (4 / 4) * 4
DO 285 I~1,L,4 ’
K = I + 3
285 WRITE<OUT»3285) (R(H?» S(M), M~IrK?
L = L + 1 •
IF(L.GT.J)• GO TO 300
WR I TE(GUT<3285? (R<M), S(M), M~L,4>
WR1TE<OUT»9999?
<~
> C
-J
 o
 o
 o
LOAD THE REFERENCES
300 IRA =? 1 '
•IRK « 1
REWIND FTEMP
DO 310 IR = 1,NR
READ(FTEMP»1101? LINE18
REF(1,IR? = LINE18C1)
REFC2UR) ~ LINE18(3?
REFC3, IR) = LINE18U? 
REFU,IR? = LINE18C5? 
REF(5,IR? - LINE18C6). 
REF(11,IR? - IRA 
REF(12,IR> = HNE18(18)
DO 301 J-8r18 .
1F(LIME18(4).EQ.0? GO TO 302 
I F( IRA.GTi.MRA) STOP 1301 
REFAC1, IRA? ~ LINE18C4?
301 IRA s IRA + 1 
STOP 1302
302 REFC10,IR? ~ 4 - 8
READ<FTEMPr1121) LINE20 
REF(7,IR? = IRK 
DU 305 4=1,20
1F<LINC20(4).EQ.0? GO TO 306 
IF(IRK.GT.MRK) .STOP 1304 
REFK(1,IRK? = LINE20C4?
305 IRK “ IRK + 1'
4 = 21
306 REFC6,IR? = 4 - 1
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310 READ ( FTEMP < 11 21 ) REF(8,IR), REF(9,IR) 
NRA " IRA - 1 .
NRK « IRK - 1
C
C
C
C
C
350
351
352
C
C
C
C
c
400
401
450
451
452
PRINT OUT THE REFERENCES IN THE ORDER THEY WERE 
ENTERED.
NUNES = 0 ' ■
IF(NCAT»NE•7) .GO TO 400 •
WRITE(OUT,9999) . .
NEW - .FALSE,
LABS - .FALSE, . ‘
LKE'Y “ .FALSE.
D U 3 51 J = 1 ,1 0 • '
PAGE(J) = LITC1)
DO 352 IR»1,NR
CALL ROUT(REF,CM,FC,KEY,REFK,BOOK,J URN'A L , MR , MK ,MRK, 
MB,MJ, IR)
OUTPUT REFERENCES TO TEMPORARY FILE;
RELOAD IN SORTED ORDER,
REWIND FTEMP . •
DO 401 J=?1 , NR 
1R = REFSRT(J)
WR I TEC FTEMP, 2401 ) (REF (I HR) 
CM(IR)
K « R E F (7 , I R )
L ~ K + R E F (6 , I R ) - 1 .
WRITE(FTEMP,1121 ) (REFK d, I ) 
K ~ R E F d 1 , I R )
L ~ R E F (1 0 , I R ) + K - 1 
WRITE(FTEMP,1121) (REFAC1 , I ) 
ENDFILE FTEMP .
REWIND FTEMP
IRA = 1
IRK - 1 '
DO 453 IR~1,NR ’
READ(FTEMP, 2401 ) (REF (I , IR) ,
CM( IR)
REF(7,IR) = IRK •
L ~ IRK + R E F(6, I R) - 1 
READ(FTEMP,1121) (REFK (1 , I ) , 
DO 451 I~IRK,L
R E F K ( 2 , I) « I R
IRK’w L + 1
REF(11,IR) - IRA
L “ IRA + REF('IO, IR) - 1 
READ(FTEMP,1121 ) (REFA(1,I),
DO 452 I-IRA,L '
REFA(2, I) « IR .
1=1,12), FC(IR),
1-1,12), FC(IR) ,
I-IRK,L)
I — K , L)
I = K , L )
I = I R A , L)
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453 IRA = L + 1 .
NRK = IRK - 1 .
NRA = IRA - 1 '
REWIND FTEMP
C
C '
C STORE THE ARRAYS REF, FC, CM, REFA, REFK ON
PERMANENT FILE,
C
c .
500 I F(NCAT•GT.7) GO TO 510
WRITE(FSEQ,1121 ) NR, NRA, NRK, NRT 
DO 501 IR»1,NR
501 WRITE(FSEQ,2401 ) (REF(I,IR), 1=1,11), FC(IR),
C M ( I R )
DO 502 IRA=1,NRA
502 WRITE<FSE0,2401) REFA(1,IRA), REFA(2,IRA)
DO 503 IRK=1,NRK
503 WRITE(FSEQ,2401 ) REFK(1,IRK), REFK(2,IRK)
C
510 ENDFILE FSEQ .. .
REWIND FSEQ 
GO TO 650
X~
> <-
> o
LOAD ARRAYS FROM THE PERMANENT SEQUENTIAL FILE.
C
C
600
601
602
603
604
610
612
613
650
READ(FSEQ,1121 ) 
DO 601 IA=1,NA 
READ(FSEQ,1121) 
DO 602 J=1,NJ 
READ(FSEQ,2211 ) 
DO 603 J=1,NB 
READ(FSEQ,1121 ) 
READ(FSEQ,1001 ) 
DO 604 J = 1,NK 
READ(FSEQ,2211 ) 
READ(FSEQ,1121 ) 
DO 610 IR = 1 , NR 
READ(FSEQ,2401 ) 
DO 6’1 2 I RA = 1 , NRA 
READ(FSEQ,2401 ) 
DO 613 IRK-1,NRK 
READ(FSEQ,2401)
J ” R E F K (1 , I R K )
I F(J.01,0,AND,J, 
WRITE(OUT,3649) 
REFK(1,IRK) = 1 
CONTINUE 
REWIND FSEQ 
WR-ITE (OUT, 3650)
■ NRT,
WRITE(OUT,9999) 
GO TO 900
NA, NJ, NB, NK •
J •
( J URN A L (I, J ) , 1 = 1',12)
BOOK(1,J), BOOK(2,J)
(BOOK(1,J), 1=3,20)
(KEY(I,J), 1=1,12)- ■
NR, NRA, NRK, NRT ‘
(REF(I,IR), 1=1,11), FC(IR),
REFA(1,IRA), REFA(2,IRA)
REFK(1,IRK), REFK (2, IRK)
LE.MK) GO TO 613 
R E F K ( 2 , I R K )
NN, NR, NA, N K, NJ, M B, NRA, 
NCAT • .
CM(IR)
NRK,
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C
C
C ABORT THE RUN
801 IR “ IR
802 IR “ IR rr, j
803 IR = IR 1
804 IR b IR "* 1
805 IR = IR 1 -
810 WRITE(OlIT,3810) IR, NN
815 WRITE(0UT,3811) N J , NB,
NERR - 1 
GO TO 999
o 
<~
i o
 
o 
<~
> o
 a
SELECT THE REFERENCES FOR THE CURRENT CATALOGUE.
900 NLINES « 0 
LABS = .FALSE.
LKEY = .FALSE.
DO 901 1-1,10
901 PA6EU) - LITC1 >
I FCNCAT.GT.7) NCAT » NCAT « 7 
GO TO (910,920,930,940,950,999,999), NCAT 
CHRONOLOGICAL CATALOGUE.
910 NEW .FALSE.
DO 912 IR = 1,NR
912 CALL ROUT(REF,CM,FC,KEY,REFK,BOOK,JURNaL,MR,MK,MRK» 
MB,MJ,IR)
GO TO 999 
C
C JOURNAL CATALOGUE.
C
920 POS = 1
LKEY = .TRUE.
LABS » .TRUE.
921 DO 922 J-1,NJ
I F ( J URNAL(1,J).EQ.PQS) GO TO 923
922 CONTINUE 
GO TO 927
923 NEW = .TRUE.
L - 3
PAGEC1) - LITC1)
PAGE (2) = LIT(1)
I F(JUKNAL<2,J)»GT.8) L s 11 « JURNAL(2,J)
K - 3
DO 924 I~-L,10 
PAGE(I) b JURNAL(K,J)
924 K - K + 1 
L - 1
925 DO 926 IR-L,NR
ir(REF(2,IR).EQ.J) GO TO 928
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926 CONTINUE
927 I F<POS,EQ•NJ ) GO TO 999 
POS « POS + 1
GO TO 921
928 CALL ROUT (REF, CM, FC , KEY# REFK, ROOK, JURNaL, MR,MK,MRK,
MB,MJ, IR)
IF(L.EQ.NR) GO TO 927 
L » IR + 1 
GO TO 925
C
C AUTHOR CATALOGUE
C -
930 POS a 1
READ(FSEQ,1121) I, J, K, L
PAGEd) « LIT(1)
PAGEC2) = LITC1).
PAGE(S) = LITC1)
PAGE(9) ~ LIT(1)
PAGEdO) - LIT(1 )
931 NEW = -TRUE,
READ(FSEQ,2211) I, J, (PAGE(L), L-3,7)
L ~ 1
932 DO 933 IRA“L,NRA
I F(REFA(1 , IRA) ,EQ,I) GO TO' 935
933 CONTINUE
934 I F(POS,EQ • NA) GO TO 936 
POS s POS + 1
GO TO 931
'935 IR - REFA(2,IRA)
CALL ROUT(REF,CM,FC,KEY,REFK,BOOK,JURMAL,MR,MK,MRK, 
MB, MJ,IR)
IF(L.EQ.NRA) GO TO 934 
L » IRA + 1 
GO TO 932
936 REWIND FSEQ 
GO TO 999
KEYWORD CATALOGUE
940 POS s 1
941 DO 942 K=1,NK 
1 F(KEY(1 ,K) , EQ,POS) GO TO 943
942 CONTINUE 
GO TO 947
943 NEW =; .TRUE.
. L « 3
PAGEd) «LIT(1)- 
PAGE.(2) « LIT(1>
IF(KEY(2,K).GT.8) L * 11 - KEY(2,K)
J -• 3
DO 944 X»L,10 
PAGEd) s KEY(J,K)
944 J » J + 1 
L "* 1
945 DO 946 IRK«L,NRK
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I FCREFKdrIRK) »EQ.K) GO TO 948
946 CONTINUE . ' •
947 IF(POS.EQ•NK) GO TO 999 
POS ~ POS + 1
GO TO 941
948 IR ~ REFK<2,IRK)
CAUL R 0 U T ( R E F , C M , F C , K E Y , R E F K , B 0 0 K , J U R N A I,, M R , M K , M R K » 
MB,MJ, I R)
I.F < L • EQ ■ MRK) GO TO 947 <
L ~ IRK + 1 ' . ‘
60 TO 945 . .
LIST SELECTED REFERENCES.
950 L - 0
NEW s .FALSE.
I LI ST » 0 
K ~ 0
951 L =‘ L + 1
952 READ(IN,1121,END-957,ERR=951) POS 
I F(POS.GT.NR) GO TO 951
IF(POS.LE.O) GO TO 958 .
I LIST - ILIST + 1 
IFCILJST.GT.500) GO TO 954 
LISTIT(I LIST) = POS
IF(ILI ST«EQ.1.0R.K.EQ.9) GO TO 954 .
I LIST - ILIST - 1
DO 953 IR-1,I LIST ‘
IF(POS.EQ.LI ST I T ( I R)) GO TO 952 '•
953 CONTINUE ' ' '
ILIST ~ ILIST * 1
954 IF(K.EQd) GO TO 951 . •
DO 955 IR-1,NR ■
IFCREFd,IR).EQ.POS) GO TO 956
955 CONTINUE 
GO TO 951
956 J - REFC1 , IR)
ira - redR) - '
IF(K„NE„9) REF(1,IR) « I •
FC(IR) « LITd) *
CALL .ROUT(REF,CM,FC,KEY,REFK,BOOK,J URNAL»MR,MK,MRK»
MB,MJ,IR) • .
REFC1 , IR) = J 
FC(IR) = IRA 
1F(K.EQ.2) GO TO 959 
GO TO 951
957 IFCK.NE.1 ) GO TO 960
K “ 2' ,
SORT BY AUTHOR, IF REQUIRED
I - 0
DO 971 IR-1, NR '
L - 0 ’
970 L - L + 1
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IF(L.GTULIST) GQ TO 971 
IF(REF(1,IR).NE»LI ST IT(L)) GO TO 970 
1-1 + 1
CM(I) ~ REF(11,IR)
971 CONTINUE
READ(FSEQ,1121) J 
I - 0 ■
DO 974 IA“1,NA
REAP(FSEQ,2211 ) J
L - 1 ’ ■
972 IRA * CM(L)
1F(REFA(1 , IRA) «NE.J) GO TO 973 
1 ~ I + 1
LISTlTd) » REFA(2,IRA)
IR = USTITU)
973 L - L + 1
IFddE.ILIST) GO TO 972
974 CONTINUE 
C
L - 0 ‘ -
GO TO 959
958 IFd.NE.1) GO TO 951
K - 9 .
IF(P0S,E0»-999) K « 1 
GO TO 952
959 IF(L + 1„GT.I LIST) GO TO 960 
L “ L + 1
IR = LISTlTd) ■
USTITU) - REFC1 , IR)
GO TO 956 '
960 DO 961 I R«1,I LI ST
R(IR) = LISTIT(IR) . ’
SUR) - LISTIT(IR)
961 TUR) s IR ’ '
CALL 0RDER(R,S,T,ILIST)
WRITE(OUT,3961)
DO 965 IR = 1,I LIST
965 WRITE(OUT,3965) IR, LISTIT(IR), T(IR), R<IR.) 
IFCL.NE.ILIST) WRITE(OUT,3966) •
END • • .
999 IF(NCAT.NE»6) WRITE(OUT,9999)
IF(NERR.EQ.O) • WRITE(OUT,3999)
STOP
END____________________________ ________________________ _____________
SUBROUTINE 11 ST(ARRAY»NW» NN,OUT)
r~
> »—
> o
 t~i
 J 
o
THIS SUBROUTINE PRINTS OUT THE AUTHOR, JOURNAL, 
BOOK AND KEYWORD 
C LISTS IN BOTH THEIR ENTERED AND ALPHABETICALLY
SORTED ORDER* •
C
240
C •
C •
IMPLICIT INTEGER(A-Z).
DIMENSION ARRAY (NV/, NN) .
C
c
c '
3130 FORMATC ’ ,1 5 , 5X , 5A4,24X , 15,5X , 5 A4)
3140 FORMATC ’ ,I 5,5X,10A4,4X,I 5,5X,10A4) .
3150 FORMATC’ ' , 2 I 5,5X,20A4)
C
C •
C
DO 160 P0S~1,NN ■
DO 110 J -1,NN
IFCARRAYC1,J).EQ.POS) 00 TO 120 
110 CONTINUE
STOP 41
120 K « ARRAY(2,J) + 2
IFCNW-12) 130,140,150
130 WRITE(OUT,3130) POS,(ARRAY(1,POS), 1=3,7),
J, CARRAY CI,J), I~3,K)
GO TO 160,
140 WRITE(OUT,3140) POS,(ARRAY(I,POS),I=3,12),
J,(ARRAY CI , J ) , 1=3,K)
GO TO 160 •
150 WRITE(OUT,3150) POS, J, (ARRAYCl,J), 1=3,K)
160 CONTINUE
RETURN
________END_____________:________________ _ _____ _ . .....
SUBROUTINE NU L I ST(ARRAY,MARR,MARRW,NARR ,NN, I N,OUT,
' . LINE20,R,S,T) .
oo
o 
n 
r. 
n 
n on
oo
THIS SUBROUTINE INPUTS THE AUTHOR, J OUR NAL, BOOK 
AND KEYWORD LISTS
FROM DATA CARDS.
IMPLICIT INTEGER(A-Z)
DIMENSION ARRAY(MARRW,MARR), LINE20C20), R(MARR), 
' S(MARR), T(MARR)
DIMENSION V(10), U(10), WC10)
DATA LIT/’ ’/
1011 FORMAT(14,1X,18A4,A3 )
1121 F0RMATCA4)
3122 FORMATC//’0’,’THE PROGRAM LIMITS HAVE BEEN 
EXCEEDED.') .
C
C
241
t_> o o
DO 120 NARR~1,MARR 
REAP<IN»1011) LINE20 
NN ~ MM + 1
I F(LINE20 <1) .EQ.O) • GO TO 140 
IFCLINE20C1).ME,MARR) GO TO 131 
DO 110 IARR”3tMARRW
J = IARR ~ 1 
M = J
IF(J.LE.1°) !T " M * 1 •
IF(LINE20(J)„EQ„LIT«AND,LINE20(M),EQ.tIT) GO TO 120 
110 ARRAY CIARR, MARR) ~ LINE20CJ)
J “ J + 1 ,
120 ARRAY(2,MARR) « J ~-2 ‘ .
READ<1N,1121) J '
IFCJ.EQ.LIT) GO. TO 200 '
WRITE(OUT,3122) '
130 MARR = 0
131 MARR ~ -MARR ‘ ‘
RETURN ’ '
140 MARR - MARR - 1
BEGIN SORT ON THE FIRST EIGHT CHARACTERS,
200
210
220
C
C
C
C
DO 210 IARR=1,MARR 
RCIARR) ~ ARRAYC3,IARR) 
SCIARR) * ARRAYC4, IARR) 
TCIARR) = IARR
CALL QRDERCR,S,T,NARR) 
DO 220 IARR=1rMARR 
J = TCIARR)
ARRAY(1,J) « IARR
THE SORT IS MOW CONTINUED WITH THOSE ENTRIES WHOSE 
FIRST EIGHT
CHARACTERS ARE IDENTICAL.
M ~ 0
DO 370 IARR~2,NARR 
IFCIARR.LE.M) GO TO 
M ~ IARR
J ~ IARR - 1
i F C S C IA R R ) . N E. S ( J ) )
IFCRCIARR).NE.R(J))
370
GO TO 370 
GO TO 370
310
C
c
c
DO 310 K~IARR,NARR
IFCSC IARR) .NE.SCK) ) GO TO 320
CONTINUE
K - K + 1 , .
POSITIONS J TO K ARE UNSORTED.
320 K
c
c
c
K - 1
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If(K,GT.IARR) GO TO 340
e~
i <~
5 r>
 
(~
i c~i 
n 
c 
c
J AND IARR ARE ADJACENT . ..
i ~ t(j)
K ~ T(IARR)
I F(ARRAY(5, I) , LT.ARRAY(5,K)) 
IF(ARRAY(5H)«GT.ARRAY(5,K)) 
1F(ARRAY(6,I).LE.ARRAY(6,K))
GO TO 370 
GO TO 330 • 
GO TO 370 '
..... AND INCORRECTLY POSITIONED. SWOP THEM.
330 ARRAYC1,I) « IARR >
ARRAYC1,K) » J 
GO TO 370
THERE ARE THREE' OR MORE UNSORTED SEQUENTIAL VALUES,
340 L « 0
DO 350 I=J,K 
L ~ L + 1 
M = TCI)
UCL) - ARRA.Y(5,M)
VCL) = ARRAY(6,M)
350 W(L) ~ M
CALL ORPERCU,V,W,L) ' .
J " J 1 
DO 360 1-1 , L 
M « W(I)
360 ARRAY(1,M) - I + J 
M = K
370 CONTINUE
RETURN e
END__________________________________________________________________
SUBROUTINE ORDER(R,S,T,N)
C THIS ROUTINE SORTS THE VALUES IN THE THREE ARGUMENT
ARRAYS- THE
C PRIMARY SORT IS BASED ON THE FIRST ARRAY VALUE BUT
WHENEVER TWO OR
C MORE OF THESE ARE IDENTICAL THE ORDER IS BASED ON
THE VALUE IN THE
C SECOND ARRAY, THE THIRD ARRAY SIMPLY TAGS ALONG
AND IS USED TO
C HOLD THE ORIGINAL POSITION OF THE SORTED NUMBER
PAIRS.
C
C
c .
IMPLICIT INTEGER(A-Z)
DIMENSION R(N) , SCN), T(N).
C
C
243
C
M “ 2
DO 1 J = 1 , N
M ~ M + M
IF(M.GT.N) GO TO 2
1 CONTINUE
2 M « M ~ 1
3 M -• CM ~ 1) / 2
NN ~ M - M
' DO 8 1=1,NN
OLD = I + M
LR = RCOLD)
LS = SCOLD)
LT " TCOLP)
DO 6 J = 1 , I ,M
NEW = OLD - M ' .
C IFCLR~RCNEW)) 5,4,7
C 4 IFCLS~SCNEW)) 5,7,7
IFCLR.LT.RCNEW)) GO TO 5
IFCLR•GT«RCNEW)„OR„LS»GE.SCNEW)) GO TO 7
5 RCOLD) = RCNEW)
SCOLD) = SCNEW)
TCOLD) = T C N E W )
OLD = NEW
6 CONTINUE
7 RCOLD) s LR
SCOLD) = LS
TCOLD) = LT
8 CONTINUE
IFCM.GT.1) GO TO 3
RETURN
END . ■
FUNCTION LENGTHCARGN)
C
C
C
C THIS FUNCTION RETURNS THE NUMBER OF DIGITS REQUIRED
BY THE VARIABLE
FORMAT STATEMENT TO OUTPUT THE ARGUMENT IN QUESTION,
C
IMPLICIT INTEGER(A-Z)
NUMBER ~ ARGN 
DO 100 1=1,11
IFCNUMBER.LE.O) GO TO 200 
100 NUMBER « NUMBER / 10
STOP 81 ' •
200 LENGTH = 1-1
IFCLENGTH.LE.O) LENGTH ■= 1 
RETURN
_______ END__________________
SUBROUTINE ROUT CREF,CM,FC,KEY,R E FK , HOOK , J URNAL , MR” 
M K , 11R K , M B , M J , I R )
C
244
C ' • 
C THIS ROUTINE PRINTS OUT REFERENCE IR, 
C ...
C
IMPLICIT INTEGER !A~2)
DIMENSION RCF!12,MR), tlQLD(2,20), REFK!2,MRK) 
DIMENSION KEY!12,MK), J URNAL(12,MJ), VORMAT(14),
UT!4), CMCMR)>
. 1 FC(MR) , BQ0K!20,MB)
LOGICAL LABS, LKEY, NEW
C
1
COMMON /ONE/ NUNES, MUNES, 
COMMON /TWO/ IN, OUT, FSEQ, 
COMMON /THREE/ LINE20C20),
NEW
DATA LIT/* ,
DATA VORMAT/’ !1H ’ , ' ,8X, ’, ’
11H,, ', ’ 2X , I ' ,
* ’ , ’ ,1H, ’ , ' ,2X, ’ , ’ I ’ , ’ ’ , ’
LABS, LKEY 
FDEF
NUMBER(20),
’ , ’ 1 H , , ' /
’,’A4,’> ’2X,
) ’/
PAGEC1Q) ,
’ , '14,* ,
3101
3153
3201
3301
3303
3601
FORMAT!’ 
FORMAT! ’1 
FORMAT!’ 
FORMAT!’ 
FORMAT!' 
FORMAT!’
’ ,.92!1H*) ,10A4,/>
’,92X,10A4,/>
’ , I4,4X,.20A4)
’ ,A4,4X,20A4)
’ ,8X,20A4)
' ,8X, ’CHEMICAL ABSTRACT NUMBER’, 14,*:’,16)
n 
a 
r>
 c
 
oo
oo
LOCATE THE DEFINE FILE AUTHOR STRING,
100 KSW = 2 .
IRT - REF(9,JR)
FIND(FDEF’IRT) •
IF NECESSARY, OUTPUT NEW HEADING
IF!NLINES + 12.GT . ML I NES) GO TO 140 
IF! .NOT.NEW) GO TO 200
101 NEW » .FALSE.
WRITE !OUT,3101) PAGE 
N LINES « MUNES + 2 
GO TO 200
C
C CALCULATE THE NUMBER OF LINES NEEDED.
C
140 LINES = REF!8,IR)
IF! LABS.AND.CM!IR).GE,25000000) LINES « LINES + 1 
IF!.NOT,LKEY) GO TO 153 
KSW » 1
150 IRK s REF(7,IR) ‘
NHK ~ KEF(6,IR)
DO 151 J~1,NHK
I K ~ R L F K ! 1 , I R K ) '
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HOLDO , J) « IK '
HOLD(a,J) = KEYC2, IK) -
151 IRK- IRK +1 ■
IFCKSW.EO.2) GO TO 501
152 CALL LOADK ( HO LD , NilK , L I NE20 , KE Y , MK , L I T (1 ) , KSW) 
I F(KSW,EQ,0) GO TO 153
LINES - LINES + 1
GO TO 152 .
PAGE, IF NECESSARY- ■
153 I F ( L I NES + ll L I NES . LE • M LI MES ) • GO TO 154
NLINES - 1 • ' •
IF(-NOT.NEW) WRITE(OUT,3153) PAGE 
IRC.NOT.NEW) NLINES =? NLINES + 1 
IF(NEW) WRITECOUT,3153) •
154 IF(NEW) GO TO '101
PRINT OUT AUTHOR STRING, . .
200 READCFDEF,RECEIPT) LINE20 
IRT ~ IRT + 1 
FINDCFDEF’IRT)
WRITE (OUT,'3201 ) REFC1 , IR) , LINE2 0 
NLINES ~ NLINES + 1 
I J = R E F ( 2 , I R )
IB « REF(4,IR)
J = RE F(5, I R ) •
M » LENGTH! J)
IFClJr.EQ.1 -AND.J-EQ.O) GO TO 402
PRINT OUT TITLE STRINGS, *
300NRT~IRT+REF(8,IR)~2 -
READ(FDEFrREC-IRT) LINE20 
NLINES - NLINES + 1 •
WRITECOUT,330.1 ) FC(IR), LINE20
301 IRT ~ IRT + 1 
IF(IRT-NRT) 302, 303, 400­
302 CONTINUE
302 FINDCFDEF'IRT)
303 NLINES = NLINES + 1
READCFDEF,REC-IRT) LINE20 •
WRITECOUT,3303) LINE20 
GO TO 301
PRINT OUT THE JOURNAL OR BOOK REFERENCE, .
400 I F ( I J , EQ, 1 ) GO TO 402
K = JURNALC2, I J ) ■
V0RMATC3) ~ NUMBER(K)
IF(REF(3,IR),GT-3000, OR.REF(3,IR).LT.1000)
GO TO 408
IF(IB-EQ.O) GO TO 403 . -
V0RMATC13) - NUMBER(M)
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C
C
C
402
403
405
406
408
M ~ LENGTH(IB) 
V0RMATC9) a NUMBER(M)
VORMAT (10) = LIT(2) .
K = K + 2
WRITE(OUT,VORMAT) (J URNAL(L,I J), L-3,K)t 
REF(3,IR), IB, J
GO TO 500
K “ B00K(2,IB) •
V0RIIAT(3) ~ NUMBER(K)
IF(REF(3, IR) , GT .3000. OR, REF (3, IR) , LT.1 000) 
60 TO 408
K - K + 2 •
VORMATC9) ~ NUMBCR(M)
VORMAT(10) = LIT(1) •'
VORMATC13) = NUMBERdO) 
IF(IB.EO.O) GO TO 406 
IF(J.EQ.O) GO TO 405 
WRITE(GUT,VORMAT) (BOOK(L,IB), 
GO TO 500
VORMATC7) * LITC1)
WRITE(OUT,VORMAT) (BOOK(L,IB), 
V0RMATC7) = LIT(4)
GO TO 500 
WRITE(OUT,VORMAT) (JURNAUL, IJ)
L~3,K), REF(3,IR), 4
L=3,K), REF(3,IR)
, 1. ~ 3 , K ) ,
60 TO 500 
K ~ K * 2 
IF(I J.EQ.1 ) 
I F ( I J . N E , 1 )
WRITE(OUT,VORMAT) 
WRITE(OUT,VORMAT)
L=3,K)
(BOOK(L,IB), L-3 , K> 
(JURNAL(L, IJ) ,
R E F (3 , I R ) , J
PRINT KEYWORD STRINGS
500 NUNES = NUNES + 1
IF( .NOT. LKEY) GO TO 600 
IFCKSW.EQ.2) GO TO 150 
KSW = 2
501 CALL LOADKCHOLD, NHK, UNE20, KEY ,MK, LIT(1 ) , KSW) 
I F(KSW.EU.O) . GO TO 600
WRITE(OUT,3303) LINE20 
NUNES = NUNES + 1 
GO TO 501
o 
o 
o 
• o <
->
 r>
PRINT CHEMICAL ABSTRACT NUMBER.
600 IF(. NOT. LABS.OR.CM(IR).LT.25000000) Go TO 700 
I = CM(IR) / 1000000 
J - CM(IR) - (I * 1000000) • .
WR I TE(OUT,3601 ) I, J 
NUNES = NLINES + 1
SPACE ONE UNE
700 WRITE(OUT,3301) •
NUNES = NUNES * 1 •
24 7
RETURN
END_________
SUBROUTINE LO/W K ( H0 LD , NIIK , LI NE20 , KE Y , MK , 11T , KSW )
O
O
O
 
O
 <“>
 O
 
<~
> O
 <"2
 
C
5O
O
 
oo
oo
o
THIS ROUTINE OPTIMISES THE INSERTION OF KEYWORDS 
INTO ARRAY LINE2O
IMPLICIT INTEGER(A-Z)
DIMENSION HOLD(2,20)
DIMENSION LINE20C20), KEY(T2,MK)
NL = 1 
100 L - 0
DO 110 1=1,NHK 
N = HOLD(2,1>
I F ( HO LD (1-, I) • LT . 0 , OR <» N • LE • L) GO TO' 110 
I F ( N + NL■GT•21) GO TO 110 
I UK = I
L •“ N
110 CONTINUE '
112 IF(L.EQ.O) GO TO 117 
4 = H0LDC1,IKK)
HOLD(1,IHK) = -J 
IF(KSW*EQ»1 ) GO TO 116
. L ~ 3
N = H0LDC2,IHK)
DO 115 1=1>N 
LINE2O(NL) = KEY(L,J)
NL ~ NL + 1
115 L = L * 1
116 1F(NL.GT„2Q) GO TO 117 
LINE20CNL) = LIT
NL = NL’»’ 1 
GO TO 100
117 IF(NL,E0.1) GO TO 130 
1F(KSW,EQ.1.OR■NL•GT , 20) RETURN 
DO 118 I=NL,20
118 LINE20(I) ~ LIT 
RETURN
130 DO 131 1 = 1,NHK
131 H0LDC1 ,1) = -HOLDC1 , I) 
KSW = 0
RETURN 
E N D
APPENDIX A2
Formation constant database for binary complex 
species used in the computer simulations
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The following list of formation constants is used 
as the database for program MIX and program ECCLES.
The values have been selected using the criteria stated 
in Section 2.1.3 (p.24). They are measured experimentally 
under the temperature and ionic strength of blood plasma 
(37C; 150 mmol dm ) or have been adjusted to conform 
to these conditions. The source of each value is indicated
by one of the following symbols: '
M - measured experimentally under model conditions
A ~ estimated from more than one measurement 
(taking averages where possible)
E - estimated from a single (i.e. unconfirmed) 
experimental determination under conditions 
different to those of the model
G - estimated from various chemical trends in 
the absence of an experimentally measured 
value
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The main literature sources of the formation constants 
in the computer database are as follows,
•’Stability Constants” (Special Publications 17 and 25) 
compiled by L.G.Sillen and A.E.Martell, 1964 and 1971, 
The Chemical Society, London '
"Stability Constants of Metal-Ion Complexes", Part B 
(Organic Ligands) compiled by D.D.Perrin, 1979, 
Pergamon, Oxford ,
"Critical Stability Constants", Volumes 1-4, 
compiled by A.E.Martell and R.M.Smith, 1974-1976,
Plenum Press, New York.
In addition, values from the following references are included
26, 41, 48, 51, 52, 53, 56, 58, 59, 60, 61, 62,
63, 66, 67, 68, 69, 77, 79,;81, 108 , 120 , 121,
183, 192, 197, 214, 235 , 243, 244, 249, 251, -252, 253,
254, 255, 256, 270, 271 , 273, 276, 277, 279, 282, 287,
288 , 306, 311, 312, 313 , 314, .315, 317, 321, 326, 328,
331, 333, 335', 336, 337 , 384, 387, 394, 425, 426, 428,
435, 440-, 448, 457, 460 , 466, 486, 499, 500, 504, 512,
514, 515, 516, 518, 524 , 630, 668, 799 , 800 , 804, 812,
817, 858, 860, 861, .919 , 947, 1007, 1008 , 1059, 1072,
1129 , 1130, 1161, 1272, 1275, 1287, 1403 , 1404, 1484,
1529 , 1572, 1579, 1580, 1582, 1583, 1584 , 1587, 1588,
1589 , 1590, 1591, 1593, 1594, 1595, 1596 , 1606, 1607,
1609 , 1632, 1697, 1745, 1753, 1754, 1763 , 1779, 1798,
1815 , 1820.
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ALA1 ALAUATf
ABA1 AMINOBUTYRATE' ‘
ARGO A R GININE
ASN1 ASPARA6INATE
ASP? ASPARTATE
CIT1 Ci TRUE II NATE
CYS2 CYSTEINATE
CIS? CYSTINATE
GLU2 GLUTAMATE
Gt.N1 GLUTAMINATE
GLY1 GLYCINATE
H I S1 H I S T I D I N A T E
HYP1 HYDROXYPROL I NATE
I L E1 ISOLEUCINATE
LCU1 LCUCINATE
L Y S 1 L Y S I N A T E
M E T1 M E T H I 0 N A T E
0 R N1 0 R N I T H I N A T E
PBE1 PHENYLAL.ANATE
P R 01 PROllNATE
S E R1 S E R I N A T E
THR1 T It R EON 1 NATE
TRP1 TRYPTOPHANATE
TYR2 TYROSINATE'
VAL1 VALINATE
HSNO HISTAMINE
C032 CARBONATE
P043 PHOSPHATE
SIL? SILICATE
SO42 SULPHATE .
SCN1 THIOCYANATE
NH30 AMMONIA
ACA2 ASCORBATE
CTA3 CITRATE
LTA1 LACTATE
MLA2 MALATE
OXA? OXALATE
PVA1 PYRUVATE
SLA? SALICYLATE
SCA2 SUCCINATE
TRA2 TARTRATE
0PN2 OX-PEN ICILLAMI NATE
GSH3 RED-GLUTATHIONATE
GSS4 OX-GLUTATHIONATE
PEN? RED-PENIC I LLAMINATE
TETO TRIETHYLTETRAMINE
EDT4 EDTA
GH 1 . GLYCYLHISTIDINATE
GGH1 DIGLYCYLH I ST I D I NATE
PMAO PEPTIDE MIMICKING ALBUMIN (N-METHYl.”
0 I G L Y C Y L’H I 3 T 1 D I N E )
BAL? 2,3 DI MERCAP lOPROPANOL (BAL)
DEO? DESFERRIOXAMINE
DTPS DTPA
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CDT4 COTA
ACT1 ACETATE ' ■ • ,
ANTI ANTHRAN I LATE
ASA1 ACETYLSAUCYLIC ACID
CIQ1 CARBOXY-ISOQUINOLINE
FENO FENAMOLE
ATH1 BENZOYLATED THIAPROLINE 012267
SGL2 012408
THP1 5,5-0 IMGTHYLTHI AZOLI 0 INE-4"CARBOXY11C ACID
DPA1 2,3-01 AMINOPRQPI ONATE
E002 EOOA (ETHYLENEDIAMJNEDI ACETIC AGIO).
NT A3 NTA
EGT4 EGTA
E H P 4 E H P G
JWT3 HOE OTA
OOT4 EEOTA
H +1
OH-1
CA + 2 '
CO + 2
CO + 2
CU + 1
CU + 2
F E + 2
FE + 3
PB + 2
MG + 2
MN + 2
NI+2
ZN + 2
CARB PROTEIN SIMULATOR - CARBOXYLATE FUNCTIONS
TFRN PROTEIN SIMULATOR - TRANSFERRIN
ALBM PROTEIN SIMULATOR - ALBUMIN
ENO
13,187 A L B M ( +1 ) CU + 2(+1)
8.187 ALBMC+1) P B + 2 (+1 )
6.187 A L 3 M ( +1 ) M N + 2 <+1 )
7,187 ALBM(+1) Z N + 2 < +1 )
22.528 TFRNC+1) FE+3C+1)
1,142 CARB < +1 ) C A + 2 ( »• 1 )
0.861 • CARB(+1) M G + 2 ( +1 )
9,502 ALAI <4-1 ) H +1 < +1 )
11,879 ALA1(+1) H +1(+2)
1.20 ALA1 (+1 ) CA+2C+1 >
10.10 ALA1 (-1-1 ) CA+2C+1) H + 1C+1)
1 .80 ALA1(+2) C A + 2 ( +1 )
19.90 ALA1(+2) CA+2C+1) H +1(+2)
8,01 ALA1(+1) CU+2C+1)
14,64 ALA1(+2) CU+2(+1)
10,57 ALA1 ( +1 ) CU+2C+1) H +1C+1)
0.40 ALA1(+1) C U + 2 ( +1 ) H +1 (-1 )
4.00 ALA1(+2) CU + 2 ( + 1 ) H +1C-1)
3.50 ALAI(+1) FE+2C+1 )
6.90 ALAI (+2) FE+2C+1 )
10,00 ALAI(+1> FE+3(+1)
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16,40 AI.A1 (+2) F E + 3 ( 41 ) G
4.20 A L A1 ( +1 ) P B 2(41) A
6.90 ALA1(+2) PB 42.(4 1 ) A
9,10 ALA1(+2) P 3 4 2 ( 41 ) OH -1(41) E
1,70 ALAI(+1) M U 4 2 ( 4 1 ) A
1 0.40 ALA1 (+1 ) M G 4 2 ( 4 1 ) H + 1 (+1 ) G
2.20 A L A1 ( + 2 ) MG+2(+1) G
20,20 ALAI(+2) M 6 + 2 ( 41 ) II +1(+2) G
2,4 0 ALA1(+1 ) MN+2(+1 ) M
4.28 ALA1( + 2) M N 4 2 ( +1 ) M
5,70 ALAI(+3) MN42(41) M
10,00 A L A1 ( +1 5 M 11 + 2 ( 4 1 ) H + 1 (+1 ) G
12.85 ALA1 (+2) MN 42( + 1) H + 1 (+1 ) M
5,40 ALAI(+1) N I+2(41) A
9.60 ALA1(+2) NI+2(41 ) A
4.57 ALA1 ( +1 ) ZN + 2(41 ) M
8.56 ALA1(+2) LN42(41) M
10,65 ALAI (+3 ) ZU+2(*1) M
-3.96 ALA1 (4-1 ) Z N + 2 ( +1 ) H +1(—1) M
9,24 A B A 1 ( +1 ) H +1(41) M
11 ,69 A B A1 ( +1 ) H 41(42) A
1.10 ABA1 (+1 ) C A 4 2 ( +1 ) G
9.70 A 0A 1 (+1 ) C A + 2 ( 41 ) II + 1 ( + 1 ) G
1,40 ABA1 (4-2 ) CA+2(41) G
19.20 ABA1 ( + 2 ) .C A + 2 ( +1 ) It +1(+2) G
7.65 A B A1 ( +1 ) CIJ + 2 ( +1 ) M
14.10 ABA1(42) C U + 2 ( +1 ) M
3,40 ABA1(+1 ) F E + 2 ( +1) E
5.00 ABA1(+2) F E + 2 ( +1 ) G
9.00 ABA1 ( + 1 ) FE+3(+1) E
16.00 A B A1 ( + 2 ) FE+3 ( 41 ) G
4.00 ‘ . A B A1 ( +1 ) P B + 2 ( +1 ) G
6.00 ABA1(>2) P B + 2 ( +1 )
~1 (+1 )'
G
3.00 ABA1 (+1 ) P B + 2 ( +1 ) Oil G
1.60 • A B A1 ( 41 ) M G 4 2 ( 4 1 ) G
1 0.00 A B A1 ( 41 ) MG + 2 ( +1 ) H + 1 (+1 ) G
2.20 ABA1(+2) MG + 2(+1) G
19,50 ABA'1 (42) MG+2(+1) H +1(+2) G
2.25 ABA1 (4.1 ) M N + 2 ( +1 ) G
4,00 ABA1(42) M N + 2 ( +1 ) G
5.20 ■ ABA1 (41 ) NI+2(+1) E
9.4 0 ABA1(42) 01+2(41) E
4.42 A B A 1 ( 4 1 ) ZN+2(+1) M
8,15 ABA1(42) Z N + 2 ( +1 ) M
8,78 A R G 0 ( 41 ) II +1 ( + 1 ) M10.81 A R G 0 ( +1 ) H +1(+2) M-12.50 A R G 0 ( +1 ) H +1(-1) A1,60 ARGO(+1) CA+2( + 1 ) A9,70 ARGO(+1 ) CA + 2(+1 ) H + 1(1-1) G
2.20 • ARG0(4-2) C A + 2 ( +1 ) G
18,80 ARgO(+2) C A + 2 ( +1 ) H +1(+2) G
7,38 ARGO(41) C U + 2( + 1) M
1 3.66 A R G 0 ( 4 2 ) CU+2(+1) M
-1 .00 A R G 0 ( 41 ) CU+2(+1) H + 1 (-1 ) M
3,17 A R 6 0 ( 4 2 ) CU+2(+2) H +1(-2) M
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'i
3.00 ARGOC+1 ) FE + 2C+1) /
4,4 0 ARGOC+2.) F e + 2 C +1 )
3,00 ARGO (4-1 ) FE + 3 ( + 1 )
15,00 ARGOC+2) F E + 3 C +1 )
3.50 ARGO(+1) P 3 + 2 C +1 )
5,00 ARGOC+2) P B + 2 C +1 )
3.00 ARGOC+1) PB+2C+1) 011-1 C + 1 )
2.00 ARGO(+1) MG+2(+1)
10.30 A R G 0 ( +1 ) MG + 2 ( +1 ) II +1 C +1 )
2.3 0 ARGOC+2) MG+2C+1)
19.00 A R G 0 ( + 2 ) M G + 2 C +1 ) H. +1 C + 2 )
2.35 ARGOC+1) MM2 C + 1 )
3.90 ARGOC+2) M N + 2 C +1 )
5.00 ARGOC+1). M+2C+1)
9.00 ARGO(+2) K I + 2 C +1 )
4,07 ARGOC + 1.) Z N + 2 ( +1 )
7.38 ARGOC+2) ZN+2C+1)
-4.25 ARGOC+1) ZN+2C+1) ft +1(-1)
8.63 ASM<+1) ft +1 C +1 )
10,91 A 5 N1 C +1 ) ft +1C+2)
1.40 ASM ( +1 ) CA + 2 C + 1 )
9,40 ASMC+1) CA+2(+1) ft +1C+1)
1 .70 AS-M ( +2) CA+2C+1)
1 3.40 ASMC+2) C A + 2 C +1 ) ft +1C+2)
7,69 ASMC+1 ) CU + 2 C + 1)
13.66 ASMC+2) C U + 2 C +1 )
3.5 0 ASMC+2) .CU + 2C + 1 ) ft +1C-1)
3.40 • ASM C+1 ) F E + 2 ( +1 )
6,00 ASM C+2) F E + 2 C +1 )
8,00 ASMC+3) FE+2C+1)
3.4 0 A S N1 C +1 ) FF+3C+1)
14.75 ASMC+2) FE + 3 C+1)
4.00 ASM(+1) P (3 + 2 C +1 )
6,00 ASMC+2) PB+2(+1)
7.00 ASMC+3) P3+2(+1)
9,20 A S M C + 2 ) PB+2C+1) OH-1C+1)
1.30 ASMC+1) M 6 + 2 ( +1 )
9.70 ASM(+1) M G + 2 C +1 ) ft +1 ( +1 )
2,30 .ASN1 (+2 ) M 6 + 2 (.+1 )
18.70 ASM C+2) M G + 2 ( +1 ) ft +1C+2)
2.4 0 ASM C+1 ) M N + 2 ( +1 )
4,00 ASM (+2) M N + 2 C +1 )
5,30 ASM C + 1 ) NI+2C+1)
9,40 ASM C+2) NI+2(+1)
11.40 ASM(+3) N I + 2 ( +1 )
4,45 ASM C + 1 ) Z N + 2 C +1 )
7.95 ASM C+2) Z N + 2 C +1 )
10.00: ASMC+3) ZN + 2 C +1)
9,266 ASP2C +1) II +1 ( +1 )
12.36 ASP2C+1) ft +1 C + 2 )
14.81 ASP2C+1) H +1 ( + 3 )
1.60 ASP2C+1) CA + 2 C + 1)
10,20 A S P 2 C +1 ) CA + 2(+1) II +1C+1)
2,10 ASP2C+2) C A + 2 ( +1 )
19.70 ASP2C+2) C A + 2 ( H ) ft +1C+2)
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8,50 ASP?(+1) C U + 2 ( +1 ) A
15,20 ASP2C+2) CU+2(+1) A
12.20 A S P 2 ( +1 ) CU + 2'(+1) H + 1 ( + I ) E
20,60 ASP2C+2) C U + 2 ( +1 ) H +1(+1) E
2 4.00 ASP2(+2) CU+2(+1 ) H +1(42) G
4.20 ASP2(+1 ) FE+2(+1) A
7.75 ASP?(+2) FE+2(+1) Q
11.00 ASP2C + 1 ) FE + 3 ( + 1 ) A
17.10 ASP2(+2) F E + 3 (+ 1 ) G
5,80 ASP?( + 1 ) PB+2(+1 ) A
8,20 ASf>2< + 2) P B + 2 ( +1 > A
10.70 ASP2C 4-1 ) P B + 2 ( +1 > H +1(+1) E
"4.00 ASP2C+1) P 8 + 2 ( +1 ) II + 1 (”1 ) E
2.20 ASP2< + 1 ) .MG + 2 (+ 1 ) A
10.60 A S P 2 (+1 ) M G + 2 ( +1 ) H +1(41) G
2.90 A S p 2 ( + 2 ) MG + 2 (+1 ) G
20,10 A S P 2 ( 4- 2 ) M G + 2 ( 4-1 ) H +1(42) G
3.20 A S P 2 ( +1 ) M N + 2 ( +1 ) A
5.20 ASP2C+2) M N + 2 (4-1 ) G
6.80 ASP?( + 1 ) N I 4-2 ( 4-1 ) A
10.50 ASP? ( i-1 ) N I 4? (4-1 ) H + 1 (+1 ) G
1 1 .60 ASP2(+?) N I + 2( + I) A
6.01 ASP?(+1) ZN + 2 (4-1 ) E
1 1 .88 A S P 2 ( +1 ) 2N+2(+1) H + 1 ( +1 ) G
9.30 ASp?(+2) • Z h + 2 < +1 > A
8.70 C I T'l(+1 ) H + 1 ( + 1 ) A
10.40 CIT1(+1) K +1(4-2) A
1 .20 CIT1(hi ) CA+2(+1) A
9.30 CIT1( + 1 ) CA+2(+1) H +1(41) G
1.50 CIT1(+2) CA+2(+1) A
18,30 . CIT1(+2) CA+2(+1) H +1(+2) G
7.00 • C I T 1 ( +1 ) C 0 4-2(4-1 ) • A
13.00 C1T1 (+2) CU+2(+1) A
3,00 CIT1 ( + 1 ) F E + 2 ( 4-1 ) G
4.8 0 C I T1 ( + 2 ) F E 4 2 ( 4-1 ) G
8,00 CIT1(+1 ) FE+3(+1 ) G
14.42 CIT1(+2) FE+3(+1) G
4.0 0 C I r 1 C +1 ) PB + 2(+1) E
6.00 CIT1(+2) PB4-2 (+1 ) G
8,00 C I T1 ( +1 ) PB+2(+1) OH m 1 ( 4 1 ) G
1.60 ’ CIT1(+1 ) M G 4 2 ( 41 ) A
9.80 CIT1( + 1 ) M G 4 2 ( 41 ) H + 1(4-1) G
1 .90 CIT1(+2) MG + 2 ( 41 ) A
18.80 CIT1(+2) MG42 (4-1 ) II + 1(+2) G
1 .70 C I T 1 ( +1 ) MH + 2(41) A
2.60 C I T1(+2) M N 4 2 (+1 ) G
4.75 C IT 1( +1 ) N142 (41 ) E
8.30 CIT1 (+2) NI 42(41 ) E
4,00 CIT1 (+1 ) Z N + 2 ( +1 ) A
7,00 ‘ CIT1<+?) Z N + 2 ( 41 ) A
10,113 C Y S 2 ( +1 ) H 41(4-1) M
18.04 C Y S 2 ( +1 ) H 41(4?) M
20,00 CYS?(+1 ) H 41(4-3) M
2,30 CYS2U1) C A + 2 ( +1 ) A
11.20 CYS2( + 'I ) C A 4 2 (4-1 ) H + 1 ( + 1 ) G
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2.70 CYS2C+2) C A + 2 (•+• 1 ) G
21 .70 CYS2C+2) CA + 2 ( +1) K +1(+2) G
13.00 CYS2U1 ) C U + 1 ( +1 ) G
17,00 CYS2C+2) CU + 1 (+1 ) G
20,50 CYS2C+1) C U +1 (+1 ) H +1 ( +1 ) G
35.50 CYS2C+2) CU +1 ( + 1 ) H + 1 (+ 2 ) G
94.00 CYS2C+4) C U M (+ 5 > G
6.00 CYS2C+1) FE+2(+1 ). A
11,00 CYS2C+2) FE+2C+1) A
11.73 . CYS2C+1) P B + 2 < +1) M
15,48 CYS2(+1) P B + 2 ( +1 ) H . +1 (+1 ) M
16.00 CY$?(+2) P B + 2 ( +1 ) A
18.40 CYS2U3) PB + 2(+1) A
26,00 CYS2C+2) . PB + 2( + 1 ) H +1 (+1 ) E
31 .00 CYS2C+2) P B + 2 ( +1 ) H +1(+2) G
2,60 CY$2(+1 ). M G + 2 ( +1 ) E
11,50 CY$2( + 1 ) M G + 2 ( +1 ) H + 1( + 1 ) G
3.40 CYS2C+2) M G + 2 ( +1 ) G
22,00 CYS2(+2) MG + 2( +1) H +1(+2) .• G
4,10 CY52O-1 ) (•! N + 2 ( +1 ) A
7,10 CYS2C+2) M N + 2 (+1 ) A
9.61 CYS2C+1) NI+2(+1) M
19.23 CYS2C +2) NI+2(+1) M
8.60 CYS2(+1) Z N + 2 (+1 ) M
17.77 CYS2C+2) Z N + 2 ( +1 ) M
14.60 CYS2C+1) Z N + 2 ( +1 ) H + 1( + 1 ) M
24.11 CYS2(+2) Z N + 2 ( +1 ) H + 1( + 1 ) M
29.72 CYS2<+2) ZN + 2(+1) H +1(+2) M
20.50 CYS2C+3) ZM+2(+1 ) M
3 0,16 CYS2(+3) ZM+2(+2) M
36.39 CY52C.+ 3) Z N + 2 (+ 2 ) H +1 (+1 ) M
41.75 CYS2C+3) Z N + 2 ( * 2 ) H +1(+2) M
42.68 CYS2C+4) ZN+2C+3) M
48.21 CY52C+4) ZN+2(+3) H + 1(+1 ) M
53.52 CYS2 <+ 4) ZN+2C+3) II +1<+2> M
8,69 CIS2C+1 ) H +1 ( +1 ) M
16,64 CIS2C+1) H +1(+2) M
18.34 CI$2(+1) K +1(+3) M
2.0 C I S2( + 1) C A + 2 < +1) G
2.5 CI52<+2) CA+2(+1) G
10,00 CI32C+1> CA + 2(+1) H + 1( + 1 ) G
17.40 CI32(+1) C A + 2 (+1 ) H + 1 (+ 2 ) G
19.50 CIS2C+2) C A + 2 (+ 1 ) II +1(+2) G
34,20 CIS2C+2) CA+2(+1) H + 1 (+ 4 ) G
6.80 CIS2(+1> CU+2(+1) G
16.87 CI$2(+1) CU+2(+1) H + 1( + 1 ) M
16,08 CIS2C+1) CU+2(+2) M
30,18: C I S 2 (-» 2 ) CU+2(+2) M
29,00 CIS2C+2) C U + 2(+1) H +1(+2) E
17.70 C1S2C+1) FE+3(+1 ) H + 1(+1 ) G
25,80 CIS2(+2) FE+3( + 1 ) II +1 (+1 ) G
31.28 CIS2C+2) FE+3(+1) H +1(+2) G
16.20 CI 52( + 1) P B + 2 C +1 ) II +1 ( +1 ) G
22.00 C I32< + 2) PB+2(+1) H + 1 ( + 2) ■ . G
10.70 CIS?<+1 ) MG+2(+1) II +1 < +1 ) G
%
«i
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17,70 CIS2(+1) M G 4 2 ( 41 ) H +1(+2) G
20,00 CI$2(+2) M G + 2 ( +1 ) H + 1 ( :-2) G
34.50 ClS?(+2) MG+2(41) II + 1 ( + 4 ) G
11,00 C I S 2 ( +1 ) M N 4 2 ( 4 1 ) H + 1 ( + I ) G
23.00 CIS2C+2) M N 4 2 ( +1 ) H +1(+2) G
5.50 CIS2<+1 ) N I 42(41 ) G
14,40 CIS2(+1) N142(41) H + 1 (+1 ) G
27.20 CIS2(+2) N I + 2 ( + 1.) H +1(+2) G
13,33 CIS2(+1) ZN42(41) II + 1 ( + 1 ) M
26.00 CIS2(+2) Z N 4 2 (+1 ) H 4 1 ( + 2 ) M
9.39 GLU2<+ 1) H 41(41) M
13.54 6LU2(+1) H 41(42) M
15.67 GLU2C+1) H +1(43) M
1.50 GLU2(+1) CA + 2 (41 ) A
10,40 GIU2C+1) C A 4 2 ( +1 ) H + 1 ( + 1 ) A
1 .90 GLU2(+2) C A 4 2 ( 41 ) A
20.10 GLU2C+2) c A + 2 ( +1 ) H .+ 1 ( + 2 ) A
8.74 GLU2(+1) CU+2(+1) M
14,91 GLU2C+2) C U 4 2 ( 4 1 ) M
12.79 GLU2(+1 ) C U + 2 ( 41 ) II + 1 (+1 ) M
20.00 GLU?(+2) CU + 2(+1) II + 1 ( + 1 ) G
24,50 GLU2(+2) c U + 2 ( 41 ) II +1(+2) G.
3.4 0 G LU2(+1 ) FE+2(+1) A*
6.00 GLU2(+2) F E + 2 ( +1 ) G
11.90 GLU2 ( + 1 ) FE+3(+1) E
18,70 GLU?(+2) FE+3(+1) G
4,50 GLU?( + 1) P B + 2 ( +1 ) E
6,00 GLU2C+2) P B 4 2 ( 4 1 ) E
8.30 • GlU2(+1) P B + 2 ( 4 1 ) OH -1(41). G
9,70 GLU2U2) PB+2(+1) OH -1 (+1 ) G
1 .80 GLU2(+1) M G.4 2 ( +1 ) A
10.60 GLU?(+1) MG + 2 (+1 ) II +1(+1) G
2,50 GLU2(+2) MG+2(+1) G
20.30 GLU2C+?) M G + 2 ( +1 ) H +1(+2) G
3.05 GLU2(+1 ) M N + 2 (+1 ) M
4.90 GLU2(+2) M N 4 2 ( 41 ) G
5,40 GLU?(+1) NI+2(+1) A
9.30 GLlJ2(+2) N I 4 2 ( 4 1 ) A
11 ,30 GLU2C+3) NI+2C+1) * G
4,76 GtU?(+1 ) ZN+2(+1) M
8.54- GLU2(+2) Z N + 2 (41 ) M
9,80 GLU?(+3) ZN+2(+1) A
8.68 G L N1 ( 1 ) H +1(41) M
10.86 GLN1( + 1 ) H +1(4?) M ‘
1 ,00 GLN1(+ 1) CA + 2( + 1 ) G
9,4 0 GLN1 ( + 1 ) CA+2(+1) I! 4 1 ( 4 1 ) G
1.40 GLN1(+2) C A + 2 (+1 ) G
18,40 GLN1(+2) CA+2(+1) H +1(+2) G
7,48 GLN1(+1) C U + 2 ( +1 ) M
13,57 GLN1(+2) C U 4 2 ( +1 ) M
3,50 GLN1(+1) FE+2(+1) A
6.00 GLN1(+2) FE + 2 ( + 1.) A
8.00 GLN1( + 3) FE + 2(+1) A
8.00 GLN1 ( +1 )’ Ft+ 3( + 1 ) G
14,79 GLN1(+2) F E + 3 (+1 )
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4.00
7,00
G L N1 (■»< 1 ) P 0 + 2 ( +1 ) E
EGLN1 (+2). PB + 2(+1)
8.00 G L N1 ( +■ 3 ) PB + 2(+1) E
8.00 GUN1 ( + 1) P B + 2 (4 1 ) OH -1 (+1 ) G
1 .70 GLN1(+1) MG+ 2(+1) G
9.80 GLU1 ( + 1 ) M 612 ( ♦• 1 ) H +.1( + 1) G
2.20 G L N1 ( + 2 ) MG+ 2 ( + 1 ) G
18,90 GLN1<+2) M6 + 2 ( +1 ). II +1(+2) G
2.60 GLNl(+1) MM + 2(+1) A
4,00 GLN1 (+2) M N + 2 ( +1 ) A
4.90 GLN1 U1 ) MI +2 (+1 ) A
8,90 GLN1(+2) N I + 2 ( +1 ) A
11.10 6LU1(+3) N I + 2 ( +1 ) G
4.17 G L N1 (4-1 ) Z N + 2 (+1) M
7,66' GLN1 ( + 2) ZN+2(+1) M
10,00 6 IN1 (+3)- ZN + 2(+1) . E
9,270 G L Y1 ( i-1 ) H +1(+1 ) M
11 .625 G LY1 (+1) rl +1 ( + 2 ) M
1 ,30 GI.Y1 (+1 ) C A + 2 ( +1 ) A
10.10 G L Y 1 ( +1 ) C A + 2 ( +1 ) II + 1( + 1 ) G
1 ,70 GLY1(+2) CA + 2(+1) G
19.80 6LY1(+2) CA + 2(*1) H +1(+2) G
8,02 CLY-1 (+1 ) CU + 2(+1) M
14.67 GLY1 (+2) CU+2C+1) M
10.11 GLY1<+1) CU + 2 < +1) H +1(+1) M
3.50 GLY1 (+1 ) FE+2(+1 ) A
5.50 GLY1(+2) FE+2(+1 ) A9,4 0 ' GLY1<+1) FE+3(+1) A16.50 GLY1(+2) F E + 3 ( +1 ) G5,00 GLY1 <+1 ) PB+2(+1) A
8.50 GLY1(+2) PB+2(+1 ) A
12.20 GLY1(+1) P B + 2 (+1 ) H + 1( + 1 ) E
-3,00 GLY1 (+1 ) P B + 2 ( +1 ) H + 1(-1 ) A
2.10 GLY1 (+1 ) MG+2(+1) A
10,60 GLY1 ( + 1 ) M G + 2 ( * 1 ) 11 + 1( + 1 ) G
2.70 G L Y1(+2) MG + 2 ( +1 ) G
20.30 GLY1(+2) MG+2(+1) H +1(+2) G
2.71 G L Y1 ( +1 ) M M + 2 ( +1 ) M4.76 GLY1 (+2) mm+2 (+1) M
5,5 2 GLY1 (+3) MN+2(+1) M
10.02 GL.Y1 (+1 ) M M + 2 ( +1 ) H +1 (+1 ) M1 2.89 GLY1(+2) M N + 2 ( » 1 ) II + 1(+1 ) M
5.70 GLY1(+1) N I + 2 (+1 ) M
10.30 GLY1(+2) MI+2(+1) M
13.50 GLY1(+3) MI+2(+1) M
4.83 GLY1( + 1 ) Z N + 2 ( +1 ) M
8,93 GI.Y1 (+2) ZN+2(+1 ) M
10.77 • GLY1(+3) Z M + 2 ( +1 ) M
10.07 GLY1 (+1 ) zn+2(+i) H + 1(4-1) M
-3,70' GLY1 ( + 1 ) Z N + 2 (+1 ) II +1(-1) M
8,777 H I S1 (•♦• 1 ) H +1 ( +1 ) M
14,60 H I 5 1 U1 ) rl +1(+2) M
16.29 HIS1(+1) II +1(+3> M
1.40. HI 51(+1) CA + 2 (4-1 ) G
9,70 HI31(+1) C A + 2 ( +1 ) it + 1 (+1 ) G
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1
1 .80 
18.90
HI 31( + 2)
K I SI (+2)
CA+2(+1)
C A + 2 ( +1 ) H +1(4-2) GG
9.75 It I 3 1 ( +1 ) CU + 2<+1 ) M •51 7 • A 0 H I S1 ( + 2 ) C U 2 ( +1 ) M •J13.70 ti I S1 (+1 ) CU + 2(+1) H +1(4-1) M if2.39 HIS1 ( + 1 ) CU + 2(+1) H +1(-1 ) M -s22.96 HI SI (+2) 0'J + 2 ( + 1 ) It +1 (+1) M
7.50 HI 31(+2) CU+2(+2) H + 1(-2) M26,16 HI 31(+2) C U + 2 (* 1) II +1(4-2) M
5.20 HIS1(+1 ) FE+2(+1) A
■Si..
9.50 H I 3 1 ( + 2 ). F E + 2 ( +1 ) A
4.20 H I 31 ( 1 ) FE+3(+1) G T7.65 H I S1( + 2) FE+3(+1) G
5,96 H I S1 ( +1 ) PD + 2 (4*1 ) M
9.50 HIS1(+2) PB+2(+1 ) M 316,80 it 131 ( + 2) P B 4- 2 ( +1 ) H +1 ( +1 ) £• s
22.50 HI 31 ( + 2) P B + 2 ( +1 ) H +1 ( + 2 ) E 18,00 H I 3 1 ( +1 ) PB + 2 (4-1 ) 0 H -1 ( +1 ) G /’«
2.20 HI 31 (+1 ) r’G + 2 ( + 1 ) G 110.10 H I S1 ( +1 ) ’ 1 3 + 2 ( + 1 ) H +1 (+1 ) G
2.90 HI 31(+2) I / G 4- 2 ( 4- 1 ) G 3
19.30 HI 31 (+2) 8 6 4-2(4-1) H +1(+2) G 1
3.24 HI 3-1 (+1 ) MM+2(+1) M
6.16 HI 31 (+2) •'lN + 2 (+1 ) M -z’
8,32 It IS1 ( + 1 ) N 14-2 (4-1 ) M -S;>•
14,86 HIS1(+2) N I + 2 ( + 1 ) M
10,25 HIS1(+1 ) N I 4-2 (4-1 ) H +1 ( +1 ) M •<
18.00 HIS1 (+2) H I + 2 ( + 1 ) It +1 ( +1 ) A is6.29 HI 31 (+1 ) Z N 4- 2 ( 4-1 ) M V
11.43 HI 31(+2) ZN + 2 (4-1 ) M
10.50 . HI 31 (+1 ) ZN + 2 (4-1 ) H +1 ( +1 ) M $
16.00 It I 31 (+2) ZN+2(+1) H +1 (+1 ) M 3
21 .00 HIS1(+2) ZW+2C+1) H +1 ( + 2 ) • E i*
9.626 HSNO (+1 ) H +1 ( +1 ) M ♦ ’*•
15.32 H S N 0 ( +1 ) II +1(+2) M '■s
9,16 HSNOC+1) CU+2(+1 ) M
15.48 HSN0C-+2) C U 4- 2 ( +1 ) M •
12.58 HS JO(+1) C U + 2 ( 4- 1 ) H +1 (4-1 ) M -i-2.00 HSM9C+1 ) CU+2(+1 ) -H +1(-1) G a
4,22 HSNO(+2) C U 4- 2(4-1) H +1(-1) M
21.02 H5U0(+2) 0 U + 2 ( + 1 ) H +1(+1) M
7.06 HSN0(+2) C 114-2(4-2) 'I +1(-2) M 5-5.95 H S N 0 ( + 2 ) C U + 2 (+1 ) H +1("2) M
4.55 HSNO(+1) 004-2(4-1 ) M
7,73 HSNOC+2) 0 0 4-2(4-1) M
-5.39 HSN0(+1 ) 004-2(4-1 ) It +1(-1) M -S'
4,90 HSNO (4-1 ) 004-2 ( 4-1 ) M i8.63 HSN0(+2) 00+2(+1 ) M *
10,67 H3U0(+3) 0 04-2 ( 4-1 ) M
-1 ,48 HS’IO(+2) 004-2 ( 4-1 ) II +1 (”1 ) M >$4.40 H S N 0 ( +1 ) FF. + 2(+1 ) G 25
8.00 HSNO(+2) F E 4- 2 ( 4-1 ) G •1
5.00 H3N0(+1 ) FE + 3 (4-1 ) G
9.00 HSNO(+2) ’ FE+3(+1 ) G
2,00 HSN0(+1 ) i-i '14-2(4-1) G
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3,40 H S N 0 ( + 2 ) M N + 2 ( +1 )
6,46 hs;jo(+i ) M I + 2 ( +1 )
11,31 H S N 0 ( + 2 ) N I + 2 ( +1 )
14.28 H S N 0 ( +3 ) N I + 2 ( +1 )
11.48 HSU0C+1) NI+2C+1) H +1 C +1 )
-2.96 11S N 0 < +1 ) N I + 2 C +1 ) H +1< * 1 )
0.00 HSNOC+2) N 1 + 2 ( +1 ) II + 1O1 )
2.78 HSNOC+3) N I + 2 ( +1 ) II +1 (*’ 1 )
4,87 MSM0(+1) zri + 2 ( + 1)
9.65 .HSNOC+2) Z N + 2 ( +1 )
11.50 H$N0(+3) Z N + 2 C +1 )
-2.74 H S N O (+1 ) Z N + 2 C +1 ) H + 1 (-1 )
9,30 HYP1(+1) H +1 ( +1 )
11.20 H Y P1 ( +1 ) H +1(+2)
1 .00 HYP1(+1) CA+2(+1)
9.80 HYPl (+1 ). C A + 2 ( +1 ) II + 1C + 1 )
1.30 HYP1(+2) C A + 2 ( +1 )
19,40 if Y P1 (+2) CA+2(+1) H +1<+2)
8.10 »IY P1 ( +1 ) CU+2C+1)
14,50 HYP1C+2) C U + 2 ( +1 )
3.80 HYP1(+1) FE+2(+1)
6,00 HYPl(+2) FE+2C+1)
8.50 HYP.1 (+1 ) FE + 3(+1)
15,00 H Y P1 ( + 2 ) FE+3C+1)
3.50 il Y P1 C +1 ) PB + 2 ( + 1 )
4.80 HYP1( + 2) PB+2C+1)
8.00 H Y P1 (+1 ) P 3 + 2 ( +1 ) OH -1( + 1 )
1 .70 • H Y P1 ( +1 ) HG+2C+1)
10.20 IIYP1 (+1 ) Pl 6 + 2 ( +1 ) II + 1( + 1 )
2.30 HYP1(+2) MG+'2 (+1 )
19,80 H Y P1 ( + 2 ) MG + 2 ( +1 ) H +1(+2)
2.70 HYP1 (+1 ) Pl .N + 2 (+1 )
4.90 HYP1(+2) M N + 2 ( +1 )
5.70 HYP1(+1) NI+2(+1)
10.00 KYP1(+2) NI+2C+1 )
4.5 0 HYP1(+1) ZN+2C+1)
8.50 HYPl(+2) ZN+2(+1)
9.36 ILE1 (+1 ) II +1(+1 )
11.72 I.EE1 (+1 ) H +1C+2)
1,10 I t,E1 (+1 ) C A + 2 ( +1 )
9.90 ILE1( + 1 ) CA + 2 ( + 1) H + 1(+1 )
1 ,40 iL e1(+2) C A + 2 C +1 )
19.60 ILE1(+2) C A + 2 ( +1 ) II +1(+2)
7.95 ILE1( + 1 ) C IH 2 ( +1 )
14,68 I LE1(+2) CU+2(+1)
0,32 ILE1(+1 ) CU + 2 ( + 1 ) H + 1 C -1 )
3.00 I L E 1 ( +1 ) F E + 2 ( +1 )
5.00 ■ ILE1(+2) FE+2(+1)
9,00 ILE1 ( + 1 ) FE+3(+1)
15,40- IL b1(+2) FE+3(+1)
3,80 ILE1(+1) P 8 + 2 ( +1 )
5,30 1LE1(+2) P 0 + 2 (+1 )
8.00 I LE1 (+1 ) PB+2C+1) OH -1 (+1 )
1,80 I LE1 (+1 ) UG + 2 (+1)
10,30 ILE1(+1) M G + 2 ( +1 ) H +1C+1)
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2.40 ILE1(+2) MG 4-2 ( 4-1 ) G ■1
20.10 ILC1(+2) M 6 + 2 ( 4-1 ) H + K+2) G .
2.60 IL E1(+1 ) M N + 2 ( +1 ) A ?£
4.70 ILE1(+2) M N + 2 (+1 ) A
5.20 IL E1<+1 ) NI4-2 <4-1 ) A t
9.40 ILE1(+2) N 14-2(4-1 ) A
11 .00 ILE1(+3) N 14-2 (4-1 ) A
4.40 ILE1( + 1 ) 7114-2(4-1 ) M
8,08 ILE1(+2) ZN *2(4-1) M
10.00 . ILEK+3) ZU + 2(*1) A •tf
-3.62 ILE1(+1 ) ZU+2(+1) II. +1 (-1) M 1
15,2 5 ILE1(+2) Z N * 2 ( * 1 ) H +1 ( +1 ). M
9,36 LEU1(+1) H + K + 1) M
1 1,72 LEU1(+1 ) H‘+1(+2) M
1.10 I, E U1 (4-1 ) C A + 2 ( * 1 ) A is
9.9 0 EEU1 (+1 ) C A + 2 (+1 ) II + 1 ( + 1 ) G
1 .40 LEU 1(+2) C A + 2 ( +1 ) G ■*g-s'
19.60 LEU1(+2) CA+2(+1) H +1(+2) G a
3.04 LEU1(+1 ) CU + 2 (4-1 ) M 1
14.69 LEU1(+2) CU+2(+1) M
11 ,49 LEU1( + 1 ) CU+2(+1) H +1(+1) M
19.43 LEU 1 < + 2) CU+2(+1) H +1 ( +1 ) M ■
3.32 LEU1 ( + 1 ) FE+2(+1 ) A ■ S
5.00 LEU1 (-1-2) FE+2(+1) E ??
9.49 LEU1 (i-1 ) F E + 3( +1 ) A •;s
15,50 LEU1(+2) FE+3(+1 ) E 14.00 IE U1 ( +1 ) PB+2(+1 ) G
5.50 • UEU1(+2) p 3 + 2 (+1 ) G
8.00 LEU1(+1) P B + 2 ( +1 ) 0 H -1 ( +1 ) G 5\t
1.80 UEU'I (+1 ) H G + 2 ( +1 ) G 1
10.40 LEIJ1 ( + 1 ) M 6 + 2 ( +1 ) H +1 < +1 ) . G
2.30 IEU1 (4-2) M G + 2 ( +1 ) G 3
20.10 LEU1(+2) M G + 2 ( +1 ) 11 +1 (+2) G }
2.30 LEU1( + 1 ) M N + 2 ( +1 ) A i
4.20 LEU1(+2) M N + 2 ( +1 ) A i
5,4 0 L E U1 ( +1 ) NI+2(+1 ) A ^Zs
9.4 0 LEU1(+2) N I + 2 ( +1 ) A
12.90 UE01(+3) N(+ 2( + 1 ) ' A ’ -s?l
4.51 .LEU1( + 1 ) Z N + 2 ( +1 ) M 'J
8.56 LEU 1 (4-2) ZU+2(+1) M
10,60 LEU1(+3) ZM+2(+1) G
^4,25 L EU 1 ( + 1 ) ZN *2( + 1 ) H +1(-1) G 'I?.rVa
15.17 U E U1 ( 4 2 ) ZU+2 ( + 1) H +1(+1) . M 1/x;
10.30 L Y S 1 (4-1 ) II +1(+1) M V
19.18 L.YS1 (4-1 ) H +1(+2) • M
21,33 L Y S 1 < +1 ) H +1(+3) M J • ►'/1 .0 LY$1 ( + 1 ) C A + 2 (+1 ) G
1 .3 : LYS1 (4-2) CA+2(+1) G f:
11 .60 LYS1 (4 1 ) C A 4- ? ( +1 ) H +1 ( +1 ) G $
20,75 LY$ 1( + 1 ) C A + 2 ( +1 ) H +1(+2) G *,
21 ,80 LYS1 (4-2) CA+2(+1) H +1(4-2) G
39.70 LYS'I (4-2) C A + 2 ( +1 ) II +1 (+ 4) G
10,85 L Y S1 ( 4-1 ) CU+2(+1) M
14.60 L.YS1 (4-2) CU+2(+1) M
17.99 LYS1 (4-1 ) C U + 2 ( +1 ) II +1(+1 ) M •
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20,64 LYS1(+1) CU + 2 (4-1 ) H +1(+2)
25.62 LYS1(+2) C U + 2 ( +1 ) II + 1( + 1 )
34,30 LYS1(+2) C U »• 2 ( 4-1 ) H +1(+2)
13.80 LYS1(+1 ) FE+2(+1 ) H + 1( + 1 )
18.30 LYS1(+2) FE + 2 ( + 1 ) H + 1( + 1 )
25.00 LYS1(+2) F E + 2 (+1 ) H + 1 (+ 2 )
18.40 LYS1(+1 ) F E + 3 ( +1 ) H +1 ( +1 )
28.88 IY51(+2) FE+3(+1) II + 1 (+1)
3 5.87 UYS1C + 2) FE+3(+1) H + 1 (+.2)
14.10 LY$1(+1) P 0 4- 2 ( +1 ) H 4-1 ( + 1 )
18.90 LY$ 1(+2) PB+2(+1) fi­ + 1 (+1 )
25.86 LYS1 (+2) P B + 2 ( + 1 ) ll + 1 (+2)
1.10 LYS1(+1) M G + 2 (4-1 )
1 .40 LYS1(+2) M G + 2 ( +1 )
12.10 U Y S1 ( + 1 ) M G + 2 ( +1 ) II + 1(+1 )
21 .20 LYS1(+1) ! 1G + 2 (4-1 ) II + i (+ 2)
22.70 LYS1(+2) M G 4- 2 ( +1 ) H +1(+2)
40.00 LYS1(+2) MG+2(+1) H +1(+ 4)
12.20 LYS1 (4-1 ) M ' •) 4- 2 < 4-1 ) H + 1(+1)
19.50 L Y S1 (+2) M N + 2 ( +1 ) II + 1(+1 )
24,35 LYS1 (4-2) M N + 2 ( +1 ) H + 1(+2)
5.50 LYS1 ( + 1 ) N I + 2 ( +1 )
9,00 LYS1 (4 2) NI+2(+1)
16.00 LYS1 (4-1 ) NI+2(+1) H +1(+1)
21 .50 LYS1 (4-2) N I + 2 (+1 ) II +1(+1)
29.80 LYS1 (4-2) N I + 2 ( +1 ) H +1(+2)
3.50 LYS1 (+1 ) ■2 N + 2 ( +1 )
7.00 LYS1(f2) ZN+2(+1)
14.37 L Y S1 (4-1 ) ZN+?(+1) H + 1 (+1 )
19.34 LYS1 (4-2) ZN+2(+1) II +1 ( +1 )
28.51 L.YS1 ( + 2) 2 N + 2 ( +1 ) H +1(+2)
8.91 MET1 (4-1 ) H +1 ( +1 )
11.17 MET1(+1) H +1(+2)
1.20 MET1 (4-1 ) CA + 2(+1)
9.50 MET1 (4-1 ) CA+2(+1) H + 1 (+1)
1.60 MET1 (4-2) CA + 2 ( + 1)
13.70 MET1 (4-2) C A + 2 ( +1 ) H +1(+2)
7.67 MET1 ( 4-1 ) C U + 2 ( +1 ).
14.08 MET1 ( + 2) CU+2C+1)
3.15 MET1 (4-1 ) FE+2(+1)
4.90 MEF1 (4-2) FE+2(+1>
8.60 MET1 (4-1 ) FE + 3( + 1 )
14.94 MET1 (4-2) FE+3(+1)
4.30 MET1 (4-1 ) P 3 + 2 ( +1 )
7.5 0 MET1 (4-2) P 3 + 2 ( +1 )
8,20 MET1 (4-1 ) P B + 2 ( + 1 ) OH -1(+1 )
1 .80 MET1 (4-1 ) M G + 2 ( +1 )
9.90 : MET1 (4-1 ) Pi G + 2 ( +1 ) H + 1(+1 )
2,4 0 MET1 (4-2) M G + 2 ( +1 )
19.10 MET1 (4-2) M G + 2 < +1 ) H +1(+2)
2.70 MET1 (4-1 ) M N + 2 ( +1 )
4,25 MET1 (4-2) M N + 2 ( +1 )
5.00 M E T1 ( +1 ) N I + 2 (+1 )
9.10 ME T1 (42) N I + 2 ( + 1 )
11.10 MET1 (+3) N { + 2 (+1 )
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4,00 PHE1( + 1 ) P B + 2 ( 4-1 ) G
7.20 PH E1 <»-2) PB + 2(41) G
8.00 PHE'1( + 1 ) PB + 2 ( +1 ) OH -1(+1 ) G
1 .70 PH E1(+1 ) M 6 4- 2 ( 41 ) G
9.80 PHE1( + 1 ) M G 4 2 ( 41 ) H + 1 ( + 1 ) G
2.30 PHE1(+2) MG+2(+1) G
19.00 PH E1(42) MG+2(+1) l-l +1(+2) G
2.4 0 PHE1(+1 ) MN + 2( + 1) A
4.30 PH E1 (+2) M N + 2 ( 41 ) A
5.10 PHE1 (+1 ) N I + 2 ( + 1 ) A
9.00 PHE1(+2) NI 42 (41 ) A
4,21 P H E 1 ( +1 ) Z N + 2 ( 41 ) M
3.17 PH E1 (+-2) ZN + 2 ( + 1 ) M
10.25 P R 01 ( 41 ) II 41(41) M
12.25 PRO1(>1 ) H +1 (+2 ) M
1 ,30 PRO1 (+1 ) CA+2(+1 ) G
11.50 PRO1 (4-1 ) C A 4 2 ( 41 ) H + 1(+1) G
1,70 PRO1 (+2) CA+2(+1 ) G
21.80 P R 0 1 ( 4- 2 ) C A 4 ? ( 41 ) H +1(+2) G
3.68 PRO1 (4-1 ) CU + 2(+1) M
16,00 P R 01 (+ 2 > CU+2(+1 ) M
10.64 P R Q1 (•<• 1 ) CU+2(+1) H + 1 (+1 ) M
4,00 PR-01 (+1 ) FE + 2(+1) G
7.00 PRO1 (4-2) FE+2(+1) E
9.69 PRO1 (4-1 )• FE+3(+1) A
17,90 PRO1(+2 ) FE+3(+1) G
4.00 PRQ1(+1) P 8 + 2 ( 4 1 ) G
6.00 PRO1(42) P3 + 2 ( i-1 ) G
8,00 PRQ1 (41 ) P 8 + 2 ( +1 ) OH ~1(+1> G
1 ,90 P R 01 ( 41 ) MG+2C+1) G
11,60 . PRO1(41 ) M G + 2 ( •-1 ) H + 1 (4-1 ) G
2.40 • PRO1(42) M 6 + 2 ( +1 ) * G
22.20 PRO1(42) M G + 2 ( + 1 ) H + 1(+2) G
2.84 PRO1( + 1 ) M N + 2 ( 41 ) M
5.53 PRO1(42) M N + 2 ( +1 ) M
6,74 PRO1(43) M N + 2 ( + 1 ) M
11 ,84 PRO1(+1 ) M N + 2 ( +1 ) H + 1( + 1) M
14.92 PRO1(42) MN+2(41) H + 1 (+1 ) M
5.80 PRO1(41 ) N I +2(+1 )• A
10.50 PRO1(42) NI+2(+1) A
5.50 ' PR01 (41 ) Z N + 2 (+1 ) M
9.90 PRO1(42) Z N + 2 ( +1 ) M
11.16 PR 01(43) Z N + 2 ( +1 ) M
12.52 PR01 ( + 1 ) Z N 4-2(41) H + 1 ( + 1 ) M
-2.60 PR01 (+ 1 ) Z N 4 2 ( 41 ) H + 1 M ) M
-0.06 P R 01 ( 4 2 ) Z N + 2 ( +1 ) H + 1 ("1 ) M
8.71 SER1 (+1 ) H +1(41) M
10.79 SER1 (41 ) H + 1 ( + 2 ) M
1 .30 SER1 (4-1 ) C A 4 2 ( + 1 ) A
9,50 SER1 (+1 ) C A 4 2 ( 4 1 ) H + 1 ( + 1 ) G
1,70 S E R1 ( 4 2 ) C A + 2 ( +1 ) G
18,60 SER1(42) C A + 2 ( 4-1 ) H 4 1 ( + 2 ) G
3,03 SER1 (41 ) C U + 2 ( 4 1 ) M
14,37 5ER1(42) CU + 2 (4-1 ) M
10,65 S E R1 ( 4 1 ) C U 4 2 ( 41 ) H 4 1 ( 4 1 ) M
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4,83 SER1(+2) CU+2(+1) H 4 1 ( ** 1 )
3.35 SER1(+1) F £ + 2(4-1)
6.00 SER1 (+2) F E + 2 ( 4-1 )
3.00 SER1(+3) F E * 2 < +1 )
8.70 SER1(+1) FE+3(+1)
15.90 SEH1(+2) FE+3(+1)
4.40 SER1(+1) PtJ + 2 (+ 1 )
7.20 SER1(+2) P 8 + 2 ( +1 ) .
8.30 SER1 ( +-3) 934-2(4-1 )
-3.50 SER1(+1) PB + 2 (+ 1 ) H + 1 (-1 )
1 .80 SER1(+1) M 0 4-2(4-1)
9.30 SER1 (+1 ) (10 + 2(4-1) H + 1 ( + 1 )
2.40 3ER1(+2) M 0 + 2 ( +1 )
18.90 SERI(+2) 110 + 2(4-1) H +1(+2)
2.43 SER1(+1) P> ‘1 + 2 ( + 1 )
4.00 SER1(+2) M N + 2 ( + 1 )
5.01 SER1(+1) NI+2(+1 )
9.09 SER1(+2) N1+2(+1)
12.49' SER1(+3) N I + 2 ( +1 )
4.39 S E R 1 ( +1 ) ZIJ + 2 (+1 )
8.17 SF.R1 (+2) Z N + 2 ( +1 )
— 1 .14 SER1(+2) ZN+2(+1) H 4-1 ( " 1 )
10.56 SER1(+3) ZN+2(+1)
8.71 THR1(+1) H +1 (+1 )
10.91 THR1 ( + 1) II +1(+2)
1.10 THR1(+1) C A + 2 (+1 )
9.50 THR1 (+1 ) CA+2(+1) H 4-1 ( + 1 )
1,40 THR1(+2) CA+2(+1)
18,50 • THR1(+2) CA + 2( + 1 ) H +1(+2)
7,79 THR1(+1) CU+2(+1)
1 4,3 0 THR1(+2) C U + 2 ( +1 )
11.00 THR1(+1) C'J + 2(+1 ) H + 1 ( + 1 )
1.60 THR1 <4-1 ) CU + 2(+1) H + 1 (”1 )
4,69 THR1(+2) CU+2(+1) M + 1 ("1 )
3,50 T H R 1 ( +1 ) FE + 2(+1)
6.00 THR1 (4-2) FE+2(+1)
8.40 THR1(+1) FE+3(+1)
15,40 THR1(+2) FE + 3(+1)
4.40 T H R 1 ( +1 ) P 3 + 2 ( +1 )
7,4 0 THR1(+2) P B + 2 (+1 )
8.00 • TI1R1 (+1 ) P3 + 2 ( + 1 ) OH -1 ( + 1 )
1.70 THR1 (+1 ) M 0 + 2 ( +1 )
9.80 TIIR1 (+1 ) M 0 + 2 ( +1 ) H + 1 ( + 1 )
2,30 THR1(+2) M G 4- 2 ( +1 )
18,70 THR1(+2) M 0 + 2 ( +1 ) H +1(+2)
2.56 THR1 (4-1 ) M N + 2 ( +1 )
3,90 THR1(+2) M N + 2 ( +1 )
5,30 THR1(+1) NI+2(+1)
9, A 0 THR1 (+2) NI+2(+1)
12,40 THR1(+3) NI+2(+1 )
4,83 THR1(+1) ZN + 2(+1)
8.28 THR1(+2) Z N + 2 ( +1 ) .
-1.16 TI1R1 (4-2) Z N + 2 ( +1 ) H + 1(-1)
10.09 TIIR1 (4-3 ) Z N + 2 ( +1 )
9,07 TRP1 (4-1 ) H +1 ( +1 )
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11.50 TRP1 ( + 1 ) II 4-1 < + 2)
1 .20 r r p 1 (+1) C A 4- 2 ( 4- 1 )
9.70 TRP1 ( + 1 ) ' C A + 2 ( +1 ) !!■ +1 ( +1 )
1 .60 TRP1(+ 2) CA+2(+1 )
19.10 TRP1 (-4-2) C A + 2 < + 1 ) H +1(+2)
3.05 T R P1 ( +1 ) C U + 2 ( 4* 1 )
15.29 TRP1(+2) C U + 2 ( +1 )
3.4 5 TRP1(+1) FE+2C+1 )
6.20 TRP1(+2) F E + 2 (+1 )
7.50 TRP1(+ 3) FF. + 2( + 1 )
8.40 TRIM(+1) FE + 3 (+1 )
16.15 T R P1 ( + 2 ) FE+3(+1)
4.40 TRP1(+1) P 8 + 2 (+1 )
3.50 TRP1 (+2) P 8 + 2 (+1 )
8.00- TRP1(+1) P 3 + 2 ( +1 ) OH w 1 ( +1 )
1 ,80 TRP1(+1). M G + 2 ( 4-1 ) •
10.10 TRIM(+1) MG+ 2( + 1 ) H ► 1 (+1 )
2,30 TRP1 (+2) M G + 2 ( +1 )
19.50 TRIM (+2) M G 4- 2 ( +1 ) H +1(+2)
2.60 T R P1 ( +1 ) M N 4- 2 ( +1 )
4.30 TRP1(+2) M N 4- 2 ( 4-1 )
5,70 TRP1(+3) M M + 2(4-1)
5.50 TRP.1 (+1 ) N I + 2 ( +1 )
9.50 TRP1(+2) N I + 2 ( +1 )
13.00 TRP1(+3) NI+2C+1)
4,50 TRP1 ( + 1 ) 2 N + 2 ( +1 )
8.76 TRP1(+2) ZN+2(+1)
11 .61 TRP1C+3) ZN+2C+1)
10,06 TYR2(+1) H +1 ( + 1 )
19,00 TYR2U1 ) H +1 ( + 2 )
21 ,35 TYR2(+1) H 4 1 ( + 3 )
1,00 TYR2U1 ) CA+2C+1)
1 .20 TYR2<+2) CA+2(+1)
11.20 TYR2C + 1 ) C A + 2.( + 1 ) H +1 (+1)
19,50 TYR2C + 1 ) CA+2(+1) H +1(+2)
20.60 TYR2(+2) CA+2C+1) H +1(+2)
38.80 TYR2(+2) CA + 2(+1) II +1(+4)
9.3 2 TYR2<+1) ClJ + 2( + 1 )
15.09 TYR2(+2) C U + 2 ( +1 )
17.63 r Y R 2 (+1 ) C U + 2(+1) H 41(+1>
2 5.03 TYR?(+2) C U + 2 ( +1 ) H + 1 ( + 1 )
3 4.44 TYR2(+2) CU+2(+1) H +1(+2)
3,00 TYR2C+1 ) F E + 2 < +1 )
13,50 TYR2(+1) FE+2(+1) H +1 (+1 )
19,00 TYR2(+2) FE»-2( + 1) H + 1( + 1 )
27.00 TYR2(+2) FE+2(+1) H +1( + 2)
7,00 TYR2C »-1 ) FE+3C+1)
18,00 ; TYR2(+1 ) IF+ 3 ( + 1 ) II + 1(+1 )
28,84 TYR2C+2) FE + 3(+1) II +1 ( +1 )
35,07 TYR2(+2) F C 4 3 ( +1 ) H + 1(+ 2 )
3.50 TYR?(+1) P 8 + 2 ( +1 )
14.16 TYR2U1 ) P 3 + 2 ( +1 ) H +1 (+1 )
28,17 TYR2(+2) p 0 + 2 ( +1 > H +1(+2)
21 .00 TYR2C+2) P 8 + 2 ( +1 ) II +1(+1)
1,10 TYR2 ( + 1 ) MG+2C+1)
2GG
1,40 TYR2(+2) MG+2<+1 ) G
11.70 1 YR2(+1) MG + 2(+1) H +1( + 1) G
19.80 TYR2C+1 ) M G * 2 ( +1 ) H + 1(+2) G
2?.10 TYR2(+2) M G + 2 ( +1 ) H +1(+2) G
39.10 TYR2(+2) M G + 2 ( +1 ) H 4-1 (+ 4) G
1.20 TYR2<+1 ) MU+2(+1) G
12.36 TYR2C+1) M N + 2 (+1 ) II + 1 <4-1 ) J5
19.28 TYR2(+2) MN>2( + 1 ) •H + 1 ( + 1 ) E
23.90 TYR2<+2) M N + 2 < + 1 ) H +1(+2) E
14.90 TYR2C+1) N I + 2 ( +1 ) H + 1 (+1 ) A
29.00 TYR2(+2) i'U+2<+1 ) H + 1(+2) E
6.08 TYR2(+1) ZN+2(+1) A
14.27 T Y R 2 ( +1 ) Z N + 2 ( +1 ) II +1(+1) A’
27.90 TYR2(+2) Z N + 2 ( +1 ) H 4-1 (+2) A
21.00 TYR2(+2) ZN + 2(+1) H + 1 (+ 1) A
9.26 VAU1(+1) H +1(+1) M
11 .66 VAL1(+1) H +1(+2) M
1.10 VAL1(+1) C A + 2 ( 4-1 ) A
9.80 VAL1( + 1 ) CA+2(+1 ) H +1 (+1) G
1.40 VAI.1 (+2) CA+2(+1) G
19.40 VAL1 (+2) C A + 2(+1 ) H + 1(+2) G
7.93 VAL1(+1) C U + 2 (+1 ) M
14.60 VA.l1 (4-2) C U + 2 < +1 ) M
10.28 VAL1(+1) CU+2(+1) H +1(+1) M
18.38 VAL1(+2). CU+2(+1) H + 1 ( + 1 ) M
3.25 VAL1(+1 ) PE4-2 ( +1 ) A
5.20 VAL1 (+2) FE+2(+1 ) G
9,20 VAL1 (+1 ) FE+3(+1) A
16.20 V A L1(+2) FE+3(+1) G
3,80 VAL1(+1) PQ+2(+1) E
5.60 VAL1 (+2) P8+2(+1) E
3,80 • VAL1(+2) P B + 2 (+1 ) OH -1 (+1) S
1 .70 V A U1 (+1 ) MG + 2 ( + 1) G
10.20 VAL.1 (+1 ) M G + 2 (+1) H +1(+1) G
2.20 VAL1<+2> M G 4 2 (+1 ) G
19.80 VAL1(+2) MG + 2 (4-1 ) H +1(+2) G
2,337 VAL1(+1) M N + 2 ( +1 ) M
3.97 VAL1(+2) M N + 2 ( +1 > M
5,19 VAL1(+3) M N + 2 ( +1 ) M
10.43 VAl.1(+1) M N + 2 ( + 1 ) H +1 (+1) M
12.73 • V AL1 (+2) MN + 2(+1) H +1(+1) M
5.15 VAL1(+1) N 14-2(4-1 ) A
9.45 VAL1(+2) M+2<+1 ) A
11,30 VAL1(+3) N I 2 ( + 1 ) A
4.44 VAL1(+1 ) Z N + 2 ( +1 ) M
r 8.24 VAL1(+2y 2 N + 2 ( +1 )• M
10,62 VAL1(+3) ZN + 2(+1) M
4 • 1 8 VAL.1(+1 ) ZN+2(+1) H + 1 (*"1 ) • M
10.24 CO32(+1) li +1(4-1) A
16.54 * C032C + 1 ) n +1(+2) A
2.90 C032 ( + 1 ) CA+ 2(+1) A
10.90 CO32<+1) CA + 2(+1) II +1(+1) A
5.50 CO32C+1) C U + 2 ( +1 ) A
8.30 CO32(+2) C U + ? (+1 ) A
13.00 C03?(+1) C U + 2 ( +1 ) H +1 (+1) G
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14,20 CO3?(+2) CU + 2 ( + 1 ) H +1(+2) G
4,50 CO32(+1 ) F fc + 2 (+1 ) A
6,00 CO32(>2) F E + 2 ( +1 ) A
12.00 C032 (+1 ) FE+2(+1 ) II +1 ( +1 ) A
13,00 0032 ( 4-2 ) FE + 2( + 1 ) H +1 ( + 2) A
6.00 0032 (4-1 ) FE+3 (4-1 ) A
9,00 0032 (4-2 ) FE+3 (4-1 ) A
13.00 0032 (4-1 ) FE + 3 (4-1 ) H +1(+1) A
14.50 0032 ( 4-2) FE+3(+1 ) H +1C+2) A
5,<30 0032 (4-1 ) PB + 2 (4-1 ) A
8,80 0032 (4-2) PB+2(+1 ) A
14.00 0032 ( 4-1 ) P B 4 2 ( 4-1 ) H + 1( + 1 ) G
14,90 0032 (4-2) P 8 + 2 ( + 1 ) H +1(+2) 15
15,30 0032(4-3) P B 4- 2 (4-1 ) H +1 (+ 3 ) A
2.90 0032 ( 4-1 ) M 6 4-2(4-1) A
10.70 0032(4-1 ) M 6 4- 2 (4-1 ) H + 1( + 1 ) A
3.10 0032 (4-1 ) M N + 2 (+1 ) A .
11.50 0032 (4-1 ) MN4-2 (4-1 ) H + 1( +1 ) A
3,3 0 0032 ( 4-1 ) ZN+2(+1 ) A
11.80 0032 ( 4-1 ) ZN4-2 (4-1 ) H + 1( + 1 ) A
-11.7 H 4-1 (-1 ) CA + 2 (4-1 ) M
-7,6 H 4-1 (-1 ) C U + 2 ( 4-1 ) • M.
-10.00 H * 1 ( — 2 ) 004-2(4-2) M
-9.50 H 4-1 (-1 ) FE+2C+1 ) A
-2.30 H 4-1 (-1 ) FE+3(+1) A
-6,00 H 4-1 (-2) FE+3 (4-1 ) A
-3,00 H 4-1 (-2) FE + 3 (4-2) A
-8.50 H 4-1 (-1 ) P B 4 - 2 ( 4-1 ) A
-17,50- H +1(-2) PB+2(+1) A
-20.0 H 4-1 (-1 ) PB + 2 (+ 4) A
-11.5 H 4- 1 ( w 1 ) MG+2(+1 ) M
-4 0,0 H 4-1 <-4) MG+2(+4) A
-10,1 H 4- 1 ( ~1 ) M N 4- 2 ( 4-1 ) M
-10,0 H 4-1 (-1 ) NI 4-2 (4-1) A
-28.0 H 4-1 (-4) N I 4-2 (4-4 ) A
-9,03 H 4-1 (~1 ) Z N + 2 ( 4-1 ) M
-17,00 H 4-1 ( — 2 ) ZN + 2 (4-1 ) A
— 8,00 H 4-1 ( "" 1 ) ZN + 2 ( + 2 ) A
11.30 PO43(+1 ) H 4-1 (4-1 ) M
18.00 PO43C+1 ) K 4-1 (4-2) M
19.92 ' PO43(+1) H 4-1 (4-3) M
39.50 PO43(+2) H 4-1 ( 4- 5 ) M
36.72 PO43C+2) H 4-1 ( 4- 4 ) M
29,63 P043(+2) II 4-1 (4-3) M
6.05 PO43(+1 ) C A + 2 ( 4-1 ) M
12.70 P043 (4-1 ) C A + 2 ( +1 ) H + 1(+1 ) M
18,60 PO43C+1 ) C A + 2 < +1 ) H +1(+2) M
16.30 PO43U2) CA+2(+2) H + 1(+ 2) M
32.30 PO43U2) CA + 2 (4-1 ) H +1 ( + 3) M
25.30 PO43(+2) CA+2(+1) H + 1 ( + 2) M
14,60 PO43<+1 ) CU+2(+1) H + K+1) M
19.30 PO4 3 (4-1 ) C U + 2 ( +1 ) H + 1 (+ 2) M
34.00 PO43 (4-2) CIJ + 2 ( + 1 ) H + 1(+ 3 ) M
31 .80 PO43(4-2)' CU+2(+2) H + 1 (+2) M
27.00 PO43 (4-2) C U + 2 ( +1 ) II +1(+2) M
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12,08 CTA3(+1 ) FE + 3(+1 ) H + 1( + 1 )
16,00 CTA3(+2) FE + 3(+1)
17,00 CTA3(+2) FE+3(+1) H + 1 (+1 )
23.00 CTA3C+2) F E + 3 ( +1 ) H + 1 (+ 2 )
9.00 CTA3C+1 ) F F + 3 ( +1 > H +1 (-»1 )
1,50 CTA3(+1 ) F E * 3 ( +1 ) H +1(-2)
3.00 CTA3C+2) FE+3(+1) H +1(-2)
18,56 CTA3C+2) FE + 3( + 2) H +1(-2)
4.3 0 CTA3(+1) P B + 2 ( +1 )
8.00 . CTA3C+1) PB+2C+1) H + 1(+ 1 >
10.50 CTA3( + 1 ) PB+2(+1) H .+1(+2)
”4.00 CTA3C+1) PB+2C+1) H +1<~1)
5.40 CTA3C+2) P B + 2 ( +1 )
10.00 CTA3C+2) PB+2C+1) H + 1( + 1 )
14.30 CTA3(+2) p 8 + 2 ( +1 ) H +1(+2)
17.90 CTA3C+2) PB + 2(+1) H +1(+3)
20,50 CTA3(+2) PB+2(+1) H +1(+4)
2,00 CTA3C+3) PB+2(+1)
6.00 CTA3( + 1 ) PB+2C+2)
14.00 CTA3C+2) PO+2(+2) H + 1(+1 )
4,00 CTA3C+2) PB+2(+2)‘ H + 1(”1 )
-3.50 CTA3 ( v2) PB+2(+2) H +1(”2)
11.50 CTA3C+3) PB+2(+2)
1 .00 CTA3(+2) PB+2C+3) H +1<”2)
8.50 CTA3(+3) PB + 2 ( + 4) H +1<”2)
3,34 CTA3(+1) MG+2C+1)
4.10 CTA3(+2) M G + 2 (+1 )
7.32 • CTA3C+1) MG+2(+1) H + 1( + 1 )
10,00 CTA3C+1 ) MG + 2(+1) H +1(+2)
3,82 CTA3C+1 ) M N + 2 ( +1 )
4.3 0 CTA3(+2) M N + 2 ( +1 )
5,00 CTA3(+1) M N + 2 ( +1 ) H +1 ( +1 )
-5,50 CTA3C+1) M N + 2 ( +1 ) H +1(~1>
4.90 CTA3(+1 ) NI+2C+1)
8,30 CTA3C+1) NI+2C+1) H +1(+1)
5,50 CTA3C+2) NI+2( + 1 ) H +1(+2)
”1.00 CTA3 (4-1 ) N I + 2 ( +1 ) H +1(”1)
4,715 CTA3(+1 ) ZN+2C+1)
8,44 CTA3(+1) Z N + 2 ( +1 ) H + 1( + 1 )
10.95 C TA3 < *1 ) ZN+2(+1) H +1(+2)
”2.50 CTA3C+1 ) ZN+2(+1) H + 1(”1 )
7.36 CTA3(+2) ZN+2(+1)
”2.21 CTA3C+2) Z N + 2 ( + 2 ) H + 1 ( ” 2)
3.78 LTA1(+1) H +1(+1 )
1 .30 LTA1(+1) CA + 2C+.1 )
2,00 I.TA1 ( + 2) CA+2(+1 )
2,20 LTA1(+1) CU+2C+1)
3,00 : LTA1( + 2) CU + 2(+1)
3.03- I.TA1 (+3) CU + 2(+1)
1,50 LTA1 (+1 ) FE+2(+1)
4,00 LTA1(+1 ) FE+3(+1)
6,00 LTA1(+2) FE+3C+1)
1.75 LTA1 (+1 ) p B + 2 ( +1 )
2.50 LTA1 ( + 2) P 0 + 2 ( +1 )
1,40 LTA1(+1 ) M G + 2 (+1 )
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14,00 0XA2U2) FE+3( + 2) H 4-1 ( - 2 )
3.90 OXA? (+1.) P B + 2(4-1)
5.70 0XA2(+2) PB+?(+1)
*•3,00 0XA2<+1 ) P B + 2 (+1) H + 1(- I)
2.40 0XA2( + 1 ) M G + 2 (+1 )
3.80 OXA2(+2) MG+2C+1)
4.8 0 QXA2( + 1 ) M G + 2 ( + 1 ) H + 1(+1 )
3.50 0XA2C+1) M h + 2 (+1)
4.80 0XA2(+2) M N + 2 (+1 )
5.00 0XA2C+1) M N + 2 ( +1 ) H + 1( + 1 )
5.00 0XA2(+1) NI+2 (+1)
7.4 0 OX A? (+2) NI+2(+1)
5,60 OXA2 ( + 1 ) NI+2 ( + 1 ) H + 1(+1 )
4,05 OXA2(+1 ) Z N + 2 (+1 )
6.6’0 0 X A 2 ( + 2 ) ZN + 2(+1)
7.10 OXA2(+3.) Z N + 2 ( +1 )
5.00 0XA2U1 ) ZM+2(+1) H +1 (+1)
7.20 OXA2(+2) Z N + 2 ( +1 ) H +1(+2)
-2.00 OXA?(+1 ) Z N + 2 ( +1 ) H + 1(-1 )
2.30 PVA1( +1) H +1 ( + 1 )
0.75 P V A 1 ( +1 ) C A + 2 ( +1 )
2,20 P V A 1 ( +1 ) CU+2(+1)
4.20 PV-A1 ( + 2) CU+2C+1).
1 .20 PVA1(+1) FE+2C+1)
1 ,90 PVA1(+2) F E + 2 ( +1 )
4.00 PVA1(+1) FE + 3( + 1 )
6.00 PVA1(+2) .FE + 3 ( + 1 )
1.50 PVA1 (4-1 ) P B + 2 ( +1 )
2.80 PVA1 (4-2) PB+2(+1)
0.7 5 PVA1 (4-1 ) MG + 2( + 1 )
1 .00 PVA1(+1) M N + 2 ( +1 )
1.00 PVA1(+1) N I + 2 ( +1 )
1.10 PVA1 (4-2) NI+ 2(+1)
1.50 PVA1 (4-1 ) Z N + 2( +1)
2.20 PVA1 (4-2) ZN+2(+1 )
13,000 SLA2(+1 ) K + 1 ( +1 )
15.751 SLA2C+1 ) H +1(+2)
4,29 $LA?<+1 ) CA + 2(+1)
7.5 .$LA2( + 2) CA+2(+1 )
14.30 SLA2(+1 ) C A + 2 ( +1 ) H + 1( + 1 )
10.045 SLA2(+1 ) CU+2(+1)
17,023 SLA?(+2) C U + 2 ( +1 )
6,00 SLA2(+1 ) FE+2C+1)
10.00 SLA2<+2) F E + 2 (+1 )
16.00 SLA2( 4-1 ) FE+3(+1)
27.00 SLA2(+2) FE+3(+1)
34.00 SLA2(+3) FE+3(+1)
17.00: SLA? (4-1 ) FE+3(+1) H + 1(+1 )
5.50 SLA2(+1 ) P B + 2 (+1 )
9.00 SLA2C+2) PB + 2 ( + 1)
5,15 SL.A2C+-1 ) PIG + 2 ( + 1 )
9.54 SLA2C+2) M 6 + 2( + 1)
13.9 SLA?(4-1 ) MG+2(+1) II + 1( + 1 )
5.50 SLA2(+1) M N + 2 ( +1 )
9,00 SLA2U2) MN+2(+1) > 
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2,10
5.30
SCA2C+2) 
SCA2(+1)
I1G + 2C + 1 ) 
I1G + 2C + 1) H + 1( + 1 )
A
A
2.71 SCA2C+1) M H.+ 2 (+1 ) A
5,44 SCA2(+2) MU+2C+1) A
7.41 SCA2(+'t) MN+2C+1) II +1(+1) A
2.00 SCA2C+1) NJ+2C+1) A
3,50 SCA2C+2) NI+2C+1) A
2,96 SCA2C+1) ZH+2<+1) A
5.09 5CA2C+2) ZN+2C+1) G
7.46 SCA2C+1) ZN+2(+1 ) H +1C+1) A
4,00 TRA2(+1) H + 1( + 1) A
6.80 TRA2 <:M > It +1(+2) A
1 .80 TRA2C+1) CA+2(+1) A
2.40 TRA2(+2) CA+2C+1) G
5.00 T R A 2 ( * 1 ) CA+2C+1) H +1 (+1 ) A
2.80 TRA2(+1) CU+2C+1) A
4.30 TRa2(+2) CU+2C+1) A
6,00 TRA2(+1) CU+2(+1) II + 1( + 1 ) G
2,00 TRA2C+1) FE+2C+1) A
3,00 TRA2C+2) FE+2C+1) G
5,40 TRA2C+1) FE+2C+1 ) II + 1( + 1 ) E
6,00 TRA2C+1) FE+3U1 ) A
10.50 TRA2C+2) FE+3C+1 ) A
- 1 .0 0 TRA2(+1) FE+3C+1) H + 1(-1 ) G
11.00 TRA2< + 2) FE + 3 ( + 2) H + 1(-2) E
2.60 TRA2(+1) PB+2C+1 ) A
3.00 TRA2(+2) PB+2C+1) G
-5,00 TRA2(*1) PB+2C+1) II + 1<~1) G
1.50 TRA2 ( + 1) MG+2(+1) A
2.00 TRA2(+2) hl G + 2 (+1 ) G
5,00 TRA2C+1) MG+2C+1) H + 1(+1 ) A
1,50 TRA2(+1) MH+2(+1 ) • A
2.50 TRA2C+2) MN+2C+1) G
5.20 TRA2(+1> Mtl + 2( + 1 ) H + 1( + 1 ) ' G
2.50 TRA2(+1) NI+2C+1) G
4.00 TRA2C+2) NI+2C+1) A
5.80 TRA2<*1) FJI+2C+1) H +1 (+1 ) G
2.40 TRA2(+1) ZU+2C+1) A
3.90 TRA2C+2) ZN+2C+1) A
5.30 TRA2(+1) ZU+2C+1) H + 1 ( + 1 ) A
-4.00 TRA2(+1) ZN+2C+1) H +1(-1) G
10.30 PEN2C+1) H +1( + 1 ) A
18,10 P E N 2 ( +1 ) H +1(+2) A
20.40 PEN2C+1) It + 1 (+3) A
2.45 PEN2C+1) CA + 2( + 1) A
2.30 PEN2C+2) CA+2(+1) • G
15,00 PEN2C+1) CU + 1( + 1 ) G
19.00 PEi-12 (+2) CU + 1(+1) G
23.00 PEh2<+1) CU+1(+1) It + 1(+1 ) G
38,40' PEN2C+2) CU + 1(+1 ) II +1( + 2) E
98,00 PEN2C+4) CU+1(+5) E
12.50 PEN2(+1 ) PB+2C+1) A
16,50 PEN2(+2) PB+2(+1) A
19.30 PEN2C+3) PB+2C+1) A
15.40 PEN2(+1) PB+2C+1) II + 1( + 1 ) A
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26,40 PEN2(+2) P B + 2 (+1 ) H + 1( + 1 ) A
32,00 PEIi2(+2) PB+2(+1) B +1(+2) E
2.55 P E N 2 ( +1 ) MG+2(+1) E
3,50 PEii2( + 2> MG+2C+1) G
5,00 PEN2(+1) MN+2C+1) E
8.90 PEN2(+2) MN+2C+1) E
10.30 PEN2(+1) Nl+2(+1) A
21 .70 PE?J2(+2) Nl+2(+1) A
24.40 PEN2(+3) IU+2( + 1 ) E
9,35 PE,\2 (*1 > ZN+2(+1) A
18,70 PEN2(+2) ZN+2(+1) A
22.00 PEN2C+3) ZN+2<+1) A
8,00 PEN2(+2) ZN+2(+1) H + 1<~1 ) A
25.00 PEN2(+2) ZN+2C+1) H + 1(+1 ) A
30.50 PEN2C+2) ZN+2(+1) H +1(+2) A
8.59 opk2(+1) II + 1( + 1 ) M
16,23 0PII2 (+1) H +1(+2) M
18.23 0PN2(+1) H + K+3) M
19.57 0PH2(+1) H +1(+4) M
9.70 0PN2C+1) CA+2(+1) H + 1( + 1 ) G
19,10 0PN2(+2) CA+2(+1) H +1(+2) G
7.22 0PH2 ( + 1) CU+2(+1) . M
15.51 QPU2(+1) CU+2(+1) H + 1(+1 ) M
27.40 0PN2(+2) CU+2(+2) M
27.00 0PN2(+2) CU + 2(+ 1 ) H +1(+2) G
17,00 0 P N 2 ( +1 ) FE+3(+1) H + 1( + 1 ) G
31.00 0Pli2(+2) FE + 3(+1) H +1(+2) G
25.00 0PN2(+2) FE+3C+1) II + 1( + 1 ) G
15.50 0PB2C+1 ) PU+2(+1) H + 1( + 1 ) G
21 .50 0Ph2(+2) PB+2(+1) II +1(+2) G
10.30 0PII2 ( + 1) MG+2(+1) li + 1( + 1 ) G
19.80 OPB2(+2) HG+2(+1 ) H + 1 (+.2) • G
10,60 op:j2(+i ) HN+2C+1 ) H + 1( + 1 ) G
22,00 0PK2C+2) MN+2C+1) B +1(+2) G
6,0 0PN2(+1) NI+2C+1) G
13.0 0Pii2( + 1) NI+2(+1) II + 1( + 1 ) G
5,18 0PN2C+1) ZN+2(+1) • M
11,73 0 P N 2 (+ 1 ) ZN+2(+1) H +1(+1) . M
25.80 0PN2 (4-2) ZN+2C+1) H +1(+2) G
9.289 GSIi3 ( + 1 ) H +1(+1) M
17,67 GSK3(+1) H + K+2) . M
21,11 OSil3 ( + 1 ) H +1(+3) M
23.14 GSH3(+1) H +1( + 4) M
3.84 6SB3(+1) CA+2C+1 ) G
4.00 GSK3(+2) C A + 2(+1 ) G
12.89 GSB3(+1) CA+2C+1) II + 1 (1-1 ) G
20.68 G5h3(+1) CA+2(+1) II +1(+2) G
1 5.0'O GSb’3 ( +1 ) CU + 1 ( + 1 ) M
19,00 GSH3(+2) CU + 1(+1) M
24.50 GSII3 (+1 ) CU+1(+1) II + 1( + 1 ) . M
38.00 GSH3(+2) CU+1(+1) H *1<+2> M
6,00 GSII3 (+1 > FE+2C+1) G
9.00 GSH3(+2) FE + 2C + 1 ) G
10,00 GSU3(+1) P8 + 2C + 1 ) G
14.00 GSB3(+2) PU + 2C + 1 ) G
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16.40 GSH3C+1) PB+2C+1) H + 1C + 1 ) • A
22.80 GSK3C+2) PB+2C+1) H + 1( + 1 ) A
29.50 GSH3 C+2) PB+.2C+1 ) H +1C+2) A
4.00 GSH3C+2) PB+2C+1) H + 1C-1) A
4.00 GSH3 C + 1) MG+2C+1) G
4.20 CSH3C+2) MG+2C+1) G
5.00 GSH3C+ 1) MN+2C+1) A
6.00 G S f 13 C + 2) MH+2C+1 ) G
7.80 6SH3 C+1) NI+2C+1) M
13.00 GSH3 C+2) NI + 2C + 1 ) M
7.98 G S i i 3 ( +1 ) ZN+2C+1) M
12.48 GSH3C+2) ZN+2C+1) M
14.11 GSH3 C + 1) ZN + 2 C + 1 ) H + 1(+1 ) M
21.36 GSn3 C + 2) ZN+2C+1 ) II + 1C+1 ) M
28.08 6SK3 C + 2) ZN+2C+1 ) H +1C+2) M
3.12 GSH3(+2) ZN + 2 C + 1 ) H +1C~1) M
09.18 GSS4 C + 1) H +1C + 1 ) M
17.78 GSS4C+1) II +1(+2) M
21 .71 GSS4 C+1) H +1C+3) M
24.80 GSS4(+1) H +1C+4) M
27.50 GSS4 C+1) II +1(+5) M
28.90 GSS4 C+1) H +1C+6) M
13.76 GSS4 C+1) CU + 2C + 1 ) M
17.48 ' GSS4C+2) CU+2C+1) M
16.05 GSS4 C + 1) CIJ + 2C+2) M
17.71 GSS4C+1) CU+2C+1) H + 1 C + 1 ) M
21.50 GSS4(+1) CU+2C+1) II +1C+2) M
28.00 GSS4C+2) CU+2C+1) H +1(+2) M
4.09 GSS4C+1) CU+2C+1) OH -1C+1 ) M
7.22 GSS4C+1) Z0+2C+1) M
10.00 - GSS4(+2) ZIJ + 2 C + 1) M
12.60 GSS4C+1) ZN+2C+1) H + 1C + 1 ) M
9.57 TETOC+1) II +1 C + 1 ) M
18.51 TETOC+1) II +1 ( + 2) M
24.95 TETOC+1) II +1 C +3 ) M
28.05 TETOC+1) II +1 C + 4) M
19.41 TETOC+1 ) CU+2C+1) M
22.03 TETOC+1) GU+2C+1) H + 1( + 1 ) M
24.95 TETO( + 1 ) CU+2C+1? H +1C+2) M
22.50 TETOC+1 ) CU+2C+1) OH -1C + 1) G
7.SO- TETO(+1 ) FE+2C+1) A
21 ,30 TETOC+1) FE+3C+1) A
9.80 TETOC+1) PB + 2 C + 1) A
4.70 TETOC+1) MN+2C+1) A
14.00 TETOC+1 ) NI+2C+1 ) A
18,00 TETOC+1) NI+2C+1) H + 1( + 1 ) A
11.19 TETOC+1) ZN+2C+1) M
15.87 TETOC + 1 ) ZN+2C+1) II +1C+1) M
9.120 EDT4C+1) II +1 C + 1) A
15,03 • EDT4 C + 1 ) H +1C + 2) A
17.80 EDT4C+1 ) II +1C+3) A
19.90 EDT4C+1) II +1 C + 4) A
9.36 EDT4C+1) CA+2C+1) A
11.50 EDT4C+1) CA+2C+1) H + 1C + 1) A
10.50 EDT4C+1) CA + 2 C + 2) A
17.00 EDT4CM ) CU+2C+1 ) * A
20. SO EDT4 CM ) CU+2C+1 ) H + 1 ( + 'J ) A
22.30 EDT4 CM ) CU.+2C + 1 ) H •M C + 2) A
19.00 EOT 4 CM ) CU + 2 C + 1 ) on -1C + 1 ) A
13.50 EDT4 C+1) FE+2C+1) * A
16.00 EOTA C+1) FE+2C+1 ) H M ( + 1 ) A
17.50 EDT4C+1 ) FE+2C+1) OH -1 (+1 ) A
21.00 EDT4(+1) FE+2C+1 ) OH -1C +2) A
24.10 EDT4CM ) Ft+3C+1) A
24.. 50 EDT4 C+1) FE+3C+1 ) H + 1C + 1 ) A
30.50 EDI 4 C + 1 ) FE + 3 C + 1) OH -1 (+1 ) A
33.50 ' EDT4 CM ) FE+3 C + 1 ) Oil -1C +2) A
16.70 EDT4 C + 1) PH+2C+1) A
20.00 EDT4C+1) PQ + 2 CM ) H +1C+1 ) A
7.76 E0T4(+1) IIG + 2C + 1 ) A
12.00 EDT4 C+1 ) MG+2C+1 ) H + 1C+1 ) A
13.00 EDT4 CM ) MN+2C+1 ) A
16.00 EDT4C+1 ) HH+2C+1 ) H + 1C + 1 ) A
17.50 EPT4 C+1) N1+2C+1 ) A
20.50 EPT4 C + 1) NI+2C+1 ) il + 1( + 1 ) A
20.00 E0T4C+1) NI+2C+1) Oil -1C+1 ) A
15.50 EDT4 C+1 ) ZH+2C+1 ) A
18.30 E0T4 C + 1) ZN+2C+1 ) II + 1C + 1 ) A
17.60 EDT4 CM ) ZIJ + 2C+1 ) OH -1(+1) A
7.97 GH 1 CM.) H +1C + 1 ) M
14.58 GH 1 (+1 ) H + 1C+2) M
17.24 GH 1(+1) II +1 (+3) M
8.63 Gil 1 C +1 ) CU+2C+1 ) M
15.41 GH 1(+2) CU+2C+1) M
12,25 GH 1(+1) CU+2(+1) H +1C+1) M
4.54 GH 1C+1) CU+2C+1) H + 1C-1 ) M
-4.94 GH 1(+1 ) CU+2C+1) li + 1 C-2) M
20.45 GH 1 C+2) CU+2C+1) H + 1C + 1 ) M
7.68 Gil 1 C+2) CU+2C+1) H +1(-1) M
5.00 GH 1(+1) NI+2C+1) G
7.50 GH 1 C+2) HI+2C+1) G
10.80 GH 1C + 1) N1+2C+1) II + 1C + 1 ) G
-1 .90 Gil 1 C + 1 ) NI+2C+1) II + 1C-1 ) A
-11.0 GH 1C + 1) IM+2C + 1) H MC-2) ©
3.65 G H 1 ( M ) ZH+2C+1) M
6.8? GH 1C+2) ZU+2C+1) M
10.00 GH 1(+1) ZN+2C+1) H + 1C + 1 ) A
-3.50 GH 1 C + 1 ) ZN+2C+1 ) H + 1C-1 ) A
7.51 GGH1(+1) H +1 CM ) M
14.03 G G li 1 ( + 1 ) H +1(+2) M
16.46 G6H1C+1) H +1C+3) M
7.04 GGH1C+1> CU + 2C + 1.) M
11.70 G G H1 C +1 ) CU+2C+1) H + 1C-M) M
3.00 GGl.1 C + 1 > CU+2C+1) H + 1C-1 ) ' A
~2.11* GGH1(+1) CU+2C+1) II +1C-2) M
3.70 GGH1C+2) CU+2(+1) H + 1(-1 ) M
1 .30 GGH1C + 2) CU + 2 C-M ) H + 1C-2) M
4.20 G G H1 ( M > N1+2C+1 ) G
10.50 GGH1 C + 1 ) H I + 2 C+1 ) H •M C + 1 ) Gr
-2.00 GGH1(+1) NI+2C+1 ) H +1(-1) A
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11.92 DTPS(+1) CA+2C+2)
20,30 D T P 5 ( +1 ) CU+2C+1 )
25.00 DTPS(+1) CU+2(+1 ) K +K + 1)
28.00 DTP5C+1) CU+2C+1) rl +1(+2)
15,50 DTPS(+1) FE+2C+1)
20.70 DTP5(+1) FE+2C+1) H +1(+1 )
20,50 DTP5C+1> FE+2C+1) 0 H -1 ( +1 )
27.00 DTPS( + 1) FE+3C+1)
30,50 D T P 5 ( +1 ) FE + 3(+1) H +1C+1)
31.20 . DTP5C+1) FE+3C+1) OH-1(+1)
17.50 DTPS(+1) P8+2C+1)
22.60 DTP5C+1) Pl3 + 2( + 1 ) tl +1( + 1)
8,48 DTPS ('M ) M G + 2 (+1 )
15,40 DTP5C+1) HG+2C+1) H +1( + 1 )
19.95 DTPS(+1) MG+2C+1) H +1(+2)
14,50 DTP5C+.1 ) Hll + 2( + 1 ) *
16.50 DTPS(+1) MH+2<+1 ) H +1(+1)
19.00 DTP5(+1) NJ+2C+1 )
24.00 DTP5(+1) • NI+2C+1) H +1(+1)
27,00 D T P 5 ( +1 ) NI+2(+1) II +1 ( + 2)
17.00 DTPS(+1) ZH+2(+1)
22.50 DTP5(+1) ZN+2C+1) H +1C+1)
25,80 0.TP5C + 1 ) ZN+2(+1) il +1( + 2)
11,90 CDT4C+1) H + 1( + 1 )
17,90 CDT4C+1) H + K + 2)
21.20 CDT4( + 1) H *1(+3)
23,60 CDT4(+1) H 4-1 ( + 4)
25.00 CDT4 ( + 1 )‘ H +1(4-5)
12,00 CDT4(+1) CA+2(+1)
21 ,70 CDT4(+1) CU+2C+1)
24,70 CDT4(+1) CU+2C+1) II +1( + 1)
18.50 CDT4C+1) FE+2C+1)
21,00 CDT4(+1) FE+2C+1) H +1( + 1 )
28,00 CDT4(+1) FE+3C+1)
28,50 CDT4C+1) FE+3(+1) II +1( + 1)
35.00 CDT4(+1) FE+3C+1) OH-1( + 1 )
19,10 CDT4'(+1 ) P8+2C+1)
23.00 CDT4C+1) PB+2C+1) H +1( + 1 )
10.90 . CDT4C+1) MG+2C+T)
16,40 CDT4C+1) MN+2C+1 )
19,50 CDT4(+1> MN+2C+1) H +1( + 1 )
19.90 CDT4C+1) NI+2C+1)
22.30 CDT4(+1) MI + 2C + 1 ) H +1( + 1 )
18,60 CDT4(+1) ZN+2C+1)
21 ,80 CDT4C+1) ZH+2/+1) H +1 (+1 )
9,40 E 0 D 2 ( +1 ) H +1 (+1 )
16.00 ED 02(+1) tl +1C+2)
18.00 ED 02(+1) H +1(+3)
19,50 EDD2(+1) II +1 ( + 4)
4,00 EDD2(+1) CA+2C+1)
16.00 EDD2 ( + 1 ) CU+2C+1)
9.00 EDD2(+1) FE+2C+1)
19,50 EDp2(+1 ) FE+3C+1)
27.00 EDD2(+1) FE+3(+1) OH-1(+1 )
29.50 EDD2C+1) FE+3C+1) OH-1 ( + 2)
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12.00 H0T3C+1 ) FE+2C+1) A
14.50 HDT3( + 1 ) FE+2(+1 ) H + K + 1) A
16.50 HDT3(+1) FE+2C+1) Oil ~1( + 1) A
19.70 HDT3(+1 ) FE+3C+1) A
15.50 H0T3C+1 ) FE+3<+1) II + 1("1 ) A
6.50 HDT3(+1) FE+3C+1) H +1<~2) A
30.00 HDT3C+2) FE+3<+2) II +1(~2) A
15.00 HOTS(+1) PB+2C+1) A
11.50 H0T3( + 1 ) PB+2C+1) II +1(+1> A
6.50 HDT3C+1) 110 + 2(4-1 ) A
10.70 . H0T3 ( M ) MG+2C+1) II + 1(+1) A
10.50 IIDT3 (+1 ) I IN + 2 (+1 ) A
11.00 HDT3(+1) MN+2(*1) H +1 (+1 > G
16.80 HDT3(+1) Nl+2(+1) A
19.20 H0T3(+1) 111+2(4-1 ) II + 1( + 1 ) A
14.20 H0T3(+1 ) ZN+2(+1) . A
16.20 H0T3(+1> ZN+2(+1) H +1(+1) G
9.30 0DT4(+1) II +1( + 1 ) A
17.90 . 0DT4C+1) II +1(+2) A
20.50 ODT4(+1) H +1(+3) A
22.20 0DT4(+1) H +1(+4) A
9.SO 0PT4(+1) CA+2C+1) A
14.00 OOT4(+1) CA+2(+1) H +1(+1> A
17.80 0PT4C+1) CU + 2( + 1 ) A
21.50 0PT4 ( + 1) CU + 2C + 1 ) H + 1( + 1) A
14,00 0DT4( + 1 ) FE+2C+1) A
17.10 0PT4(+1) FE+2(+1) H + 1(+1) A
24.20 0DT4(+1) FE+3(+1) A
30.00 OOT4C+1) F E +3(+ 1) OH -1(+1> G
14.70 QDT4(+1> PB + 2(+ 1 ) A
18.20 0DT4C+1) P B + 2 (4' 1 ) H + 1( + 1) A
8.30 0DT4(+1) II G + 2 (+1 ) • A
13.00 0DT4C+1) MG + 2(+1) H +1(+1) A
13.40 0PT4( + 1 ) MN+2C+1) A
16.50 0DT4< + 1 ) MN+2(+1> H +1(+1> G
15.10 OOT4(+1) III+2( + 1 ) A
18.00 0PT4(+1) Nl+2(+1) H +1(4-1) A
14.80 00T4( + 1 ) ZN+2(+1) A
17.80 0PT.4 (+1 ) ZN+2(+1) H +1 (+1) A
9,50 NTA3(+1) II +1 (+ 1) A
12,00 NTA3(+1) H +1(+2) A
14.00 NTA3(+1) II +1 (+3) A
15,00 NTA3C+1) li +1 (+4) A
6.20 NTA3(+1) CA+2(+1) A
8.50 NTA3(+2) CA+2C+1) A
13.00 NTA3(+1) CU+2C+1) A
17,00 NTA3(+2) CU + 2 (+ 1) A
17,00 NTA3(+1) CU+2(+1) OH -1(+1) A
8,00 NTA3(+1) F fc + 2 ( +1 ) A
12,50 NTA3(+2) FE+2C+1) A
9,60 NTA3(+1) FC+2(+1) II + 1(+1) A
’->3,00 NTA3(+1) FE+2(+1) If +1 ("• 1) A
15.50 NTa3(+1) FE+3(+1 ) A
24.00 NTA3(+2) FE+3(+1) A
11,00 NTA3(+1) FE+3<+1) H +1(-1) A
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3,00 NTA3(+1) FE- + 3( + 1 ) II +1 (* 2) A
25.00 NTA3(+2) FE+3C+2) II + 1.( ”«2) A
11.00 NTA3(+1) PB+2C+1 ) A
14.50 NTA3(+2) PB+2C+1) G
1 .00 NTA3C+1> PB + 2 C + 1 ) H + 1(-1 ) G
5,20 NTA3(+1) MG+2C+1) A
7.00 NTA3(+2) MG+2C+1) G
7,20 NTA3(+1) MN+2C+1 ) A
10,20 NTA3(+2) MN+2C+1) A
11,30 NTA3(+1) NI+2C+1) • A
15.30 NTA3C+2) NI+2C+1) A
"1,00 NTA3(+1) MI+2C+1) II +1(-1) A
10,30 NTA3C+1) ZN+2C+1) A
13.50 NTA3(+2) ZN+2C+1) • A
0,00 NTA3(+1) ZN+2C+1) H +1("1) A
4 • 4 ACT1(+1) K +1( + 1 ) A
1.24 A C T1 ( +1 ) CA+2C+1) A
1 ,9 ACT1(+2) CA+2C+1) G -
1,51 ACTK+1 ) CU+2C+1) A
2.31 ACT1(+2) CU+2C+1 ) A
1.21 ACT1(+1) MG+2C+1) A
1 .8 ACT1(+2) MG+2C+1) G
1.22 ACT'l (+1 ) ZN+2C+1) E ’
2,0 ACT1(+2) ZN+2C+1 ) E
4,6 ANTI(+1) H +1C+1) A
6.4 ANTI(+1) H +1(+2) E
0.67 ANTI(+1) CA+2C+1) E
4.1 ANTI(+1) CU+2C+1) A
7.3 . ANTI(+2) CU+2C+1) G
0,72 ANTI(+1) MG+2C+1 ) E
2,5 ANTI(+1) ZN+2C+1 ) A
4,5 ANTI(+2) ZN+2C+1) G
3,44 ASA1(+1) H + 1( + 1 ) M
2,94 ASA1(+1) CA+2C+1) M
4.7 ASA1(+2) CA+2C+1 ) G
1.26 A S A1 ( +1 ) CU+2C+1 ) M
3.03 ASA1(+2) CU+2C+1) M
2,29 ASA1(+1) MG+2C+1 ) M
4,0 A$A1(+2) MG+2C+1) • • G
2,5 ASA1( + 1 ) ZN+2C+1) G
4,3 • ASA1(+2) ZN+2C+1 ) G
4.8 CIQ1 (+1 ) H + 1C + 1) E
7.6 C101 (+1 ) CU+2C+1) G
14.35 C101(+2) CU+2C+1) G
3.9 CI 01( + 1) ZN+2C+1) G
8.0 CIO1(+2) ZN+2C+1) G
6.2 FEN0C+1 ) H +1( + 1) G
6.0 ■ FEN0C+1) CU+2C+1 ) G
11.0 FEN0(+2) CU+2C+1) G
3.0 FEN0C+1) ZN+2C+1 ) G
5,8 FENOC+2) ZN+2C+1) G
8.796 DPA1(+ 1) H + 1( + 1 ) M
14.65 DPA1 (+1 ) H + 1(F2) M
16,62 DPA1C+ 10 H +1(+3) M
10,587 DPA1(+1) CU+2C+1 ) M
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18.775 DPA'!(+2) CU+2C+1) M
14.973 DPA1(+1) CU+2C+1) II +1 ( + 1 ) M
24.088 DPA1 (+2), CU+2C+1) H +1(+1) M
28.2 DPA1(+2) CU+2(+1) H +1(+2) M
5.20 DPA1( + 1) FE+2(+1) G
9.50 DPA1(+2) F E + 2 (+1 ) G
4.50 DPA1(+1) FE+3C+1) G
8.00 DPA1(+2) FE+3(+1) G
8.148 DPA1(+1) NI+2C+1) M
14.966 DPA1(+2) NI+2C+1) M
13.224 DPA1(+1) Nj+2( + 1) H +K + 1) M
20.49 DPA1(+2) Ml+2( + 1 ) 'll +1 ( + 1 ) M
6,38 DPA1(+1) ZN+2(+1) M
11,67 0PA1(+2) ZII + 2(+1) M
12,44 DPA1(+1) ZN+2(+1) H +1(+1) M
17.97 0PA1(+2) ZN + 2C+1) H.+ K+1) M
3.24 DPA1(+1) MM+2(+1) G
6,16 DPA1(+2) MN + 2C+1 ) G
9.6 DPA1(+1) MN+2(+1) H +K + 1) . G
5.96 .DPA1 (+1 ) PB+2(+1) G
9.00 DPA1(+2) PB+2(+1) G
6,1 THP1(+1) H +1(+1) G
7,6 THP1(+1) H +1(+2) G
6,0 THP1(+1) CU+2(+1) G
11.2 THP1(+2) CU+2C+1) G
3.1 T rl P1 ( +1 ) ZN+2(+1) G
5.6 THP1( + 2) ZN+2(+1) G
3.7 THP1(+1) NI+2C+1) G
6.8 THP1(+2) NI+2(+1) G
8,2 THP1(+3) NI+2(+1) G
7.5 S6L2(+1) H +1( + 1 ) G
8.6 SGL2(+1) H +1(+2) G
6.9 SGE2(+1 ) CU+2(+1 ) G
12,7 5GL2(+2) CU+2C+1) G
4.2 SGL2(+1 ) NI+2C+1) G
7.6 SGL2C+2) NI+2C+1) G
3.7 SGL2(+ 1 ) ZN+2C+1) G
7.9 SGL2(+2) ZN+2C+1) G
3.9 ATM ( + 1 ) H +1(+1) G
1 ,8 ■ ATHK + 1) CU+2(+1 ) G
1.0 ATM (+1) NI+2C+1) G
1.5 ATM ( + 1) ZN + 2( + 1 ) G
APPENDIX A3
Instructions and FORTRAN listings of the 
computer programs MIX and ECCLES
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i
DATA PREPARATION FOR COMPUTER SIMULATION PROCEDURES USING . ..
THE ECCLES AND MIX COMPUTER PROGRAMS ,
This document describes, how the input data for the ECCLES and 
MIX computer programs in the Bio-inorganic Chemistry computer ' 
library held by the South West Universities Computer Network 
should be punched onto data cards. It refers only to the - 
simulation of metal ion-ligand equilibria in aqueous solutions 
where the free hydrogen ion concentration and all the formation 
constants of the .reactions are known. A separate document, 
entitled "The MIXECC Macro’, gives details of the Job Control *-
commands required to call and execute the programs* ''
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Introduction
The simulation of the equilibrium distribution of metal ions, 
ligands and their complexes, involves the computation of the •
, concentrations of all the species which co-exist in a defined 
■solution. Thi3 requires a knowledge of the formation constants .
of each equilibrium reaction and of the total or free concen­
trations of each component in the mixture.
In the present context, these calculations are performed by 
program ECCLES. The name stands for ^valuation of Constituent 
Concentrations in Charge Equilibrium Systems. The program was 
specifically designed to treat cases in which there were many 
components and very many (i.e. thousands) of complex species. . 
Several of its facilities reflect this. For example, ECCLES 
identifies each component by a user-designated, four-character 
symbol so that restrictions on the number or type of component • 
are minimised. Strings of these symbols interspersed with 
indications of-the appropriate stoichiometry are used to define 
complex species. (This is described under Stage 8 of these 
instructions.) Users should be aware that in some regards smaller 
systems are processed somewhat inefficiently by ECCLES.
Nevertheless, the program has several features not offered by 
other simulation outlines, so its use in the study of systems • .
with only two or three components is often justified.
The most obvious of these features concerns utilization of the .. 
large formation constant database originally built up for the 
simulation of metal ion-ligand equilibria in blood plasma. Well 
over 2000 values have been critically selected from the literature. 
Users can access this database by implementing the MIXECC macro.
This procedure first invokes program MIX to prepare input data 
for program ECCLES as shown in the Figure. Once the user has 
de/ined the system in terms of its components (using the symbols 
given in the instructions on the MIXECC macro) and their.respective 
concentrations, program MIX generates the intermediate data file ' 
by performing three main tasks. These are (i) the selection of 
the applicable binary formation constants for the system in 
question from the database, (ii) the calculation of formation 
constant estimates for all ternary complex species that may be 
assumed to exist in the solution on the basis of the chosen binary 
formation constants and (iii) the substitution, adjustment or . . 
extension of these ternary formation constant estimates in respect ■ 
of those for which experimental data has been collected. .
Much of the input data for program MIX is prepared in exactly 
the same way as that for program ECCLES. Accordingly, it is 
convenient to describe the format of this data for both programs 
together. Note, however, that a number of the following 
instructions are simply transferred through program MIX to 
programECCLES.
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Stage 1: I dentification  .
Three cards are required with alpha-numeric information for 
identification purposes. This is usually the title of the 
simulation, the investigator's name and the date.
(A failure in program MIX which warrants a termination of the 
simulation run is signalled to program ECCLES by over-writing 
the user's title with the phrase 'ABORT THIS RUN'. Accordingly, 
the word 'ABORT' should not appear as part of the title 
specified by the user on the first card image.) •
FORMAT (20 A4) : .
FORMAT (10 A4) ‘ : I ' "/........ •
FORMAT (10 A4) ‘ • •
Stage 2: The component monitor
One card is required to specify which, if any, of the components 
is to be specially monitored by the program. This means that 
after the equilibrium distribution has been calculated, all the 
complex species of the component in question are sorted into . 
order of highest concentration so that a list of. the topmost 
35-40 can be printed. .
This device is usually necessary only when there are many
components in the equilibrium mixture. It then becomes tedioys 
to sort through the usual output of all complex species looking 
for the most important of those which include a component of interest
If no component monitor is desired, punch 'FALSE' in columns 1-5. 
Otherwise, punch the logical indicator 'TRUE '. followed by a list 
of symbols for up to 15 selected components. Monitored •
components must appear in at least three complex species. The 
word 'ALL' in columns 7-9 inclusive indicates that every component 
in the system is to be monitored. The word 'PUNCH' in columns 6-10 
indicates that each monitor output list is to be sent to the card 
punch (device=7).
FORMAT (L5, IX, 14 (A4, IX), A4) ■
Stage 3: The component concentration scan • .
One card is required to specify which, if any, of the component 
concentrations .is to be scanned. This means that the equilibrium 
distribution is repetitively calculated, first using the
component concentration as specified under Stages 5 or 6 below and ’ 
then at various increased values.
If no scan is desired, punch 'FALSE' in columns 1-5. Otherwise, 
punch the logical indicator 'TRUE ' followed by the component symbol 
in columns 7-1(1 inclusive. The factor or increment by which the 
component concentration is to be increased must be given in
columns 11-20 and the maximum concentration of the component (after 
reaching which the scan is to be terminated) must appear in columns 
21-30. .. ' . •
For example: \ .
TRUE WXYZ 10.0 0.001
■ -----
' $
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Component concentrations can be raised additivcly or in a
multiplicative fashion: if the number in columns 11-20 i3
less than or equal to 1.00 it is taken to be an additive
increment u/hereas otherwise it is taken as a multiplicative factor.
It is possible to scan the concentrations of up to ten other 
components simultaneously With that of the component stipulated 
in columns 7-10. This is done by listing the symbols of these 
other components from column 32-onwards. The same increment or 
factor will then be applied to the concentrations of those 
components. . , . .•/; :
FORMAT (L5, IX, A4, 2G10.4, 10(lX, A4)) .... - n, h ; , •. r-.-j
• . - - - . . ■ t ; J ‘ : i ! « • • • ■;
• •. ; •. ■ ; ■»: '
Stage 4: The program options • ' . . • •
The following card images are optional but if .included they must 
appear in the order shown below. Each string begins in column 1.
SUPPRESS OUTPUT - • • • '• • • ' \
TEST PROGRAM . ‘ ‘ ‘ " ' ' ' ' '
OMIT INPUT CHECKS . • ■ J'
SWITCH DATA FILES ' - ■ .
(a) The option to supress output.
This option is invoked when a lengthy■print-out of all the’.; • 
complex species concentrations is not required. Most often'' 
this will occur when the necessary information is obtained 
through the component monitor (see Stage 2). .
(b) The program test option. •
This option terminates the program prematurely. It is occasionally 
useful as a means of checking an input deck but most often 
employed when ECCLES is being loaded onto a computer system for ' 
the first time. By itself, the ’TEST PROGRAM' command sets the 
iteration limit to zero. However, if the command is executed 
in conjunction with a component concentration scan card (under 
Stage 3) with ’TRUE’ in columns 1-4) and ’TEST’ in columns 7-10, 
the iteration limit will be set to the value given in columns 11-20. 
This value must be a real number between 1.0 and 500.0.
(c) The option to omit the input checking procedures. . •
Program ECCLES performs a large variety of checks whilst the input 
data is being loaded. The most expensive of these (in terms of 
computer time) involves a search for duplication amongst the
list of complex species. This and a few other checking procedures . 
can be bypassed by including the 'OMIT’ option. •
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(d) The option to switch data files. .
It is sometimes convenient to have program MIX prepare an
intermediate data file which contains only the formation
constant list. In other words, the data for ECCLES is submitted 
in two parts: (i) the input described in Stages 1-6 of 
this document on computer cards and (ii) that detailed in Stage 8, 
in the intermediate computer file by itself. This situation 
arises most commonly when a series of models are all based on 
the same components but utilize assorted concentration conditions. 
As the formation constant set is unchanged from one model to 
another it is uneconomic to generate it again and again using 
program MIX. Rather, the list is prepared on the first occasion 
only and then accessed by ECCLES whenever it is subsequently 
required. This may be accomplished by including the 'SWITCH’ 
option in the data check. Program MIX executes the instruction 
by obliterating from the intermediate file all data required by 
ECCLES which precedes the list of formation constants. ,
Program ECCLES, on the other hand, switches its internal logical 
device number for input so that the formation constants can be 
read in from a separate computer file (with device = 9) as ' 
opposed to that containing the initial input data (device = 5). 
FORMAT (A4) . • ’ .f
Stage 5: Total concentration input
This stage of the input is initiated by a card reading ’TOTAL 
CONCENTRATIONS' and terminated by a card, reading 'END'. Both 
images begin in column 1. • , ■ •
•i’.'
• $
FORMAT (A4)
Between these delimiters are placed the cards defining the
symbols and concentrations of the components in the equilibrium 
solution whose total concentrations are known. The components, one 
per card image, may appear in any order. •
The four-character component symbol specified by the user or
as taken from the instructions on the MIXECC macro is placed in
columns 1-4. This is followed by the total concentration of the 
component and if available, by an estimate of its free concen- .
tration. The free concentration estimate is mandatory for program MIXi|
FORMAT (A4, IX, 2G10.4).
■ O'
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Staqe 6: Free concentration input |=
This stage of the input is initiated by a card reading
’FREE CONCENTRATIONS’ and terminated by a card reading ’END’.
Both images begin in column 1.
FORMAT (A4) : .. • . • ’•
Between these delinities are placed the cards defining the
symbols and concentrations of the components in the equilibrium 
solution whose free concentrations are known. The components, 
one per card image, may appear in any order.
The four-character component symbol specified by the user
or as taken from the instructions on-the MIXECC Macro is placed 
in columns 1-4. This is followed by the free concentration of 
the component and if available by an estimate of its total 
concentration. The total concentration estimate is mandatory 
for program MIX. .
FORMAT (A4, IX, 2G10.4) / . • ‘ ' •
Note: Although ECCLES does not require any free concentrations
it would be most unusual for a user not to provide one in 
respect of the hydrogen ion. This is because ECCLES cannot 
process total hydrogen ion concentrations. The restriction 
arises from the choice of iterative formulae, these being 
unable to accommodate negative total concentrations-. Thus, the 
hydroxide ion must be regarded as a separate component whose 
free concentration is supplied by the user from a knowledge of 
the dissociation constant for water. The latter parameter must 
not be included in the formation constant list (described 
under Stage 8). Its value is calculated by ECCLES as the product 
of the two free ion concentrations provided by the user at 
this stage. This is necessary when, for example, the free 
hydrogen ion concentration is to be scanned and the free - 
hydroxide ion concentration must be adjusted accordingly.
Program ECCLES will accept complex species defined in terms of 
a negative hydrogen subscript but these are immediately transformed 
by the program into the corresponding hydroxo-complexes (with 
appropriately altered formation constant values).
Stage 7: Selector options for program MIX 4 ~ ' • • ••
The selector option is only recognised by program MIX. It is *
used to exclude species in the formation constant database <
from the current model. In other words, the species in question 
are not transferred to the intermediate computer file which is J
to be used for ECCLES input. The option is effected by the
command 'BLOCK' in columns 1-5 followed by a list of f ou r-charac te r 
component symbols which begin in column 7*and are- separated from each 
other by a blank space. . . J
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For example:
BLOCK WXYZ PQRS ABCD
Program MIX will omit any species in the masterfiles which 
contains all of the listed components.
The ’BLOCK’ command may be repeated as often as required. 
Redundant combinations such as the one shown below should be 
avoided.
BLOCK PQRS WXYZ ABCD 
BLOCK PQRS ABCD
The ‘BLOCK’ option is used most often to include a new set of 
formation constants in a model without having to alter the 
masterfiles. These "trial” constants are included in the card 
deck as described under Stage 8. Note that users must include 
’BLOCK’ commands to ensure that duplication of these species from 
the masterfiles is impossible. In other words, each of the
complex species entered 7ia the card, deck must be encompassed 
by the set of ’BLOCK’ exclusion criteria. This remains the case
even when they include components which are not part of the 
masterfile database.
FORMAT (A4, 2X, 10 (A4, IX))
Stage 8: formation constant input '
This stage of the input is initiated by a card reading 
'SPECIES CONSTANTS'. The image begins in column 1. •
The cards following this each define the formation constant 
value and stoichiometry of a complex species. The formation 
constant is entered as a log value in columns 1-9. The complex 
is specified by an alphanumeric string beginning in column 11.
The string comprises the various component symbols, each followed 
by its stoichiometric ratio as a signed integer in parentheses 
and separated from the next one by a blank space.
This is shown in the following examples:
16.957
22.322
9.650
-2.2
FORMAT
WXYZ(+1) ABCD(+1) 
WXYZ(+1) ABCD(+2)
GLYK+l) H +1(+1) 
GLYH + l) H +1(~1)
CU+2(+l)
CU+2(+l)
(G9.4, IX, 5(A4, IX, 12, 2X))
Program ECCLES is currently dimensioned to accept up to 5000 complex 
species. There is no equivalent limit for.Program MIX but note 
the restrictions discussed under Stage 7 of this document.
1
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FLOW DIAGRAM FOR PROGRAM MIX
. Stop
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C PROGRAM MIX,. . ■
C
C DEVELOPED AT THE UNIVERSITY OF CAPE TOWN DURING
1975, . .
C .
C THIS PROGRAM PRODUCES, ON FILE, THE EQUILIBRIUM
DATA REQUIRED AS INPUT
FOR PROGRAM ECCLES, • =
FOR A GIVEN SET OF MODEL COMPONENTS, IT SELECTS THE 
APPROPRIATE COMPLEX
SPECIES FROM'A STANDARD FORMATION CONSTANT DATA 
FILE AND OUTPUTS THESE
AS WELL AS PROJECTED VALUES FOR ALL THE 1:1 ;1 MIXED 
LIGAND CONSTITUENTS
OF THE MIXTURE. A USER SPECIFIED DEFAULT VALUE. IS 
USED AS A
STABILISATION FACTOR UNLESS A MORE SPECIFIC VALUE 
CAN BE TAKEN DIRECTLY .
OR CALCULATED FROM DATA SUPPLIED IN A FILE ON MIXED 
LIGAND COMPLEXES,
(THIS FILE MAY ALSO CONTAIN SPECIES TO BE OUTPUT 
WITHOUT ALTERATION).
SPECIES'WHICH HAVE COMPONENTS THAT DO NOT APPEAR IN 
THE COMPONENT LIST
ARE IGNORED. THIS FACILITATES MANIPULATION OF THE 
INPUT TO ECCLES.
THE PROGRAM IS WRITTEN IN FORTRAN IV. ’
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SECTION ONE STORAGE ALLOCATION AND FORMAT
’ . STATEMENTS. .
INTEGER KEY(5,1500,2), NUMK1 500), NUM2< 1 500) 
INTEGER DUP(116,2), OMIT(1000,2)
BOTH OF THE ABOVE INTEGER SPECIFICATIONS COULD BE 
. INTEGER*2
INTEGER OUT, OUTF, HCOMP
INTEGER BUFC20), PCOMP(IOO), CHEK, PURGE(5,10) 
DIMENSION CONSTC1500), NC0MPC116), NPUM(10),
LIT(10)
DIMENSION C0NSTMC116), MC0MPC116), CONSTII (1 00 ) ,
HCOMP(100)
DIMENSION CIIIX(5000), STABC5000), CBUp(116) 
DIMENSION METARRC15), STBARRC15), XXC116),
TREAL(116), XXMCT16)
REAL LGMIXC5000), TREALMC116)
LOGICAL 5WTCH, SUPRES, IPRT, ERCONC, BLOCK 
DATA LIT/’ TOTAFREESPECH +1END SWITBLOC
’/
293
NS « 1500
NX -100 ’ .
NXX « 15 
NKEY « 5 
NPMAX « 100 
NDMAX » 110 
NZMAX =•’ 1000 
NND ~ NKEY * 2 
NXP'1 => NX + 1
NSP1 = NS + 1 , •
NXXX ~ NX + NXX 
NtUX = (NX ** 2) / 2
C
C
C
10201 FORMAT(14)
10301 FORMAT!20A4)
10303 FORMAT(A4,1X,2G10.4)
10330 -FORMAT (A4,2X , 1 0 (A4,1 X ) )
10401 FORMAT!G9•4,1X,5(A4,1X,12,2X))
10501 FORMAT!A4»1X,G10•4)
20303 FORMAT(A4, 1X,1P2E10.4,55!1H ))
20304 FORMAT!’END’,77(1H ))
20331 FORMAT!'SPECIES CONSTANTS',63(1H ))
204 01 FORMAT!F9»4,1X,5!A4, I3,2X) , TSO,A1)
20999 FORMAT!'ABORT TIUS RUN. ERROR IN THE MIXED LIGAND 
CONSTANT CALCU
1LATIONS. ’,10(1H~)>
30300 FORMATOH , 'MISSING INSTRUCTION IN DATA. PROGRAM
TERMINATED AFTER
1CARD ’,13)
30201 FORMAT!'1')
30301 FORMAT!' ’,20A4)
30302 FORMAT!//’0END OF COMPONENT DATA,
CARD IMAGES READ s ’ , I 3 , / / / )
30303 FORMAT!' ' , A4,1X,2(1PE12,4))
30304 FORMAT(’ END’)
30305 FORMAT!//’O','NO COMPONENT DATA OUTPUT TO THE
SEQUENTIAL FILE.') .
30331 FORMAT!' ’, 'SPECIES CONSTANTS')
30332 FORMAT!' ’BLOCK ' ,10(A4,1X))
30334 FORMAT!'0ERROR TERMINATION',/^’,
1 . 'BLOCK OPTION SPECIFICS UNIDENTIFIABLE 
COMPONENT’,5X,A4»///> .
30401 FORMAT! ' ','OMIT-,1PE12,4,1X,5!A4,’!', I2,')'<
1 X) )
30402 FORMAT!/'0*SPECIES’,16,' ON CARD NUMBER’,15,’ IS
IN ERROR’,///)
30403 FORMAT!//'0’,’END OF BASIC STABILITY CONSTANT DATA.
CARD IMAGES
1READ 15,5X,'TOTAL NUMBER OF SPECIES =',I5,////) 
30410 FORMAT!'' 'INSERT ..,. ’ , 5 X , F9.4,1 X , 5 (A4 , ’ ( ’ , 12 , ’ ) '
IX))
30416 FORMAT! 'O’>'NO. FREE HYDROGEN ION CONCENTRATION???’)
294
30417 FORMAT<»0’#'NPMAX EXCEEDED, EXECUTION
TERMINATED.')
30418 FORMAT!'O'ERROR TERMINATION',/»0',
1 'LAST SPECIES NOT COVERED BY THE BLOCK 
option’,i t n
30494 FORMAT!///'O',’THE FOLLOWING METAL IONS ARE
RECOGNISED.’,/’0’)
30495 FORMAT!’ ',A4,1PE14.3 )
30501 FORMAT !'0',A4,' IS NOT IN THE COMPONENT LIST.’,/1
. ' PLEASE RETYPE. ‘ -
' TYPE END TO EXIT.') .
30502 FORMAT! '0',10(1H*>,5X,’CHECK THIS SPECIES’,5X,3!A4,
'!',I2,')*,?X))
30601 FORMAT!'0','EXECUTION TERMINATED.
• MIXED SPECIE ARRAYS TOO SMALL’)
30602 FORMAT ('0','O.M I T THE PREDICTION FOR ’ , 5x , 1 PE1 0.4,5X ,
A4, • ! 1) ',
1 A4, ’ ! 2) Il +1 ( 1) ' ,4X, 16) '
30603 FORMAT!'O','COMBINE PREDICTIONS FOR IDENTICAL MIXED
SPECIES.',
1 /’ ’ ,1PE10.4,5X#3(A4, ’ ( 1) '),'H +1(
1 ) ’ ,5X,2!1PE1O,4),316)
30604 FORMAT!'. ' , A4,5X , 3 ! 1 PE1 5.4,5X ) )
30605 FORMATIZ/’O','THE.FOLLOWING COMPONENTS ARE USED FOR
THE ',A4, .
1' TERNARY CONSTANT CALCULATIONS;’,///)
30606 FORMAT!//'0','TOTAL NUMBER -',14,/' ','NUMBER OF
• BARE LIGANDS =',
1 14,/' ','NUMBER WITH ONE PROTON ~'»I4»/////)
30607 FORMAT!//'O','METAL CONCENTRATION FACTORS;’,
. 2!1PE15.4)) . •
30731 FORMAT!' OUTPUT TO FILE ',10X,1PE10.4,1X,8!A4, * ! ' ,
12, ') ' ,1X))
30741 FORMAT!’ COMPONENT NOT IN LIST.')
30742 FORMAT!'O', 'OMIT THE SPECIE ON CARD NUMBER’,I 4,//)
30745 FORMAT!///'O' , 'ERROR ON CARD NUMBER ' , I 4,//)
30746 FORMAT!' MODE CODE =',I4,//)
30747 FORMAT!///'0','ERROR TERMINATION. " .
. FORMAT ERROR ON CARD', I 5,///)
30748 FORMAT!'O’,'STABILISATION FACTOR HAS ALREADY BEEN
SET.')
30749 FORMAT!'O', 'MIXED SPECIES MUST HAVE H +1
AS THE LAST COMPONENT')
30761 FORMAT!//'O','A BINARY CONSTANT FOR MIXED LIGAND 
STABILITY CALCULA
1TION IS MISSING',/’ ','OR A NECCESSARY BINARY . 
SPECIES DOES NOT APP
1E:AR IN THE BASIC DATA FILE.’,///) .
30763 FORMAT! *0’,’PREDICTION FOR ' , 8 < A4 , ' ( ’ , .1 2 , ' ) ’ , 1 X))
30764 FORMAT!' ' , T40,4 ! 1PE12.4))
30771 FORMAT!' ', 'ADJUST THE STAB. FACTOR ’ , 1 OX,3 ! A4, ’ (
. 1 ) ' , 1 X ) ♦ * H +1 !' ,
1 12, ' ) ' ,4X,2!1PE10.4))
30781 FORMAT! ’OREPLACED SPECIE' , 1 OX , 1 PE'1 0,4,1 X , 8 ! A4 , ' ! ' , 
12,')’,1X>)
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30301 FORMATC'O',15,’ CONSTANTS FOR THE MIXED LIGAND 
COMPLEXES OF ',A4,
1’ HAVE BEEN CONSIDERED.’,/' ',15,' HAVE BEEN 
SELECTED,’,/' •
2'THE ELIMINATION FACTOR WAS',1 PE 14.4)
30802 FORMAT!'O','NUMBER OF APPLICABLE CARDS IN THE
MIXED-DATA FILE ,
1 15,////) ■
30892 FORMAT!' ',16,2 I 8,1PE15,4,5X,'OMIT -
IDENTICAL TO SPECIES NUMBER
1 ' , 15)
30893 FORMAT! ’ ',16,2 18,6! 1PE15.4))
30899 FORMAT!'0','IMPERFECT ELIMINAT I ON.*,I 6, ’ COMPLEXES 
SHOULD HAVE BEE-
IN SELECTED.',//)
30901 FORMAT(//’0’,I 5,* CONSTITUENTS FOR ECCLES'') . 
80902 FORMAT !//'0’,*END MIX.',/’1')
30903 FORMAT!'O’,15, ’ SPECIES WERE SELECTED FROM A TOTAL 
OF',16, ’ THAT W . -
1ERE CONSIDERED,’)
.20994 FORMAT!'0'FREE CONCENTRATION GREATER THAN TOTAL!’)
30995 FORMAT! ’O’, 'SYMBOL
FACTOR
ERROR
FILE')
IN METAL STABILISATION
3 0996 FORMAT!* O', ' SYMBOL ERROR IN BASIC CONSTANT DATA
F.ILE. ' , 5 X , A 4 )
30997 FORMAT! ’!)' , ’ SYMBOL ERROR IN' M I X E D CONSTANT DATA
FILE.’ , 5 X , A 4 )
3 0998 FORMAT!'O', ’ERROR ON CARD NUMBER', 16,////)
30999 FORMAT!///'0ABORT ECCLES RUN.’) 
C '
c
C . • .
c SECTION TWO INITIALISATION.
C
C . '
200 IN « 5
IN1 ~ 9 .
INS =3 '
IN3 = 4 ■
INS = IN1
JSTART ~ 1 -
OUT a 6
OUTF ~ 7
N1 « NXP1
N2 « nxX ♦ 1
N3 = NSP1
NNN = 0
NPURGE ~ 0 ■ •
SWTCH ~ .FALSE,
NREJEK « 0 .
WRITEIOUT,30201)
SUPRES = .TRUE.
IPRT ~ .FALSE. •
ERCONC « .FALSE.
■ GO TO 300
%
'S
■ y
■I
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250 IPRT * .TRUE.’
SUPRES s .FALSE.
O
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SECTION THREE, COMPONENT DATA INPUT AND OUTPUT.
300 READCIN1 , 1 0301 ) IXA, IXB, NDUM, I, J, K, L, M, N,
• NN, NM
N N N « N N N * 1
IF (NNN .GT, 15) WR I TE < OU'T, 3 0300) NNN
WRITECOUT,30301) IXA, IXB, NDUM, I, J, K, L, M, N,
N N , -N M
• I F(NNN,EC1.1.AND.IXA.EQ.EITC3)) GO TO 250 
WRITECOUTF, 1 0301 ) IXA, IXB,' NDUM, I, J, K, L, M, N,
NN, NM
I FCIXA.EQ,LITC7)) SWTCII = .TRUE.
1 F (1 X A . N E . L I T ( 2 ) ) GO TO 300
D 0 3 01 N I »1 , N1 i
READC INI,10303) IXA, AXA, BXA 
NNN ~ NNN + 1
IF (NNN .GT. 120) GO TO 3011 
I FCIXA.EQ.LITC6)) GO TO 302 
WRITE(OUTF,20303) IXA, AXA, BXA 
WRITECOUT,30303) IXA, AXA, BXA 
IF(BXA.LT.1,0E-2S) BXA = 1.0E-28 
TPEAL(Nl) ~ AXA
XX(NI) = BXA
IF(XXCNI),EE.0.0000) ERCONC » .TRUE.
301 NCOMP(NI) = IXA 
STOP 301
3011 WRITECOUT,30300) NNN 
GO TO 9999 •
302 NI ~ NI « 1 
WRITECOUTF,20304)
WRITECOUT,30304)
READ(IM,10301) IXA, IXB, NDUM, 1, J, K, L, M, N, 
NN, NM
NNN = NNN + 1
WRITECOUTF,10301) IXA, IXB, NDUM, I, J, K, L, M, Nr 
NN, NM
WRITECOUT,30301) IXA, IXB, NDUM, I, J, K, L, M, N, 
NN, NM
IFCIXA.NE.LITC3)) GO TO 9998
N«NI
DO 303 NI I'=1 , N2
READCIN1,10303) IXA, AXA, BXA 
N N N ~ N N N + 1
o 
o 
o
IF (NNN .GT. 150) GO TO 3011 
IF(I XA•EQ»LIT(6)) GO TO 304 
WRITECOUTF, 20303) • IXA, AXA, BXA 
WRITE(OUT»30303) IXA, AXA, BXA 
ifCbxa.lt.t.oe-20) bxa » 1.0E-20,
N - N + 1
TREAL(N) = BXA 
XX (N) - AXA
IFCTREALCN).LT.XXCN)), ERCONC * .TRUE.
IF(TREALCN).LE.0.0000) ERCONC « .TRUE.
. 303 NCOMP(N) « IaA 
STOP 303
304 Nil •” Nil - 1
WRITECOUTF,20304)
WR I TE(OUT r30304)
N I 11 = N I + H I 1 
IFCSWTCH) REWIND OUTF 
IFCSWTCH) WRITE(OUT,30305)
WRI T£COUT»30302) NNN
C
C BLOCK OPTION TO IGNORE SPECIES IN MASTER FILE,
C
330 READCIN1,10330,END-331) IXA, NDUM 
IFC IXA.NE.LITC4)) GO TO 332
331 WRITECOUTF,20-331 )
WRITECOUT,30331)
SWTCH = .FALSE.
GO TO 350
332 IFCIXA.NE.LIT(8)) GO TO 3011
WRITECOUT',30332) NDUM 
NPURGE = NPURGE + 1 
IF(NPURGE.GT.NND) STOP 332 •
DO 336 N = 1,NKEY
IF(NDUMCN).EQ.LITC1)) 60 TO 335
DO 334 M-1,NII I
IFCNDUMCN).EQ.NCOMP(M)) GO TO 336
334 CONTINUE
WRITE(OUTr30334) NDUMCN)
GO TO 9999
335 IFCN.EQ.1) STOP 335
336 PURGECN,NPURGE) a NDUM(N)
GO TO 330
EXPAND LIST OF PERMITTED SYMBOLS,
350 NNN = 0 
NP = 0
DO 352 1-1,400 ' •
READ(IN2,10301) IXA 
NUN = NNN * 1
IFC IXA.EQ.LITC6)) GO TO 400 
DO 351 M~1,NI 11
IFCIXA.EQ.NCOMPCM)) GO TO 352
351 CONTINUE
IFCNCOMPCNII I).EQ,LIT(6)) GO TO 400
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NP « NP + 1 '
IF(NP.GT.NPMAX) GO TO 416 
PCOMP(NP) a IXA
352 CONTINUE
SECTION FOUR , BASIC STABILITY CONSTANT DATA 
INPUT AND OUTPUT.
C
C
400
401
DO 412 NJ=1»N3
READCIN8,10401,EIW«4410,ERR-413) CONST(NJ), NDUM 
NNN a NNN + 1 .
I F(NPURGE.GT.0) SWTCH a BLOCK(NDUM,PURGE,NND,NKEYr 
NPURGE, L I T < 1 ) )•
I F (SWTCH . AND'. IN3.EQ. I N2) GO TO 401
NUMKNJ) = 0
NUM2(NJ) ~ 0 , .
NPM a 1
402
DO 402 N~1,NKEY 
KEY(N,NJ , 1 ) a 0 
KEY(N,NJ,2) a 0 
DO 407 'N--1 , NND, 2
403
404
IF(NDUM(N).EQ.LIT(1)) GO TO 408 
IF(IWUM.(N + 1 ) ,EQ.0) GO TO 413 
DO 404 M«NPM»NJIJ
I F.(NDUM (H) • EQ.NCOMP(M) ) GO TO 405 
CONTINUE
IF(NPM.EQ.I) ND a N
IF(NPM.EQ.I) NUH1(NJ) « 0 
I F(NPM,EQ. 1 ) NUI12CNJ ) - 0 
IFCNPM.EQ.1) GO TO 409 
NPM = 1
405
GO TO 403
NPM a M
IF(M.GT.NI-) GO TO 406 
L = NUMKNJ) * 1
406
NUMKNJ) » L 
KEY(L,NJ,1) a M 
GO TO 407
L a NKEY - NUU2CNJ)
407
408
409
410
411
NUM2(NJ) = NUM2CNJ) 1
KEY(L,NJ,1) = M - NI '
KEY ( L, NJ ,2) a NDU1KN + 1 )
I FCNUM1(NJ)+NUM2(Nj) . LE.1) GO TO 413
DO 410 N=2,NND,2
IF(NDUM(N) .EQ.O) GO TO 411
CONTINUE
N » NND + 2 . '
N N « N 2
IXA a NUMKNJ) * NUM2(NJ)
I F(IXA.GT.1) GO TO 4411
IF(IXA.EQ.1) GO TO 413
I F( IPRT) WRITE(OU f,30401 ) CONST(NJ),(NDUM(N), fKl f NN)
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IF(NUU2(NJ ) .EQ.NN/2) 60 TO 401
IF(CHEK<NDUM(ND) ,PCOMP,NP).EQ.-1) 00 TO 9996
GO TO 401
Q •K’'k-k'fi'k-k-k'k-fe-k-k'fc'tt'k-k-k-k'k'ft'k
-k'tr'k-k-k'kJe'k-k'kJc'/t •
4410 IF<INS.EQ.IN2) GO TO 414 ' •
INS = IN2
J START - NJ
NNN = NNN - NJ + 1 >
GO TO 401 -
Q *****>>******** * * -k -Jr * * * iV Vr * A- ******** A ****** *•** * * * ^ *
‘ ******** ■
4411 IFdN8.EQ.IN1 ) WRITE<OUT,30410)
' CONST(NJ), (NDUM(N); N~1,NN)
• I F ( .NOT. SWTCII. AND. INS, EQ, JN1 ) GO TO 418
NNX ~ NN + 1 •
IF(NNX.GE»NND) GO TO 412 ’
DO 4412 N~NNX,NND,2
NDUM(N) = LIT(1) •
4412 NDUHCN+1) ~ 0
412 WRITECOUTF,20401) CONST(NJ), NDUM, LIT<1)
. ********
STOP
413 WRITE(OUT,30402) NJ, NNN 
GO TO 9999
414 NJ ” NJ - 1 ‘
WRITE(OUT,30403) NNN, NJ
NTOT = NJ 
NI1ET - 0
NHYDR « NI .
DO 415 II~1,NIl * -
NHYDR ~ NHYDR + 1 .
IFCNCOMP(NHYDR).EQ.LITC5)) GOTO 480
415 CONTINUE •
WRITE(OUT,30416) ‘
GO TO 9999‘
416 WRITECOUT,30417)
GO TO 9999 '
418 WRITECOUT,30418)
GO TO 9999O O
 C
J 
<_> SECTION FIVE SELECTION OF THE MIXED COMPLEX
COMPONENTS.
C
c . .
480 NNN - 1
. DO 481 NM,NND,2 . ’
NDUM(N) - LIT(1)
481 NDUM (MM) « 0
READ(IN,10201,END-494,ERR-745) NSECC 
490 NMET ~ NMET * 1 • ’ ■ ’
.300
491 RE AD Uh, 105 01 , END-494 , ERR-745 ) 'MET ARR( NMET ) ,
STBARR(NMET)
IF(HETARRCNMET)>EQ.LIT<6)) GO TO 494
IF(BLOCK(NDUM,PURGE,NND,NKEY,NPURGE, LIT(1)))
GO TO 491
DO 492 1-1,NII I
IFCNCOMP(I).EQ.METARR (NMET)) GO TO 493
492 CONTINUE
WRITE(OUT,30501) METARR(NMET)
IF(CHEK(METARR(NMET),PCOMP,NP).EQ.~1) GO TO 9995
GO TO 491
493 METARR (NMET) ~ I
GO TO 490
494 NNN = NMET - 1
IF(NNN.LE.O) GO TO 900
WRITL(OUT,30494)
DO 495 1-1,NNN
METAL = METARR<I)
495 WRITECOUT,30495) NCOMP<METAL), STBARR(I)
WRITECOUT,30201)
NSECC - NSECC - NJ - 2 
C 
C 
C
500 NMET ~ NMET « 1
IF(NMET.LE.O) GO TO 900
METAL ~ METARR(NMET)
STABF - STBARR(NMET)
C
C I F ( STAB F .IT . 0 ) PRINT TERNARY CONSTANT DETAILS,
C
MAX-MIX = NSECC / NMET
TOTLM = AL0G1OCTREAL(METAL)) •
FREEM = ALOG10(XX(METAL))
NM ~ 0
NH - 0
NT - 0
NNN *= 0
METALF ~ 0
IF(METAL.GT.NI) METALF = METAL - NI 
C '
DO 516 J-JSTART,NJ
I F(METALF.GT.O) GO TO 504
NL « NUMKJ)
DO 503 L=1,NL
I F(KEY(L,J,1)•EQ.METAL) GO TO 506
503 CONTINUE
GO TO 516
504 IF(NUM2<J).EQ.O) GO TO 516
NL « NKEY - NUM2CJ) + 1
DO 505 L=NL,NKEY
IF(KEY(L,J,1),EQ,METALF) GO TO 506
505 CONTINUE
60 TO 516
506 IF(KEY(L,J,2)•NE . 1 ) GO TO 516
KEY(L,J,2) - 2 
MM -• NUM1CJ)
ML « NKEY " MUH2CJ) * 1 
DO 507 M-1,NKEY
IF(M.GT,NN■AND.M.LT.NL) GO TO 507 
IF(KLY(M,J,2)-ME.2) GO TO 515
507 CONTINUE
NN = NN + NUM2(J)
IF(NN•GT.2) GO TO 508 
Nfl = Nil + 1
CONSTM(NM) = CONST(J) / 2,0 
MCOMP(NM) = KEY(1 ,J, 1 )
IF(L.EG.1> MCOI-IP(NM) = KEY(NKEY,J , 1 ) + NI 
GO TO 515 ' •
508 IF(NN.GT„3) GO TO 515 
NL = NKEY - 1
IF(KEY(NItJ»1)•NE•11»AND•KEY(NKEY»J♦1)•NE. 11) GO TO 
514
Nil « NH * 1
IF(NUM2(J) ■ EG»1 ) GO TO 513 
IF(L.GT.NUM1(J ) ) GO TO 512 
HCOMP(NH) ~ KEYCNL,J,1) + NI
IF(KEY(NL,J,1).EQ•11) HCOMP(NH) ~ KEY(NKEY,J , 1 ) + NI
511 CONSTH(NH) = CONST(J) / 2.0
GO .TO 515 •
512 HCOMP(NH) = KEYC1 , J ,1 )
GO TO 511
513 HCOMP(NH) « KEY(1 , J ,1 )
IFCL.EQ.1) HCOMP(NH) -• KEY(2,J,1)
GO TO 511
514 KEY(L,J,2) - 1 
NN = KEY(1 , J,1 )
NL = KEYCNKEY, J ,1 ) * N I 
IXA ~ 2
IF(K£Y(2,J,1).EQ.O) IXA « NKEY - 1 
IXB = KEY(IXA,J,1)
IF(KEY(2,J,1).EQ.O) IXB « IXB + NI 
WRITE(OUT<3 0502) NCOMP(NN), KEY(1 , J , 2) ,
NCOMP(IXB) , KEY(IXA,J,2) i 
1 NCOMP(NL), KEY(NKEY,J,2)
515-KEY(L,J,2) = 1
516 CONTINUE
o 
n 
n 
c
SECTION SIX CALCULATION OF THE UNSTABILISED
MIXED LIGAND CONSTANTS.
C
C
600 ‘NMH « NM + NH
• NMX = ((NMH ** 2) NMH) / 2
IF(NHX.GT.NMIX) GO TO 605 
DO 601 M-1,NMX
601 STAB(M) = 550,0
DO 602 1-1, Mil
302
N « NM + I ‘
MCOMP(N) » HCOMP(I)
602 CONSTM(N) » CONSTHU)
C
c ■
c
J = 0
DO 604 M=2,NMH 
N = M ~ 1 • . .
DO 604 1 = 1,N
J ~ J + 1
604 CMIXCJ) - CONSTM(M) CQNSTM(I) 
GO TO 610
605 WRITECOUT,30601 )
GO TO 9999
on
e 
o 
o 
o
610 WRITECOUT,30605) NCOMP(METAL) •
AXA » AL0610(XX(HHYDR))
DO 611 M=1,MMH 
NPM = HCOMP(M)
MCOMP(M) ~ NCOMP(NPM)
XXM(M) ~ ALOG1OCXX(NPM))
TREALMCM) = ALUGl0(TREAL(NPM)) 
IF(M.GT.NM) XXM(H) = XXM(M) + AXA
611 WRITECOUT,30604) MCOMPCM), CONSTM(M),
TREALM(M)
WRITECOUT,30607) FREEM, TOTLM 
WRITECOUT,30606) NMH, NM, NH 
DO 612 M=1,NH
NPM = HCOMP CM)
612 HCOMP(M) » NCOMP(NPM)
XXMCM),
ND = 0
DO 623 I»1,NH 
DO 621 M=1,NM
IFCHCOMP(I).EQ.MCOMPCM)) GO TO 622
621 CONTINUE 
GO TO 623
622 NO ~ ND + 1
IF(ND»GT«NDMAX) STOP 622 
DUP(ND,1) = I + NM 
DUP(ND,2) = M
623 CONTINUE
. OMIT(1,1) ~ 0 
NZ - 0
IF(IID.EQ-O) GO TO 700
DO 026 1 = 1.,ND
DO 626 L=I*,ND
M = DUPC'1,1) ~ 1
IF(I.NE.L) GO TO 624
M = CCCM ** 2) - M) / 2) + DUP(I,2)
303
oo
oo
 o o <
~s
 o
J = 0 ' ■
N3 = DUP<L,2>
XA •“ CM IX CM) + STABF 
IF(SUPRES) GO TO 625
WR I TE(OUT,30uQ2) XA, NCOMP(METAL), MC0MPCN3), M 
GO TO 625 •
624 J = (<(M ** 2) - M) / 2) + DUP(L,2)
M = OOP(I,1) - 1
M = (((M ** 2) - M) / 2) + DUP(I,2)
XA ~ CMIX(J) ■ .
IFCCMIX(H) .GT.XA) XA ~ CMIX(M)
AXA = CMIX(J) - CMIX(M)‘
AXA=ABS(AXA>
iF(AXA«LT.0.5). XA = XA + 0,1 •
. IF(AXA„LT„0.1) XA = XA + 0.075
I F(AXA. LT.0.05) XA « XA ■+ 0.05
XA ~ XA * STABF •
N1 - J - I ' ’
N3 « DUPO.1), ■
N2 = DUP(L,2) '
IF(IPRT) WRITE(OUT,30603) XA, MCOMP(META L),
MCOMP(M3), MC0MP(N2),
1 CM1X(J), CMIX(H), J, M, N1
CMIX(J) ~ XA ~ STABF G
625 NZ - NZ + 1 • ' • ■ ■
IF(NZ.GT.NZMAX) STOP 625
NMX = MMX ~ 1 •
0MIT(NZ,2)
626 OMITCNZ,1) = M
SECTION SEVEN INPUT, PROCESS AMD OUTPUT MIXED
LIGAND DATA,
READ THE CARD; TEST IF IT APPLIES TO THE CURRENT 
METAL ION, ' •
700 KSW ~ Q
701 NNN p MNN +1 ■ ’
READCIN3,10401,END=80Q,ERR-746) XA, NDUM 
I F(NDUM(1),EQ.LIT(1)) GO TO 770 
IF(NDUM(1),EO.NCOMP(MET AL)) GO TO 702 
DO 99701 1=1,Mill ' '
I F(NDUM(1).EQ,NCOMP(I)) GO TO 700
99701 CONTINUE
N1 = 1 ,
I F(CHEK(NDUM(1),PCOMP,NP).EQ,-1 ) GO' TO 9997 
GO TO 700
C
C DETERMINE WHETHER EACH COMPONENT APPEARS IN THE
CURRENT MODEL, •
304
o 
o 
<i
 
o o o
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703 IFCKSW.EQ.100) KSW ~ 0 •
NT « NT ♦ 1 ’
X "* 1 •
DO 705 N=4»NND,2 . . •
I FCNDUH(N) .EQ.O) GO TO 706
N1 ~ N ~ 1
N2 « I '
703 DO 704 I=N2, NIII •
IF(N.COMPU) .EQ.NDUMCN1 ) ) GO TO 705.
704 CONTINUE
IFCN2.EQ.1) Go TO 740 
N2 = 1 ‘
GO TO 703
705 CONTINUE •
N « N + 2
706 NN ~ N - 2 . •
TEST FOR ’ll + 1 ’ POSITIONAL ERROR.
IFCNDUUC1 ),EQ.LITC5).OR.NDUM (3). EQ.LITC5))
GO TO 749
IF(NDUM(2)•LE.0•OR•NDUM(4).LC•0) GO TO 745 
IF(NDUIK5).EQ.LITC5).AND. NDUM(7),ME.LIT(1>)
GO TO 749
1FCMDUMC6).LT.O) GO TO 745
IF(NDUM($).LT•0•AND•NDUM(7).NE•LIT(5)) GO TO 745 
IFCNDUMC8) .LT.O) GO TO 730
IF(NDUM(9)•NE.LIT(1)) GO TO 730 '
ESTABLISH THE CATEGORY. I F ( K S W . EQ , 0 )
MAKE A NEW START.
IF(KSW.NE.O) GO TO 720 
IFCNDUI1C2).NE.1) GO TO 730 ’
I F(NDUM(4)«EQ»2) GO TO 711 • •
KSW = 87
IF(NDUM(4)•NE.1„OR.NDUM(6).NE.1) GO TO 730 
1FCNDUMC8).EQ.O. AND.NDUMC7).EQ.LITC1)) GO TO 780 
IFCNDUMC7). NE.LITC1).AND,NDUM(7).NE.LIT(5)) •
GO TO 730 • ‘
IFCNDUM(8)•LE.2.AND•NDUM(7)•EQ.LIT(5)) GO TO 780 
GO TO 730
711 IFCNDUMC6).EQ.O.AND,NDUMC8).EQ.O) GO TO 750
I F(NDUM(o).EQ.2.AND.NDUMC5).EQ.LITC5)) GO TO 750 
GO TO 730 ■ .
720 IFCKSW.EQ.31) GO 
I FCNDUMC2) .NE.1 ) 
IFCKSW.NE.52) GO 
I F(NDUMC4).NE.2)
' I F C N DUl-i C 8) • N E , 0) 
IF(NDUM(6).EO.O) 
IFCNDUIK6) .EQ.2.
TO 723
GO TO 73 0
TO 722
GO TO 721
GO TO 745
GO TO 752
.NDUMC5),EQ.LITC5)) GO TO 752
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GO TO 745
721 IFCNDUM(4)•NE ■ 1 „ AND • NDUMC6)•NE,1} GO TO 745
I F C N DUli C8) ■ EQ, 0) 60 TO 760 '
IFCNDUMC8) • LE , 2 • AND»NDUM(7),EQ,LITC5)) GO TO 760
GO TO 745 •'
722 IFCKSW•NE•87) GO TO 725 ■
723 I F C NDUFi C4 ) • NE ■ 1 , OR • NDUM C 6) . NE , 1 ) GO TO 730
KSW = 87
724 IFCNDUMC8) ,EQ.O) GO TO 780
1 FCNDUMC8),LE«2,AND•NDUMC7),EQ , L IT C 5 ) ) GO TO 780
GO TO 730
725 IFCKSW,ME•61) GO TO 7'45
IFCNDUMC4),NE„1, AND.NDUM(6),NE,1) GO TO 745
60 TO 724 • 1
OUTPUT UNCATEGORISABLE MiXED SPECIES,
730 KSW - 31
731 IF(KSW,GE,5O,AN|).K$W,LT.8O) GO TO 741
IF(BLOCK(NOUN, PURGE,NND,NKEY,MPURGE,LIT(1)))
GO TO 701
IF(IPRT) WR ITE(OUT,30731 ) XA, CNDUMCN), N=1,NN>
*’*•**★★'**
WRITECOUTF,20401) XA, CNDUMCN), N~1,NN)
NNX “ NN + 1
IFCNNX.GE.NND) GO TO 435
DO 434 N=NNX,NND,2
NDUM(N) = LITC1)
434 NDUUCND) ~ 0
435 WRITECOUTF,20401) XA, NDUM, LITC1)
■k'k-k-k-k'k-k'k'k'k'k'kk-to •k-k-k-k'k-k'k-klfic'k-te'kk-k-it'k'kk'k'k'kic-k-k'k'kic-k-k'k'k-k 
******** ’
NTOT « NTOT + 1
NSECC » NSECC ~1 .
IFCNMET.E0.1 ) MAXMIX ~ MAXMIX 1 .
GO TO 701 . •
OMIT THE SPECIES, ’ ' .
740 IF(IPRT) WRITECOUT,30741) . ' .
IFCCHEKCNDUMCN1),PCOMP,NP)»EQ„-I) GO TO 9997
741 IF(IPRT) WRITECOUT,30742) NNN 
IFCKSW.NE.O) GO TO 701 
IFCNDUMC4) ,NE,2) . GO TO 701
I F(NDUMC6).EO.O.OR.(NDUMC5)•EQ•IIT(5)„AND»NDUM(6) 
.EQ.2)) KSW ~ 100
GO TO 701 . . '
C ■ , •
C . ERROR EXIT . ' ’
C .
745 WRITECOUT,30745) NNN ' ' ■
WRITECOUT,30746) KSW
GO TO 9999 ■ ’
746 WR I TbCOUT<30747) NNN .
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GO TO 9999
747 WRITE(OUT,30748)
GO TO 745
749 WRITE(OUT,30749)
GO TO 745
C
C
C
750 DO 751 1=1,NMH
751 CBUF(I) = -1001 .0 
KSW = 52
C
C IDENTIFY THE LIGAND. IF(KSW»NE.71> FILL CBUF FOR
PREDICTION LATER.
C
752 I F ( NDI.JH (5 ) .EQ.LIT(5) ) GO TO 753 
N1 = 1
N2 = Nt-l 
GO TO 754
753 N1 = NM * 1 
N2 = NMH
754 DO 755 I=N1,N2
I F(NDUM(3)•EU.MCQMP(I)) GO TO 756
755 CONTINUE
XFCKSW.EQ.71) GO TO 775 
GO TO 741
756 IF(CeUFd).GT.-100.0) GO TO 745 
IF(KSW.EQ.71) GO TO 771
. NB = I .
CBUF(I) = XA / 2.0 
GO TO 701
<-
><
->
 C3
760 IF(KSW.NE»52) GO TO 745 
KSW = 61 
GO TO 780
C
C PREDICT TERNARY STABILITY CONSTANT FROM THE BINARY
VALUES IN CBUF
C . WHICH HAVE BEEN DETERMINED UNDER NON~P H-Y S I 0 LOG I C A L 
CONDITION'S-
C
761 IF(LX,LE•NM.AND„LY•LE.NM) GO TO 768 
I F(LX.GT.NM.AND.LY.GT.NM) GO TO 768
C . ‘
C IF THERE ARE TWO WAYS OF PREDICTING, USE THE ONE
WHICH IS CLOSEST.
C
IF(ND.LQ.O) GO TO 767 
IXA « MI NO(LX,LY)
IXB ~ LY ' ,
IF(IXA.EQ.LY) IXB » LX 
N1 = 0
N2 = 0 ,
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DO 762 I~1,ND
I F(PUP<I,1).EQ,IXB) N1 * DUPO,2) 
IF(PUPU,2).E«.IXA) N2 ~ DUPU,1) '
762 CONTINUE
IF(N1.CO.0.OR.N2.EQ.0) GO TO 767
IF(CBUf-(Nl ) .LT.-100.0.0R. CBUF (N2) .LT.-1 00.0) •
GO TO 767
IF(CBUFOXA>.GT.~100.0.AND.CBUF(IXB).GT.-100.0)
GO TO 764
763 LX “ N2 ’ .
LY « N1
GO TO 767 ‘
764 AXA ® XA - (CON STM(IXA) * COMSTM(IXB))
XB ” XA ~ (CONSTM(N1) + CONSTM(N2)> .
• AXA s= ABS(AXA)
XB = ABS(XB) ' • 1
IF(AXA.GT.XB) GO TO 763 •
767 C!1IX(J) = CONST?) (LX) + CONSTM(LY)
I F (CBUF ( LX) .GT.-1 00.0. AND. CBUF ( L-Y) .GT.-100.0)
• GO TO 768 ’
WRITE(OUT, 30761.) •
GO TO 745
768 XB ® XA - (CBUF(LX) + CBUF(LY))
IF(IPRT) WR I TE(OUT#30763) (NDUM(N), N=1,NN)
1F(IPRT) WRITE(OUT,30764) CBUF(LX), CbUF(LY), XB,
XA
IF(STAB(J)•LT.500.0) GO TO 747
STAB(J) n XB' * ((CONSTM(LX) + CONSTM(LY>> /
(CBUF(LX) + CBUF(LY)))
XB « CMIX(J) + STAB(J)
IF(SUPRES) GO TO 701 .
WRITE (OUT » 30764) .CON STM ( LX) , CONSTM(LY) r STAB ( J >
XB
' GO TO 701 '
C
C CATEGORISE SPECIES FOR STABILISATION FACTOR
. • SUBSTITUTION (KSW=71)»
c
' 770 IF(NDUM(3)«EO•LIT(1)) GO TO 700 '
IF(KSW«EQ.100) NT = NT + 1
IF(KSW.EQ.0•OR.KSW.EQ»100) GO TO 701 .
IFCKSW.NE.52.AND,KSW.NE.71.AND.KSW.NE. 72) GO TO 745 
NT NT + 1
' KSW - 71
LX » NB
XB - CONSTM(LX) / CBUF(LX)
GO TO 752
C . '
C PREPARE FOR STABILISATION FACTOR SUBSTITUTION (BY
. . ADJUSTflENT MECHANISM) . ‘ '
C .
771 LY ~ I
CBUF(I) ~ XA ,
KSW ® 72 ■ •
GO TO 785
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C
C ADJUSTMENT MECHANISM. XA * STAB. FACTOR;
XB = CONDITIONS RATIO.
C
772 I F(STAB(J)•LT•500.0) GO TO 767 
STAB(J) = XA * XD 
N1 = 0
IF(LX.GT.NM) N1 = N1 + 1 
IF(LY.GT.NM) N1 « N1 + 1 
IF(SUPRES) GO TO 701
WRITE(OUT#30771) NCOMP(METAL),MCOMP(LX)»MCOMP(LY)r 
N1,XA,$TAB(J)
GO TO 701 
C
C DECIDE WHY THE SPECIES IS TO BE OMITTED.
C
775 DO 776 1=1,Nil I
IF(NDUM(3)•EQ•NCOMP(I)) GO TO 741
776 CONTINUE
N1 =3 -
GO TO 740
C
C DETERMINE THE INDEXES LX AND LY FOR THE COMPONENTS
IN NDUM(3) AND NDUM(5),
C
780 IF(NDUM(3).EQ.NDUMC5)) GO TO 745 
LX = 0
LY = 0
IF(NDUM(8).EQ.0) GO TO 782
N1 = NM + 1 • '
DO 781 I=N1,NMH
I F(NDUM(3)•EQ.MCOMP(I)) LX = I
I F(NDUM(5).EQ.MCOMP(I)) LY ~ I ’
781 CONTINUE
IF(NDUM(8).EQ.2) GO TO 735 
IF(LX.EQ.O.AND.LY.EQ.O) GO TO 731 
N2 = 0
N3 = 0 ' •••
IF(LX.EQ.O.OR.LY.EQ.O) GO TO. 782 
N1 = MINO(LX,LY)
N2 = LX 
N3 = LY 
L X = 0 
LY = 0
782 DO 783 1=1,NM
IF(LX.EO.O.AND.NDUM(3).EQ.MCOMP(I)) LX = I 
IF(LY.EQ.O.AND.NDUM(5).EQ.MCOMP (I )) LY = I
783 -CONTINUE
IF(NDUM(8).EQ.O) GO TO 785 
IF(LX.EQ.O.OR.LY,EQ.O) GO TO 784 
IF(N1.EQ.N2) LX = N2
IF(N1,EQ.N3) LY = N3 
GO TO 785
784 1 F ( LX . EQ . 0 . A.ND , L Y . EQ. 0 ) GO TO 731 
IF(LX.EQ.O) LX = N2
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IF(LY.EQ,0> LY w N3 
C
C CALCULATE THE MIXED SPECIES INDEX AND CORRECT IT IF
NECCESSARY.
C
785 IF(LX.EQ•O»OR»LY•EQ«0) GO TO 731 
L a MAXOC LX,LY)
M = L - 1 
I a LX
IP(I.EQ»L) I » LY 
L — M •" 1
J a (CM * L) 7 2) I 
IF(NZ.EQ.O) GO TO 787 
DO 786 l«1,NZ
1 F(J,EQ•OMIT(1,1)) J a 0MIT(I,2)
786 CONTINUE
787 IF(J.LE.O) GO TO 745
IFCKSW.EQ. 72) GO TO 772
IFCKSW.EQ. 61 ) GO TO 761
IFCKSW.NE, 87) GO TO 74 5
C
C DIRECT STABILITY CONSTANT SUBSTITUTION.
C
1F(STAB(J>•LT•500,0) GO TO 747 
STAB(J) = XA - CMIX(J)
CMIX(J) = XA - STAB(J)
IF(SUPRES) GO TO 701
WRITE(OUT,30781) XA, (NPUMCN),' Na1,NN) 
.GO TO 701
:£
" *
'Ji
^3
Ai
n 
n 
n 
c
SECTION EIGHT OUTPUT THE CALCULATED MIXED - -<
LIGAND FORMATION CONSTANTS. . 1
C . • |
c • 1
800 REWIND IN3 •-?
NN a NNX + NZ •
DO 801 Ia1,NN . ' -
LGMIX(J) a 0,0000 ' '
. IF(STAB(I).GT.500i0) STAB(I) a STABF \
801 CMIX(I) a CMIX(I) + STAB(I) j
C ' 1
C • THE PRE-SCAN, . . *
c . . :
NNN a NTOT .
FACNEW a -20,00 }
•IFCNMX.LE.MAXMIX) GO TO 899 3
IF(ERCONC) GO TO 9994 I
FACMAX a 0,0000
FACIIIN a -500.0 • '
J a 0 ' ‘ '1
DO 893 M«2,NMH ’
N » M ~ 1 . ’ •
DO 893 Ia1,N ’ • . • 1
a
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J ~ J + 1
AXA = AMJN1 (TOTEM, TREALM(M) , TREALMC I) >
AXALGMIX(J) » CMIX(J) + FREEM + XXM(M) * XXM(I) - 
IF(SUPRES) GO TO 893
IF(M.EE.NM) GO TO 892
I F(0MIT(1,1).EQ.O) 
DO 890 K=1,NZ 
IF(0MIT(K,1) .GQ.J >
GO TO 892
GO TO 891
890 CONTINUE
891
GO TO 892
.1 F ( OM I T ( K , 2 )-EQ.O) GO TO 893
892
WRITE(OUT,30892) J 
GO TO 893
WRITE(OUT,30893) J,
, I, M, CMIX(J), OMIT(K,2)
I,M,CM I X(J),STAB(J),XXM (I)
893
894
XXM(M),
CONTINUE .
IXA = 0
AXArLGMIX(J)
DO 895 1=1,NN
. IF(LGMIXd) ,GT.FACNEW) IXA = IXA + -1 
895 CONTINUE
896
897
898
IF(IXA - MAXMIX) 896,899,897 
FACMAX = FACNEW 
GO TO 898
FACMIN '= FACNEW
FACNEW = (FACMAX + FACMIN) / 2,0
IF(FACMAX - FACNEW,GT.0,00001 ) GO TO 894 
WRITE(OUT,30899) MAXMIX
899
FACNEW = FACMAX 
NDUMC1) a NCOMP(METAL) 
NDUMC2) = 1
NDUMC3)
NDUMC4)
» MCOMPd) 
« 1
NDUM<5) = MCOMp(2) 
NDUMC6) a 1 
J = 0.
DO 804 M=2,NMH
802
803
N = M « 1
DO 304 1=1 ,N
J = J + 1
NDUMC3) = MCOMPd)
NDUM(5? = MCOMP(M) .
NN = 6
IF(LGMIXU) ,EE. FACNEW) GO TO 804
IF(M,EE,NM) GO TO 803
NN s 8
NDUMC7) = LIT(5)
NDUH(8) = 1
IFd,GT,NM) NPUM(S) = 2
I F(BLOCK(NDUH,PURGE,NND,NKEY,NPURGE,EIT(1 ) ) ) 
GO TO 304
IF(0MIT(1,1),EQ,O) GO TO 803
DO 802 K = 1,NZ
IF(0MIT(K,1).EQ.J) GO TO 804
CONTINUE
NTOT = NTOT + 1
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tV'A-*-Ar ★**■/(•
WRITE(OUTF,20401) CMIX(J), (NDUM(N1), N1=1 ,NN)
NNX = NN + 1
IF(NNX.GE.NND) GO TO 806 
DO 805 N1”NNX,NND,2 
NDUM(N1) « LIT(1)
805 NDU1KN1+1 ) = 0
806 WRITE(QUTF, 20401 ) CM1X(J), NDUM, I.IT(1)
****•>+* A*************** *★*★**•*•***★****•0 'k *-k -k -k -k 'ft +< jc'k -fr 
•k^^'/ck-k'k'k
804 CONTINUE
NNN = NTOT - NNN
NSECC = NSECC « NNN
NREJEK = NREJEK + NMX ~ NNN
WRITE(OUT,30801) NMX, NCOMP(METAL), NNN, FACNEW 
WRITE(OUT,30802) NT 
GO TO 500
900
9994
9995
9996
9997
9998
9999
901
SECTION NINE FINISH!
NNN = NTOT + NREJEK 
NT = NTOT
NTOT = NTOT + Nil I
WRITE(OUT,30901) 
IF(NREJEK.GT.O) 
GO TO 901 
WR ITE(OUT,30994) 
GO TO 9999 
WR1TE(OUT,30995) 
GO TO 9999 
WRITE(OUT,30996) 
GO TO 9998 
WRIT£(OUT,30997) 
WRITE(OUT,30998) 
WR1TE(OUT,30999)
NTOT
WRITE(QUT,30903)
NDUM(NO)
NDUMCN1) 
NNN
NT, NNN
ENDFILE OUTF 
NT « 0 
REWIND OUTF 
WR1TE(OUTF,20999) 
CALL EX IT(3) 
WRITE(OUT,30902) 
ENDFILE OUTF 
STOP
END___________________________________________ ;
INTEGER FUNCTION CHEK(NCHEK,PCOMP,NP) 
INTEGER PCOMP(NP)
CHEK = 1
DO 100 1=1,NP
I F ( NCHEK•EQ»PCOMP(I)) RETURN 
100 CONTINUE
CHEK = -1
312
RETURN
BNP_____________________________________________________________
LOGICAL FUNCTION BLOCK(NDUM, PURGE , NND , N KEY , NPURGE, 
LIT)
INTEGER NPUM(NNP), PURGE(NKEY,NND)
BLOCK » .FALSE, •
IF(NPURGE•LT . 1) RETURN
DO 104 IPURGE=1,NPURGE '
DO 102 IKEY=1rNKEY
IF<PURGE(I KEY,IPURGE),EQ.LIT) GO TO 103 
DO 101 IMD-1,NND,2 •
I F(PURGE(I KEY,I PURGE)•EG.NDUM(IND)) go to 102
101 CONTINUE
GO TO 104 ■ •
102 CONTINUE ' •
103 BLOCK = .TRUE, ' ■
RETURN ‘
104 CONTINUE
RETURN . •
END •
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FLOW DIAGRAM FOR PROGRAM ECCLES'
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DEVELOPED AT THE UNIVERSITY OF CAPE TOWN DURING 
- 1974 AND 1975 .
RE-WRITTEN AT THE UNIVERSITY OF ST. ANDREWS DURING 
. ' 1976 AND 1977. ' •
MODIFIED AT THE UNIVERSITY OF WALES INSTITUTE OF 
SCIENCE AND
TECHNOLOGY DURING 1978 AND 1979. .
THIS PROGRAM EVALUATES THE CONSTITUENT 
. CONCENTRATIONS IN LARGE
EQUILIBRIUM SYSTEMS. IN ADDITION, IT IS DESIGNED 
TO REFLECT THE MORE •
PRONOUNCED EFFECTS OF SYSTEMATIC CONCENTRATION 
' CHANGES IN THE
EQUILIBRIUM MIXTURE.
THE PROGRAM IS WRITTEN IN FORTRAN IV.
SECTION ONE. ’ STORAGE ALLOCATION AMD FORMAT
- STATEMENTS
DOUBLE PRECISION CONST(SOOO), SPEC I E(5000), 
TIEC2) '
DIMENSION KEYC18000), NUMT(SOOO), NUMF0OO0), 
NSTC5000), N5FC5000)
DIMENSION' UNIQC5, 5000)
DIMENSION NCQMP(HO), XC100), XXd5), FDASHdOO) 
. TREALC100)
1 TCALCC115), BETALG(SOOO), JSPC5000), IM0NC15), 
LITC15), SPCC5000)
INTEGER CHECKC115), TITLEdS), NAME(9), DATE(9), 
OUT, CARD, .
1 SIMULdQ)
REAL LGKWD, PMH15), XXLOGdS), PQWERdOO)
LOGICAL MON IT,MONALL,SCAN,MULT I P,SUPRES,TRIAL, . ■
UCHECK,SWTCK,PUNCH .
INTEGER*? KEY, NUMT, NUMF, NST, N$F, UNIQ
EQUIVALENCE (CONSTd), UNIQdd), JSP(1)) 
EQUIVALENCE (CONST(5000), TIEd)), (SPECIEd),
TIE(2) )
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■ 5 40(2H<>)
20303 FORMAT! '0
20304 FORMAT! '0
20305 FORMAT! ’
20306 FORMAT ! '
20307 FORMAT! ’
*1 5X,'MAX.
20308 FORMAT ! ’
20309 FORMAT! ’
20310 FORMAT! '
2031 1 FORMAT ! ’
20312 FORMAT! ’
20313 FORMAT! ’()
20314* FORMAT! *0
EQUIVALENCE (TITLE!!), XXL0G(1))
DATA LIT/’ ’ , ’ ABOR' , ’ALL XXXXSUPR • ,
’TEST’, ’OMIT*,'TOTA'
1 ,'END SPEC ', 'FREE','H +1 ’ , ' OH-1 ' , ’ S W I T ’ , ' UN C H * / 
C •
C THE PARAMETER VARIABLES.
C
NK = 18000
NS = 5000 ‘ -
NX - 100 .
NXX -15
NXXX -.NX + NXX
NLINES-63 • - . •
C
C THE FORMAT STATEMENTS.
C
10300 F0RMAT!18A4) •
10301 F0RMATC9A4)
10302 FORMAT(L5,1X,14(A4,1X),A4)
10303 FORMAT<L5,1X,A4,2G1O.4,1O(1X,A4>) •
10311 FORMAT(A4,A1,2610.4)
10321 FORMAT(G9.5,1X,5(A4,1X,I2,2X), 8A1)
20000 FORMAT( ’ 1 ’ ,/ ’ 0 ’ ) ' .
20301 FORMAT!//'O',18A4,///) ■
20302 FORMAT! '1’,5!1H*),2 !6X,4!1H*)),5X,1H*,4X,2(5X,
- 5!1H*)),/' ' , ‘
1 6!1H*,9X), / ’ ',4 ! 1H*),6X#3(1H*,9X),4!1H*),6X,
5!1H*),/' ' .
2 5!1H*,9X),4X,1H*,/’ ',5!1H*),2!6X,4!1H*>),3!5X,
5(1H*)),/' ’,
3 55 (1 H-)’,//////'0T25,40 (2H<> ), 2 !/ '
. ' , T25,2IIO , T1 03,2HO ,
4 /' ',T25,4H<> 18A4,4H <>,/’ ',T25,2H<>,T103,
2IIO),/' ',T25, •
////)
,'OUTPUT SUPRESSED,»)
COMPLETE OUTPUT REQUIRED.')
,'MONITORED COMPONENTS: ’,15(A4,1X))
,'NO COMPONENTS MONITORED.')
,'SCAN COMPONENT: ’,A4,/’ ','SCAN 
INCREMENT -' ,1PE12.4,
VALUE = ’,1PE12.4> -
,'MULTIPLICATIVE INCREMENT’)
,'ADDITIVE INCREMENT’)
,'NO SCAN REQUIRED.')
, 'NO DATA CHECK REQUIRED. ' )
,'ECCLES DATA CHECKING PROCEDURES 
EMPLOYED.') .
,'THE MAXIMUM NUMBER OF VARIABLE . 
COMPONENTS IS', 13)
r’********** WARNING ******★***’,/'
','IF THE SOLUTION
1 IS AQUEOUS A FREE HYDROGEN lOil CONCENTRATION IS 
REQUIRED.',//)
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20315 FORMAT!’0’-,’THE MAXIMUM NUMBER OF FIXED COMPONENTS
IS’ ,13)
20316 FORMAT!’ S I MULTANEOUS SCAN 0F',2X,16!A4,1X))
20321 FORMAT!'O’INCORRECT NEGATIVE SUBSCRIPT. SPECIES
NUMBER’,15,
1 ’ IS IN ERROR.’)
20322 FORMAT!’0’,'A FREE HYDROXYL ION CONCENTRATION IS
REQUIRED. ' )
20331 FORMAT(*0THE MAXIMUM NUMBER OF COMPLEX SPECIES 
IS’,15)
20350 FORMAT!'0TOO MANY COMPONENTS.’)
20351 FORMAT!'O',•'THE PROGRAM LIMITS HAVE BEEN EXCEEDED.’)
20352 FORMAT!’O', 'EXECUTION TERMINATED.
ERROR ON CARD’,15) .
20353 FORMAT!’ 'SPECIES NUMBER',15)
20354 FORMAT!'O' , 'TEST AND SCAN OPTIONS INCOMPATIBLE,')
20355 FORMAT!'O' , 'MISPLACED FIELD?’)
20356 FORMAT ! '.0 COMPONENT DUPLICATION.
COMPONENT',A4,' HAS ALREADY B 
1E E N ENTERED,')
20357 FORMAT!’O', 'COMPONENT ERROR DETECTED.')
2035S FORMAT!'O', 'SPECIES MUST HAVE AT LEAST TWO
COMPONENTS.')
20360 FORMAT!'0A POSITIVE CONCENTRATION FOR COMPONENT’
' , A 4,
1 * IS REQUIRED.') '•
20370 FORMAT!'1DUMP OF ARRAYS TO ESTABLISH EXTENT OF')
20371 FORMAT!//'0','COMPONENT SYMBOLS AND -
CONCENTRATIONS’,//)
20372 FORMAT!'- ', 14,5X,A4,2X,1PE15.4)
20373 FORMAT !//’0SPEC IES ARRAY :',8X,I 6,1PE15.4,5X,
• 5!A4, 13,3X) ,////./)
20375 FORMAT!'O',.'PREVIOUS BETA VALUE: ' , I 4,1 PE 15.4)
20401 FORMAT!' ', 'THERE ARE',13,’ SPECIES WITH DEFINED
CONCENTRATIONS.')
20421 FORMAT!'O', 'SPECIES DUPLICATION. '
SPECIES NUMBERS',216,
1 ' ON CARD NUMBERS',216)
20441 FORMAT!'O' ,'UNIDENTIFIABLE SCAN COMPONENT,')
20451 FORMAT!'O', 'UNIDENTIFIABLE MONITOR COMPONENT.')
20452 .FORMAT!'O', 'A MONITORED COMPONENT MUST APPEAR IN AT
LEAST THREE SP
1ECIES',/’ ’,A4,' HAS BEEN REMOVED FROM THE 
LIST. ' ,//)
20470 FORMAT!»0*,'EXECUTION TERMINATED.’,/' 'COMPONENT
NUMBER' , 13,
1’ IS NEVER REFERENCED.*,//)
20471 FORMAT!'O','THE MAXIMUM NUMBER OF COMPONENT
ENTITIES IN THE LIST 0
1-F SPECIES IS* , 16,/'0’EXECUTION TERMINATED,')
20472 FORMAT!’0’, 'EXECUTION TERMINATED,
ERROR COUNT ~',I4)
20474 FORMAT!'O','THE SCAN INCREMENT FACTOR IS TOO 
SMALL. ' )
317 '
20475 FORMATS’O’.,’THE MAXIMUM SCAN CONCENTRATION IS LOWER
THAN THE START
1 IMG VALUE. ’ ) . '
20476 FORMATS' ’,’THE CONCENTRATION OF THE SCANNED
COMPONENT MUST INCREA
1SE.’)
20480 FORMATS’0’,’DATA INPUT SUCCESSFULLY COMPLETED , ’ , / ’
i r
1’TOTAL NUMBER OF COMPONENTS a’, I 4,2X, ’(L IMIT
=',I4,’ )'»/'
2'NUMBER OF COMPONENTS WITH FIXED FREE .
CONCENTRATIONS a» , J 3 , .*
3 2X,'(LIMIT =’,13,* ) ’ , / ' ’ ,
4’TOTAL NUMBER OF SPECIES a',I 6,2X,'SL IMIT a',16,’ 
>’./' *r
S’TOTAL NUMBER OF COMPONENTS ENTERED IN KEY ARRAY
—' , 161
6 2X,’(LIMIT =',16, ’ ) ') -
20481 FORMATS'O', 'EXPERIMENTAL PH a’,F12,3)
20482 FORMAT(’+T45,’CALCULATED LOG KW s',F12»4) ‘
20485 FORMATS//'O','ITERATION RECORD’,/' ',16(1H~),// •
1' TOTAL AND FREE CONCENTRATIONS OF THE FIRST FEW 
COMPONENTS',//) •
20701 FORMATS' ’ , 'CYCLE',14,6X,3(1PE12.4,2X,’(',E10,4, ’ ) ' , 
5X)) •
20801 FORMAT S'0','********** ITERATION LIMIT EXCEEDED,
* * -k -k * ★ * ★ * 1 )
21000 FORMATS'1',T5O,'ECCLES: SCAN CYCLE NUMBER',13,/’
',T50,30(1H*)///)
21001 FORMAT S1 ill )
21002 FORMATS'O', 'CONCENTRATIONS OF THE FREE
COMPONENTS.’,/' ’,37(1H-)/)
21003 FORMATS '0 COMP, ’, T1 4 ,' FREE', T34 ,'REAL', T54-, ' CALC ,» r
T72,’COMP.’,
1 T84,’ITERATION12X, ’ LOG',/
2 3X,'NO.', T14,'CONC.', T34,'TOTAL',T54,’TOTAL*, T?2,
'NAME',T83,
4 'INFORMATION' , 1 OX , ' P . M . I , ' , / / ) *.
21004 FORMATS ' ’,14,2X,5(1PE15.6,5X>,T72,A 4,I 8,3X,OPF7.2)
21 005 FORMATS’ ',14,2X,1PE15.6,6X, 'F I XED FREE *
. CONG.',3X,1PE15.6,5X,T72,
1 A4,I 8,18X,OPF7.2) ‘
21011 FORMATS' CONCENTRATIONS OF THE SPECIES.’,/’
’,29(111-),///)
21012 FORMATS' SPEC ICS',T14,’SPEC IES',T32,'LOG
STAB.’,T50,
1 'COMPOSITION.' ,/4X,’NO.',T15, 'CONC.’,T3 4, 'CONST. ’ , •
• //)
21021 FORMATS' ’,I 5,1 PE15.4,5X,0pF12.3,T50,10(A4, ' ( ' , 11 ,
’) '))
21022 FORMATS/'O’ , 'THE SOLUTION WAS REACHED AFTER', 15,'
ITERATIONS.') '
210-23 FORMATS'O'» 'EXECUTION TERMINATED WITHOUT
CONVERGENCE,')
21024 FORMATS'0'»'THE PRECISION LIMIT WAS ’,1PG10,3)
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21101
21131
31100
31101 
99999
C
C
C
C
C
200
FORMAT('1MON I TOR COMPONENT ' , A4,TSO,’FREE CONC.
1PE12.4,OPF7.1,’ ,22<1H«),//>
FORMAT(’ *, 16,1PC14.4,0PF6„1,,2X,F8.2,T50,10(A4»
’(‘,11,') ’))
FORMAT(A4,5X, 2015,5)
FORMAT (61 5.5,3X, 1 0 (A4, 11 , 1X> )
FORMAT<’1',34H'WELL DONE ECCLES', SAID
MORIARTY,,/////)
SECTION TWO, IN I T I ALSAT I ON.
*
•J
201
202
203
204
IN - 5
ISWTCH = 9 
QUT = 6 
CARD ~ 7 
NN=4 .
NXP1 =5 NX + 1 
NXXP1 ~ NXX + 1 
NSP1 = NS + 1 
MULTIP. = .FALSE. 
SUPRES«. FALSE. 
TRIAL*.FALSE. 
MONALL«.FALSE, 
UCHECK*.FALSE. 
SWTCH = .FALSE, 
.PUNCH = ,FALSE, 
LGKWD=0.00000 
DO 201 1*1,NK
KEY(I) s 0 
DO 202 I=?1 , NXXX 
CHECK(I) « 0 
DO 203 J*1,NS 
DO 203 1=1,5 
UNI0(1,J) = 0 
DO-204 1=1,NX 
POWER(I) = 0,00 
NKT = 1
NKF=NK
NJ = 0
NCYCLEsI 
NSTOP s 300 
NSUPF = 0 
TLIM = 1.5E-6
C
c
c
c
c
SECTION THREE. INPUT.
READCIN,10300) TITLE
I F(TITLE(1) .EG,LIT(2)) WR I TE(OUT,20301 ) TITLE 
IF(TITLE(1).-EQ,LIT(2)) GO TO 9999 
READCIN,10301) NAME, DATE
319
o 
n 
o
READCIN,10302,ERR»352) MONIT, IMON 
I FCI MONC1).EQ.LITC3 )) MONALL = .TRUE.
IFCIMON(1).EO.LITC15) ) PUNCH ~ .TRUE.
NN-5
READCIN,10303,ERR=352) SCAN, ISCN, SCNINC, SCNMAX 
S IM U L
IFCSCAN.AND.SCNINC.GT,1.0) MULTIP » .TRUE.
NN "6
READCIN,10301) IXA 
IFCIXA.EQ.LITC5)) SUPRES « .TRUE,
IFC.NOT.SUPRES) GO TO 301 
READ(IN,10301) IXA
N N =5 N N +1
301 I FCI XA.EQ.L ITC 6) ) TRIAL ~ .TRUE.
IFC. NOT. TRIAL) GO TO 302 
READCIN,10301) IXA
NN-NN+1
IF(ISCN■EQ.LIT(6)) NSTOP ~ I F I X(SCN I NC) .
' IFCNSTOP.LT.0.OR.NSTOP.GT,1000) GO TO 354
302 IFCIXA.EO.LITC7)) UCHECK ~ .TRUE,
I F( .NOT.UCHECK) GO TO 303 
READCIN,10301) IXA
NN=NN+1
303 IFCIXA.EQ.LITC14)) SWTCH » .TRUE.
IFCSWTCH) READCIN,10301) IXA 
IFCSWTCH) NN » NN + 1
IFCIXA.NE.LITC8)) GO TO 352
OUTPUT IDENTIFICATION.
IFCDATEC1),EQ.LIT C1).AND,DATEC2).EQ.LITC1))
GO TO 306
304 IFCDATEC9).NE.LITC1)) GO TO 306 
1-1 = 10
DO 305 L«1,8 
M = M-1 
N=M-1
305 DATE(M)“DATE(N)
DATEC1) » LITC1)
GO TO 304
306-IFCTITLEC17),NE.LITC1).OR,TITLEC18).NE.LITC1))
GO TO 310 ‘
M = 17 
L~1
307 L = L + 1
IFCL.EG.18) GO TO 310 
H = M«1
'IFCTITLE(M) .EQ.LITC1 ) ) GO TO 307 
IXA=18~CL / 2)
308 IFCTITLECIXA).NE.LITC I )) GO TO 310 
M = 19
DO 309 L=1,17
l-l=M-1
N=M~1
309 TITLECH)=TITLECN)
320
TITLE (1) -LITd) •
60 TO 308
310 WRITECOUT,20302). .TITLE, NAME, DATE
IF(SUPRES) WRITECOUT,20303) •
I F(»NOT • SUPRES) WRITE(OUT,20304)
M = 1
IF(PUNCH) M « 2
IF(MONIT) WRITECOUT,20305) (IMON(I), I=M,'15) 
IF( .NOT,MON IT) WRITE(OUT,20306)
. IF(SCAN) WR ITE(OUT,20307) ISCN, SCNINC, SCNMAX 
IF(MULTIP) WRITE(OUT,20308)
IF( .NOT. MULTI P.AND,SCAN) WRITE(OUT, 20309)
I F( .NOT. SCAN) WRITE(OUT, 2 031 0)
I F(UCHECK) WRITE(OUT,2031 1 )
I F( .NOT. UCHECK) WR ITE(OUT,20312)
o 
<-
> <
~t
INPUT COMPONENT DATA.
WRITECOUT,20316)
NCOMP(NI), IXA, TREAL(NI),
GO TO 313
I F(SCAN. AND. SI MOL(1) .NE.LITd ) )
SIMUL •
DO 312 NI«1,NX 
NN = NN + 1
READ(IN,10311,ERR=352)
X ( N I)
1 F(NCOUP(H1)»EQ.LIT(9))
IF(X(NI) .LE.0,000) X(NI) =TREAL(NI) 
IF(UCHECK) GO TO 312
I F(TREAL(NI).LE.0.00) GO TO 359 
IF( IXA.NE,LIT(1)) GO TO 355 
IF(NI .EQ.1) GO TO 312 
M « NI - 1
DO 311 1-1,M ' •
I F ( N COMP (il I ) .EQ.HCOMPd ) ) GO TO 356
311 CONTINUE
312 CONTINUE
READ(IN,10311, ERR = 352) IXA 
NI « NI + 1
1 F( I XA•EQ,LIT(9)) GO TO 313 
N - NX • •
WRITE(OUT,20313) N '
GO TO 351
313 NI « NI - 1 ' -
Nil - 0
NH « 0 
NOB - 0
NN = NN + 1 ' • '
READ(IN,10301) IXA 
IF(lXA.EQ.LITdO) )
314 I F( I XA.EQ.L I T(10))
I*F ( I X A . N E . L I T (11 ) )
N ~ NI
DO 316 NI 1-1 ,NXX 
N = N + 1 
NN- NN * 1
WRITE(OUT,20314) 
GO TO 318 
GO TO 352
321
READCIN,10311,ERR=352) NCOMP(N). IXA, XXCNII), 
PMI(NII)
IF(NCOOP(N),CO«LIT(9)) . GO TO 317 
IFCUCIIECK) GO TO 316 .
IF(XXCNII) .IE.0,00) GO TO 360 
IF(IXA,NL«LIT(1 ) ) GO TO 355 
M~N~1
DO 315 1=1, M
IF<NCOMP(N> .EQ.NCOMPU)) GO TO 356
315 CONTINUE '
316 CONTINUE
READUh,10311,ERR-352) IXA 
Nil a Nil + 1
IF(I XA,EQ•11T(9)) GO TO 317 
' N = NXX
WRITECOUT,20315) N 
GO TO 351
317 Nil « NII - 1 
READC1N, 1 0301 ) ' IXA 
GO TO 314
313 I F(Nil. EQ.O) GO TO 320 
I = NI
DO 319 J 1=1,Nil 
1 = 1 + 1
IFCNCOMP<I)•EQ.IIT<12)) NN » II.
IFCNCOmPCI)•EQ»LITC13)) NON = II
319 CONTINUE
IF(NH.EQ.O) WRITECOUT,20314)
IFCNJI.EQ.O) GO TO 320 
PH = XXCNH)
PH a -1,000 * ALOG10CPH)
N = NH
Nil = NH + Nl 
IFCNOH.EQ.O) GO TO 320 
LGKWD ~ XXCN) * XXCNOH)
LGKWD = ALOG10<LGKWD)
NUH = NON '+ NT
C
C INPUT. SPECIES CONSTANTS AND COMPOSITION,
C
320 NIII « NI + Nil 
IFCSWTCH) IN s ISWTCH 
DO 339 NJ=1,NS
NN = NN + 1
READ(IN,10321,ERR=352,END=400) BETALG(NJ), TITLE
NOMT(NJ) = 0
NUMFCNJ) = 0
IFCUCIIECK) GO TO 322
DO 321 L=11,13
IFCTITLECL).NE.LITC1)) GO TO 355
321 CONTINUE
322 IXA a 1 
C
DO 334 N«1,10,2
1FCTITLECN),EQ,LIT(1)) GO TO 335
322
323 DO 324 IXA^ N 111
IFCTITLECM)•EQ.NCOMPCM)) GO TO 325
324 CONTINUE
I F(IXA. EQ.1) GO TO 357 
IXA « 1 
GO TO 323
325 CHECKCM) » CHECKCM) +1 
IXA “ M
L 53 N + 1 
KIJ - TITLECL)
IFCKIJ -GE.1) GO TO 330- .
IFCM.GT.UI.AND.TITLECN).EQ9LITC12)) GO TO 327
326 WRITECOUTi20321) NJ
I FCNH.EQ . 0■AND.NOH•EQ„0) NGH = Nil X 
IFCNOH.EQ.O)- NOH =* NH 
NOH = I AB SCNOH)
NOB = ~NQll
GO TO 328
327 IFCKIJ.GT.-I.OR.KIJ.LT.«5) GO TO 326 
IFCNOH.NE.0) GO TO 328
WRITECOUT#20322)
GO TO 326
328 CHECKCM) - CHECKCM) - 1 
M a IABS(NOH)
CHECKCM) » CHECKCM) + 1 
KIJ = IABSCKIJ.)
KIJ = MODCKIJ»5)
DO 329 L~1,KIJ
329 BETALGCNJ) = BETALGCNJ) - LGKWD
330 IML = N/2 * 1
IF C.NQT. UCBECK) UN IQ< I ML,NJ)a CKIJ * 1 000) + M
IFCM. GT.NI) GO TO 332
IF(FLOAT(KIJ)«GT.POWER(M)) POWER(M) - FLOATCKIJ) 
NUMTCNJ) = NUMTCNJ) + KIJ 
DO 331 L~1',KIJ
KEYCNKT) » M
331 NKT s. NKT + 1 
GO TO 334
332 NUMFCNJ) * NUMFCNJ) »• KIJ 
DO 333 L = 1r KIJ 
KEYCNKF) » M
333 NKF a NKF - 1
334 CONTINUE
IFC,NOT.UCBECK) GO TO 337
335 IFCUCBECK) GO TO 339 
DO 336 L»N»10,2
IF(TITLECL).NE.LITC1)) GO TO 357
336 CONTINUE
337 N = N - 2
IFCNUMTCNJ) .EQ.O) NSUPF a NSUPF + 1
IFCN. LT.3) GO TO 358
3 23
oo
ei
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no
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DO 338 IXA=3,N,2 
KIJ = IXA - 2 
DO 338 L = 1,KIJ,2
I F CTIT tE ( L) » EQ „ TIT EE CIXA) ) GO TO 337
338 CONTINUE • •
339 CONTINUE
READ CIN,103 21 ,ERR = 352,END = 400) XOED 
WRITECOUT,20331) NJ 
GO TO 351
OUTPUT ERROR MESSAGES
350 WRITECOUT,20350)
351 WRITECOUT,20351)
352 WRITECOUT,20352) NN
IFCNJ.GT.O). WRITECOUT,20353) NJ 
GO TO 370
354 WRITECOUT,20354)
GO TO 352
355 WRITECOUT,20355)
IFCNJ.GT.O) GO TO 350 
GO TO 352
356 WRITECOUT,20356) NCOMRCN)
GO TO 352
357 WRITECOUT,20357)
GO TO 352
358 WRITECOUT,20358)
GO TO 352
359 N « NI
360 WRITECOUT,20360) NCOMP(N)
GO TO 352
•DUMP ARRAY PARAMETERS AND CONTENTS*
I, NCOMPCI), TREAE(I)
370 WRITECOUT,20370)
N = NKT + NK - NKF +1
WRITE(OUTi20480) NIII, NXXX, Nil, NXX, NJ, NS, N, 
N K
WRITECOUT,20371)
DO 371 1=1,NI
371 WRITECOUT,20372)
WRITECOUT,20372)
I = NI
DO 372 N = 1,Nil 
1 = 1 + 1
372 WRITECOUT,20372)
IFCNJ.GT.O)
I, NCOMPCI), XXCN)
NJ, BETALGCNJ),WRITECOUT,20373) 
CTITEECN), N=1,10)
NJ = NJ - 1 
IFCNJ .GT.O) 
GO TO 9999-
WRITECOUT,20375) NJ, BETaLG(NJ)
SECTION FOUR. INPUT CHECKING'PROCEDURES AND 
OTHER PRELIMINARIES.
324
C
C
400 NJ » NJ - 1 
NKT = NKT ” 1 
NKF - NKF * 1 
KOUNT - MN
I F(NSUPF , GT,0) WRITE(OUT,20401) NSUPF 
DO 401 1-1,N 111 
IF(CHECK(I) ,LE.O> GO TO 470 •
401 CONTINUE 
IXA = NKF NKT 
IF(IXA.LE.Q) GO TO 471 
DO 402 1 = 1,NI
402 POWER(I) = ,1,000 / PQWER(.I)
TEST FOR SPECIES’ UNIQUENESS,
I F(UCHECK) GO TO 440 
DO 413. J-1 ,NJ 
DO 412 1=1,4 
K - I * 1 
LAYBY = UNIQ(K,J)
IF(LAYBY•EQ,0) GO TO 413 
DO 411 L = 1 , I 
N - K - 1
IF(LAYBY„LE.UNIG(N, J)) GO TO 412 
UN IQ(K,J) = UN IQ(N,J)
11 k s n
412 UNIQ(K,J) = LAYBY
413 CONTINUE
r. 
on
 
no
n
K ~ 0
DO 422 J-2,NJ 
N — J — 1 .
LAYBY = UNIQd , J)
DO 422 1 = 1 ,N
I F(LAYBY,NE,UN IQ(1,I)) GO TO 422 
DO 421 L-2,5
I F(UN IQ(L,J) • NE , UN I Q(L, I)) GO TO 422
421 CONTINUE
L » KOUNT ~ NJ + I 
M ~ KOUNT ~ NJ + J 
K ~ K + 1
WRITE(OUT,20421) I, J, L, M
422 CONTINUE 
•IFCK.NE.O.) GO TO 472
' NUMBER THE SCAN COMPONENT,
440 IF(,NOT.SCAN) GO TO 4*50 
DO 441 1-1,Nil!
I F (IICOMP ( I) ,EQ, I SCN) GO TO 443
441 CONTINUE
325
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NH = 5
442 WRITECOUT,20441) ‘ <
GO TO 473
443 IF(UGT.NI) I I =? I - NI
IFC.NOT,MULTIP.AND.SCNINC.LE, 0.000) GO TO 474 
IFCMULTIP.AND.SCNINC.LE.1.000) GO TO 474 
IFCI•LE»NI•AND.TREALCI)•GT•SCNMAX) GO TO 475 
IFCI.GT.NI.AND.XXCI I).GT.SCNMAX) GO TO 475 
1SCN -I
NUMBER THE COMPONENTS SCANNED SIMULTANEOUSLY.
DO 446 K = 1,10
IFCSIMULCK) .EQ.LITC1 ) ) GO TO 448 
DU 445 I~1,NI11
IFCSIMULCK).EQ.NCOHP(I)) GO TO 446
445 CONTINUE 
GO TO 442
446- SIMULCK) ~ I 
K ~ 11
448 NSIMUL - K ~ 1
NUMBER THE MONITORED COMPONENTS.
450 IFC.NOT.MONIT.OR.MONALL) GO TO 460 
L ~ 1
IFCPUNCH) L “ 2
451 N ~ 1
452 DO 453 I=N,N1II
IF(I MONCL).EQ.NCOMP( I )) GO TO 454
453 CONTINUE 
IFCN.NE.1) GO TO 451 
NN = 4
WRITECOUT,20451>
GO TO 473
454 N~ 1+1 
IFCN.GT.NIII) N =? 1 
IFCCilECK(I) .GE.3) GO TO 456 
WRITECOUT,20452) NCOMP(i)
M = L + 1
I-FCM.GT.15) GO TO 457 
IFCIMON(K).EQ.LITC1)) go TO 457 
DO 455 M =» 1,9
IX A s H + 1 '
455 IMONCM) ~ 1M0NCIXA)
I MONC15) - LITC1)
GO TO 452
456 IMONCL) s I 
L - L + 1
IFCL.GT.15) GO TO 457 
IFCIMONCL).NE.LITC1)) GO TO 452
457 NMON ~ L ~ 1
326
460 1F(NOH.GE„O> GO TO 480 
GO TO 9999
C
C OUTPUT ERROR MESSAGES,
C
• 470 WRITECOUT,20470) I 
GO TO 9999
471 N - NK
WRITECOUT,20471) N ' - 
WRITECOUT,20351)
GO TO 9999
472 WRITECOUT,20472) K 
GO TO 9999
473 NJ ~ 0
• GO TO 352
474 WRITE(OUT,20474)
GO TO 476
475 WRITECOUT,20475)
476 WRITECOUT,20476)
NN ~ 5‘
GO TO 473
r, 
r, 
n 
r~
i o
 r> o 
oo
o
ACKNOWLEDGE THAT ALL’S WELL.
480 N = NKT + NK - NKF + 1
WRITECOUT,20480) Will, NXXX, Nil, NXX, NJ, NS, N,
NK
IFCNH.GT.NI) WRITECOUT,20481) PH
IFCNH.GT.NI.ANP.LGKWD„LE."10,0) WRITE(OUT,20482)
LGKWD
IF(NSTOP.EO.O) GO TO 1000 
IF(TRIAL) WRITECOUT,20485)
SECTION FIVE. CONSTANT EVALUATION,
500 K « NK
KOUNT =; 0 
DO 505 1 1=1 ,Nil
505 XXLQG(II) = ALOG10CXXCI I) )
DO 512 J=1,NJ 
CONST(J) - BETALG(J) 
IF(NUMFCJ).EQ.O) GO TO 512 
N = NUMFCJ)
DO 511 L = 1,N
II = KEY(K) - NI
CONST(J) » CONST(J) + XXLOG(II)
511 K ~ K « 1
512C0NSTCJ) « 10.0Q0D0 ** CONST(J)
SECTION SIX. EVALUATION OF CALCULATED SPECIES
CONCENTRATIONS.
C
327
c
600 K = 1
DO 602 J=1,NJ 
SPECIE(J) = CONSTCJ)
N = NUMTCJ)
IF(N.EQ.Q) GO TO 602 
DO 601 L = 1,N 
I = KEY(K)
SPECIE(J) = SPECIE(J) * XU)
601 K = K + 1
602 CONTINUE 
C
c
C SECTION SEVEN. . EVALUATION OF- CALCULATED TOTAL
CONCENTRATIONS.
C
C -
700 K = 1
DO 701 1 = 1,NI
701 TCALCU) = XU)
DO 703 J=1,NJ
N = NUMTCJ)
IF(N.EQ.O) GO TO 703 
DO 702 'L = 1 , N ; .
I = KEY(K)
TCALCU) = TCALCCI) + SPECIE <J)
702 K = K + 1
703 CONTINUE
IF(.NOT.TRIAL) GO TO 800 
L - MIH0C3.NI)
WRITECOUT,20701 ) KOUNT, (TCALCU), X(I), 1=1,L)
O
O
O
 
O
 O 
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SECTION EIGHT. TEST FOR CONVERGENCE.
800 KOUNT = KOUNT 1
IFCMOD(KOUNT,100)•EG ■ 25) TLIM = TLIM * 1.5 
L = 0
DO 801 1 = 1,N I
CRIT = TREALCI) - TCALCU)
CRIT = ABSCCRIT)
CRIT = CRIT - CTREAL(I) * TLIM)
IFCCRIT.LE.0.0000) L = L + 1
801 CONTINUE
IFCKOUNT.LT.NSTOP.AND.L.LT.NI) GO TO 900 
IFCKOUNT.LT.NSTOP) GO TO 1000 
T FC.NOT.TRIAL) WRITE(OUT,20801 )
SCAN = .FALSE.
GO TO 1000
SECTION NINE. EVALUATION OF THE COMPONENTS NEW
FREE CONCENTRATIONS.
328
C
C
900 DO 901 1-1,NI
901 FDASH(I) » TREAKl) / TCALC(I)
IF(KOUNT.LT,4.0R.KOUNT.GT.49.OR,
1 KOUNT.EQ.30.OR.KOUNT.EQ.40.OR.KOUNT.EO.46)
GO TO 903 .
IF(KOUNT.GT.14.AND.MOD(KOUNT,3),EQ.1) GO TO 905 
DO 902 1-1t NI 
GRIT - FDASH(I)
902 FDASH(I) “ SQRT(CRIT)
GO TO 905
903 DO 904 1-1,01 •
904 FDASK(I) ~ FDASH(I) ** POWER(I)
IF(KOUNT.LT.10.OR.HOD(KOUNT»50) .EQ.0) GO TO 915
905 DO 906 1-1,01
906 X(I) - X(X) * FDAS1ICI)
GO TO 600
O
 O
 <->
915 1F(SCAN•AND•NCYCLE.GT.1 , AND.KQUNT.GT.1) GO TO 905 
DO 919 0-1,NI
IXA - 1
POWER (II) = 1.000 / POWER (M) :
DEN - X(M)
K = 1
DO 918 4«1,NJ
N - NUMT(J) • ' ‘
IF(N.EQ.Q) GO TO 918 
KIJ = 0 •
DO 916 L-1 ,N
IF(KEY(K).EQ.M) KIJ = KIJ + 1 ’
916 K = K + 1 
IF(KIJ.EQ.O) GO TO 918
1 F(SPECIE(J )*1 00•0»GT•TCALC (M) .ANP.KI J .GT. IXA)
IXA - KIJ
FACTOR = 1 ..000000 
K - K ~ N 
DO 917 L = 1 , N 
I s k e y ( k )
FACTOR - FACTOR * FDASH(I)
917 K = K + 1
DEN = DEN + (FACTOR * SPECIE(J) * KIJ / FPASH(M))
918 CONTINUE
XOLD « FLOAT(IXA)
IFCXOLD+O.1.LT.POWER(M)) POWER(M) = PQWER(M) ~ 
1.000
1F.(XOLD,GT.POWER(M)> POWER(M) a XOLD 
POWER(M) « 1.000 / POWER(M)
XOLD = X(M)
X(M) ~ XOLD * TREAL(M) /. DEN
919 FDASH(li) - X(M> / XOLD 
GO TO 600
329
r*
> r>
 o
 
oo
oo
o 
n 
n 
c 
o 
r.
SECTION TEN, OUTPUT
1000 IF(SCAN) WRITECOUT,21000) NCYCLE 
IF(,NOT,SCAN) WRITE(OUT,21001) 
WRITE(OUT,21002)
WRITECOUT,21003)
SUM TOTAL CONCENTRATIONS FOR SPECIES WITH FREE 
CONCS, FIXED,
DO 1001 11 = 1 , Nil
I = NI + II
1001 TCALC(I) = XX(II)
• K = NK
DO 1003 J=1,NJ 
‘ N = NUMF(J)
IF(N,EQ,0) GO TO 1003 
DO 1002 L = 1,N
II = KEY(K)
TCALC(II) = TCALC(II) + SPECIE(J)
1002 K = K ~ 1
1003 CONTINUE - -
OUTPUT COMPONENT CONCENTRATIONS
1004 IXA = NUNES -10 
IF(SCAN) IXA a IXA - 5
KIJ = ( (Nil I - IXA) Z (NUNES - 5) ) + 2 
IF(NIII,LE,IXA) KIJ = 1 
N = ( N I I I / K I J ) + 1 
IF(IXA,GE,N) IXA = N 
IF(I XA,GE•N,OR,KI J,EQ , 1) GO TO 1005 
NSS((NIII-’IXA)/(KIJ-1)) +1
1005 KIJ = IXA
DO 1006 1=1,NI
• I F (I, LT, KIJ , OR , I » E'Q • N I) GO TO 1006 
KIJ = KIJ + N 
WRITECOUT,21001)
WRITECOUT,21003)
1006 WRITECOUT,21004) I, X(I), TREAL(I), TCALC(i),
NCOMP(I), CHLCK(I) ,
1 POWER! I)
M = ni
DO 1008 11=1,Nil 
M = M + 1
IF(M«LT»KI J•OR, 11,EQ,N 11) GO TO 1007.
KIJ = KIJ + N 
WRITE(OUT,21001)
WRITECOUT,21003)
1007 XOLD = 0,0
330
I F(NCONP(I1) ,EQ. LIT (12) . OR, N COMP (M) . EQ.LlT( 1 3) )
GO TO 1008
I F ( PMI (11) • L'E . 0.000 ) GO TO 1008 
XOLD = TCALC(M) Z PMI (II)
XOLD ~ AL0G10(XOLD)
1008 WRITE(OUT,21005) M, XX(II), TCALC(M), NCOMP(M), 
CHECK(M), XOLD
IF(.NOT.SCAN) GO TO 1010 
I F((N I + N 11).IE . 10) WR I TE(OUT,20301)
IF(NH.GT.NI) WIUTE(OUT,20481) PH
C
C OUTPUT SPECIES CONCENTRATIONS
C
1010 IF(SUPRES) GO TO 1028
• IF(NLINE$.LT. 50 .OR»N111+ NJ.GT„NLINES~40)
WRITE(OUT,20000)
WRITE(OUT,20301)
WRITE(OUT,21011 )
WRITE(OUT,21012)
NJ = NJ + 5
IXA a NLINES - 10
KIJ = ((NJ - IXA) Z (NLINES - 5)) + 2
IF(NJ wLE. IXA) KIJ ~ 1
NSP1 ~ (NJ Z KIJ) * 1
IF(IXA.GT.NSPI) IXA = NSP1
IF(I XA.GE•NSP1.OR•KIJ•EQ»1) GO TO 1011
NSP1 ~ ((NJ « IXA) Z (KIJ - 1)) + 1
1011 KIJ « IXA 
NJ a NJ " 5
NXP1 a KIJ + (3+NSP1) + 6 '
<~
5 <
->
NKT s 1
N’KF a NK
DO 1027 J~1,NJ
IF(J.LT.KIJ.OR.J.EO.NJ) GO TO 1020 
IF(KIJ•LT.NXP1) KIJ a KIJ + 1 
KIJ a KIJ + NSP1
WRITE(OUT,20000)
WRITE(OUT,21001 )
WRITE(OUT,21012)
1020 N = 1
NN « NUMT(J)
IF(NN.EQ.O) GO TO 1023 
L = 0
1021 K a KEY(NKT)
M = 0
1022 I » t + 1
. M a M + 1 . ‘
NKT = NKT + 1
IF(L.LT.NN.AND.K.EQ.KEY(NKT)) GO TO 1022 
TITLE(N) a NCOMP(K)
N « N * 1
• TITLE(N) a m
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N « N + 1
IF(L.LT.NN) 60 TO 1021 
IF(NUMF(J ) »EQ,0.) . 60 TO 1026
1023 L ~ 0
NN =• NUMF(J)
1024 K ~ KEY(NKF)
M ** 0
1025 L ~ L * 1
M ~ M 1
NKF ~ NKF -
I F ( L, LT , Nil « AND , K , £Q > KEY (NKF ) ) 60 TO 1025
TITLE(N) ~ 'NCOMP(K)
N ~ N + 1
TITLE(N) « M 
N « N + 1
IF(L.LT.NN) GO TO 1024
1026 NN N ~ 1
1027 WRITECOUT,21021) J, SPECIE(J), BETALG(J),
(TITLE(N), N~1,NN)
102S WRITECOUT,21022) KOUNT
I F(KOUNT,GE.NSTOP) WR I TE(OUT,21023) 
WRITECOUT,21024) TLIM
r>
 o
 o
 <-
> o
SECTION ELEVEN, THE COMPONENT MONITOR.
1100 I F(»NOT,MON IT) GO TO 1200 
IF(MOHALL) NMON ~ Nil I 
LAYBY » T
IF(PUNCH) LAYBY = 2
DO .1136 KI J = LAYBY»NMON
IF(PUNCH) WRITECCARD,31100) LITC1)
IXA « NLINES - 10 
NN « 0
M ~ KIJ
IFC .NOT.MONALL) M « IMQNCKIJ)
I ML = M - NI
IFCM.LE.NI) XOLD ~ X(M)
IF(tl.GT.NI) XOLD ~ XX(IML)
DEN = XOLD * 100,0 Z TCALC(M)
WRITECQUTi21101 ) NCOMPCM), XOLD, DEN
C
C LOAD THE SPECIES WHICH CONTAIN THIS MONITORED
COMPONENT,
C
IF(M.GT.NI) Go TO 1110
IFCPUHCII) WRITE (CARD, 31100) N COMP CM) , TCALC(M) , 
X(M)
NKT = 1
DO 1104 J=1, NJ 
N « NUMT(J)
IF(N.EQ.O)
• K - NKT 
DEN = 0,00
GO TO 1104-
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DO 1101 l>1,N
I F ( KEYCK)•EQ,M) DEN a DEN + 1*0
1101 K= K + 1
I F ( D GN • L.T , 0,1 ) GO TO 1103
1102 NN “ NN +1 . .
JSP(NN) = J
SPC(NN) a SPECIE(J) * DEN
1103 NKT = NKT + N
1104 CONTINUE 
GO TO 1120
1110 NKF a NK • •
J = M ~ NI
IF(PUNCH) WRITE(CARD,31100) NCOMP(M), TCALC(M), 
XX (J )
DO 1113 J~1,NJ 
N = NUMF(J)
IF(N.EO.O) GO TO 1113 
X » NKF'
DEN « 0,00 
DO 1111 1 = 1,N
IKKEY(K).EQ.M) DEN « DEN + 1,0
1111 K ~ K - 1 
IFCDEN-.LT.0.1 ) GO TO 1113
1112 NN ~ NN +1 •
JSP(NN) » J ■
SPC(NN) = SPECIG(J) * DEN
1113 NKF = NKF N
SORT THEM.
1120 CALL SORT(SPC#JSP»NN)
WRITE (OUT , 21 Oi 2) ’
SET UP THE DIRECTORY ARRAYS,
NKT a 1
NKF a NK
DO 1121 J-1,NJ
NST(J) a NKT
NSF(J) « NKF
NKT = NKT + NUMTU)
1121 NKF » NKF - NUMF(J)
OUTPUT EACH SPECIES IN TURN,
IF(IXA.GTwNN) IXA ~ NN 
DO 1136 1 = 1 , IXA 
J = JSP(I>
N = 1
NN = NUIIT(J)
IF(NN.GQ.O) GO TO 1132 
L ~ 0
NKT « NST(J) .
1130 K = KEY(NKT)
NXP1 a 0
■ •it,'-
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1131 L ~ L + 1
NXP1 ~ MXP1 + 1 • ■
NKT « NKT * 1
IF(L•LT•NN.AND„K»EQ•KEY(NKT)) GO TO 1131 
TITLE(N) ~ NCOMP(K) ,
N » N + 1
TITLE(N) « NXP1 .
N — N + 1
IF(L.LT.NN) go to 1130 
I F(NUMF(J > . EQ.O) 'GO TO 1135
1132 L ~ 0
NN = NUMFO )
NKF = N S F ( J )
1133 K = KEY(NKF)
NXP1 ~ 0
1134 L ~ L + 1
NXP1 = NXP1 + 1 
NKF = NKF - 1
IFCL.LT.NN.AND.K.EQ.KEY(NKF)) GO TO 1134 
TITLE(N) =. NCOHP(K)
N = N + 1 "
TITLE(N) = NXP1 ,
N = N + 1 ‘
IF(L.LT.NN) GO TO 1133
1135 NN = N «• 1
IF(PUNCH) WRITE(CARD,31101) SPECXE<J>, (TITLE(N)r 
N=?1 , NN)
DEN = (SPC(I) * 100.0) / TCALC(M)
1136 WR1TE(OUT,21131) J, SPECIE(J), DEN, BETALG(J),
(TITLE(N), N»1,NN)
o 
o 
o
SECTION TWELVE. THE SCAN MECHANISM. ' •
C
c
1200 IF(.NOT.SCAN) GO TO 9999 
C
C ’ .
NCYCLE ~ NCYCLE * 1 • . .
TLIM = 1,5E-6 ' ' .
•IF(ISCN.GT.Nl) GO' TO 1201 
■ IF(IIULTIP) TREAL(ISCN) - TREAL(ISCN) * SCNINC
I F ( . NOT . ML) LT I P ) TREAL(ISCN) » TREAL(lSCN) + SCNINC
IF(TREALCISCN).GT.SCNMAX) GO TO 9999 '
IF(NSIMUL.GT.O) GO TO 1210
IF(MON IT) GO TO 500
GO TO 600 . •
1201 'II « ISCN - NI
IF(MULTIP) XX(II) a XX(II) * SCNINC
IF(.NOT.MULTIP) XX(II) « XX(II) * SCNINC
IF(NH.NE.ISCN) GO TO 1202
NN “ Nil - NI
' PH « XX(NN) ' ,
PH ~ ~1 .000 * ALOGIO(PII) ‘
IF (NON .EQ. 0) GO TO 1202 ■
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NN - NOH - NI
XX(NN) = 10-000 ** LGKWD / XX(II)
1202 I F(XX( I I)-GT.SCNMAX) GO TO 9999
IF(NSIMUL.EQ.O) GO TO 500 
C
1210 II » -1
00 1212 K»1.NSIMUL
1 “ SIMUL(K) •
IFCI.GT.NI) GO TO 1211
IF(MULTIP) TREAL(I) ” TREAL(I) * SCNINC
I F(•NOT•MULTJP) TREAL(I) ~ TREAL(I) * SCNINC
GO TO 1212 '
1211 IF(II.EQ.NOH) GO TO 1212
II ~ I - NJ . •
. IF(flULTIP) XX(II) » XX<m * SCNINC
IF(»NOT.MULTIP) XX (I I) «. XX < I J ) + SCNINC
1212 CONTINUE ‘ . •
IF(•NOT•MON IT-AND -11„EQ»-1) 60 TO 600
GO TO 500 •
C • • '
C - •
C THE END-
C
C
9999 WRITE(OUT»99999)
STOP
END
SUBROUTINE SORT(ARRAY,NARRAY,N) 
DIMENSION ARRAYCN), NARRAY(N) 
REAL LAYBY
INTEGER OLD 
M = 2
DO 1 ,N
M = M + M '
IF(M-GT.N) GO TO 2
1 CONTINUE •
2 M M *“• T
3 M = < M - 1 > / 2
4 MN ~ N - M •
DO 7 1 = 1,NN
OLD ~ I + M 
LAYBY = ARRAY(OLD)
NLAYBY = NARRAY(OLD)
DO 5 J~1,I,M 
NEW = OLD * M
IF<LAYBY-LE-ARRAY(NEW)) GO TO 6 
ARRAY(OLD) « ARRAY(NEW)
. NARRAY(OLD) a NARRAY(NEW)
OLD = NEW
.5 CONTINUE
6 ARRAY(ULD) * LAYBY 
NARRAY(OLD) = NLAYBY
7 CONTINUE-
1FCM.GT.1) GO TO 3 .
RETURN
END
APPENDIX A4
FORTRAN listing of program MAGEC
FLOW DIAGRAM FOR PROGRAM MAGEC
Stop
FLOW DIAGRAM FOR PROGRAM MA6EC (contd)
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PROGRAM MAGEC,
MULTIPLE ANALYSIS 
OF TITRATION DATA FOR
• GLASS ELECTRODE CALIBRATION
•k k
kkkkkkkkkkkkkk
THE PROGRAM ANALYSES POTENTIOMETRIC DATA FROM 
TITRATIONS IN WHICH
THE TITRAND AND THE TITRANT ARE (1) A STRONG ACID 
OR A STRONG
BASE, (2) A LIGAND OR (3) A COMBINATION OF (1) AND 
(2) .
ESTIMATES OF THE CONCENTRATIONS, THE EQUILIBRIUM 
CONSTANTS AND
THE PARAMETERS FOR THE NERNSTIAN EQUATION OF THE 
GLASS ELECTRODE
RESPONSE TO HYDROGEN ION CONCENTRATION CAN. Be' 
REFINED. THE USER
SPECIFIES WHICH ARE TO BE SIMULTANEOUSLY OPTIMISED. 
UPPER AND
LOWER LIMITS CAN BE IMPOSED ON ALL PARAMETERS BEING
refined.
THE OPTIMISATION IS PERFORMED BY SUBROUTINE NELM 
AND GENERALLYi
THE EQUILIBRIUM CONCENTRATIONS ARE EVALUATED BY 
SUBROUTINE ML AND
SUBROUTINE FUNCT.
SUBPROGRAM CALIBT ONLY ACCEPTS DATA PERTAINING TO 
MONOBAS I C
REACTANTS. IT IS MAINLY USED TO ANALYSE STRONG. 
ACID VERSUS
STRONG BASE TITRATIONS. THE PARAMETERS OF THE 
NERNSTIAN
EQUATION ARE FOUND BY LINEAR LEAST SQUARES BEST FIT 
IN ADDITION IT PERFORMS.GRAN PLOT CALCULATIONS,
SCANS VALUES OF
PKW AND PK1 AND ADJUSTS THE CONCENTRATIONS OF 
REACTANTS IF THIS
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C
C
C
C
C
C
. C
c
c
c
c
IMPROVES THE AGREEMENT BETWEEN THE THEORETICAL AND 
THE OBSERVED
SLOPE FOR THE GLASS ELECTRODE RESPONSE.
THE PROGRAM WAS DEVELOPED AT THE UNIVERSITY OF 
WALES INSTITUTE
OF SCIENCE AND TECHNOLOGY IN 1978. IT IS WRITTEN IN 
FORTRAN IV.
* * * ★ W ***★**★**•*★ -***iSrJr***
******** * * * * * *
c
c
c
INTEGER TITLE, LIT(15)
DIMENSION X(7)r Y<7), H(7), XS(7), FP(8), ID(7) 
INTEGER OUT, REFINE 
REAL LVESSL, L8URET 
LOGICAL TITEND
COMMON /ONE/ PK(7,3), VZERO(3>, HVES$l(3)» 
LVESSLC3), HBURET(3),
* LBURET(3), EZEROC3), SLQPEC3), REFINEC15), NDPV,
N D P B
COMMON /TWO/ CI(7)rCX(2),TT(2),HX(2)»TO 1C(2),DT(2), 
DDT(2,2)
COMMON /THREE/ V(1OO), EC1OO), NP
COMMON /FOUR/ BETA(7), ARRAYC3), TOL, NCONST,
NBETAH, JQR(2,7) •
COMMON /FIVE/ IN, OUT, IFAIL, JFAIL, AL10, KOUNT 
COMMON /SIX/ TITLEC2O), P(63)
C
C
DATA LIT / ’ PKW*, ’PK1’,*PK2’,*PK3’,’PK4* , ’ PK5 ’ , 
•PK6»,
* 1 VZO’ , ’H+V', 'LGV’ , ’H + B’, 'LG8 ’ , ’EZO’, ’SLP', ’ ’ /
C
C
C
10200 FORMAT(20A4)
10231 FORMAT(8G10.3)
10205 FORMAT(A3,2X,11,1X,I1,2X,3G1O.3)
20000 FORMATC’1 ’)
20001 FORMAT (/ / ’0’ , 1 H* , 3X , 11l* , 6X , 3 (1 H* ) ,7X,4(1H*) »5X,
5(1H*),6X,
* 4(1H*),/ ' ’,2(2(1H*),1X),4X,1H*,3x,1H*,5X,3 <1H*,
9X) r
* / ’ ’ , 1 H * , 1 X , 1 H * , 1 x , 1 H * , 5 X , 5 < 1 H * ) , 5 X , 1 H * , 1 X ,
3(1H*) ,
* 5X,4(1H*),6X»1H*,/’ ',3(1H*,3X,1H*,5X),1H*,9X,
1 H * r
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20200
20203
20204
20205
20206 
20208 
20234
20250
20260
20270
20290
20302
20305
20306 
2031 0 
2031 1 
C 
C 
c 
c 
c
c
c
c
c
c
200
/ * ',2 S1H*,3X,1H*,5X>,1X,4 S1H*),5X,5(1H*> » 6X,
• 4S1H*), ’ • • .
/' ',45C1H~),////)
FORMAT < X/Z•0’,30x, 20A4)
FORMATS////’O',4X, ’INPUT VALUES FOR THE TITRATION 
PARAMETERS AREj»
,///’0',4X,'IDENTIFIER',4X,'REFINE 
KEY’,7X, 'NOP’,1 OX, 'VALUE',
26X,'LOWER AND UPPER LIMITS’,//)
FORMATS'0',8X,A3,12X,11,13X,F17„3,17X,2F15,3)
FORMATS’0',8X,A3,12X,11,13X,1PE17.4,17Xr2El5,4) 
FORMATS’0’,8X,A3,12X,I1,12X,I1,1PE17.4,20Xi2E15,4) 
FORMATS’ + ’ ,89X, ’N/A »)
FORMATS///’ODI MENS ION LIMITS OF TITRATION DATA 
ARRAYS EXCEEDED')
FORMATS///’0SEQUENCE ERROR.DETEcTED IN THE DATA’) 
FORMAT(///’0ERROR IN THE LIMITS FOR REFINEMENT') 
FORMATS///'O', 'ACID DISSOCIATION CONSTANT ERROR'')
FORMATS'O', 'EXECUTION TERMINATED,',///)
FORMATS///'O',4X, 'VSOBS,) VS CALC,) EMFSOBS,)
> EMFSCALC.)',
7X,'RESIDUALS',12X,’PH',9X,'FL’,8X, .
’EZOSCALC.) SLPSCALC,)»,///) ’
FORMAT<////'0’,2X,'REFINED VALUES FOR THE 
PARAMETERS ARE NOW;',///
'0',2X,'OBJ. FUNCT,',5X,A4,6(8X,A4>) ‘
FORMATS ' + » ,102Xr'OPTIMIZATION RECORD », / /)
FORMATS'0’,1P8E12.3)
FORMATS» + » ,102X,7S1H*),3X,'CONVERGED',//) .
SECTION ONE; INITIALISATION,- "
IN - 5
OUT = 6
IFAIL = 0
J FA IL = 0
EPS = 1,0 E - 6 
TOL = 1,0E”4 
AL10 ~ ALOG(10,00)• 
TITEND = „ FALSE.
SECTION TWO; DATA INPUT
WRITESOUT,20000) .
READ(IN,10200,END=299) TITLE
WRITESOUT, 20001 ) .
WRITESOUT,20200) TITLE '
WRITESOUT,20203)
M ~ 1
DO' 207 1=1,7"
READSIN,10205) KEY, IVALr JVAL, SPK(I,J), J=1,3)
; .
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N « 1
IF( I VAL • E0»2) N = 3
WRITE<OUT,20204) KEY, IVAL, (PK(I,J), J ~ 1 , N) 
IF(N.EQ.1) WRITE (OUT, 20208)
I F ( KEY • EQ « L IT (.8 ) ) GO TO 210 
IF(KEY,NE.LIT( I)) GO TO 250 
00 205 L = 1,3
205 ARRAY(L) « PK(I,L)
IF(IVAL.GTwO) CALL SETUP(ID,LIT(I),M,X,H,IVAL, 
ARRAY)
IFCI.LE.2) GO TO 207 
IF(PK(I,1)•LT.PK(I-1,1)) GO TO 270
207 REFINECI+7) « IVAL
READ(IN,10205)- KEY, IVAL, JVAL, VZERQ
• IF(KEY.NE.LIT(8)) GO TO 290
IF(lVAL.EQ-2.ANDp(PK(I,2)>GTePK(I,1).0RFPK(I,
' 3 ) „ LT , PK ( I , 1 ) ) )
* GO TO 260
GO TO 215
tn
r^
oo
rjo
of
-jo
oo R E F I N E (1 ) 
REFINEC2) 
R E F I N E ( 3 ) 
R E F I N E ( 4) 
REFINEC5) 
R E F I N E ( 6) 
REFINE(7) 
REFINEC8) 
REFINE(9)
- VZERO
- HVESSL
- LVESSL
- H B U R E T
- lburet
- EZERO
- SLOPE 
« • PKW
TO REFINEC14) *» PK1 TO PK6
210 NCONST = I - 1 
DO 212 J=1,3
212 VZERO(J) = PKd , J)
215 REFINE(1) = IVAL
IF(REFINE(1)wE0.2,AND.(VZERO(2)„GT.VZERQ<1)
. OR.VZERO(3)
* wLT.VZEROd ) ) ) GO TO 260 
IF(REFINE(1)wGT.O) CALL SETUP(ID,L I T(8),M,X,H,
REF I NE<1) , VZERO)
READ( IN,10205) KEY, REFINE(2), JVAL, HVESSL 
N “ 1
IF(REFINE(2)«EQr2) N ~ 3
WRITE(OUT,20205) KEY, REFINE(2), (HVESSL(J), J-1,N) 
IF<N„EQ.1) WR I TE(OUT, 20208)
IF(KEY.NE.LIT(9)) GO TO 250
IF(REFINE(2).EQ.2.AND.(HVESSL(2),GT.HVESSL<1) 
.0R,HVESSL(3)
* •LT.HVESSL(1>>> GO TO 260
' I F(REF I NE(2 ) . GT • 0 ) CALL SETUP(ID,L I T(9),M,X,H, 
REFINEC?),HVESSL)
•READCIN,10205) KEY, REFINEC3), NDPV, LVESSL 
N ~ 1
!F(REFINE(3)„EQ.2) N = 3
WRITECOUT,20206) KEY, REFINEC3), NDPV, (LVESSL(J), 
J=1,N)
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IFCN.EQ.1) ’WRITECOUT,20208)
I F ( K E Y , N E . L I T (1 0 ) ) GO TO 250. 
IF(REFINE(3)»EQ*2.AND.(LVE$SL(2).GT»LVES$L(1)
.OR. LVESSLC3)-
* .LT.LVESSLC1 ) ) ) GO TO 260 
IF(REFINE(3).GT.O) CALL SETUP(I 0,LIT(10),M,X,H,
REFINEC3),LVESSL)
READCIN,10205) KEY, REFINEC4), JVAL, HBURET 
N ~ 1
IFCREFINEC4) .EQ.2) N « 3
WRITECOUT,20205) KEY, REFINEC4), (HBURET(J), J=1,N) 
IFCN.EQ.1) WRITECOUT,20208)
IF(KEY.NE. LIT (11 ) ) GO TO 250
IF(REFINE(4).EQ.2. AND.(HBURETC2).GT.HBURETd)
• OR.HBURET (3)
* -LT.HBURETC1))) GO TO 260
IF(REFINE(4).GT.0) CALL SETUP(ID,LITC11),Mr X»H, 
REFINEC4),HBURET)
READCIN,10205) KEY, REFINEC5), NDPB, LBURET 
N = 1
IFCREFINEC5) ,£Q.2> N = 3
WRITECOUT,20206) KEY, REFINEC5), NDPB, CLBURET(J), 
J=1rN)
IFCN.EQ.1) WRITECOUT,20208)
IF(KEY.NE.LIT(12)) GO TO 250 
IFCREFINE(5).EQ.2.AND.(LBURET(2).GT.LBURET<1)
.OR•LBURET(3)
* .LT.LBURETC1))) GO TO 260
IFCREFINEC5) .GT.O) CALL SETUP<ID,LIT(12),M,X,H ,
REFINEC5),LBURET) ’
READCIN,10205) KEY, REFINEC6), JVAL, EZERO 
N » 1
IF(REFINEC6).EQ.2) N = 3
WRITECOUT,20204) KEY, REFINEC6), (EzERQ(J), J=1,N) 
IFCN.EQ.1) WRITE(OUT,20208)
IF(KEY.NE.LIT(13 )) GO TO 250 
XFCREFINEC6).EQ.2.AND.(EZER0C2).GT.EZER0C1)
.0R.E2ER0C3)
* .LT,EZEROC1))) GO TO 260
IFCREFINE(6) .GT.O) CALL SETUPCID,LITC13),MrX>H, 
REFINEC6),EZERO)
READCIN,10205), KEY, REFINEC7), JVAL, SLOPE 
N « 1
IFCREFINEC7).EQ.2) N = 3
WRITECOUT,20204 ) KEY, REFINEC7) , (SLOpE(j) , J=1,N) 
IFCN.EQ.1 ) WRITE(OUT,20208)
IFCKEY,NE . LIT(14 ) ) GO TO 250 
IFCREFINE(7).EQ.2.AMD.(SLOPE(2).GT.SLOPE(1)
.0R.SL0PEC3)
* .LT.SLOPE C1))) GO TO 260
I FCREFINE (7) .GT.O) CALL SETUP ( I D , |, I T C1 4) , M , X , If,' 
REFINEC7),SLOPE)
DO 231 1=1,100.
READCIN,10231 ,END-235) VC I) , ECI)
34 2
IF(VCI).LT. 0,000) GO TO 239 
231 CONTINUE
1-101
READ(IN,10205,EN0=235) KEV 
WRITECOUT,20234)
GO TO 290
235 TITENO = .TRUE,
239 NP = 1-1 
GO TO 300
250 WRITECOUT,29250)
GO TO 290
260 WRITECOUT,20260)
GO TO 290
270 WRITECOUT, 20270)
290 WRITECOUT, 20290)
299 STOP
rjo
oo
oo
o'
oo
rj 
o 
o 
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SECTION THREE; REFINEMENT BY SUBROUTINE NELM.
300 NBETAH .= NCONST - 1 
M = M *• 1
IFCNBETAH.LT,1) GO TO 400 
DO 301 1=1,NBETAH
JQR<1,I) ~ I
301 JQRC2,I) = 1
JOR(1,NCONST) = -1 
J0RC2,NCONST) = 0 
IFCM-1) 350, 320, 340
320 KOUNT a -50 . •
X (1 ) = Y (1 ) + H C1 )
WRITECOUT,20302)
CALL C A L C ( M , X , F ,&3 2 5 )
325 X(1 ) = Y(1) - H <1)
WRITECOUT,20302)
CALL CALC(M,X,F.&327)
327 X <1) = Y(1)
GO TO 350
JFCM.EQ.O) GO TO 350
340 KOUNT = -25 
WRITECOUT,20302)
CALL CALCC0,X,F,&341)
341 KOUNT = 0
WRITECOUT,20305) (IDCI), 1=1,M) 
WRITECOUT,20306)
DO 344 1 = 1 ,M
344 YCI) = x< I)
IFCM.LT.7) YCM + 1) = SL0PEC1)
M1 = M + 1
MP = M * (M + 2)
CALL NE l,M ( X , F , E PS , P , FP , X S , II, 0 , M , M1 , Mp ) 
IFCKOUNT-LE.M) GO TO 355 
WRITECOUT, 2031 0) F, (X(I), 1=1,M)
343
IFCIFAJL.EQ.O) WPITE(OUT, 20311 )
IFAIL a 0
C
350 KOUNT = *100
WRITECOUT,20302)
CALL CALC(M,X,F,&355)
C RESET ORIGINAL PARAMETER VALUES,
355 REFINEC7) = 2
SLOPEC3) » SL0PEC1) « ABS(SLOPE (1 ) ) / 10,00 
SL0PEC2) = SL0PEC1)
360 CALL CALCCM,Y,F,S400)
C
3?
U U (J (J
SECTION FOUR
400 IFCNBETAH.GT.1.OR.ABS(LBURET(1)).GT.1,0E*8> 1
GO TO 999 $
IFCLVESSLC1).GT.1.0p~8.AND.HBURETC1) ft
. LE-O. . Ar4D.NDPV.NE-1 ) GOTO 999 1
IF(LVESSL(1).GT.1.0E~8.AND.HBURETC1 ) 't
.GT.O..AND.NDPV.NE.O) GOTO 999 'ft
PKWMIN = PK (1 , 1 )
PKWMAX '= 0.000 ' 1
BLGMIN « P K < 2 r1 ) *
BLGMAX s 0.000 : 4
IFCREFINE(8),NE.2) GO TO 401 3
PKWMIN a PK(1,2) d
PKWMAX a PK(1,3) ' It
GO TO 450. • 1
401 IFCREFINEC9).NE.2) GO TO 450 1
BLGMIN = PK(2,2) . 'j
BLGMAX = PK(2,.3) j
450 CALL CALIBT (VZERO(1),EZEROC1), SLOPEC1),HVESSL(1), J
LVESSLC1),
C ' • I
* HBURETC1),PKWMIN,PKWMAX,BLGMIN,BLGMAX) 1
C ft
c i
999 IF(.NOT.TITENO) GO TO 200 i
STOP
END___________________________________________________________  -4
SUBROUTINE SETUPCI 0 , LIT , M,X,H,IREF,ARRAY)
DIMENSION X(7), HC7), ARRAYC3), ID(7) i
INTEGER OUT *!
. . COMMON /FIVE/ IN, OUT, IFAIL, JFAIL, AL10, KOUNT ?-
IFCM.GE.8) GO TO 20 ' J
IF < IREF.EQ.2) GO TO 10 • • . '-1
IXA = 1 ‘ |
X-A = ARRAY (1 ) / 1 2.000 J
I FCXA.LT. 0.0000) IXA a -1 ft
ARRAYC2) “ ARRAYC1) « XA * IXA
ARRAYC3) = ARRAYC1) + X.A * IXA 1
10 K(M) a (A R R A Y C 2) + (A R R A Y C 3) « A R R A Y(2)) / 10.0) «
A R R A Y (1 ) .
4
X ( M) ~ A R R A Y (1 )
ID(M) = LIT 
M = M + 1 
RETURN
20 WR ITE<OUT,99)
99 FORMATC//'0»,'ATTEMPT TO REFINE TOO MANY 
PARAMETERS’,/’ * 1 2 3 * 5 6 7 * * 10,
1 'ERROR TERMINATION',///)
STOP
■ ENO______________________________________________________
SUBROUTINE NELM(X,F,EPS,P,FP,XS,H,IX,N,N1,NP) 
DIMENSION X(N), P(NP), FPCN1), H(N), XS(N> 
ISH = 1
IS = 0
NN = N * (N + 1)
CALL CALCCN,X,F,8100)
F P C1) = F
IF(IX.NE.O) GO TO 2 
DO 1 1 = 1 ,N
K = I
DO 1 J = 1,N1 
P(K) = XCD
1 F(I+1.NE.0) GO TO 1 
P < K) = X < I > + H ( I)
1 K = K + N
2 K = 1 + N 
DO 3 1=2,N1 
D 0 4 J = 1 , N 
XCJ) = PCX)
4 K = K + 1 ’
CALL CALC(N,X', F,8100)
3 FP(I) = F . ’
1F(FP(1)-FP(2).GT.0.0) GO TO 5- 
IH = 2 
IL = 1 
GO TO 6
5 IH * 1 
IL = 2
6 DO 7 1=3,N1'
IF(FP(l)"EP(JH).GT.0,0) GO TO 8 
IF(FP(I)~FP(IL)-GE.0,0) GO TO 7 
IL = I
GO TO 7
8 IH = I
7 CONTINUE 
XN = N
50 K1 = NN
DO 9 1=1,N ’
K = I , ■
S » 0.0
DO 10 J=1,N1 
IF(J-IH.EQ.O) GO TO 10 
S = S + P(K)
10 K « K + N 
K1 = K1 + 1
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9 P!K1) « S / XN •
K " NN + 1 
00 11 1=1,N 
X ( I) » P ! K)
11 K ~ K + 1 .
CALL CALC(N,X,F0,&100)
WRITE(6,12341) IL, IK, IS.
12341 FORMAT!'+’,100X,3l3,3X,’TEST')
S a 0.0 .
DO 12 1=1,N1
12 S « S + (FP! I) - FO) ** 2
$ = S / XN . ■
IF(S-EPS.LE.O.OO) GO TO 100 
I F ( ! I H»»1 ) . EQ „ 0) GO TO 13 
IS a 1
GO TO 14 •
13 IS a 2
14 DO 15 I»1,N1
IF(I*IH.EQ.O') GO TO 15 ■ '
IF(FP! I)-FP!IS),LE,O„O) GO TO 15 
IS a I
. 15 CONTINUE
C**** REFLECTION •
K s (IH " 1) * N ♦ 1
KO = NN + 1 ■
DO 16 1 = 1,N
X(I) » 2,0 * P(KO) - p(K)
K - K + 1
16K0=K0+1- 
K = K * N
CALL CALC(N,X,F,& 100) .
WRITEC6,12342) IL, IH, IS
1 2342 FORMAT!• + ’,100X,313,3X,'REFLECTION'> 
IF!F-FP(IL).GE,O,O) GO TO 20
C**** EXPANSION
KO = NN + 1 
DO 17 1 = 1 ,N
XS!I) a 2.0 ★ x(I) - P!KO)
17 KO. = KO + 1
CALL CALC!N,XS,FS,S100)
WRITEC6,1 2343) IL, III, IS
1 2343 FORMAT!'+',1OOX,313,3X,’EXPANSION’) 
IF(FS-FP(IL).GE.O„O) GO TO 18 
DO 19 1=1,N .
P!K) = XS(I) •
19 K = K + 1 
FP!IH) a FS 
IL = IH ’
IH = IS .
’ GO TO 50
18 IL = IH . • -
IH “ IS.
FP(IL) = F .
.21 DO 22 1=1 ,N • -
P(K) = XCI)
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22 K« K + 1 *
GO TO 50
20 I FCF-FPCIS).GE.O.Q) GO TO 23 
FPCIH) = F 
IB = IS 
GO TO 21
23 IFCF-FPCIH).GE.0.0) GO TO 25 
DO 24 1=1 ,N
PCK) = X< I )
24 K = K * 1 
FPCIB) = F
C*-*** CONTRACTION *
K = K « N
25 KO = NN + 1
DO 26 1=1,N '
XS(I> =f 0.5 * CPCK) + PC KO))
K = K + 1
26 KO = KO + 1 
K = K - N
CALL CALC(N,XS,FS,&100)
WRITEC6,12344) IL, IB, IS
1 2344 FORMAT<’+’,l00X,3l3,3X,' CONTRACTION’) 
I FCFS-FP(IH).GE,0.0) GO TO 40
' DO 27 1=1,N 
PCK) = XS(I)
27 K = K + 1 
FPCIH) = FS
IFCFPC1)”FP(2),GT.0.0) GO TO 28 
IB = 2 
GO TO 29 •
28 IK = 1
29 DO 31 1=3, N1
I F<FP(I)-FP<IB>.LE.0,0) GO TO 31 
IB = I
31 CONTINUE
GO TO 50
40 FPC1 ) = FPCIL)
KKK = MOD CI SB,10)
I SB = ISH + 1
I F (( I L *•1 ) . E Q . 0 )
K- = CIL ” 1) * N
DO 41 1 = 1 ,N
K = K + 1
X C I ) = P ( K)
P ( K ) = PCI)
41 PCI) = 
IL = 1
XCI)
43 K = N 
DO 4 2 1=2,N1
DO 42 J=1,N .
K = K. + 1
PCK) = 0,5 * CPCK) + PC J)) 
ISB = ISB + 1
42 CONTINUE 
GO TO 2
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100 IL ~ 1
00 101 1=2,N1 '
I F(FP(I)-FP(IL)•GE•0,00) GO TO 101 
IL = I
101 CONTINUE
C WRITE(6,2349) IL, F0, (FP(I), 1=1,N1>
C2349 FORMAT(’0’,’NELM EX IT’,I 5,1P7E15•4,//)
F = F0
IF(F.LT.FPUL)) RETURN 
K=(1L-1)*N’
DO 102 1=1,N 
K = K + 1 
X < I > = P < K)
102 CONTINUE
F = FP(IL)
RETURN
________ ENO_______________________________
SUBROUTINE CALC(M,X,F,*)
INTEGER OUT, REFINE 
REAL LVESSL, LOURET
COMMON /ONE/ PK(7,3), VZERO(3), HVESSL<3)r 
LVCSSLC3), HBURETC3),
* LBURETC3), EZER0C3), SLOPE(3), REFINE(15), NDPV, 
NDPB
COMMON /TWO/ CI(7),CX(2),TT(2),HX(2),TOLC(2),OT(2 ) , 
DDT(2,2)
COMMON /THREE/ V(1OO), E(100), NP
COMMON /FOUR/ BETAC7), ARRAYC3), TOL, NCONSfr
N B E T A H , J Q R ( 2,7 )
COMMON /FIVE/ IN, OUT, IFAIL, JFAIL, AL10, KOUNT 
DIMENSION X(M)
C '
c
IF(M.EQ.O) GO TO 20
KOUNT a KOUNT * 1
IF<KOUNT■GE»M*50+80) GO TO 60O U U LOAD THE PARAMETERS BEING REFINED,
I = 0 
J = 7
DO 15 K=1,NC0NST 
J = J + 1
IF(REFINE(J) ,L-T.1 ) 
DO 10 L=1,3 
10 ARRAY(L)
CALL
PK(K, 1)
15 CONTINUE
GO TO 15
= P K ( K , L )
LOAD(S50,F,I,M,X,REFINE(J),ARRAY) 
= ARRAYC1)
IF(REFINE(1),GTw0) 
VZERO)
CALL
I F ( R E F I N E (2 ) . G T B 0 ) CALL
H V E S S L)
IF(REFINE(3),GT•0) CALL
LVESSL)
LOAD(&56,F,I,M,X,REF I NE(1) ,
LOAD(&56,F,I,M,X,REFINE(2) ,
LOAD<&56,F,I,M,X,REF INE<3 ) ,
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I F(REFINE(4) .GT.O) CALL
H B U R E T )
IF(REFINE(5) .GT.O). CALL
LBURET)
IF(REFINE(6) .GT.O) CALL
EZERO)
IF(REFINE(7) .GT.O) CALL
SLOPE)
L0AD(&56,F, I ,M,X,REFINE(4) , 
L0AD<&$6,F, I ,M,X,REFINE<5) ,
L0AD<&56,F»I,M,X,REFINE(6),
LOAD(856,F,I,M,X,REFINE<7),
<-
j <r
j -r~
>
CALCULATION of the sum of squared residuals,
20 I = 1 
J = NCONST
ALFH = 0.000 ' -
21 ALFH s ALFH + PK(4,1) * AL10
BETA(I) = ALFH • -
1 = 1 + 1
J = J « 1
IF(J.GT.I) GO TO 21 . -
BETA(I) = -PKd,1) * AL10
C
C I F(KOUNT«GE.4) GO TO 60
C WRITE(OUT,10008) VZER0(1),HVESSL(1),LVESSL(1),
HBURETd), .
C * LBURETd), EZEROd), SLOPEd)
C WRITE(OUT,10008) BETA
C
THZERO =s (HVESSLd) + LVESSLd) * NOPV) * VZER0(1) 
THBC = HBURETd) + LBURETd) * NDPB 
TLZERO = LVESSLd) * VZL'ROd)
ALSLP a AL10 / SLOPEd ) -
C •
F « 0,000 .
DO 3 5 I = 1,NP
VOL = VZER0C1) + Vd)
TTd) = (THZERO + THBC * V(I)> / VOL 
TT(2) = (TLZERO + LBURETd) * V(I)) / VOL 
ALFH = (E(I) ~ EZERO(D) * ALSLP 
CXd) = EXP(ALFH) .
ALFL = 1 .0000 . •
DO 31 K=1,NBETAH
31 ALFL = ALFL + EXP(BETA(K) + ALFH * K)
CX(2) = TT(2) / ALFL
ALFL = AL0G(CX<2>>
DO 32 K = 1,NBETAH
32 CI (K) = EXP(BETA(K>+ALFL+AIFH*K>
CI(NCONST) = EXP ( B ET A ( N CON ST ) »■ A LF H )
THCALC « CXd) ‘ •
DO 33 J«1,NCONST
33 THCALC - THCALC + Cl (J) * JQR(1,J)
VCALC = (THZERO -- THCALC * VZER0C1)) / (THCALC - 
THBC) •
RESID = VCALC - V(I)
IF(KOUNT.GT.O) GO TO 35 .
C WRITE(OUT,10008) TT, CX, TOL, ALFL
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C WRITECOUT,10008) CI • .
CALL MIC N CO N ST , 2 , T 0 L , 2 , B ET A , C'I , CX,TT,HXrTOLC, DT,DDT,
JQR)
IFCIFAIL,GT.0> GO TO 60 .
ECALC = EZERCK1) + ALOG(CXd)) Z AL$LP 
ALFH = ”ALOG 10(CX(1)) . . ■
ALFL « ECALC - ECI)
THCALC = ECI) + SL0PEC1) * ALFH 
SCALC « (EZEROCD - Ed)) / ALFH
WRITECOUT,10001) VCI), VCALC, ECI), ECALC, RESIP, 
ALFL, ALFH, .
1 CXd), THCALC, SCALC 
IFdFAIL.LT.JFAIL) WRITECOUT,10005)
JFAIL = IFAIL .
TTC1) a CTHZERO + THBC*CVCI)+0•004 ) ) / VOL
CALL ML<NCON ST,2,TOL,2,BETA,CI,CX.TT,HXrTOLC,DT , DDT ,
JQR) .
ALFH = ALFH + AL0G10(CXC1))
ALFH = ABSCALFH) * 60.0 ' .
IF(ALFH.Gt,0.3,AND.KOUNT.LE.O) WRITE(OUT,1 0007)
35 F = F + RESID ** 2
50 I F(KOUNT■GT,0) 60 TO 55
IFCIFAIL.NE.O) GO TO 58
55
56
58
60
RETURN
WRITECOUT, 1 0008) F, CXd), Id, M) 
IFAIL = 0 
JFAIL " 0 
RETURN
WRITECOUT,10006) .
WRITECOUT,10002)
IFCIFAIL.NE.O) WRITE(OUT,10003) 
IFdFAIL.LT.1) WRITECOUT, 1 0004) 
IFAIL a 10
JFAIL a 0
1 0001
RETURN 1 
FORMATC’ »
1 0002 FORMAT C’ t
1 0003 FORMATC’ t
1 0004 FORMATC’ »
1 0005 FORMAT C ’ + ’
1 0006 FORMATC ’ 0’
1 0007 FORMATC ’ + ’
1 0008 FORMATC’ 
END
»
, 2F9.3,2 F1 0,2 , F1 2,3 , F9• 3 , F1 3.3,1 PE1 3.2 , 
OPF16.3,F11.3) -
, ’FAILURE IN SUBROUTINE CALC) •
, ’CAUSED BY NON-CONVERGENCE IN SUBROUTINE 
ML’ )
,’THE MAXIMUM .NUMBER OF ITERATIONS HAS 
BEEN EXCEEDED,’)
, 118X, ’?’)
,’A QUESTION MARK INDICATES A’) • ’
,120X,’UNBUFFERED’)
,1P8E12.3) .
SUBROUTINE LOA D(*,F,I,M,X,IR E F,ARR A Y)
DIMENSION XCM), ARRAYC3)
1 = 1 + 1
ARRAYC1) = X CI) , .
IFCIREF.E0.1) RETURN .
IF (ARRAY(2). LT.X(I).AND.ARRAY(3).GT.XCD) RETURN
XA a CARRAYC3)’ + ARRAYC2)) / 2.0
XA = (XCI) - XA) / CARRAYC3) - ARRAYC2))
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IF(XA«LT•0»000) XA =
F = XA * 1.00E10
RETURN 1
END . .
XA
SUBROUTINE ML(N K,N MB E,T 0 L,N C, 111NB,CI,CX,T T,HX,T 0 IC, 
DT,DDT,JQR) '
DIMENSION HLNB(NK),CI(NK)
DIMENSION J OR(NMBE,NK) .
DIMENSION CX(NMBE),TT(NMBE),HX(NMBE)
DIMENSION TOLC(NC),DT(NC),DDT(NC,NC> '
COMMON /FIVE/ JINP, JOUT, IFAIL, JFAIL, AL10, KOUNT
C THIS ROUTINE CALCULATES ESTIMATES OF THE FREE
' CONCENTRATIONS 0
C LIGAND ETC. USING A NUMBER OF MASS-BALANCE
EQUATIONS EQUAL TO
C NUMBER OF UNKNOWNS (THOSE FOR WHICH THERE IS NO
POTENTIAL), TH
C ' NEWTON-RAPHSON• METHOD IS USED, WITH FIRST-
DERIVATIVES ONLY.
C ESTIMATES ARE ALSO REQUIRED FOR THIS ROUTINE
. BUT 1 .E-07 WILL
C SUFFICE IF A MORE ACCURATE VALUE IS NOT
AVAILABLE.
NEMF = MMBE - NC
IF(NEMF.EQ.O) go TO 103 .
DO 102 1=1,NEMF 
I PNC = I + NC -•
102 HX(I PNC)~ALOG(CX(IPNC)) ‘
103 NCICL = 0 .
C A CYCLE COUNTER, 100 CYCLES ARE PERMITTED AS
maximimum. . .
DO 1 05 1=1,NC '
C TOLC(I) PROVIDES A RELATIVE TOLERANCE FOR USE
WITH THE ' •
C CONVERGENCE CRITERION ’
105 TOLC(I)=ABS(TT(I))*TOL
121 NCICL=NCICL+1 
DO 125 J = 1,NC
C XC(J) IS ONE OF THE UNKNOWN CONCENTRATIONS THAT
• ARE BEING CALC
C AS IT CANNOT TAKE A NEGAT IVE VALUE , THE STEP
- ' LENGTH OF THE COR
C VECTOR HX IS REDUCED SO THAT NONE OF THEM TAKES
A NEGATIVE VAL
122 I F(CX(J) ) 1 23,123,125
123 DO 124 1=1,NC
HX(I)=0•5*HX (I) ■
124 CX(I)=CX(I)-HX(I)
GO TO 122 • . .
12.5 CONTINUE .
DO 126 1=1,NC 
HX(I)=ALOG(CX(I))
C DT( I) IS THE DIFFERENCE BETWEEN T OBSERVED ANO
T CALCULATED
’ • ‘ ' Iu
•
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C for THE MASS-BALANCE EQUATION (I), I.E. it is
the RESIDUAL. ' -
126 OT CI ) =C X < I) **TT < I ) 
c
C CHANGES AS RECOMMENDED BY LEGGETT (TALANTA, 1978)
c •
DO 128 J=1,nK 
W=HLNB(J)
DO 127 1=1,NMBE .
127 W=W+HX(I)*JQR<I,J) ■ •
C CI(J) IS THE CONCENTRATION OF THE SPECIES (1)
DEFINED BY
C THE INDICES IN JQR
CICJ)=EXP(W)
DO 128 1=1,NC ' '
128 DTCI)=DT(I)+JQR <I,J)*CI<J)
IF(KOUNT.GT.1000) RETURN .
DO 129 1=1,NC , ' -
C • CONVERGENCE CRITERION. WHEN ALL THE
MASS-BALANCE EQUATIONS '
C SATISFIED TO THE REQUIRED RELATIVE TOLERANCE,
CONTROL IS .
C PASSED BACK TO THE CALLING PROGRAM. ’
IF (ABS(DT(D)-TOLC (0) 1 29,1 29,131
129 CONTINUE 
GO TO 190
131 DO 152 1=1,NC
DO 151 J=I,NC •
C . DDT IS THE JACOBIAN FOR THE SYSTEM, AND IT IS
SYMMETRICAL AND • •
C • SQUARE. ITS ELEMENTS ARE THE RELATIVE
DERIVATIVES, SO THAT ’
C THEY ARE OBTAINED DIRECTLY FROM THE ■
CONCENTRATION TERMS
C PREVIOUSLY CALCULATED.
DDT(I,J)=O.
DO 151 L=1»NK
I F (JQR< I ,L))149,151,149 '
149 IF(JQR(J,L))150,151,150 ■
150 W=JQRCI,L)*JQR(J,L)*CI(L) *
DDT(I,J)=DDT(I,J)+W •
151 CONTINUE •
152 DDT( I , I)=DDT(I, I )+CX( I)
CALL LINEQ(DDT,NC,DT,4) •
IF (IFAIL) 160,160,190
C DT CONTAINS THE RELATIVE CORRECTIONS TO THE
PARAMETERS.
C * . HX WILL CONTAIN THE ABSOLUTE
CORRECTIONS.
160 DO 165 1=1,NC
HX(I)=~DT(I)*CX<I)
165 CX(I)=CX(I)+HX(I)
C - IF 100 CYCLES HAVE' BEEN EXCEEDED CONTROL IS
RETURNED TO CALC.
IFCNCICL.LT.101) GO TO 121
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IFAIL = I FAIL - 1 
190 RETURN
END_________________________________________________________ ___
SUBROUTINE LINEQ(A,N,B,KFAII)
DIMENSION A(N,N) , B ( N )
COMMON /FIVE/ IN, OUT, IFAIL, JFAIL, AL10» KOUNT 
C SOLVES THE N SIMULTANEOUS LINEAR EQUATIONS
A*X = B WITH M RIGHT"
C SIDES IN B, THE SOLUTION VECTORS ARE LEFT IN B
AND THE MATRIX
C replaced BY its INVERSE. AFTER choleski
FACTORING OF A TO GIVE
C THE FORWARD SUBSTITUTIONS L*Y = B AND L*Z~E AND
THE BACKWARD SUB
C LT*X=Y AND LT*AINV-Z ARE PERFORMED
IF (N-1) 455,5,9
5 T = A(1,1 )
IF(T.LE.O) GO TO 455
6 A(1,1)=1./T
B (1 ) = 8 C1 ) 7 T
RETURN
• 9 DO 80 I=1,N
11=1-1 .
DO 70 J=I,N
S=A(I,J)
IF (11) 10,30,10 
10 DO 20 K=1,11 
20 S=S-A(I,K)*A(J,K)
30 X.= S
IF (J-I) 60,40,60 
40 IF (X) 45,45,50 
45 IFAIL=KFAIL
GO TO 400
50 A(I,I)=1,/SORT(X)
GO TO 70
60 A(J ,I)sX*A(I , I)
70 CONTINUE 
80 CONTINUE
C FORWARD SUBSTITUTION ON RIGHT HAND SIDES
B < 1 ) ~ B (1 ) * A (1 ,1 ) , * •
BO 120 1=2,N
H = I-1
S = B(I)
DO 110 K=1,I1 
110 S = S « A(I,K) * B(K)
120 B(I) = S * AC I, I)
C FORWARD SUBSTITUTION FOR INVERSION
D’O 170 J=1,N
J 1 = J +1
IF (41—N) 140,140,170 
140 DO 160 t=Jl,N
I1=I«1
s=o„
DO 150 K = J, 11 *
150 S=S-A(I,K)*A(J,K)
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160 A(J,I)=S*A(Ir I)
170 CONTINUE
C BACKWARD SUBSTITUTION
B(N) » B(N) * A(N,N)
DO 220 J=1,N
220 A(J,N)= A(J,N)*A (N , N) «
DO 290 1 1=2 , N'
I=N-I 1 + 1 
T=A(I,I)
11=1+1 
S = B(I)
DO 240 K~I1,N
240 S = S « A(K, I ) * B(K> .
245 B(I) « S * T
DO 280 J=1 , I 
S=A(J,I)
DO 270 K~ 11,N
270 $=S-A(K,I)*A<J,K)
•A ( J , I )=S*T
280 CONTINUE 
290 CONTINUE
DO 300 1=2,N 
11=1-1
DO 300 J = 1 , 11
300 A (I , J ) = A ( J , I )
400 RETURN
C
455 IFAU = KFAIU 
RETURN
_______ END______
C ****•***** + + *★★+•*★★ + ** + '*+■****'*’*•*•
SUBPROGRAM CAUBT
CALIBRATION AND ANALYSIS 
OF TITRATION DATA BY 
LINEAR BEST-FIT TECHNIQUES
*********************** * **★** + ** + + * + + ********+•* *★**•* -k
************
THIS PROGRAM CALCULATES THE PH (AS THE NEGATIVE LOG 
OF THE FREE
C HYDROGEN CONCENTRATION) AT EACH POINT'IN A
TITRATION AND THEN
C DETERMINES THE•GRAD I ENT AND INTERCEPT OF THE LEAST
SQUARES
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C BEST-FIT WITH RESPECT TO THE GLASS ELECTRODE
RESPONSE.
C THE CALIBRATION IS IMPROVED BY OPTIMISATION OF THE
REAGENT
C CONCENTRATIONS OR THE RELEVANT EQUILIBRIUM
CONSTANTS.
A GRAN PLOT ANALYSIS IS PROVIDED FOR COMPARISON.
oo
o oo
oo
oo
oo
oo
 o o
 rjoo
oo
oo
o <-» o
 <->
 o
 <~>
THE FOLLOWING KINDS OF TIT.RATION, ALL INVOLVING 
MONOBASIC
REACTANTS, ARE APPLICABLE.
<1 > 
(2)
(3)
(4)
STRONG ACID VERSUS STRONG BASE 
WEAK ACID 'VERSUS STRONG BASE, 
STRONG BASE VERSUS STRONG ACID 
WEAK BASE VERSUS STRONG ACID.
STRONG ACID OR BASE MAY BE ADDED TO A CORRESPONDING 
WEAK ACID
OR WEAK BASE IN THE VESSEL PRIOR TO TITRATION. 
STANDARD ADDITIONS
ARE TREATED AS SUBSETS OF THE ABOVE TITRATION 
SCHEMES.
THE NERNST SIGN CONVENTION IS TAKEN TO BE POSITIVE 
(I.E. INCREASING PH GIVES DECREASING EMF VALUES,)' 
TITRATION VOLUMES MUST INCREASE MONOTON 1CALtY.
WITH STRONG ACID / STRONG BASE TITRATIONS, A SCAN 
OF PKW CAN BE
IMPLEMENTED 'TO ESTIMATE AN OPTIMUM VALUE,
IT IS IMPORTANT TO OBTAIN AGREEMENT BETWEEN:
(1) THE. OBSERVED AND THEORETICAL SLOPE FOR THE 
ELECTRODE RESPONSE
C AND (2) THE VALUES OF EZERO FOUND FOR DATA
CORRESPONDING TO THE
C ACID RANGE COMPARED WITH THAT COVERING ALL BUFFERED
POINTS,
C THESE ARE BETTER CRITERIA THAN A MINIMUM STANDARD
DEVIATION.
C A SCAN OF THE LIGAND PROTONATION CONSTANT IS ALSO
POSSIBLE.
C
c
c
c
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C •
SUBROUTINE CALIBT(VZERO,EZERO,SLOPE,THZEROrTLZERO, 
AHZERO,
1 PKWMIN,PKWMAX,BLGMIN , BLGMAX)
<"
><
“> 
O
 <-J 
<-
><
->
 o
DIMENSION W(100),H<100),PH(100),PHA(100),PHB(100), 
G(100),VG(100), .
1 VO IT d 00) , X(1OO) , Yd 00) , ET(100> ,EA(1OO) , EBdOO) , 
THT(100) •
INTEGER IN, OUT, CARD .
REAL NERNST
LOGICAL LIGAND, ALKALI, ADJUST
COMMON /TWO/ CI(7),Cx!2),TT(2),HX(2),T0LC!2) ,DT!2) ,
DDT(2)
COMMON /THREE/ V(1OO), EdOO), N
COMMON /FOUR/ (3ETA(7), ARRAY!3), TOL, NCONST,
NBETAH, J OR (2,7) * .
■COMMON /FIVE/ IN, OUT, IFAIL, JFAIL, AL10r KOUNT 
COMMON /SIX/ CARDC20), P(63)
EQUIVALENCE (P!D,Wd))
200 FORMAT! • 1 ' )
201 FORMAT! ’0’ )
210 FORMAT!/’0’
211 FORMAT! ’0’ ,
////’O’ ,20A4,//>
1’ ',’THE EXPECTED ELECTRODE INTERCEPT IS’,F8„2,/ 
2* ','THE EXPECTED NERNSTIAN SLOPE IS',F7.2)
212 FORMAT! ’0’ ,’THE ACID CONCENTRATION IN THE TITRATION 
VESSEL IS’ , •
11PE11.3 ,/’ THE LIGAND CONCENTRATION IN THE • ’
TITRATION VESSEL IS’,
21PE11.3 ,/’ THE ACID CONCENTRATION IN THE BURETTE
IS’ ,1PE11,3)
213 FORMAT! ,'TIIE END POINT IS EXPECTED AT',F“/,3) .
215 FORMAT! ,’THE VALUE OF PKW IS',F7.3,/»
’,26!1H«),/)
216 FORMAT! , i ,'THE VALUE OF LOG BETAII IS’,F7.3,/’ 
’,31(111-),/)
220 FORMAT! •0’ , ’TITRATION POINT NUMBER’,13,' IS IN 
ERROR' ,15X,2F12.2) *
222 FORMAT( 'O' , ’INITIAL CONCENTRATION DATA PROBABLY 
INCORRECT’,//)
231. FORMAT! ’0’ ,'THE GRAN-PLOT VALUES AT EACH POINT . 
ARE;’ , 11X , ’ I ’ ,7X,
1 ’VOL’ , 6X , ’EMF’,8X, 'V(I) ’ ,12X, 'G(I) ’,///)
235 FORMAT! •O' , ’PKW IS IN ERROR ’ )
356
236 FORMAT!'0THE VALUE OF LOG BETAH IS IN ERROR’)
240 FORMAT (’ 0 THE SEARCH FOR UNSUITABLE POINTS HAS
REMOVED ' )
241 FORMAT!' ’ , 45X , I 6,2 FI 0-2,7(1PE15„4))
245 FORMAT !'•►', 45X , ' NONE ’ )
250 FORMAT!’ !50% OF THE POINTS, TAKEN ABOUT THE MIDDLE
OF THE SET) ' >
251 FORMAT!’ 'BEST-FIT I tl VO L V I NG ' , I 3 , ’ POINTS GIVES
EZERO s’,
1 F7.1, » !’.F4-2,') AND A SLOPE =’,F7.2»'
( ’ ,F4-2, ’ ) ’ ,/
2 ’ ’,’OVERALL STANDARD DEVIATION = ’ , 1 PE 11„3>
252 FORMAT!///’0’ ,'USING DATA BEFORE THE ENDPOINT,’)
253 FORMAT!'O', ’USING DATA AFTER THE ENDPOINT,')
254 FORMAT!’0’,’USING ALL THE BUFFERED DATA,’)
255 FORMAT!// / ' 0 ’ , 8X, ' VOLUME'9X,'TH*,12X,’PH’,10X, •
’E(OBS-)’,
1 7X,’E(CALC.)’,8X,'RESIDUAL',5X,'PKW!CALC.)',4X,
’EZERO(CALC•)’,//)
256 FORMAT!’ ' , I 3 , F1 0.2,1 P E1 5 - 3,0 P F1 2 - 3,5 F1 5,2 )
257 FORMAT('0PKW(CALC-) IS OBTAINED USING THE
CURRENT VALUE FOR’,
1 ’ EZERO <»,F6-1,') AND THE NERNSTlAN SLOPE,
AVERAGE s’ , F7.3)
258 FORMAT (’0'.EZERO ( CALC - ) IS OBTAINED USING THE
CURRENT VALUE FOR’,
1 ’ PKW <’,F6,2,') AND THE NERNSTlAN SLOPE-
AVERAGE s’ ,F7.1,///)
260 FORMAT('1',/’01 OX,35!1H*)»5X,’NEW SCAN
ITERATION',5X,35!1K*),/)
261 FORMAT !' + ’, 1 NOT REQUIRED-',/
1 ’THE RESULTS ARE INDEPENDENT OF THE VALUE OF 
PKW,’)
262 FORMAT !//////'0’,44X, 'CALIBT CONCENTRATION
ADJUSTMENT’)
263 FORMAT!’ ’,43X,'AND TO DETERMINE A VALUE FOR PKW,’)
264 FORMAT(///'0’,’WITH A VESSEL-ACID CONCENTRATION
OF',1PE11.3,/’ ',
1 'AND A BURETTE-ACID CONCENTRATION 0F ' , 1 PE 11 - 3, / ’
LJ 
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266
2 'THE FOLLOWING RESULTS ARE OBTAINED',////)
’,'THE ENDPOINT NOW OCCURS AT’,F7-3 ,///) 
’,36X,'TO DETERMINE THE BURETTE-ACID 
CONCENTRATION.',//)
’,37X,'TO DETERMINE THE VESSEL-ACID 
CONCENTRATION')
FORMAT ! ’ 
FORMAT ! '
267 FORMAT!
10 ‘WRITE! OUT, 200) 
LIGAND = .FALSE- 
ALKALI = -FALSE. 
ADJUST = -FALSE- 
NADJ = -10
WRITE(OUT,210) CARD 
NERNST = SLOPE
WRITE(OUT, 211) VZERO, EZERO, NERNST 
IF(AHZERO.GT.0.000) ALKALI = .TRUE.
•DUMMY = TLZERO 
IFCALKALI) DUMMY - -DUMMY
ENDPT = -VZERO * (THZERO + DUMMY) / AHZERO 
ARESET = AHZERO 
TRESET = THZERO 
ERESET s ENDPT
WRITE(OUT,212) THZERO, .TLZERO, AHZERO 
WRITE(OUT,213) ENDPT 
IF(TLZER0.GT..1E-7) LIGAND = .TRUE.
PKW = PKWMIN
• WRITE(OUT , 215) PKW
PKWINC = (PKWMAX - PKWMIN)' / 5.000 
IFCPKWINC.LT.0.000) PKWINC = o.oo'o 
BLGINC = 0.000
IF(.NOT.LIGAND) GO TO 16
BLG = 'BLGMIN
WR I TE(OUT,216) BLG
IF(BLGMAX.GT.BLGMIN) BLGINC » (BLGMAX - BLGMIN) / 
5.000
IF(BLGINC.GT.0.000) PKWINC ~ 0.000 
16 CONTINUE
O
 O
 
O
 fi
 o
DO 20 1=2, N
I F(V(I),LT•V (I-1 ) ) GO TO 21
20 CONTINUE .
GO TO 30
21 WRITE(OUT,220) I, V(I), E(I) 
IF(I .EQ.2) WRITE(OUT, 222)
GO TO 65
30 DO 31 1=1,N
31 HCI) = 10.000 ** ((E(I) - EZERO) / SLOPE)
WRITE(OUT,231)
IG = 1 
DO 32 1=1,N
IFdIGAND.AND.V(I).LT.0.00099) GO TO 32 
IF(V(I) .GT.ENDPT) .GO TO 33 
G(IG) = VZERO + Vd)
IF(LIGAND) G( I G ) = V(I)
:HOLD = H(I)
IF(ALKALI) HOLD = 1.000 / HOLD 
■ G(IG) = G(IG) * HOLD
VGCIG) = V(I)
WRITE(OUT,241) I, VCI), E(I), VG(IG), G(IG) 
IG = IG + 1
32 CONTINUE
33 IG = IG - 1
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INIT = 1
IFCIG.GT.5) CALL STRAIT<VG,G,W,IG,ENDpT,INIT,I FIN, 
X,Y,OUT) ,
NF LAG a IG + 1 
IFCNFlAG.GT.N~3) GO TO 35 
IG = N ~ NFLAG *2 
IF(NF LAG-GT.1) WRITE(OUT,231)
DO 34 I=NFLAG,N ' ‘ .
IG = IG - 1
G(IG) = VZERO > VCD .
HOLD « H(D .
ifc.not,alkali) hold = 1,000 / hold 
G(IG) = G(IG) * HOLD 
VG(IG) “ VCI) .
34 WRITE (OUT,241 ) I, VCD, E(I), VGCJG), GGG)
1G = N - NFLAG * 1 ’
INIT = N
IFCIG.GT.5) CALL STRAIT(VG,G,W,IG,ENDpT,INlTfIFIN, 
X,Y,OUT) • ‘
35 IF<PKW.GT'.12,0. AND, PKW.LT. 15,00) GO TO 36
IFCPKW.GT.O.S.OR.PKW.LT.-0.5) WRITECOUT,235)
GO TO 65- -
36 IFC.NOT,LIGAND) GO TO 37 ‘
I F (BLG-. GT • 2.00. AND. B LG • LT » 1 2.00 ) GO TO 40 
IF(BLG.GT.0.5.0R,BLG.LT,~0.5> WRITE(OUT,236)
60 TO 65 •
37 TH2 = THZERO * 0.1 
IFCNADJ.GT.15) TH2 = TH2 / 5.00 
TH1 = THZERO + TH2
TH.2 « THZERO «• TH2
40 IT = 0
IA = 0
IB = 0 '
NFLAG a 0
KWSCAN a 1 ’ . ‘
THMOL = THZERO * VZERO
IFC,NOT.(LIGAND,OR.ADJUST)) WRITECOUT,2153 
IFCLIGAND) WRITE(OUT,216) BLG 
IF(.NOT.ADJUST) WRITECOUT , 240)
IF(.NOT.LIGAND) GO TO 45
C
PKW
TLMOL = TL2ER0 * VZERO
IFC.NOT.ALKALI) THMOL a THMOL + TLMOL 
DUMMY « -PKW *
WK = 10.00 ** DUMMY
BETAH = 10,000 ** BLG
DO 44 1=1 ,N
WCI) = 1.000
VOL = VZERO + VCD '
TL = TLMOL / VOL
TH = (THMOL + AHZ6R0 * V(D> / VOL
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HLO = -1.000 
HHI = -1.000 . '
HFREE = -1.000 . '
I F(TH.IE.0.000) GO TO 41
ACID APPROXIMATION
HOLD -1,0 + BETAH * (TL - Til)
HLO = HOLD ♦ * 2 + 4,0 * BETAH * TH .
HLO a (SORT(HLO) - HOLD) 7 (2.0 * BETAH)
HFREE = HLO •
41 IF(TL.LE.TH) GO TO 42
ALKALI APPROXIMATION ’
HOLD = -(TH + WK * BETAH)
HHI = HOLD ** 2 + 4,0 * BETAH * (TL - TH) * WK 
HHI = (SORT(HHI) - HOLD) / (2,0 * BETAH * (TL - Til)) 
I F ( HFREE . LE.0.Q00) HFREE c HHI
IF(HL0.LT,1.00E-12.OR.HHI,LT.1.00E-12) GO TO 42 
C
DUMMY -- SQRT(WK)
HFREE -1,000 - •
IF(HLO,6T,DUMMY*100.0) HFREE a HLO ' 
IF(HHI,LT.DUMMY/100,0) HFREE = HHI 
IFCHFREE.GT.0.000) 60 TO 42
HOLD = HLO ★ HHI / WK '
DUMMY a 1 .000 /. HOLD 
I F(HOLD.LT .1•000) HOLD a 1.000 
I FCDUMMY.LT,1.000) DUMMY a 1.000 
HLO = ALOG(HLO) * HOLD .
HHI a ALOG(HHI) * DUMMY
HFREE a (HLO + HHI) / (HOLD + DUMMY)
HFREE = EXP(HFREE)
42 I F ( H F RE E • LT • 1 • 0 E-1 2 ) GO TO 43 
FREEL a TL / (1.0 + BETAH * HFREE)
FREELH a TL - FREEL
IF((FREEL. LT.1.0E-3. OR.FREELH.LT.1.Oe-3).AND.
1 (HFREE.GT.1.0E-11.AND.HFREE.LT.1.OE-3)) GO TO 43
IT = IT + 1
PH(IT) a -ALOGlO(HFREE)
VOLT(IT) = VCI)
THT(IT) = TH 
ET(IT) a E(I)
I F (V(I).GT.ENDPT) GO TO 421 
IA = IA + 1 .
EA(IA) a E(I) ■ .
P H A(I A) ~ P H(I T )
GO TO 44 
421 IB a IB + 1
EBdB) a E(I)
PIIB (IB) = PH (IT) • •
GO TO 44
43 IT = IT +1
IF(IT.EQ.I) WR I TE(OUT»201)
360
IT = IT - 1
WRITE(OUT,241) 1, V<I)r E(I)
44 CONTINUE
IF(IT.EQ.N) WRITE(OUT,245)
GO TO 52 <
45 00 48 I«1,N
W(I) ~ 1.0000 .
VOL " VZERO + VCI) • .
TH =• (THMOL + AHZERO * V(I)) / VOL 
IF(TH,LT.9.999E-4) GO TO 46 
KWSCAN =1 .
IT = IT + 1 .
IA « IA + 1 . ' •
' ET(IT) - ECI) .
EA(IA) = E(I)
PHUT) ~ ™ALOG10(TH) •
P H A(I A) ~ P H(IT ) .
VOLT(IT) = V(I) •’
THT(IT) s TH
GO TO 48 '
46 IF(TH,LE,-9,999E-4.AND,TH . GT.-0.01) GO TO 47
IF(AOJUST) 60 TO 48 ■
IT = IT + 1
IF(IT.EQ.I) WRITE(OUT,201) .
IT « IT ~ 1
WRITE(OUT,241). I, V(I), ECI)
GO TO 48
47 IT - IT + 1 
IB = IB + 1
EF(IT) a E(I) -
EB(IB) a E(I)
Pfl(IT) a PKW + ALOG10C-TH)
P H B(IB ) a P H(IT)
VOLT(IT) = V(I) . . •
THT(IT) a TH .
48 CONTINUEo u u
so iFdNOT.adjust.and.it.eq.N) write(Out,243> 
IF(IT.LE.O) STOP 50 .
IFCIT.LE.5) GO TO 54
IFdA.LT. 5. OR.IB.LT, 5) GO TO 52
CALL LINFlT(PHA,£A,W,IA,SLOPE,EZEROrSXSLP,SXlNTr
STPDEV)
SLOPE = -SLOPE 
ACIDSL = SLOPE
IF(ADJUST) GO TO 52 . .
IF(.NOT,ALKALI.OR.LIGAND) WRITE(OUT,252)
IF(.NOT.LIGAND.AND,ALKALI) WRITE(OUT#253)
I F ( I B . EQ.O.) WR I TE (OUT , 250)
WRITE(OUT,251) IA, EZERO, SXINT, SLOPE, SXSLPr 
STDDEV ‘
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CALL LINFIT(PHB,EB,W, I B , SLOPE,EZERO,SXSLP , SXI NT, 
STDDEV)
SLOPE = -SLOPE . .
1F(,NOT.ALKALI.OR.LIGAND) WR I TE(OUT, 253)
I F(.NOT.LIGAND.AND-ALKALI) WRITE(OUT,252) 
IF(IA.EQ.fl) WRITE(OUT, 250)
WRITE(OUT,251) IB, EZERO, SXINT, SLOPE, SXSLP, 
STDDEV •
52IF(ADJUST.AND.NADJ.LT.1O.AND.IA.GE.5.AND.IB.GE.5) 
GO TO 59
CALL LI NF IT (P'H,ET,W, IT, SLOPE, EZERO, SXSLP, SXINT, 
STDDEV) .
SLOPE = -SLOPE •
IF(IA.LT.5.OR.IB.LT.5) ACIDSL SLOPE 
BASESL = SLOPE
IF(ADJUST) GO TO 59 
WRITE(OUT,254)
WRITE(OUT,251) IT, EZERO, SXINT, SLOPE, SXSLP, 
STDDEV
f}
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54 WR I TE(OUT, 255)
HOLD = 0.000 .
DUMMY = 0.000 ••
PKWCLC s 0,000
Ir(IA.EQ.O) IA s IT + 1 •
DO 55 1=1,IT 
X(l) = PH (I)
Y(I) = ETd)
ECALC ~ EZERO - SLOPE * PH (I) „
ERES ID = ETd) - ECALC
EZOCLC = ET(I) + NERNST * PH(I)‘
HOLD = HOLD + EZOCLC 
IF(I.LE.IA) GO TO 55 
I F(I,EQ,IA + 1) WRITE(OUT,201)
PKWCLC = ((EZERO - ET(I)) / NERNST) - PH(I) + PKW 
DUMMY = DUMMY + (1.0 / 10,00 ** PKWCLC)
55 WR ITE(OUT,256) I, VOLT(I), THT(I), PH(I), ETd),
• ECALC, ERESID,
1 PKWCLC, EZOCLC
WRITE(OUT,201 )
IFdT.LE.5.OR.IA.LT.5) GO TO 65 
IFdB.LT.3) GO TO 56 
PKWCLC = DUMMY / FLOAT(IB)
PKWCLC = -ALOG1O(PKWCLC) • . »
WR I TE ( OUT , 2 57 ), EZERO, PKWCLC •
56 EZOCLC = HOLD / FLOAT(IT)
WR ITE(OUT,258) PKW, EZOCLC
59 IF(LIGAND) GO TO 60
362
591
592
NAD J a NA I) J + 1
IF(NADJ-11) 591, 592, 594 •
ADJUST ~ .TRUE,
ACIDSL = ACIDSL - NERMST 
IFCNERNST.LT.0.00) ACIDSL = -ACIDSL 
IFCACIDSL, GT. 0,000) TH1 - THZERO 
IFCACIDSL.LT.0.000) TH2 ~ THZERO 
THZERO = CTH1 + TH2) / 2.000 
GO TO 40 -
I FC .NOT.ADJUST) GO TO 593 
ENDPT =s -VZERQ * THZERO t AHZERO 
WRITECOUT,262)
WRITECOUT,267)
IFCIB.6T.3) WRITECOUT,263) 
WRITECOUT,201)
WRITECOUT,264) THZERO, AHZERO
593
594
595
596
597
WRITECOUT,265) ENDPT 
ADJUST a .FALSE,
NADJ a 10 
GO TO 40
ADJUST ss .TRUE, - 
TH2 = AHZERO * 0.1 
IFCNADJ..GT.15) TH2 - 
TH1 a AHZERO + TH2 
TH2 a AHZERO - TH2 
NADJ = NADJ + 1 
IFCNADJ-21) 597, 37, 
IFCNADJ-31) 
I.FCNADJ-40)
TH2 / 5.00
595
591, 593, 596 
597, 598, 60
BASESL - RASESL - NERNST 
IFCNERNST.LT.0.00) BASESL 
IFCDASESL.GT.0.000) TH2 a 
I FCBASESL.LT.0,000) TH1 = 
AHZERO = (TH1 + TH2) / 2
-BASESL 
= AHZERO , 
AHZERO 
000
598
THZERO a 
GO TO 40
AHZERO * ENDPT / VZERO
1FCIA,LT.S.OR.IB.LT.5) GO TO 65 
WRITECOUT,262) '
WRITECOUT,266) •
WRITECOUT,264) THZERO, AHZERO 
WRITECOUT,265) ENDPT
ADJUST “ .FALSE. ‘
GO TO 40
o 
r»
 rj
60 I FCPKWINC.LE.0.0001 ) GO TO 62 
NADJ a 0
PKW « PKW + PKWINC ’
I F(PKW.GT.PKWMAX) GO TO 62 
WRITECOUT,260)
I FCKWSCAN.EQ.O) WR I TE COUT, 260) 
• I FCKWSCAN.EQ.O) GO TO 62
THZERO a TRESET ‘
AHZERO a ARESET
363
ENDPT ’ ERESF.T
WRITE(OUT,264) THZERO, AHZERO 
WRITECOUT,213) -ENDPT 
GO TO 35
C
62 IFC.NOT.LIGAND,OR.BLGINC.LE,0.0001 ) GO TO 65 
BLG = BIG + BLGINC 
I FCBLG.GT.BL6MAX) GO TO 65 
WRITE(OUT,260)
GO TO 35
C •
65 WRITECOUT,200)
RETURN
END
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THE FOLLOWING SUBROUTINE SEARCHES DATA STORED IN 
THE ARRAYS
NAMED V AND G TO FIND THE SEGMENT GIVING THE 
straigutest LINE.
ONLY THOSE LINES WITH ABSSICA INTERCEPTS WITHIN 
PTOL PERCENT OF
THE ESTIMATED END POINT VALUE ARE ACCEPTED;
IF THIS CONDITION IS
SATISFIED, THE SEGMENT GIVING THE LOWEST STANDARD 
DEVIATION IS
LOCATED; OTHERWISE, THE LINE FOUND IS THAT GIVING 
THE CLOSEST
AGREEMENT WITH THE END POINT ESTIMATE.
SUBROUTINE LINFIT IS
CALLED BETWEEN 20 AND 50 TIMES; ITER DETERMINES 
H 0 W F I N E L Y
THE DATA IS DIVIDED INTO LINE SEGMENTS.
SUBROUTINE STRA IT CV,G,W,N,ENDPT,INIT,IFIN,X,Y,OUT) 
DIMENSION VCN), G<N), WCN), X(N), Y(N)
INTEGER OUT
201 FORMATC///’0GRAN-PLOT EXTRAPOLATIONS’ ,/’
*,24C1H*),///’0’,
1 • 2XSEGMENT’,8XEND PT.’,5X,'STB• DEV.’,//')
202 FORMAT(’ »,I 3,2X,’-’,14,4X,F10.4,3C1PE15,4 ))
203 FORMAT (//’0.'THE STRAIGIIIEST SEGMENT
G I V E S ’ , 3 X , F1 0.4 , / * 0 ’ ,
1 ’THE MINIMUM STD. DEVIATION G I VES ’ ,3X,F ') 0.4 )
364
205 FORMAT(*+',48X,'OMITTED BECAUSE THE ESTIMATED 
ENDPOINT IS OUTSIDE
1THE PERMITTED RANGE OF’, F5.1 , '%’)
207 FORMATC'O’,'THE WEIGHTED AVERAGE G I VES • ,3X,F3.4,
Z’O' ,
1 ’THE ACTUAL AVERAGE G I V E S ' , 3 X , F 8.4 , / / / / )
210 FORMATC’ FAILED TO FIND THE ENDPOINT',//)
211 FORMATC CLOSEST AGREEMENT WITH THE ESTIMATED VALUE
IS WITHIN' ,
1 F6»1,'%’,//)
215 FORMATC'0ANOTHER ATTEMPT WITH INCREASED ENDPOINT 
RANGE', ///)
218 FORMATC ' 0',I 5, ’ POINTS HAVE BEEN OMITTED BECAUSE 
THEIR ESTIMATED
1ENDPOINTS ARE OUTSIDE A RANGE 0F',F6 „ i , ’% *,Z//)
n 
o 
o
PTOL = 5.0
ISTART a INIT
ITER - 5
I F(I START . EQ.1) ISTART ~ -1 
INIT - O’
ENDOLD a 1.000E19
STDOLD « 1.000E19
STDSTD = 1.000E19
SAVINT = 0.000
SAVSLP = 0.000
KOUNT a 0
WGTAVE a 0.000
ENDAVE = 0.000.
STDAVE = 0,000
NDUD a 0
C
IFCN.LT.6) 
MM IN a 5 
IFCN.GT.12) 
I F ( N . G T . 2 5 ) 
IF(N.GT.50) 
NM1 a N ~ 1
STOP
MM IN a 6 
MM IN = 7 
MM IN = 9
10
-MINC = (N - MMIN) / ITER
IFCMINC.LT,1) MINC a 1 
DO 10 I~1,N 
W( I ) “ 1.000
IFCPTOL.IT.7.00) UR I TE(OUT,2 01) 
DO 35 M=MMtN,NMl,MINC 
MP1 = M + 1
IINC a C C N ” M) Z ITER) , 
IFCINC.LT.1 ) IINC » 1
C
DO 35 IaM,N,I INC 
DO 20 J=1,M 
K = I + J ~ M 
X C J ) - V ( K)
Y < J ) = G C K)20
365
J ~ I — M + 1
CAUL LINFITCX, Y,W,M, SLOPE, XINT, SXS|.P»SX I NT, STDDEV) 
ENDTRY =s «XINT / SLOPE ’ •
, ENDAVE » ENDAVE * ENDTRY '
WGTAVE = WGTAVE + • ENDTRY / STDDEV 
STDAVE ~ STDAVE + 1-000 / STDDEV 
KOUNT « KQUNT + 1
K = IABS(I3TART-J+1)
L = IAbS(I START-I+1)
I F ( PTO.L • LT ■ 7 • 00 ) WR I TE (OUT , 202') K, L, ENDTRY, 
STDDEV .
ENDNEW = (AgS(ENDTRY-ENDPTj / ENDPT) * 100-0
I F(ENDNEW.LT-PTOL) GO TO 30
IF(PTOL.LT.7.00) -WRITE(OUT, 205 ) PTOl
ENDAVE = ENDAVE - ENDTRY
KOUNT = KOUNT - 1 ’
WGTAVE - WGTAVE - ENDTRY / STDDEV ‘
STDAVE = STDAVE - 1-000 / STDDEV
NDUD ~ NDUD + 1 •
IF(ENDNEW.GT.ENDOLD) GO TO 35 .
ENDOLD = ENDNEW . ' '
GO TO 32
30 ENDOLD = 0,0000
IF(STDDEV/FLOAT(I-J+2).GT-STDOLD) GO TO 34
32 I NIT = J 
IFIN = I
SAVINT = XINT ' .
SAVSLP s SLOPE ’
3TDOLD a STDDEV / FLOAT (I-J*2)
34 I F(STDDEV.GT»STDSTD) GO TO 35
STDSTD = STDDEV ' .
SAVEND = ENDTRY ,
35 CONTINUE
I F(KOUNT • GE -1) GO TO 38 •
WRITE(OUT,210) -
IFCEND0LD.LT.1-0E2) WR I TE ( OUT,211) ENDOLD
36 IF(PTOL-GT-7;0) GO TO 39
PTOL = PTOL * 2 ' .
IF(ENDOLP.GT.PTOL) RETURN
WR ITE(OUT,215) ' .
GO TO 5
38 STDDEV « STDOLD * FLOAT (I F I N-1NIT + 2)
ENDTRY ~ -SAVINT / SAVSLP
ENDAVE « ENDAVE / FLOAT(KOUNT)
WGTAVE » WGTAVE / STDAVE
WR I TEC OUT,203) ENDTRY, SAVEND
WRITE(OUT,207) WGTAVE, ENDAVE
I F(FLOAT(NDUD)-GT-FLOAT(KOUNT)/2 - 0) GO TO 36
RETURN
39 WRITE(0UT,218) NDUD, PTOL ‘
RETURN . . '
END
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LINEAR LEAST SQUARES FIT ROUTINE
366
DEFINITION OF VARIABLE NAMES;
oo
o o 
o
X, Y « DATA ARRAYS
W » ARRAY FOR WEIGHTING FACTORS
N « NUMBER OF DATA POINTS
NW . = FLAG FOR WEIGHTING
XINT, XSLOPE . = INTERCEPT AND SLOPE OF LEAST
SQUARES LINE
SXINT, SXSLP = STANDARD DEVIATIONS OF XINT AND
XSLOPE
STDDEV = STANDARD DEVIATION OF THE .LINE
FIT ‘
SUBROUTINE LlNFIT(X,Y,W,N, XSLOPE, XINT, SXSI„P,3XINT, 
STDDEV)
DIMENSION X(N), Y(N), W(N)
WW =0.000 , .
WX =• 0.000
WY = 0.000 .
WXY = 0.000
WXX = 0.000 . ‘
WYY - 0.000 
DO 10 1=1,N 
WW - WW * W(I)
WY = WY + W.(I) * Y(l) .
WX = WX + W(I) * X(l)
WXY “ WXY + W(I) * X(I) * Y< I)
WXX = WXX + W<I) * X(I) ** 2
10 WYY ~ WYY + W(I) * Y(I) ** 2
DENOM = WW * WXX - WX ** 2 ' .
XSLOPE = (WW * WXY - WX * WY? Z DENOM 
XINT = (WXX * WY - WX * WXY) / DENOM
VSUM = .0.000
DO 20 1=1,N .
20 VSUM = VSUM + (Y(I) - XINT - XSLOPE * xd)> ** 2 
SS = VSUM / FLOAT(N»?)
STDDEV = SQRT(SS)
SXINT = SORT((SS/WW)*(1„0+((WX**2)/DENOM)))
SXSLP = SQRt(SS*WW/DENOM)
• RETURN 
END
/
APPENDIX A5
Instructions and FORTRAN listing of the 
computer program FORMAT
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DATA PREPARATION FOR MINIQUAD, SCOGS, ZPLOT, PSEUDOPLOT, 
COMICS, ECCLES AND MAGEC COMPUTER PROGRAMS i-
A COMMON INPUT PROCEDURE . - -
This document describes how the input data for programs 
in the Bio-inorganic Chemistry computer library held by 
the South West Universities Computer Network should be 
punched onto data cards. It refers only to those equilibrium 
systems in which there are not more than one kind of metal 
ion and two kinds of ligand. Glass electrode potentiometric 
data can be analysed using the MINIQUAD, SCOGS, ZPLOT, 
PSEUDOPLOT or MAGEC computer programs. Complex distribu­
tions as a function of pH can be calculated using the COMICS 
or ECCLES programs. ZPLOT, PSEUDOPLOT and COMICS can produce 
graphical output. Separate documents giving details on . •
each of the above programs, one describing the Job Control 
commands required to call and execute the programs, a'nd 
one about graphical procedures are available. :
INDEX • • ' . ‘ ’
Introduction ' *' ■
' ’’ ’• " J?” ’I '
Generalinputrequirements . .
Program keywords . ’ ' -' ' ' ' ’ ‘ v ••• •
■' ■ . • . ii.., ' ; ■ ■ ■
Title keyword ; -, / • . - ■ . *
Formation constant input . ’? ‘ '
Concentration data input ■ - • . • '• .. . . .......
Glass electrode parameter input. ' : '
Titration data input ' .
Error diagnostic
Program options • •
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Section 1 : Introduction
A variety of compute 
process data from or 
titrations of bioino 
the same kind of dat 
have different requi 
their input data mus 
punch a separate dec 
wants to use, a prog 
so that data prepare 
into the particular
r programs are generally used to 
pertaining to potentiometric
rganic equilibrium systems, While 
a is needed in each case, the programs 
rements concerning the way in which 
t be prepared. To avoid having to 
k of cards for each program that one . 
ram called FORMAT may be executed first 
d in a standard way is
layout required by the
trans formed 
user.
toThe program for which data is to be prepared is referred 
hereunder as the main program. The- data generated for it 
by program FORMAT is stored in a temporary computer file 
and is not normally seen by the user. The. printed output 
from program FORMAT is usually produced only if an error 
has been detected and the execution o.f the main program 
has consequently been abandoned. ’ . . . .
Program FORMAT can deal with equilibrium systems having 
the following components. •
fa) proton only ... ? . .
(b) ligand and proton .............. .
(c) ligand,. metal ion and proton .
(d) two ligands, metal ion and proton "
Up to 20 complexes may be specified by the user. '
Potentiometric data can be accepted if the titrand and 
titrant are solutions of any one or a combination of the 
following’components.
(a) a strong acid or a strong base
(b) a ligand . • • . . , , r-
(c) a second ligand . .. ?
(d) a metal ion .
A maximum of 100 data points per titration and an overall 
total of 500 points can be accommodated.
Most programs in the Bio-inorganic computer library do not 
permit such a wide range of input possibilities, It is the 
responsibility of the user to ensure that the main program 
which is specified will be compatible with the system as 
defined for program FORMAT. This also applies to options 
made available by program FORMAT. Incompatible or 
inapplicable data may be ignored or they may cause execution 
of the main program to be terminated.
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Section 2: General input requirements
The input for program* FORMAT is intended to bo general,
easy to prepare and above all systematic. Broadly, the 
program requirements may be categorised as follows (the 
section numbers used here are cross-referenced throughout 
this document and in the print out produced by the program),
1. The name of the main program for which data is to be 
prepared (see Section 3).
2. A title for identification purposes (see Section 4),
3. Definition of the equilibrium system in terms of the 
complex formation Constants or estimates thereof when 
this is applicable (see Section 5),
4. Definition of the equilibrium system in terms of the 
concentrations of components or estimates thereof when 
this is applicable (see Section 6).
5. The glass electrode parameters for each titration or 
estimates thereof when this is applicable (see Section 7),.
6. The titration data, usually in terms of millilitres 
and millivolts, (see Section 8),
7. An input terminator .(see Section 9).
The above order is mandatory but it may be appropriate to 
omit category 6. When a series of titrations is involved, .
categories 4, 5 and 6 are repeated as often as required.
All cards except those bearing the actual titration data . 
have the same basic format: columns 1 through 5 contain a . 
keyword - a string of characters and/or digits - which serves 
to identify the data appearing in subsequent fields on that 
card. Recognisable keywords for each category required by 
the program are given in the appropriate sections below,
With one exception, detailed in Section 4, the data on all 
cards containing a keyword is entered as one or two digits in 
columns 7 and 9 respectively and one or more ’’real” numbers 
in columns 11 through 20, 21 through 30, 31 through 40, etc,
In computer terminology, a “real” number is one which
(a) has a decimal point and
(b) may have an exponent - if so, this is signified by
an ’E' placed directly after the number containing the decimal 
and immediately before the appropriate power of ten by which 
the number must be multiplied. If thereat number has 
an exponent, it must be "right justified", (i.e. positioned as 
far as possible towards the righthand side of the field so that 
the last digit of the power of ten appears in the last column
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of the field.) If there is no exponent, the real number 
may be positioned anywhere inside each field. A value c ° 
zero is assumed if the number is omitted.
The general FORTRAN statement for input format may thus 
be represented by:
(5A1, 1X, 11, 1X, 11, 1X, 7G10.2)
Some examples are given below.
KEYUD • 1 4 8.1759E-13 10.000
KEYUD 1 : 22.00 2.22222E12
KEYUD
i
■ 1.000 1.0E7
KEYUD
i • •
KEYUD 0.00463 • 
i
! ‘ -
Section 3 : Program keywords
The first.card read by program FORMAT specifies the main 
program for which data is to be prepared.
The following keywords are
Keyword 
(cols 1-5)
MINIQ
MINI1
MINI2
SCOGS
COMIC
PPLOT
ZPLOT
MAGEC
ECCLS
CHECK.
recognised. ' ' '*•/'
Meaning
Call main program 
MINIQUAD. MINIQ and MINI1 refer 
to the original version of this 
program while MINI2 calls 
MINIQUAD (75)
Call main program SCOGS 
Call main program COMICS 
Call main program PSEUDOPLOT 
Call main program ZPLOT 
Call main program MAGEC •
Call main program ECCLES
No main program required 
(FORMAT will just check tha dat'a)
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Only one such keyword may appear. In other word's, it. is 
not possible to prepare output for more than one r.air 
program on each occasion FORMAT is e,xecuted. •
The general format for the rest of the card is as follows.
Integer field 
(cols 7+9)
Real field 
(cols 11-20,
21-30 etc)
Digit or digits indicating which of the 
options provided by the main program 
are required.
(Called IPROG and OPROG respectively)
Data required by the main program 
options (e.g. as specified in the integer 
field). Usually graph plotting parameters
Specific details appropriate to each main program can be 
found in Sections 11 through 19. t " •
' ■: ' .• . * j
Section 4:, Title keyword ,
Most of the main programs.require a title or some other 
data for identification purposes. .
The data field following the keyword ’TITLE’ is given a 
special format so that any alphanumeric string is acceptable. 
The data should be placed in columns 11 through 76..
In most cases, the alphanumeric string is transferred directly 
to the main program which simply prints it out as a heading,
A title must be supplied, however, even when the main 
program does not require one. • . . ., ..... :' I J ' J’ : • ■■ W.‘. ' . •
N.B. The last four columns on this title card are reserved 
for user identification. See PMM or DRU about this.
If program FORMAT is called by the BIONIC Macro, this 
identification is automatically transferred from the macro 
to this card image. Thus, users need not actually punch 
the information in these columns. . .
EXCEPTIONAL FORMAT: (5A1, 5X, 70A1) ; ..
z'l.
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Section 5: Formation constants
The formation constant .data is headed by a c-ard on which • 
one of the keywords ’LBETA1 or ’BETAF* must be punched.
(The usual number fields on these cards are ignored.)
The leader keyword is followed by a series of cards on 
each of which appears a string of digits defining the 
composition of a complex and a value for the appropriate •
formation constant. The keyword ’LBETA’ indicates that log' 
values are supplied while ’BETAF1 signifies that the formation 
constants themselves are provided. . • .
The formation constant or its log value is placed in the
first "real" number field (columns 11 through 20).
The string of digits representing the composition of each 
complex species comprises the keyword and occupies up to 
5 columns starting in column 1. The number of times each 
component appears in each complex•(i.S. its multiplicity) 
must be given as follows:
(i) the multiplicity of the ligand or ligands;
(ii) the multiplicity of the metal ion, if there is one
(iii) the multiplicity of protons in the complex.
Each figure must be a single digit, although that referring to
the number of protons may be signed or unsigned. The string 
should contain no spaces. It will thus occupy less than 
5 columns when the metal ion and/or second ligand are absent 
or when the last digit is. unsigned. However, every component 
present in the system must be represented in the digit string 
defining each complex species, i.e. a zero is used whenever 
the component is not part of the complex being defined. The 
number of protons in the complexes must always be specified, 
even in those (unusual) computations where protonation constants 
are not involved. The multiplicity of the ligand must also 
always be represented.
In general, a card image having the form \ /. . / . . ' .
abed ■ • •. • . . logbeta ' : , •
gives rise to a complex species concentration calculated
as follows.
complex concentration=beta.(ligand 1)?(ligand 2)^(metal)?(h)d
When the metal ion or second ligand are absent, the corresponding 
terms in the above expressions disappear.
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Section 6: Concentration data . •
A distinction is made at this stage between those main 
programs required to calculate equilibrium distributions 
and those which are to process titration data. COMICS 
and ECCLES can only determine equilibrium concentrations; 
PSEUDOPLOT can do both; all the other main programs require 
titration data.
A* Equilibrium simulations
The concentration data is headed by a card on which the 
keyword ’CONCS’ must be punched. (The usual number fields 
following the keyword on this card are ignored.) . •
The following keywords referring to concentration data for 
equilibrium simulations are recognised. ' .
Keyword
(cols 1-5 on cards 
fallowing ’CONCS1)
; . Meaning f
ACIDT Total concentration of strong acid in the ; 
equilibrium system. A negative quantity 1 
is meaningful; referring to an excess of i 
hydroxide ion or hydroxo-complexes. T
LIG1T Total concentration of ligand in the 
equilibrium system. . . .
LIG2T . : - Total concentration of the second ligand I 
in the equilibrium system, if applicable. *
METLT Total concentration of metal ion in the i
equilibrium system, if applicable. ' ‘J»
ACIDF ‘ Free hydrogen ion concentration in the ;
equilibrium system. . .
LIG1F Free concentration of ligand in the. • -j
equilibrium system. ... i
LIG2F .. - ; j . ...
Free concentration of the second ligand in^ 
the equilibrium system, if applicable. -M
METLF Free concentration of the metal ion in the4 
equilibrium system, if applicable. 1
SCNPH .
SCNPA . See note (3) below. . . j
The order of the keywords following ’CONCS’ is not important.- . 
Omit those which are not applicable (e.g. when the concentration 
is zero). . . •
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Note that if the multiplicity of the protons is negative, 
an hydroxo-complex is being specified: the calculation of 
the complex concentration involves taking a reciprocal of 
the free hydrogen ion concentration. The concentration of 
free hydroxide ion is thus calculated from the dissociation 
constant of water (say, pl< = 14.00) as follows. .
0-1 ’ -14.00
Some other examples are
00-1 ’’ -14.0Q
101 ....... .. 9.20
102 .. •' ‘ • 11.68
110 , 6.04
111 ' ' “ " 10.11
210 . 10..60
11-1 0.50
11 -................... • 5.80
12 8.27
0-1. -14.00
three component system: 
ligand, metal and proton
two component system: 
ligand and proton only
In respect of those programs which calculate or optimise 
formation constant values, the digit »1 ’ placed in column 7 
flags the complex species in question for refinement of its 
formation constant. -
A digit '21 placed in column 7 also indicates the formation 
constant is to be refined but in this case the value will 
only be permitted to vary between the limits provided in 
columns 21-30 (lower value) and 31-40 (upper value), .
This option is valid only for program MAGEC. Otherwise, it 
has the same effect as the digit ’ 1 •. * ..
The order of the formation constants is unimportant. . .
The art in determining or using formation constants lies in 
choosing the correct model. Great care must be exercised to 
ensure that all significant complex species (including metal- 
hydroxy complexes, protonated ligand species as well as the ■ 
various metal-ligand-proton complexes) appear in the set •
prepared for simulation or refinement programs. Not all 
formation constants should necessarily be optimized
simultaneously. Beginners will require help with , these matters.
‘G! 'C .
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Ths order of the keywords following 'CQNCS' is not important. 
The general numerical format is as follows, .
Integer field - 
(cols 7+9)
Real fields
Digit in column 7 indicating whether the 
concentration of a component is to be 
scanned. (See below for further details.) 
For each ligand concentration, the value 
of NDP is required in column 9 (see 
note (4) below). . •
The concentrations of the components in 
question in columns 11 through 20. •
.. If the concentration is to be scanned, the
.... ‘ initial value is increased till its
• „• exceeds a maximum value provided in
’ columns 21 through 30. The digit '3r in . 
column 7 indicates that the concentration 
is to be incremented additively by the 
amount specified in columns 31 through 40. 
The digit ’4' in column 7 indicates that 
the concentration is to be multiplied by 
the factor in columns. 31 through 40. .
Notes (1) Only one component may be flagged for a concentration 
scan. . . . ' .
(2) Either the free concentration or the total
concentration of each component should be provided, 
not both. • . .
(3) The main programs CONICS and PSEUDOPLOT permit the
calculation of equilibrium concentrations at a -
number of pH values specified by the user. To 
exercise this option, the keyword 'SCNPH' replaces 
»ACIDF». . ‘
The pH value is provided iff columns 11 through 21. 
More than one 'SCNPH' data point may be provided - 
in this way. . . ,
PSEUDOPLOT offers a similar facility for a scan 
of pA (negative log of the free ligand concentration) 
In this case, the keyword is 'SCNPA'. This replaces 
’LIGIF*. Implementation of either the 'SCNPH' or 
the 'SCNPA1 options precludes scanning the concen-
. tration of any other component,
(4) The number of dissociable protons (NDP) for each ■
ligand (i.e. parent acid) in the form they were 
added to the solution, ’ .
For example, ... ..... ............. . . .. NDP
I
 a) histamine ; ? 0
b) glycine ’ , 1
c) sodium glycinate • \.i,' ,.J.‘ \ 0
d) succinic acid '" 2
e) phosphoric acid’ • . • 3
f) sodium dihydrogen phosphate 2
g) disodium hydrogen phosphate 1
(h) trisodium phosphate . 0
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B, Titration data processing '' ' ■ ' .
For titrations, the concentrations of components in the system 
are defined as follows. . .
(1) The concentrations, of components in the titration 
vessel. This, data is headed by a card on which 
the keyword ‘VESSL’ must be punched.
(2) The concentrations of components in the burette.
This data is headed by a card on which the 
keyword ‘BURET’ must be punched.
The above order is important - titration vessel data must be 
entered before that referring to the concentrations in the 
burette. (The usual number fields (following the keywords . 
‘VESSL’ and ‘BURET’ are ignored.) ■ •
The following keywords are recognised.
Keyword (on cards 
following ‘BURET’)
--------------------------------------------------------------
Meaning ’
INITV . Initial volume in the titration vessel
ACIDV Initial concentration of strong acid in
. . the titration vessel. A negative quantity^
refers to strong alkali,
LIG1V Initial concentration of ligand in the -
. . L .. titration vessel, if applicable.
' * " ' ' "
LIG2V. . Initial concentration of the second ligandf
in the titration vessel, if applicable. • |
METLV .... „ Initial concentration of metal ion in the
/ titration vessel, if applicable, ■
* V "sk
ACIDB Concentration of strong acid in the burette,
. "j. ‘ A negative quantity refers to strong alkali,
LIG1B •’ . • Concentration of ligand in the titration
. ?• . vessel, if applicable. 1
LIG2B .. Concentration of the second ligand in the -a
. burette, if applicable, . j
METLB . • . Concentration of the metal ion in the .
burette, if applicable. I
The order of the keywords following ’VESSL' or ’BURET' is 
not important. Omit those which are not applicable (e.g. 
when the concentration is zero). . ..
'X
■4s
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Tlw order of the keywords following ’VESSL’ and ’BURET1 is 
not important. The general numerical format is a3 follows.
Integer field 
(cols 7 + 9)
Either of the digits ’1* or ’2’ in column 7 
causes refinement of that concentration by 
program MAGEC, in the same way as described 
for the refinement of formation constants 
in Section 5. •
For each ligand concentration, the value 
of NDP is provided in column 9 (see note (4) 
above). Otherwise, this column is ignored.
Real field - The value or best estimate for the concen­
tration in columns 11 through 20. If 
required for MAGEC refinement, a lower 
limit in cols 21-30 and an upper limit in 
cols 31-40.
A value of.zero is assumed if the figure is omitted.
Section 7: Glass electrode parameters
The glass electrode parameters are headed by a card on which • 
the keyword ’GLASS” must be punched. (The usual numerical 
fields on this card are ignored.) It is followed by data 
which defines or estimates the intercept and slope of the 
Nernstian equation for the glass electrode response to' free 
hydrogen ion concentration. v . .. . . ... . —
. ’ . E = EQ + slope. 'log[H+] ; i A-.- - ' •
The following keywords are recognised.
Keyword (in cols 
1-5 on cards 
following ’GLASS'
. Meaning ,
........ "■ ■ .
EZERO The standard emf of the glass electrode.
(i.e. the emf corresponding to log[H+] ~ 0.
SLOPE The gradient.of the Nernstian equation having 
log[H+] as the independent variable. .
TEMPC -• The temperature of the solution in celcius. 
Optional.•This value may be supplied instead 
of the slope .in which case a theoretical . .
gradient is calculated. Otherwise a ' • -
' * . ■ * '• . ' ' theoretical value is calculated only for .... f * - ,* ’.• t: • .. a j. t ♦ purposes of comparison. . . . - .
If 'TEMPC' is given instead of the slope it must be preceded 
by ’EZERO*. The signs of Eq and slope must, be the same.
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The general numerical format is as follows.
Integer field 
(cols 7-9)
- The digits ’1’ or *2’ in coluron 7 cauau 
. refinement of either EZERO or SLOPE by 
• program MAGEC in the same way as described
in Section 5. •
Real field - The value or best estimate for the glass
electrode parameter in columns 11 through 20,
• If required for MAGEC refinement, a lower
•' - ~ limit in cols 21-30 and an upper limit
• ’ ' - in cols 31 -40,
-r . • ■ ■ ■ ■; . f:'. . Js. i.1
• ' • ' *. •: • - ;j;> .
Section 8: Titration data ‘ r '-------------------------------- ----- -......- . ---- - ■ . r
Each set of titration data must be headed by a card on which 
one of the keywords ’ML/MV’ or ’ML/PH’ is punched, (The usual 
numerical fields on these cards are ignored.) The header is 
followed by a series of cards, one for each titration point, 
showing two ’’real numbers” without exponents and separated 
by a comma, .................... - ......
The keyword ’PIL/PIV’ indicates that the data which follows are 
pairs of millilitre and millivolt readings (in that order).- 
The keyword ’ML/PH-’ signifies that the pairs are millilitre 
and pH values.
The data are unformatted apart from the delimiting comma.
That is, the numbers may be positioned anywhere in columns 1-20 
with or without spacing. It is however advisable to keep the 
data in columns 1-10 ;whenever possible because this improves 
error diagnosis by the program. . . . . > - -
A set of titration data is terminated by- - .....—-------------
(a) the keyword ’FINIS1 (see Section 9) r;. •-*.
(b) the definition of a new titration in terms of different
component concentrations (see Section 6). This is • 
indicated by the keyword ’VESSLr . ■’
(c) the physical end of the data.
A maximum of 100 data points per titration may be entered.
As none of the main programs can accept more than 500 data 
points in total, program FORMAT also tests to determine whether 
this limit has been exceeded. . ’ ■.
Titre volumes must increase monotonically, Changes in emf must 
always be in the same sense. Program FORMAT will register a 
sequence error if either of these conditions is violated. 
Mispunched data is the .usual cause of this. ...........
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Section 9: Termination of input
Input to program FORMAT is properly terminated by a card on 
which the keyword ’FINIS’ has been punched* .
A digit in the first integer field (col.7) indicates that 
the main program should not be executed and that the 
intermediate data file should be printed* . - . •
• ! . -x «. * ’» * ...1 ».
i
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Section 10: Error diagnostic procedures
Program FORMAT will usually continue processing input data . 
after errors have been detected. Thus, remaining data is 
at least partially checked although execution of the main 
program is to be aborted. ’
When the program detects an error it usually ignores the 
card in question and proceeds to input the next one. If 
this generates a second error or the program finds itself out of 
sequence, the section number becomes ill-defined and all 
further data cards are rejected until a recognisable keyword •• 
is encountered. Obviously, no checking procedures can be 
applied to data uhich is ignored in this way.
The failure of program FORMAT to recover from an error in the 
data will in all probability have been caused by a transposition 
of the input card images. . •
It has previously been stated that the user must ensure 
compatibility between the system as defined for program FORMAT 
and that which can be accepted by the specified main program. 
Although certain checks are made, the consequences of this 
kind of error are unpredictable. If, however, such an .
incompatibility is detected one of the following codes will 
be generated by program FORMAT and execution of the main . .
program will be terminated. . •
Mode code Error
1 Burette concentrations are required but are not 
provided, . . '
2 The concentrations refer to titration data 
and not to equilibrium simulations
3 The concentrations refer to equilibrium simulation
and not to the processing of titration data “
10 The number of system components is incompatible
with the specified main program .
20 The attempt to refine a parameter is not •
permitted by the specified main program .
25 pKu cannot be refined by the specified main program
30 The number of titration data sets is incompatible
with the specified main program .
40 Two kinds of ligand are not permitted by the
specified main program •
45 More than 1 component is required by the . • -
specified main program . . '
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ZiO A value- for pKu is required by the specified
main program. No value is provided or the 
value is unreasonable (e.g. check tr.e sign)>
50 At least one formation constant is required to
be (nominally) refined by the specified main 
program '
55 A formation constant value required by the
specified main program has been omitted •
70 Dimension limits of the main program would bo
exceeded • • .....
81 The scan mode required by the user is not
. permitted by the specified main program
90 Total concentrations are required by the
• specified main program but free concentrations
have been provided •
95 The main program does not permit changes in 
NDP between one titration and another
96 The main program does not permit a different 
NDP for a ligand in the vessel and that in 
the burette
97 . MODE = 95 and MODE = 96 both apply ..
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Section 11: HINIQUAD
This program accepts potentiometric data to refine estimates 
of formation constants for any equilibrium system applicable 
to program FORMAT excepting strong acid versus strong base 
reactions. • •
Keywords MINIQ or MINI1 ; ; . ’ . ‘ .
***** • . . •
The program options are as follows.
IPROG cv., . •'
(Col 7) .
n - This digit corresponds to LARS in the main
program: it causes every nth point in each
. titration to be included inthe refinement. .
• The default is 1.
□PROG ' • .
(Col 9) , ' . . . ...
1 - Causes a species distribution to be evaluated
.. . for the given formation constants and conditions
2 - Gives maximum suppression of output
3 - Suppresses output from subroutine STATS only
4 - Generates STATS graphical output • •’
5 . - Sets the maximum number of iterations in the .
refinement cycle, MAXIT = 10
6 . - Sets MAXIT = 20 ; ' . •
7 - Sets MAXIT =40 ' . ' *
8 - Sets MAXIT =80 .
9 - Sets MAXIT =160 .
OPROG values between 5 and 9 should be unnecessary - use with 
caution. The default sets MAXIT = 50 when IPROG = 1 and 
MAXIT = 25 when IPROG 1.
The real number fields in cols 11-80 are ignored.
Miniquad reference: Talanta 1974, 21. 53 . .
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Section ,12: MINI,QUAD (75)
This program accepts potentiometric data to refine estiniatta. 
of formation constants for any equilibrium system applicable 
to program FORMAT excepting strong acid versus strong base 
reactions.
Keyword: MINI2 -
The program options are the same as those for MINI1.
Miniquad (75) reference: Inorg.Chim.Acta 1976, 18, 237.
Section 13: SCOGS
This program accepts potentiometric data to refine estimates 
of formation constants for any equilibrium system applicable 
to program FORMAT excepting strong acid versus strong base 
reactions. .
Keyword: SCOGS ‘ • •* •' - ;
The program options are as follows.
XPROG ‘ \
(Col 7) * ri ' ‘ v '
n - This digit corresponds to LARS in the main
program; it causes every nth point in each 
titration to be included in the refinement. 
The. default is 1.
jprog :: . • . . > . . ...r'
(Col 9) ••• bf ’ •
n - This digit gives the number cycles to be
calculated by the program (i.e. the number of 
cycles to be refined + 1). The default is 6.
A value of 1, therefore, causes a species 
distribution to be evaluated for the given
'■■ ■ formation constants andconditions.
A value of 2 causes one cycle of refinement 
and soon. • • •
The other data fields are ignored. , .
SCOGS reference: Talanta 1968, 15, 1397
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Section 14: COMICS
This program calculates the equilibrium concentrations of 
all species in solutions of metals and ligands at specified 
pH values. The total concentrations of the metal and ligand(s) 
must be provided for program FORMAT as well as the formation 
constant for each complex.
Keyword: COMIC
- •’ ; i t :
Tharg fflo program options.
COMICS reference: Talanta, 1967, 14, 833
Section 13: PSEUDOPLOT , • •
This program calculates the equilibrium distribution of species 
in solutions of ligands and metal ions. It is primarily used 
to simulate titrations of such systems and to treat the 
simulated data to a ZPLOT analysis. Comparison of the 
PSEUDOPLOT with the experimental ZPLOT curves provides a 
stringent test of the formation constants selected to represent 
theequilibriainsolution.
Keyword: PPLOT
The program options are as follows.
IPROG V . 3 *•' '?*, \ ’ / •
(coi 7) '•...... . <•, ‘ -
n This digit corresponds to LARS in the MINIQUAD program:
it causes every nth point in each titration to be 
included in the refinement. The default is 1 and 
IPROG=1 is used to include every odd point rather than 
every even one as would result from IPROG=2.
. •. • d ■; ?• -• . •• .
JPROG
(Col 9) ' •• : ■
n This digit controls the number of graphs to be drawn.
With n=0 all titration curves are superimposed on one 
graph. With n=l individual plots of each curve are drawn.
GRAPH , h t f... Ar. ? v*./r -1-1 ’
(Cols 11-20,
21-30,21-40 etc. ..<• ;
a,b,c,d,e , f,g These seven parameters initiate the plotting routine 
and control the size of the graph.
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a=maximum value for pA (or pH) ••
b=Minimum value for pA (or pH) •
c=Length of pA (or pHD axis in cms (thesis size=22cn'
d=Maximum value for Z, .
e=Minimum value for Z
f=Length of T axis in cms (thesis size=14cm) 
g=size of characters on the plot in inches
(use 0.14 usually and 0.07 for smaller graphs) 
PSEUDOPLOT reference: J . C.S.Dalton, 1975, 105. . .... '
/ r
Section 16: • ZPLOT .... J
This program calculates the 1 function from experimental 
titration data. If there is no metal present in the solution 
curves of versus pH are generated (values of the protonation 
constants are not required for the calculation but dummy values 
should nevertheless be provided for program FORMAT.) ~
If there is metal present in the solution, curves of Z versus pH 
are produced (Values for the protonation constants are required 
and dummy values foi? some metal formation constants should also 
be provided.)
Keyword: ZPLOT . . , , ; . ■ t ■ : '
The program options are identical to those for PSEUDOPLOT except 
that JPROG (Col 9) is ignored.
ZPLOT reference: Rossot'ti , H . S . The Study of Ionic Equilibria, 
Longman, London, (1978) p.53. • • .
Section 17: Dummy program
Section 18: ECCLES
This program calculates the equilibrium concentrations of all 
species in solutions of metals and ligands. The total or free 
concentrations of the components must be provided. Any such 
concentration can be scanned upwards from the initial value. 
Keyword: ECCLS . • . . . • ■
There are no program options. . . •
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ECCLES reference: J.C.S.Dalton , 1977 , 5Q8.
• , *
Section 19: MAGEC
This program accepts potentiometric data for any equilibrium 
system applicable to program FORMAT excepting those which 
involve a metal ion. The primary use of this program is to 
optimise for the electrode parameters and equilibrium constants 
applicable to the system simultaneously. . It can also be used 
to refine the concentrations of components in solution. ' 
Keyword: MAGEC • '
The program options are as follows’.
IPROG . • .
(Col 7) " ’ ‘ \
n This digit corresponds to LARS in the • MINIQUAD program
it causes every nth point in each titration to be 
included in the refinement. The default is 1 and 
IPROG=1 is used to include every odd point rather than 
every even one that would result from IPROG=2.
JPROG 
(Col 9)
n This digit specifies which of the titration data sets
is to be prepared for program MAGEC. The default is 
to process all the data sets.
MAGEC reference: unpublished
FLOW DIAGRAM FOR PROGRAM FORMAT '
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Variable initialisation
Input the name 
of the program for u/hich 
data is to be prepared -
Input the set of 
formation constants
Input the
concentration data
Input.glass electrode 
parameters
Input titration data
Output data 
for program selected
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PROGRAM FORMAT
rj
oo
oo
oo
r>
<~
» o 
o o o 
r>
DEVELOPED AT THE UNIVERSITY OF WALES INSTITUTE OF 
SCIENCE AND ■
TECHNOLOGY DURING 1978, - •
THIS PROGRAM TRANSFORMS DATA PREPARED ACCORDING TO’ 
A STANDARD
FORMAT INTO THE PARTICULAR FORMAT REQUIRED BY THE 
MINIOUAD,
SCOGS, PSEUDOPLOT, ZPLOT, COMICS, ECCLES AND MAGEC 
COMPUTER
PROGRAMS. . ’
THE PROGRAM IS WRITTEN IN FORTRAN IV, -
SECTION ONE: STORAGE ALLOCATION AND FORMAT
STATEMENTS,
INTEGER 
INTEGER
INTEGER
INTEGER 
DIMENSION
DIMENSION 
DIMENSION
DOUBLE PRECISION X, Y
PROGRM, OUTF, OUT, SEXHUN, ERROR ’ 
TITLEC18), SPECIE<5), MATRIX(4,3)» 
REFINE(30) . ■
JQR(4r20), NDPVC2), NDPB(2), LlT<40>,
S I H N (4)
ALPHAC26), NUMBERdO), IDCHEk<20)
VALUEC3), VZEROC3), EZEROC3), SLOPEC3) 
CONCC4)
BETA(3,20), CV(3,4), CB(3,4), GRAPH(7) 
TITREC1OO), EMFC1OO)
*
DATA IDCHEK /’
TW*
1 ’ AC•r ' HA’
2 ’XXXX’,'XXXX ’ 
C
C ■
PM’,’ DW'r' 13’,
JD’,’ KQ’,’ CJ
XXXX ’ , 'XXXX’,’XXXX
CF’ , ’ BT’ , ’
G S ’ r ' G K ’ 
XXXX' , ’XXXX'
i
I
DATA LIT /
1 ’ECCL',
2 'CONC*,
' ' , ’ M I N I
'NEWP', 
’MAGE’,'CHEC
’BURE’ , 
'GIAS * , 'MLZ'M
‘•LIG1 • ,
SCOG’
TITL'
ML/P’
’ COMI’ , 'PPlO','ZPLO', 
’BETA' , ’ LBET’,’VESS', 
' $CNP*,'INIT',’AC I D ’ ,
389,
3 • MET U 'LIG2', ’EZER'SLOP','TEMP'XXXXFINI»
’ H * 1 ' ,
4 '0H~1*, 'XXXX*, 'XXXX', 'XXXX*,'XXXX',’XXXX', 'XXXX'
’ X X X X ’ r ’ X X X X 1 /
DATA NUMBER / ' 1 ' , ' 2 ’ , • 3 ’ , ' 4 ' , • 5 ' , ' 6 * , ’ 7 ' , ’ 8 ' , ' 9 ' , 
'O' /
DATA SIHN / ' ’ /
DATA MATRIX / 2,4,3,1,Z,3,1,0,2,1,0,0 /
DATA ALPHA / • A* , ' B* , ' C ’ ,’D’,'E’,'F','G','H’,’I',
’ J ' , ’ K ’ , ’ I. ’ ,
1 » M * , ' N ' , ‘ 0 ' , ’ P ' , ' Q.» , ’ R ' , ' S ’ , ’ T ' , ' U ' , » V ' , ' W ' , ’ X
' Y* , 'Z' /
C
C THE PARAMETER VARIABLES
C
IN = 5 
OUT = 6 
OUTF = 7 
MAXPTS = 100 
MAXTOT = 500
C
C THE FORMAT STATEMENTS
C
1 0301 FORMAT<A4,A1,1X,11,I2,1X,7G1O,3)
10401 FORMAT<A4,A1,3X,18A4)
10511 FORMAT(5A1, 1X,11,3X,7G1O,3)
10611 FORMAT(A4,A1,1X,I1,1X,A1,1X,7G10.3)
20000 FORMAT(18A4)
21201.FORMAT(16I5)
21211 FORMATCF10.6,715)
21221 FORMAT(8F10,6)
21222 FORMAT(I 5,8F8.3) • '
21311 FORMAT(40I2)
21321 FORMAT(5 I 2,F8,4)
21325 F0RMATC10f3„4)
21331 FORMAT(I 2,F10,3)
21342 FORMAT(5F10w6,2F10•3)
21340 FORMATC18A4,1X,'EXPT’,13)
21351 FORMAT<2F10„3,4X,II)
21411 FORMAT(21 I 2,8X,F8,4)
21412- F0RMATC2I2,13)
21430 FORMAT (1 Of'8,6)
21452 FORMAT(F10 • 4, 11 )
21511 F0RMATC25I3)
21531 FORMAT<7F10,4)
21534 FORMAT(13F6,3)
21542 FORMAT(13,E11,4)
21 550' F0RMAT( I 3,2X, ’SIMULATION DATA PRODUCED BY PROGRAM 
FORMAT')
21552 FORMAT<6E11,4)
21530 FORMAT(13,2X»'TITRAT I ON DATA PRODUCED BY PROGRAM 
FORMAT')
21802 FORMATC’A SMALL EQUILIBRIUM SYSTEM’,/
1 'DATA PREPARED BY PROGRAM FORMAT’)
21803 FORMAT(’FALSE’)
5
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21 805 
21806 
21810 
2181 2 
21815 
21830 
21835 
21820 
21901
21921
21922 
30000
30001
30002
30003
30004
30005 
30100
FORMAT(’TRUE’,2X,A4,1P2E10,4)
FORMAT!»MULTIPLY 1)
FORMAT!'TOTAL CONCENTRATIONS')
FORMATCA4,1X,1PE1O»4)
FORMAT('END')
FORMAT!'SPECIES CONSTANTS')
FORMAT(F9.4,1X,5 ! A4,I3,2X>)
FORMATC'FREE CONCENTRATIONS’)
FORMAT<*PK’,A1,2X,I1,4X,1P3E10»3)
FORMAT! 3A1, 2X,11, 4 X , 1 P3 E1 0.3 )
FORMAT(’LG'tA1,2X,11,1X, 11,2X,1P3E10,3)
FORMAT!////////'0*,15X,35!1H*), 8X»'THE 
END’,8X,35!1H*),//////)
FORMAT!'O')
FORMAT!’0’, ’OUTPUT TO THE INTERMEDIATE DATA FILE’) 
FORMAT!»0'OUTPUT TO THE MAIN PROGRAM (',11,').
COMPLETED.')
FORMAT!'O',I5,2X, 'TITRATION DATA POINTS IN TOTAL') 
FORMAT!'O','OUTPUT TO THE MAIN TO BE DELETED.') 
FORMAT('1',/'0',5!1H*),6X,3(1H*),6X,4(1H*),6x,1H*,
3X,1H*,
5
4
30101
30102 
30201 
30304
30330
30331
30332
30333
30334
30335
30336
30337
30338
30339
30350
30351 
30360 
30450 
30460
30521
30541
30545
A
6X,3(1H*),6X,5(1H*),/' ’,1H*,9X,2(1H*,3X,1H*, 
5X) ,
2(2<1H*),1X),4X,1H*,3X,1H*,7X,1H*,/' ’ , 
4(1H*),6X,2!1H*,3X),2X,4!1H*),6X,3<1H*»1X),4X, 
5(1H*),7X,1H*,/' ',1H*,9X,2!1H*,3X),2X,1H*,2X, 
1H*,6X,2!2(1H*,3X)»2X),2X,1H*,/' ' ,
1 H * < 1 0 X » 3 (1 H *) ,6X,1H*,3X,1H*,2!2X, 2(3X,1H*)) , 
7X,1H*,/»
55(1H«),///////)
FORMAT!//’O','SECTION',13,/' ' ,10(1H-),/)
FORMAT!' ', 'EXECUTION COMMENCED’)
FORMAT!' 'PROGRAM INITIALISED')
','DATA PREPARATION FOR PROGRAM:')
+ ' ,3OX, 'MIN I QUAD')
+ ' ,3OX, ' MIN I QUAD(75)')
+ ' ,3OX, ’SCOGS’ )
►' ,30X, ’ COMICS' )
+ ' ,3OX, 'PSEUDOPLOT')
+ ' ,3OX, 'ZPLOT')
+ ' ,3QX, ’UNKNOWN’)
+’,30X, ’ECCLES’)
+’,30X,’MAGEC')
+ ’ ,3OX, ’ FORMAT ONLY’)
O', ’PROGRAM OPTIONS;’,3X,214)
0 ’ , ’NO PROGRAM OPTIONS’)
O', ’GRAPH OPTIONS;',3X,7(1pE15„4))
» , 'THE TITLE IS: ' ,2X,18A4,/)
0’ ,20!1H*),5X,’I DENT IFI CATION 
ERROR’ ,5X,20(1H*),/)
0 ’ , ’ LOGARITHM ERROR')
’, ’THERE ARE’,12,’ COMPONENTS',/)
O', 'UNRECOGNISABLE CHARACTER USED IN 
DEFINING THE SPECIES;
FORMAT! 
FORMAT! 
FORMAT! 
FORMAT! 
FORMAT! 
FORMAT! 
FORMAT! 
FORMAT! 
FORMAT( 
FORMAT! 
FORMAT( 
FORMAT! 
FORMAT! 
FORMAT! 
FORMAT! 
FORMAT!
FORMAT ! 
FORMAT! 
FORMAT!
1 ',5A1)
39.1
30555 FORMATC'O 
30565 FORMATC’O 
30567 FORMATC'O
•MISPLACED 
’INCORRECT 
• FORMATION 
represent
SIGN* )
NUMBER OF COMPONENTS’ 
CONSTANTS’, 13, ’ AND* 
DUPLIC
13,
1ATED SPECIES’)
30570 FORMATC 'FORMATION CONSTANT LOG VALUE ~',F8.3,’ 
FOR SPECIES’,
1 2X,5A1,2X,'TO BE ' )
30572 FORMATC85X,’WITH LIMITS',F8.3,» AND *,F8,3)
30573 FORMATC' + ’,67X,’REFINED’)
30574 FORMAT('*’,67XHELD CONSTANT')
30581 FORMATC’ ','FORMATION CONSTANT ERROR ON CARD 
NUMBER’,14)
30591 FORMATC’O’,'NO- FORMATION CONSTANT DATA 
PROVIDED,',//)
30593 FORMATC'O',’WATER DISSOCIATION CONSTANT DUPLICATED') 
30596 FORMATC’0’, 'UNREASONABLE ACID ASSOCIATION CONSTANT’) 
30598 FORMATC'O','NO PROTONATIQN CONSTANTS PROVIDED.',/) 
30605 FORMATC'O','CONCENTRATION DATA PROBABLY STARTED
PREMATURELY')
30 609 FORMATC ’,74X,5 C1H-),3X,A 4,A1,1X,'INPUT',3X,5C1H-)) 
3061 0 FORMATC* + ',1O8X,'STARTS AT CARD NO,’,14)
3061 1 FORMATC 'REFINE THE VALUE FOR ',A4,A1)
30612 FORMATC' + ',30X,’BETWEEN THE LIMITS',1PE12.4, '
AND ’ , 1P E12.4)
30613 FORMATC’0’,'THE ESTIMATE DOES NOT LIE BETWEEN THE
LOWER AND UPPER
1LIMITS, WHICH MUST BE SPECIFIED IN THAT ORDER,')
30614 FORMATC ','SCAN THE VALUE FOR ',A4,A1)
30622 FORMATC ','THE INITIAL VOLUME IN THE VESSEL
IS;',l-7.2)
30631 FORMATC'O','NO FORMATION CONSTANT DATA FOR 
COMPONENT’,1X,A4)
30634 FORMATC'O','MISSING COMPONENT1X,A4)
30636 FORMATC0NO COMPONENTS IN VESSEL AND/OR BURETTE') 
30639 FORMATC’OTHERE IS NO VALUE FOR THE INITIAL VOLUME
IN THE VESSEL')
30644 FORMAT C'0',38x,A4,4X,1PE15,4)
30645 FORMATC+ ’ ,30X, 'FREE')
30646 FORMATC'*’,30X,’TOTAL')
30648 FORMATC///'OTHE EQUILIBRIUM CONCENTRATIONS ARE TO
BE CALCULATED',/
1 ’ ','AT EACH OF THE FOLLOWING NEGATIVE LOG
VALUES FOR ' , A4,///)
30649 FORMATC ' , 3 0 X , F1 0., 3 )
30650 FORMATC///'0','THE COMPONENT CONCENTRATIONS
ARE:',//’O',
1 26X,4<A4,11X)>
30651 FORMATC/ ’ 0',1 OX, ’VESSEL ' ,4X,4(1PE15,4))
3 0652 FORMATC ’0 ' , 10x, ’ BURETTE ’ ,3X,4 C1 PE1 5.'4) )
30655 FORMATC’O’.,A4,A1 , ’ INPUT DATA DUPLICATED')
30656 FORMATC'0PARITY CHECK ON 5TH LETTER OF KEYWORD
FAILS')
30658 FORMATC'O', 'UNREASONABLE VALUE PROVIDED FOR ',A4,A1>
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30661
30662
30663 
30666
30670
30671 
30722
30733
30740
30745
30750
30752
30801
30802 
30850
30855
30870
30872
30880
30881
30882
FORMAT!» ','THE NUMBER OF DISSOCIABLE PROTONS FROM 
* » A A »
1 ' IN THE VESSEL!’,13)
FORMAT(’0NOP COLUMN IS BLANK’) .
FORMAT!'0'INVALID NDP ENTRY FOR »,A4,A1)
FORMAT!’ ','THE NUMBER OF DISSOCIABLE PROTONS FROM 
*»A4,
1 ’ IN THE BURETTE;’, 13)
FORMAT!’O’,’ONLY ONE SCAN COMPONENT PERMITTED.’) 
FORMAT!’ ',A4,1X, 'HAS', I2,1X, 'DISSOCIABLE PROTONS’) 
FORMAT!’ ','THE INTERCEPT OF THE ELECTRODE RESPONSE 
• IS;’,F7.2)
FORMAT!' ',’THE SLOPE OF THE ELECTRODE RESPONSE 
IS:’,F7.2) •
FORMAT!’ ','THE TEMPERATURE IS;',F6,2,
1 ’ (USED TO CALCULATE THE NERNSTlAN SLOPE)').
FORMAT!’0TEMPERATURE MUST FOLLOW A VALUE FOR 
EZERO. ' ,//)
FORMAT!'O', ’GLASS ELECTRODE PARAMETER MISSING') 
FORMAT!' ',’ARBITARY POSITIVE VALUE SUPPLIED’,//) 
FORMAT!’O', 'TITRATION DATA INPUT BEGINS.',
1 10X, 'TITRATION NUMBER', 13 ,//)
FORMAT!'O',1 OX,’CARD NO.',12X,'VOL,',5X,A4,A1,1) 
FORMAT!///'OTITRATION DATA STORAGE BUFFER CAPACITY 
EXCEEDED' ,////)
FORMAT!////’!)', 'SUBSEQUENT CARDS ARE IGNORED UNTIL 
A RECOGNISABLE
KEYWORD IS ENCOUNTERED',///) '
FORMAT!//'0TITRATION DATA INPUT COMPLETED;»,1 OX ,
1 13,» POINTS REGISTERED IN CORE,') ' '
FORMAT!'0',15, ’ DATA POINTS EXCEED THE PERMITTED 
LIMIT OF’,15,//) .
FORMAT!'O','POINT NUMBER',IA,3X»'!',F7,3,'
, ',F3.2, ' ) ' ,
1 ' CORRESPONDS TO AN UNREASONABLE PH
= ',1PE12.3, / / ) •
FORMAT!» + ',59X, ' , BUT NOT NECESSARILY IN ERROR,') 
FORMAT!'O’,'POINT NUMBER',IA,3X,'<•» F7.3, ♦
• ,',F8.2,» )',
1 ' IS OUT OF SEQUENCE')
FORMAT(' + ',99X,'CHECK THE PREVIOUS POINT.’)
FORMAT!’O','ASSUME THERE HAS BEEN A SWITCH IN 
DIRECTION ,,,’,//)
FORMAT!'O','PROBABLY DUE TO AN AN ERROR IN’# •
1 * THE FIRST AND/OR SECOND DATA POINT,')
FORMAT!'O','THE TITRATION DATA AND THE ELECTRODE 
PARAMETERS ARE IN ’
1COMPATIBLE ' ,///) 1 •
FORMAT!' ’,'ELECTRODE PARAMETERS PROBABLY IN 
♦ ERROR',//)
FORMAT!' ','INPUT TERMINATED')
FORMAT('0',»INCOMPLETE DATA CAUSES PROGRAM 
TERMINATION')
FORMAT!'O','WHERE? OH, WHERE IS YOUR INPUT DATA?’)
30883
30884
30885
30887
3038S
30901
31001
31002
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31010 FORMATC•0',A4,A1,2X,’IS AN UNRECOGNISABLE OR
MISPLACED KEYWORD’)
31011 FORMATC ’O’ , ’THE KEYWORD ENTRY IS BLANK’)
31051 FORMAT(’O’,’ERROR DETECTED ON CARD NUMBER',14)
31 052 FORMATC ' + ',70X, ’THE CARD IS IGNORED.’)
31077 FORMATC'0*,'SEQUENCE ERROR ON CARD NUMBER’,14)
31091 FORMATC/'O* ,’THE CURRENT’)
31092 FORMAT(/’0’,'THE FINAL')
31093 FORMATC,12X,'TOTAL FOR ERRORS DETECTED ON INPUT
53 ' , 13)
31 097 FORMATC 'CHAS PROVED IMPOSSIBLE.',/’
1 'AN UNSUITABLE SYSTEM HAS BEEN DEFINED,',/'
2 'MAIN PROGRAM EXECUTION IS TERMINATED,',/’ ',
3 'ERROR MODE CODE s',14)
31 099 FORMAT(///'0 *,' IF YOU HAD TO RELY ON THIS FOR A 
LIVING',/' »,
1 ’YOU WOULD SURELY STARVE!',///)
31901 FORMATC'O','TITRATION DATA SET IGNORED’)
C
C - '
WRITECOUT,30100)
SEXHUN a 1
WRITECOUT,30101) SEXHUN 
WRITECOUT,30102)
C
C
C
C SECTION TWO; INITIALISATION,-
C
c
SEXHUN a 2
WRITECOUT,30101) SEXHUN
ERROR a 0
NNN a 0
NFLAG » 0
NTITR a 0
ISCN ~ 0
IGRAPH a 0
IKW = 0
NP = 0
NPTOT = 0
MODE =0
NDPSTR = -1
SCNINC a 0,000
SCNMAX = 0,000
DO 201 1=1,20
DO 201 J=1,4
201-JQRCJ,I) = 0 
DO 202 1=1,4
202 CONCCI) = 0.000 
DO 205 1=1,30
205 REFINE(I) = -1 
WRITECOUT,30201)
C
C
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SECTION THREE; PROGRAM KEYWORDS.
300 SEXHUN » 3 
WRITECOUT,30101) SEXHUN
301 NNN = NNN + 1
READ(IN,10301,EN0=1000,ERR=1050) K E Y1 , KEY2, IVAL, 
JVAL, GRAPH
304 WRITECOUT,30304)
I = SEXHUN ~ 10 
IFCI.GT.0) ' GO TO 320 
DO -310 1=2,10
IFCKEY1 .EQ.LIT(I)) GO TO 320
310 CONTINUE 
GO TO 1010
320 PROGRM = I
IPROG = IVAL 
JPROG = JVAL
GO TO (331,331,332,333,334,335,336,337,338,339), 
PROGRM
331 I FCKEY2.EQ.NUMBER(1).OR.KEY2.EQ.ALPHA(17)>
PROGRM = 1
I F(PROGRM.EQ.1) WR I TE(OUT,30330)
I F (PROGRM. EQ.2) WR I T E ( O'J T , 3 03 31 )
I F( I PROG.GT.1) MAXTOT = MAXTOT * IPROG 
GO TO 350
332 WRITECOUT,30332)
GO TO 350
333 WRITE(OUT,30333)
GO TO 350
334 WRITECOUT,30334)
GO TO 350
335 WRITE(OUT,30335>
GO TO 350
336 WRITECOUT,30336)
GO TO 350
337 WRITECOUT,30337)
GO TO 350
338 WRITECOUT,30338)
GO TO 350
339 WRITECOUT,30339)
350 I F (SEXHUN.GT.4) GO TO 1092
IF(IPRQG +J PROG.EQ.0) GO TO 351 
WRITECOUT,30350) IPROG, JPROG 
GO TO 352
351 WRITECOUT,30351)
352 DO 353 1=1,7
I F (GRAPH(I).GT.0.000) GO TO 360
353 CONTINUE 
GO TO 400
360 WRITECOUT,30360) GRAPH 
IGRAPH = 1
C
3,9-5
r*
 o
 o
 e~>
 
r»
 
00
00
0
SECTION FOUR: -T.ITLE KEYWORD,
400 SEXHUN a 4 
WRITECOUT,30101) SEXHUN
401 NNN = NNN +1
READCIN,10401,END=1OOO,ERR=1O5O) KEY1 , KEY2, TITLE 
I F ( KEY1 ,NE,LIT (11 ) > GO TO 1010 
WRITECOUT,30450) TITLE
DO 450 1=1,20
IFCTITLEC18) ,EQ. IDCHEKC I)) ‘GO TO 500 
450 CONTINUE
ERROR a ERROR + 1 ■ ‘
WRITECOUT,30460)
SECTION FIVE; FORMATION CONSTANTS.
C
C
500 SEXHUN 5
WRITECOUT,30101) SEXHUN
501 NNN = NNN + 1
READ (IN,1 0301,END=1000,ERR=1050) KEY1, KEY 2
IF(KEY1 ,NE.LIT(12),AND.KEY1,NE•L I T (13 ) ) GO TO 1010 
505 NS = 0
NC = «1 •
NREF = 0 
C
510 NS a NS + 1
NEWERR = ERROR
511 NNN = NNN +1
READ (IN , 10511,END = 1 000, ERR = 580) SPECIE, IVAL,
VALUE
I F (SPECIE <1 > .EQ.AIPI1AC22) .OR.SPECIEC1 ).EG>, ALPHA <3)) 
GO TO 590
REFINE(NS) = IVAL 
C
C LOAD THE FORMATION CONSTANTS, TAKING LOGS IF
NECESSARY,
C
520 IFCKEY1 .EO.LITC13)) 00 TO 525
IFCVALUEC1).GT.0,000) GO TO 522
521 WRITECOUT,30521)
KEY1 = LITC13)
GO TO 580
522 VALUE(1) a ALOG10(VALUEC1))
IFCIVAL.NE.2) GO TO 525
I FCVALUEC2) .LE.0.000.OR.VALUEC3).LE.O.OOO)
GO TO 521
VALUEC2) = AL0G10CVALUEC2))
VALUEC3) = ALOG10CVALUEC3))
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IF(VALUE<1!).GE.VAlUE(2).AND.VALUE<1), LE.VALUE<3 )) 
GO TO 525 ’
WR I TE(OUT,30613)
ERROR a ERROR + 1
525 DO 526 1=1,3 • •
526 BETACI,NS) = VALUE(I) .
SET NC » NUMBER OF COMPONENTS.. *
530 IF(NC<GT.O> GO TO 540 " '
DO 535 NC = 1,5 . .
I F(SPECIE(NC) .EQ,SlHN(1)) GO TO 538 ‘
535 CONTINUE
NC a 6 . •
538 NC = NC « 2 • '
IFCNC.GE.1 ) GO TO 539
NC = -1 
GO TO 565
539 IF(SPECIE(NC).EQ.SIHN(2).OR.SPECIE(NC) . Eq . SIH N(3))
NC * NC - 1
NC « NC * 1
N = 5 ~ NC ■■
WRITE(OUT,30541) NC
IF(NC • GT ■ 1•AND.NC . LT.5) GO TO 540 .
WR I TE(OUT,30565)
ERROR a ERROR +1 
IFCNC.LT.2) NC - 2 
IF(NC.GT,4) NC »• 4
LOAD THE JQR MATRIX WITH SPECIES’ COMPONENT ' 
MULTIPLICITIES,
540 I = 0 - •
M a 1
K = 0
543 I ~ I + 1
IF(SPECIE(I).EQ.SIHN(1),OR.I„EQ.,6) GO TO 560 
I F(SPEC IE(I).EQ,SIHN(2)) GO TO 555 •
IF(SPECIE(I).EQ,SIHN(3)) GO TO 550 .
DO 545 J=1,10
•IF(SPEC IE(I)•EQ•NUMBER (J ) ) GO TO 548
545 CONTINUE '
IFCNEWERR.GT.ERROR) GO TO 1055 
NEWERR = ERROR + 2
WRITECO’JT, 30545 ) SPECIE 
GO TO 580
548 K 3 K + 1
'IF(K.GT.NC) GO TO 565 
L = MATRIX<K,N)
I F(J .EQ.10) J = 0 - .
JQR(L,NS) => J * M ' .
GO TO 543 .
MAKE THE HYDROGEN ION MULTIPLICITY NEGATIVE.
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550 M - "1
555 IFCI,EQ,NC) GO TO 543 '
WRITECOUT,30555)
GO TO 530
CHECK THE NUMBER OF COMPONENTS IN THE SPECIES,
560 IF(K.EQ.NC) GO TO 566 •
565 WRITECOUT,30565)
IFCNS.EC).2-OR.NEWERR.GT.ERROR) NC = -1 
NEWERR s NEWERR + 2 .
GO TO 580 •
CHECK FOR SPECIES DUPLICATION, .
566 IFCNS.EQ.1) GO TO 570 
JVAL = NS - 1
DO 568 I~1,JVAL
DO 567 L-1,NC .
IF(JQR(l» I),NE.JGR(L,NS>) GO TO 568 ''
567 CONTINUE
ERROR = ERROR + 1 •
WRITECOUT,30567) I, NS *
568 CONTINUE
PRINT THE FORMATION CONSTANT, .
570 WRITECOUT,30570) BETA(I.NS), CSPECIECD, 1=1,5) 
•IFCJQR(1,NS).EQ.-1,AND.JQRC2,NS).EQ.O.AND.JQRC3,
NS).EQ.O
1 .AND,JOR(4,NS).EQ.O) IKW = IKW * NS 
IFCIVAL-1) 574, 573, 572 • ’
572 WRITECOUT,30572) BETAC2,NS), BETAC3,NS) ‘
573 WRITECOUT,30573)
NREF = NREF + 1 
GO TO 510
574 WRITECOUT,30574)
GO TO 510 .
ERROR DETECTED AMONGST THE FORMATION CONSTANTS,
580 ERROR » ERROR + 1
WRITECOUT,30581) NNN 
IFCERROR,GT,20) GO TO 1090 
GO TO 511
TEST FOR STRONG ACID Z STRONG BASE TITRATION,
590 NS = NS — 1
IFCNS.EQ.1.AND.J ORC2,1) .EG•0,AND.NC»EQ.2) NC = 1 
IFCNC.GT.O) GO TO 593 
ERROR = ERROR + 2 
WRITECOUT,30591) '
593 IFCIKW.IE.NS’) GO TO 594 
WRITECOUT,30593)
398
oo
r»
oo
o 
•<
“>
<-
>
ERROR a ERROR +1
594 PKW = 14-00
IFCIKW.LT,1) GO TO 600 
PKW = -BETA(1,IKW)
TEST FOR PROTONATION CONSTANTS.
M = 0
IFCNC.LE-1.OR.NC.GT.3) GO TO 600 
DO 598 1=1,NS
IF(I.EQ.1KW.GR.CNC*EQ.3„AND.JQRC3,I).NE.O)>
'GO TO 598
IFCM.LT.-900) GO TO 596 
M = M + 1
I FCBETAC1»I)*jQR<1»I)•GT•0»000001 ) GO TO 598 
IFCM.NE.1) GO TO 596 
M = -1000
GO TO 598 .
596 ERROR a ERROR + 1
IFCM.LT.-900) M = -500 
WRITECOUT,30596)
598 CONTINUE
IFCM.NE.,0) GO TO 600 
ERROR = ERROR + 1 
WRITECOUT,30598)
SECTION SIX: CONCENTRATION DATA,
600 SEXHUN = 6
WRITECOUT,30101) SEXHUN 
NEWERR = ERROR
DO 602 1=21,30
602 REFINEC I) = -1 
DO 603 1=1,3 
VZEROCI) = 0.000 
EZEROCI) = 0.000 
SLOPECl) = 0.000 
DO 603 J=1,4 
CVCI, J) = 0.000
603 CBCI,J) = 0.000 
DO 604 1=1,2 
NDPVCI) = -1
604 NDPBCI) = -1 
EMFC1) = 0.000 
EMFC2) = 0.000 
KEY1 = LITC1)
IFCSPECIEC1 ).EQ.ALPHAC22)-AND.SPECIEC2).EQ.ALPHAC5) 
.AND,SPEC I EC3)
1 .EQ,ALPHA(19),AND.$PECIEC4).EQ,ALPHAC19)>
K E Y1 = L I T (1 4 )
IFCSPECIEC1 ).EQ.ALPHA(3).AM 0,SPECIEC2), EQ , ALPHAC15) 
• AN0 • SPEC IEC3)
399
1 »EQ,ALPHAC14) , AND,SPEC IE(4). EQ,ALPHA(3)> 
KEY1 = LIT(16)
605 MODE = -1
606
607
608 
609
O
O
O
C
JO
O
O
C
JC
JO
O
O
O
O
tU
O
O
IFCKEY1 •EQ,LITC14)) MODE 
I F(KEY1 .EQ.LITC15)) MODE 
I F(KEY1 .EQ.L1TC16)) MODE 
IFCMODE-2) 606, 607, 608 
K = ALPHAC12)
IF(MODE,GT•0) GO TO 609 
WRITECOUT,30605)
K = ALPHAC20)
GO TO 609 
K = ALPHA(19)
1
2
3
WRITECOUT, 30609) KEY1 , K •
WRITECOUT, 30610) NNN
REFINEMENT KEY
' A
j
REFINEC1) - RE FI NEC 20) FOR BETA
REFINEC21 ) FOR VZERO :-
REFINEC22) FOR ACIDV OR ACIDT/ACIDF 5
REFINEC23) FOR L I G1 V OR LIG1T/LIG1F J
REFINEC24) FOR METLV OR METLT/METLF
REFINEC25) FOR LIG2V OR LIG2T/LIG2F X
REF I NEC 26) FOR AC I DB
REFINEC27) FOR LIG1B
REFINEC28) FOR METLB
REFINEC29) FOR LIG2B OR EZERO i
REFINEC30) FOR TEMP OR SLOPE ■if
610 NNN = NNN + 1
READ(IN,10611,END=659,ERR=65?) KEY1 , KEY?, IVAl, 
JVAL, VALUE
IFCIVAL.E0.1.0R.IVAL.EQ.2) WRITECOUT,30611)
KEY1, KEY2
IFCIVAL.EQ.3.OR.IVAL.EQ.4) WRITE(OUT,30614)
KEY1, KEY2
DO 611 1-1,9
IF(JVAL , EQ•NUMBERCI)> GO TO 612
611 CONTINUE 
1 = 0
IF(JVAL.EQ,NUMOER(1O)) GO TO 612 
I = -*1
I F C J V A L • N E • S I H N C1 )) GO TO 663
612 JVAL ~ I 
. K - 0
IF(IVAL.NE,2 ) GO TO 613 
WRITECOUT,30612) VALUEC2), VALUEC3)
IFCVALUEC1) . GE, VALUE(2)wAND•VALUE<1),LE.VALUE(3))
GO TO 613 
WRITECOUT,30613)
ERROR s ERROR +1 '
613 I FCKEY1 .NE. LITC22) • AND,VALUEC1)•LT.1,0E”20) K = 1
400
614
615
618
DO 615 1=22,25
IF(KEY1,EQ.LIT (I) )
CONTINUE
IF(M0DE-2)
J = I *21 
IFIK.EQ.1)
I F(MODE-2)
GO TO 618
620, 630, 640
GO TO 658 
660, 665, 670
r»
oo
 
oo
oo
oo
oo
 
oo
o
LOAD THE VALUE FOR THE INITIAL VOLUME.
620 I F ( K E Y1 . N E . LI T ( 21 )) GO TO 625
IF(K.EQ,1) GO TO 658 '
IF<KEY2.NE.ALPHA(22)) GO TO 656 
I F ( R E F I N E ( 21 ) • N E ,-1 ) GO TO 655
• DO 621 1=1,3
621 VZERO(I) = VALUE(I)
REFINEC21) = IVAL
WRITE(OUT,30622) VZER0(1)
GO TO 610
625 I F ( K E Y1 , N E • LI T (1 5 ) ) GO TO 1010 
MODE = 2 • •
GO TO 607
TITRATION MODE EXIT CHECKING PROCEDURES.
CHECK THAT THERE ARE NOT TOO MANY COMPONENTS,
630 I F(ERROR•GT•0.AND.ERROR»NE»NEWERR) GO TO 650
WRITE(OUT,30609) LIT(10), ALPHA(11)
I F(KEY1 . NE.LIT(17).AND.KEY1.NE.LIT(18> 
.AND.KEY1 ,NE,LIT(19))
1 GO TO 1010 
IF(NC-3) 631, 632, 634
631 IF(NC.EQ.I) GO TO 637
IFCNC.LT.1.AND.RE FINE(23)+REFINE(27).NE.-2)
WRI TE(OUT,30631 )LIT(23 )
IF(REFINE(24)+REFINE(28),EQ.-2«0R.NC.EQ,2)
GO TO 632
ERROR « ERROR + 1 
NC * 3
WRITECOUT,30631 ) L I T(24)
632 lF(REFlNE(25)+REFINE(29).EQ.-2) GO TO 635 
ERROR s ERROR + 1
NC = 4
.WRITECOUT,30631 ) LI T(25)
. CHECK THAT THERE ARE NOT TOO FEW COMPONENTS.
634 I F ( R E F I N E ( 2 5 )-»■ R E F I N E ( 29 ) ,GT.~2) GO TO 635 
ERROR = ERROR + 1 
WRITE(OUT.30634) LIT(25)
401
63 5 IFCNC.EQ.2.0R,REFINEC24)+REFINEC28).GT,«2)
GO TO 636
ERROR s ERROR + 1 
WRITECOUT,30634) LITC24)
636 I F < RE F I NE C 23 )+RE FI NE < 27). GT • •*2) GO TO 637 
error a error + 1
WRITECOUT,30634) LITC23)
C
C CHECK THAT THE COMPONENTS EXIST IN REALISTIC
CONCENTRATIONS,
C
637 SUMV = -1.OE-18 
SUMB = -1.OE-18 
DO 638 1=1,NC
SUMV = SUMV + ASSCCVC1 , I))
638 SUMB = SUMB + ABS C C0 C1 , I) )’
IFCSUMV.GT.0.000,AND.SUMB.GT.0,000) GO TO 639 
ERROR a ERROR + 1
WRITECOUT,30636)
CHECK THAT THE INITIAL VOLUME IS KNOWN,
639 IFCREFTNEC2D.NE.-1) GO TO 650 
WRITECOUT,30639)
ERROR = ERROR * 1 
GO TO 650
<-
> o
 n
 o
 
<-
» r»
SIMULATION MODE EXIT PROCEDURES,
C
C DEAL WITH SCNPH OR SCNPA. CEMF = -LOG(CONC))
C
C
640 I FCKEY1,EQ.LITC30)) GO TO 643 
IFCKEY1,NE.LIT(20)) GO TO 1010 
IFCISCN.NE.O) GO TO 671 
IVAL = 0 .
I F C K E-Y2 , EO , A LPH A C 8) ) IVAL = 1 
IFCKEY2,E0,ALPHA(1)) IVAL - 2 
IFCIVAL,EQ,O) GO TO 656 
J = IVAL + 21
IFCREFJNE(J).NE.-1.AND„REFINECJ).NE.10> GO TO 671 
REFINECJ) = 10 
NP = NP + 1 
EMFCNP) = VALUEC1)
GO TO 610
C
643 IFCISCN.NE.O) GO TO 645
IF(REFINEC22) . EQ . 10) ISCN = 1 
IFCREFINEC23) .EQ.10) ISCN = 2 
IFC ISCN.E.Q.0) GO TO 645 
A = -EMFC1)
CONCCISCN) = 10,000 ** A
402
C
C
PRINT OUT THE CONCENTRATION DATA (SIMULATIONS).
645 NFLAG = 2 • •
DO 647 1 = 1 ,NC
J a I 4- 21
WRITECOUT,30644) LIT(J), CONCCI)
IFCREFINE(J),EQ.1> GO TO 646 
WRITECOUT,30645) ■
GO TO 647
646 WRITECOUT,30646)
647 CONTINUE
IFCNP.LE.1 )‘ GO TO 900 
J = ISCN ♦ 21
WRITECOUT,30648) 1.1 T ( J ) '
DO 649 1=1,NP
649 WRITECOUT,30649) EMFCI)
GO TO 900
C
c
c
PRINT OUT THE CONCENTRATION DATA (TITRATIONS).
650 K = NC + 21
WRITECOUT,30650) 
WRITECOUT,30651) 
WRITECOUT,30652) 
WRITECOUT,30001) 
GO TO 700
(LITCI), 1=22,K) 
(CV(1,I), 1=1,NC) 
(CBC1 , I) , 1=1,NC)
no
n 
rs
 o
 o
ERRORS DETECTED IN THE CONCENTRATION DATA.
655 WRITECOUT,30655) KEY1 , KEY2 
GO TO 657
656 WRITECOUT,30656)
657 ERROR = ERROR + 1 
WRITECOUT,31051 ) NNN 
WRITECOUT,30001)
GO TO 610
658 K = 0
WRITECOUT,30658) KEY1, KEY2 
ERROR = ERROR + 1 
GO TO 614
659 IF(MODE.EQ .3) GO TO 645 
GO TO 1000
SET CONCENTRATION VALUES FOR THE TITRATION.
660 I FCKEY2.NE.ALPHAC22)) GO TO 656
IF(REFINECI).NE."1) GO TO 655 
REFINE(I) a IVAL ' -
DO 661 1=1,3
661 CV(I,J) = VALUECI)
IF(J.NE,2.AND.J.NE.4) GO TO 610 
IF(J V AL.IT.0) GO TO 662 
4 = J / 2
NDPVCJ) = JVAL
WRITECOUT,30661) KEY1, JVAL '
403
GO TO 610
662 WRITECOUT,30662)
663 WRITECOUT,30663) KEY1, KEY2 
GO TO 657
665 I = I + 4 .
IFCKEY2.NE.ALPHAC2) ) GO TO 656 
IFCREFINEC I ),NE.~1) GO TO 655 
REFINE(I) “ IVAL
00 666 I«1 ,3
666 COCI, J) ~ VALUECI) ‘
IF(J.NE .2.AND , J•NE»4) .GO TO 610 • 
IFCJVAL.LT.O) GO TO 662 
J “ J / 2
NDPBCJ) ~ JVAL*
* WRITECOUT,30666) KEY1, JVAL 
GO TO 610 . *
C
C SET CONCENTRATION VALUES FOR THE EQUILIBRIUM
DISTRIBUTION CALC. .*
C
670 IFCREFINECI).NE,«1) GO TO 655 
CONCCJ) = VALUEC1)
IFCIVAL • EG•0) GO TO 673 
IFCISCN.EQ.O) GO TO 672
671 WRITECOUT,30670) .
GO TO 657
672 IFCIVAL.GT.O) ISCN = J 
IFCIVAL.EQ.4) ISCN s -J 
SCNMAX = VALUEC2)
SCNINC = VALUEC3)
IVAL ~ 0 .
673 IFCKEY2.EO.ALPHAC20)) IVAL = 1 
IFCKEY2•EQ.ALPHA(6)) IVAL « 2 
IFCIVAL.EO.O) GO TO 656
REF I NEC I) 5 IVAL •
IFCJ.NE.2.AND,J.NE.4) GO TO 610 
J - J / 2'
NDPVCJ) « JVAL
WRITECOUT,30671) KEY1, JVAL
GO TO 610 .
r>
 o
 o
 o
 <->
 f~>
SECTION SEVEN; GLASS ELECTRODE PARAMETERS.
700 IFCKEY1 .NE.LITC17)) GO TO 800 .
: SEXHUN a 7
WRITECOUT,30101) SEXHUN .
710 NNN « NNN •+ 1
READCIN, 1 0301 , END = 1 000 , ERR = 1 050 ) KEY1, KEY2, IV.AL, 
JVAL, VALUE
IFCIVAL.GT.O) WRITECOUT,30611) KEY1, KEY2 
IF(I VAL•EQ.2) WRITECOUT,30612) VALUEC2), VALUE<3>
404
DO 715 1=26,28
I F ( K E Y1 • E Q • LI T (I) ) 60 TO 718
715 CONTINUE . .
IF<KEY1,EQ.LITC18) .0R.KEY1 ,EQ„LITC19)) -GO TO 750 
GO TO 1010
718 IFCI-27) 720, 730, 740
719 ERROR = ERROR +1
WRITECOUT,30655) KEY1, KEY2 
WRITECOUT,31051) NNN 
GO TO 710
720 IF(REFINEC29).NE„~1) GO TO 719 
REFINE(29) a IVAL
DO 722 1=1,3
722 EZERO(I) = VALUE(I)
WRITECOUT,30722) VALUEd)
GO TO 710
730 I F ( RE F I NE C30) • NE ,-1 ) GO TO 719 
REFINEC30) = IVAL 
DO 733 1=1,3
733 SLOPECD = VALUECI)
WRITECOUT, 30733) VALUEd)
GO TO 710
740 WRITECOUT, 30740) VALUEd)
IF(REFINE(29).LT.0) EZEROC1) = 400.0 
DO 741 1=1,3
741 VALUECI)’ = SI GN(CCVALUECI)+273.15)*0w1984161), ,
EZER0C1))
KEY1 = LIT <27)
KEY2 = ALPHAC5)
I FCREFIMEC29),GT,~1) GO TO 730 
WRITECOUT,30745)
WRITECOUT,30752)
ERROR a ERROR + 1 
GO TO 730
750 IFCREFINEC29)„GT.-1,AND.REFINEC30)„GT,-1) GO TO 800 
WRITECOUT,30750)
ERROR = ERROR + 1
IFCREFINEC29)wLT»0) EZER0C1) = 400.0 
IFCREFINEC30).LT.0) SLOPECD = 5 IGN(60,0 , EZER0C1)) 
WRITECOUT,30752)
o 
o 
<*
i o
 o
SECTION EIGHT; TITRATION DATA INPUT,
800 SEXHUN = 8 
WRITECOUT,30101) SEXHUN
801 NP = 0 
K = 1
405
o 
o 
o
IFCIPR0G.EQ.1> K = 0 
I = IPROG
IFCI PROG•EQ • 1> L « 2 
NTITR a NTITR + 1 
WRITECOUT,30301) NTITR 
WRITECOUT,30802) KEY1 , KEY2 
NEWERR = ERROR + 1 
NFLAG = 0 •
GO TO 803
802 IFCNEWERR.EO, ERROR) GO TO 855 
ERROR = ERROR + 1 
IF(ERROR,GT, 20) GO TO 1090 
NFLAG = 0
803 NNN = NNN + 1 
K « K + 1
CALL FREED(X,Y,NNN,NF LAG,I N , OUT»NUMBER 
ALPHAC22) ,SPECIE)
IFCNFLAG) 802, 804, 870
804 NEWERR = ERROR +2
805 IF<I PROG■EQ,0) GO TO 806 
IFCMODCK,L) ,NE,O) GO TO 803
806 NP « NP + 1
IF(MAXPTS-NP+1) 803, 350, 807
807 TITRECNP) = X 
EMFCNP) = Y 
GO TO 303
ERROR PROCESSOR,
850 WRITECOUT,30850)
ERROR = ERROR + 1 
GO TO 803
855 WRITECOUT,30855)
ERROR = ERROR + 1
856 READCIN,10301,END=1000,ERR=1050) KEY1 
DO 857 1=2,30
IFCKEY1.EQ.LITCI)) GO TO 1060
857 CONTINUE 
GO TO 856
C
C TITRATION DATA CHECKING PROCEDURES,
C
870 IFCNP.GT.MAXPTS) NP s MAXPTS 
WRITECOUT,30870) NP 
K = 0
NPTOT = NPTOT + NP 
IFCNPTOT.LE.MAXTOT) GO TO 872 
WRITECOUT,30372) NPTOT, MAXTOT 
ERROR = ERROR + 1
■NPTOT a -100000
872 IFCKEY1 ,EQ,LITC18)) GO TO 880 
DO 875 1-1,NP
875 EMF(I) = EZER0C1) - SL0PEC1) * EMFCI)
I
ALPHAC6).,
KEY2
380 DO 881 1=1,NP
406;
A = (EZER0C1) » EMFCl)) / SE0PEC1)
IFCA.GT.-1.0.AND.A.IT,15,0) .GO TO 881 
WRITECOUT,30830) I, TITRECI), EMF(I), A 
ERROR = ERROR + 1
IF(I,EQ„1 ) GO TO 888 
K « K + 1 '
IFCK.GT.3) GO TO 1090
881 CONTINUE
A = EMF(2) - EMFC1) •
B » EMFC1) , .
C = 0.00
0 - 0,00 ' .
NEWERR a 0 
K = 0
DO 886 1=2,NP' ■
I FCTITRE(I).LT,TITRE<1-1)> GO TO 882 
B « E M F ( I ) - B
IF(A*B.GT.0.00000) GO TO 884 
• IF(I.NE,NEWERR+1.0R.ABS<C).GT.20.0.0R„AB5(D)
.GT.20.0) GO TO 882 
WRITECOUT,30881)
GO TO 883 ■
882 JFCK.GE.2) ERROR = ERROR * K
K = 0 '
ERROR a ERROR * 1 
I F C ERROR • GT , 20 ) GO .TO 1090
883 WRITECOUT,30882) I, TITRECI), EMFCl) 
IF(ABS(D).GT.20.O) WRITE(OUT,30883)
C = B
NEWERR a I 
K = K + 1
IFCK.EQ.2) ERROR = ERROR - 1 •
I F(K•LT.5.AND•I.NE.NP) GO TO 886 .
IFCK.LT.4) GO TO 884
WRITECOUT,30881)
NEWERR a 0 
WRITECOUT,30884)
A = ™A ’
IFCI.GT.K+2) GO TO 885 . '
WRITECOUT,30885) '
QO TO 1090 •
884 JFCK.GE.2) ERROR = ERROR + K 
IFCERROR.GT.20) GO TO 1090
885 K ~ 0 .
D =’ C
C = 0.00
886 B = EMFCl)
00 887 1=2,NC
I FCCBC1,I).GT.0,000) GO TO 889 
837 CONTINUE
A = CEZER0C1) - EMFC1)) / SLQPEC1)
A « (EZER0C1) - EMFC2)) / SLOPED) -A 
I F ( A*CB (1 , 1 ) • LT • 0.00 )■ GO TO 839 
WRITECOUT,30887)
ERROR a ERROR + 1 <
407
O
 <~i 
Ci
 
Cl
 O
 Ci Ci 
Ci
 
Ci
 O
 Ci
 Ci
 Ci
GO TO 889 •.
888 WRITECOUT,30888)
8S9 IFCNFLAG.NE.2) GO TO 1090
section nine: input termination.’
900 SEXHUN - 9
WRITECOUT,30101) SEXHUN 
WRITECOUT,30901 )
GO TO 1090 •
SECTION TEN: ERROR DIAGNOSTIC PROCEDURES.
1000 SEXHUN s 10
WRITECOUT,31001)
IFCNNN.EQ.1) WRITECOUT,31 002)
ERROR » ERROR + 1
1002 NFLAG x 2 
GO TO '1091
1010 IFCKEY1 .EQ.LITC1)) GO TO 1011 
WRITECOUT,31010) KEY1 , KEY2 
GO TO 1050
1011 WRITECOUT,31011)
ATTEMPT TO RE-ESTABLISH THE DATA SEQUENCE.
1050 NEWERR * ERROR
IFCNN.N.LE.2.AND.ERROR.GE.1.AND.CKEY1.EQ,LIT(12) 
.0R.KEY1.EQ.LITC13)
1)) GO TO 505
1051 ERROR = ERROR + 1 
WRITECOUT,31051) NNN 
IFCNNN.EQ.1) GO TO 400 
IFCERROR.GT.20) GO TO 1090 
IFCKEY1.NE.HTCD) GO TO 1060
1055 NNN = NNN + 1
READCIN,10301,END=1002,ERR~1050) KEY1, KEY2, IVAL 
JVAL, VALUE
WRITECOUT,.31 052)
1060 DO 1061 1x2,29
I F(KEY1 .EQ.LIT(I)) GO TO 1070
1061 CONTINUE
IFCKEY1 .EQ.LITC30)) GO TO 1093 
NEWERR a NEWERR + 1 
IFCERROR.EQ.NEWERR) GO TO 1055 
WRITECOUT,31010) KEY1 , KEY2 
KEY1 = LITC1)
GO TO 105.1
408
1070 IFCSEXHUN.GT.10) GO TO 1050 
WRITECOUT,30001)
GO TO (1071,1071,1071,1072,1073,1074,1075,1076,1077,
1077), SEXHUN
1071 KEY1 = LITC1)
1072 IFCI.LE.10) GO TO 400
1073 IFCI.EQ.11) GO TO 500
1074 IFCI.LE.13) GO TO 505
1075 IF(X.LE.16) GO TO 605
1076 IFCI.EQ.17) GO TO 71.0
1077 IFCI.LE.19) GO TO 800
IFCI-21) 640 620,, 1078
1078 IFd.LE.25) GO TO 618
I F( I . LE , 23) GO TO 718 
WRITECOUT,3(077) NNN 
NEWERR = NEWERR + 1 
GO TO 1055
C
C END OF INPUT* OUTPUT ERROR COUNT,
C
1090 SEXHUN =10
1091 WRITECOUT,30101) SEXHUN
I F(NFLAG.EQ.1) WRITE(OUT,31091)
IFCNFLAG.NE.1) WRITE(OUT,31092)
WRITECOUT,31093) ERROR
IFCERRQR.EQ.O.AND,PROGRM,LT.10) GO TO 1095 
IF(ERROR,GT.20) GO TO 1093 
IFCNFLAG.NE.2) GO TO 600 
IF(ERROR.GT,5) WRITE(OUT,31099)
GO TO 1093
C
1092 WRITECOUT,31097) MODE
1093 PROGRM = 10
IF(NT I TR . GT.1) GO TO 9999 
WRITECOUT,30000)
CALE EXIT(IO)
STOP
C
1095 GO TOC1100,1200,1300,1400,1500,1600,1700,1800,1900), 
PROGRM
oo
or
»o
o oooo
oo
SECTION ELEVEN; MINIQUADC74)
1100 SEXHUN = 11 
GO TO 1201
SECTION TWELVE; MlNlQUAD(75)
409
1200
1201
SEXHUN = 12
WRITE(OUT,30101 ) SEXHUN 
IFCNC.EQ.1) ' MODE = 10 
IFCPKW.LT.10.00) MODE = 48 
IF(NREF,LT.1.ANP,JPROG,NE,1) 
I F(MODE . NE , 2) GO TO 304 
WRITECOUT,30002)
DO 1202 1=1,2
MODE = 50
1202
IFCNDPVCD.EO.
I FCNDPB( I) .EQ, 
CONTINUE 
IFCNTITR.GT.1 )
I = 25 
J = NC - 1 
K = 1
M = 2 .
IFCJPR0G.E0.1 )
IFCJPR0G.EQ.2)
L = K
I FCJ PROG . EQ . 3) 
IFCJPR0G.EQ.4) 
NEWERR = IPROG 
I F C NEWE.RR . LE , 0) 
IF(NEWERR . EQ , 1) 
IFCJPR0G.LT.5)
I = 5
1) NDPVCI) = 
1) NDPBC I) =
GO TO 1220
I * 0 
K = 0
L = 0
M = NC + 1
NEWERR = 1 
1 = 1*2
GO TO 1208
0
0
1206
1208
DO 1206 N=5,JPR0G 
1 = 1*2
C
WRITECOUTF,20000) TITLE
NEWERR a 1
WRITECOUTF,21201) NEWERR, NS, NREF, I, 
CL, N=1,M)
K., NC, J,
1210
C
1220
C
DO 1210 1=1,NS
J = I FIX(BETAC1 , I ))
A = 10,000 ** CBETAC1,!) - FLOAT(J))
WRITECOUTF’,21211 ) A, J, (JQR(L,I), L = 2,NC>,
JQRC1 , I) , REFINECI)
A = SLOPED). . •
IFCA.LT,0.0000) A = -A 
A = A / 0,1984161 - 273.15
CVC1 ,1) = CVC1 ,1 ) + CVC1,2) * NDPV(1) + CV(1 ,4) * 
NDPVC2)
WRITECOUTF, 21221 ) VZER0C1), A, CCVdrl), 1=2,NC), 
C V (1 ,1 )
J = 1
WRITECOUTF,21222) J, EZER0C1), SLOPED)
IFCPR0GRM.EQ.2) WRITECOUTF, 21 222) J
CD (1,1) = CBC1,1) * CD(1,2) * NDPB(I) + CB(1,4) *
• . NDPBC2)
WRITECOUTF,21221 ) CCBC1, I), 1=2,NC), CB(1,1)
IF(NPTOT*(NC-1)•LE.1200) GO TO 1230
MODE = 70
410
GO TO 304
1230 NP = NP ~ 1 
J = 0
DO 1235 1=1,MP
1235 WRIT£(OUTF,21222) J, TITRE(I), EMF(I)
NP = NP + 1 
J = 1
IF(NFLAG•EQ.2) J » -1 •
WRITECOUTF,21222) J, TITRE(Np), EMF(Np) 
IF(NFLAG.FQ•1 ) GO TO 600 
I F(PR0GRM.EQ.2) GO TO 1239 
J = 2
1F<J PROG•EQ•3) J = 1 
I F (J PROG , EO, 4). 1 = 4
M = NC * 1
WRITECOUTF,21201) J, Mr <K, K=1,M)
1239 J = -1
IF(PR0GRM,E0.1) WRITECOUTF,21222) J 
IFCPROGRM.EQ„2) WRITE ( OUTFr21311) J 
GO TO 9999
r»
 <->
 o
 o
 o 
o
SECTION THIRTEEN: SCOGS
1300 SEXHUN = 13 
WRITECOUT,30101) SEXHUN 
IF(NC.EQ.I) MODE = 10 
IFCIKW.EQ.O) MODE « 48
I F(NREF , LT.1 . AND. JPRQG.NE, 1) MODE = 50 
CALL COPNDPCNDPSTR,MODE,NDPVrNDPB)
I F(MODE.NE,2) GO TO 304
WRITECOUT,30002)
1301 IFCNTITR.GT.1) GO TO 1340 
I - 1
WRITECOUTF,21311) I 
WRITECOUTF,21311 ) I
1305 1=19
WRITECOUTF,21311) I 
1 = 2
J = 1
K = NS - 1
IFCNC-3) 1311, 1312, 1313
1311 J = 0
1312 I = 1
1313 WRITECOUTF,21311) I, J, K
A = 0,000 
B = 1 .000 
K = 0
DO 1322 1=1,NS 
J = -JQRC1,I)
IF(IKW,EQ.I) GO TO 1321
411
WRITECOUTF,21321) J ORC2,I), JQRC4,I), 
J, BETAC1,I)
60 TO 1322
1321 A = BETA <1, I )
M » I
1322 CONTINUE
IFCA.LT.-10.0Q.AND.REFINECM).EQ.O) go 
.mode » 4 8
IFCREFINECM).EQ.O) MODE = 25 
END FILE OUTF 
WRITECOUT,30001)
GO TO 304
1325 WRITECOUTF,21325) A, B 
1=5
• I FCJPROG.NE.O) I = JPROG - 1 
WRITECOUTF,21311) I, NREF 
A = 0.0005
DO 1331 1=1,NS
I F<RE FI NEC I) .EQ.O) GO TO 1331 
J « I •
J 0 R C 3 , I) , K
TO 1325
IFCI.GT.M) J = I •» 1
WRITECOUTF,21331) J , A
1331 CONTINUE
WRITECOUTF,21311) NDPVC1), NDPVC2)
1340 WRITECOUTF,21340) TITLE, NTITR.
A = 0.000
WRITECOUTF,21342) CVC1,3), A, CVC1r2)
CVC1, 1),
1 VZER0C1)
WRITECOUTF,21342) CBC1 ,3), A, CBC1,2)
C B < 1 , 1 ) ,
C V C1 , 4) ,
CBC1 ,4) ,
n 
o o
 r> 
r»
 n
1 EZER0C1), SL0PEC1)
J = 0
K = NP - 1 
DO 1351 1=1,K
1351 WRITECOUTF,21351) TITRE(I), EMF(I), J 
J = 1
IFCNFLAG.EQ • 2) J = 9
WRITECOUTF,21351) TITRECNP), EMF(NP)r 
IFCNFLAG.EQ „ 1) GO TO.600 
GO TO 9999
SECTION FOURTEEN: . COMICS
1400 SEXHUN = 14
WRITECOUT,30101) SEXHUN
■ IFCNC.EQ.1) MODE = 10 
IFCPKW.LT.1.0,00) MODE = 48 
IFCNS.LT.1) MODE = 55 
IFCMODE.N'E.3) GO TO 304 
DO 1405 1=2,NC
1 « I + 21
412
1405
1411
1412
1413
1421
1425
I F C R E F I N E C J ) • N E • 1 ) MODE - 90
CONTINUE
I F(MODE . NE ■ 3 ) GO TO 304
WRITE(OUT,30002)
1 = 1
WR I TE(OUTF,21411 ) I
WRITECOUTF,20000) TITLE
1 = 2
J = 1
IFCNC-3) 1411 , 1412, 1413
J = 0
1 = 1-
WRITECOUTF,21412) I, J, NS •
DO 1421 1=1,18 '
TITLE(I) = 0
K = 0 '
DO 1425 1=1,NS
TITLEC8) = JQR.C3, I)
TITLE (.18) = -JQRC1 , I)
WRITECOUTF,21411) JQRC2U), JQR(4,I)r K 
BETA(1,I)
TITLE,
1451
1452 
1455
WRITECOUTF,21430) 
WRITECOUTF,21430)
K = 0
IFCNP.GT-1) GO TO 
IF(NP,LT,1) EMFC1) 
NP = 1
GO TO 1455 
J = NP - 1 
DO 1452 1=1,J 
WRITECOUTF,21452)
K = 1
WRITECOUTF,21452)
GO TO 9999
CONCC2), C0NCC4) 
CONC(3)
1451
= *ALOG10(CONC (1 ))
EMFCI), K
EMFCNP), K
O O «J O <J o
SECTION FIFTEEN;. PSEUDOPLOT
1500 SEXHUN =15 •
WRITECOUT,30101 ) SEXHUN 
IFCNC.EQ.1) MODE = 10 
IF(NTITR-GT.0.AND.NC.EQ.4) MODE = 40 
IFCNC.LE.1) MODE = 45
IF(IKW.EQ.0.OR•PKW•LT.10»00 ) MODE = 48 
IFCNS.LT.2) MODE = 55 
CALL COPNDP(NDPSTR,MODE,NDPV,NDPB) 
IFCMODE.EQ.1.OR.MODE.GT.3) GO TO 304 
WRITECOUT,30002)
I FCNT I TR . GT . 1) GO TO 1580 
1=0
J = 1
413
r>
 o
 o
 
o 
<-
> 
<1
 <->
 r>
WRITECOUTF,21511) I, I 
WRITECOUTF,20000) TITLE
GRAPH OPTION
IFCIGRAPH.EO.0) GO TO 1520 
K = 3
IFCNC.EQ.3) K « 2
WRITECOUTF,21511) I# Ir Jr K 
K = 1 •
I F C'J PROG • EQ. 1 ) K « NTITR 
M « NC + 2 ' ■
L = M + 1 •
WRITECOUTF,2151.1) K, L, M, I, I 
WRITECOUTF,21221) GRAPH
1 520 WRITECOUTF,21511 ) NC, NS •
IFCNC.EQ.4) J = 2 
IFCNC.GE.3) 1 = 1 .
K = 1 • . '
L = 0 -
WRITECOUTF,21511) J, I, K, NDPVC1), L, NDPVC2)
WRITECOUTF,21531> 
A n -1,000 .
B = 0,000 
WRITECOUTF,21534) 
00 1535 1=1,NS
BETAC1,IKW)
A, B, 8, B
1531
1532
1533
1534
1535
IFCI.EQ.IKW) GO TO 1535 
WRITE C0UTF,21531) BETAC1rI) 
C « 0,000
0 = 0,000
IFCNC-3) 1534, 1533, 1532 
C = FLOATCJQR<4,1) >
D = FL0ATCJQRC3,I))
GO TO 1534 
C = FL0ATCJQRC3, I))
A = FLOATCJQRC1, I ) )
B = FL0ATCJ0RC2,I)) .
WRITECOUTF,21 534.) A, B, C, 0 
CONTINUE •
I = 0
WRITECOUTF,21511 ) I
IFCNTITR.GT.O) GO TO 1570
OUTPUT FOR SIMULATIONS.
I « NS + NC 
WRITECOUTF,21511 ) I.
K = 1
00 1 54V 1=1 , NS
1541 WRITECOUTF,21511) I, K 
K a 2 • .
J a -1
WRITECOUTF,21511) J, K
414
'S-
1542
1543
o 
r>
 o
 
rj
 o o
1544
1545
1546
1548
1550
1551
1552
1553
1554
1555
1557
K 1 • ■
DO 1542 1=2,NC
J = J ~ 1
WRITECOUTF,21511) J, K
I * NP
IFCI.EQ.O) I = 1
A ~ 0,40
WRITECOUTF,21542) I, A
GENERATE AND STORE THE BUR NUMBERS FOR EACH 
COMPONENT,
DO 1548 1=1,NC
J = I + 21
K = REFINECj)
IFCK.NE.2) GO TO 1545
K = 5 • *
CONCCI) = A LOG 10CCONCCI))
IFCIABS(I$CN).NE.I.OR.NP.GT„O.OR.ClSCN,LT,O.AND.K, 
EQ.1),0R,
(I SCN , GT . 0 , AND . K , EQ . 5)) GO TO <548
COMPONENT SATISFIES SCAN CONDITIONS,
K s: K + 1
IFCK.NE.6) GO TO 1546
SCNINC ss ALOG10CSCNINC)
SCNMAX = AL0G10CSCNMAX)
A = CSCNMAX - CONCCI)) / SCNINC 
M = IFIXCA * 1.0001 )
REFINECJ) 3 K
WRITECOUTF,21550)
A = -4.00 '
B = 1,00E~6 
DO 1555 1=1,NC 
L = I
J 3 E + 21 
WRITECOUTF,21511)
I F CREF I NE ( J ) .GE.5). 
WRITECOUTF,21552) 
WRITECOUTF,21552) 
GO TO 1554 
WRITECOUTF,21552) 
IF(REFINECJ).EQ.6) 
IFCL.NE.2.OR.NC.NE 
-L = 4
GO TO 1551 
CONTINUE 
NP 3 NP - 1 
IFCNP.LT.1 ) GO TO 
DO 1557 1=1,NP 
J 3 I + 1 
EMFCI) = EMFCJ)
M
REFINECJ)
GO TO 1553
A, -8
CONCCL), SCNINC
CONCCL)
WRITECOUTF,21552) 
4) GO TO 1555
SCNINC
1559
‘415
n 
r>
 a
 n
 
o 
o 
o
1559
1570
1571
157?
1573
1 580
1 581
1 599
A » " E M F (1 )
CONCCISCN) s 10,000 ** A 
60 TO 1550 
I = **1
WRITECOUTF,21511) I, I
GO TO 1599 .
OUTPUT FOR TITRATION .PSEUDOPLOTS 
I = NS + NC*2 + 3
WRITECOUTF,21511)
J » 0 
K « 0
WRITECOUTF,21511 )
K — 2
DO 1571 1=1,NC 
J = -1
WRITECOUTF,21511)
K = 10 
J ~ -1
IFCNC-EQ.3) J ® - 
WRITECOUTF,21511)
K = 11
WRITECOUTF,21511)
K = 4
DO 1572 1-1,NC 
J = «I
WRITECOUTF,21511)
K = 1
DO 1 573 .1=1 ,N$ 
WRITECOUTF,21511)
A = 0.40 
I = 19
WRITECOUTF,21 542) 
WRITECOUTF,21580)
A = -4,00 
B « 1.00E-6 
■J = 4
CVC1,1) = CV C1,1 ) 
CBC1 ,1 ) = C B <1 ,1 ) 
DO 1581 1=1 ,NC 
WRITECOUTF,21511)- 
WRITECOUTF,21552) 
WRITECOUTF,21552) 
WRITECOUTF,21552) 
WRITECOUTF,21534)
IF(NFLAG•EQ , 1) GO 
I = -1
WRITECOUTF,21511)
.CONTINUE
GO TO 9999
I
J t K
J , K
J, K
1, K
J , K
I< K
I, A
NP
CVC1 ,2) * NDPVC1) 
C B C1 ,2) * NDPBC1 )
•J
A, B
CVC1,I), CBC1,I) 
VZEROC1)
CTITRECI), 1=1,NP) 
TO 600
I, I
SECTION SIXTEEN ZPLOT
416
C ‘ •
C
1 600 SEXHUN a 16
WRITE(OUT,30101) SEXHUN 
I F(NC . GT • 3»OR , NC , EQ . 1) MODE - 10 
IFCIKW.EQ.0) MODE a 48 .
CALL COPNDP(NDPSTR»MODE,NDPV,NDPB) 
I F(MODE»NE•2) GO TO 304 
WRITECOUT,30002)
I F(NT ITR . GT.1) GO TO 1340 
WRITECQUTF,21311) IGRAPH '
GRAPH OPTIONS HERE, ' .
A = 0.000 • 1
WRITECQUTF,21221) A, GRAPH 
GO TO 1305 . 1
n 
n 
n 
o 
o 
o 
n 
o 
n 
o 
n 
n 
oo
o
SECTION SEVENTEEN; NEW PROGRAM
1700 SEXHUN. a 17
WRITECOUT,30101) SEXHUN 
I F(MODE . NE.2) GO TO 304 
WRITECOUT,30002)
GO TO 9999
SECTION EIGHTEEN: ECCLES
1800 SEXHUN s 18 .
WRITECOUT,30101) SEXHUN 
IFCNC.EQ.1) MODE = 10 
IFCIKW.EO.0) MODE a 48 •
I F ( NS . LT . 1 ) MODE = 55
IF(REFINE(22)+REFINE (23 ) • GT.6) MODE a 81 
IFCMGDE•NE,3) GO TO 304 .
WRITECOUT,30002)
WRITECQUTF,20000) TITLE 
WRITECQUTF,21802) ■
WRITECQUTF,21803)
LITC22) « LITC31) .
JVAL a 0
IFCISCN) 1801, 1809, 1805
1801 JVAL = 1
• ISCN » -ISCN '
1805 ISCN = ISCN + 21 '
WRITECQUTF,21805 ) LITCISCN), SCNINC, SCNMAX 
IFCJVAL.EO.1) WR I TECOUTF,21806)
GO TO 1810 • .
417
1809 WRITECOUTF,21803)
C
1810 WRITECOUTF,21810) .
JVAE a 0
J = 21 ■
DO 1815 1=1,NC 
J = J + 1
IFCREFINECJ ) .EQ,1) WRITECOUTF, 21812)
LIT(J)« CONCCI)
IFCREFINECJ) „EQ„2) JVAl = 1 
1815 CONTINUE
WRITECOUTF,21815) . •
C . •
IF(JVAL.EQ.O) GO TO 1830 .
. WRITECOUTF,21820)
J « 21 . •
DO 1821 1=1,NC ' -
J - J * 1
IFCREFINECJ ) ,EQ. 2) W R I T E C OUT F , 2.1 81 2 )'
• EIT(J), CONCCI) • ■
1821 CONTINUE - -
DO 1823 1=1,NS
IFCJQRC1 , I) .IT.0.AND.UNE.IKW) GO TO 1825 
1823 CONTINUE
GO TO 1828
1825 A = 1,0 / C10.00 ** PKW * C0NCC1))
WRITECOUTF,21812) LITC32), A •
1328 WRITECOUTF,21815)
C
1 830 WRITECOUTF,21830) -
DO 1838 1=1,NS
1F<I„EQ„IKW) GO TO 1838 *
1832 K = 0
DO 1833 J=2,NC -
IF<JQR(J,I) . EQ , 0) GO TO 1833 
K = K + 2
TITLECK-1) = UTCj+21) •
TITLECK) = JQRCJ , I)
1833 CONTINUE •
IFCJQRC1, I).EQwO) GO TO 1835
K = K + 2 •
TITLECK-1) = LITC31 ) '
TITLECK) = J0RC1 ,D
1835 WRITECOUTF,21835) BETAC1,1), (TITLE(J), J=1,K) 
1338 CONTINUE
GO TO 9999 *
O
 O
 <-
><
-»
 O
 <">
SECTION NINETEEN; MAGEC
1900 SEXHUN =• 19
WRITECOUT,30101) SEXHUN
■
■'I
418
IF(J PROG•EQ.0.OR„NT I TR • GE •J PROG.OR„NFLAG„NE.1)
GO TO 1901
WRITECOUT,31901 )
GO TO 600
1901 IFCNC.GT.2) MODE = 10
IFCIKW„EQ.0.OR.PKW.LT•10.00) MODE = 48 
IF(MOPE.NE .2) GO TO 304
WRITECOUT,30002)
WRITECOUTF,20000) TITLE ,
DO 1905 1-1,3
1905 VALUED) * ’-BETA CI , I KW)
WRITECOUTF,21901) ALPHA(23),REFINECIKW),VALUEC1) ,.
VALUE(3),VALUE(2)
N = NS ~ 1
1911 IFCN.Eo.O) GO TO 1920 
K * 0
A = 0,000
DO 1912 J=1,NS
IFCJ0RC1 , J) „EQ.N) K * J
I FCJQRC1»J) .EQ.N«1) A * BETAC1,J)
1912 CONTINUE
IFCK.EO.O) GO TO 1915 
VALUED) * RETAD, K) - A 
VALUEC-2) = 0.000
VALUEC3) * 0,000
IFCREFINECK)-NE.2) GO TO 1913
VALUEC2) = VALUECD - CBETAC1,K) - BETAC2,K))
VALUEC3) = VALUECD + (BETAC3,K) - B£TAC1,K))
1913 L = NS - N
•WRITECOUTF,21901 ) NUMBERCL), REFINECK), VALUE 
N = N 1 
GO TO 1911
1915 MODE a 58
ENDFILE OUTF 
GO TO 304
1920 DO 1921 1*21,30 
IFCREFINECD.LT.0) REFINEC I) = 0
1921 CONTINUE
IFCNC.EQ.1) NDPVC1) = 0 
IFCNDPVCD.EQ.-1) NDPVC1) * NDPBC1)
I FCNDPBC1)-EQ.-1) NDPBC1) = NDPVC1)
•WRITECOUTF,21921 ) ' ALPHAC22), ALPHAC26), ALPHAC15), 
REFINE C21 ) ,
1 VZERO
WRITECOUTF,21921 ) ALPHAC8), 3IHNC2) , ALPHAC22), 
REFINEC22),
1 CCVCl,1), 1*1,3)
WRITECOUTF,21922) ALPHAC22), REFINEC23), NDPVC1), 
CCVCI,2), 1=1,3)
WRITECOUTF,21921 ) ALPHAC8), SIHNC2), ALPHAC2), 
REFINEC26),
1 CCB(I,1), 1*1,3)
WRITECOUTF,21922) AIPHAC2), REFINE<27), NDPBC1), 
CCBCI,2), 1=1,3)
419
WRITECOUTF,21921) ALPHA<5), ALPHAC26), ALPHA Cl 5), 
REFINEC29),
1 EZERO
WRITECOUTF,21921) ALPHAC19), ALPHAC12), ALPHAC16), 
REFINEC30) ,
1 SLOPE 
DO 1931 1 = 1 ,NP
1931 WRITECQUTF,21351) TITRECI), EMF(I)
A « -1,000
WRITECOUTF,21351) A
I FCJ PROG■EO•0,AND.NFLAG,EQ,1) GO TO 600 '
O
O
O
 
O
 O
 O
| 
oo
oo
o
THE END.
9999 ENDFILE OlJTF
WRITECOUT,30003) PROGRM 
I FCNPTOT-GT.0) WRITECOUT,30004) NPTQT 
IFCPRQGRM.EQ.1O) WR I TECOUT, 30005)
WRITECOUT,30000)
IFCKCY1 .EQ,LITC3O),AND.IVAL,NE,O) PROGRM « 11 
CALL EXITCPROGRM)
STOP • •
END
SUBROUTINE freedcx,y,n,nflag,in,out,digit,lfinis, 
. LVESSL,SPECIE)
C
DOUBLE PRECISION X, Y
INTEGER CARDC80), NUMBERC10), DIGITC10), LIT<5), 
OUT, SPECIEC5).
LOGICAL'NE6, FILLY •
DATA LIT/ ’ /
C
C
101 FORMATC80A1)
102 FORMATC ’ , 1 OX , I 5,1 OX , 2 F1 0,3 )
103 FORMATC//’0ERROR DETECTED ON CARD
NUMBER ’ , 14,/’0’,1 OX,80A1,///)
204 FORMATC’O'NEGATIVE VOLUME’)
C
c
10 ISTART = 1
FILLY = .FALSE.
READCIN,101,END-80,ERR=90) CARD • ‘
NUM = 0 
DO 15 1 = 1-,80
IF(CNUM.EQ.2.0R. I .GT.20).AND.CARD CI).NE.LIT(1)) 
GO TO 90
420
1 F(CARD(I)•EQ»LIT(2)) 
15 CONTINUE
NUM a NUM + 1
20 NUM « 0
NPOINT =? -1
NEG = .FALSE,
DO 25 I=ISTART,2O
IFCCARDCI).E0.LITC1)) GO TO 25
IFCCARDCI).EQ.LITC2)) GO TO 30
IFCCARDCI).NE.LITC3)) GO TO 21
IFCNP0INT.NE.-1) GO TO 90
NPOINT a NUM
GO TO 25
21 IFCCARDCI ).NE.LITC4)) GO TO 22
IFCNEG.OR.NUM.NE.O) GO TO 90
NEC a .TRUE,
GO TO 25
22 NUM = HUM + 1 
IFCNUM.GT.10) GO TO 90 
DO 23 J=1,1Q
IFCCARDCI).EQ.DIGITCJ)) GO TO 24 .
23 CONTINUE
IFCNUM.NE.1 .OR.CARD(I) ,NE.LIT<5)) GO TO 90 
N'UM = 0 -
GO TO 25
24 IFCJ.EQ.10) J « 0
NUMBER (NUM) = J 1
25 CONTINUE •
I = 0 ‘ ‘
.1 F (, NOT. FILLY) GO TO 90
C . •
C .
30 Y = 0,000 .
IF(NUM.EQ.O) GO to 90
ISTART =? I + 1 
IFCNPOINT) 34, 40, 35
34 NPOINT a NUM
35 I FCNP0INT.E0.1) GO TO 37
NPM1 a NPOINT * 
DO 36 1=1,NPM1
1
36 Y ~ Y + FLOAT(NUMBER(I)) * 10.00 ** (NPOINT ~ I)
37 Y » Y + FLOAT(NUMBER(NPOI NT))
40 NPOINT a NPOINT + 1
IFCNPOINT.GT.NUM) GO TO 50 
DO 45 I»NPOINT<NUM
45 Y « Y + FLOAT(NUMBER(I)) Z 10,00 ** (I ~ NPOJNT + 1)
50 IF(FILLY) GO TO 60 ’
FILLY a .TRUE.
X s Y *
IFC.NOT.NEG) GO TO 20 
WRITECOUT,204)
GO TO 90
421
60 IF(HEG) Y = -Y 
WRITECOUT,102) N, X, V 
RETURN
80
81
82
NFLAG = 2 
GO TO 82 
NFLAG * 1 
X ~ 0,00 
Y « 0,00 
RETURN
90
91
IFCCARDC1 ).EQ.LFINIS) GO TO 80 
DO 91 I~1 ,5 
SPECIE(l) - CARD(I)
I F C CARD C1 )• F.Q , LVESSL) GO TO 81
NFLAG a NFLAG - 1 
IFCN.EO.O) RETURN 
WRITECOUT,103) N, CARD 
GO TO 82
END
subroutine copndpcndpstr,mode,ndpv,ndpb)
INTEGER N D P V C 2 ) , N D P B C 2 )
IFCN0PVC1),EQ."1) NDPVC1) = NDPBC1)
IFCNDPVC2).EQ.-1) NDPVC2) = NDPBC2)
IFCNDPBC1).EO,-1) NDPBC1) « NDPVC1)
IF CNDPB(2) ,EQ,-1 ) NDPBC2). = NDPV(2) 
J=NDPVC1)*10+NDPVC2) .
IF CNDPSTR.NE.~1.AND.NDPSTR,NE,J) MODE « 
NDPSTR a J • •
J a NDPBC1) * 10 + NDP8C2)
IFCNDPSTR.EG.J) RETURN
95
J = 0
IFCM0DE.EQ.95) J ~ 1 
MODE - ,J + 96 
RETURN 
END
APPENDIX A6
Review of the biological significance of 
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1.. INTRODUCTION • .
In the past a great deal of controversy, often verging on confusion, 
has surrounded the topic of low molecular weight (low mol wt) com­
plexes in physiological environments. Much of the disagreement may 
be attributed to the interdisciplinary nature of the subject; 
differing viewpoints, multifarious experimental approaches, and even 
partisan logic play a part. It is therefore prudent to commence by 
attempting to place these low mol wt bioinorganic species in their 
true perspective.
Owing to the very powerful metal-binding properties of the 
macromolecules which occur in biological fluids, the concentrations 
of metal ions available for the formation of low mol wt complexes 
are severely limited. Hence the concentrations of these low mol wt 
complexes are extremely small, usually immeasurably so. Nevertheless, 
these concentrations are orders of magnitude greater than the corre­
sponding aqueous metal ions. Moreover, in spite of their low concen­
trations, the low mol wt complexes are believed to be of immense 
biological significance.
Probably the most important function of these low mol wt 
complexes involves the transport of metal ions (1) through biological 
membranes and (2) both into and out of macromolecules/membrane-bound 
biological receptor sites [l]. Metal ions held in the low mol wt 
fraction are far more readily accessible than those bound within . 
proteins. Macromolecules cannot passively diffuse through membranes. 
Hence, in both the above-mentioned attributes small complexes possess 
a kinetic advantage over their macromolecular counterparts.
Additional features of low mol wt complexes include (1) an 
ability to alter the potential of certain redox couples, (2) their 
role in the process of dissolving certain metal prosthetics, and 
(3) the selectivity that low mol wt complexes confex' upon metal ions 
in vivo. In this last respect it has been suggested that differences 
in the distribution of low mol wt complexes might be exploited during
I • „
metalloprotein synthesis, whereby differences between the stereo- ,
. chemistries of related complexes are recognized [2],
425
Turning more specifically to Fe(III) complexes, their physiology 
is governed to a large extent by the chemical properties of low mol wt 
species. In particular the concept of bioavailability is dominant.
This emanates out of the pronounced tendency of this metal ion to form 
insoluble hydrolysis and polymerization products and leads to an ambi­
valent importance of the Fe(III) low mol wt complexes.
On the one hand, chelates can enhance bioavailability because, 
through suppressing irreversible polymerization, the metal ion is 
held in solution. On the other hand, evolution has circumnavigated 
this problem of insolubility by producing unique mechanisms which 
lessen the need for these low mol wt mediators.
In some microorganisms, the evolution of improved means for • 
assimilating and handling iron has produced some hydroxamate and 
phenolate ligands with very tenacious Fe(III) binding capacities.
These siderochromes are of great biological importance and are dis­
cussed in Chap. 3. Much research has been directed at elucidating 
the nature and properties of the iron complexes involved in plant 
physiology, but this topic cannot be treated in detail here. This 
chapter deals with the biological significance of low mol wt complexes 
of Fe(III) in the context of mammalian physiology. The objectives are 
threefold: (1) to review work which directly implicates low mol wt
complexes in iron metabolism, (2) to present the results of computer 
simulation studies which reveal the nature and concentration of these 
low mol wt complexes occurring under in vivo conditions, and (3) to 
consider the mechanisms through which low mol wt complexes participate 
in the regulation of iron metabolism. . , .
Any review dealing with the role of low mol wt complexes and 
iron metabolism must reflect the early and major contribution to this 
subject made by the researches of Saltman and co-workers [3-23]. The 
basic ideas behind their pioneering approach have been, and continue 
to be, substantiated by other investigators. It is now clear that, 
whether low mol wt compounds do in fact mediate in a specific biolog­
ical process, experiments must be designed with this possibility in 
mind. Neglect,of equilibrium considerations in general and of chela­
tion phenomena in particular have been responsible for many conflicting
LOW MOLECULAR WEIGHT IRON(III) COMPLEXES - ‘
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reports not only as discussed for iron but also for other transition 
metals. • .
2. AQUEOUS COORDINATION CHEMISTRY •
The aqueous coordination chemistry of Fe(III) has often been reviewed. 
A number of articles have specifically dealt with the biochemical 
implications of its chemical versatility [l9, 22 L 24]. No doubt 
these properties account for the wi'de-ranging physiological utiliza­
tion of this metal reflected, for example, throughout this volume.
Both Fe(II) and Fe(III) form complexes with a broad selection 
of ligands, showing a marked preference for octahedral coordination. 
With a few exceptions, chelation is much stronger with the higher 
charged, smaller, Fe(III) ion. Fe(III) binds substances such as 
polyols, organic oxyacids, and phosphates very powerfully and may 
be classified in HSAB terminology as hard, intermediate.
Many of the biological functions of iron hinge upon its ability 
to act as a redox catalyst. Facile reversibility is an essential 
feature of the Fe(II)-Fe(III) couple which makes it ideal as a physio­
logical electron sink and source. With a standard electrode potential 
of some 0.77 V (25°C), Fe(II) ion reacts with molecular oxygen even 
at reasonably high pH values. Although many agents, including a. 
number of metabolites, are able to reduce Fe(III) ions, the pronounced 
advantages the latter enjoy in all aerobic environments needs to be 
stressed. Only ligands which form high-spin complexes, thereby in­
creasing the electrode potential, stabilize Fe(II) over Fe(XII). 
Examples are porphyrin-like molecules, o-phenanthroline and bipyridyl, 
the first named being extremely potent in this respect. Most other 
ligands lower the electrode potential and thus enhance the stability 
of the Fe(III) state. This should be borne in mind whenever ^eduction 
is postulated to occur in vivo. Such reactions probably only occur 
spontaneously in the presence of high local concentrations of reducing 
metabolite or junder the influence of special enzyme mechanisms.
. PETER M'. MAY ET AL.
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The three most conspicuous chemical properties of aqueous ' ' 
Fe(III) ions are closely related, and so it is easier to outline them 
together. They are (1) the marked tendency to hydrolyze, (2) the 
extreme insolubility of the hydrolysis products, and (3) the common 
and readily occurring hydrolytic polymerization reactions. Many of 
the reported contradictions concerning iron metabolism stem from an 
inadequate appreciation of these properties. Even when Fe(III) . 
appears to be solubilized it may well be present in large aggregates 
[19] which are unable to pass through biological membranes and tend 
to be adsorbed onto glass or other surfaces.
Extensive studies of Fe(III) hydrolysis-have been made, for 
example, by Hedstrom [25] and Biedermann [26]. They report the 
formation of Fe(OH)^+, FefOH)^ as well as higher poly- ■
mers. The dinuclear dimer and the high polymers, involve hydroxo 
bridging. With increasing alkalinity, more highly condensed species 
are produced leading to the formation of the classical ferric-hydroxy 
gel. '
As the solubility product of FeCOH)^ is below 10-3^ mol^ dm-^,. 
it is clear that in order for Fe(III) to be maintained in solution at 
neutral or higher pH, protection by strong binding to suitable ligands 
is necessary. Polymerization is then restricted by the reduction in 
the number of aquated sites vulnerable to hydrolysis, the lowering 
of the effective charge on the metal ion, and the consequent dimin­
ished acidity of any coordinated water molecules remaining. It is 
important to note that although the possibility of dinuclear/oligo- 
nuclear Fe(III) complex formation in experimental solutions should 
never be neglected, the exceedingly low concentrations of free Fe(III) 
ion, combined with the preponderance of ligands in vivo, makes their 
existence in biofluids much less likely. When ligands are not strongly 
bound to Fe(III) or if they occupy only two or three of the coordina­
tion sites on the metal, polymerization reactions do occur. For 
example, both citrate [12] and fructose [2l] form high mol wt struc­
tures. Nevertheless, when in excess, the ligands can suppress polymerI *
formation [l3, 19, 2l], • . .
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Spiro and Saltman have drawn attention to a number of inter­
esting similarities exhibited by these high mol wt Fe(III) polymers 
[19]. They do not appear to be just metastable intermediates in the 
precipitation process as they cannot easily be encouraged to proceed 
further along such a route. They form compact, we11-separated 
spherical particles around which a coating of the ligand tends to 
form and thus prevent further hydrolysis. Certain analogies can be 
drawn with the ferric polyhydroxy-phosphate core of the iron storage 
agent, ferritin. This subject will.be pursued further in Sec. 3.2.2.
Due to the experimental difficulties which we have just 
described, relatively little work has been published about Fe(III) 
complexation equilibria in aqueous solution especially at physio- ' 
logical pH values. Citrate is a ligand of obvious potential bio­
logical importance. Nevertheless there is little known about the 
Fe(III) complexes it forms except when the pH is low. A number of 
suggestions have been put forward on the grounds of potentiometric 
studies; while the species Fe*citrate•OH” (i.e., with the ligand 
being citrate3”) has been postulated most often, [l2, 13, 27-30] 
whether it competes successfully with Fe’citrate*(OH)[28], 
Fe2*citrate2*(0H)2" [29], or Fe’citrate2-(0H)2~ [l3] is still 
unclear. Another unresolved question concerns the participation 
of the citrate hydroxyl function in the binding.” The marked tendency 
for Fe(III) ion to form ligand-hydroxy complexes argues against its 
formation. Although Fe(III) ion complexation by carbohydrates and 
polyols is well known and has been the subject of several researches 
[12, 3l], exceedingly little quantitative information is available. 
Davis and Deller have assessed the chelating ability of a series of 
sugars by a solubility technique [32]. Those with hydroxyl groups 
on carbon atoms 1 and 3, namely fructose, sorbose, and tegatose, 
were found to bind Fe(III) most strongly.
. PETER M. MAY ET AL.
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3. EVIDENCE FOR LOW MOLECULAR WEIGHT COMPLEXES 
• • INFLUENCING IRON METABOLISM • '
The emphasis in this section concerns what are believed broadly to 
be the major roles of low mol wt Fe(III) complexes, namely in the 
transport of the metal across membranes and in the exchange of iron 
between macromolecules. • . ■ •
LOW MOLECULAR WEIGHT IRON( III) COMPLEXES • .
3.1. Metal Ion Transport Through Membranes
The bioassimilation of substances and their subsequent distribution 
between body compartments depends primarily upon the ease with which 
they traverse biological membranes [33]. Consequently, a great deal 
of research has been concerned with the ways in which transport 
across membranes is accomplished in vivo. .
Broadly speaking, transport processes are classified as either 
active or passive. Active transport is characterized by at least a 
majority of the following features: (1) consumption of metabolic, 
energy, (2) inhibition by metabolic poisons, (3) partial or complete 
substrate specificity, (4) transport against concentration gradients 
and, if the substance is charged, against a potential gradient, and 
(5) saturation of the transport mechanism at higher substrate levels. 
On the other hand, passive transport is diffusion-controlled and 
only permits the transit of lipophilic molecules. Charged species 
are unable to penetrate the membrane due to the high- energy required 
to move them from an aqueous into a lipid phase. * ' . .
In three important instances, the classification of membrane 
transport processes as either active or passive is inadequate [33].
' 1. In the intermediate case of facilitated diffusion. This
kind of mechanism is saturatable and can move charged • .
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species. It does not however rely upon oxidative 
metabolism. Neither can it work against a concentration 
gradient. The motion of the membrane-bound receptor is 
slight and the procedure is probably accomplished simply 
by a regularly reversing shift of charge density.
2. When pores exist in the membrane. A prominent example 
of this is provided by glomerular filtration in the 
kidneys. Only the passage of molecules larger than 
albumin (mol wt - 70,000)- is restricted.
3. The processes of pinocytosis and phagocytosis whereby 
larger particles can traverse membranes through the 
extrusion of vesicles.
The movement of transition metal ions across a biomembrane is 
complicated by a number of factors. The most obvious of these is 
the ability to form complexes with both high and low mol wt compo­
nents. While this propensity can clearly be exploited in facilitated 
diffusion or active transport mechanisms, it also means that the 
metal ion can passively diffuse through the lipid membrane in the 
form of a neutral complex. Interpretation of experimental results 
is made difficult because every one of the criteria used to identify 
the kind of transport process can be ambiguous. Protein binding in 
the cell can lead to a net uptake of the metal ion. This may be as * 
a result of irreversible metalloprotein synthesis as well as the 
labile protein interactions that should always be expected when 
investigating the physiology of transition metal ions. Coupled with 
other phenomena, the synthesis of ferritin in mucosal cells has a 
pronounced, albeit sometimes indirect, effect upon observations 
pertaining to iron absorption. Thus transport phenomena can be 
altered by protein synthesis inhibitors, other metabolic, poisons, 
and the deprivation of metabolic energy. Complexation can quite 
generally cause passive movement of the metal ion against a concen­
tration gradient. Often this will show the typical effects of 
saturation. It may well be specific for a certain kind of metal ion 
or for a group with similar chemical properties. Most deceptively,
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changes in species distribution between the media on either side of 
the membrane, due to differences in composition, or pH, will tend to 
produce a flux for reasons by no means easy to discern. Finally, 
changes in oxidation state which certain transition elements can 
undergo introduces another type of complication.
The above-mentioned considerations do not imply that active 
transport of transition metal ions never occurs; only that the 
interpretation of experimental evidence is not straightforward.
3.1.1. Lipophilicity
As most semipermeable membranes, including those surrounding cells, 
are certainly not endowed with active transport mechanisms specific 
for transition metal ions, passive diffusion constitutes the only 
means whereby metal ions can penetrate these. Under such circum­
stances neither protein-bound nor free (i.e., aqueous) metal ions 
can enter directly and so low mol wt lipophilic complexes become the 
key to understanding how the metal is distributed between body com­
partments. Glomerular filtration by the kidneys provides a most 
important exception, but otherwise these principles, well known for 
ligands, have also been established for metal complexes [33-35],
In the case of Fe(III), the chemical nature of the element 
imposes restrictions not applicable to other essential trace elements 
such as zinc or copper, at least not to the same extent. So there 
is undoubtedly a greater need for special biological methods to 
handle this element. Nevertheless, substantial evidence exists that 
lipophilic Fe(III) complexes traverse biomembranes just like lipo.- 
philic complexes of other metals.
This is well illustrated by studies of the transfer of iron 
from synthetic iron chelates to reticulocytes. Normally these cells 
take up iron from transferrin in plasma. Iron presented in the form 
of its EDTA chelate is unavailable for incorporation into hemoglobin 
[36]. However, if this charged, hydrophilic complex is replaced by 
others with higher lipid/water partition coefficients, the failure 
to deliver iron to the cell is reversed. Rubin has used a series
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of ligands related to EHPG [34]. He found that the more lipophilic 
the complex, the greater the amount of iron incorporated into the 
cell by transfer through the membrane. •
Similar results have been found in another investigation [37]. 
Complexes which are both lipophilic and strongly formed simulate the 
functions of transferrin in that they inhibit nonselective membrane 
adsorption and promote its utilization within the reticulocyte.
Highly polar, anionic iron chelates such as those formed by EDTA 
and DTPA inhibit both nonselective deposition of iron on the cell 
wall and the incorporation of the metal into hemoglobin.
The role of lipophilic complexes in iron absorption is a . . '
question that arises on several occasions throughout this review.
Here it is necessary only to mention a few clearcut examples. The 
fat-soluble chelate ferrocene is almost quantitatively absorbed 
following oral administration [38]. As opposed to their poor 
absorption of normal ’’inorganic’* iron, sla-mice (see Sec. 3.3.1) 
fed another (unidentified) lipophilic organic iron compound showed 
effective transfer of the iron from the lumen into plasma [39].
These very strong and/or inert complexes provide good illustrations 
because they survive the sharp changes of pH experienced as they 
pass along the gastrointestinal tract and also because they are 
unscathed by the variety of iron-binding components in the intes­
tinal fluid and within mucosal cells. Generally the absorption of 
metal ions administered orally is relatively limited and in sharp 
contrast to the rapid and complete uptake of complexes associated 
with intraperitoneal, intramuscular, or subcutaneous injection.
Another instructive demonstration is afforded by the transfer 
of iron through rat gut segments in the presence of 8-hydroxyquinoline 
or its sulfonic acid analog [40]. Compared with normal controls which 
absorbed about 8% of the ferric chloride dose, 8-hydroxyquinoline 
promoted the absorption of about 35%, while 8-hydroxyquinoline-5~ 
sulfonic acid permitted the uptake of less than 1%. These effects 
are entirely attributable to the charge on the iron complex formed 
by the respective ligands.
. PETER M. MAY ET AL.
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Fructose is a most effective agent for moving iron(III) across 
membranes [6]. It strongly promotes oral iron absorption [7, 20, 4lJ. 
At high concentrations, iron polymerizes in the presence of fructose, 
but the polymers also dissociate fairly readily [2l], Definitive 
information concerning the nature of the low mol wt complex formed 
between iron and fructose in the presence of the polymer is not yet 
available. However, a neutral species seems highly probable. The 
inference made by comparison-with the gluconate-iron(III) system [3l] 
supports this. *
There is some uncertainty with regard to the effect of EDTA 
upon iron absorption. The negatively charged complexes it forms are
• not expected to be well absorbed. There seems little doubt that in 
vivo EDTA suppresses iron uptake [41-43]. NTA is much more effective 
at increasing the unidirectional influx of iron into the mucosal cell 
[44], but this could be due to factors other than the difference in 
complex lipophilicity.
The series of investigations by Princiotto, Rubin, and coworkers 
extending over two decades has clearly revealed how the distribution 
of iron within the body,and the route of excretion the metal subse­
quently takes depend upon the lipophilicity of the ferric chelate 
[34, 37, 45-51]. In essence, nonpolar compounds.are excreted by the 
liver. This is part of the rationale behind the design of entero- 
hepatic chelating agents [52]. Polar complexes are confined to the 
extracellular space until they are excreted by the kidneys. Thus, 
complexes which enhance iron uptake by reticulocytes also induce • 
biliary iron excretion [37, 47]. However, bile duct ligation or 
changes in the chelate structure which reduce the lipid/water parti­
tion coefficient shunt the iron excretion into the urine [47, 48]. 
Esterification of acid groups on certain chelating agents was also 
observed to cause a shift in excretion pattern toward the fecal 
route [53]. .
3.1.2, Active Versus Passive Transport .t
Much controversy surrounds the mechanisms whereby iron is normally 
transported across membranes in vivo, particularly in iron absorption.
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Numerous investigators have -reported results consistent with a 
simple process of passive diffusion of iron across the gut wall [9,
11, 54-57], Some even find that the transfer is unaffected by with­
drawal of oxidative metabolic energy [54-56]. Interestingly, Terato 
et al. [57] showed that the absorption of iron chelates and polymers 
could be related to their molecular weights as well as to the iron 
concentration in the mucosal medium.
The physiological importance of the passive movement of iron 
through membranes is indicated by the uptake of the metal ion by rat 
liver slices [3, 4], The fact that iron passes through the cell wall 
in both directions in a manner not affected by agents which inhibit 
respiration or the utilization of metabolic energy argues against an 
active process. Further, conditions which disrupt the integrity of 
the cell membrane do not change the iron metabolism. The accumulation 
of the metal ion against a concentration gradient appears to be due 
to iron binding by specific sites within the cell.
It should be noted, however, that evidence exists for the 
energy-dependent accumulation of iron by the mitochondria of rat . .
liver [58]. Romslo suggests that the effect of added ATP was twofold: 
it provided energy and it chelated the iron. .
Early research by Hahn et al. [59] convinced them that the 
transfer of iron across the intestinal epithelium is influenced by 
cell metabolism. Since then it has been shown repeatedly that a 
process dependent upon metabolic energy is involved [11, 54, 55, 60­
64]. Many of these results may merely reflect a change in cell status 
with regard to either ferritin synthesis or electrode potential under 
the experimental conditions.
Some work demonstrating an active transport mechanism for 
Fe(II) ion has-been published [60-63, 65], Iron is thereby trans­
ferred against potential and concentration gradients. The process 
is inhibited by deprivation of metabolic energy or the addition of 
metabolic blocking agents [60-63]. The two-step process shows rapid 
uptake by the cell followed by slow release at the serosal surface 
[61]. There is some disagreement about the saturation kinetics of
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the system [61, 63], This may be due to the loss of cellular func­
tion which can occur when gut sacs are incubated over several hours 
[56].
A question which merits a great deal of attention concerns the 
oxidation state of iron during absorption. Belief that only Fe(II) 
could be carried across the membrane was once very widespread. How­
ever, it is now known that early work was aggravated by the extreme 
insolubility of Fe(III) salts in neutral/alkaline biofluids. Iron 
is equally well absorbed in either "oxidation state provided it is 
kept in solution [9, 23, 40, 66]. For Fe(III) ion this means it 
must be complexed. Manis and Schacter have suggested that both Fe(II) 
and Fe(III) are taken up by the mucosal cell but that active transport 
to the serosal surface is relatively specific for the divalent cation 
[6l]. Thus the mucosal Fe(II) pool turns over relatively rapidly 
[65]. A little is converted into Fe(III) which acts as a storage 
depot for excess. Although reducing agents such as cysteine, liber­
ated in the breakdown of proteins, may cause Fe(II) to be formed in • 
the gastrointestinal tract [40], it seems unlikely that this form 
persists in intestinal fluid under normal circumstances (vide supra). 
Saltman has pointed to the drastic conditions required to reduce 
Fe(III) in vivo [23]. '
In conclusion, it seems that both active and passive transport 
mechanisms have a role to play. The relative importance of each is 
difficult to evaluate. Dowdle et al. have suggested that the active 
transport mechanism for iron will become important if passive diffu­
sion is restricted [60], This fits the fact that at low concentra­
tions "iron absorption appears to be a saturatable process, but at 
higher concentrations the process exhibits unlimited capacity [40]. 
Cyclic life processes obviously require some active physiological . 
perturbation to keep them going, but it is well to remember that the 
efficiency for which Nature is renowned makes it likely that these 
processes are used sparingly and selective exploitation of spontaneous 
reactions and of equilibrium conditions are employed instead whenever 
possible. •
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3.1.3. Low Molecular Weight Complexes in Iron Absorption
(a) Bioavailability in the-Lumen. Absorption of iron takes 
place throughout the intestine but mainly in the duodenum. An 
exceedingly large number of studies have shown that a principal 
factor involved is simply that of iron solubility (vide infra). 
Anything which tends to make iron more soluble, thereby preventing 
hydroxide precipitation as the pH rises upon leaving the acid stomach, 
will promote iron absorption. Therefore Fe(II) forms are preferred 
to Fe(III). Furthermore, both chelating agents and reducing agents 
are almost always beneficial. Alternatively, substances which form 
insoluble salts depress absorption as do any agents which promote 
the formation of inert polymers or powerful hydrophilic complexes.
Substances which promote absorption by complexation include 
(1) amino acids, (2) sugars and polyols, (3) most proteins, probably 
following proteolysis, and (4) some organic oxyacids [40, 67, 68]. 
These promoting effects appear to be quite variable; lack of enhance­
ment has been reported [69]. However, fructose and histidine seem 
most instrumental (Sec. 3.1.1).
It has been suggested that some of these substances promote 
iron absorption by providing the intestinal epithelium with oxidative 
metabolic energy. In their studies on active transport, Dowdle et al. 
found that iron transfer was enhanced if glucose was replaced by 
fructose in the incubation medium [60]. Manis and Schacter noted 
that mannose was even better than fructose in this respect [61]. It 
seems that complexation is. in all likelihood a more dominant factor, 
however* Jacobs et al. could not confirm the effectiveness of mannose 
[63], Transfer, they found, was increased by citric acid and a-keto- 
glutaric acids, but other metabolites gave equivocal results. The 
minimum concentration of carbohydrate sufficient to prevent iron 
hydroxide precipitation provides a measure that permits a correlation 
between iron-chelating and absorption-promoting ability: fructose > 
sorbitol > glucose > sucrose [7]. Proposals that the enhancing effect 
of amino acids is achieved by the active transport mechanism in 
intestinal epithelium which is specific for these metabolites are
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refuted by the observation that L isomers do not do significantly 
better than the D forms [70]. •
Although Fe(III) and Fe(II) are absorbed equally well if they 
are both properly solubilized [40], in practice the difficulty in . 
fulfilling this condition places Fe(III) at a distinct disadvantage 
[68]. Hence, reducing agents promote absorption. Ascorbic acid 
and cysteine are known to be most effective [68, 7l]. The ability 
of these ligands to form soluble Fe(II) chelates is probably an 
equally important function [7l]. Reduction can, in addition, liberate 
Fe(III) ions bound in inert metalloproteins [40]. Substances which 
depress absorption by decreasing transfer into the mucosal cell 
include phosphates, phytates, carbonates, oxalate, hydroxide, iron­
binding proteins, and synthetic chelating agents [40, 67, 68, 7l].
Suggestions which assign the control of iron absorption to 
substances secreted into the intestinal milieu have produced a fair 
measure of confusion and much controversy. Such secretions have 
been claimed to regulate the passage of iron through the intestinal 
membrane by chelating the metal while it is rendered soluble in the 
acid content of the stomach. Whether this binding enhances or 
inhibits absorption is, however, in the face of contradictory 
assertions, unclear, and governance by such means is currently 
thought unlikely [56, 68, 7l]. More attractive is the concept that 
iron remains soluble by binding to either high mol wt mucopoly­
saccharides [72] or to low mol wt ligands. These may be from food 
or from the amino acids secreted into the lumen. In any event, the 
macromolecular component is unable to penetrate the intestinal 
epithelium. Hence, iron must be released either to low mol wt 
chelators for passive diffusion into the cell or to acceptor sites 
on the intestinal brush borders. The latter process might need to 
be mediated by small ligands. , .
Actually, the effects of all these agents upon iron absorption 
should be seen as the result of an influence on the metal in a multi­
component, multiphase equilibrium system as the solution undergoes 
a transition from acid to neutral pH. Hydrochloric acid in gastric
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juice dissolves sparingly soluble compounds and releases iron in 
food [68, 73]. Reduction of Fe(III) is routinely accomplished by 
cysteine and glutathione end products of protein digestion [40], 
However, the reversal to the higher oxidation state becomes increas­
ingly favored as the medium gets more alkaline; it is under such 
circumstances that chelation assumes paramount importance if precipi­
tation (or inert polymer formation) is to be forestalled and the 
metal is to remain bioavailable. ; .
(b) Transfer into the Mucosal' Cell. It is generally accepted 
that whatever active transport mechanisms may be associated with 
iron absorption, these are not located at the mucosal surface [40] 
in spite of a few contrary assertions. This being the case, transfer 
into the mucosal cell can proceed by either passive or facilitated 
diffusion (Sec. 3.1). The former process will hinge upon the concen­
tration of lipophilic low mol wt species in the intestinal fluid 
while the latter would probably not depend on the charge of the 
complex but rather its concentration, binding strength, and stereo­
chemistry. Little research has been aimed at distinguishing between 
these two possibilities because of the problems connected with 
identifying low mol wt. complexes formed in biofluids (Sec. 4). .
However, iron deficiency anemia has been named second only to protein 
malnutrition in the number of people it affects [74], so the need to 
find better iron supplementing therapeuticals without the side effects 
commonly caused by these hematics is obvious. Understanding how an 
agent facilitates penetration of the mucosal cell will certainly help.
Forth and Rummel have proposed that acceptor, sites exist on the 
brush border of mucosal cells and that these .compete for iron with 
ligands in the lumen [40]. They attribute the different absorptive 
capacities of gut segments to diminishing stability of the complexes 
formed with binding sites on segments taken closer to the ileum.
They categorize ligands according to binding ability:
1. Strong ligands whose complexes do not release the metal 
to the brush borders
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2. Intermediate ligands which do yield iron for absorption but 
which are capable of preventing hydrolytic precipitation
3. Weak ligands which do not bind in the face of competition
from hydroxide ion ,
Recently, Sheehan has published a study on the unidirectional 
uptake of iron which suggests that this occurs by passive diffusion 
[44]. He found a linear relationship with respect to concentrations 
between 0.1 and 10 mmol dm”°. This is in good agreement with many of' 
the observations of Saltman. Sheehan also noted that uptake was a 
process with a low energy of activation. No features characteristic 
of a rate-controlling step could be demonstrated. Unidirectional 
uptake depended only on the iron concentration and the nature of the 
complex: Fe-ascorbate > Fe-NTA » Fe-EDTA. ... -
Two important instances where penetration into the mucosal cell 
is accomplished with ease should be mentioned:
1. Heme absorption: Following the degradation of hemoglobin 
in food, the heme moiety is drawn into the mucosal cell intact [75].
In fact, it is the only low mol wt iron chelate experimentally demon­
strated within mucosal cells under physiological conditions [40], no 
doubt reflecting the inert nature of this complex. Absorption of 
hemoglobin iron is not affected by those factors so important in 
determining the availability of ’’inorganic” iron in intestinal fiuid, 
e.g., ascorbic acid, phytates, and DFO [67, 7l]. It has been shown 
that differences in iron absorption of heme can be related to molec­
ular weight, monomers being absorbed best [71]. Polymer formation
of porphyrins is probably the reason they are not absorbed as well 
as hemoglobin iron [40]. Once the heme has entered the mucosal cell, 
it is .split enzymatically (possibly by xanthine oxidase.) and there­
after joins the same pathway as that taken by absorbed inorganic 
iron [75]. •
2. Bantu-siderosis: This pathology, widespread in southern 
Africa, has been directly attributed to the formation of iron- 
carbohydrate complexes which remain soluble and undissociated in 
intestinal fluid and which pass easily through the epithelium into
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plasma [23]. The consequences of this uncontrolled bypass of normal 
iron absorption pathways is excessive deposition of the metal in the 
liver and spleen which ultimately proves fatal. The complexes are 
apparently formed with ligands generaged during fermentation: the 
Bantu peoples consume large quantities of maize-based ’’beer” brewed 
in iron pots and a similar iron overload is observed in sweet-wine 
alcoholics [23], It is noteworthy that even when ferrous sulfate 
is ingested with maize, alcohol, or unfermented gruel, iron absorp­
tion does not become exceptionally high [76]. Neither does the 
consumption of teff, an Ethiopian cereal grass having a sizable iron 
content, cause a comparable siderosis [76],
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3.2. Macromolecules and Low Molecular • '
Weight Fe(III) Complexes 
3.2.1. Transferrin
The mutual interaction between transferrin, low mol wt chelating 
agents and Fe(III) provides a sad example of a lack of communication 
between the chemical and physiological disciplines of researchers 
concerned with iron metabolism. Time and again statements appear 
in the literature to the effect that ’’transferrin-bound iron is not ‘ 
vulnerable to chelate binding” [77, 45, 78-81]. While this may be 
essentially valid in the context being used, unqualified assertions 
like this create an incorrect impression, namely that transferrin 
Iron is always completely inaccessible to chelating agents because 
an equilibrium cannot be set up. There is a real danger that such 
a misconception can mask phenomena vital to the unraveling of iron 
metabolism, particularly with regard to its regulation.
The fact that iron can be removed from transferrin directly by 
chelating agents is well established, i.e., the reaction is reversible 
[82]. When serum is dialyzed against water, the amount of radio iron 
removed from transferrin is neglible; however, dialysis against EDTA, 
citrate, or NTA is effective [5, 15]. Similarly, equilibrations in 
which iron was'dialyzed out of transferrin were featured among the
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experiments used to estimate the strength of metal binding to the 
protein [8]- Reversible titration curves are obtained in the 
presence of citrate both with transferrin [8] and the similar iron­
binding protein found in egg white, conalbumin [83]. •
The impression that transferrin iron is not available for 
binding to chelating agents originates from two factors. The first 
is the very high iron association constant exhibited by this protein. 
The extent to which chelating agents are able to compete with macro­
molecules in vitro and in vivo cannot be determined simply by com­
paring equilibrium constants; generally this kind of calculation can 
only be achieved satisfactorily by means of computer simulation (see 
Sec. 4). It transpires that very few low molwt chelates at equimolar 
concentration with transferrin can hold a significant fraction of the 
total iron at equilibrium. So, the approximation that no iron is 
removed on these occasions is quantitatively, if not conceptually, 
justified. The second factor is kinetic in origin. Even with those 
chelating agents which,’ according to thermodynamic calculations, 
spontaneously extract measurable amounts of iron from transferrin, 
it may be that no such release is observed because equilibrium is . 
not actually attained. This accounts for the many observations that 
chelating agents added as iron complexes are able to retain the metal 
in the presence of iron-binding apoprotein but are unable to strip 
iron from the iron-protein species.
The iron-exchange reactions between transferrin and chelating 
agents as well as from Fe(III) complexes to apotransfcrrin have been 
studied in detail by Bates et al. [14, 15]. The rate at which iron 
is transferred depends on the chemical nature and stereochemistry of 
the complexing agent; equilibrium concentrations are related to the 
magnitude of the relative stability constants. In the removal of 
iron from transferrin, citrate and NTA reach equilibrium at approxi­
mately the same rate (the reaction was essentially complete after
3 hr) but EDTA takes much longer. The time required to half-saturate 
apotransferrin binding sites was 3 sec for NTA, 8 hr for citrate, and
4 days for EDTA. The rate of donation from iron(III) citrate is
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limited by the depolymerization of this system, the low mol wt .
product (in all likelihood the monomer) interacting rapidly [12, 14].
The transfer of iron between transferrin and chelating agents 
almost certainly takes place via the formation of a ternary complex 
[15]. The formation of a ternary species accounts for the importance 
of ligand stereochemistry. It also does away with the need for 
spontaneous separation of a Fe(III) ion which, it has been estimated 
[84], would take about 10,000 years!
The role of low mol wt complexes in iron sequestration by
apotransferrin has been emphasised by findings that■interaction with
Fe(III) salts is nonspecific [2, 85, 86]. Although divalent iron is
only very weakly bound to transferrin [87], at neutral pH the apo- ‘
2+ 3+protein reacts far more satisfactorily with Fe than Fe . No 
doubt this is due both to the hydrolysis of the Fe(III) ion and to 
the facilitated oxidation of Fe(II) ion in the presence of powerful 
iron (III) complexing agents [88]. Poor results are also found when 
the Fe(III) ion is generated in situ [2]. In contrast, iron from 
monomeric Fe(III) chelates is rapidly and stoichiometrically seques­
tered [2], For example, titration of apotransferrin with Fe(III)-NTA 
yields a linear function having a sharp endpoint, but with iron(III) 
chloride only a sigmoidal curve can be obtained [86]. It has rela­
tively recently become appreciated that these facts are most pertinent 
in the preparation of experimental transferrin solutions [86, 89],
Of great relevance to the question of iron transfer between 
physiological iron-binding’sites via complexes formed by naturally 
occurring low mol wt ligands has been the demonstration by two 
separate investigations of a citrate-mediated exchange of Fe(III). 
ions between transferrin molecules [84, 90]. The statement that 
there is no appreciable movement of iron between transferrin molecules 
[91] again applies in the context of gross ferrokinetics only. In 
fact, even then a small ’’reflux” is noticeable which can be attributed 
to intermolecular transferrin iron exchange [84]. Whether this 
exchange in plasma has physiological importance in itself is debatable. 
What cannot be'disputed, however, is that it provides a good model for
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the phenomenon of transfer mediated by concentrations of low mol wt 
complexes at the limit of analytical detection [84, 90]. The impli­
cations of this, in plasma or in other biofluids, are still largely 
speculative, but possible effects arising therefrom should be borne 
in mind in both the design and interpretation of the results of 
future experiments.
Aisen and Leibman [84] used chromatographic differences between 
asialotransferrin and the native protein to monitor the iron exchange. 
One of these was labeled with radio iron and then incubated with an 
equimolar concentration of the other in the presence and in the 
absence of citrate. Exchange caused the appearance of two radio­
active peaks corresponding to the separation of the two forms of 
protein. Only one radiopeak was observed when citrate mediator was
absent. The exchange took 5 days to complete if the citrate concen- 
-5 ' -3tration was 10 mol dm , but only 24 hr if the concentration was
-3 -3raised to 10 mol dm
Ganzoni et al. [90] used the iron-donating ability of trans­
ferrin to reticulocytes to follow the ability of citrate to change 
diferrictransferrin into the monoferric species. (Transferrin mole­
cules with two iron atoms are better at donating iron to reticulo­
cytes than those with only one.) They prepared two solutions: in 
the first, apo- and diferrictransferrin predominated; in the second, 
monoferrictransferrin was formed. The solutions were preincubated 
with citrate for differing periods before being exposed to the 
reticulocytes. When the time of this preincubation was short, the ' 
first solution donated by far the greater percentage of radio iron 
to the cells reflecting the presence of the diferric species. With 
longer preincubation with citrate this difference in iron-donating 
ability between the two solutions disappeared commensurate with the 
increasing formation in the first solution of the monoferrictrans­
ferrin. The half-life of the exchange appears to be about 18 hr. 
Subsequently these results have been confirmed and extended [92],
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3.2.2. Ferritin ‘
Iron homeostasis is achieved primarily by manipulating the amount of 
this element held in the reticuloendothelial and parenchymal cells 
of the body by the storage proteins ferritin and hemosiderin; control 
by excretion is negligible, while absorption is directly related to 
the status of body iron stores [91, 93], Hence, the mechanisms by ‘ 
which these proteins (1) remove iron when the system is faced with 
possible overload and (2) release it in time of need is of great 
interest and physiological importance. Although the importance of 
hemosiderin increases in siderosis, ferritin normally accounts for 
most of the iron in storage [93]. It also, appears to be the more 
labile font. For these reasons most research has concentrated on 
ferritin, and here we shall be solely concerned with it.
.., Iron can be released from ferritin simply by the presence of
low mol wt chelating agents. DFO liberates iron from ferritin in
vivo to the limit of the chelating agent’s binding capacity [79],
Removal is also achieved by 1,10-phenanthroline [94]. As the rate
of release of iron in this case is independent of the chelating agent
concentration, it has been reasoned that the rate-controlling step
lies in the degradation of the phosphate micelles; subsequent uptake
of the metal held at the ferritin surface is relatively fast [94].
Pape et al. found that physiologically significant quantities could
be mobilized by specific low mol wt agents under mild temperatures *
and at neutral pH values [17]. NTA was much more effective than'EDTA
in spite of an iron-binding stability constant smaller by a factor- 
-9of 10 . This led them to conclude that the avidity of the chelator *
for iron does not uniquely determine the rate or amount of metal 
mobilized [17]. Citrate was less effective than EDTA; removal of 
the iron depended on the concentration of this chelating agent.
Extraction of ferritin iron is most often achieved in vitro by 
reducing agents. Originally, sodium dithionate in the presence of 
bipyridyl was used, but now thioglycollie acid, an agent which can 
both reduce and(chelate, is employed instead [93]. Although ascorbic 
acid, cysteine, reduced glutathione, and some other metabolites can
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mobilize iron from ferritin in this manner, it does not occur at 
physiologically significant rates unless unrealistic concentrations 
of the reagents are used [95].
There is disagreement concerning the role of ascorbic acid in 
iron metabolism. It has long been believed that the vitamin is 
necessary for incorporation of iron into ferritin and therefore 
increases iron uptake by cells [96]. Ascorbic acid has also been 
implicated in iron release from ferritin both in vitro (vide supra) 
and in vivo [97, 98], but not all investigators agree with this 
conclusion [99, 100]. .
It is well known that apoferritin is not analogous to iron­
binding proteins such as transferrin in that it does not occur in 
substantial quantities regardless of its degree of utilization.
Rather, the presence of iron stimulates de novo synthesis and iron 
release is followed by protein degradation [101]. The mechanism of 
induction remains unclear and there is controversy about the method 
of iron incorporation. Historically, it has been believed that 
divalent iron must be present because many experiments showed that 
Fe(III) ions were not taken up [93]. The extent to which this tenet 
has been founded upon faulty results because of unsuspected Fe(III) 
hydrolysis reactions needs to be explored. Pape et al. found that 
in the presence- of suitable low mol wt chelates which permit a limited 
polymerization, iron micelles formed that could be coated by apo­
ferritin protein subunits thereby being transformed into ferritin 
[16]- Further, they noted that the product of attempts to reconsti­
tute this protein using Fe(II) was ’’distinctly different” from'the 
native substance. Their idea does suggest how ferritin induction 
might be prompted in vivo only in the event of increasing iron 
accumulation.' In spite of this, Jacobs has recently concluded that 
primary formation of an apoferritin shell followed by iron uptake 
through spaces between the subunits is currently the widely accepted 
mechanism [101].’ Whichever hypothesis is closest to the truth, one 
thing is absolutely clear: low mol wt Fe(III) or Fe(II) species are 
involved.. ' . .
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The movement of iron from transferrin to ferritin and back 
again is the process with which most of the above-mentioned arguments 
are ultimately concerned. Th^ iron resides in both protein bound 
forms in the Fe(III) state. So the question is whether mediation by 
low mol wt Fe(III) complexes suffices. There is no dispute that 
reduction is sufficient to effect the release of the very powerfully 
bound transferrin iron atoms. Indeed, this has been postulated to 
occur at the cell membrane following transferrin attachment [102], 
Miller and Perkins have produced an. interesting model of the transfer 
between transferrin and ferritin [103]. They show that in the pres­
ence of a reducing agent which can also chelate Fe(II) reversible 
passive transfer of iron between the two proteins occurs. On the 
other hand, one can envisage a balance within the cell between the 
ferritin and the membrane receptor sites mediated by low mol wt 
Fe(III) complexes. The low concentrations that need be involved 
would make such a role possible for a naturally occurring ligand 
such as citrate.
3.3; Iron in Cells ’
Recently, studies concerning the regulation of iron absorption have 
illuminated the nature of intracellular iron-binding components and 
their relationships to one another. In this section we review these 
findings with special emphasis upon the involvement of a low mol wt 
fraction in cellular iron metabolism.
3.3.1. Iron in Mucosal Cytoplasm ■
It appears almost universally agreed that a major iron-binding • 
species in mucosal cells is ferritin [40]. In fact, all types of 
cell have the ability to synthesize this storage protein when the 
intracellular load rises [104], The evident production of ferritin~ 
in mucosal cells following an oral dose of iron led to proposals 
that it was involved in controlling iron absorption; now it is
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believed to play a more passive role [40], Iron, not immediately 
required by the organism, is sequestered, thus protecting against 
absorption. The amount of iron occurring in ferritin therefore 
depends to a lai-ge extent upon the needs of the animal and the 
amount of iron which has recently entered the cell. Hence, wide 
variations in the percentage of iron in the mucosal pool attributable 
to ferritin have been reported [64, 55, 105-107].
It also appears very likely that at least one other nonhemo- 
protein which specifically binds iron occurs in the mucosal cell.
A substantial number of investigators have detected a high mol wt 
cytoplasmic carrier, apparently associated with the rapid phase of 
iron absorption. It is not certain whether these all refer to the 
same substance but consensus is for a transferrin--like protein [40], 
There are good grounds for believing that this carrier determines, 
at least in part, the rate and amount of iron appearing at the 
serosal surface of the cell [40]. The evidence includes the fact 
that the genetic defect of mice with sex-linked anemia (s.l.a.) is 
associated with reduced iron binding by this transferrin-like protein 
[40]. However, it should be mentioned that several researches into 
the subcellular distribution of iron during absorption did not reveal . 
this high mol wt species. •
Halliday and Powell applied a chromatographic analysis to the 
supernatant liquid from intestinal cell homogenates and found four 
distinct iron-containing fractions [96]. Three of these were of high 
molecular weight; ferritin was identified and probably the transferrin­
like protein described in the previous 'paragraph as well. The fourth 
low mol wt fraction was found consistently. The three fractions, 
other than ferritin, appeared within 2 min of radio iron administra-
I
tion which suggests they are involved in the transport of the metal 
across the cell as well as into ferritin. On the other hand, electro­
phoretic studies by Linder et al. [64] indicated that the iron taken 
up by the mucosal cell is about equally distributed between ferritin 
and the low mol wt fraction. .
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Some of these studies refer to the possibility of free ionic 
iron in the cytoplasm [64, 96, 107]. In view of what has already 
been said in the introduction, significant proportions of Fe(III) 
aquo-ion are out of the question and even Fe(II) is probably to be 
found associated with low mol wt ligands present in the biofluid.
So, in the authors' opinion, the observations more likely constitute 
evidence for a low mol wt complex fraction. The identity of these 
complexes will be discussed in Sec. 4. However, it is interesting 
to note that the labile nature of this pool can easily be responsible 
for reports of a confusing nature if they are not interpreted in this 
light. Brown and Rother identified a low mol wt fraction and then, 
using chromatography, decided that the ligands involved were glycine 
and serine [105, 106]. Several investigators could not confirm that 
it was these amino acids that were complexed to the iron. Instead, 
they attributed the earlier observations to the use of EDTA in the 
preparative procedures [107-109], Clearly, the low mol wt complex
• distribution will readily rearrange whenever the equilibrium is 
disturbed [l]. The low mol wt fraction has been made all the more 
elusive by its adherence to Sephadex columns [64, 100, 107].
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3.3.2. A Labile Iron Pool
While work on this review has been in progress, Jacobs has published 
an article surveying the evidence for labile iron pools within all 
cells [104]. Hence, there is no need to review this subject in 
detail. Rather, an attempt will be made to provide a slightly 
different perspective. . . ’ .
In general, cellular iron uptake, say from membrane-bound 
transferrin, is diverted between two pathways: (1) to the mitochon­
dria for metalloprotein synthesis and (2) to ferritin for storage.
In some cells, such as those from the intestinal epithelium, other 
specific iron-binding macromolecules probably occur as intermediates 
although the evidence presently favors the view that ’’transferrin­
like” proteins do not exist in all cases [104]. It is therefore 
pertinent to try to identify the intracellular agents which trans-
449
port iron between the various known binding sites and to elucidate 
their properties and contribution to iron metabolism.
The evidence in favor of low mol wt complex participation in 
the labile iron pool is substantial [lOO, 110-115]. It also appears 
that an equilibrium is set up between this low mol wt fraction and
(1) transferrin or chelating agents outside the cell [lOO, 104] and
(2) ferritin within the cell [ll6]. Enlargement of the ’’prerelease’*
iron pool in reticuloendothelial cells probably causes the induction 
of ferritin synthesis [ll6]. There, may even be an equilibrium set 
up between Fe(II) and Fe(III) compounds determined by the redox 
potential within the cell [104], .
It is quite probable that the size of the low mol wt complex 
pool is the cause of most disagreement over the labile iron content 
of cells. It seems highly unlikely that the low mol wt Fe(III) 
fraction will be quantitatively significant for two reasons:
(1) the ever-present competition from nonspecific protein binding 
sites which occur in relatively high effective concentration and
(2) the general impression which can be obtained from computer simu­
lations (see Sec. 4). This is not as true for Fe(II) even if only 
because of its greater solubility. In most biofluids, the size of 
the labile pool will not be the same as the size of the low mol wt 
complex fraction; reports that 95% of the cytosol radio iron is 
chelatable by DFO or even that 35% of the cytosol nonheme, non­
ferritin iron is dialyzable [lOO] do not refer to the amount of low 
mol wt complexed iron; they merely indicate that this quantity of 
iron, in kinetic terms, is rapidly released to low mol wt chelating 
agents. *
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There are three important pathologies in which iron overload causes 
massive deposition of the metal in the parenchyma of a number of 
organs, causing tissue damage and ultimately proving fatal [117].
•• -
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These are idiopathic haemochromatosis, Bantu siderosis, and trans- 
fusional siderosis. In the first two cases, overload is consequent 
to excessive absorption and is therefore most easily treated by •
phlebotomy. The fact that 250 mg of iron is removed for every 500 ml 
of whole blood lost should be borne in mind throughout this discussion 
of the alternative chelation therapy. However, in the case of blood 
transfusions, phlebotomy is obviously not a realistic proposition. 
Repeated transfusions constitute the only effective treatment for 
sufferers of chronic aplastic anemia or 3-thalasemia major [53, 114], 
The large intake of iron associated with this treatment cannot be 
homeostatically controlled because the body has no means of signifi­
cantly increasing iron excretion. So a pathological buildup of the 
metal occurs and most of the afflicted die in their teens from the 
heart or liver failure that is caused [114]. ■
There is consequently a serious need to develop iron chelating 
agents which can be used to combat iron overload. Unfortunately, ' .
those in common use today are not very satisfactory; they are by no 
means as effective as could be hoped and oral administration is not 
currently possible due to poor absorption.
Urinary iron excretion is not significantly enhanced by any of 
the common chelating agents except in cases of overload [74]. The 
most commonly used therapeuticals are DFO and DTPA, both of which 
can achieve iron losses up to 50 mg per day [74, 79, 118]. More 
often 10-15 mg per day is excreted in the urine of patients receiving 
these two agents [ll9-12l]. Neither EDTA nor HEDTA are as effective 
[34, 46, 119] although some potentially better agents have been 
recognized [53, 122-124]. Although differing experimental conditions 
make it difficult to compare these studies, it is possible to produce 
a list of iron-chelating agents in order of decreasing effectiveness:
DFO, EHPG > CDTA > DTPA > EDTA, HEDTA > NTA
A considerable effort has been expended researching the chem­
istry and physiology of desferrioxamine, DFO, and its iron chelate 
ferrioxamine. . The ligand is a hydroxamic acid condensation product 
of acetic and succinic acids with L-amino-5-hydroxylaminopentane [79].
. PETER M.MAY ET AL.
451
* ’ j
Tlie three hydroxamic groups each lose a proton to bind Fe(III) with ..
extraordinary avidity. The complex formed has a single positive
charge at physiological pH values due to the protonation of an amino
side group. In addition, the polarity of the molecule is increased
by partial negative charges on the nitroso functions [48], This
explains why ferrioxamine is poorly absorbed from the gastrointestinal
tract and excreted by renal filtration [79],
As a chelating agent, DFO is certainly one of the most specific; £
it is not found to influence the excretion of any other trace element 
[79]. It suffers from two disadvantages, however. It has a very 
short half-life in vivo, probably less than 1 hr [79]. Also, its 
phenomenal binding strength depends upon its ability to wrap itself 
around the Fe(III) ion. It is therefore unable to form a satisfactory 
ternary complex with transferrin. Instead it must rely either upon 
spontaneous dissociation (vide supra) or upon other chelating agents 
which can mediate in an iron exchange. Thus the reaction, although *
thermodynamically favored, is slow. In practice, the short metabolic ,j
half-life means that DFO is unable to obtain significant amounts of 
iron from transferrin in plasma. Thus, DFO has no effect on plasma 
ferrokinetics [77-80] and excretion of transferrin-bound radio iron 
is not enhanced by DFO administration [77, 80]. The occurrence of 
nonspecifically bound iron in plasma has probably given rise to* the 
few conflicting reports- [79, 80],
The physiological site of iron-chelating agent action has been 
a widely discussed topic. .No clear answer has been forthcoming 
except that neither transferrin nor the gastrointestinal tract can ;
be a major source [77, 8l]. The effect on organ radioactivity 
appears limited to the liver so the problem really is whether the 
. iron stems from parenchymal or reticuloendothelial cells. However, 
a fact which seems to be forgotten too often is that if the system 
is sufficiently labile (Sec. 3.3), the site of action and the body 
compartment from which most iron disappears are not necessarily one 
and the same. . - *
The situation with DTPA is simpler than with DFO. This poly- • 
aminocarboxylate forms complexes in plasma that are highly charged,
i’
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so it does not penetrate intracellular space [125], Accordingly, it - 
binds iron in the plasma compartment once transferrin has been satu­
rated [126]. Whether the amount of chelatable iron in plasma is at 
equilibrium with body stores is not clear [81, 126].
The evidence suggesting that DFO-induced iron excretion is 
derived from reticuloendothelial (RE) cells was put forward by 
Karabus and Fielding [127]. They suggested that the chelatable iron 
was derived from hemoglobin when mature or defective red blood cells 
are catabolized. Iron in the RE cell was proposed to be in equilib­
rium with storage iron on the one hand and transport iron on the 
other; DFO sequestered the metal from this pool. Their view was 
supported by the observations of Lipschitz et al. who thought that 
the major immediate source was probably an unknown compound on the 
pathway between ferritin and plasma transferrin [l28]. •
However, these suggestions have been refuted by Finch and 
coworkers [77, 129] whose evidence indicates that DFO enters liver 
parenchymal cells where it binds excess storage iron.
The analysis and interpretation of the experimental data con- . 
cerning DFO chelation therapy are further complicated by the fact 
that this agent is not completely confined to the extracellular 
space [79, 8l]. Following DFO administration, about one-third of 
the induced iron excretion appears in the feces via the bile [l24, 
129]. However, intravenously administered ferrioxamine does not 
follow this pathway; it is largely unable to enter the hepatic 
parenchymal cells (vide supra). These facts strongly support the 
view that at least some of the DFO enters these liver cells and 
therein chelates iron [77, 129], •
The conclusion that the remaining two-thirds of the intra­
cellularly formed ferrioxamine passes back into plasma to be excreted 
by the kidney [77] is somewhat less sound. To begin with it assumes 
that ferrioxamine is capable of traversing the membrane only in one 
direction. No evidence in support of this contention is provided.
It seems highly unlikely that iron in plasma which is available to 
DTPA is not likewise chelated by DFO. Until considerably more
. • • PETER M. MAY ET AL.
c
45
LOW MOLECULAR WEIGHT IRON(III) COMPLEXES
evidence on this matter is forthcoming, it is probably wise to assume 
that the fraction of iron excreted via the urine is chelated in the 
blood plasma compartment, while that appearing in bile arises from 
DFO penetration of the parenchymal cell. The ability of the ligand 
to traverse this membrane is discussed further in Sec. 4. The manner 
in which the chelating agents bind iron in plasma remains speculative. 
The idea that they compete with transferrin at the cell membrane [127] 
has been disputed [8l]. Nevertheless, it is known that following DFO 
administration, serum iron concentrations increase owing to the 
mobilization of iron from tissues• [130]. •
3.5. Regulation of Iron Metabolism
Ever since it was discovered that the body has very limited ability 
to excrete iron either in urine or feces, it has been realized that 
homeostasis is maintained by regulating the rate of iron absorption 
[131], This finding has prompted many hundreds of investigations 
aimed at elucidating how the mucosal cell senses and responds to the 
need for this essential trace element. The question is how do these 
parameters influence the mucosal cell? Explanations must lie in 
changes within the cell itself because absorptive characteristics 
are imprinted upon gut segments. The failure to demonstrate a role 
for (other) humoral factors makes it increasingly obvious that the 
homeostatic feedback is via. iron itself although how this is achieved 
is not easily shown.
Current ideas concerning the regulation of iron metabolism are 
presented in Chap. 9. Here, special emphasis needs to be given to 
the possible role of equilibrium and low mol wt complexing phenomena.
Saltman has proposed a model of iron metabolism in which 
absorption is almost completely controlled by chelation, solubility, 
diffusion, and equilibrium [lO, 23]. Solubilization of the iron in 
the lumen by low mol wt chelates is followed by their penetration 
into the mucosal cell. Subsequently, their passage is controlled
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only by their interaction with binding sites in the cell, such as 
those associated with ferritin, other proteins, or other low mol wt 
ligands. The iron is released directly into the blood stream as a 
low mol wt Fe(III) chelate which there reacts with transferrin.- 
There can be little doubt that with lipophilic complexes strong 
enough or inert enough to survive the competition for iron within 
the mucosal cell, this hypothesis adequately describes the position. 
However, no control is exerted under these circumstances. The extent 
to which it also applies when only weaker complexes could be absorbed 
is of great interest.
Recently Cavill et al. have suggested that iron absorption is 
regulated by internal iron-exchange considerations, namely by the 
relative sizes of exchangeable iron pools within the body and by the 
rate at which iron is cleared from the plasma by erythropoeisis [132] 
They argue that the probability of an iron atom being picked up from 
the intestinal lining by a transferrin molecule in plasma is propor­
tional to the ratio of exchangeable iron in that tissue to the 
exchangeable iron in the whole body. The number of iron atoms.trans­
ferred from all body compartments into plasma is equal to the number 
cleared, so absorption is related to the expression,
Intestinal exchangeable iron 
total exchangeable iron • x plasma iron turnover
This explains how iron absorption may be altered according to either 
iron status or erythropoietic activity. Cavill et al. cite several 
other instances where this relationship accounts satisfactorily for 
experimentally observed phenomena in iron metabolism [l32]. Their 
proposal implies that serosal transfer of iron is governed by an 
equilibrium between plasma iron and the exchangeable iron in all 
tissues [l04].
If an equilibrium between exchangeable iron pools does indeed 
regulate iron metabolism it seems more than likely that mediation by 
low mol wt complexes will be important. This will be considered 
further in Secs..4 and 5.
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Cavill et al. do not suggest the means through which the 
equilibrium is maintained, they only consider the one-way reaction 
from mucosal cells into plasma. However, if any control is to be 
exerted, iron must also be returned. Two possibilities which need 
investigation are clear: Is transferrin able to donate sufficient 
iron to the mucosal cell once it has matured, or is the feedback 
achieved only while the cell is being formed? .
A further difficulty is to be found when one considers experi­
mental data concerning transferrin and iron absorption. There is 
conflicting evidence on whether transferrin concentration or satura­
tion regulates the transfer of iron into plasma. On the whole it 
appears that it does not, in which case the longstanding issue of ' 
how the mucosal cell is informed of the need for iron remains unre­
solved. Solvell found that while the total amount absorbed was 
unaffected by transferrin saturation, the rate of transfer was influ­
enced markedly [l33]. So it looks as if the kinetics of this compli­
cated system may obscure exact relationships (Sec. 5). Further, it 
is tempting to speculate that the functional heterogeneity of trans- ■ 
ferrin as proposed by Fletcher and Huehns [134] may prove to be the 
key to understanding this problem: iron absorption may be related . 
primarily to the concentration and saturation of the reticulocyte- 
oriented iron-binding site. - •.
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. 4. COMPUTER SIMULATION STUDIES
The Investigation of low mol wt complexes in biofluids by experimental 
techniques is virtually excluded by the extremely low concentrations 
involved and by the labile nature of the equilibria. In principle, 
some insight can be obtained by applying knowledge gained from rela­
tively large-scale experiments in vitro, but if such attempts are to 
be anything more than qualitative guesses, it is essential to take
• all the relevant factors operating on the multicomponent system into 
account. These1 include the concentrations of the components as well
r
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as the equilibrium constants of all the competitive binding -inter­
actions for the metal ions in the biofluid. Powerful computer 
programs are available to accomplish this task; models of 5,000 
potentially important complex .species formed by 40 ligands are 
presently possible [l]. Recently it has been shown that despite a 
lack of quantitative information about metal-protein binding in the 
biofluid, computer simulations are able to yield a number of useful 
conclusions concerning the low mol wt fraction. For example, the 
percentage distribution of transition metal ions in normal plasma 
can be obtained [l]. Further, the models show that physiological 
interactions between transition metal ions do not reflect competitive 
effects on the low mol wt equilibria in blood plasma. •
Naturally, the difficulties associated with experimental 
studies of Fe(III) complexes in aqueous solution have severely 
affected computer models. The importance of iron as a trace metal 
is simply not consistent with the number of Fe(III) ion formation 
constants available from the literature or with the reliability of 
many of those reported. Nevertheless, certain conclusions pertinent 
to iron can be drawn from those'computer studies so far conducted.
1. The models show that at neutral pH, citrate enjoys a con­
siderable advantage over the other low mol wt (Fe(III) ion-binding 
agents occurring in plasma. In all likelihood, ternary Fe(III) 
complexes will predominate with citrate being at least one of the 
ligands. Until more formation constant data become available the
other ligands cannot be identified with as much certainty.
2- 2- 2- . Salicylate , oxalate , and glutamate are strong possibilities 
but hydroxide anion presently seems the most likely. Even in this
event, several species have been postulated (see Sec. 2); our current 
- 2- .models suggest Fe*citrate-OH and Fe*citrate*OH2 m approximately 
equal concentrations. Spectrophotometrica'lly determined formation 
constants for Fe(III) hydroxyphosphate complexes [135] indicate 
these should also be considered; quantitatively, this is not yet 
feasible because (1) the free phosphate ion concentration in plasma 
is still ill defined [l] and (2) the above-mentioned study appears 
to have neglected the well-known binuclear FezCOH^ species (Sec. 2).
. PETER M. MAY ET AL.
2. In spite of the many uncertainties listed in item 1, the
evidence of the models strongly supports the idea that* the low mol , 
wt Fe(III) complexes which predominate in plasma are all negatively 
charged. This is a consequence of the ubiquitous citrate complexing 
in conjunction with any other anionic ligand. . •
3. At least 10 orders of magnitude separate the concentrations
of the predominant low mol wt complexes and that of the aqueous Fe(III)
' ' - ' 2- ion. This figure pertains to the Fe’citrate’OH and Fe‘citrate‘OH^
species mentioned in item 1 which are estimated to exist in concen- 
-12 -3 *trations of about 10 mol dm . Of course, these figures would be 
increased if it transpired that another complex was more important.
As only very small amounts of hemoglobin and ferritin occur in 
blood plasma almost all the Fe(III) in this biofluid therefore is 
bound to transferrin. Indeed, it is probable that less than 0.000001% 
of the iron in plasma is complexed to low mol wt ligands. Two reasons 
why the concentrations of low mol wt Fe(III) complexes need to be 
repressed, in addition to those applicable to transition metals gen­
erally, are reflected in the extraordinary iron-transferrin binding 
strength: (1) bacterial proliferation depends upon iron bioavail- .
ability, and (2) loss by renal excretion is effectively avoided thus 
satisfying the paramount need to conserve this trace element.
Some experimental attempts to identify the low mol wt complexes 
in plasma have been made by measuring the amount of low mol wt iron 
in native and predialyzed serums incubated with various amounts of 
added radioactive metal [l36, 137]. They show a dramatic decrease 
in the percentage of radio iron in the ultrafiltrate/supematant when 
low mol wt ligands are absent. However, these studies do not neces­
sarily identify the ligands normally involved because the pertinent 
effect is only exhibited in the presence of unphysiological amounts 
of the metal (i.e., after the specific binding sites of the protein 
have been saturated). This exemplifies the hazards of drawing con­
clusions from experiments in which the equilibrium is severely dis­
rupted. It may also account for the different results obtained 
[136, 137]. ■ . ■
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Perhaps the most promising application of computer models lies 
in their ability to predict how well administered agents can bind 
metal ions in vivo [125]. Almost all drugs are potential metal­
binding agents but far fewer can compete successfully with endogenous 
ligands. Clearly, some identification of those which can do so is 
desirable as is a knowledge of the relative avidities they display 
towards different kinds of metal ion. Comparison of two or more 
systems simply on the basis of the 1:1 complex-formation constant 
is a common malpractice: such neglect of the competitive effects 
of other metal ions and especially of protons often leads to palpably 
nonmeaningful results.
The introduction of a plasma mobilizing index (PMI) calculated 
from the- computer simulation results makes a valid comparison among 
the chelating agents in blood plasma possible [125]. The index is 
defined as follows:
• total concentration of low mol wt metal complex species
PMj _ __________________ in the presence of drug______
“ total concentration of low mol wt metal complex species
' in normal plasma
By formulating the index in such a manner, it is independent of the 
exact free-metal ion concentration chosen for the simulations, so 
errors arising from the uncertainty associated with these values due 
to poorly categorized metal-protein equilibria are avoided.
PMI curves for a number of chelating agents with ferric ion 
are depicted in Fig. 1 (Table 1). There is good correlation between 
the order of the curves and the decreasing effectiveness of these 
compounds as iron-removing therapeutical? listed in Sec. 3.4. The 
results show that several agents are able to compete effectively 
with transferrin for Fe(III) ion. The strongest include DFO and 
EHPG. Reasons why they may be unable to remove Fe(III) ions already 
complexed to this iron-binding protein have been discussed (see 
Sec. 3.4). . •
A model of blood plasma in which the exchange of iron between 
DFO and transferiin is restricted showed that neutral, doubly
PETER M. MAY ET AL.
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FIG. 1. PMI curves calculated for Fe(III) chelating agents by using 
computer simulation and the formation constants given in Table 1.
protonated DFO accounts for about 10% of the ligand. The intra­
cellular penetration of this chelating agent may thus be attributed 
to this, the most lipophilic DFO species predominating in the .
biofluid.
At present, models for low mol wt complexation in biofluids 
other than plasma have not been constructed or suffer from certain 
theoretical limitations. For example, the nature of the metal ion 
binding to low mol wt ligands in cytoplasm awaits elucidation.
However, if such fluids are less oxidizing than plasma, there is.the 
possibility that low mol wt Fe(II) complexes may exist. The ligands 
which are most likely to be found complexed to Fe(II) may be suggested 
by inserting Fe(II) into the plasma model. (This tacitly assumes that 
the ligand and metal ion composition and especially the pH of the 
biofluid are not too unlike that of plasma.) The suggested percentage 
distribution of Fe(II) complexes is shown in Table 2. This indicates 
that the carbonate and ascorbate complexes are likely to be amongst 
the most predominant low mol wt Fe(II) species in vivo at about 
neutral pH. While this inference is by no means rigorous, it is
660
. ■ TABLE 1 •
Important Species Formed by Chelating Agents in 
Blood Plasma as Found by Computer Simulation
Chelating
agent
administereda
Species 
formed.......
Formation 
constant 
(log values)^5
Percentage
total
ligand0
Percentage 
total Fe(III) 
in low mol wt
fraction0
DFO Fe«DFO+ 29.8 98 99
Fe*DFO*OH 34.0 1 1
EHPG Fe’EHPG" 33.5 98 100
CDTA ZiVCDTA2’ 18.6 77
Ca-CDTA2" 12.0 22
Fe*CDTA*OH2" 35.0 ^0 86 ..
Fe’CDTA- 28.0 ‘ ^0 14
DTPA .Zn’DTPA3- 17.8 91.
Ca’DTPA3- 10.6 7
Fe’DTPA2" 27.8 ^0 99
EDTA Ca’EDTA2"- 10.4 73
Zn’EDTA2" 16.0 26
Fe’EDTA- 24.8 ^0 51
Fe*EDTA*OH2- 31.0 'uq . 48
HEDTA 2n* HEDTA" 14.2 58
Ca*HEDTA’ . 8.0 41
Fe"HEDTA*OH' 29.1 • 'vo 97
EEDTA Ca*EEDTA2- 9.8 91
Zn*EEDTA2- 14.8 8
Fe“EEDTA- 24.2 'vo 72 .
Fe’EEDTA’OH2" 30.0 'VO 27
NTA Ca’NTA- 6.2 88 * .
H’NTA2- 9.5 6
Fe*NTA*0H- 24.6 'vo 31
EGTA Ca’EGTA2- . 10.3 100
Fe*EGTA*OH2- 28.5 X) 12
aSymbols represent anionic forms of the agents defined in Sec. 6; in 
addition, Fe(III), Ca(II), and Zn(II). .
^Formation constants have been selected from the literature and 
corrected to conform with the temperature and ionic strength of blood 
plasma as previously described [l, 125], •
Percentages refer to a total ligand concentration - 10 mol dm 3.
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TABLE 2 .
Percentage Distribution of Fe(II) Ions Among Low Molecular 
Weight Human Blood Plasma as Found by Computer 
Simulation (-log [H+] = 7.4)
Complex Charge
Percentage of the 
total metal in the 
low mol wt fraction
Protonated carbonate 1+ . 27 .
Carbonate 0- 21
Ascorbate , 0 13
Histidinate 1+ 8
Citrate 1- 5
noteworthy that if these neutral complexes are significant in cyto­
plasm, they could be responsible for a unidirectional passive flux 
into plasma. Thus, they would be the compounds suggested by Lipschitz 
et al. as the major immediate donors of iron to DFO (Sec. 3.4). Such 
speculation is to some extent supported by the iron excretion induced 
by the Fe(II) chelating agents bipyridyl and 1,10-phenanthroline [53].
Computer simulations, like all models, are often regarded with 
deep suspicion. This is a misplaced distrust, better reserved for 
careless interpretation of results of the models. Models are an 
integral part of the scientific method: they are constructions 
attempting to imitate by representation. As such, they exhibit the 
strengths and weaknesses in the understanding of the system in ques­
tion, not only serving to expose fallacious hypotheses but also being 
an extremely useful aid in the interpretation of experimental results 
which are consistent with current ideas. •
' 5. CONCLUSIONS ./
Reference has been made throughout, this chapter to the difficulties 
associated with studies of Fe(III) complexing equilibria. Our motive 
has been to emphasize the extent to which the understanding of iron
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metabolism is thereby restricted. While any study of biological 
ligand-biometal interactions is of interest, those pertaining to 
their behavior in their biological environment are indisputably of 
greatest value. The physiology of a trace element is primarily a 
reflection of how the concentrations of its compounds are regulated 
in vivo. Thus, in spite of the problems inherent in studies of 
biological concentrations, it is important that research efforts do 
not polarize away from those techniques which illuminate the kinetics 
and equilibria of iron species in solutions under physiological 
conditions. • .
The distinct advantages of computer models to such studies 
have been outlined in Sec. 4. There is an obvious need to extend 
such simulations to embrace both the kinetically controlled distribu­
tion of metal ions between body compartments as well as equilibrium 
constraints imposed in each of the respective fluids. Although much 
of the necessary computer input data is not yet available, in our 
opinion, a viable model could nevertheless be constructed. The 
primary objective would be to faithfully represent the observed 
ferrokinetic parameters and their dependence upon prevailing 
conditions.
The protracted quest to uncover the mechanism controlling iron 
absorption has properly been directed at finding and characterizing 
the rate-determining step. This has meant that most experiments 
have studied a single process. However, it now seems probable that 
all the factors important in influencing iron absorption are not 
mediated through only one process. Overall control, therefore, 
resides in the complicated interplay of individual reactions. For 
example, the increase in iron absorption that occurs in patients 
deficient in iron is not merely a reversal of the decreased absorp­
tion occurring in iron overload [138].
Although present models provide much information concerning the 
role of low mol wt Fe(III) complexes, a more sophisticated simulation 
that also depicts the relationship between body compartments would be 
particularly useful. It could reflect the extent to which low mol wt
• • PETER M. MAY ET AL.
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complexes need to be invoked if equilibrium is indeed the key to the 
regulation of iron metabolism.. Clearly, the transfer of low mol wt 
complexes through biological membranes depends upon many factors; 
the concentrations of species on either side of the membrane, their 
molecular weights, and lipophilicities all contribute to the rates 
at which equilibrium is approached. The situation is further compli­
cated by the ability of transferrin to become attached to some vari­
eties of cell while accepting or donating metal ions. This may 
bypass the necessity for low mol wt’Fe(III) complexes to transport 
the metal through membranes (e.g., the serosal membrane of intestinal 
epithelium) under normal circumstances; an evolutionary adaptation 
(it is tempting to speculate) necessitated by problems arising from 
a predominance of negatively charged low mol wt species (Sec. 4) ■ 
Under these circumstances, low mol wt complexes would be confined to 
mediating the exchange of metal between macromolecular iron-binding 
components in the cell and the transferrin receptors attached t© the 
membrane. •
The value of correlating computer simulation and biological 
response data ought to be emphasized. While the participation of 
low mol wt complexes in iron physiology does not necessarily require 
high in vivo concentrations, the nature and concentration of these 
complexes will in part determine the behavior of the system in which 
they occur. Thus it is in these observable phenomena that the role 
of low mol wt iron complexes is manifest and from which their bio-, 
logical significance must be deduced.
• • ' - . r
ABBREVIATIONS
ATP: adenosine 5’-triphosphate .
CDTA: cyclohexane-1,2-diarainetetraacetic acid .
DFO: desferrioxamine
DTPA: diethylenetriaminepentaacetic acid •
I
EEDTA: bis-2-aminoethylethertetraacetic acid- *
EDTA: ethylenediaminetetraacetic acid
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EGTA:
EHPG:
HEDTA:
NTA:
ethylenebis (oxyethylenenitrilo) tetraacetic acid 
ethylenediaminebis(o-hydroxyphenyl)glycine 
hydroxyethylethylenediaminetetraacetic acid 
nitrilotriacetic acid .
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